# Patent

## Title
Compounds and methods for treatment of hypertension

## Abstract

Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α1B. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.

## Background
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority to U.S. Provisional Patent Application No. 61/444,642 filed Feb. 18, 2011, U.S. Provisional Patent Application No. 61/444,655 filed Feb. 18, 2011, U.S. Provisional Patent Application No. 61/444,659 filed Feb. 18, 2011, U.S. Provisional Patent Application No. 61/469,664 filed Mar. 30, 2011, U.S. Provisional Patent Application No. 61/529,745 filed Aug. 31, 2011, U.S. Provisional Patent Application No. 61/529,816 filed Aug. 31, 2011, U.S. Provisional Patent Application No. 61/562,927 filed Nov. 22, 2011 and U.S. Provisional Patent Application No. 61/562,938 filed Nov. 22, 2011, the disclosures of each of which are incorporated herein by reference in their entireties.


BACKGROUND OF THE INVENTION
Hypertension is a serious condition that can damage vital organs, such as the heart and kidneys, and other parts of the body, such as the central nervous system. Individuals who have hypertension may have, or be at risk of developing, dangerous diseases such as coronary heart disease and kidney failure. Hypertension, which is the leading modifiable risk factor for cardiovascular disease mortality, causes more than 7 million deaths every year worldwide.
Hypertension is the most common chronic medical condition in developed countries as well as the most common indication for physician visits and prescription medication use. Hypertension affects more than 50 million individuals in the United States and over one billion individuals worldwide, and overall prevalence may continue to increase with the advancing age of the population.
Unfortunately, despite the importance of blood pressure control and the availability of multiple classes of antihypertensive agents, the treatment of hypertension remains suboptimal. Data from the most recent National Health and Nutrition Examination Survey demonstrate that only 34% of patients with hypertension have blood pressures at their therapeutic goal. Additionally, it was shown that the majority of patients with hypertension will require two or more antihypertensive agents to achieve their goal blood pressure. Even with optimal compliance with multiple antihypertensive agents of different classes, a significant fraction of patients will not be able to achieve their goal blood pressure. The overall prevalence of resistant hypertension, defined as elevated blood pressure in spite of the use of three or more antihypertensive agents, is unknown, but small studies suggest that it ranges from 5%-16% in primary care settings to greater than 50% in nephrology clinics. Given data suggesting that increasing age and obesity are important risk factors for the development of resistant hypertension, it is expected that the overall prevalence of this condition is likely to increase due to demographic changes in the population.
Systolic blood pressure tends to increase with age and systolic hypertension is an important health issue, prominent in the elderly (Duprez, Am. J. Med. 121:179-184 (2008)). It has been suggested that this occurs as large vessels such as the aorta lose their elasticity with age and is less able to buffer the pulsative nature of cardiac output. There exists a need for a treatment for patients in such clinical setting, for example, patients with systolic hypertension accompanied with low diastolic pressure (Franklin et al. J. Hypertension 29:1101-1108 (2011).
Metabolic syndrome is a cluster of disorders including obesity, hypertension, hypertrigleridemia, hypercholesterolemia and elevated blood sugar. Individuals with this spectrum of disorders are at increased risk of diabetes, heart disease and stroke. Agents capable of treating more than one of these disorders are desirable.
Hypertensive emergencies are defined as severe elevations in blood pressure associated with resultant organ damage (i.e. pulmonary edema, renal impairment, visual impairment, intracranial hemorrhage, or encephalopathy). The treatment of hypertensive emergencies involves aggressive and controlled blood pressure lowering in a highly monitored intensive care setting using intravenous blood pressure lowering agents. Therapeutic agents and method of treatment is needed to gradually lower blood pressure and minimize damage of end organs such as the brain, kidney, heart, and eye.
The frequency of chronic kidney disease also continues to increase worldwide as does the prevalence of end-stage renal disease. Although chronic kidney disease is often caused by hypertension, other factors such as a decrease in renal blood flow and increase in sodium retention or reabsorption can lead to renal diseases. Increased age and diabetes can also contribute to renal disease. Especially the elderly, which are a growing segment of the world population, are at increased risk for renal disease. The presence of chronic kidney disease is also associated with a large increase in cardiovascular morbidity and mortality. Consequently, the identification and reduction of chronic kidney disease has become a vital public health priority.
Thus, there remains a need for new and useful agents that are capable of (i) reducing an individual's blood pressure and/or (ii) promoting renal blood flow and/or (iii) inhibiting or decreasing sodium reabsorption.
BRIEF SUMMARY OF THE INVENTION
Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. Compositions and kits comprising the compounds are also provided, as are methods of using and making the compounds. Compounds provided herein may find use in treating a disease or condition that is, or is believed to be responsive to any one or more of: (i) a decrease in blood pressure; (ii) an increase in renal blood flow and (iii) a decrease or inhibition of sodium reabsorption. In one aspect, compounds provided herein are selective adrenergic receptor α2B antagonists that may find use in treating a disease or condition that is, or is believed to be responsive to any one or more of: (i) a decrease in blood pressure; (ii) an increase in renal blood flow and (iii) a decrease or inhibition of sodium reabsorption. Compounds provided may also find use in treating diseases and/or conditions such as hypertension, congestive heart failure or a renal disease or condition.
In another aspect, compounds that promote mitochondrial health and cellular viability are also described. The compounds provided herein are selective adrenergic receptor α2B antagonists that may find use in treating a disease or condition that is associated with dysfunction of mitochondria in a renal or cardiac cell. Compounds provided may also find use in treating diseases and/or conditions selected from the group consisting of acute renal failure, chronic renal failure, coronary ischemia, acute congestive heart failure, chronic congestive heart failure, coronary artery disease, sleep apnea, respiratory distress, hypertension, and peripheral vascular disease.
In one aspect, provided is a method of lowering blood pressure in an individual in need thereof comprising administering to the individual an effective amount of a compound of the formula (I):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl, SO3H, SR1a, S(O)R1a, SO2R1a and perhaloalkyl; C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; or —C(O)O—C1-C5 alkyl; or is taken together with R2a or R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R4a or R5a, where present, to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety;
R1a is H or optionally substituted C1-C5 alkyl;
R2a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R1 or R5a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R3a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R4a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R3a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R1 or R4a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R2a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R5a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R4a, where present, is H; halo; hydroxyl; cyano; carboxyl; —OC(O)N(R14a)R15a; —C(O)N(R14a)R15a; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R2a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety; or is taken together with R5a, where present, to form a methylene (—CH2—) moiety;
R5a, where present, is H H; halo; hydroxyl; cyano; carboxyl; —OC(O)N(R14a)R15a; —C(O)N(R14a)R15a; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R2a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R3a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety; or is taken together with R4a, where present, to form a methylene (—CH2—) moiety;
each R2b and R3b is independently H, optionally substituted C1-C5 alkyl, optionally substituted C2-C5 alkenyl, or optionally substituted aryl;
each R4b and R5b, where present, is independently H, halo, optionally substituted C1-C5 alkyl, optionally substituted C2-C5 alkenyl, or optionally substituted aryl;
each n and m is 1, or n is 0 and m is 1, or n is 1 and m is 0;
each X1, X2, X and U is independently N or CR6;
each R6 is independently H; hydroxyl; halo; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl; optionally substituted C1-C5 alkoxy; or optionally substituted —C(O)C1-C5 alkyl;
R7 is H; halo; optionally substituted C1-C5 alkyl; or optionally substituted aryl; or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety; or is taken together with R9 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R8 is H; halo; hydroxyl; azido; aminoacyl, carboxyl; carbonylalkoxy; N(R11)R12; SR13, S(O)R13; SO2R13; —OC(O)N(R14)R15; —C(O)N(R14)R15; optionally substituted —OC(O)-aryl; optionally substituted —OC(O)-heteroaryl; —OC(O)C1-C6 alkyl optionally substituted with amino or carboxyl; or —OC1-C5 alkyl optionally substituted with carboxyl; or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety; or is taken together with R10 to form a bond;
R9 is H or optionally substituted C1-C5 alkyl, or is taken together with R7 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R10 is H or optionally substituted C1-C5 alkyl, or is taken together with R8 to form a bond;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl, or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl; or R14 and R15 are taken together to form a C3-C5 alkylene;
each R14a, and R15a is independently H or optionally substituted C1-C5 alkyl; and
Q is optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
In some embodiments, the individual has high blood pressure. In other embodiments, the method reduces one or more of any of the following: systolic blood pressure, diastolic blood pressure, mean arterial blood pressure, and pulse pressure of the individual, following administration of the compound. In other embodiments, the method does not substantially increase heart rate of the individual. In yet other embodiments, the individual has one or more risk factors for developing high blood pressure.
Provided is also a method of (i) increasing renal blood flow, and/or (ii) decreasing sodium reabsorption, in an individual in need thereof comprising administering to the individual an effective amount of a compound of the formula (I) or any variations detailed herein. In some embodiments, the method results in one or more of any of the following: increase in renal blood flow, decrease in sodium reabsorption, increase in urine sodium content and/or increase in urine volume, reduction in edema, reduction in elevated blood urea nitrogen to creatinine (BUN/Cr) ratio, and decrease in creatinine levels.
In some embodiments, the individual has or is at risk of developing acute or chronic congestive heart failure, acute decompensated congestive heart failure, acute or chronic renal failure, or acute or chronic renal failure due to renal insufficiency.
Provided is also a method of treating a disease or condition that is responsive to any one or more of: (i) a decrease in blood pressure; (ii) an increase in renal blood flow; and (iii) a decrease of sodium reabsorption, comprising administering to an individual in need thereof an effective amount of a compound of the formula (I) or any variations detailed herein. In some embodiments, the disease or condition is hypertension. In certain embodiments, the disease or condition is treatment-resistant hypertension, or hypertensive emergency. In yet other embodiments, the disease or condition is a cardiac or renal disease or condition.
In some embodiments, the compound used in the methods described above is a compound of formula (A-III):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; or —C(O)O—C1-C5 alkyl; or is taken together with R2a or R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R4a or R5a, where present, to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety;
each n and m is 1, or n is 0 and m is 1, or n is 1 and m is 0;
R2a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R1 or R5a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R3a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R4a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R3a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R1 or R4a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R2a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R5a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R4a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R2a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety; or is taken together with R5a, where present, to form a methylene (—CH2—) moiety;
R5a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R2a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R3a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety; or is taken together with R4a, where present, to form a methylene (—CH2—) moiety;
each R2b, R3b, R4b and R5b is independently H, optionally substituted C1-C5 alkyl, optionally substituted C2-C5 alkenyl, or optionally substituted aryl;
X is N or CR6a;
t is 1, 2 or 3;
each R6 and R6a is independently H; hydroxyl; halo; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl; optionally substituted C1-C5 alkoxy; or optionally substituted —C(O)C1-C5 alkyl;
R7 is H; halo; optionally substituted C1-C5 alkyl; or optionally substituted aryl; or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety; or is taken together with R9 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R8 is H; halo; hydroxyl; N(R11)R12; SR13, S(O)R13; SO2R13; —OC(O)N(R14)R15; OC(O)-aryl; —OC(O)-heteroaryl; or —OC(O)C1-C5 alkyl optionally substituted with amino; or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety; or is taken together with R10 to form a bond;
R9 is H or optionally substituted C1-C5 alkyl; or is taken together with R7 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R10 is H or optionally substituted C1-C5 alkyl; or is taken together with R8 to form a bond;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl; or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl; or R14 and R15 are taken together to form a C3-C5 alkylene; and
Q is unsubstituted aryl; unsubstituted heteroaryl; aryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino; or heteroaryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.
In some embodiments, the compound used in the methods described above is a compound of formula (A-III), wherein any one or more of provisions (1) to (34) apply:
(1) X is CR6a, wherein each R6a is independently H, halo or C1-C5 alkyl;
(2) each R6 is independently H, halo or C1-C5 alkyl;
(3) X is N;
(4) R1 is H or C1-C5 alkyl;
(5) R2a and R3a is H;
(6) R7 is H or C1-C5 alkyl;
(8) R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl;
(9) R7 is H or C1-C5 alkyl, and R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl;
(10) R7 is H, and R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl;
(11) R7 is C1-C5 alkyl, and R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl;
(12) R7 is H or C1-C5 alkyl, and R8 is H or hydroxyl;
(13) R7 is H or C1-C5 alkyl, and R8 is hydroxyl;
(14) R7 is H, and R8 is hydroxyl;
(15) R7 is methyl, and R8 is hydroxyl;
(16) R7 is H, and R8 is NH2;
(17) R7 is H, and R8 is —OC(O)C1-C5 alkyl;
(18) R9 is H or C1-C5 alkyl;
(19) R10 is H or C1-C5 alkyl;
(20) each R9 and R10 is H;
(21) one of R9 and R10 is H and the other is C1-C5 alkyl;
(22) Q is: unsubstituted pyridyl; unsubstituted pyrimidyl; unsubstituted pyrazinyl; unsubstituted phenyl; unsubstituted imidazolyl; unsubstituted triazolyl; pyridyl substituted with 1 to 3 substituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl; pyrimidyl substituted with 1 to 3 substituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl; pyrazinyl substituted with 1 to 3 substituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl; or phenyl substituted with 1 to 3 substituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl; imidazolyl substituted with 1 to 3 substituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl; or triazolyl substituted with 1 to 3 substituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl;
(23) X is CR6a, wherein R6a is H, halo or C1-C5 alkyl; and each R6 is independently H, halo or C1-C5 alkyl;
(24) wherein R1 is H or C1-C5 alkyl, R7 is H or C1-C5 alkyl, and R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl;
(25) wherein R1 is H or C1-C5 alkyl, R7 is H or C1-C5 alkyl, and R8 is H or hydroxyl;
(26) R1 is H or C1-C5 alkyl, R7 is H or C1-C5 alkyl, and R8 is hydroxyl;
(27) wherein R1 is CH3, R7 is H, R8 is hydroxyl, n is zero and m is 1;
(28) R1 is CH3, R7 is methyl, R8 is hydroxyl, n is zero and m is 1;
(29) X is CR6a, wherein R6a is H, halo or C1-C5 alkyl; each R6 is independently H, halo or C1-C5 alkyl; R1 is H or C1-C5 alkyl, R7 is H or C1-C5 alkyl, R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl; each R9 and R10 is hydrogen; and Q is unsubstituted pyridyl; or pyridyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl;
(30) n is 0 and m is 1; R1 is H or CH3; R7 is H or CH3; and R8 is H or hydroxyl;
(31) X is N; R1 is H or C1-C5 alkyl, R7 is H or C1-C5 alkyl, R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl; each R9 and R10 is hydrogen; and Q is unsubstituted pyridyl; or pyridyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl;
(32) n is 0 and m is 1; R1 is H or CH3; R7 is H or CH3; and R8 is H or hydroxyl;
(33) n is 0 and m is 1; R1 is taken together with R2a to form a propylene (—CH2CH2CH2—) moiety; X is CR6a, wherein R6a is H, halo or C1-C5 alkyl; each R6 is independently H, halo or C1-C5 alkyl; R7 is H or C1-C5 alkyl, R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl; each R9 and R10 is hydrogen; and Q is unsubstituted pyridyl; or pyridyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl; and
(34) R7 is H or CH3; and R8 is H or hydroxyl.
In some embodiments, the compound used in the methods described herein is a compound of formula (A-IIIA) detailed herein, wherein any one or more of provisions (35)-(45) apply:
(35) X is CH;
(36) X is N;
(37) R1 is H or CH3;
(38) R2a is H or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety;
(39) each R6 and R6a is independently H, halo or C1-C5 alkyl;
(40) R7 is H or CH3;
(41) R8 is hydroxyl;
(42) Q is: unsubstituted pyridyl; unsubstituted pyrimidyl; unsubstituted pyrazinyl; unsubstituted phenyl; pyridyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3; pyrimidyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3; pyrazinyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3; or phenyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3;
(43) Q is: unsubstituted pyridyl; unsubstituted pyrimidyl; unsubstituted pyrazinyl; unsubstituted phenyl; unsubstituted imidazolyl; unsubstituted triazolyl; pyridyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3; pyrimidyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3; pyrazinyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3; or phenyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3;
(44) X is CH; R1 is H or CH3; each R6 is independently H, halo or C1-C5 alkyl; R7 is H or CH3; R8 is hydroxyl; and Q is unsubstituted pyridyl, or pyridyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3; and
(45) R1 is CH3; R6 is CH3; and Q is unsubstituted pyridyl.
In some embodiments, the compound is an adrenergic receptor α2B antagonist. In other embodiments, the compound is also an adrenergic receptor α1B antagonist. In yet other embodiments, the compound is also an adrenergic receptor α1D antagonist.
Further provided is a kit comprising (i) a compound of formula (I) or any variations detailed herein, or a pharmaceutically acceptable salt thereof, and (ii) instructions for use according to the method described above. Also provided is a kit comprising a compound of formula (A-IIIA) or any variations detailed herein, or a pharmaceutically acceptable salt thereof, and (ii) instructions for use according to the method described above.
Also provided is use of a compound detailed herein, such as a compound of formula (I) or any variations thereof, or a salt, solvate or N-oxide thereof, in lowering blood pressure, increasing renal blood flow, and/or decreasing or inhibiting sodium reabsorption. Further provided are uses of a compound detailed herein, such as a compound of formula (I) or any variations thereof, or a salt, solvate or N-oxide thereof, for the manufacturing of a medicament for the treatment of a disease or condition that is responsive to any one or more of: (i) a decrease in blood pressure; (ii) an increase in renal blood flow; and (iii) a decrease of sodium reabsorption.



BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 illustrates the α2B antagonist activity of Compound Nos. 3a and 3b in the cell-based Aequorin Assay. The word “Compound” may be abbreviated as “Cpd.” in the figures.
FIG. 2 illustrates the α2B antagonist activity of Compound No. 3b in the Aequorin Antagonist Activity Assay.
FIG. 3 illustrates the binding activity of Compound No. 3b in the α2A and α2B receptor assays.
FIG. 4 illustrates the inhibitory effects of Compound No. 3b in a human α2B cell membrane-based GTPgS binding activity assay (24 nM cirazoline (EC80)).
FIG. 5 illustrates the α1B antagonist activity of Compound No. 3b in the Aequorin Antagonist Activity Assay.
FIG. 6 illustrates the inhibitory effects of Compound No. 5b in a α2B receptor in a cell-based activity assay.
FIG. 7 illustrates the effects of Compound Nos. 3, 3b, 4a and 5b on Systolic Blood Pressure in a SHR model.
FIG. 8 illustrates the effects of Compound Nos. 3 and 3b (SC Treatment) on Systolic Blood Pressure in a SHR model.
FIG. 9 illustrates the effects of Compound No. 3b on Systolic Blood Pressure in SHR model (administration: 15 mg/kg SC vs. 20 mg/kg PO).
FIG. 10 illustrates the effects of Compound Nos. 13b and 41a on Systolic Blood Pressure in a SHR model.
FIG. 11 illustrates the effect of Compound No. 3b on Systolic Blood Pressure in a dexmedetomidine induced dog model of hypertension.
FIG. 12 illustrates the effect of Compound No. 5b on Systolic Blood Pressure in a dexmedetomidine induced dog model of hypertension.
FIG. 13 illustrates the effect of Compound No. 5b on Systolic Blood Pressure in a dexmedetomidine induced dog model of hypertension, with DEX challenge.
FIG. 14 illustrates the effect of Compound No. 41a on Systolic Blood Pressure in a dexmedetomidine induced dog model of hypertension.
FIG. 15 illustrates the effect of Compound No. 3b on Systolic Blood Pressure in a dexmedetomidine induced dog model of hypertension—chronic mode, day 1.
FIG. 16 illustrates the effect of Compound No. 3b on Systolic Blood Pressure in a dexmedetomidine induced dog model of hypertension—chronic mode, day 2.
FIG. 17A illustrates the mitochondrial effects of Compound Nos. 3b, 4a, 5b and 39a and dimebon when subjected to hydrogen peroxide toxicity. The word “Dimebon” may be abbreviated as “DMB” in the figures.
FIG. 17B illustrates the mitochondrial effects of Compound Nos. 3b, 4a, 5b and 39a and dimebon when subjected to calcium overload toxicity.
FIGS. 18A and 18B illustrate the cytoprotective effects of Compound Nos. 3b, 4a, 5b and 39a and dimebon from α-Synuclein (α-syn) toxicity.
FIG. 19 illustrates the effects of Compound No. 144b (10 mg/kg, i.v.) in SHR model on Systolic Blood Pressure (Change from baseline).
FIG. 20 illustrates the effects of Compound No. 27a in SHR on Systolic Blood Pressure in an i.v. dose escalation model (Change from baseline).
FIG. 21 illustrates the effects of Compound No. 176a in SHR on Systolic Blood Pressure in an i.v. dose escalation model (Change from baseline).
FIG. 22 illustrates the effects of Compound No. 26a in SHR on Systolic Blood Pressure in an i.v. dose escalation model (Change from baseline).
FIG. 23 illustrates the effect of Compound No. 129d (PO) on Systolic blood pressure in SHR rats.
FIG. 24 illustrates the effect of Compound No. 129d (i.v., Bolus) on Systolic blood pressure in SHR rats.
FIG. 25 illustrates the effect of Compound No. 129d (i.v., Escalating Doses) on Systolic blood pressure in SHR rats.
FIG. 26 illustrates the dose-response effects of Compound No. 3b, clonidine and vehicle on mean arterial blood pressure, systolic blood pressure, diastolic blood pressure and heart rate in rabbits.
FIG. 27 illustrates the time-course effect of Compound No. 3b at 3 mg/kg and vehicle on mean arterial blood pressure, systolic blood pressure, diastolic blood pressure and heart rate in rabbits.
FIG. 28 illustrates Compound No. 129d in a human adrenergic α2A receptor inverse agonist activity assay (using GTPg35S binding functional assay).



DETAILED DESCRIPTION OF THE INVENTION
Definitions
Unless clearly indicated otherwise, the terms “a”, “an”, and the like, refer to one or more.
It is also understood and clearly conveyed by this disclosure that reference to “the compound” or “a compound” includes and refers to any compounds (e.g., selective adrenergic receptor α2B antagonists) or pharmaceutically acceptable salt or other form thereof as described herein.
Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. For example, description referring to “about X” includes description of “X”.
Unless clearly indicated otherwise, “an individual” as used herein intends a mammal, including but not limited to a human. The invention may find use in both human medicine and in the veterinary context.
As used herein, an “at risk” individual is an individual who is at risk of developing a disease or condition. An individual “at risk” may or may not have a detectable disease or condition, and may or may not have displayed detectable disease prior to the treatment methods described herein. “At risk” denotes that an individual has one or more so-called risk factors, which are measurable parameters that correlate with development of a disease or condition and are known in the art. An individual having one or more of these risk factors has a higher probability of developing the disease or condition than an individual without these risk factor(s).
As used herein, “treatment” or “treating” is an approach for obtaining a beneficial or desired result, including clinical results.
As used herein, “delaying” development of a disease or condition means to defer, hinder, slow, retard, stabilize and/or postpone development of the disease or condition. This delay can be of varying lengths of time, depending on the history of the disease and/or individual being treated. As is evident to one skilled in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the individual does not develop the disease or condition.
As used herein, the term “effective amount” intends such amount of a compound of the invention which should be effective in a given therapeutic form. As is understood in the art, an effective amount may be in one or more doses, i.e., a single dose or multiple doses may be required to achieve the desired treatment endpoint. An effective amount may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable or beneficial result may be or is achieved. Suitable doses of any of the co-administered compounds may optionally be lowered due to the combined action (e.g., additive or synergistic effects) of the compounds.
As used herein, “unit dosage form” refers to physically discrete units, suitable as unit dosages, each unit containing a predetermined quantity of active ingredient, or compound which may be in a pharmaceutically acceptable carrier.
As used herein, by “pharmaceutically acceptable” is meant a material that is not biologically or otherwise undesirable, e.g., the material may be incorporated into a pharmaceutical composition administered to an individual without causing significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained. Pharmaceutically acceptable carriers or excipients have preferably thus in some embodiments met the required standards of toxicological and manufacturing testing and/or are included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug administration.
“Pharmaceutically acceptable salts” are those salts which retain at least some of the biological activity of the free (non-salt) compound and which can be administered as drugs or pharmaceuticals to an individual. Such salts, for example, include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, oxalic acid, propionic acid, succinic acid, maleic acid, tartaric acid and the like; (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth metal ion, or an aluminum ion; or coordinates with an organic base. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine and the like. Acceptable inorganic bases include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like. Further examples of pharmaceutically acceptable salts include those listed in Berge et al., Pharmaceutical Salts, J. Pharm. Sci. 1977 January; 66(1):1-19. Pharmaceutically acceptable salts can be prepared in situ in the manufacturing process, or by separately reacting a purified compound of the invention in its free acid or base form with a suitable organic or inorganic base or acid, respectively, and isolating the salt thus formed during subsequent purification. It should be understood that a reference to a pharmaceutically acceptable salt includes the solvent addition forms or crystal forms thereof, particularly solvates or polymorphs. Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and are often formed during the process of crystallization. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Polymorphs include the different crystal packing arrangements of the same elemental composition of a compound. Polymorphs usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility. Various factors such as the recrystallization solvent, rate of crystallization, and storage temperature may cause a single crystal form to dominate.
The term “excipient” as used herein includes an inert or inactive substance that may be used in the production of a drug or pharmaceutical, such as a tablet containing a compound detailed herein, or a pharmaceutically acceptable salt thereof, as an active ingredient. Various substances may be embraced by the term excipient, including without limitation any substance used as a binder, disintegrant, coating, compression/encapsulation aid, cream or lotion, lubricant, solutions for parenteral administration, materials for chewable tablets, sweetener or flavoring, suspending/gelling agent, or wet granulation agent. Binders include, e.g., carbomers, povidone, xanthan gum, etc.; coatings include, e.g., cellulose acetate phthalate, ethylcellulose, gellan gum, maltodextrin, enteric coatings, etc.; compression/encapsulation aids include, e.g., calcium carbonate, dextrose, fructose dc (dc=“directly compressible”), honey dc, lactose (anhydrate or monohydrate; optionally in combination with aspartame, cellulose, or microcrystalline cellulose), starch dc, sucrose, etc.; disintegrants include, e.g., croscarmellose sodium, gellan gum, sodium starch glycolate, etc.; creams or lotions include, e.g., maltodextrin, carrageenans, etc.; lubricants include, e.g., magnesium stearate, stearic acid, sodium stearyl fumarate, etc.; materials for chewable tablets include, e.g., dextrose, fructose dc, lactose (monohydrate, optionally in combination with aspartame or cellulose), etc.; suspending/gelling agents include, e.g., carrageenan, sodium starch glycolate, xanthan gum, etc.; sweeteners include, e.g., aspartame, dextrose, fructose dc, sorbitol, sucrose dc, etc.; and wet granulation agents include, e.g., calcium carbonate, maltodextrin, microcrystalline cellulose, etc.
An inverse agonist is a compound that binds to a receptor and inhibits the activity of the receptor in the absence of an agonist. An inverse agonist requires that the receptor have some constitutive basal activity in the absence of an agonist. While an agonist increases activity of the receptor over basal level an inverse agonist reduces receptor activity below basal level.
“Alkyl” refers to and includes saturated linear, branched, or cyclic univalent hydrocarbon structures and combinations thereof. Particular alkyl groups are those having 1 to 20 carbon atoms (a “C1-C20 alkyl”). More particular alkyl groups are those having 1 to 8 carbon atoms (a “C1-C8 alkyl”). When an alkyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons are intended to be encompassed and described; thus, for example, “butyl” is meant to include n-butyl, sec-butyl, iso-butyl, tert-butyl and cyclobutyl; “propyl” includes n-propyl, iso-propyl and cyclopropyl. This term is exemplified by groups such as methyl, t-butyl, n-heptyl, octyl, cyclohexylmethyl, cyclopropyl and the like. Cycloalkyl is a subset of alkyl and can consist of one ring, such as cyclohexyl, or multiple rings, such as adamantyl. A cycloalkyl comprising more than one ring may be fused, spiro or bridged, or combinations thereof. A preferred cycloalkyl is a saturated cyclic hydrocarbon having from 3 to 13 annular carbon atoms. A more preferred cycloalkyl is a saturated cyclic hydrocarbon having from 3 to 8 annular carbon atoms (a “C3-C8 cycloalkyl”). Examples of cycloalkyl groups include adamantyl, decahydronaphthalenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
“Alkylene” refers to the same residues as alkyl, but having bivalency. Examples of alkylene include methylene (—CH2—), ethylene (—CH2CH2—), propylene (—CH2CH2CH2—), butylene (—CH2CH2CH2CH2—) and the like.
“Alkenyl” refers to an unsaturated hydrocarbon group having at least one site of olefinic unsaturation (i.e., having at least one moiety of the formula C═C) and preferably having from 2 to 10 carbon atoms and more preferably 2 to 8 carbon atoms. Examples of alkenyl include but are not limited to —CH2—CH═CH—CH3 and —CH2—CH2-cyclohexenyl, where the ethyl group of the latter example can be attached to the cyclohexenyl moiety at any available position on the ring. Cycloalkenyl is a subset of alkenyl and can consist of one ring, such as cyclohexyl, or multiple rings, such as norbornenyl. A more preferred cycloalkenyl is an unsaturated cyclic hydrocarbon having from 3 to 8 annular carbon atoms (a “C3-C8 cycloalkenyl”). Examples of cycloalkenyl groups include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and the like.
“Alkynyl” refers to an unsaturated hydrocarbon group having at least one site of acetylenic unsaturation (i.e., having at least one moiety of the formula C≡C) and preferably having from 2 to 10 carbon atoms and more preferably 2 to 8 carbon atoms and the like.
“Substituted alkyl” refers to an alkyl group having from 1 to 5 substituents including, but not limited to, substituents such as alkoxy, substituted alkoxy, acyl, acyloxy, carbonylalkoxy, acylamino, substituted or unsubstituted amino, aminoacyl, aminocarbonylamino, aminocarbonyloxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryloxy, substituted aryloxy, cyano, halo, hydroxyl, nitro, carboxyl, thiol, thioalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, aminosulfonyl, sulfonylamino, sulfonyl, oxo, carbonylalkylenealkoxy and the like.
“Substituted alkenyl” refers to alkenyl group having from 1 to 5 substituents including, but not limited to, substituents such as alkoxy, substituted alkoxy, acyl, acyloxy, carbonylalkoxy, acylamino, substituted or unsubstituted amino, aminoacyl, aminocarbonylamino, aminocarbonyloxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryloxy, substituted aryloxy, cyano, halo, hydroxyl, nitro, carboxyl, thiol, thioalkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, aminosulfonyl, sulfonylamino, sulfonyl, oxo, carbonylalkylenealkoxy and the like.
“Substituted alkynyl” refers to alkynyl groups having from 1 to 5 substituents including, but not limited to, groups such as alkoxy, substituted alkoxy, acyl, acyloxy, carbonylalkoxy, acylamino, substituted or unsubstituted amino, aminoacyl, aminocarbonylamino, aminocarbonyloxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryloxy, substituted aryloxy, cyano, halo, hydroxyl, nitro, carboxyl, thiol, thioalkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, aminosulfonyl, sulfonylamino, sulfonyl, oxo, carbonylalkylenealkoxy and the like.
“Acyl” refers to the groups H—C(O)—, alkyl-C(O)—, substituted alkyl-C(O)—, alkenyl-C(O)—, substituted alkenyl-C(O)—, cycloalkyl-C(O)—, substituted cycloalkyl-C(O)—, alkynyl-C(O)—, substituted alkynyl-C(O)—, aryl-C(O)—, substituted aryl-C(O)—, heteroaryl-C(O)—, substituted heteroaryl-C(O)—, heterocyclic-C(O)—, and substituted heterocyclic-C(O)—, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.
“Acyloxy” refers to the groups H—C(O)O—, alkyl-C(O)O—, substituted alkyl-C(O)O—, alkenyl-C(O)O—, substituted alkenyl-C(O)O—, alkynyl-C(O)O—, substituted alkynyl-C(O)O—, cycloalkyl-C(O)O—, substituted cycloalkyl-C(O)O—, aryl-C(O)O—, substituted aryl-C(O)O—, heteroaryl-C(O)O—, substituted heteroaryl-C(O)O—, heterocyclic-C(O)O—, and substituted heterocyclic-C(O)O—, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.
“Heterocycle”, “heterocyclic”, or “heterocyclyl” refers to a saturated or an unsaturated non-aromatic group having a single ring or multiple condensed rings, and having from 1 to 10 annular carbon atoms and from 1 to 4 annular heteroatoms, such as nitrogen, sulfur or oxygen, and the like. A heterocycle comprising more than one ring may be fused, spiro or bridged, or any combination thereof. In fused ring systems, one or more of the rings can be aryl or heteroaryl. A heterocycle having more than one ring where at least one ring is aromatic may be connected to the parent structure at either a non-aromatic ring position or at an aromatic ring position. In one variation, a heterocycle having more than one ring where at least one ring is aromatic is connected to the parent structure at a non-aromatic ring position.
“Substituted heterocyclic” or “substituted heterocyclyl” refers to a heterocycle group which is substituted with from 1 to 3 substituents including, but not limited to, substituents such as alkoxy, substituted alkoxy, acyl, acyloxy, carbonylalkoxy, acylamino, substituted or unsubstituted amino, aminoacyl, aminocarbonylamino, aminocarbonyloxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryloxy, substituted aryloxy, cyano, halo, hydroxyl, nitro, carboxyl, thiol, thioalkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, aminosulfonyl, sulfonylamino, sulfonyl, oxo, carbonylalkylenealkoxy and the like. In one variation, a substituted heterocycle is a heterocycle substituted with an additional ring, wherein the additional ring may be aromatic or non-aromatic.
“Aryl” or “Ar” refers to an unsaturated aromatic carbocyclic group having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl) which condensed rings may or may not be aromatic. In one variation, the aryl group contains from 6 to 14 annular carbon atoms. An aryl group having more than one ring where at least one ring is non-aromatic may be connected to the parent structure at either an aromatic ring position or at a non-aromatic ring position. In one variation, an aryl group having more than one ring where at least one ring is non-aromatic is connected to the parent structure at an aromatic ring position.
“Heteroaryl” or “HetAr” refers to an unsaturated aromatic carbocyclic group having from 1 to 10 annular carbon atoms and at least one annular heteroatom, including but not limited to heteroatoms such as nitrogen, oxygen and sulfur. A heteroaryl group may have a single ring (e.g., pyridyl, furyl) or multiple condensed rings (e.g., indolizinyl, benzothienyl) which condensed rings may or may not be aromatic. A heteroaryl group having more than one ring where at least one ring is non-aromatic may be connected to the parent structure at either an aromatic ring position or at a non-aromatic ring position. In one variation, a heteroaryl group having more than one ring where at least one ring is non-aromatic is connected to the parent structure at an aromatic ring position.
“Substituted aryl” refers to an aryl group having 1 to 5 substituents including, but not limited to, groups such as alkoxy, substituted alkoxy, acyl, acyloxy, carbonylalkoxy, acylamino, substituted or unsubstituted amino, aminoacyl, aminocarbonylamino, aminocarbonyloxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryloxy, substituted aryloxy, cyano, halo, hydroxyl, nitro, carboxyl, thiol, thioalkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, aminosulfonyl, sulfonylamino, sulfonyl, oxo, carbonylalkylenealkoxy and the like.
“Substituted heteroaryl” refers to a heteroaryl group having 1 to 5 substituents including, but not limited to, groups such as alkoxy, substituted alkoxy, acyl, acyloxy, carbonylalkoxy, acylamino, substituted or unsubstituted amino, aminoacyl, aminocarbonylamino, aminocarbonyloxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryloxy, substituted aryloxy, cyano, halo, hydroxyl, nitro, carboxyl, thiol, thioalkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, aminosulfonyl, sulfonylamino, sulfonyl, oxo, carbonylalkylenealkoxy and the like.
“Aralkyl” refers to a residue in which an aryl moiety is attached to an alkyl residue and wherein the aralkyl group may be attached to the parent structure at either the aryl or the alkyl residue. Preferably, an aralkyl is connected to the parent structure via the alkyl moiety. In one variation, an aralkyl is a fused ring system where at least one cycloalkyl moiety is fused with at least one aryl moiety. A “substituted aralkyl” refers to a residue in which an aryl moiety is attached to a substituted alkyl residue and wherein the aralkyl group may be attached to the parent structure at either the aryl or the alkyl residue. When an aralkyl is connected to the parent structure via the alkyl moiety, it may also be referred to as an “alkaryl”. More particular alkaryl groups are those having 1 to 3 carbon atoms in the alkyl moiety (a “C1-C3 alkaryl”).
“Alkoxy” refers to the group alkyl-O—, which includes, by way of example, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, and the like. Similarly, alkenyloxy refers to the group “alkenyl-O—” and alkynyloxy refers to the group “alkynyl-O—”. “Substituted alkoxy” refers to the group substituted alkyl-O.
“Unsubstituted amino” refers to the group —NH2.
“Substituted amino” refers to the group —NRaRb, where either (a) each Ra and Rb group is independently selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, provided that both Ra and Rb groups are not H; or (b) Ra and Rb are joined together with the nitrogen atom to form a heterocyclic or substituted heterocyclic ring.
“Acylamino” refers to the group —C(O)NRaRb where Ra and Rb are independently selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic or Ra and Rb groups can be joined together with the nitrogen atom to form a heterocyclic or substituted heterocyclic ring.
“Aminoacyl” refers to the group —NRaC(O)Rb where each Ra and Rb group is independently selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic or substituted heterocyclic. Preferably, Ra is H or alkyl.
“Aminosulfonyl” refers to the groups —NRSO2-alkyl, —NRSO2 substituted alkyl, —NRSO2-alkenyl, —NRSO2-substituted alkenyl, —NRSO2-alkynyl, —NRSO2— substituted alkynyl, —NRSO2-cycloalkyl, —NRSO2-substituted cycloalkyl, —NRSO2-aryl, —NRSO2-substituted aryl, —NRSO2-heteroaryl, —NRSO2— substituted heteroaryl, —NRSO2-heterocyclic, and —NRSO2— substituted heterocyclic, where R is H or alkyl and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.
“Sulfonylamino” refers to the groups —SO2NH2, —SO2NR-alkyl, —SO2NR-substituted alkyl, —SO2NR-alkenyl, —SO2NR-substituted alkenyl, —SO2NR-alkynyl, —SO2NR-substituted alkynyl, —SO2NR-aryl, —SO2NR-substituted aryl, —SO2NR-heteroaryl, —SO2NR-substituted heteroaryl, —SO2NR-heterocyclic, and —SO2NR-substituted heterocyclic, where R is H or alkyl, or —SO2NR2, where the two R groups are taken together and with the nitrogen atom to which they are attached to form a heterocyclic or substituted heterocyclic ring.
“Sulfonyl” refers to the groups —SO2-alkyl, —SO2-substituted alkyl, —SO2-alkenyl, —SO2-substituted alkenyl, —SO2-alkynyl, —SO2-substituted alkynyl, —SO2-aryl, —SO2-substituted aryl, —SO2-aralkyl, —SO2-substituted aralkyl, —SO2-heteroaryl, —SO2-substituted heteroaryl, —SO2-heterocyclic, and —SO2-substituted heterocyclic.
“Aminocarbonylalkoxy” refers to the group —NRaC(O)ORb where each Ra and Rb group is independently selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclyl.
“Carbonylalkylenealkoxy” refers to the group —C(O)—(CH2)n—OR where R is a substituted or unsubstituted alkyl and n is an integer from 1 to 100, more preferably n is an integer from 1 to 10 or 1 to 5.
“Halo” or “halogen” refers to elements of the Group 17 series having atomic number 9 to 85. Preferred halo groups include the radicals of fluorine, chlorine, bromine and iodine. Where a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached, e.g., dihaloaryl, dihaloalkyl, trihaloaryl etc. refer to aryl and alkyl substituted with two (“di”) or three (“tri”) halo groups, which may be but are not necessarily the same halogen; thus 4-chloro-3-fluorophenyl is within the scope of dihaloaryl. An alkyl group in which each H is replaced with a halo group is referred to as a “perhaloalkyl.” A preferred perhaloalkyl group is trifluoroalkyl (—CF3). Similarly, “perhaloalkoxy” refers to an alkoxy group in which a halogen takes the place of each H in the hydrocarbon making up the alkyl moiety of the alkoxy group. An example of a perhaloalkoxy group is trifluoromethoxy (—OCF3).
“Carbonyl” refers to the group C═O.
“Cyano” refers to the group —CN.
“Oxo” refers to the moiety ═O.
“Nitro” refers to the group —NO2.
“Thioalkyl” refers to the groups —S-alkyl.
“Alkylsulfonylamino” refers to the groups —R1SO2NRaRb where Ra and Rb are independently selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, or the Ra and Rb groups can be joined together with the nitrogen atom to form a heterocyclic or substituted heterocyclic ring and R1 is an alkyl group.
“Carbonylalkoxy” refers to as used herein refers to the groups —C(O)O-alkyl, —C(O)O-substituted alkyl, —C(O)O-aryl, —C(O)O-substituted aryl, —C(O)O-alkenyl, —C(O)O-substituted alkenyl, —C(O)O-alkynyl, —C(O)O-substituted alkynyl, —C(O)O-heteroaryl, —C(O)O-substituted heteroaryl, —C(O)O-heterocyclic or —C(O)O-substituted heterocyclic.
“Geminal” refers to the relationship between two moieties that are attached to the same atom. For example, in the residue —CH2—CHR1R2, R1 and R2 are geminal and R1 may be referred to as a geminal R group to R2.
“Vicinal” refers to the relationship between two moieties that are attached to adjacent atoms. For example, in the residue —CHR1—CH2R2, R1 and R2 are vicinal and R1 may be referred to as a vicinal R group to R2.
Receptor Binding Profile
In some embodiments, compounds that bind to and are antagonists of the adrenergic receptor α2B, but which are not antagonists of the adrenergic receptor α2A, and pharmaceutically acceptable salts thereof, are provided. The compounds may find use in therapy for decreasing blood pressure in an individual and in treating diseases or conditions which are responsive to (i) a decrease in blood pressure and/or (ii) an increase in renal blood flow and/or (iii) a decrease or inhibition of sodium reabsorption or sodium retention. Thus, an individual who has a disease or condition that is responsive to (i) a decrease in blood pressure and/or (ii) an increase in renal blood flow and/or (iii) a decrease or inhibition of sodium reabsorption or sodium retention will experience one or more beneficial or desirable results upon administration of a compound provided herein, or pharmaceutically acceptable salt thereof. In one aspect, the beneficial or desirable result is a reduction in the individual's mean arterial blood pressure for a period of time following administration of the compound or pharmaceutically acceptable salt thereof. In another aspect, the beneficial or desirable result is a reduction in the individual's systolic blood pressure for a period of time following administration of the compound or pharmaceutically acceptable salt thereof. In a further aspect, the beneficial or desirable result is an increase in renal blood flow (e.g., by altering the vascular tone of renal efferent and afferent arterioles) for a period of time following administration of the compound or pharmaceutically acceptable salt thereof. In another aspect, the beneficial or desirable result is a decrease or inhibition in sodium reabsorption (e.g., thereby exerting a natriuretic and diuretic effect) for a period of time following administration of the compound or pharmaceutically acceptable salt thereof. In another aspect, the beneficial or desirable result is an increase in urine sodium and/or urine volume for a period of time following administration of the compound or pharmaceutically acceptable salt thereof. In one variation, the compounds may find use in therapy in treating diseases or conditions which are responsive to (i) a decrease in blood pressure and (ii) an increase in renal blood flow. In one variation, the compounds my find use in therapy in treating diseases or conditions which are responsive to (i) a decrease in blood pressure and (ii) a decrease or inhibition of sodium reabsorption. In one variation, the compounds may find use in treating diseases or conditions which are responsive to (i) an increase in renal blood flow and (ii) a decrease or inhibition of sodium reabsorption. In one variation, the compounds may find use in therapy in treating diseases or conditions which are responsive to (i) a decrease in blood pressure and (ii) an increase in renal blood flow and (iii) a decrease or inhibition of sodium reabsorption.
Compounds that bind to and are antagonists of the adrenergic receptor α2B should reduce an individual's blood pressure. However, compounds that antagonize the adrenergic receptor α2A in some instances may actually increase an individual's blood pressure. Thus, compounds that antagonize the adrenergic receptor α2B but do not antagonize the adrenergic receptor α2A (compounds referred to herein as “selective adrenergic receptor α2B antagonists”) are desirable agents in therapy. Selective adrenergic receptor α2B antagonists find further use in therapy of cardiovascular and renal indications. The selective adrenergic receptor α2B antagonists provided herein (i) bind to and are antagonists of the adrenergic receptor α2B, and (ii) are not antagonists of the adrenergic receptor α2A.
The selective adrenergic receptor α2B antagonists may in some variations also bind to and be agonists of the adrenergic receptor α2A. The selective adrenergic receptor α2B antagonists may also be used in conjunction with other agents that are agonists of the adrenergic receptor α2A.
The selective adrenergic receptor α2B antagonists may in some variations also bind to and be antagonists of the adrenergic receptor α1B. The selective adrenergic receptor α2B antagonists may also be used in conjunction with other agents that are antagonists of the adrenergic receptor α1B 
The selective adrenergic receptor α2B antagonists may in some variations also bind to and be antagonists of the adrenergic receptor α1D. The selective adrenergic receptor α2B antagonists may also be used in conjunction with other agents that are antagonists of the adrenergic receptor α1D 
The selective adrenergic receptor α2B antagonists may in some variations both (i) bind to and be agonists of the adrenergic receptor α2A and (ii) bind to and be antagonists of the adrenergic receptor α1B and/or α1D.
In one variation, a selective adrenergic receptor α2B antagonist exhibits (i) equal to or greater than about 60% inhibition of α2B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α2B and (ii) equal to or less than about 30% inhibition of α2A ligand binding at 0.1 μM and absence of antagonist activity to adrenergic receptor α2A. In one variation, a selective adrenergic receptor α2B antagonist exhibits (i) equal to or greater than about any one of 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or between about 60% and about 90%, between about 70% and about 90%, or between about 80% and about 100% inhibition of α2B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α2B, and (ii) equal to or less than about any one of 30%, 25%, 20%, 15%, 10%, or 5%, or between about 0% and about 30%, between about 10% and about 30%, or between about 20% and about 30% inhibition of α2A ligand binding at 0.1 μM and absence of antagonist activity to adrenergic receptor α2A. In one variation, a selective adrenergic receptor α2B antagonist exhibits (i) equal to or greater than about 60% inhibition of α2B ligand binding at 0.1 μM and antagonist activity to adrenergic receptor α2B and (ii) equal to or less than about 30% inhibition of α2A ligand binding at 0.1 μM and absence of antagonist activity to adrenergic receptor α2A. In one variation, a selective adrenergic receptor α2B antagonist exhibits (i) equal to or greater than about any one of 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or between about 60% and about 90%, between about 70% and about 90%, or between about 80% and about 100% inhibition of α2B ligand binding at 0.1 μM and antagonist activity to adrenergic receptor α2B, and (ii) equal to or less than about any one of 30%, 25%, 20%, 15%, 10%, or 5%, or between about 0% and about 30%, between about 10% and about 30%, or between about 20% and about 30% inhibition of α2A ligand binding at 0.1 μM and absence of antagonist activity to adrenergic receptor α2A. It is understood and clearly conveyed herein that a selective adrenergic receptor α2B antagonist can exhibit any of the adrenergic receptor α2B binding profiles described herein in combination with any of the adrenergic receptor α2A binding profiles described herein, as if each and every combination were listed separately. For example, a selective adrenergic receptor α2B antagonist may exhibit (i) equal to or greater than about 65% inhibition of α2B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α2B, and (ii) equal to or less than about 25% inhibition of α2A ligand binding at 0.1 μM and absence of antagonist activity to adrenergic receptor α2A.
In one variation, a selective adrenergic receptor α2B antagonist exhibits (i) equal to or greater than about 60% inhibition of α2B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α2B and (ii) equal to or less than about 30% inhibition of α2A ligand binding at 0.03 μM and absence of antagonist activity to adrenergic receptor α2A. In one variation, a selective adrenergic receptor α2B antagonist exhibits (i) equal to or greater than about any one of 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or between about 60% and about 90%, between about 70% and about 90%, or between about 80% and about 100% inhibition of α2B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α2B, and (ii) equal to or less than about any one of 30%, 25%, 20%, 15%, 10%, or 5%, or between about 0% and about 30%, between about 10% and about 30%, or between about 20% and about 30% inhibition of α2A ligand binding at 0.03 μM and absence of antagonist activity to adrenergic receptor α2A. In one variation, a selective adrenergic receptor α2B antagonist exhibits (i) equal to or greater than about 60% inhibition of α2B ligand binding at 0.1 μM and antagonist activity to adrenergic receptor α2B and (ii) equal to or less than about 30% inhibition of α2A ligand binding at 0.03 μM and absence of antagonist activity to adrenergic receptor α2A. In one variation, a selective adrenergic receptor α2B antagonist exhibits (i) equal to or greater than about any one of 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or between about 60% and about 90%, between about 70% and about 90%, or between about 80% and about 100% inhibition of α2B ligand binding at 0.1 μM and antagonist activity to adrenergic receptor α2B, and (ii) equal to or less than about any one of 30%, 25%, 20%, 15%, 10%, or 5%, or between about 0% and about 30%, between about 10% and about 30%, or between about 20% and about 30% inhibition of α2A ligand binding at 0.03 μM and absence of antagonist activity to adrenergic receptor α2A. It is understood and clearly conveyed herein that a selective adrenergic receptor α2B antagonist can exhibit any of the adrenergic receptor α2B binding profiles described herein in combination with any of the adrenergic receptor α2A binding profiles described herein, as if each and every combination were listed separately. For example, a selective adrenergic receptor α2B antagonist may exhibit (i) equal to or greater than about 65% inhibition of α2B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α2B, and (ii) equal to or less than about 25% inhibition of α2A ligand binding at 0.03 μM and absence of antagonist activity to adrenergic receptor α2A.
In another variation, a selective adrenergic receptor α2B antagonist has a Ki ratio of α2A to α2B that is greater than about any one of 5 or 15 or 50. Ki is the binding affinity from the Cheng-Prusoff equation: Ki=IC50/(1+[S]/Kd), wherein [S] is the concentration of the radioligand and Kd is dissociation constant (affinity) of the radioligand for the protein (Cheng, Y., Prusoff, W. H., Biochem. Pharmacol. 22:3099-3108, 1973). It is understood that the Ki ratio of α2A to α2B may be combined with any binding and/or other activity profile details described herein for selective adrenergic receptor α2B antagonists the same as if each were specifically and individually listed. For example, in one variation, a selective adrenergic receptor α2B antagonist may exhibit (i) equal to or greater than about 65% inhibition of α2B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α2B, and (ii) equal to or less than about 25% inhibition of α2A ligand binding at 0.1 μM and absence of antagonist activity to adrenergic receptor α2A; and a Ki ratio of α2A to α2B that is greater than about any one of 5 or 15 or 50.
The selective adrenergic receptor α2B antagonists may in some variations also bind to and be antagonists of the adrenergic receptor α1B. In one variation, the selective adrenergic receptor α2B antagonists may exhibit (i) equal to or greater than about 60% inhibition of α2B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α2B, (ii) equal to or less than about 30% inhibition of α2A ligand binding at 0.1 μM and absence of antagonist activity to adrenergic receptor α2A, and (iii) equal to or greater than about 60% inhibition of α1B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α1B. In one variation, the selective adrenergic receptor α2B antagonists may exhibit (i) equal to or greater than about 60% inhibition of α2B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α2B, (ii) equal to or less than about 30% inhibition of α2A ligand binding at 0.1 μM and absence of antagonist activity to adrenergic receptor α2A, and (iii) equal to or greater than about any one of 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or between about 60% and 90%, between about 70% and 90%, or between about 80% and about 100% inhibition of α1B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α1B. In one variation, the selective adrenergic receptor α2B antagonists may exhibit (i) equal to or greater than about 60% inhibition of α2B ligand binding at 0.1 μM and antagonist activity to adrenergic receptor α2B, (ii) equal to or less than about 30% inhibition of α2A ligand binding at 0.1 μM and absence of antagonist activity to adrenergic receptor α2A, and (iii) equal to or greater than about 60% inhibition of α1B ligand binding at 0.1 μM and antagonist activity to adrenergic receptor α1B. In one variation, the selective adrenergic receptor α2B antagonists may exhibit (i) equal to or greater than about 60% inhibition of α2B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α2B, (ii) equal to or less than about 30% inhibition of α2A ligand binding at 0.1 μM and absence of antagonist activity to adrenergic receptor α2A, and (iii) equal to or greater than about 60% inhibition of α1B ligand binding at 0.1 μM and antagonist activity to adrenergic receptor α1B. In one variation, the selective adrenergic receptor α2B antagonists may exhibit (i) equal to or greater than about 60% inhibition of α2B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α2B, (ii) equal to or less than about 30% inhibition of α2A ligand binding at 0.1 μM and absence of antagonist activity to adrenergic receptor α2A, and (iii) equal to or greater than about any one of 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or between about 60% and 90%, between about 70% and 90%, or between about 80% and about 100% inhibition of α1B ligand binding at 0.1 μM and antagonist activity to adrenergic receptor α1B. It is understood and clearly conveyed herein that a selective adrenergic receptor α2B antagonist can exhibit any of the adrenergic receptor α2B binding profiles described herein in combination with any of the adrenergic receptor α2A binding profiles described herein and any of the adrenergic receptor α1B binding profiles, as if each and every combination were listed separately. For example, a selective adrenergic receptor α2B antagonist may exhibit (i) equal to or greater than about 65% inhibition of α2B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α2B, (ii) equal to or less than about 25% inhibition of α2A ligand binding at 0.1 μM and absence of antagonist activity to adrenergic receptor α2A, and (iii) equal to or greater than about 65% inhibition of α1B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α1B. The selective adrenergic receptor α2B antagonists may also be used in conjunction with other agents that antagonize the adrenergic receptor α1B. Administration in conjunction with another compound includes administration in the same or different composition, either sequentially, simultaneously, or continuously.
The selective adrenergic receptor α2B antagonists may in some variations also bind to and be antagonists of the adrenergic receptor α1D. In one variation, the selective adrenergic receptor α2B antagonists may exhibit (i) equal to or greater than about 60% inhibition of α2B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α2B, (ii) equal to or less than about 30% inhibition of α2A ligand binding at 0.1 μM and absence of antagonist activity to adrenergic receptor α2A, and (iii) equal to or greater than about 60% inhibition of α1D ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α1D. In another variation, the selective adrenergic receptor α2B antagonists may exhibit (i) equal to or greater than about 60% inhibition of α2B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α2B, (ii) equal to or less than about 30% inhibition of α2A ligand binding at 0.1 μM and absence of antagonist activity to adrenergic receptor α2A, (iii) equal to or greater than about 60% inhibition of α1B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α1B and (iv) equal to or greater than about 60% inhibition of α1D ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α1D. In one variation, the selective adrenergic receptor α2B antagonists may exhibit (i) equal to or greater than about 60% inhibition of α2B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α2B, (ii) equal to or less than about 30% inhibition of α2A ligand binding at 0.1 μM and absence of antagonist activity to adrenergic receptor α2A, and (iii) equal to or greater than about any one of 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or between about 60% and 90%, between about 70% and 90%, or between about 80% and about 100% inhibition of α1D and/or α1B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α1D and/or α1B. In one variation, the selective adrenergic receptor α2B antagonists may exhibit (i) equal to or greater than about 60% inhibition of α2B ligand binding at 0.1 μM and antagonist activity to adrenergic receptor α2B, (ii) equal to or less than about 30% inhibition of α2A ligand binding at 0.1 μM and absence of antagonist activity to adrenergic receptor α2A, and (iii) equal to or greater than about 60% inhibition of α1B and/or α1D ligand binding at 0.1 μM and antagonist activity to adrenergic receptor α1B and/or α1D. In one variation, the selective adrenergic receptor α2B antagonists may exhibit (i) equal to or greater than about 60% inhibition of α2B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α2B, (ii) equal to or less than about 30% inhibition of α2A ligand binding at 0.1 μM and absence of antagonist activity to adrenergic receptor α2A, and (iii) equal to or greater than about 60% inhibition of α1B and/or α1D ligand binding at 0.1 μM and antagonist activity to adrenergic receptor α1B and/or α1D. In one variation, the selective adrenergic receptor α2B antagonists may exhibit (i) equal to or greater than about 60% inhibition of α2B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α2B, (ii) equal to or less than about 30% inhibition of α2A ligand binding at 0.1 μM and absence of antagonist activity to adrenergic receptor α2A, and (iii) equal to or greater than about any one of 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or between about 60% and 90%, between about 70% and 90%, or between about 80% and about 100% inhibition of α1B and/or α1D ligand binding at 0.1 μM and antagonist activity to adrenergic receptor α1B and/or α1D. It is understood and clearly conveyed herein that a selective adrenergic receptor α2B antagonist can exhibit any of the adrenergic receptor α2B binding profiles described herein in combination with any of the adrenergic receptor α2A binding profiles described herein and any of the adrenergic receptor α1B and/or α1D binding profiles, as if each and every combination were listed separately. For example, a selective adrenergic receptor α2B antagonist may exhibit (i) equal to or greater than about 65% inhibition of α2B ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α2B, (ii) equal to or less than about 25% inhibition of α2A ligand binding at 0.1 μM and absence of antagonist activity to adrenergic receptor α2A, and (iii) equal to or greater than about 65% inhibition of α1D ligand binding at 0.03 μM and antagonist activity to adrenergic receptor α1D. The selective adrenergic receptor α2B antagonists may also be used in conjunction with other agents that antagonize the adrenergic receptor α1D. Administration in conjunction with another compound includes administration in the same or different composition, either sequentially, simultaneously, or continuously.
In some instances, compounds provided herein bind to and are antagonists of adrenergic receptor α2B and may also be antagonists for the adrenergic receptor α2A. In such instances, it is preferable that the compound is more potent at inhibiting the adrenergic receptor α2B compared to the adrenergic receptor α2A. In one variation, the compound inhibit both the adrenergic receptor α2B and the adrenergic receptor α2A, and wherein the compound has limited or no brain bioavailability and so cannot easily activate adrenergic α2A receptors in the brain. In one variation, the compound inhibits both the adrenergic receptor α2B and the adrenergic receptor α2A, and wherein the compound has brain bioavailability. In some other instances, compounds provided herein bind to and are antagonists of adrenergic receptor α2B and may be inverse agonists for the adrenergic receptor α2A. In some embodiments, the compound (1) binds to and is an antagonist of adrenergic receptor α2B, and (2) binds to and is an antagonist and/or inverse agonist of the adrenergic receptor α2A. In some embodiments, the compound (1) binds to and is an antagonist of adrenergic receptor α2B, (2) binds to and is an antagonist and/or inverse agonist of the adrenergic receptor α2A, and (3) binds to and is antagonist of the adrenergic receptor α1B and/or the adrenergic receptor α1D. It is understood and clearly conveyed herein that an adrenergic receptor α2B antagonist can exhibit any of the adrenergic receptor α2B binding profiles (in terms of % inhibition at a given concentration and/or in terms of Ki) described herein in combination with any of the adrenergic receptor α1B and/or α1D binding profiles, as if each and every combination were listed separately.
The binding properties to adrenergic receptors of compounds disclosed herein may be assessed by methods known in the art, such as competitive binding assays. In one variation, compounds are assessed by the binding assays detailed herein. In one variation, inhibition of binding of a ligand to a receptor is measured by the assays described herein. In another variation, inhibition of binding of a ligand is measured in an assay known in the art.
Functional Assay Profile
Antagonist activity to the adrenergic receptor α2B receptor may be assessed by methods known in the art, such as standard α2B receptor cell membrane-based or intact cell-based activity assays. For example, the GTPγS binding or Aequorin-based assays may be used. In one variation, the selective adrenergic receptor α2B antagonists exhibit an IC50 value equal to or less than about any one of 100 nM, 30 nM or 10 nM at a given concentration of agonist (e.g., concentration corresponding to EC80 of oxymetazoline (for Aequorin assay) or guanfacine (for GTPγS assay)) in an α2B antagonist assay. In one variation, a selective adrenergic receptor α2B antagonist exhibits an IC50 value in an α2B antagonist assay equal to or less than about 10 nM at a given concentration of agonist (e.g., concentration corresponding to EC80 of oxymetazoline (for Aequorin assay) or guanfacine (for GTPγS assay)) in an α2B antagonist assay. In one variation, a selective adrenergic receptor α2B antagonist exhibits an IC50 value in an α2B antagonist assay equal to or less than about any one of 100 nM, 30 nM or 10 nM at a concentration of oxymetazoline corresponding to its EC80 concentration as obtained by assay protocols described herein. In one variation, a selective adrenergic receptor α2B antagonist exhibits an IC50 value in an α2B antagonist assay equal to or less than about any one of 100 nM, 30 nM or 10 nM at a concentration of oxymetazoline between about 50 nM and about 5000 nM. In one variation, a selective adrenergic receptor α2B antagonist exhibits an IC50 value in an α2B antagonist assay equal to or less than about any one of 100 nM, 30 nM or 10 nM at a concentration of about 480 nM oxymetazoline. In one variation, a selective adrenergic receptor α2B antagonist exhibits an IC50 value in an α2B antagonist assay equal to or less than about any one of 100 nM, 30 nM or 10 nM at a concentration of guanfacine between about 50 nM and about 5000 nM. In one variation, a selective adrenergic receptor α2B antagonist exhibits an IC50 value in an α2B antagonist assay equal to or less than about any one of 100 nM, 30 nM or 10 nM at a concentration of about 500 nM guanfacine, which in a particular variation is 504 nM guanfacine.
The absence of antagonist activity to the adrenergic receptor α2A may be assessed by methods known in the art, such as standard α2A receptor intact cell-based activity assays. For example, the Aequorin-based assay may be used. It is understood and clearly conveyed that absence of antagonist activity to the adrenergic receptor α2A intends activity that is sufficiently reduced, but not necessarily eliminated or undetectable, at the adrenergic receptor α2A. In one variation, a compound will exhibit an undetectable amount of antagonist activity to the adrenergic receptor α2A. In another variation, a compound will lack antagonist activity to the adrenergic receptor α2A if it exhibits an IC50 value in an α2A antagonist assay that is greater than about any one of 50 nM, 100 nM or 200 nM at a given concentration of agonist (e.g., concentration corresponding to EC80 of UK14304). In one variation, the adrenergic receptor α2A exhibits an IC50 value in an α2A antagonist assay that is greater than about 200 nM at a given concentration of agonist (e.g., concentration corresponding to EC80 of UK14304). In one variation, a selective adrenergic receptor α2B antagonist exhibits an IC50 value in an α2A antagonist assay greater than about any one of 50 nM, 100 nM or 200 nM at a concentration of UK14304 corresponding to its EC80 concentration as obtained by assay protocols described herein. In one variation, a selective adrenergic receptor α2B antagonist exhibits an IC50 value in an α2A antagonist assay greater than about any one of 50 nM, 100 nM or 200 nM at a concentration of UK14304 between about 0.4 nM and about 40 nM. In one variation, a selective adrenergic receptor α2B antagonists exhibits an IC50 value in an α2A antagonist assay greater than about any one of 50 nM, 100 nM or 200 nM at a concentration of about 5 nM UK14304, which in a particular variation is 4.57 nM UK14304. Alternatively, a compound that does not bind the α2A receptor will be neither an agonist nor antagonist of the α2A receptor.
In some variations, regardless of IC50 values obtained from α2B and α2A assays, a compound may nonetheless be a selective adrenergic receptor α2B antagonist if it exhibits a Ki ratio of α2A to α2B that is higher than about any one of 5, 10, or 15. For example, where a compound exhibits an IC50 value between about 50-100 nM in an α2B antagonist assay at a given concentration of agonist (e.g., concentration corresponding to EC80 of oxymetazoline) and an IC50 value between about 50 and 100 nM in an α2A antagonist assay at a given concentration of agonist (e.g., concentration corresponding to EC80 of UK14304), the compound is considered, in one variation, a selective adrenergic receptor α2B antagonist if it exhibits a Ki ratio of α2A to α2B higher than about any one of 5, 10, or 15.
Antagonist activity to adrenergic receptor α1B may be assessed by methods known in the art, such as standard α1B receptor intact cell-based activity assays, including the Aequorin-based assay. In one variation, a selective adrenergic receptor α2B antagonist will also antagonize the adrenergic receptor α1B and exhibit an IC50 value equal to or less than about any one of 100 nM or 30 nM or 10 nM at a given concentration of agonist (e.g., concentration corresponding to EC80 of cirazoline) in an adrenergic receptor α1B antagonist assay. In one variation, a selective adrenergic receptor α2B antagonist will also antagonize the adrenergic receptor α1B and exhibit an IC50 value equal or less than about 10 nM at a given concentration of agonist (e.g., concentration corresponding to EC80 of cirazoline) in an adrenergic receptor α1B antagonist assay. In one variation, the selective adrenergic receptor α2B antagonists exhibit an IC50 value in an α1B antagonist assay equal to or less than about any one of 100 nM, 30 nM or 10 nM at a concentration of cirazoline corresponding to its EC80 concentration as obtained by assay protocols described herein. In one variation, the selective adrenergic receptor α2B antagonists exhibit an IC50 value in an α1B antagonist assay equal to or less than about any one of 100 nM, 30 nM or 10 nM at a concentration of cirazoline between about 2.3 nM and about 230 nM. In one variation, the selective adrenergic receptor α2B antagonists exhibit an IC50 value in an α1B antagonist assay equal to or less than about any one of 100 nM, 30 nM or 10 nM at a concentration of about 25 nM cirazoline, which in a particular variation is 23.56 nM cirazoline.
Antagonist activity to adrenergic receptor α1D may be assessed by methods known in the art, such as standard α1D receptor intact cell-based activity assays, including the Aequorin-based assay. In one variation, a selective adrenergic receptor α2B antagonist will also antagonize the adrenergic receptor α1D and exhibit an IC50 value equal to or less than about any one of 100 nM or 30 nM or 10 nM at a given concentration of agonist (e.g., concentration corresponding to EC80 of cirazoline) in an adrenergic receptor α1D antagonist assay. In one variation, a selective adrenergic receptor α2B antagonist will also antagonize the adrenergic receptor α1D and exhibit an IC50 value equal or less than about 10 nM at a given concentration of agonist (e.g., concentration corresponding to EC80 of cirazoline) in an adrenergic receptor α1D antagonist assay. In one variation, the selective adrenergic receptor α2B antagonists exhibit an IC50 value in an α1D antagonist assay equal to or less than about any one of 100 nM, 30 nM or 10 nM at a concentration of cirazoline corresponding to its EC80 concentration as obtained by assay protocols described herein. In one variation, the selective adrenergic receptor α2B antagonists exhibit an IC50 value in an α1D antagonist assay equal to or less than about any one of 100 nM, 30 nM or 10 nM at a concentration of cirazoline between about 2.3 nM and about 230 nM. In one variation, the selective adrenergic receptor α2B antagonists exhibit an IC50 value in an α1D antagonist assay equal to or less than about any one of 100 nM, 30 nM or 10 nM at a concentration of about 25 nM cirazoline, which in a particular variation is 23.56 nM cirazoline.
In one variation, the selective adrenergic receptor α2B antagonists exhibit (i) equal to or greater than about 60% inhibition of α2B ligand binding at 0.03 μM and an IC50 value in an α2B antagonist assay equal to or less than about any one of 100 nM, 30 nM or 10 nM at a given concentration of agonist (e.g., concentration corresponding to EC80 of oxymetazoline (for Aequorin assay) or guanfacine (for GTPγS assay)), and (ii) equal to or less than about 30% inhibition of α2A ligand binding at 0.1 μM and an IC50 value in an α2A antagonist assay that is greater than about any one of 50 nM, 100 nM or 200 nM at a given concentration of agonist (e.g., concentration corresponding to EC80 of UK14304). In some variations, the selective adrenergic receptor α2B antagonists exhibit (i) equal to or greater than about 60% inhibition of α2B ligand binding at 0.03 μM and an IC50 value in an α2B antagonist assay equal to or less than about any one of 100 nM, 30 nM or 10 nM at a given concentration of agonist (e.g., concentration corresponding to EC80 of oxymetazoline (for Aequorin assay) or guanfacine (for GTPγS assay)), and (ii) equal to or less than about 30% inhibition of α2A ligand binding at 0.1 μM and an IC50 value in an α2A antagonist assay that is greater than about any one of 50 nM, 100 nM or 200 nM at a given concentration of agonist (e.g., concentration corresponding to EC80 of UK14304), and (iii) equal to or greater than about 60% inhibition of α1B ligand binding at 0.03 μM and an IC50 value in an α1B antagonist assay equal or less than about any one of 100 nM or 30 nM or 10 nM at a given concentration of agonist (e.g., concentration corresponding to EC80 of cirazoline). In some variations, the selective adrenergic receptor α2B antagonists exhibit (i) equal to or greater than about 60% inhibition of α2B ligand binding at 0.03 μM and an IC50 value in an α2B antagonist assay equal to or less than about any one of 100 nM, 30 nM or 10 nM at a given concentration of agonist (e.g., concentration corresponding to EC80 of oxymetazoline (for Aequorin assay) or guanfacine (for GTPγS assay)), and (ii) equal to or less than about 30% inhibition of α2A ligand binding at 0.1 μM and an IC50 value in an α2A antagonist assay that is greater than about any one of 50 nM, 100 nM or 200 nM at a given concentration of agonist (e.g., concentration corresponding to EC80 of UK14304), and (iii) equal to or greater than about 60% inhibition of α1D ligand binding at 0.03 μM and an IC50 value in an α1D antagonist assay equal or less than about any one of 100 nM or 30 nM or 10 nM at a given concentration of agonist (e.g., concentration corresponding to EC80 of cirazoline). In some variations, the selective adrenergic receptor α2B antagonists exhibit (i) equal to or greater than about 60% inhibition of α2B ligand binding at 0.03 μM and an IC50 value in an α2B antagonist assay equal to or less than about any one of 100 nM, 30 nM or 10 nM at a given concentration of agonist (e.g., concentration corresponding to EC80 of oxymetazoline (for Aequorin assay) or guanfacine (for GTPγS assay)), and (ii) equal to or less than about 30% inhibition of α2A ligand binding at 0.1 μM and an IC50 value in an α2A antagonist assay that is greater than about any one of 50 nM, 100 nM or 200 nM at a given concentration of agonist (e.g., concentration corresponding to EC80 of UK14304), (iii) equal to or greater than about 60% inhibition of α1B ligand binding at 0.03 μM and an IC50 value in an α1B antagonist assay equal or less than about any one of 100 nM or 30 nM or 10 nM at a given concentration of agonist (e.g., concentration corresponding to EC80 of cirazoline); and (iv) equal to or greater than about 60% inhibition of α1D ligand binding at 0.03 μM and an IC50 value in an α1D antagonist assay equal or less than about any one of 100 nM or 30 nM or 10 nM at a given concentration of agonist (e.g., concentration corresponding to EC80 of cirazoline).
In another variation, the selective adrenergic receptor α2B antagonists exhibit (i) equal to or greater than about 60% inhibition of α2B ligand binding at 0.03 μM and an IC50 value in an α2B antagonist assay equal to or less than any about one of 100 nM, 30 nM or 10 nM at a given concentration of agonist (e.g., concentration corresponding to EC80 of oxymetazoline (for Aequorin assay) or guanfacine (for GTPγS assay)), and (ii) binding to and agonist activity to adrenergic receptor α2A.
In another variation, the adrenergic receptor α2B antagonists exhibit (i) equal to or greater than about 60% inhibition of α2B ligand binding at 0.03 μM and an IC50 value in an α2B antagonist assay equal to or less than any about one of 100 nM, 30 nM or 10 nM at a given concentration of agonist (e.g., concentration corresponding to EC80 of oxymetazoline (for Aequorin assay) or guanfacine (for GTPγS assay)), and (ii) greater than or equal to about 30% inhibition of α2A ligand binding at 0.1 μM and IC50 value in an adrenergic receptor α2A antagonist assay equal to or less than about any one of 100 nM, 30 nM or 10 nM at a concentration of UK14304 (for Aequorin assay) corresponding to its EC80 concentration obtained by assay protocols described herein.
It is understood and clearly conveyed herein that compounds provided herein, including selective adrenergic receptor α2B antagonists provided herein can exhibit any of the binding profiles and any of the antagonist or agonist activity profiles detailed herein, the same as if each and every combination were individually listed. For example, in one variation, the selective adrenergic receptor α2B antagonists exhibit (i) greater than about 65% inhibition of α2B ligand binding at 0.03 μM and an IC50 value in an α2B antagonist assay equal to or less than about 10 nM at a concentration of oxymetazoline corresponding to its EC80 concentration as obtained by assay protocols described herein, and (ii) less than about 25% inhibition of α2A ligand binding at 0.1 μM and an IC50 value in an α2A antagonist assay that is greater than 200 nM at a concentration of UK14304 corresponding to its EC80 concentration as obtained by assay protocols described herein, and (iii) equal to or greater than about 60% inhibition of α1B ligand binding at 0.03 μM and an IC50 value in an α1B antagonist assay equal or less than 10 nM at a concentration of cirazoline corresponding to its EC80 concentration as obtained by assay protocols described herein. In one aspect, such a compound will also exhibit a Ki ratio of α2A to α2B that is greater than about any one of 5 or 15 or 50.
Medical Use
Without being bound by theory, it is believed that the compounds provided herein are capable of (i) reducing blood pressure and/or (ii) promoting renal blood flow and/or (iii) decreasing or inhibiting sodium reabsorption. In some embodiments, the compounds are adrenergic receptor α2B antagonists (e.g., selective adrenergic receptor α2B antagonists). In some embodiments, it is believed that the selective adrenergic receptor α2B antagonists provided herein are capable of (i) reducing blood pressure and/or (ii) promoting renal blood flow and/or (iii) decreasing or inhibiting sodium reabsorption without concomitantly antagonizing the α2A receptor, which would reduce or potentially eliminate the beneficial blood pressure lowering and renal effects modulated by antagonizing α2B. Furthermore, the selective adrenergic receptor α2B antagonists provided herein may be capable of decreasing blood pressure sensitivity to salt, decreasing sodium retention, decreasing vasoconstriction in small arteries and veins, increasing insulin secretion, increasing basal metabolic rate, decreasing platelet aggregation and/or enhancing mitochondrial function. However, in certain cases where the compound has strong antagonist activities against adrenergic receptor α2B and/or adrenergic receptor α1B, some antagonist activity against adrenergic receptor α2A may be tolerated and even beneficial.
Compounds provided herein may be capable of mediating control of the renal function. Adrenergic α2B receptors are located within the kidney. Regard et al. (Cell 2008; 135:561) have demonstrated that the gene for the adrenergic α2B receptor is most abundantly expressed in the kidney. Meister et al. (J. Pharmacol. Exp. Therapeutics 1994; 268:1605) have shown by in situ hypbridization that expression predominates in the medulla outer stripe with extensions into the cortical S3 segment of the proximal tubules. Adrenergic α2B receptor antagonists provided herein may be capable of disrupting sodium reabsorption resulting in natriuresis and diuresis. Methods to determine effects of adrenergic α2B antagonists on renal function in a rabbit model of hypertension have been described by Burke et al. (J Hypertens 29:945-952).
In addition to reducing blood pressure, compounds disclosed herein, including adrenergic α2B antagonists, are capable of a reduction in blood volume that might result from diueresis and/or the movement of fluid from the vascular space to the extravascular space. Reduction of blood volume results in increase in hematocrit levels which can be measured by methods known in the art, for example, by estimation of erythrocyte volume fraction. Characterization of the effect of α2B antagonists on renal function are determined by measuring urine volume, urine sodium and urine potassium using methods described by Burke et al. (Effects of chronic sympatho-inhibition on renal excretory function in renovascular hypertension Sandra L. Burke, Roger G. Evans and Geoffrey A. Head. Journal of Hypertens 29:945-952 (2011).
The compounds detailed herein are expected to find use in therapy, particularly in cardiac and renal diseases and conditions, in addition to hypertension and other conditions in which a (i) reduction in blood pressure and/or (ii) increase in renal blood flow and/or (iii) decrease in sodium reabsorption would be beneficial. In the methods provided herein, an effective amount of a compound detailed herein is administered to an individual. Methods of using compounds as described herein to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption in an individual in need thereof are provided. The compounds may also find use in treating a disease or condition that is, or is expected to be, responsive to (i) a reduction in an individual's blood pressure and/or (ii) an increase in renal blood flow and/or (iii) a decrease or inhibition of sodium reabsorption. The individual may be a human who has been diagnosed with or is suspected of having high blood pressure or a disease or condition that is, or is expected to be, responsive to (i) a reduction in an individual's blood pressure and/or (ii) an increase in renal blood flow and/or (iii) a decrease or inhibition of sodium reabsorption. The individual may be a human who exhibits one or more symptoms associated with high blood pressure or a disease or condition that is, or is expected to be, responsive to (i) a reduction in an individual's blood pressure and/or (ii) an increase in renal blood flow and/or (iii) a decrease or inhibition of sodium reabsorption. The individual may be a human who is genetically or otherwise predisposed to developing high blood pressure or a disease or condition that is, or is expected to be, responsive to (i) a reduction in an individual's blood pressure and/or (ii) an increase in renal blood flow and/or (iii) a decrease or inhibition of sodium reabsorption. In one variation, the compounds may find use in treating metabolic syndrome. In some embodiments, the compounds are adrenergic receptor α2B antagonists. In one variation, the adrenergic receptor α2B antagonists are selective adrenergic receptor α2B antagonists. In one variation, a compound that is an adrenergic receptor α2B antagonist also showing adrenergic receptor α2A antagonist and/or inverse agonist activity may find use reducing blood pressure in an individual with hypertension who is also suffering from obesity, type-2 diabetes and/or metabolic syndrome. Thus, provided is a method for lowering blood pressure in hypertensive patients with a disease or condition that is responsive to treatment using an antagonist or inverse agonist of adrenergic receptor α2A, such as obesity and/or type-2 diabetes and/or metabolic syndrome.
Compounds detailed herein may be used in a method of treating a disease or condition that is responsive to (i) a reduction in an individual's blood pressure and/or (ii) an increase in renal blood flow and/or (iii) a decrease or inhibition of sodium reabsorption. For example, the compounds may find use in treating hypertension, including treatment-resistant hypertension. In some embodiments, the compounds may be used in a method of treating hypertension in an individual not suffering from obesity or type-2 diabetes. In some embodiments, the compounds are adrenergic receptor α2B antagonists. In some embodiments, the compounds are selective adrenergic receptor α2B antagonists.
In one aspect, the disease or indication is a cardiac or renal disease or indication for which (i) a reduction in an individual's blood pressure and/or (ii) an increase in renal blood flow and/or (iii) a decrease or inhibition of sodium reabsorption would be, or would be expected to be, beneficial. Such cardiac indications include, but are not limited to, heart failure, such as compensated heart failure, decompensated heart failure, acute decompensated congestive heart failure and chronic congestive heart failure, coronary heart disease, cardiac arrhythmias, myocardial ischemia, and hypertrophy. Such renal indications include, but are not limited to, renal failure such as chronic renal failure, acute renal failure and endstage renal failure, renal ischemia and chronic kidney disease. Other indications for which (i) a reduction in an individual's blood pressure and/or (ii) an increase in renal blood flow and/or (iii) a decrease or inhibition of sodium reabsorption would be, or would be expected to be, beneficial include but are not limited to sleep apnea and ischemic attacks.
Compounds detailed herein may also ameliorate symptoms of a disease or condition that have a cardiac or renal component in which (i) a reduction in an individual's blood pressure and/or (ii) an increase in renal blood flow and/or (iii) a decrease or inhibition of sodium reabsorption would be, or would be expected to be, beneficial. For example, the compounds may reduce elevated blood pressure, improve shortness of breath, reduce tachycardia, reduce edema, reduce elevated blood urea nitrogen to creatinine (BUN/Cr) ratio, improve creatinine levels, improve the ability to lie flat, reduce the incidence or severity of high blood pressure, reduce the risk and/or number of acute cardiac events (e.g., acute decompensation or myocardial infarction) an individual experiences over a period of time (e.g., one year, 2 years, 5 years, etc.), reduce the incidence of acute heart failure an individual experiences over a period of time (e.g., one year, 2 years, 5 years, etc.), reduce the severity and/or incidence of pulmonary congestion and/or reduce the risk of stroke, reduce shortness of breath and/or tachycardia in individuals after myocardial infarction, improve left ventricular ejection fraction (LVEF) post infarct and/or lower weight and blood pressure in obese individuals (e.g., men and women) with pre-hypertension. In some embodiments, the compounds are adrenergic receptor α2B antagonists. In some embodiments, the compounds are selective adrenergic receptor α2B antagonists.
Compounds detailed herein (such as the adrenergic receptor α2B antagonists detailed herein) may find use in the treatment of hypertensive emergencies. Provided is a method of treating hypertensive emergencies, comprising administering intravenously an effective amount of an adrenergic receptor α2B antagonist to an individual in need thereof. In some embodiments, the method comprises administering intravenously an effective amount of an adrenergic receptor α2B antagonist to an individual in need thereof in a highly monitored intensive care setting, wherein the administration results in aggressive and controlled blood pressure lowering in the individual. In some embodiments, intravenous administration of an adrenergic receptor α2B antagonist in an individual results in gradually lowering of blood pressure in the individual and minimizing damage of end organs such as the brain, kidney, heart, and eye. Particularly useful in the treatment of hypertensive emergencies or crisis are parenteral formulations of an adrenergic receptor α2B antagonist detailed herein. In one variation, the compound is an adrenergic receptor α2B antagonist. In some variations, the compound is a selective adrenergic receptor α2B antagonist. In one variation, the adrenergic receptor α2B antagonist also exhibits adrenergic receptor α2A antagonist and/or inverse agonist activity.
In one variation, a method of decreasing the severity and/or incidence of shortness of breath, tachycardia, edema, and/or the inability to lie flat is provided, comprising administering an effective amount of a compound detailed herein to an individual who has or is suspected of having heart failure (e.g., compensated heart failure and decompensated heart failure). In another variation, a method of decreasing the severity and/or incidence of elevated BUN/Cr, and/or edema is provided comprising administering an effective amount of a compound detailed herein to an individual who has or is suspected of having renal failure (e.g., acute or chronic renal failure). In another variation, a method of reducing blood pressure in an individual is provided comprising administering an effective amount of a compound detailed herein to an individual who has or is suspected of having hypertension (e.g., treatment-resistant hypertension). In another variation, a method of decreasing the severity and/or incidence of shortness of breath, tachycardia, and/or improving LVEF post infarct in an individual is provided comprising administering an effective amount of a compound detailed herein to an individual who has experienced myocardial infarction (e.g., an individual who has recently experienced myocardial infarction such as within 30 minutes, 1, 3, 6, 12, or 24 hours of treatment). In some of the variations, the adrenergic receptor α2B antagonist is a selective adrenergic receptor α2B antagonist. In some of the variations, the adrenergic receptor α2B antagonist also exhibits antagonist activity for the adrenergic receptor α2A. In some embodiments, the compounds are adrenergic receptor α2B antagonists. In some embodiments, the compounds are selective adrenergic receptor α2B antagonists.
In one variation, provided is method for lowering the blood pressure in an individual in need thereof comprising administering to the individual a compound described herein, or a pharmaceutically acceptable salt thereof. Administration of an adrenergic receptor α2B antagonist detailed herein lowers the blood pressure in the individual from a level considered above the desired level for such individual. The blood pressure lowering therapy such as administration of compounds detailed herein is intended to help hypertensive individuals reach their blood pressure goals defined by their individual cardiovascular risk factors. For example, for otherwise healthy individuals without diabetes or known cardiovascular disease, goal blood pressure is less than about 140/90 mmHg; for patients with known cardiovascular disease (e.g., prior myocardial infarction, peripheral vascular disease) goal blood pressure is less than about 130-135/85 mmHg; for patients with diabetes, goal blood pressure is less than about 130/80 mmHg.
In one variation, compounds provided herein may have any one or more of the following beneficial effects on an individual: (1) reduce arterial blood pressure (e.g., in an individual with hypertension, certain forms of heart failure and/or renal failure); (2) reduce pulse pressure (e.g., in an individual with hypertension, certain forms of heart failure and/or renal failure); (3) tachycardia-preserved baroreceptor activity (e.g., in an individual whose systolic blood pressure is expected to or does fall in response to an α2B antagonist), which may suggest a lack of orthostatic hypotension; and (4) bradycardia-reduced cardiac work load and added reduction on blood pressure reduction by further reducing cardiac output (e.g., in an individual who has been administered a therapy that is an α2B and α1B mixed antagonist).
In another variation, compounds provided herein may exert their therapeutic effect with no or reduced side-effects, such as when compared to other therapies used in the treatment of the same or similar indication. In one aspect, compounds provided herein exhibit no or reduced side effects upon administration to an individual, wherein the side effects may be any one or more of: (i) reduced libido, (ii) orthostatic hypotension, (iii) muscle weakness, (iv) fatigue, (v) erectile dysfunction, (vi) constipation, (vii) depression, (viii) dizziness, (ix) dry mouth, (x) impaired thinking, (xi) weight gain, (xii) persistent cough, (xiii) chest pain, (xiv) headache, (xv) fluid retention, (xvi) racing pulse, and (xvii) emesis.
In one aspect, compounds are provided that do not bind appreciably any one or more of the histamine, dopamine and serotonin receptors. In any of the methods detailed herein, in one variation the individual does not have a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or neuronal disorder. As used herein, the term “cognitive disorders” refers to and intends diseases and conditions that are believed to involve or be associated with or do involve or are associated with progressive loss of structure and/or function of neurons, including death of neurons, and where a central feature of the disorder may be the impairment of cognition (e.g., memory, attention, perception and/or thinking). These disorders include pathogen-induced cognitive dysfunction, e.g., HIV associated cognitive dysfunction and Lyme disease associated cognitive dysfunction. Examples of cognitive disorders include Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, schizophrenia, amyotrophic lateral sclerosis (ALS), autism, mild cognitive impairment (MCI), stroke, traumatic brain injury (TBI) and age-associated memory impairment (AAMI). As used herein, the term “psychotic disorders” refers to and intends mental diseases or conditions that are believed to cause or do cause abnormal thinking and perceptions. Psychotic disorders are characterized by a loss of reality which may be accompanied by delusions, hallucinations (perceptions in a conscious and awake state in the absence of external stimuli which have qualities of real perception, in that they are vivid, substantial, and located in external objective space), personality changes and/or disorganized thinking. Other common symptoms include unusual or bizarre behavior, as well as difficulty with social interaction and impairment in carrying out the activities of daily living. Exemplary psychotic disorders are schizophrenia, bipolar disorders, psychosis, anxiety and depression. As used herein, the term “neurotransmitter-mediated disorders” refers to and intends diseases or conditions that are believed to involve or be associated with or do involve or are associated with abnormal levels of neurotransmitters such as histamine, serotonin, dopamine, norepinephrine or impaired function of aminergic G protein-coupled receptors. Exemplary neurotransmitter-mediated disorders include spinal cord injury, diabetic neuropathy, allergic diseases and diseases involving geroprotective activity such as age-associated hair loss (alopecia), age-associated weight loss and age-associated vision disturbances (cataracts). Abnormal neurotransmitter levels are associated with a wide variety of diseases and conditions including, but not limited, to Alzheimer's disease, Parkinson's Disease, autism, Guillain-Barré syndrome, mild cognitive impairment, schizophrenia, anxiety, multiple sclerosis, stroke, traumatic brain injury, spinal cord injury, diabetic neuropathy, fibromyalgia, bipolar disorders, psychosis, depression and a variety of allergic diseases. As used herein, the term “neuronal disorders” refers to and intends diseases or conditions that are believed to involve, or be associated with, or do involve or are associated with neuronal cell death and/or impaired neuronal function or decreased neuronal function. Exemplary neuronal indications include neurodegenerative diseases and disorders such as Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, canine cognitive dysfunction syndrome (CCDS), Lewy body disease, Menkes disease, Wilson disease, Creutzfeldt-Jakob disease, Fahr disease, an acute or chronic disorder involving cerebral circulation, such as ischemic or hemorrhagic stroke or other cerebral hemorrhagic insult, age-associated memory impairment (AAMI), mild cognitive impairment (MCI), injury-related mild cognitive impairment (MCI), post-concussion syndrome, post-traumatic stress disorder, adjuvant chemotherapy, traumatic brain injury (TBI), neuronal death mediated ocular disorder, macular degeneration, age-related macular degeneration, autism, including autism spectrum disorder, Asperger syndrome, and Rett syndrome, an avulsion injury, a spinal cord injury, myasthenia gravis, Guillain-Barré syndrome, multiple sclerosis, diabetic neuropathy, fibromyalgia, neuropathy associated with spinal cord injury, schizophrenia, bipolar disorder, psychosis, anxiety or depression.
Individuals who have high blood pressure, or a disease or condition that is, or is expected to be, responsive to (i) a reduction in an individual's blood pressure and/or (ii) an increase in renal blood flow and/or (iii) a decrease or inhibition of sodium reabsorption may benefit from the compounds detailed herein, including the adrenergic receptor α2B antagonists (e.g., the selective adrenergic receptor α2B antagonist) detailed herein.
An individual who does not have high blood pressure or a disease or condition that is, or is expected to be, responsive to (i) a reduction in an individual's blood pressure and/or (ii) an increase in renal blood flow and/or (iii) a decrease or inhibition of sodium reabsorption may nevertheless benefit from the compounds detailed herein if the individual has one or more risk factors for high blood pressure, or a disease or condition that is, or is expected to be, responsive to (i) a reduction in an individual's blood pressure and/or (ii) an increase in renal blood flow and/or (iii) a decrease or inhibition of sodium reabsorption. Risk factors for developing high blood pressure may include gender, race, ethnicity, age, family history, weight and/or lifestyle. For example, African-Americans, men (particularly if over age 45), woman over age 55, anyone over age 60, pre-hypertension individuals (individuals with a blood pressure of 120-130/80-89 mmHg), individuals who are overweight or obese, individuals with sleep apnea (such as obstructive sleep apnea), individuals who smoke, individuals who have a high salt diet, individuals who have a low potassium diet, individuals with chronic heavy alcohol use, individuals with a sedentary lifestyle, individuals with moderate to high stress, individuals with compromised renal function or renal failure and individuals with close relatives who have high blood pressure are each at an increased risk of developing high blood pressure themselves, or diseases or conditions associated with high blood pressure. Individuals with more than one such risk factor are particularly susceptible to developing high blood pressure. Risk factors for developing kidney disease may include diabetes, high blood pressure (hypertension), cardiovascular diseases, smoking, obesity, high cholesterol, a family history of kidney disease, and/or age 65 or older. Members of certain ethnic groups are also at higher risk for kidney disease including people of Aboriginal, Asian, south Asian, Pacific Island, African/Caribbean, American Indian and Hispanic origin.
Cell Viability and Mitochondrial Health
Methods of promoting cellular viability by promoting mitochondrial health are provided, the methods comprising contacting the cell with a compound detailed herein. The methods are applicable to various cells, such as neuronal and non-neuronal cells. In one variation, the cell is a non-neuronal cell, such as a renal or cardiac cell (e.g., myocardial muscle cell). In one aspect, methods of promoting cellular viability are provided wherein the cell is one whose viability would be, or would be expected to be, promoted by nutrient influx and/or oxygenation. Methods of promoting cellular viability in a cell experiencing, or exhibiting symptoms of, mitochondrial stress are also provided.
Methods of treating a disease or condition that is, or is expected to be, responsive to promoting mitochondrial health and cell viability are also described, the methods comprising administering to an individual in need thereof an effective amount of a compound provided herein. In one variation, the disease or condition is one which is associated with dysfunction of mitochondria in a non-neuronal cell. In a particular variation, the disease or condition is one which is associated with dysfunction of mitochondria in a renal or cardiac cell (e.g., myocardial muscle cell). In another variation, the disease or condition is one which would benefit from cellular (e.g., renal or cardiac) nutrient influx and/or oxygenation.
Thus, individuals who have a disease or condition that is associated with, or believed to be associated with, mitochondrial dysfunction may benefit from the compounds detailed herein, or pharmaceutically acceptable salts thereof. An individual who has a disease or condition that is associated with mitochondrial dysfunction should experience one or more beneficial or desirable results upon administration of an effective amount of a compound provided herein, or pharmaceutically acceptable salt thereof. In one aspect, the beneficial or desirable result is an increase in nutrient influx and/or oxygenation of a cell. In another aspect, the beneficial or desirable result is a reduction in the number and/or severity of symptoms associated with a disease or condition that is associated with mitochondrial dysfunction.
In one variation, a method of treating a renal or cardiac condition is provided, comprising administering to an individual in need thereof a compound as detailed herein. Such conditions include, but are not limited to, renal failure, such as acute renal failure and chronic renal failure, coronary (e.g., myocardial) ischemia, heart failure, such as acute and chronic congestive heart failure (including the muscle fatigue associated with these conditions), and coronary artery disease. Methods of treating other diseases and conditions are also described, such as methods of treating sleep apnea, acute respiratory distress syndrome (adult and infant) and peripheral vascular disease. The compounds as provided herein may also be used in a method of delaying the onset and/or development of a disease or condition associated with mitochondrial dysfunction, comprising administering a compound as provided herein, or a pharmaceutical salt thereof, to an individual who is at risk of developing a disease or condition associated with mitochondrial dysfunction.
Compounds that do not bind appreciably to neurotransmitter receptors but nevertheless enhance mitochondrial function, e.g., when administered to cells in the setting of mitochondrial stress (e.g., excess intracellular calcium), may be used in the methods herein to promote cell survival. In one aspect, the compounds exhibit the ability to enhance mitochondrial function by protecting against cell death mediated by mitochondrial dysfunction in an assay detailed herein. Thus, it is understood and clearly conveyed that enhancing mitochondrial function includes protecting a cell against cell death mediated by mitochondrial dysfunction. The compounds may also be assessed in assays known in the art.
It is understood and clearly conveyed that the binding and activity profiles detailed herein (e.g., in the disclosure above) in one variation apply to the formulae provided herein (e.g., the formulae for use in the methods). In one aspect, selective adrenergic receptor α2B antagonists are of the formula (I), (A-I), (A-IIA), (A-IIB), (A-IIC), (A-IID), (A-IIA-1), (A-IIB-1), (A-IIC-1), (A-IID-1), (A-III), (A-IIIA), (A-IIIB), (A-IIIC), (A-IIID), (A-IIIE), (A-IIIE-1), (A-IIIE-2), (A-IIIE-3), (A-IIIE-4), (A-IIIE-5), (A-IIIE-6), (A-IIIE-7), (A-IIIE-8), (A-IIIF), (A-IIIF-1), (A-IIIF-2), (A-IIIF-3), (A-IIIF-4), (A-IIIG-1), (A-IIIG-2), (A-IIIG-3), (A-IIIH), (A-IIIH-1), (A-IIIH-2), (A-IIIH-3), (A-IIIH-4), (A-IIIA′), (A-IV), (A-V), (A-VI), (A-VIIA), (A-VIIB), (A-VIIC), (A-VIID), (A-VIIE), (A-VIIF), (A-VIIIA-1), (A-VIIIA-2), (A-VIIIA-3), (A-VIIIA-4), (A-VIIIA-5), (A-VIIIA-6), (A-VIIIA-7), (A-IXA), (A-IXB), (A-IXC), (A-IXD), (B-I), (B-IA), (B-IB), (B-IC), (B-ID), (C-I), (C-IA), (C-IB), (C-IA-1), (C-IA-2), (C-IA-3), (C-IA-4), (C-IA-5), (C-IA-6), (C-IA-7), (C-IB), (C-IB-1), (C-IB-2), (C-IB-3), (C-IC-1), (C-II), (C-IIA), (C-IIB), (C-IIIA), (C-IIIB), (C-IIIC), (C-IIID), (CIII-E), (C-IIIF), (C-IVA), (C-IVB), (C-IVC), (C-IVD), (C-IVE), (C-IVF), (C-IVG), (C-VA), (C-VB), (D-I), (D-IIA), (D-IIB), (D-IIA-1), (D-IIA-2), (D-IIIA), (D-IIIB), (E-I), (E-IIA), (E-IIB), (F-I), (F-IIA), (F-IIB), (F-IIA-1), (F-IIA-2), (G-I), (G-IIA), (G-IIB), (G-IIA-1), (G-IIA-2), (H-IA), (H-IB), (H-IC), (H-ID), (H-IA-1), (H-IB-1), (H-IC-1), (H-ID-1), (H-IE-1), (H-IF-1), (J), (J-IA), (J-IB), (J-IC), (J-ID), (J-IA-1), (J-IB-1), (J-IC-1), (J-ID-1), (K-IA), (K-IB), (K-IC), (K-ID), (K-IE) or (K-IF), or any variations detailed herein.
Compounds of the Invention
Compounds according to the invention are detailed herein, including in the Brief Summary of the Invention and elsewhere. The invention includes the use of all of the compounds described herein, including any and all stereoisomers, including geometric isomers (cis/trans or E/Z isomers), tautomers, salts, N-oxides, and solvates of the compounds described herein, as well as methods of making such compounds.
In one aspect, provided is a compound of formula (I):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl, SO3H, SR1a, S(O)R1a, SO2R1a and perhaloalkyl; C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; or —C(O)O—C1-C5 alkyl; or is taken together with R2a or R1a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R4a or R5a, where present, to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety;
R1a is H or optionally substituted C1-C5 alkyl;
R2a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R1 or R5a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R3a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R4a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R3a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R1 or R4a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R2a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R5a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R4a, where present, is H; halo; hydroxyl; cyano; carboxyl; —OC(O)N(R14a)R15a; —C(O)N(R14a)R15a; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R2a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety; or is taken together with R5a, where present, to form a methylene (—CH2—) moiety;
R5a, where present, is H; halo; hydroxyl; cyano; carboxyl; —OC(O)N(R14a)R15a; —C(O)N(R14a)R15a; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R2a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R3a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety; or is taken together with R4a, where present, to form a methylene (—CH2—) moiety;
each R2b and R3b is independently H, optionally substituted C1-C5 alkyl, optionally substituted C2-C5 alkenyl, or optionally substituted aryl;
each R4b and R5b, where present, is independently H, halo, optionally substituted C1-C5 alkyl, optionally substituted C2-C5 alkenyl, or optionally substituted aryl;
each n and m is 1, or n is 0 and m is 1, or n is 1 and m is 0;
each X1, X2, X and U is independently N or CR6;
each R6 is independently H; hydroxyl; halo; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl; optionally substituted C1-C5 alkoxy; or optionally substituted —C(O)C1-C5 alkyl;
R7 is H; halo; optionally substituted C1-C5 alkyl; or optionally substituted aryl; or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety; or is taken together with R9 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R8 is H; halo; hydroxyl; azido; aminoacyl, carboxyl; carbonylalkoxy; N(R11)R12; SR13, S(O)R13; SO2R13; —OC(O)N(R14)R15; —C(O)N(R14)R15; optionally substituted —OC(O)-aryl; optionally substituted —OC(O)-heteroaryl; —OC(O)C1-C6 alkyl optionally substituted with amino or carboxyl; or —OC1-C5 alkyl optionally substituted with carboxyl; or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety; or is taken together with R10 to form a bond;
R9 is H or optionally substituted C1-C5 alkyl, or is taken together with R7 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R10 is H or optionally substituted C1-C5 alkyl, or is taken together with R8 to form a bond;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl, or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl; or R14 and R15 are taken together to form a C3-C5 alkylene;
each R14a, and R15a is independently H or optionally substituted C1-C5 alkyl; and
Q is optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
It should be understood that when two substituents are taken together to form a bond, an additional bond is formed. For example, as shown below, when Ry and Rw are taken together to form a bond, an additional bond is formed such that Rx and Rz is a double bond.




In some variations, one of X1, X2, X and U is N, and the other three of X1, X2, X and U are independently CR6. In other variations, two of X1, X2, X and U is N, and the other two of X1, X2, X and U are independently CR6. In yet other variations, each X1, X2, X and U is independently CR6.
In some variations, R1 is H, optionally substituted C1-C5 alkyl, or optionally substituted C3-C8 cycloalkyl, wherein the C1-C5 alkyl or the C3-C8 cycloalkyl is independently unsubstituted or substituted with hydroxyl. In some variations, R1 is unsubstituted C2-C5 alkenyl. In other variations, the C1-C5 alkyl is substituted with SO3H. In some variations, R1 is methyl, ethyl, n-propyl, or i-propyl. In some variations, R1 is CF3, or CH2CF3. In some variations R1 is H. In some variations, R1 is hydroxyethyl, hydroxypropyl, or hydroxybutyl. In some variations, R1 is cyclobutyl, or cyclopropyl. In some variations, R1 is CH2CH2—SO3H. In some variations, R1 is CH2CH═CH2.
In some variations, R4a is halo; hydroxyl; cyano; carboxyl; —OC(O)N(R14a)R15a; —C(O)N(R14a)R15a; optionally substituted C1-C5 alkyl. In some embodiments, R4a is optionally substituted C1-C5 alkyl. In other embodiments, R4a is monohaloalkyl, dihaloalkyl, or perhaloalkyl. In one embodiment, R4a is CF3, CHF2, or CH2F. In another embodiment, R4a is CCl3, CHCl2, or CH2Cl. In some variations, R4a is halo. In some variations, R4a and R4b are each halo. In certain variations, each R4a and R4b is fluoro or chloro. In one variation, each R4a and R4b is fluoro. In one variation, each R4a and R4b is chloro.
In some variations, R5a is halo; hydroxyl; cyano; carboxyl; —OC(O)N(R14a)R15a; —C(O)N(R14a)R15a; optionally substituted C1-C5 alkyl. In some embodiments, R5a is optionally substituted C1-C5 alkyl. In other embodiments, R5a is monohaloalkyl, dihaloalkyl, or perhaloalkyl. In one embodiment, R5a is CF3, CHF2, or CH2F. In another embodiment, R5a is CCl3, CHCl2, or CH2Cl. In some variations, R5a is halo. In some variations, R5a and R5b are each halo. In certain variations, each R5a and R5b is fluoro or chloro. In one variation, each R5a and R5b is fluoro. In one variation, each R5a and R5b is chloro.
In some variations, R7 is a C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, —N(R7a)(R7b), —C(O)N(R7a)(R7b), —C(O)OR7a, and —C(O)R7a. In other variations, R7 is an optionally substituted C3-C8 cycloalkyl. In some variations, R8 is hydroxyl or NH2. In some variations, R8 is —OC(O)C1-C5 alkyl optionally substituted with amino or carboxyl. In some variations, R8 is taken together with R10 to form a bond. In some variations, R9 is H or CH3. In some variations, in R10 is H or CH3. In some variations, each R9 and R10 is H. In some variations, R10 is an optionally substituted C3-C8 cycloalkyl. In other variations, R11 or R12 is an optionally substituted C3-C8 cycloalkyl.
In some variations, Q is unsubstituted aryl; unsubstituted heteroaryl; aryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl, N(R16)(R17), —C(O)OR18, SR18, S(O)R18 and SO2R18; or heteroaryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl, N(R16)(R17), —C(O)OR18, SR18, S(O)R18 and SO2R18, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl, or R16 and R17 are taken together to form C3-C5 alkylene, and wherein R18 is an optionally substituted C1-C5 alkyl.
In one embodiment of the compound of formula (I):
R1 is H; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl; C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl; or —C(O)O—C1-C5 alkyl, or is taken together with R2a or R1a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R2a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R3a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R4a is selected from the group consisting of halo, hydroxyl, cyano, carboxyl, —OC(O)N(R14a)R15a, —C(O)N(R14a)R15a, and optionally substituted C1-C5 alkyl;
each R2b and R3b is independently H;
R4b is H, halo, optionally substituted C1-C5 alkyl;
n is 0 and m is 1;
each X1, X2, and U is CH;
X is independently N or CR6a;
each R6 and R6a is independently H; hydroxyl; halo; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl; optionally substituted C1-C5 alkoxy; or optionally substituted —C(O)C1-C5 alkyl;
R7 is H; halo; optionally substituted C1-C5 alkyl; or optionally substituted aryl; or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety; or is taken together with R9 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R8 is H; halo; hydroxyl; azido; aminoacyl, carboxyl; carbonylalkoxy; N(R11)R12; SR13, S(O)R13; SO2R13; —OC(O)N(R14)R15; —C(O)N(R14)R15; optionally substituted —OC(O)-aryl; optionally substituted —OC(O)-heteroaryl; —OC(O)C1-C6 alkyl optionally substituted with amino or carboxyl; or —OC1-C5 alkyl optionally substituted with carboxyl; or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety; or is taken together with R10 to form a bond;
R9 is H or optionally substituted C1-C5 alkyl, or is taken together with R7 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R10 is H or optionally substituted C1-C5 alkyl, or is taken together with R8 to form a bond;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl, or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl; or R14 and R15 are taken together to form a C3-C5 alkylene; and
Q is cycloalkyl, aryl or heteroaryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.
In some embodiments, R4a is an optionally substituted C1-C5 alkyl. In certain embodiments, R4a is a monohaloalkyl, a dihaloalkyl, or perhaloalkyl. In some variations, R4a is halo, hydroxyl, and cyano. In some variations, R4a is halo. In some variations, R4a and R4b are each halo. In certain variations, each R4a and R4b is fluoro or chloro. In one variation, each R4a and R4b is fluoro.
In certain embodiments, with respect to the compounds of formula (I), X is CR6, R8 is —OC(O)C1-C5 alkyl substituted with carboxyl, and the compound is Compound No. 25, 54, 130, 146, 147, 338, II-15, II-16, or II-19.
In certain embodiments, with respect to the compounds of formula (I), R8 is azido, and the compound is Compound No. II-261, II-266, II-276, II-298, V-1, V-2, V-3, V-21, V-22, or V-23.
In one embodiment, the compound is of formula (A-I):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl or cycloalkyl optionally substituted with 1 to 3 halogen atoms or hydroxyl, C2-C5 alkenyl, or —C(O)OR11;
each R2a, R2b, R3a, R3b, R4a, R4b, R5a and R5b is independently H or optionally substituted C1-C5 alkyl;
each n and m is 1, or n is 0 and m is 1, or n is 1 and m is 0;
or R1 and R2a, or R1 and R3a, or R2a and R5a, or R3a and R4a, where present, are taken together to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety,
or R1 and R4a, or R1 and R5a, or R2a and R3a, where present, are taken together to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety,
or R2a and R4a, or R3a and R5a, where present, are taken together to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety,
or R4a and R5a, where present, are taken together to form a methylene (—CH2—) moiety;
X is N or CR6a;
each R6 and R6a is independently H, halogen, C1-C5 alkyl optionally substituted with 1 to 3 halogen atoms, hydroxyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
each R7, R9 and R10 is independently H or optionally substituted C1-C5 alkyl;
R8 is H, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, or —OC(O)C1-C5 alkyl optionally substituted with amino;
or R7 and R8 are taken together with the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
or R10 and R8 are taken together to form a bond;
or R9 and R7 are taken together to form an alkylene bridge of 3-5 carbon atoms when R10 and R8 are taken together to form a bond;
each R11, R12 and R13 is independently H or optionally substituted C1-C5 alkyl; and
Q is aryl or heteroaryl optionally substituted with 1 to 3 substituents including halogen, C1-C5 alkyl or cycloalkyl, halo-substituted C1-C5 alkyl or cycloalkyl, C1-C5 alkoxy or cycloalkoxy, —CN or —C(O)N(Ra)Rb where each Ra and Rb is independently H or C1-C5 alkyl.
In another embodiment, the compound is of the formula (A-IIA), (A-IIB), (A-IIC) or (A-IID):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl or cycloalkyl optionally substituted with 1 to 3 halogen atoms or hydroxyl, C2-C5 alkenyl, or —C(O)OR11;
each R2a, R3a or R5a is independently H or optionally substituted C1-C5 alkyl;
or R1 and R2a, or R1 and R3a are taken together to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
X is N or CR6a;
each R6 and R6a is independently H, halogen, C1-C5 alkyl optionally substituted with 1 to 3 halogen atoms, hydroxyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
each R7, R9 and R10 is independently H or optionally substituted C1-C5 alkyl;
R8 is H, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, or —OC(O)C1-C5 alkyl optionally substituted with amino;
or R7 and R8 are taken together with the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
or R10 and R8 are taken together to form a bond;
or R9 and R7 are taken together to form an alkylene bridge of 3 to 5 carbon atoms when R10 and R8 are taken together to form a bond;
each R11, R12 and R13 is independently H or optionally substituted C1-C5 alkyl; and
Q is aryl or heteroaryl optionally substituted with 1 to 3 substituents including halogen, C1-C5 alkyl or cycloalkyl, halo-substituted C1-C5 alkyl or cycloalkyl, C1-C5 alkoxy or cycloalkoxy, —CN, —CO2H or —C(O)N(Ra)Rb, wherein each Ra and Rb is independently H or C1-C5 alkyl.
In some embodiments, the compound is of formula (A-IIA). In some variations, X is CR6a, wherein R6a is H. In some variations, R6 is H. In other variations, R1 is H or CH3. In yet other variations, R7 is H or CH3. In yet other variations, R8 is hydroxyl. In yet other variations, Q is optionally substituted pyridyl, optionally substituted pyrimidyl, optionally substituted pyrazinyl, or optionally substituted phenyl.
In some embodiments, the compound is of formula (A-IIB). In some variations, X is CR6a, wherein R6a is H. In some variations, R6 is H. In other variations, R1 is H or CH3. In yet other variations, R7 is H or CH3. In yet other variations, R8 is hydroxyl. In yet other variations, Q is optionally substituted pyridyl, optionally substituted pyrimidyl, optionally substituted pyrazinyl, or optionally substituted phenyl.
In one embodiment, the compound is of formula (A-IA):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl or cycloalkyl optionally substituted with 1 to 3 halogen atoms or hydroxyl, C2-C5 alkenyl, or —C(O)OR11;
each R2a, R2b, R3a, R3b, R4a, R4b, R5a and R5b is independently H or optionally substituted C1-C5 alkyl;
each n and m is 1, or n is 0 and m is 1, or n is 1 and m is 0;
or R1 and R2a, or R1 and R3a, or R2a and R5a, or R3a and R4a, where present, are taken together to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety,
or R1 and R4a, or R1 and R5a, or R2a and R3a, where present, are taken together to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety,
or R2a and R4a, or R3a and R5a, where present, are taken together to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety,
or R4a and R5a, where present, are taken together to form a methylene (—CH2—) moiety;
X is N or CR6a;
each R6 and R6a is independently H, halogen, C1-C5 alkyl optionally substituted with 1 to 3 halogen atoms, hydroxyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
each R7, R9 and R10 is independently H or optionally substituted C1-C5 alkyl;
R8 is N(R11)R12, SR13, S(O)R13, SO2R13, or —OC(O)C1-C5 alkyl optionally substituted with amino;
each R11, R12 and R13 is independently H or optionally substituted C1-C5 alkyl; and
Q is aryl or heteroaryl optionally substituted with 1 to 3 substituents including halogen, C1-C5 alkyl or cycloalkyl, halo-substituted C1-C5 alkyl or cycloalkyl, C1-C5 alkoxy or cycloalkoxy, —CN, —CO2H or —C(O)N(Ra)Rb, wherein each Ra and Rb is independently H or C1-C5 alkyl.
In one aspect, the present invention provides compounds according to formula (A-IB), (A-IC) or (A-ID):




wherein Q, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R6, R7, R8, m, and n are as described for formula (A-I), above; and each X1, U, X2 and X is independently CR6.

In certain embodiments, with respect to the compounds of formula (A-IB), R7 is optionally substituted cycloalkyl; R8 is OH; R1 is methyl; n is 0; each of R2b, R3a, R3b, R4b, R9, and R10 is H; each R2a and R4a is H; or R2a taken together with R4a, when present, to form an ethylene (—CH2CH2—) moiety; each X1, X2 and X is CH, U is CR6, and R6 is methyl or chloro; and Q is other than unsubstituted phenyl, phenyl substituted with F, or unsubstituted pyridyl.
In certain embodiments, with respect to the compounds of formula (A-IB), R7 is C1-C5 alkyl substituted with acylamino. In one embodiment, R7 is CH2—CON(H)CH3; R1 is methyl or ethyl; n is 0; each of R2b, R3a, R3b, R4b, R9 and R10 is H; each R2a and R4a is H; or R2a taken together with R4a, when present, to form an ethylene (—CH2CH2—) moiety; each X1, X2 and X is CH, U is CR6, and R6 is methyl or chloro; and Q is other than phenyl substituted with fluoro, chloro, methoxy, or difluoro, unsubstituted pyridyl, pyridyl substituted with methyl, or unsubstituted pyrimidinyl
In certain embodiments, with respect to the compounds of formula (A-IB), R7 is C1-C5 alkyl substituted with —C(O)OR7a, wherein R7a is H or optionally substituted C1-C5 alkyl; R1 is methyl or ethyl; n is 0; each of R2b, R3a, R3b and R4b is H; each R2a and R4a is H, or R2a taken together with R4a, when present, to form an ethylene (—CH2CH2—) moiety; each X1, X2 and X is CH, U is CR6, and R6 is methyl or chloro; and Q is other than phenyl substituted with fluoro, chloro, methoxy, or difluoro, unsubstituted pyridyl, pyridyl substituted with methyl, or unsubstituted pyrimidinyl.
In certain embodiments, with respect to the compounds of formula (A-IB), R7 is C1-C5 alkyl substituted with 1 to 3 halo; R7 is CF3′R8 is OH; R1 is methyl; n is 0, each of R2b, R3a, R3b and R4b is H; each R2a and R4a is H; or R2a taken together with R4a, when present, to form an ethylene (—CH2CH2—) moiety; each X1, X2 and X is CH, U is CR6, and R6 is methyl; and Q is other than phenyl substituted with fluoro.
In certain embodiments, with respect to the compounds of formula (A-IB), R7 is optionally substituted phenyl; R8 is OH; R1 is methyl or ethyl; n is 0; each of R2b, R3a, R3b and R4b is H; each R2a and R4a is H; or R2a taken together with R4a, when present, to form an ethylene (—CH2CH2—) moiety; each X1, X2 and X is CH, U is CR6, and R6 is methyl or chloro; and Q is other than unsubstituted phenyl, phenyl substituted with fluoro or unsubstituted pyridyl.
In certain embodiments, with respect to the compounds of formula (A-IB), R8 is halo. In one embodiment, R8 is fluoro or chloro; R1 is methyl, ethyl, isopropyl, or cyclopropyl; n is 0; each of R2b, R3a, R3b and R4b is H; each R2a and R4a is H; or R2a taken together with R4a, when present, to form an ethylene (—CH2CH2—) moiety; R7 is H or methyl; each X1, X2 and X is CH, U is CR6, and R6 is methyl or chloro; and Q is other than unsubstituted phenyl, phenyl substituted with methoxy, chloro, fluoro, difluoro, unsubstituted pyridyl, pyridyl substituted with methyl, or unsubstituted pyrimidinyl.
In certain embodiments, with respect to the compounds of formula (A-IB), R8 is —C(O)N(R14)R15; and each R14 and R15 is independently H or optionally substituted C1-C5 alkyl; or R14 and R15 are taken together to form a C3-C5 alkylene; R1 is methyl; n is 0; each of R2b, R3a, R3b and R4b is H; each R2a and R4a is H; or R2a taken together with R4a, when present, to form an ethylene (—CH2CH2—) moiety; each X1, X2 and X is CH, U is CR6, and R6 is methyl; and Q is other than cyclobutyl.
In certain embodiments, with respect to the compounds of formula (A-IB), R8 is —OC(O)N(R14)R15, —OC(O)-aryl, —OC(O)-heteroaryl, —OC(O)C1-C5 alkyl optionally substituted with amino, —OC(O)C1-C5 alkyl substituted with carboxyl, or —OC1-C5 alkyl optionally substituted with carboxyl; and each R14 and R15 is independently H or optionally substituted C1-C5 alkyl, or R14 and R15 are taken together to form a C3-C5 alkylene.
In certain embodiments, with respect to the compounds of formula (A-IC), Q is optionally substituted 5-membered heteroaryl; n is 0; R7 is fluoro or methyl; R1 is methyl; each of R2a, R2b, R3a, R3b, R4a and R4b is H; each X1, X2 and X is CH, U is CR6, and R6 is methyl or chloro; and Q is other than unsubstituted thienyl or unsubstituted thiazolyl.
In certain embodiments, with respect to the compounds of formula (A-IC), Q is optionally substituted pyridyl, each of R2a, R2b, R3a, R3b, R4a and R4b is H; each X1, X2 and X is CH, U is CR6, and R6 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted C1-C5 alkoxy; and Q is other than unsubstituted pyridyl, or pyridyl substituted with methyl, chloro, bromo, methoxy, or dimethyl.
In certain embodiments, with respect to the compounds of formula (A-IC), Q is optionally substituted pyrimidinyl; R1 is methyl; each of R2a, R2b, R3a, R3b, R4a and R4b is H; each X1, X2 and X is CH, U is CR6, and R6 is methyl or chloro; and Q is other than unsubstituted pyrimidin-4-yl, pyrimidin-4-yl substituted with methyl, unsubstituted pyrimidin-5-yl, or pyrimidin-5-yl substituted with methyl.
In certain embodiments, with respect to the compounds of formula (A-ID), each of R2b, R3a, R3b, R4b, R5a and R5b is H; each R2a and R4a is H; or R2a taken together with R4a, where present, an ethylene (—CH2CH2—) moiety; U is CR6, and R6 is selected from the group consisting of CF3, methyl, Cl, CONHCH3, COOH, COOCH3, H and F; then R1 is other than methyl.
In certain embodiments, with respect to the compounds of formula (A-ID), each of R2b, R3a, R3b, R4b, R5a and R5b is H; each R2a and R4a is H; or R2a taken together with R4a, where present, an ethylene (—CH2CH2—) moiety; X is CR6, and R6 is F; then R1 is other than methyl.
In certain embodiments, with respect to the compounds of formula (A-IB), (A-IC), or (A-ID), n is 0. In certain embodiments, with respect to the compounds of formula (A-IB), (A-IC), or (A-ID), n is 1. In certain embodiments, with respect to the compounds of formula (A-IB), (A-IC), or (A-ID), m is 0. In certain embodiments, with respect to the compounds of formula (A-IB), (A-IC), or (A-ID), m is 1.
In certain embodiments, with respect to the compounds of formula (A-IB), (A-IC), or (A-ID), each R2a, R2b, R3a, R3b, R4a, R4b, R5a, and R5b is H.
In certain embodiments, with respect to the compounds of formula (A-IB), (A-IC), or (A-ID), R2a together with R1 form a butylene or propylene moiety.
In certain embodiments, with respect to the compounds of formula (A-IB), (A-IC), or (A-ID), R2a together with R3a form a propylene or ethylene moiety.
In certain embodiments, with respect to the compounds of formula (A-IB), (A-IC), or (A-ID), R2a together with R4a form a propylene or ethylene moiety.
In certain embodiments, with respect to the compounds of formula (A-IB), (A-IC), or (A-ID), R5a together with R3a form a methylene or ethylene moiety.
In certain embodiments, with respect to the compounds of formula (A-IB), (A-IC), or (A-ID), R2a together with R4a form a methylene or ethylene moiety.
In certain embodiments, with respect to the compounds of formula (A-IB), (A-IC), or (A-ID), R3a together with R1 form a butylene or propylene moiety.
In one embodiment, the present invention provides compounds according to formula (A-IE):




wherein X1, U, X2, X, Q, R1, R6, R7 and R8 are as described for formula (A-IB).

In another embodiment, the compound is of the formula (A-IIA-1), (A-IIB-1), (A-IIC-1) or (A-IID-1):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl or cycloalkyl optionally substituted with 1 to 3 halogen atoms or hydroxyl, C2-C5 alkenyl, or —C(O)OR11;
each R2a, R3a or R5a is independently H or optionally substituted C1-C5 alkyl;
or R1 and R2a, or R1 and R3a are taken together to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
X is N or CR6a;
each R6 and R6a is independently H, halogen, C1-C5 alkyl optionally substituted with 1 to 3 halogen atoms, hydroxyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
each R7, R9 and R10 is independently H or optionally substituted C1-C5 alkyl;
R8 is H, azido, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, or —OC(O)C1-C5 C5 alkyl optionally substituted with amino;
each R11, R12 and R13 is independently H or optionally substituted C1-C5 alkyl; and
Q is aryl or heteroaryl optionally substituted with 1 to 3 substituents including halogen, C1-C5 alkyl or cycloalkyl, halo-substituted C1-C5 alkyl or cycloalkyl, C1-C5 alkoxy or cycloalkoxy, —CN or —C(O)N(Ra)Rb where each Ra and Rb is independently H or C1-C5 alkyl.
In one variation, each R6 and R6a is independently H, CH3 or Cl.
In one variation, R8 is H, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, or —OC(O)C1-C5 alkyl optionally substituted with amino, where R11, R12 and R13 are each independently H or optionally substituted C1-C5 alkyl. In a particular variation, R8 is H, OH, NH2, —OC(O)CH(NH2)—CH3, —OC(O)CH(NH2)—CH(CH3)2, and —OC(O)CH(NH2)—CH3—CH(CH3)2.
In one variation, R10 and R8 are taken together to form a bond.
In one variation, R10 and R8 are taken together to form a bond, and R7 and R9 are taken together to form an alkylene bridge of 3 to 5 carbon atoms.
In one embodiment, the compound is of formula (A-IIA-1). In some variations, X is CR6a, wherein R6a is H. In other variations, R6 is H. In other variations, R1 is H or CH3. In yet other variations, R7 is H or CH3. In yet other variations, R8 is hydroxyl or NH2. In yet other variations, Q is optionally substituted pyridyl, optionally substituted pyrimidyl, optionally substituted pyrazinyl, or optionally substituted phenyl.
In another embodiment, the compound is of formula (A-IID-1). In some variations, X is CR6, wherein R6 is H. In other variations, R1 is H or CH3. In yet other variations, R7 is H or CH3. In yet other variations, R8 is hydroxyl or NH2. In yet other variations, Q is optionally substituted pyridyl, optionally substituted pyrimidyl, optionally substituted pyrazinyl, or optionally substituted phenyl.
In another embodiment, the compound is of formula (A-III):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; or —C(O)O—C1-C5 alkyl; or is taken together with R2a or R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R4a or R5a, where present, to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety;
each n and m is 1, or n is 0 and m is 1, or n is 1 and m is 0;
R2a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R1 or R5a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R3a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R4a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R3a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R1 or R4a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R2a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R5a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R4a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R2a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety; or is taken together with R5a, where present, to form a methylene (—CH2—) moiety;
R5a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R2a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R3a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety; or is taken together with R4a, where present, to form a methylene (—CH2—) moiety;
each R2b, R3b, R4b and R5b is independently H, optionally substituted C1-C5 alkyl, optionally substituted C2-C5 alkenyl, or optionally substituted aryl;
X is N or CR6a;
t is 1, 2 or 3;
each R6 and R6a is independently H; hydroxyl; halo; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl; optionally substituted C1-C5 alkoxy; or optionally substituted —C(O)C1-C5 alkyl;
R7 is H; halo; optionally substituted C1-C5 alkyl; or optionally substituted aryl; or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety; or is taken together with R9 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R8 is H; halo; hydroxyl; N(R11)R12; SR13, S(O)R13; SO2R13; —OC(O)N(R14)R15; OC(O)-aryl; —OC(O)-heteroaryl; or —OC(O)C1-C5 alkyl optionally substituted with amino; or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety; or is taken together with R10 to form a bond;
R9 is H or optionally substituted C1-C5 alkyl; or is taken together with R7 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R10 is H or optionally substituted C1-C5 alkyl; or is taken together with R8 to form a bond;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl; or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl; or R14 and R15 are taken together to form a C3-C5 alkylene; and
Q is unsubstituted aryl; unsubstituted heteroaryl; aryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino; or heteroaryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.
In some variations, Q is unsubstituted aryl; unsubstituted heteroaryl; aryl substituted with halo, CH3, CF3, or OCH3; or heteroaryl substituted with halo, CH3, CF3, or OCH3. In other variations, Q is unsubstituted pyridyl; unsubstituted pyrimidyl; unsubstituted pyrazinyl; unsubstituted phenyl; pyridyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3; pyrimidyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3; pyrazinyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3; or phenyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3.
In one variation, the compound is of the formula (A-III), wherein Q, X, m, n, t, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R6, R6a, R11, R12, R13, R14 and R15 are as defined for the formula (A-III), R7 is H, halo, optionally substituted C1-C5 alkyl, R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15, or —OC(O)C1-C5 alkyl optionally substituted with amino, and each R9 and R10 is independently H or optionally substituted C1-C5 alkyl; or a salt, solvate or N-oxide thereof.
In some variations of the compound of the formula (A-III), R1 is C1-C5 alkyl (e.g., methyl), each R2a and R3a is H, R6 is methyl or chloro, and X is CR6a where R6a is methyl or chloro. In some of these variations, t is 1, 2 or 3. In some of these variations, R7 is H or C1-C5 alkyl (e.g., methyl) and R8 is H or hydroxyl. In some of these variations, each R7 and R8 is H. In some of these variations, R9 is H or C1-C5 alkyl (e.g., methyl) and R10 is H. In some of these variations, each R9 and R10 is H. In some of these variations, each R7, R8, R9 and R10 is H. In some of these variations, Q is an unsubstituted pyridyl group which may be attached to the parent structure at any position (e.g., 2-pyridyl, 3-pyridyl or 4-pyridyl). In some of these variations, Q is 3-pyridyl or 4-pyridyl. In some of these variations, Q is pyridyl substituted a methyl (e.g., 6-methyl-3-pyridyl and 3-methyl-4-pyridyl). In some of these variations, Q is phenyl substituted with a halo group (e.g., fluorophenyl). In some of these variations, Q is 4-fluorophenyl. In some of these variations, Q is phenyl substituted with —C(O)NR16R17, wherein each R16 and R17 is H. In some of these variations, Q is 4-carbamoylphenyl.
In some variations, X is CR6a, wherein R6a is H, halo or C1-C5 alkyl; and each R6 is independently H, halo or C1-C5 alkyl. In other variations, X is N. In some variations, R1 is H or C1-C5 alkyl. In some variations, R7 is H or C1-C5 alkyl, and R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl. In other variations, R7 is H or C1-C5 alkyl, and R8 is H or hydroxyl. In yet other variations, R7 is H or C1-C5 alkyl, and R8 is hydroxyl. In yet other variations, R7 is H, R8 is hydroxyl, n is zero and m is 1. In certain variations, R7 is methyl, R8 is hydroxyl, n is zero and m is 1.
In some variations, Q is unsubstituted pyridyl; unsubstituted pyrimidyl; unsubstituted pyrazinyl; unsubstituted phenyl; unsubstituted imidazolyl; unsubstituted triazolyl; pyridyl substituted with 1 to 3 substituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl; pyrimidyl substituted with 1 to 3 substituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl; pyrazinyl substituted with 1 to 3 substituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl; phenyl substituted with 1 to 3 substituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl; imidazolyl substituted with 1 to 3 substituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl; or triazolyl substituted with 1 to 3 substituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl.
In certain variations, X is CR6a, wherein R6a is H, halo or C1-C5 alkyl; each R6 is independently H, halo or C1-C5 alkyl; R7 is H or C1-C5 alkyl; R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl; each R9 and R10 is hydrogen; and Q is unsubstituted pyridyl; or pyridyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl. In some variations, n is 0 and m is 1; R7 is H or CH3; and R8 is H or hydroxyl.
In yet other variations, X is N; R7 is H or C1-C5 alkyl; R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl; each R9 and R10 is hydrogen; and Q is unsubstituted pyridyl; or pyridyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl. In some variations, n is 0 and m is 1; R7 is H or CH3; and R8 is H or hydroxyl.
In some variations, n is 0 and m is 1; R1 is taken together with R2a to form a propylene (—CH2CH2CH2—) moiety; X is CR6a, wherein R6a is H, halo or C1-C5 alkyl; each R6 is independently H, halo or C1-C5 alkyl; R7 is H or C1-C5 alkyl; R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl; each R9 and R10 is hydrogen; and Q is unsubstituted pyridyl; or pyridyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl. In some variations, R7 is H or CH3; and R8 is H or hydroxyl.
In some variations, the compound is Compound No. 3a, 3b, 39a, 4a, 5b, 13b, 14a, 41a, 74a, 26a, 26b, 27a, 29b, 31a, 127a, 129d, 134b, 144b, 148, 173a, 174a, 150a, 176a, IV-210a, 151a, II-4-b, II-132b, 148b, 141b, 154b, II-135b, II-138, II-139, II-140, II-244a, II-7, II-146a, II-152a, II-227c, II-220, II-148a, II-13a, II-212a, II-260a or II-260b, or a salt, solvate or N-oxide thereof.
In one aspect, compounds provided herein used in the methods described above is a compound of formula (A-III), wherein any one or more of the following conditions applies: (1) X is CR6a, wherein each R6a is independently H, halo or C1-C5 alkyl; (2) each R6 is independently H, halo or C1-C5 alkyl; (3) X is N; (4) R1 is H or C1-C5 alkyl; (5) R2a and R3a is H; (6) R7 is H or C1-C5 alkyl; (8) R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl; (9) R7 is H or C1-C5 alkyl, and R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl; (10) R7 is H, and R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl; (11) R7 is C1-C5 alkyl, and R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl; (12) R7 is H or C1-C5 alkyl, and R8 is H or hydroxyl; (13) R7 is H or C1-C5 alkyl, and R8 is hydroxyl; (14) R7 is H, and R8 is hydroxyl; (15) R7 is methyl, and R8 is hydroxyl; (16) R7 is H, and R8 is NH2; (17) R7 is H, and R8 is —OC(O)C1-C5 alkyl; (18) R9 is H or C1-C5 alkyl; (19) R10 is H or C1-C5 alkyl; (20) each R9 and R10 is H; (21) one of R9 and R10 is H and the other is C1-C5 alkyl; (22) Q is: unsubstituted pyridyl; unsubstituted pyrimidyl; unsubstituted pyrazinyl; unsubstituted phenyl; unsubstituted imidazolyl; unsubstituted triazolyl; pyridyl substituted with 1 to 3 substituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl; pyrimidyl substituted with 1 to 3 substituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl; pyrazinyl substituted with 1 to 3 substituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl; or phenyl substituted with 1 to 3 substituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl; imidazolyl substituted with 1 to 3 substituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl; or triazolyl substituted with 1 to 3 substituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl; (23) X is CR6a, wherein R6a is H, halo or C1-C5 alkyl; and each R6 is independently H, halo or C1-C5 alkyl; (24) wherein R1 is H or C1-C5 alkyl, R7 is H or C1-C5 alkyl, and R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl; (25) wherein R1 is H or C1-C5 alkyl, R7 is H or C1-C5 alkyl, and R8 is H or hydroxyl; (26) R1 is H or C1-C5 alkyl, R7 is H or C1-C5 alkyl, and R8 is hydroxyl; (27) wherein R1 is CH3, R7 is H, R8 is hydroxyl, n is zero and m is 1; (28) R1 is CH3, R7 is methyl, R8 is hydroxyl, n is zero and m is 1; (29) X is CR6a, wherein R6a is H, halo or C1-C5 alkyl; each R6 is independently H, halo or C1-C5 alkyl; R1 is H or C1-C5 alkyl, R7 is H or C1-C5 alkyl, R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl; each R9 and R10 is hydrogen; and Q is unsubstituted pyridyl; or pyridyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl; (30) n is 0 and m is 1; R1 is H or CH3; R7 is H or CH3; and R8 is H or hydroxyl; (31) X is N; R1 is H or C1-C5 alkyl, R7 is H or C1-C5 alkyl, R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl; each R9 and R10 is hydrogen; and Q is unsubstituted pyridyl; or pyridyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl; (32) n is 0 and m is 1; R1 is H or CH3; R7 is H or CH3; and R8 is H or hydroxyl; (33) n is 0 and m is 1; R1 is taken together with R2a to form a propylene (—CH2CH2CH2—) moiety; X is CR6a, wherein R6a is H, halo or C1-C5 alkyl; each R6 is independently H, halo or C1-C5 alkyl; R7 is H or C1-C5 alkyl, R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl; each R9 and R10 is hydrogen; and Q is unsubstituted pyridyl; or pyridyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl; (34) R7 is H or CH3; and R8 is H or hydroxyl.
In another embodiment, the compound of formula (A-III) has the formula (A-IIIA):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl; C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl; or —C(O)O—C1-C5 alkyl, or is taken together with R2a or R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R2a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R3a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
X is N or CR6a;
each R6 and R6a is independently H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl, or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety, or is taken together with R9 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15, —OC(O)-aryl, —OC(O)-heteroaryl, or —OC(O)C1-C5 alkyl optionally substituted with amino, or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety, or is taken together with R10 to form a bond;
R9 is H or optionally substituted C1-C5 alkyl, or is taken together with R7 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R10 is H or optionally substituted C1-C5 alkyl, or is taken together with R8 to form a bond;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl, or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl, or R14 and R15 are taken together to form a C3-C5 alkylene; and
Q is unsubstituted aryl; unsubstituted heteroaryl; aryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino; or heteroaryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.
In some variations, Q is unsubstituted aryl; unsubstituted heteroaryl; aryl substituted with halo, CH3, CF3, or OCH3; or heteroaryl substituted with halo, CH3, CF3, or OCH3. In other variations, Q is unsubstituted pyridyl; unsubstituted pyrimidyl; unsubstituted pyrazinyl; unsubstituted phenyl; pyridyl substituted with halo, CH3, CF3, or OCH3; pyrimidyl substituted with halo, CH3, CF3, or OCH3; pyrazinyl substituted with halo, CH3, CF3, or OCH3; or phenyl substituted with halo, CH3, CF3, or OCH3.
In one variation, the compound is of the formula (A-IIIA), wherein Q, X, R1, R2a, R3a, R6, R6a, R11, R12, R13, R14 and R15 are as defined for the formula (A-IIIA); R7 is H, halo, optionally substituted C1-C5 alkyl; R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15, or —OC(O)C1-C5 alkyl optionally substituted with amino; and each R9 and R10 is independently H or optionally substituted C1-C5 alkyl.
In some variations of the compound of the formula (A-IIIA), each R2a and R3a is H. In some variations, R1 is C1-C5 alkyl (e.g., methyl). In some variations, each R6 and R6a is independently halo (e.g., chloro) or C1-C5 alkyl (e.g., methyl). In some variations, each R6 and R6a is independently halo (e.g., chloro or fluoro). In some variations, each R6 or R6a is chloro. In some variations, each R6 and R6a is independently C1-C5 alkyl (e.g., methyl). In some variations, X is CR6a, wherein R6a is H or halo. In some variations, X is CR6a, wherein R6a is H. In some variations, X is CR6a, wherein R6a is chloro. In some variations, X is CR6a, wherein R6a is halo (e.g., chloro or fluoro). In some variations, R6 is H or halo. In some variations, R6 is H. In some variations, R6 is chloro. In some variations, R6 is halo (e.g., chloro or fluoro). In some variations, R7 is H or C1-C5 alkyl (e.g., methyl). In some variations, X is N. In some variations, R7 is H. In some variations, R7 is C1-C5 alkyl (e.g., methyl). In some variations, R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl. In some variations, R8 is H or hydroxyl. In some variations, R8 is N(R11)R12 where each R11 and R12 is H. In some variations, R8 is —OC(O)C1-C5 alkyl (e.g., —OC(O)-t-butyl). In some variations, R7 is H or C1-C5 alkyl (e.g., methyl) and R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl. In some variations, R7 is H; and R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl. In some variations, R7 is C1-C5 alkyl (e.g., methyl); and R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl. In some variations, R7 is H or C1-C5 alkyl (e.g., methyl); and R8 is H or hydroxyl. In some variations, R7 is H or C1-C5 alkyl (e.g., methyl); and R8 is hydroxyl. In some variations, R7 is H; and R8 is hydroxyl. In some variations, R7 is methyl; and R8 is hydroxyl. In some variations, R7 is H; and R8 is N(R11)R12, wherein each R11 and R12 is H. In some variations, R7 is H; and R8 is —OC(O)C1-C5 alkyl (e.g., —OC(O)-t-butyl). In some variations, R9 is H or C1-C5 alkyl (e.g., methyl). In some variations, R10 is H or C1-C5 alkyl (e.g., methyl). In some variations, each R9 and R10 is H. In some variations, one of R9 and R10 is H and the other of R9 and R10 is C1-C5 alkyl (e.g., methyl). In some variations, Q is an unsubstituted heteroaryl (e.g., pyridyl). In some variations, Q is an unsubstituted pyridyl group which may be attached to the parent structure at any position (e.g., 2-pyridyl, 3-pyridyl or 4-pyridyl). In some variations, Q is 3-pyridyl or 4-pyridyl. In some variations, Q is heteroaryl substituted with a substituent selected form the group consisting of halo (e.g., fluoro or chloro), C1-C5 alkyl (e.g., methyl), halo-substituted C1-C5 alkyl (e.g., CF3) and carboxyl. In some variations, Q is heteroaryl substituted with halo (e.g., fluoro or chloro) or C1-C5 alkyl (e.g., methyl). In some variations, Q is heteroaryl substituted with C1-C5 alkyl (e.g., methyl). In some variations, Q is a pyridyl optionally substituted with a methyl where the pyridyl group may be attached to the parent structure at any position and the methyl group may be attached to the pyridyl group at any open position (e.g., 6-methyl-3-pyridyl and 3-methyl-4-pyridyl). In some variations, Q is phenyl substituted with a substituent selected form the group consisting of halo (e.g., fluoro or chloro), C1-C5 alkyl (e.g., methyl), halo-substituted C1-C5 alkyl (e.g., CF3), carboxyl and —C(O)NR16R17 where each R16 and R17 is independently H or optionally substituted C1-C5 alkyl. In some variations, Q is phenyl substituted with a halo group (e.g., fluorophenyl). In some variations, Q is 4-fluorophenyl. In some variations, Q is phenyl substituted with —C(O)NR16R17 where each R16 and R17 is H.
In some variations of the compound of the formula (A-IIIA), R1 is C1-C5 alkyl (e.g., methyl), each R2a and R3a is H, R6 is methyl or chloro, and X is CH. In some of these variations, R7 is H or C1-C5 alkyl (e.g., methyl) and R8 is hydroxyl. In some of these variations, R7 is H and R8 is hydroxyl. In some of these variations, R7 is methyl and R8 is hydroxyl. In some of these variations, R9 is H or C1-C5 alkyl (e.g., methyl) and R10 is H. In some of these variations, each R9 and R10 is H. In some of these variations, R7 is H or C1-C5 alkyl (e.g., methyl), R8 is hydroxyl, and each R9 and R10 is H. In some of these variations, Q is an unsubstituted pyridyl group which may be attached to the parent structure at any position (e.g., 2-pyridyl, 3-pyridyl or 4-pyridyl). In some of these variations, Q is 3-pyridyl or 4-pyridyl. In some of these variations, Q is pyridyl substituted a methyl (e.g., 6-methyl-3-pyridyl and 3-methyl-4-pyridyl). In some of these variations, phenyl substituted with a halo group (e.g., fluorophenyl). In some of these variations, Q is 4-fluorophenyl. In some of these variations, Q is phenyl substituted with —C(O)NR16R17 where each R16 and R17 is H. In some of these variations, Q is 4-carbamoylphenyl.
In some variations of the compound of the formula (A-IIIA), R1 is C1-C5 alkyl (e.g., methyl), each R2a and R3a is H, R6 is methyl or chloro, and X is CH. In some variations, R7 is H and R8 is N(R11)R12, wherein each R11 and R12 is H. In some variations, R7 is H and R8 is —OC(O)C1-C5 alkyl (e.g., —OC(O)-t-butyl). In some of these variations, R9 is H or C1-C5 alkyl (e.g., methyl); and R10 is H. In some of these variations, each R9 and R10 is H. In some of these variations, R7 is H, R8 is NH2, and each R9 and R10 is H. In some of these variations, Q is an unsubstituted pyridyl group which may be attached to the parent structure at any position (e.g., 2-pyridyl, 3-pyridyl or 4-pyridyl). In some of these variations, Q is 3-pyridyl or 4-pyridyl. In some of these variations, Q is pyridyl substituted a methyl (e.g., 6-methyl-3-pyridyl and 3-methyl-4-pyridyl). In some of these variations, Q is phenyl substituted with a halo group (e.g., fluorophenyl). In some of these variations, Q is 4-fluorophenyl. In some of these variations, Q is phenyl substituted with —C(O)NR16R17, wherein each R16 and R17 is H. In some of these variations, Q is 4-carbamoylphenyl.
In some variations of the compound of the formula (A-IIIA), R1 and R2a are taken together to form a propylene (—CH2CH2CH2—) moiety and R3a is H. In some of these variations, X is N. In some of these variations, X is CH. In some of these variations, R6 is C1-C5 alkyl (e.g., methyl) or halo (e.g., chloro). In some of these variations, R6 is methyl or chloro. In some of these variations, R7 is H or C1-C5 alkyl (e.g., methyl) and R8 is H or hydroxyl. In some of these variations, R7 is H and R8 is hydroxyl. In some of these variations, R7 is methyl and R8 is hydroxyl. In some of these variations, each R7 and R8 is H. In some of these variations, R9 is H or C1-C5 alkyl (e.g., methyl) and R10 is H. In some of these variations, each R9 and R10 is H. In some of these variations, R7 is H or C1-C5 alkyl (e.g., methyl), R8 is H or hydroxyl, and each R9 and R10 is H. In some of these variations, each R7, R8, R9 and R10 is H. In some of these variations, Q is an unsubstituted pyridyl group which may be attached to the parent structure at any position (e.g., 2-pyridyl, 3-pyridyl or 4-pyridyl). In some of these variations, Q is 3-pyridyl or 4-pyridyl. In some of these variations, Q is pyridyl substituted a methyl (e.g., 6-methyl-3-pyridyl and 3-methyl-4-pyridyl). In some of these variations, Q is phenyl substituted with a halo group (e.g., fluorophenyl). In some of these variations, Q is 4-fluorophenyl. In some of these variations, Q is phenyl substituted with —C(O)NR16R17, wherein each R16 and R17 is H. In some of these variations, Q is 4-carbamoylphenyl.
In some variations, X is CH. In other variations, X is N. In yet other variations, R1 is H or CH3. In yet other variations, R2a is H or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety. In some variations, each R6 and R6a is independently H, halo or C1-C5 alkyl. In yet other variations, R7 is H or CH3. In one variation, R8 is hydroxyl.
In some variations, Q is: unsubstituted pyridyl; unsubstituted pyrimidyl; unsubstituted pyrazinyl; unsubstituted phenyl; unsubstituted imidazolyl; unsubstituted triazolyl; pyridyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3; pyrimidyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3; pyrazinyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3; or phenyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3.
In some variations, X is CH; each R6 is independently H, halo or C1-C5 alkyl; R7 is H or CH3; R8 is hydroxyl; and Q is unsubstituted pyridyl, or pyridyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3.
In some variations, the compound is Compound No. 3a, 3b, 39a, 4a, 5b, 74a, 26a, 26b, 27a, 29b, 31a, 127a, 129d, 134b, 144b, 148, 173a, 174a, 150a, 176a, IV-210a, 151a, II-4b, II-132b, 148b, 141b, II-135b, II-138, II-139, II-140, II-244a, II-7, II-146a, II-151b, II-152a, II-227c, II-220, II-148a, II-13a, II-212a, II-260a and II-260b, or a salt, solvate or N-oxide thereof.
In another embodiment, the compound of formula (A-III) has the formula (A-IIIB):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1-3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl, or is taken together with R2a or R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R2a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R3a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
X is N or CR6a;
each R6 and R6a is independently H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl, or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety, or is taken together with R9 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15, —OC(O)-aryl, —OC(O)-heteroaryl, or —OC(O)C1-C5 alkyl optionally substituted with amino, or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety, or is taken together with R10 to form a bond;
R9 is H or optionally substituted C1-C5 alkyl, or is taken together with R7 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R10 is H or optionally substituted C1-C5 alkyl, or is taken together with R8 to form a bond;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl, or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl, or R14 and R15 are taken together to form a C3-C5 alkylene; and
Q is unsubstituted aryl; unsubstituted heteroaryl; aryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino; or heteroaryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.
In some variations, Q is unsubstituted aryl; unsubstituted heteroaryl; aryl substituted with halo, CH3, CF3, or OCH3; or heteroaryl substituted with halo, CH3, CF3, or OCH3. In other variations, Q is unsubstituted pyridyl; unsubstituted pyrimidyl; unsubstituted pyrazinyl; unsubstituted phenyl; pyridyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3; pyrimidyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3; pyrazinyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3; or phenyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3.
In some variations of the compound of the formula (A-IIIB), R1 is C1-C5 alkyl (e.g., methyl), each R2a and R3a is H, R6 is methyl or chloro, and X is CH. In some of these variations, R7 is H or C1-C5 alkyl (e.g., methyl) and R8 is hydroxyl. In some of these variations, R7 is H and R8 is hydroxyl. In some of these variations, R7 is methyl and R8 is hydroxyl. In some of these variations, R9 is H or C1-C5 alkyl (e.g., methyl) and R10 is H. In some of these variations, each R9 and R10 is H. In some of these variations, R7 is H or C1-C5 alkyl (e.g., methyl), R8 is hydroxyl, and each R9 and R10 is H. In some of these variations, Q is an unsubstituted pyridyl group which may be attached to the parent structure at any position (e.g., 2-pyridyl, 3-pyridyl or 4-pyridyl). In some of these variations, Q is 3-pyridyl or 4-pyridyl. In some of these variations, Q is pyridyl substituted a methyl (e.g., 6-methyl-3-pyridyl and 3-methyl-4-pyridyl). In some of these variations, Q is phenyl substituted with a halo group (e.g., fluorophenyl). In some of these variations, Q is 4-fluorophenyl.
In another embodiment, the compound of formula (A-III) has the formula (A-IIIC):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1-3 substituents selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl, or is taken together with R2a or R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R2a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R3a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R5a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl;
X is N or CR6a;
each R6 and R6a is independently H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl, or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety, or is taken together with R9 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15, —OC(O)-aryl, —OC(O)-heteroaryl, or —OC(O)C1-C5 alkyl optionally substituted with amino, or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety, or is taken together with R10 to form a bond;
R9 is H or optionally substituted C1-C5 alkyl, or is taken together with R7 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R10 is H or optionally substituted C1-C5 alkyl, or is taken together with R8 to form a bond;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl, or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl, or R14 and R15 are taken together to form a C3-C5 alkylene; and
Q is unsubstituted aryl; unsubstituted heteroaryl; aryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino; or heteroaryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.
In some variations, Q is unsubstituted aryl; unsubstituted heteroaryl; aryl substituted with halo, CH3, CF3, or OCH3; or heteroaryl substituted with halo, CH3, CF3, or OCH3. In other variations, Q is unsubstituted pyridyl; unsubstituted pyrimidyl; unsubstituted pyrazinyl; unsubstituted phenyl; pyridyl substituted with halo, CH3, CF3, or OCH3; pyrimidyl substituted with halo, CH3, CF3, or OCH3; pyrazinyl substituted with halo, CH3, CF3, or OCH3; or phenyl substituted with halo, CH3, CF3, or OCH3.
In one variation, the compound is of the formula (A-IIIC), wherein Q, X, R1, R2a, R3a, R5a, R6, R6a, R11, R12, R13, R14 and R15 are as defined for the formula (A-IIIC), R7 is H, halo, optionally substituted C1-C5 alkyl, R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15 or —OC(O)C1-C5 alkyl optionally substituted with amino, and each R9 and R10 is independently H or optionally substituted C1-C5 alkyl; or a salt, solvate or N-oxide thereof.
In another embodiment, the compound of formula (A-III) has the formula (A-IIID):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl, or is taken together with R2a or R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R2a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R3a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
X is N or CR6a;
each R6 and R6a is independently H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl, or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety, or is taken together with R9 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15, —OC(O)-aryl, —OC(O)-heteroaryl, or —OC(O)C1-C5 alkyl optionally substituted with amino, or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety, or is taken together with R10 to form a bond;
R9 is H or optionally substituted C1-C5 alkyl, or is taken together with R7 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R10 is H or optionally substituted C1-C5 alkyl, or is taken together with R8 to form a bond;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl, or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl, or R14 and R15 are taken together to form a C3-C5 alkylene; and
Q is unsubstituted aryl; unsubstituted heteroaryl; aryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino; or heteroaryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.
In some variations, Q is unsubstituted aryl; unsubstituted heteroaryl; aryl substituted with halo, CH3, CF3, or OCH3; or heteroaryl substituted with halo, CH3, CF3, or OCH3. In other variations, Q is unsubstituted pyridyl; unsubstituted pyrimidyl; unsubstituted pyrazinyl; unsubstituted phenyl; pyridyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3; pyrimidyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3; pyrazinyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3; or phenyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3.
In one variation, the compound is of the formula (A-IIID), wherein Q, X, R1, R2a, R3a, R6, R6a, R11, R12, R13, R14 and R15 are as defined for the formula (A-IIID), R7 is H, halo, optionally substituted C1-C5 alkyl, R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15, or —OC(O)C1-C5 alkyl optionally substituted with amino, and each R9 and R10 is independently H or optionally substituted C1-C5 alkyl; or a salt, solvate or N-oxide thereof.
In some variations of the compound of the formula (A-IIID), R1 is C1-C5 alkyl (e.g., methyl), each R2a and R3a is H, R6 is methyl or chloro, and X is CH. In some of these variations, R7 is H or C1-C5 alkyl (e.g., methyl) and R8 is H or hydroxyl. In some of these variations, R7 is H and R8 is hydroxyl. In some of these variations, R7 is methyl and R8 is hydroxyl. In some of these variations, R9 is H or C1-C5 alkyl (e.g., methyl) and R10 is H. In some of these variations, each R9 and R10 is H. In some of these variations, R7 is H or C1-C5 alkyl (e.g., methyl), R8 is hydroxyl, and each R9 and R10 is H. In some of these variations, Q is an unsubstituted pyridyl group which may be attached to the parent structure at any position (e.g., 2-pyridyl, 3-pyridyl or 4-pyridyl). In some of these variations, Q is 3-pyridyl or 4-pyridyl. In some of these variations, Q is pyridyl substituted a methyl (e.g., 6-methyl-3-pyridyl and 3-methyl-4-pyridyl). In some of these variations, Q is phenyl substituted with a halo group (e.g., fluorophenyl). In some of these variations, Q is 4-fluorophenyl.
In certain embodiments, with respect to the compounds of formula (IIID), X is CH, R7 is H or methyl, R8 is H or OH, Q is phenyl, unsubstituted or substituted with F, Cl, or methoxy; and R6 is other than methyl or chloro.
In another embodiment, the compound of formula (A-III) has the formula (A-IIIE):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl; C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl; or is taken together with R2a or R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R2a is H; optionally substituted C1-C5 alkyl; optionally substituted alkenyl; or optionally substituted aryl; or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R3a is H; optionally substituted C1-C5 alkyl; optionally substituted alkenyl; or optionally substituted aryl; or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
each R2b and R3b is independently H or optionally substituted C1-C5 alkyl;
R6 is H; hydroxyl; halo; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl; optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H; halo; optionally substituted C1-C5 alkyl; or optionally substituted aryl; or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
R8 is H; halo; hydroxyl; N(R11)R12; SR13; S(O)R13, SO2R13; —OC(O)N(R14)R15; —OC(O)-aryl; —OC(O)-heteroaryl; or —OC(O)C1-C5 alkyl optionally substituted with amino, or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl, or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl; or R14 and R15 are taken together to form a C3-C5 alkylene; and
Q is unsubstituted aryl; unsubstituted heteroaryl; aryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino; or heteroaryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.
In some variations of the compound of formula (A-IIIE), R1 is C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl. In certain variations, R1 is C1-C5 alkyl substituted with a hydroxyl. In other variations, R1 is methyl. In yet other variations, R1 is H.
In some variations of the compound of formula (A-IIIE), R6 is halo, C1-C5 alkyl, or perhaloalkyl. In certain variations, R6 is methyl or isopropyl. In other variations of the compound of formula (A-IIIE), each R2a, R2b, R3a and R3b is H. In yet other variations of the compound of formula (A-IIIE), R7 is an optionally substituted H or an unsubstituted C1-C5 alkyl, and R8 is hydroxyl. In certain variations, R7 is methyl, and R8 is hydroxyl.
In yet other variations of the compound of formula (A-IIIE), Q is cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino; aryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino; or heteroaryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino. In other variations, Q is an optionally substituted pyridyl, an optionally substituted pyrimidyl, an optionally substituted pyrazinyl, or an optionally substituted phenyl, wherein each of the pyridyl, pyrimidyl, pryazinyl and phenyl is independently unsubstituted or substituted with 1 to 3 substituents independently selected from halo, carboxyl, alkoxy and C1-C5 alkyl. In one variation, Q is an unsubstituted pyridyl. In another variation, Q is an unsubstituted pyrimidyl. In yet another variation, Q is an unsubstituted pyrazinyl. In yet another variation, Q is an unsubstituted phenyl. In yet another variation, Q is a phenyl substituted with 1 to 3 substituents independently selected from the group consisting of halo or C1-C5 alkyl. In one variation, Q is fluoro-phenyl.
In another embodiment, the compound is of the formula (A-IIIE-1), (A-IIIE-2), (A-IIIE-3) or (A-IIIE-4):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl;
R6 is H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl, or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15, —OC(O)-aryl, —OC(O)-heteroaryl, or —OC(O)C1-C5 alkyl optionally substituted with amino, or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl, or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl; or R14 and R15 are taken together to form a C3-C5 alkylene; and
each Y1, Y2, Y3, Y4 and Y5 is independently N or CR4 such that no more than two of Y1, Y2, Y3, Y4 and Y5 are N, wherein R4 is H, halo, CH3, CF3, or OCH3.
In some variations of the compound of the formula (A-IIIE-1), (A-IIIE-2), (A-IIIE-3) or (A-IIIE-4), one of Y1, Y2, Y3, Y4 and Y5 is N and the other four of Y1, Y2, Y3, Y4 and Y5 are independently CR4, and wherein R4 is H, halo, CH3, CF3, or OCH3. In other variations, Y5 is CH, and each Y1, Y2, Y3 and Y4 is independently N or CR4 such that two of Y1, Y2, Y3 and Y4 are N, and wherein R4 is H, halo, CH3, CF3, or OCH3. In some variations, R4 is halo. In other variations, R4 is CH3. In one embodiment, R4 is F. In another embodiment, R4 is Cl. In some embodiments, any two of Y1, Y2, Y3, Y4 and Y5 are CR4, and each R4 is independently Cl or F. In one embodiment, each R4 is Cl. In another embodiment, each R4 is F.
In some embodiments, the compound is of formula (A-IIIE-1), when each R7 and R8 is H; R1 is H or methyl; R6 is methyl or chloro; each Y1, Y2, Y4 and Y5 is CR4, and Y3 is CH, CF, or CCl; then at least one of Y1, Y2, Y4 and Y5 is other than CH.
In certain embodiments, with respect to the compounds of formula (A-IIIE-1), the compound is Compound No. 214.
In some embodiments, the compound is of formula (A-IIIE-2). In some variations, X is CH. In other variations, R1 is H or CH3. In yet other variations, R7 is H or CH3. In yet other variations, R8 is hydroxyl. In some variations, one of Y1, Y2, Y3, Y4 and Y5 is N, and the other four of Y1, Y2, Y3, Y4 and Y5 are independently CR4 (e.g., optionally substituted pyridyl). In other variations, two of Y1, Y2, Y3, Y4 and Y5 is N, and the other three of Y1, Y2, Y3, Y4 and Y5 are independently CR4 (e.g., optionally substituted pyrimidyl or optionally substituted pyrazinyl). In yet other variations, each Y1, Y2, Y3, Y4 and Y5 is CR4 (e.g., optionally substituted phenyl). In certain variations, R4 is H, halo, CH3, CF3, or OCH3. In one embodiment, R4 is F. In another embodiment, R4 is Cl. In some embodiments, any two of Y1, Y2, Y3, Y4 and Y5 are CR4, wherein each R4 is independently Cl or F. In one embodiment, each R4 is Cl. In another embodiment, each R4 is F.
In some embodiments, the compound is of formula (A-IIIE-2), R7 is optionally substituted cycloalkyl, R8 is OH, R1 is methyl, R6 is methyl or chloro, each Y1, Y2, Y3, Y4 and Y5 is CR4 wherein at least one R4 is other than H or fluoro. In another embodiment, one of Y1, Y2, Y3, Y4 and Y5 is N and the rest are independently CR4, wherein at least one R4 is other than H.
In some embodiments, the compound is of formula (A-IIIE-2), R7 is C1-C5 alkyl, substituted with acylamino, R8 is CH2—CON(H)CH3, R1 is methyl or ethyl, R6 is methyl or chloro, each Y1, Y2, Y3, Y4 and Y5 is CR4, wherein at least one R4 is other than H, fluoro, chloro, methoxy, or difluoro. In another embodiment, one of Y1, Y2, Y3, Y4 and Y5 is N and the rest are independently CR4, wherein at least one R4 is other than H or methyl. In another embodiment, two of Y1, Y2, Y3, Y4 and Y5 are N and the rest are independently CR4, wherein at least one R4 is other than H.
In some embodiments, the compound is of formula (A-IIIE-2), R7 is C1-C5 alkyl, substituted with —C(O)OR7a, R7a is H or optionally substituted C1-C5 alkyl, R1 is methyl or ethyl, R6 is methyl or chloro, each Y1, Y2, Y3, Y4 and Y5 is CR4, wherein at least one R4 is other than H, fluoro, chloro, methoxy, or difluoro. In another embodiment, one of Y1, Y2, Y3, Y4 and Y5 is N and the rest are independently CR4, wherein at least one R4 is other than H, or methyl. In another embodiment, two of Y1, Y2, Y3, Y4 and Y5 are N and the rest are independently CR4, wherein at least one R4 is other than H.
In some embodiments, the compound is of formula (A-IIIE-2), R7 is C1-C5 alkyl, substituted with 1-3 halo, R7 is CF3, R8 is OH, R1 is methyl, R6 is methyl, each Y1, Y2, Y3, Y4 and Y5 is CR4, wherein at least one R4 is other than H or fluoro.
In some embodiments, the compound is of formula (A-IIIE-2), R7 is optionally substituted phenyl, R8 is OH, R1 is methyl or ethyl, R6 is methyl or chloro, each Y1, Y2, Y3, Y4 and Y5 is CR4, wherein at least one R4 is other than H, or fluoro. In another embodiment, one of Y1, Y2, Y3, Y4 and Y5 is N and the rest are independently CR4, wherein at least one R4 is other than H.
In some embodiments, the compound is of formula (A-IIIE-2), R8 is halo. In one embodiment, R8 is fluoro or chloro, R1 is methyl, ethyl, isopropyl, or cyclopropyl, R6 is methyl or chloro, each Y1, Y2, Y3, Y4 and Y5 is CR4, wherein at least one R4 is other than H, fluoro, chloro, methoxy, or difluoro. In another embodiment, one of Y1, Y2, Y3, Y4 and Y5 is N and the rest are independently CR4, wherein at least one R4 is other than H, or methyl. In another embodiment, two of Y1, Y2, Y3, Y4 and Y5 are N and the rest are independently CR4, wherein at least one R4 is other than H.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), each R7 and R8 is H, and the compound is Compound No. 60, 61, 84-86, 89, 91, 117, 180, 184, 200, 201, 202, 204, 206-210, 213, 217-19, 297-299, 317, 319-320, or 332, or a salt, solvate or N-oxide thereof.
In certain embodiments, with respect to the compounds of formula (I), each R7 and R8 is H, and the compound is Compound No. II-39 or II-40.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), R7 is H, R8 is OH, each Y1, Y2, Y3, Y4 and Y5 is CR4, and the compound is Compound No. 30, 52, 66, 67, 139, 142, 183, or 203.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), R7 is H, R8 is OH, each Y1, Y2, Y3, Y4 and Y5 is CR4, and the compound is Compound No. II-88 or II-192.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), R7 is H, R8 is OH, each Y1, Y3, Y4 and Y5 is CR4, Y2 is N, and the compound is Compound No. 7, 21, 51, 59, 62, 140, or 144.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), R7 is H, R8 is OH, each Y1, Y3, Y4 and Y5 is CR4, Y2 is N, and the compound is Compound No. II-57, II-92, II-94, II-190 or II-191.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), R7 is H, R8 is OH, each Y1, Y3, Y4 and Y5 is CR4, Y2 is N, and the compound is Compound No. III-1.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), R7 is H, R8 is OH, each Y1, Y2, Y4 and Y5 is CR4, Y3 is N, and the compound is Compound No. 3, 4, 6, 11, 23, 49, 63, 69-72, 81, 133, or 135.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), R7 is H, R8 is OH, each Y1, Y2, Y3 and Y5 is CR4, Y2 is N, and the compound is Compound No. II-60, II-63, II-64, II-65, II-67, II-68, II-75, II-83, II-84, II-90, II-93, or II-97.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), R7 is methyl, R8 is OH, each Y1, Y2, Y3, Y4 and Y5 is CR4, and the compound is Compound No. 90, 98, or 254.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), R7 is methyl, R8 is OH, each Y1, Y2, Y3, Y4 and Y5 is CR4, and the compound is Compound No. II-36, 47, 163, 189, 194 to 203, or II-205.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), R7 is methyl, R8 is OH, each Y1, Y2, Y3, Y4 and Y5 is CR4, and the compound is Compound No. III-36, III-47, III-50, or III-51.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), R7 is methyl, R8 is OH, each Y1, Y2, Y4 and Y5 is CR4, Y3 is N, and the compound is Compound No. 1, 2, or 253.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), R7 is methyl, R8 is OH, each Y1, Y2, Y4 and Y5 is CR4, Y3 is N, and the compound is Compound No. II-58, II-168, II-172, II-173, II-181, II-182, or III-49.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), R7 is methyl, R8 is OH, each Y1, Y3, Y4 and Y5 is CR4, Y2 is N, and the compound is Compound No. 5, 29, 31, 56, 64, 93, 143, 169, 174, or 179.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), R7 is methyl, R8 is OH, each Y1, Y3, Y4 and Y5 is CR4, Y2 is N, and the compound is Compound No. II-80, 105, 118, 123, 124, 136, 141, 145, 148, 154, 193, 220, 269, II-280, or III-48.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), R8 is N(R11)R12, and the compound is Compound No. 27, 149 to 152, or 157.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), R8 is N(R11)R12, and the compound is Compound No. II-1, II-8 to II-14, or II-260.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), R7 is other than H or methyl, R8 is OH, and the compound is Compound No. 33 to 35, 223, or 263.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), R7 is other than H or methyl, R8 is OH, and the compound is Compound No. II-160, II-162, II-166, II-167, II-174, II-186, II-206, II-255, II-257, II-259, II-264, II-265, II-278, or III-52.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), R7 is methyl, R8 is H, and the compound is Compound No. 255, 288, or 289.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), R7 is substituted C1-C5 alkyl, R8 is H, and the compound is Compound No. II-216 to II-218, II-221 to II-231, II-232, or III-224 to III-253.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), the compound is Compound No. 25, 54, 68, 83, 94, 102, 130, 141, 146, 147, 260, or 338.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), the compound is Compound No. II-15, II-16, II-19, II-207-II-213, II-256, II-258, II-262, II-263, II-274, II-277, II-295, II-296, II-299, or V-14.
In some embodiments, the compound is of formula (A-IIIE-3), when each R7 and R8 is H; R1 is methyl; R6 is chloro; each Y1, Y2, Y4 and Y5 is CR4, and Y3 is CH, CF, or CCl; then at least one of Y1, Y2, Y4 and Y5 is other than CH.
In certain embodiments, with respect to the compounds of formula (A-IIIE-3), the compound is Compound No. 40, 53, 65, 119, 215, 315, II-169, or II-184.
In some embodiments, the compound is of formula (A-IIIE-4), when each R7 and R8 is H, or R7 taken together with R8 form a —CH2 moiety, R1 is methyl; R6 is F, Cl, CF3, ethenyl, or propenyl; each Y1, Y2, Y4 and Y5 is CR4, and Y3 is CH, CF or CCl; then at least one of Y1, Y2, Y4 and Y5 is other than CH.
In certain embodiments, with respect to the compounds of formula (A-IIIE-4), the compound is Compound No. 32, 44, 45, 48, 57, 82, 216, II-170, or II-183.
In another embodiment, the compound is of the formula (A-IIIE-5), (A-IIIE-6), (A-IIIE-7) or (A-IIIE-8):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl;
R6 is H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl, or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15, —OC(O)-aryl, —OC(O)-heteroaryl, or —OC(O)C1-C5 alkyl optionally substituted with amino, or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety, or is taken together with R10 to form a bond;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl, or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl; or R14 and R15 are taken together to form a C3-C5 alkylene;
Q is




wherein

    
    
        each Z1, Z2, Z3 and Z4 is independently N or CR4 such that no more than two of Z1, Z2, Z3 and Z4 are N, wherein R4 is H, halo, CH3, CF3, or OCH3;
        each Z5 and Z10 is independently O, S or NR4a, wherein R4a is H or CH3; and
        each Z6, Z7, Z8, Z9, Z11 and Z12 is independently N or CR4, wherein R4 is H, halo, CH3, CF3, or OCH3.
    
    


In other embodiments, the compound is of formula (A-IIIE-6). In other variations, R1 is H or CH3. In yet other variations, R7 is H or CH3. In yet other variations, R8 is hydroxyl.
In some variations, Q is




In some variations, R4 is H, halo, CH3, CF3, or OCH3.

In some variations of the compound of formula (A-IIIE-1), (A-IIIE-2), (A-IIIE-3), (A-IIIE-4), (A-IIIE-5), (A-IIIE-6), (A-IIIE-7) or (A-IIIE-8), R1 is C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl. In certain variations, R1 is C1-C5 alkyl substituted with a hydroxyl. In other variations, R1 is methyl. In some variations, R6 is halo, C1-C5 alkyl or perhaloalkyl. In certain variations, R6 is methyl or isopropyl. In yet other variations of the compound of formula (A-IIIE-1), (A-IIIE-2), (A-IIIE-3), (A-IIIE-4), (A-IIIE-5), (A-IIIE-6), (A-IIIE-7) or (A-IIIE-8), R7 is an optionally substituted or an unsubstituted C1-C5 alkyl, and R8 is hydroxyl. In certain variations, R7 is methyl, and R8 is hydroxyl.
In some embodiments, the compound is of formula (A-IIIE-6), when each R7 and R8 is H, R6 is H, methyl, Cl, F, CF3, or methoxy; then R1 is other than methyl or cyclopropyl.
In certain embodiments, with respect to the compounds of formula (A-IIIE-6), the compound is Compound No. 131, 307, 308, 318, 326, II-106, or II-142.
In another embodiment, the compound is of the formula (A-IIIF):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl, or is taken together with R2a or R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R2a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R3a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
each R2b and R3b is independently H or optionally substituted C1-C5 alkyl;
R6 is H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl, or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15, —OC(O)-aryl, —OC(O)-heteroaryl, or —OC(O)C1-C5 alkyl optionally substituted with amino, or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl, or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl; or R14 and R15 are taken together to form a C3-C5 alkylene; and
Q is unsubstituted aryl; unsubstituted heteroaryl; aryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino; or heteroaryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.
In another embodiment, the compound is of the formula (A-IIIF-1), (A-IIIF-2), (A-IIIF-3) or (A-IIIF-4):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl;
R6 is H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl, or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15, —OC(O)-aryl, —OC(O)-heteroaryl, or —OC(O)C1-C5 alkyl optionally substituted with amino, or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl, or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl; or R14 and R15 are taken together to form a C3-C5 alkylene; and
each Y1, Y2, Y3, Y4 and Y5 is independently N or CR4 such that no more than two of Y1, Y2, Y3, Y4 and Y5 are N, wherein R4 is H, halo, CH3, CF3, or OCH3.
In some variations, one of Y1, Y2, Y3, Y4 and Y5 is N and the other four of Y1, Y2, Y3, Y4 and Y5 are independently CR4, and wherein R4 is H, halo, CH3, CF3, or OCH3. In other variations, Y5 is CH, and each Y1, Y2, Y3 and Y4 is independently N or CR4 such that two of Y1, Y2, Y3 and Y4 are N, and wherein R4 is H, halo, CH3, CF3, or OCH3. In some variations, R4 is halo. In other variations, R4 is CH3. In one embodiment, R4 is F. In another embodiment, R4 is Cl. In some embodiments, any two of Y1, Y2, Y3, Y4 and Y5 are CR4, and each R4 is independently Cl or F. In one embodiment, each R4 is Cl. In another embodiment, each R4 is F.
In some embodiments, the compound is of formula (A-IIIF-1), when R7 is methyl, R8 is OH, R1 is methyl, R6 is chloro; then Y3 is other than N.
In some embodiments, the compound is of formula (A-IIIF-2), when each Y1, Y2, Y3, Y4 and Y5 is independently CR4; and R1 is methyl, ethyl, iso-propyl, or cyclopropyl; then R6 is other than Cl or methyl.
In some embodiments, the compound is of formula (A-IIIF-2), R7 is optionally substituted cycloalkyl, R8 is OH, R1 is methyl, R6 is methyl or chloro, each Y1, Y2, Y3, Y4 and Y5 is CR4, wherein at least one R4 is other than H or fluoro. In another embodiment, one of Y1, Y2, Y3, Y4 and Y5 is N and the rest are independently CR4, wherein at least one R4 is other than H.
In some embodiments, the compound is of formula (A-IIIF-2), R7 is C1-C5 alkyl, substituted with acylamino. In one embodiment, R7 is CH2—CON(H)CH3, R1 is methyl or ethyl, R6 is methyl or chloro, each Y1, Y2, Y3, Y4 and Y5 is CR4, wherein at least one R4 is other than H, fluoro, chloro, methoxy, or difluoro. In another embodiment, one of Y1, Y2, Y3, Y4 and Y5 is N and the rest are independently CR4, wherein at least one R4 is other than H, or methyl. In another embodiment, two of Y1, Y2, Y3, Y4 and Y5 are N and the rest are independently CR4, wherein at least one R4 is other than H.
In some embodiments, the compound is of formula (A-IIIF-2), R7 is C1-C5 alkyl, substituted with —C(O)OR7a, R7a is H or optionally substituted C1-C5 alkyl, R1 is methyl or ethyl, R6 is methyl or chloro, each Y1, Y2, Y3, Y4 and Y5 is CR4, wherein at least one R4 is other than H, fluoro, chloro, methoxy, or difluoro. In another embodiment, one of Y1, Y2, Y3, Y4 and Y5 is N and the rest are independently CR4, wherein at least one R4 is other than H, or methyl. In another embodiment, two of Y1, Y2, Y3, Y4 and Y5 are N and the rest are independently CR4, wherein at least one R4 is other than H.
In some embodiments, the compound is of formula (A-IIIF-2), R7 is C1-C5 alkyl, substituted with 1-3 halo, R7 is CF3, R8 is OH, R1 is methyl, R6 is methyl, each Y1, Y2, Y3, Y4 and Y5 is CR4, wherein at least one R4 is other than H or fluoro.
In some embodiments, the compound is of formula (A-IIIF-2), R7 is optionally substituted phenyl, R8 is OH, R1 is methyl or ethyl, R6 is methyl or chloro, each Y1, Y2, Y3, Y4 and Y5 is CR4, wherein at least one R4 is other than H, or fluoro. In another embodiment, one of Y1, Y2, Y3, Y4 and Y5 is N and the rest are independently CR4, wherein at least one R4 is other than H.
In some embodiments, the compound is of formula (A-IIIF-2), and R8 is halo. In one embodiment, R8 is fluoro or chloro, R1 is methyl, ethyl, isopropyl, or cyclopropyl, R6 is methyl or chloro, each Y1, Y2, Y3, Y4 and Y5 is CR4, wherein at least one R4 is other than H, fluoro, chloro, methoxy, or difluoro. In another embodiment, one of Y1, Y2, Y3, Y4 and Y5 is N and the rest are independently CR4, wherein at least one R4 is other than H, or methyl. In another embodiment, two of Y1, Y2, Y3, Y4 and Y5 are N and the rest are independently CR4, wherein at least one R4 is other than H.
In certain embodiments, with respect to the compounds of formula (A-IIIF-2), R8 is OH, each Y1, Y2, Y3, Y4 and Y5 is CR4, and the compound is Compound No. 18 or 20.
In certain embodiments, with respect to the compounds of formula (A-IIIF-2), R8 is OH, each Y1, Y2, Y3, Y4 and Y5 is CR4, and the compound is Compound No. II-20, II-48, II-49, II-52, II-53, II-55, II-156, II-157, or II-158.
In certain embodiments, with respect to the compounds of formula (A-IIIF-2), R8 is OH, each Y1, Y2, Y3, Y4 and Y5 is CR4, and the compound is Compound No. III-6, III-7, III-8, III-64-68, III-74, III-78, III-92, III-95 to III-97, or III-98.
In certain embodiments, with respect to the compounds of formula (A-IIIF-2), each Y1, Y2, Y3, Y4 and Y5 is CR4, and the compound is Compound No. III-189-191, III-196, III-256 to III-257, or III-258.
In certain embodiments, with respect to the compounds of formula (A-IIIF-2), R8 is OH, each Y1, Y3, Y4 and Y5 is CR4, Y2 is N, and the compound is Compound No. 14, 28, 43, 128, 196, II-87, or III-93.
In certain embodiments, with respect to the compounds of formula (I) or (A-IIIF-2), each Y1, Y3, Y4 and Y5 is CR4, Y2 is N, and the compound is Compound No. II-249, III-192, or III-194.
In certain embodiments, with respect to the compounds of formula (I) or (A-IIIF-2), R8 is OH, each Y1, Y2, Y4 and Y5 is CR4, Y3 is N, and the compound is Compound No. 8, 19, 41, III-69, III-75 to III-82, III-87 to III-88, III-90, or III-94.
In certain embodiments, with respect to the compounds of formula (A-IIIF-2), each Y1, Y2, Y4 and Y5 is CR4, Y3 is N, and the compound is Compound No. 153, III-187, III-188, III-195 or III-197.
In some embodiments, the compound is of formula (A-IIIF-3), when each R7 and R8 is H; R1 is methyl; R6 is chloro; each Y1, Y2, Y4 and Y5 is CR4, and Y3 is CH, CF or CCl; then at least one of Y1, Y2, Y4 and Y5 is other than CH.
In some embodiments, the compound is of formula (A-IIIF-4), when each R7 and R8 is H, or R7 taken together with R8 form a —CH2 moiety, R1 is methyl′ R6 is F, Cl, CF3, ethenyl, or propenyl; each Y1, Y2, Y4 and Y5 is CR4, and Y3 is CH, CF or CCl; then at least one of Y1, Y2, Y4 and Y5 is other than CH.
In some embodiments, the compound is of formula (A-IIIF-3), when R7 is H or methyl; R8 is OH; R6 is chloro or iso-propyl; Y2 or Y3 is N; then R1 is other than methyl.
In certain embodiments, with respect to the compounds of formula (A-IIIF-3), the compound is Compound No. III-4, III-71, or III-90.
In some embodiments, the compound is of formula (A-IIIF-4), when R7 is H or methyl, R8 is OH, R1 is methyl, R6 is Cl, F, or methoxy; then Y3 is other than N.
In certain embodiments, with respect to the compounds of formula (A-IIIF-4), the compound is Compound No. III-5, III-70, III-72, or III-89.
In another embodiment, the compound is of the formula (A-IIIG-1), (A-IIIG-2) or (A-IIIG-3):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl;
R6 is H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl, or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15, —OC(O)-aryl, —OC(O)-heteroaryl, or —OC(O)C1-C5 alkyl optionally substituted with amino, or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl, or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl; or R14 and R15 are taken together to form a C3-C5 alkylene; and
each Y1, Y2, Y3, Y4 and Y5 is independently N or CR4 such that no more than two of Y1, Y2, Y3, Y4 and Y5 are N, wherein R4 is H, halo, CH3, CF3, or OCH3.
In some embodiments, the compound is of the formula (A-IIIG-2). In some variations, R1 is H or CH3. In other variations, R7 is H or CH3. In yet other variations, R8 is hydroxyl or NH2. In yet other variations, each R7 and R8 is H. In yet other variations, one of Y1, Y2, Y3, Y4 and Y5 is N and the other four of Y1, Y2, Y3, Y4 and Y5 are independently CR4, and wherein R4 is H, halo, CH3, CF3, or OCH3. In other variations, Y5 is CH, and each Y1, Y2, Y3 and Y4 is independently N or CR4 such that two of Y1, Y2, Y3 and Y4 are N, and wherein R4 is H, halo, CH3, CF3, or OCH3. In some variations, R4 is halo. In other variations, R4 is CH3. In one embodiment, R4 is F. In another embodiment, R4 is Cl. In some embodiments, any two of Y1, Y2, Y3, Y4 and Y5 are CR4, and each R4 is independently Cl or F. In one embodiment, each R4 is Cl. In another embodiment, each R4 is F.
In some embodiments, the compound is of the formula (A-IIIG-1), (A-IIIG-2), or (A-IIIG-3), R6 is H, R1 is methyl, each of R7 and R8 is H, each Y1, Y2, Y3, Y4 and Y5 is CR4 wherein at least one R4 is other than H.
In certain embodiments, with respect to the compounds of formula (A-IIIG-2), R8 is OH, and the compound is Compound No. 55, 136, 138, 145, II-99, II-100, II-108, II-109, II-111, or II-114.
In certain embodiments, with respect to the compounds of formula (A-IIIG-2), the compound is Compound No. 156, 159, II-110, II-119, II-240, or V-2.
In another embodiment, the compound is of the formula (A-IIIH):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl;
R6 is H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl, or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15, —OC(O)-aryl, —OC(O)-heteroaryl, or —OC(O)C1-C5 alkyl optionally substituted with amino, or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl, or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl; or R14 and R15 are taken together to form a C3-C5 alkylene; and
each Y1, Y2, Y3, Y4 and Y5 is independently N or CR4 such that no more than two of Y1, Y2, Y3, Y4 and Y5 are N, wherein R4 is H, halo, CH3, CF3, or OCH3.
In certain embodiments, with respect to the compounds of formula (A-IIIH), the compound is Compound No. 13, 15, 92, 154, 172, 221, or 339.
In certain embodiments, with respect to the compounds of formula (A-IIIH), the compound is Compound No. II-22, II-24 to II-35, II-37, II-38, II-41 to II-46, II-51, II-134, II-135, II-155, II-159, II-246, or II-289.
In certain embodiments, with respect to the compounds of formula (A-IIIH), the compound is Compound No. III-9-46, III-209 to III-220, III-320 to III-351, or III-352.
In certain embodiments, with respect to the compounds of formula (A-IIIH), the compound is Compound No. V-21.
In another embodiment, the compound is of the formula (A-IIIH-1), (A-IIIH-2), (A-IIIH-3) or (A-IIIH-4):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 independently substituents selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl;
R6 is H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl, or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15, —OC(O)-aryl, —OC(O)-heteroaryl, or —OC(O)C1-C5 alkyl optionally substituted with amino, or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl, or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl; or R14 and R15 are taken together to form a C3-C5 alkylene; and
each Y1, Y2, Y3, Y4 and Y5 is independently N or CR4 such that no more than two of Y1, Y2, Y3, Y4 and Y5 are N, wherein R4 is H, halo, CH3, CF3, or OCH3.
In some variations, R1 is H or CH3. In other variations, R7 is H or CH3. In yet other variations, R8 is hydroxyl or NH2. In yet other variations, each R7 and R8 is H. In some variations, each Y1, Y2, Y3, Y4 and Y5 is independently N or CR4 such that no more than two of Y1, Y2, Y3, Y4 and Y5 are N, wherein R4 is H, halo, CH3, CF3, or OCH3. one of Y1, Y2, Y3, Y4 and Y5 is N and the other four of Y1, Y2, Y3, Y4 and Y5 are independently CR4, and wherein R4 is H, halo, CH3, CF3, or OCH3. In other variations, Y5 is CH, and each Y1, Y2, Y3 and Y4 is independently N or CR4 such that two of Y1, Y2, Y3 and Y4 are N, and wherein R4 is H, halo, CH3, CF3, or OCH3. In some variations, R4 is halo. In other variations, R4 is CH3. In one embodiment, R4 is F. In another embodiment, R4 is Cl. In some embodiments, any two of Y1, Y2, Y3, Y4 and Y5 are CR4, and each R4 is independently Cl or F. In one embodiment, each R4 is Cl. In another embodiment, each R4 is F.
In certain embodiments, with respect to the compounds of formula (A-IIIH-2), R6 is methyl or chloro, R7 is H or methyl, R8 is H or OH, Y1 or Y2 is independently C—H, C—F, C—Cl, or C-methoxy, and Y3 is other than CH, CF, CCl, or C—OCH3.
In certain embodiments, with respect to the compounds of formula (A-IIIH-2), R6 is Cl or methyl, R7 is methyl, R8 is hydroxyl, and the compound is Compound No. 221.
In certain embodiments, with respect to the compounds of formula (A-IIIH-2), R6 is Cl or methyl, R7 is methyl, R8 is hydroxyl, and the compound is Compound No. II-24, II-25, or II-26.
In certain embodiments, with respect to the compounds of formula (A-IIIH-2), R6 is Cl or methyl, R7 is methyl, R8 is hydroxyl, and the compound is Compound No. III-11 to III-20, III-22, III-26 to III-38, or III-44 to III-46.
In one aspect, provided is a compoud of formula (A-IIIA′):




or a salt, solvate or N-oxide thereof, wherein:

    
    
        X, R1, R3a, R6, R7, R8, R9, R10 and Q are as defined for formula (A-IIIA),
        R4a is selected from the group consisting of hydrogen; halo; hydroxyl; cyano; carboxyl; —OC(O)N(R14a)R15a; and —C(O)N(R14a)R15a;
        R4b is selected from the group consisting of hydrogen, halo, and optionally substituted C1-C5 alkyl;
    
    


In one embodiment, when R4b is hydrogen, R4a is other than hydrogen. In some variations, R4a is halo. In some variations, R4a is chloro. In some variations, R4a is fluoro. In some variations, each R4a and R4b is halo.
In one aspect, provided is a compound of formula (A-IV):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1-3 substituents selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl, or is taken together with R2a or R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R4a or R5a, where present, to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety;

each n and m is 1, or n is 0 and m is 1, or n is 1 and m is 0;
R2a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 or R5a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R3a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, taken together with R4a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R3a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 or R4a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R2a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, taken together with R5a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R4a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, or is taken together with R2a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety, or is taken together with R5a, where present, to form a methylene (—CH2—) moiety;
R5a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R2a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, or is taken together with R3a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety, or is taken together with R4a, where present, to form a methylene (—CH2—) moiety;
each R2b, R3b, R4b and R5b is independently H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl;
X is N or CR6a;
each R6 and R6a is independently H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl; and
Q is cycloalkyl, aryl or heteroaryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.
In one variation, the compound is of the formula (A-IV), wherein m, n and R1 are as defined for the formula (A-IV);
R2a is H or optionally substituted C1-C5 alkyl, or is taken together with R1 or R5a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R3a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, taken together with R4a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R3a is H or optionally substituted C1-C5 alkyl, or is taken together with R1 or R4a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R2a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, taken together with R5a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R4a is H or optionally substituted C1-C5 alkyl, or is taken together with R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, or is taken together with R2a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety, or is taken together with R5a, where present, to form a methylene (—CH2—) moiety;
R5a is H or optionally substituted C1-C5 alkyl, or is taken together with R2a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, or is taken together with R3a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety, or is taken together with R4a, where present, to form a methylene (—CH2—) moiety;
each R2b, R3b, R4b and R5b is independently H or optionally substituted C1-C5 alkyl;
X is N or CR6a;
each R6 and R6a is independently H, hydroxyl, halogen, C1-C5 alkyl optionally substituted with 1 to 3 halogen atoms, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
Q is aryl or heteroaryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, —NHC(O)CH3 and —C(O)NR16R17; and
each R16 and R17 is independently H or optionally substituted C1-C5 alkyl.
In one embodiment, the compound is of formula (A-IV), each of R2b, R3a, R3b, R4b, R5a and R5b is H; each R2a and R4a is H, or R2a is taken together with R4a, when present, to form an ethylene (—CH2CH2—) moiety; each R6 and R6a is independently CF3, methyl, Cl, CONHCH3, COOH, COOCH3, or F; X is CR6; and R1 is other than methyl. In another embodiment, X is CR6, R6 is F; and R1 is other than methyl.
In one aspect, provided is a compound of formula (A-V):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 halogen atoms or hydroxyl, cycloalkyl optionally substituted with 1 to 3 halogen atoms or hydroxyl, C2-C5 alkenyl, or —C(O)OR11, or is taken together with R2a or R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R4a or R5a, where present, to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety;
each n and m is 1, or n is 0 and m is 1, or n is 1 and m is 0;
R2a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 or R5a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R3a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, taken together with R4a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R3a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 or R4a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R2a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, taken together with R5a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R4a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, or is taken together with R2a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety, or is taken together with R5a, where present, to form a methylene (—CH2—) moiety;
R5a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R2a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, or is taken together with R3a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety, or is taken together with R4a, where present, to form a methylene (—CH2—) moiety;
each R2b, R3b, R4b and R5b is independently H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl;
X is N or CR6a;
each R6 and R6a is independently H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
s is 0 or 1;
each R9 and R10, where present, is independently H or optionally substituted C1-C5 alkyl;
R18 is H or optionally substituted C1-C5 alkyl, and  indicates the presence of either an (E) or (Z) double bond configuration; and
Q is cycloalkyl, aryl or heteroaryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.
In one variation, the compound is of the formula (A-V), wherein m, n and R1 are as defined for the formula (A-V);
R2a is H or optionally substituted C1-C5 alkyl, or is taken together with R1 or R5a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R3a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, taken together with R4a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R3a is H or optionally substituted C1-C5 alkyl, or is taken together with R1 or R4a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R2a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, taken together with R5a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R4a is H or optionally substituted C1-C5 alkyl, or is taken together with R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, or is taken together with R2a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety, or is taken together with R5a, where present, to form a methylene (—CH2—) moiety;
R5a is H or optionally substituted C1-C5 alkyl, or is taken together with R2a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, or is taken together with R3a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety, or is taken together with R4a, where present, to form a methylene (—CH2—) moiety;
each R2b, R3b, R4b and R5b is independently H or optionally substituted C1-C5 alkyl;
X is N or CR6a;
each R6 and R6a is independently H, hydroxyl, halogen, C1-C5 alkyl optionally substituted with 1-3 halogen atoms, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
s is 0 or 1;
each R9 and R10, where present, is independently H or optionally substituted C1-C5 alkyl;
R18 is H or optionally substituted C1-C5 alkyl, and  indicates the presence of either an (E) or (Z) double bond configuration;
Q is aryl or heteroaryl optionally substituted with 1-3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, —NHC(O)CH3 and —C(O)NR16R17; and
each R16 and R17 is independently H or optionally substituted C1-C5 alkyl.
In certain embodiments, with respect to the compounds of formula (A-V), the compound is Compound No. 116, 121, or 132.
In one aspect, provided is a compound of formula (A-VI):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl, or is taken together with R2a or R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R4a or R5a, where present, to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety;
each n and m is 1, or n is 0 and m is 1, or n is 1 and m is 0;
R2a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 or R5a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R3a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, taken together with R4a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R3a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 or R4a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R2a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, taken together with R5a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R4a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, or is taken together with R2a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety, or is taken together with R5a, where present, to form a methylene (—CH2—) moiety;
R5a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R2a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, or is taken together with R3a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety, or is taken together with R4a, where present, to form a methylene (—CH2—) moiety;
each R2b, R3b, R4b and R5b is independently H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl;
X is N or CR6a;
each R6 and R6a is independently H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl, or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety, or is taken together with R9, where present, to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15, —OC(O)-aryl, —OC(O)-heteroaryl, or —OC(O)C1-C5 alkyl optionally substituted with amino, or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety, or is taken together with R10, where present, to form a bond;
s is 0 or 1;
each R9 and R10, where present, is independently H or optionally substituted C1-C5 alkyl;
each R11, R12, R13, R14 and R15 is independently H or optionally substituted C1-C5 alkyl; and
Q is acylamino, carbonylalkoxy, acyloxy, aminoacyl, aminocarbonylalkoxy or aminoaryl.
In one variation, the compound is of the formula (A-VI), wherein m, n, Q and R1 are as defined for the formula (A-VI);
R2a is H or optionally substituted C1-C5 alkyl, or is taken together with R1 or R5a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R3a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, taken together with R4a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R3a is H or optionally substituted C1-C5 alkyl, or is taken together with R1 or R4a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R2a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, taken together with R5a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R4a is H or optionally substituted C1-C5 alkyl, or is taken together with R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, or is taken together with R2a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety, or is taken together with R5a, where present, to form a methylene (—CH2—) moiety;
R5a is H or optionally substituted C1-C5 alkyl, or is taken together with R2a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, or is taken together with R3a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety, or is taken together with R4a, where present, to form a methylene (—CH2—) moiety;
each R2b, R3b, R4b and R5b is independently H or optionally substituted C1-C5 alkyl;
X is N or CR6a;
each R6 and R6a is independently H, hydroxyl, halogen, C1-C5 alkyl optionally substituted with 1-3 halogen atoms, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H or optionally substituted C1-C5 alkyl;
R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15, or —OC(O)C1-C5 alkyl optionally substituted with amino;
s is 0 or 1;
each R9 and R10, where present, is independently H or optionally substituted C1-C5 alkyl; and
each R11, R12, R13, R14 and R15 is independently H or optionally substituted C1-C5 alkyl.
In another embodiment, the compound is of formula (A-VIIA), (A-VIIB), (A-VIIC), (A-VIID), (A-VIIE) or (A-VIIF):







or a salt, solvate or N-oxide thereof, wherein:

R1, where present, is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl;
each X1, X2, X and U is independently N or CR6;
each R6 is independently H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl, or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, OC(O)N(R14)R15, —OC(O)-aryl, —OC(O)-heteroaryl, or —OC(O)C1-C5 alkyl optionally substituted with amino, or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl, or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl; or R14 and R15 are taken together to form a C3-C5 alkylene; and
each Y1, Y2, Y3, Y4 and Y5 is independently N or CR4 such that no more than two of Y1, Y2, Y3, Y4 and Y5 are N, wherein R4 is H, halo, CH3, CF3, or OCH3.
In certain embodiments, with respect to the compounds of formula (A-VIIA), R8 is OH, and the compound is Compound No. II-107, II-164, II-165, III-2, III-102-107, III-114, III-131, III-135, III-137, or III-138.
In certain embodiments, with respect to the compounds of formula (A-VIIA), each X1, X2, X and U is independently CR6; and the compound is Compound No. 211, III-100, III-200-202, III-207, III-289 to III-296, III-307, III-309, III-316, III-318, or III-319.
In certain embodiments, with respect to the compounds of formula (A-VIIA), each X1, X2, X and U is independently CR6, each Y1, Y3, Y4 and Y5 is independently CR4, Y2 is N, and the compound is Compound No. III-132, III-133, III-203, III-205, III-294, III-299, III-303, III-306, III-312, or III-315.
In certain embodiments, with respect to the compounds of formula (A-VIIA), each X1, X2, X and U is independently CR6, each Y1, Y2, Y4 and Y5 is independently CR4, Y3 is N, and the compound is Compound No. 73, 154, II-66, III-101, III-108 to III-113, III-115 to III-121, III-125 to III-130, III-134, III-138, III-198, III-199, III-206 to III-208, III-297, III-298, III-301, III-302, III-305, III-308, III-311, III-314, or III-317.
In certain embodiments, with respect to the compounds of formula (A-VIIA), each X1, X2, and X is CR6; U is N, and the compound is Compound No. III-2.
In certain embodiments, with respect to the compounds of formula (A-VIIB), each X1, X2, X and U is independently CR6, R8 is OH, and the compound is Compound No. III-59.
In certain embodiments, with respect to the compounds of formula (A-VIIC), each X1, X2, X and U is independently CR6, R8 is OH, each Y1, Y2, Y4 and Y5 is independently CR4, Y3 is N, and the compound is Compound No. 36, 38, or II-69.
In certain embodiments, with respect to the compounds of formula (A-VIID), each X1, X2, X and U is independently CR6, R8 is OH, and the compound is Compound No. III-58.
In certain embodiments, with respect to the compounds of formula (A-VIIE), each X1, X2, X and U is independently CR6, R8 is OH, and the compound is Compound No. III-60.
In certain embodiments, with respect to the compounds of formula (A-VIIE), each X1, X2, X and U is independently CR6, R8 is OH, and the compound is Compound No. III-56.
In another embodiment, the compound is of formula (A-VIIIA) or (A-VIIIB):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl;
each X1, X2, X and U is independently N or CR6;
each R6 is independently H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl, or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15, —OC(O)-aryl, —OC(O)-heteroaryl, or —OC(O)C1-C5 alkyl optionally substituted with amino, or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl, or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl; or R14 and R15 are taken together to form a C3-C5 alkylene; and
Q is aryl or heteroaryl, wherein the aryl or heteroaryl is independently optionally substituted with 1 to 3 substituents including halogen, C1-C5 alkyl or cycloalkyl, halo-substituted C1-C5 alkyl or cycloalkyl, C1-C5 alkoxy or cycloalkoxy, —CN or —C(O)N(Ra)Rb, and wherein each Ra and Rb is independently H or C1-C5 alkyl.
In some variations of the compounds of formula (A-VIIIA) or (A-VIIIB), one of X1, X2, X and U is N, and the other three of X1, X2, X and U is CR6. In other variations, two of X1, X2, X and U is N, and the other two of X1, X2, X and U is CR6. In some variations, R7 is a C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, —N(R7a)(R7b), —C(O)N(R7a)(R7b), —C(O)OR7a, —C(O)R7a. In other variations, R7 is an optionally substituted C3-C8 cycloalkyl. In some variations, R10 is an optionally substituted C3-C8 cycloalkyl. In other variations, R11 or R12 is an optionally substituted C3-C8 cycloalkyl. In some variations, Q is optionally substituted pyridyl, optionally substituted pyrimidyl, optionally substituted pyrazinyl, or optionally substituted phenyl.
In some variations of the compounds of formula (A-VIIIA), X1 is N; each X2 and X is CR6, wherein each R6 is H; U is CR6, wherein each R6 is H or methyl; R1 is methyl; each R7 and R8 is H; and Q is other than unsubstituted pyridyl, or pyridyl substituted with methyl or CF3.
In some variations of the compounds of formula (A-VIIIA), U is N, each X1, X2 and X is CR6, wherein each R6 is H; R1 is methyl; R7 is H or methyl; R8 is H, OH or methyl; and Q is other than unsubstituted phenyl, phenyl substituted with chloro, unsubstituted pyridyl, or pyridyl substituted with methyl or CF3.
In some variations of the compounds of formula (A-VIIIA), X2 is N, each X2 and X is CR6, wherein each R6 is H; U is CR6, wherein R6 is H or methyl; R1 is methyl; each of R7 and R8 is H; and Q is other than unsubstituted phenyl, unsubstituted pyridyl, or pyridyl substituted with CF3.
In some variations of the compounds of formula (A-VIIIA), X is N, each X1, U and X2 is CR6, wherein each R6 is H; R1 is methyl; each of R7 and R8 is H; and Q is other than unsubstituted phenyl.
In some variations of the compounds of formula (A-VIIIA), each X and U is N, each X1 and X2 is CR6, wherein each R6 is H; R1 is methyl; each of R7 and R8 is H; and Q is other than unsubstituted phenyl.
In some variations of the compounds of formula (A-VIIIA), the compound is according to formula (A-VIIIA-1), (A-VIIIA-2), (A-VIIIA-3), (A-VIIIA-4), (A-VIIIA-5), (A-VIIIA-6), or (A-VIIIA-7):







or a salt, solvate or N-oxide thereof, wherein Q, R1, R6, R7, and R8, are as described for formula (A-VIIIA), and each X1, U, X2, or X (where present) is independently CR6.

In one embodiment, the compound is according to formula (A-VIIIA-1), each X1, U and X2 is CR6, wherein each R6 is H; R1 is methyl; each of R7 and R8 is H; and Q is other than unsubstituted phenyl.
In one embodiment, the compound is according to formula (A-VIIIA-2), each X1 and X is CR6, wherein each R6 is H; U is CR6, wherein R6 is H or methyl; R1 is methyl; each of R7 and R8 is H; and Q is other than unsubstituted phenyl, unsubstituted pyridyl, or pyridyl substituted with CF3.
In one embodiment, the compound is according to formula (A-VIIIA-3), each X1, X2 and X is CR6, wherein each R6 is H; R1 is methyl; R7 is H or methyl; R8 is H, OH or methyl; and Q is other than unsubstituted phenyl, phenyl substituted with chloro, unsubstituted pyridyl, or pyridyl substituted with methyl or CF3.
In one embodiment, the compound is according to formula (A-VIIIA-4), each X2 and X is CR6, wherein each R6 is H; U is CR6, wherein R6 is H or methyl; R1 is methyl; each R7 and R8 is H; and Q is other than unsubstituted pyridyl, or pyridyl substituted with methyl or CF3.
In one embodiment, the compound is according to formula (A-VIIIA-5), each X1 and X2 is CR6, wherein each R6 is H; R1 is methyl; each of R7 and R8 is H; and Q is other than unsubstituted phenyl.
In one embodiment, with respect to the compounds of formula (A-VIIIA-1), (A-VIIIA-2), (A-VIIIA-3), (A-VIIIA-4), (A-VIIIA-5), (A-VIIIA-6), or (A-VIIIA-7), each X1, U, X2, or X (where present) is independently CR6, and each R6 is H. In another embodiment, each R6 is independently selected from H, C1-C5 alkyl, and halo C1-C5 alkyl. In certain embodiments, each R6 is independently selected from H, methyl, ethyl, fluoro, chloro, CH2F, and CF3.
In one embodiment, with respect to the compounds of formula (A-VIIIA-1), (A-VIIIA-2), (A-VIIIA-4), (A-VIIIA-6), or (A-VIIIA-7), each X1, X2, or X (where present) is CH, U is CR6, and R6 is selected from H, C1-C5 alkyl, and halo C1-C5 alkyl. In certain embodiments, each R6 is independently selected from methyl, ethyl, fluoro, chloro, CH2F, and CF3.
In one embodiment, with respect to the compounds of formula (A-VIIIA-1), (A-VIIIA-2), (A-VIIIA-3), (A-VIIIA-4), (A-VIIIA-5), (A-VIIIA-6), or (A-VIIIA-7), each R7 and R8 is H. In another embodiment, R7 is H or methyl, and R8 is H, OH or methyl.
In one embodiment, with respect to the compounds of formula (A-VIIIA-1), (A-VIIIA-2), (A-VIIIA-3), (A-VIIIA-4), (A-VIIIA-5), (A-VIIIA-6), or (A-VIIIA-7), Q is optionally substituted phenyl.
In another embodiment, with respect to the compounds of formula (A-VIIIA-1), (A-VIIIA-2), (A-VIIIA-3), (A-VIIIA-4), (A-VIIIA-5), (A-VIIIA-6), or (A-VIIIA-7), Q is phenyl substituted with C1-C5 alkyl, halo, halo C1-C5 alkyl, or C1-C5 alkoxy.
In another embodiment, with respect to the compounds of formula (A-VIIIA-1), (A-VIIIA-2), (A-VIIIA-3), (A-VIIIA-4), (A-VIIIA-5), (A-VIIIA-6), or (A-VIIIA-7), Q is phenyl substituted with methyl, ethyl, fluoro, chloro, methoxy, or CF3.
In another embodiment, with respect to the compounds of formula (A-VIIIA-1), (A-VIIIA-2), (A-VIIIA-3), (A-VIIIA-4), (A-VIIIA-5), (A-VIIIA-6), or (A-VIIIA-7), Q is optionally substituted pyridyl, or optionally substituted pyrimidinyl.
In another embodiment, with respect to the compounds of formula (A-VIIIA-1), (A-VIIIA-2), (A-VIIIA-3), (A-VIIIA-4), (A-VIIIA-5), (A-VIIIA-6), or (A-VIIIA-7), Q is pyridyl substituted with C1-C5 alkyl, halo, halo or C1-C5 alkyl.
In another embodiment, with respect to the compounds of formula (A-VIIIA-1), (A-VIIIA-2), (A-VIIIA-3), (A-VIIIA-4), (A-VIIIA-5), (A-VIIIA-6), or (A-VIIIA-7), Q is pyridyl substituted with methyl, ethyl, fluoro, chloro, or CF3.
In one embodiment, provided are compounds of formula (A-IXA), (A-IXB), (A-IXC) or (A-IXD):




wherein U, Q, R1, R6, R7, and R8 are as described for formula (A-I).

In certain embodiments, R8 is azido. In certain embodiments, R8 is N(R11)R12. In certain embodiments, each R11 and R12 is independently H or optionally substituted C1-C5 alkyl, or R11 and R12 are taken together to form C3-C5 alkylene. In certain embodiments, R7 is H or methyl, R8 is azido, or N(R11)R12, and each R11 and R12 is independently H or optionally substituted C1-C5 alkyl, or R11 and R12 are taken together to form C3-C5 alkylene. In certain embodiments, R8 is SR13, S(O)R13, or SO2R13; and R13 is independently H or optionally substituted C1-C5 alkyl. In one embodiment, R13 is methyl, ethyl, i-propyl, n-propyl, n-butyl, or t-butyl. In certain embodiments, R7 is C1-C5 alkyl, substituted with amino or substituted amino. In certain embodiments, R7 is C1-C5 alkyl, substituted with OH or optionally substituted C1-C5 alkoxy. In certain embodiments, R7 is C1-C5 alkyl, substituted with —C(O)N(R7a)R7b; and each R7a and R7b is independently H or optionally substituted C1-C5 alkyl, or R7a and R7b are taken together to form C3-C5 alkylene. In certain embodiments, R7 is C1-C5 alkyl, substituted with acyl.
In certain embodiments, R8 is halo. In one embodiment, with respect to the compounds of formula (A-IXB) or (A-IXC), when R8 is fluoro or chloro, R1 is methyl, ethyl, i-propyl, or cyclopropyl, R7 is H or methyl, U is CR6, and R6 is methyl or chloro, then Q is other than unsubstituted phenyl, phenyl substituted with methoxy, chloro, fluoro, difluoro, unsubstituted pyridyl, pyridyl substituted with methyl, or unsubstituted pyrimidinyl.
In certain embodiments, R7 is optionally substituted cycloalkyl. In one embodiment, with respect to the compounds of formula (A-IXB) or (A-IXC), when R7 is optionally substituted cycloalkyl, R8 is OH, R1 is methyl, U is CR6, and R6 is methyl or chloro, then Q is other than unsubstituted phenyl, phenyl substituted with fluoro, or unsubstituted pyridyl. In one embodiment, R7 is optionally substituted cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. In certain embodiments, R7 is C1-C5 alkyl, substituted with acylamino.
In one embodiment, with respect to the compounds of formula (A-IXB) or (A-IXC), when R7 is CH2—CON(H)CH3, R1 is methyl or ethyl, U is CR6, and R6 is methyl or chloro, then Q is other than phenyl substituted with fluoro, chloro, methoxy, or difluoro, unsubstituted pyridyl, pyridyl substituted with methyl, or unsubstituted pyrimidinyl.
In certain embodiments, R7 is C1-C5 alkyl, substituted with —C(O)OR7a, and R7a is H or optionally substituted C1-C5 alkyl.
In one embodiment, R7 is C1-C5 alkyl, substituted with —C(O)OR7a, R7a is H or optionally substituted C1-C5 alkyl, R1 is methyl or ethyl, U is CR6, and R6 is methyl or chloro; and Q is other than phenyl substituted with F, chloro, methoxy, or difluoro, unsubstituted pyridyl, pyridyl substituted with methyl, or unsubstituted pyrimidinyl.
In certain embodiments, R7 is C1-C5 alkyl, substituted with 1-3 halo.
In one embodiment, with respect to the compounds of formula (A-IXB), R7 is CF3, R8 is OH, R1 is methyl, U is CR6, and R6 is methyl; and Q is other than phenyl substituted with fluoro. In one particular embodiment, R7 is CF3.
In certain embodiments, R8 is —C(O)N(R14)R15; and each R14 and R15 is independently H or optionally substituted C1-C5 alkyl, or R14 and R15 are taken together to form a C3-C5 alkylene.
In one particular embodiment, R8 is —C(O)N(R14)R15; and each R14 and R15 is independently H or methyl, R1 is methyl, U is CR6, and R6 is methyl; and Q is other than cyclobutyl.
In certain embodiments, R8 is —OC(O)N(R14)R15, —OC(O)-aryl, —OC(O)-heteroaryl, —OC(O)C1-C5 alkyl optionally substituted with amino, —OC(O)C1-C5 alkyl substituted with carboxyl, or —OC1-C5 alkyl optionally substituted with carboxyl; and each R14 and R15 is independently H or optionally substituted C1-C5 alkyl, or R14 and R15 are taken together to form a C3-C5 alkylene.
In certain embodiments, R7 is optionally substituted phenyl. In one particular embodiment, R7 is optionally substituted phenyl, R8 is OH, R1 is methyl or ethyl, U is CR6, and R6 is methyl or chloro; and Q is other than unsubstituted phenyl, phenyl substituted with fluoro or unsubstituted pyridyl.
In certain embodiments, R8 is OH. In some embodiments, R8 is OH, and R7 is other than H, or C1-C4 alkyl.
In some embodiments, compounds of the formula (B-I) are provided:




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1-3 substituents selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl, or is taken together with R2a or R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R4a or R5a, where present, to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety;
each n and m is 1, or n is 0 and m is 1, or n is 1 and m is 0;
R2a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 or R5a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R3a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, taken together with R4a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R3a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 or R4a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R2a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, taken together with R5a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R4a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, or is taken together with R2a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety, or is taken together with R5a, where present, to form a methylene (—CH2—) moiety;
R5a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R2a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety, or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety, or is taken together with R3a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety, or is taken together with R4a, where present, to form a methylene (—CH2—) moiety;
each R2b, R3b, R4b and R5b is independently H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl;
X is N or CR6a;
t is 1, 2 or 3;
each R6 and R6a is independently H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1-3 substituents selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl;
R8 is azido, acylamino, carboxyl, carbonylalkoxy, —OC(O)C1-C5 alkyl substituted with carboxyl, or —OC1-C5 alkyl optionally substituted with carboxyl;
each R9 and R10 is independently H or optionally substituted C1-C5 alkyl; and
Q is cycloalkyl, aryl or heteroaryl optionally substituted with 1-3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.
In one variation, Q, X, m, n, t, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R6, R6a, R7, R9 and R10 are as defined for the formula (B-I), and R8 is azido, acylamino, —OC(O)C1-C5 alkyl substituted with carboxyl, or —OC1-C5 alkyl substituted with carboxyl, or a salt, solvate or N-oxide thereof. In another variation, Q, X, m, n, t, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R6, R6a, R7, R9 and R10 are as defined for the formula (B-I), and R8 is carboxyl, or carbonylalkoxy, or a salt, solvate or N-oxide thereof.
In one variation, Q is cycloalkyl, aryl or heteroaryl optionally substituted with 1-3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, —NHC(O)CH3 and —C(O)NR11R12 where each R11 and R12 is independently H or optionally substituted C1-C5 alkyl.
In some variations, R1 is C1-C5 alkyl (e.g., methyl), each R2a and R3a is H, R6 is methyl or chloro, and X is CR6a where R6a is methyl or chloro. In some of these variations, t is 1, 2 or 3. In some of these variations, R7 is H or C1-C5 alkyl (e.g., methyl). In some of these variations, R7 is H. In some of these variations, R9 is H or C1-C5 alkyl (e.g., methyl) and R10 is H. In some of these variations, each R9 and R10 is H. In some of these variations, each R7, R9 and R10 is H. In some of these variations, Q is an unsubstituted pyridyl group which may be attached to the parent structure at any position (e.g., 2-pyridyl, 3-pyridyl or 4-pyridyl). In some of these variations, Q is 3-pyridyl or 4-pyridyl. In some of these variations, Q is pyridyl substituted a methyl (e.g., 6-methyl-3-pyridyl and 3-methyl-4-pyridyl). In some of these variations, Q is phenyl substituted with a halo group (e.g., fluorophenyl). In some of these variations, Q is 4-fluorophenyl. In some of these variations, Q is phenyl substituted with —C(O)NR11R12 where each R11 and R12 is H. In some of these variations, Q is 4-carbamoylphenyl.
In another embodiment, the compound of formula (B-I) has the formula (B-IA):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1-3 substituents selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl, or is taken together with R2a or R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R2a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R3a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
X is N or CR6a;
each R6 and R6a is independently H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl;
R8 is azido, acylamino, carboxyl, carbonylalkoxy, —OC(O)C1-C5 alkyl substituted with carboxyl or —OC1-C5 alkyl optionally substituted with carboxyl;
each R9 and R10 is independently H or optionally substituted C1-C5 alkyl; and
Q is cycloalkyl, aryl or heteroaryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.
In one variation, the compound is of the formula (B-IA), wherein Q, X, R1, R2a, R3a, R6, R6a, R7, R9 and R10 are as defined for the formula (B-IA), and R8 is azido, acylamino, —OC(O)C1-C5 alkyl substituted with carboxyl, or —OC1-C5 alkyl substituted with carboxyl, or a salt, solvate or N-oxide thereof. In another variation, Q, X, R1, R2a, R3a, R6, R6a, R7, R9 and R10 are as defined for the formula (B-IA), and R8 is carboxyl, or carbonylalkoxy.
In some variations of the compound of the formula (B-IA), each R2a and R3a is H. In some variations, R1 is C1-C5 alkyl (e.g., methyl). In some variations, each R6 and R6a is independently halo (e.g., chloro) or C1-C5 alkyl (e.g., methyl). In some variations, each R6 and R6a is independently halo (e.g., chloro or fluoro). In some variations, R6 and R6a is chloro. In some variations, each R6 and R6a is independently C1-C5 alkyl (e.g., methyl). In some variations, X is CR6a where R6a is H or halo. In some variations, X is CR6a where R6a is H. In some variations, X is CR6a where R6a is chloro. In some variations, X is CR6a where R6a is halo (e.g., chloro or fluoro). In some variations, R6 is H or halo. In some variations, R6 is H. In some variations, R6 is chloro. In some variations, R6 is halo (e.g., chloro or fluoro). In some variations, R7 is H or C1-C5 alkyl (e.g., methyl). In some variations, X is N. In some variations, R7 is H. In some variations, R7 is C1-C5 alkyl (e.g., methyl). In some variations, R8 is azido. In some variations, R8 is carboxyl, —OC(O)C1-C5 alkyl substituted with carboxyl, or —OC1-C5 alkyl optionally substituted with carboxyl. In some variations, R8 is acylamino. In some variations, R7 is H or C1-C5 alkyl (e.g., methyl) and R8 is azido, acylamino, —OC(O)C1-C5 alkyl substituted with carboxyl or —OC1-C5 alkyl optionally substituted with carboxyl. In some variations, R7 is H and R8 is azido, acylamino, —OC(O)C1-C5 alkyl substituted with carboxyl or —OC1-C5 alkyl optionally substituted with carboxyl. In some variations, R9 is H or C1-C5 alkyl (e.g., methyl). In some variations, R10 is H or C1-C5 alkyl (e.g., methyl). In some variations, each R9 and R10 is H. In some variations, one of R9 and R10 is H and the other is C1-C5 alkyl (e.g., methyl). In some variations, Q is an unsubstituted heteroaryl (e.g., pyridyl). In some variations, Q is an unsubstituted pyridyl group which may be attached to the parent structure at any position (e.g., 2-pyridyl, 3-pyridyl or 4-pyridyl). In some variations, Q is 3-pyridyl or 4-pyridyl. In some variations, Q is heteroaryl substituted with a substituent selected form the group consisting of halo (e.g., fluoro or chloro), C1-C5 alkyl (e.g., methyl), halo-substituted C1-C5 alkyl (e.g., CF3) and carboxyl. In some variations, Q is heteroaryl substituted with halo (e.g., fluoro or chloro) or C1-C5 alkyl (e.g., methyl). In some variations, Q is heteroaryl substituted with C1-C5 alkyl (e.g., methyl). In some variations, Q is a pyridyl optionally substituted with a methyl where the pyridyl group may be attached to the parent structure at any position and the methyl group may be attached to the pyridyl group at any open position (e.g., 6-methyl-3-pyridyl and 3-methyl-4-pyridyl). In some variations, Q is phenyl substituted with a substituent selected form the group consisting of halo (e.g., fluoro or chloro), C1-C5 alkyl (e.g., methyl), halo-substituted C1-C5 alkyl (e.g., CF3), carboxyl and —C(O)NR11R12 where each R11 and R12 is independently H or optionally substituted C1-C5 alkyl. In some variations, Q is phenyl substituted with a halo group (e.g., fluorophenyl). In some variations, Q is 4-fluorophenyl. In some variations, Q is phenyl substituted with —C(O)NR11R12 where each R11 and R12 is H.
In some variations of the compound of the formula (B-IA), R1 is C1-C5 alkyl (e.g., methyl), each R2a and R3a is H, R6 is methyl or chloro, and X is CH. In some of these variations, R7 is H or C1-C5 alkyl (e.g., methyl) and R8 is azido. In some of these variations, R7 is H and R8 is azido, acylamino, —OC(O)C1-C5 alkyl substituted with carboxyl or —OC1-C5 alkyl optionally substituted with carboxyl. In some of these variations, R7 is methyl and R8 is azido, acylamino, —OC(O)C1-C5 alkyl substituted with carboxyl or —OC1-C5 alkyl optionally substituted with carboxyl. In some of these variations, R9 is H or C1-C5 alkyl (e.g., methyl) and R10 is H. In some of these variations, each R9 and R10 is H. In some of these variations, R7 is H or C1-C5 alkyl (e.g., methyl), R8 is azido, and each R9 and R10 is H. In some of these variations, Q is an unsubstituted pyridyl group which may be attached to the parent structure at any position (e.g., 2-pyridyl, 3-pyridyl or 4-pyridyl). In some of these variations, Q is 3-pyridyl or 4-pyridyl. In some of these variations, Q is pyridyl substituted a methyl (e.g., 6-methyl-3-pyridyl and 3-methyl-4-pyridyl). In some of these variations, phenyl substituted with a halo group (e.g., fluorophenyl). In some of these variations, Q is 4-fluorophenyl. In some of these variations, Q is phenyl substituted with —C(O)NR11R12 where each R11 and R12 is H. In some of these variations, Q is 4-carbamoylphenyl.
In some variations of the compound of the formula (B-IA), R1 is C1-C5 alkyl (e.g., methyl), each R2a and R3a is H, R6 is methyl or chloro, and X is CH. In some variations, R7 is H and
R8 is azido, acylamino, —OC(O)C1-C5 alkyl substituted with carboxyl or —OC1-C5 alkyl optionally substituted with carboxyl. In some variations, R7 is H and R8 is azido, acylamino, —OC(O)C1-C5 alkyl substituted with carboxyl or —OC1-C5 alkyl optionally substituted with carboxyl. In some of these variations, R9 is H or C1-C5 alkyl (e.g., methyl) and R10 is H. In some of these variations, each R9 and R10 is H. In some of these variations, Q is an unsubstituted pyridyl group which may be attached to the parent structure at any position (e.g., 2-pyridyl, 3-pyridyl or 4-pyridyl). In some of these variations, Q is 3-pyridyl or 4-pyridyl. In some of these variations, Q is pyridyl substituted a methyl (e.g., 6-methyl-3-pyridyl and 3-methyl-4-pyridyl). In some of these variations, Q is phenyl substituted with a halo group (e.g., fluorophenyl). In some of these variations, Q is 4-fluorophenyl. In some of these variations, Q is phenyl substituted with —C(O)NR11R12 where each R11 and R12 is H. In some of these variations, Q is 4-carbamoylphenyl.
In some variations of the compound of the formula (B-IA), R1 and R2a are taken together to form a propylene (—CH2CH2CH2—) moiety and R1a is H. In some of these variations, X is N. In some of these variations, X is CH. In some of these variations, R6 is C1-C5 alkyl (e.g., methyl) or halo (e.g., chloro). In some of these variations, R6 is methyl or chloro. In some of these variations, R7 is H or C1-C5 alkyl (e.g., methyl) and R8 is azido, acylamino, —OC(O)C1-C5 alkyl substituted with carboxyl or —OC1-C5 alkyl optionally substituted with carboxyl. In some of these variations, R7 is H and R8 is azido, acylamino, —OC(O)C1-C5 alkyl substituted with carboxyl or —OC1-C5 alkyl optionally substituted with carboxyl. In some of these variations, R7 is methyl and R8 is azido, acylamino, —OC(O)C1-C5 alkyl substituted with carboxyl or —OC1-C5 alkyl optionally substituted with carboxyl. In some of these variations, R9 is H or C1-C5 alkyl (e.g., methyl) and R10 is H. In some of these variations, each R9 and R10 is H. In some of these variations, R7 is H or C1-C5 alkyl (e.g., methyl), R8 is azido, and each R9 and R10 is H. In some of these variations, Q is an unsubstituted pyridyl group which may be attached to the parent structure at any position (e.g., 2-pyridyl, 3-pyridyl or 4-pyridyl). In some of these variations, Q is 3-pyridyl or 4-pyridyl. In some of these variations, Q is pyridyl substituted a methyl (e.g., 6-methyl-3-pyridyl and 3-methyl-4-pyridyl). In some of these variations, Q is phenyl substituted with a halo group (e.g., fluorophenyl). In some of these variations, Q is 4-fluorophenyl. In some of these variations, Q is phenyl substituted with —C(O)NR11R12 where each R11 and R12 is H. In some of these variations, Q is 4-carbamoylphenyl.
In certain embodiments, with respect to the compounds of formula (B-IA), X is CR6, R8 is azido, and the compound is Compound No. II-261, II-266, II-276, II-298, V-1, V-3, V-22, or V23.
In certain embodiments, with respect to the compounds of formula (B-IA), X is CR6, R8 is acylamino, carboxyl, or carbonylalkoxy, and the compound is Compound No. II-258, II-262, II-263, or II-277.
In certain embodiments, with respect to the compounds of formula (B-IA), X is CR6, R8 is —OC(O)C1-C5 alkyl substituted with carboxyl, and the compound is Compound No. V-18.
In certain embodiments, with respect to the compounds of formula (B-IA), X is CR6, R8 is —OC1-C5 alkyl optionally substituted with carboxyl, and the compound is Compound No. II-256, II-274, II-281, V-14 or V-15.
In another embodiment, the compound of formula (B-I) has the formula (B-IB):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1-3 substituents selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl, or is taken together with R2a or R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R2a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R3a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
X is N or CR6a;
each R6 and R6a is independently H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl;
R8 is azido, acylamino, carboxyl, carbonylalkoxy, —OC(O)C1-C5 alkyl substituted with carboxyl, or —OC1-C5 alkyl optionally substituted with carboxyl;
each R9 and R10 is independently H or optionally substituted C1-C5 alkyl; and
Q is cycloalkyl, aryl or heteroaryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.
In one variation, the compound is of the formula (B-IB), wherein Q, X, R1, R2a, R3a, R6, R6a, R7, R9 and R10 are as defined for the formula (B-IB), and R8 is azido, acylamino, —OC(O)C1-C5 alkyl substituted with carboxyl, or —OC1-C5 alkyl substituted with carboxyl, or a salt, solvate or N-oxide thereof. In another variation, Q, X, R1, R2a, R3a, R6, R6a, R7, R9 and R10 are as defined for the formula (B-IB), and R8 is carboxyl, or carbonylalkoxy.
In some variations of the compound of the formula (B-IB), R1 is C1-C5 alkyl (e.g., methyl),
each R2a and R3a is H, R6 is methyl or chloro, and X is CH. In some of these variations, R7 is H or C1-C5 alkyl (e.g., methyl) and R8 is azido. In some of these variations, R7 is H and R8 is azido, acylamino, —OC(O)C1-C5 alkyl substituted with carboxyl or —OC1-C5 alkyl optionally substituted with carboxyl. In some of these variations, R7 is methyl and R8 is azido, acylamino, —OC(O)C1-C5 alkyl substituted with carboxyl or —OC1-C5 alkyl optionally substituted with carboxyl. In some of these variations, R9 is H or C1-C5 alkyl (e.g., methyl) and R10 is H. In some of these variations, each R9 and R10 is H. In some of these variations, R7 is H or C1-C5 alkyl (e.g., methyl), R8 is azido, acylamino, —OC(O)C1-C5 alkyl substituted with carboxyl or —OC1-C5 alkyl substituted with carboxyl, and each R9 and R10 is H. In some of these variations, Q is an unsubstituted pyridyl group which may be attached to the parent structure at any position (e.g., 2-pyridyl, 3-pyridyl or 4-pyridyl). In some of these variations, Q is 3-pyridyl or 4-pyridyl. In some of these variations, Q is pyridyl substituted a methyl (e.g., 6-methyl-3-pyridyl and 3-methyl-4-pyridyl). In some of these variations, Q is phenyl substituted with a halo group (e.g., fluorophenyl). In some of these variations, Q is 4-fluorophenyl.
In another embodiment, the compound of formula (B-I) has the formula (B-IC):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1-3 substituents selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl, or is taken together with R2a or R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R2a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R3a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R5a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl;
X is N or CR6a;
each R6 and R6a is independently H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1-3 substituents selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl;
R8 is azido, acylamino, carboxyl, carbonylalkoxy, —OC(O)C1-C5 alkyl substituted with carboxyl or —OC1-C5 alkyl optionally substituted with carboxyl;
each R9 and R10 is independently H or optionally substituted C1-C5 alkyl; and
Q is cycloalkyl, aryl or heteroaryl optionally substituted with 1-3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.
In one variation, the compound is of the formula (B-IC), wherein Q, X, R1, R2a, R3a, R5a, R6, R6a, R7, R9 and R10 are as defined for the formula (B-IC), and R8 is azido, acylamino, —OC(O)C1-C5 alkyl substituted with carboxyl, or —OC1-C5 alkyl substituted with carboxyl, or a salt, solvate or N-oxide thereof. In another variation, Q, X, R1, R2a, R3a, R5a, R6, R6a, R7, R9 and R10 are as defined for the formula (B-IC), and R8 is carboxyl, or carbonylalkoxy.
In another embodiment, the compound of formula (B-I) has the formula (B-ID):




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1-3 substituents selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl, or is taken together with R2a or R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R2a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R3a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
X is N or CR6a;
each R6 and R6a is independently H; hydroxyl; halo; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl; optionally substituted C1-C5 alkoxy; or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl;
R8 is azido, acylamino, carboxyl, carbonylalkoxy, —OC(O)C1-C5 alkyl substituted with carboxyl, or —OC1-C5 alkyl optionally substituted with carboxyl;
each R9 and R10 is independently H or optionally substituted C1-C5 alkyl; and
Q is cycloalkyl, aryl or heteroaryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.
In one variation, the compound is of the formula (B-ID), wherein Q, X, R1, R2a, R3a, R6 and R6a are as defined for the formula (B-ID), R7 is H, halo, or optionally substituted C1-C5 alkyl;
R8 is azido, acylamino, —OC(O)C1-C5 alkyl substituted with carboxyl or —OC1-C5 alkyl substituted with carboxyl; and each R9 and R10 is independently H or optionally substituted C1-C5 alkyl, or a salt, solvate or N-oxide thereof.
In some variations of the compound of the formula (B-ID), R1 is C1-C5 alkyl (e.g., methyl), each R2a and R3a is H, R6 is methyl or chloro, and X is CH. In some of these variations, R7 is H or C1-C5 alkyl (e.g., methyl) and R8 is azido, acylamino, —OC(O)C1-C5 alkyl substituted with carboxyl or —OC1-C5 alkyl optionally substituted with carboxyl. In some of these variations, R7 is H and R8 is azido, acylamino, —OC(O)C1-C5 alkyl substituted with carboxyl or —OC1-C5 alkyl optionally substituted with carboxyl. In some of these variations, R7 is methyl and R8 is azido, acylamino, —OC(O)C1-C5 alkyl substituted with carboxyl or —OC1-C5 alkyl optionally substituted with carboxyl. In some of these variations, R9 is H or C1-C5 alkyl (e.g., methyl) and R10 is H. In some of these variations, each R9 and R10 is H. In some of these variations, R7 is H or C1-C5 alkyl (e.g., methyl), R8 is azido, and each R9 and R10 is H. In some of these variations, Q is an unsubstituted pyridyl group which may be attached to the parent structure at any position (e.g., 2-pyridyl, 3-pyridyl or 4-pyridyl). In some of these variations, Q is 3-pyridyl or 4-pyridyl. In some of these variations, Q is pyridyl substituted a methyl (e.g., 6-methyl-3-pyridyl and 3-methyl-4-pyridyl). In some of these variations, Q is phenyl substituted with a halo group (e.g., fluorophenyl). In some of these variations, Q is 4-fluorophenyl.
In one particular embodiment, the compound is of the formula (B-IA), (B-IB), (B-IC) or (B-ID), or a salt, solvate or N-oxide thereof, wherein:
R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo and hydroxyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo and hydroxyl, C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from halo and hydroxyl, or —C(O)O—C1-C5 alkyl;
each R2a, R3a or R5a (where applicable) is independently H or optionally substituted C1-C5 alkyl;
or R1 and R2a, or R1 and R3a are taken together to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
X is N or CR6a;
each R6 and R6a is independently H; halogen; C1-C5 alkyl optionally substituted with 1 to 3 substituents selected from halogen atoms and hydroxyl; optionally substituted C1-C5 alkoxy; or optionally substituted —C(O)C1-C5 alkyl;
each R7, R9 and R10 is independently H or optionally substituted C1-C5 alkyl;
R8 is azido, acylamino, —OC(O)C1-C5 alkyl substituted with carboxyl or —OC1-C5 alkyl optionally substituted with carboxyl; and
Q is aryl or heteroaryl optionally substituted with 1 to 3 substituents including halogen, C1-C5 alkyl or cycloalkyl, halo-substituted C1-C5 alkyl or cycloalkyl, C1-C5 alkoxy or cycloalkoxy, —CN, —CO2H or —C(O)N(Ra)Rb where each Ra and Rb is independently H or C1-C5 alkyl.
In certain embodiments of the compounds of any formula detailed herein, where applicable, such as compounds of the formulae (B-I), (B-IA), (B-IB), (B-IC) and (B-ID), R1 is H, C1-C5 alkyl (e.g., methyl) or —C(O)OR11 where R11 is C1-C5 alkyl. It is understood that any descriptions of R1 may be combined with any descriptions of other moieties (e.g., X, R6, R6a, R7, R8, R9, R10 and Q) the same as if each and every combination were specifically and individually listed.
In certain embodiments of the compounds of any formula detailed herein, where applicable, such as compounds of the formulae (B-I), (B-IA), (B-IB), (B-IC) and (B-ID), each R6 and R6a is independently H, CH3 or Cl. It is understood that any descriptions of R6 or R6a may be combined with any descriptions of other moieties (e.g., X, R1, R7, R8, R9, R10 and Q) the same as if each and every combination were specifically and individually listed.
In certain embodiments of the compounds of any formula detailed herein, where applicable, such as compounds of the formulae (B-I), (B-IA), (B-IB), (B-IC) and (B-ID), X is N. In certain embodiments of the compounds of the formulae (B-I), (B-IA), (B-IB), (B-IC) and (B-ID), X is CR6a. In some of these embodiments, R6a is H, CH3 or Cl. It is understood that any descriptions of X, R6 and R6a may be combined with any descriptions of other moieties (e.g., R1, R7, R8, R9, R10 and Q) the same as if each and every combination were specifically and individually listed.
In certain embodiments of the compounds any formula detailed herein, where applicable, such as compounds of the formulae (B-I), (B-IA), (B-IB), (B-IC) and (B-ID), R8 is azido. In another variation, R8 is carboxyl. In another variation, R8 is carbonylalkoxy. In another variation, R8 is —OC(O)C1-C5 alkyl substituted with carboxyl (e.g., —OC(O)CH2CO2H, —OC(O)CH2CH2CO2H, or —OC(O)CH2CH2CH2CO2H). In one variation, R8 is —OC1-C5 alkyl optionally substituted with carboxyl. In another variation, R8 is —OC1-C5 alkyl substituted with carboxyl (e.g., —OCH2CO2H, —OCH2CH2CO2H, or —OCH2CH2CH2CO2H). In yet another variation, R8 is —OC1-C5 alkyl. In another variation, R8 is acylamino of the formula —C(O)NR13R14 where each R13 and R14 is independently H or optionally substituted C1-C5 alkyl (e.g., —C(O)NH2, —C(O)NHCH3 or —C(O)N(CH3)2). In some variations, R8 is acylamino of the formula —C(O)NR13R14 where R13 and R14 are joined with the nitrogen to which they are attached to form a heterocycle (e.g., —C(O)-pyrrolidinyl). It is understood that any descriptions of R8 may be combined with any descriptions of other moieties (e.g., X, R1, R6, R6a, R7, R9, R10 and Q) the same as if each and every combination were specifically and individually listed.
In certain embodiments of the compounds of any formula detailed herein, where applicable, such as compounds of the formulae (B-I), (B-IA), (B-IB), (B-IC) and (B-ID), Q is aryl or heteroaryl optionally substituted with 1, 2 or 3 substituents independently selected form the group consisting of halo (e.g., fluoro or chloro), C1-C5 alkyl (e.g., methyl), halo-substituted C1-C5 alkyl (e.g., CF3), carboxyl and —C(O)NR11R12. In some variations, Q is unsubstituted heteroaryl. In some variations, Q is aryl or heteroaryl substituted with a substituent selected form the group consisting of halo (e.g., fluoro or chloro), C1-C5 alkyl (e.g., methyl), halo-substituted C1-C5 alkyl (e.g., CF3), carboxyl and —C(O)NR11R12. In some variations, Q is aryl or heteroaryl optionally substituted with 2 substituents independently selected form the group consisting of halo (e.g., fluoro or chloro), C1-C5 alkyl (e.g., methyl), halo-substituted C1-C5 alkyl (e.g., CF3), carboxyl and —C(O)NR11R12. In some variations, Q is aryl or heteroaryl optionally substituted with 3 substituents independently selected form the group consisting of halo (e.g., fluoro or chloro), C1-C5 alkyl (e.g., methyl), halo-substituted C1-C5 alkyl (e.g., CF3), carboxyl and —C(O)NR11R12 (e.g., —C(O)NH2). It is understood that any descriptions of Q may be combined with any descriptions of other moieties (e.g., X, R1, R6, R6a, R7, R8, R9 and R10) the same as if each and every combination were specifically and individually listed.
In certain embodiments, with respect to the compounds of formula (B-ID), the compound is Compound No. V-21.
In some embodiments, compounds of the formula (C-I) are provided:




or a salt, solvate or N-oxide thereof, wherein:

R6 is H; halo; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halogen atoms or hydroxyl; C2-C5 alkenyl; or —C(O)OR11; or cycloalkyl optionally substituted with 1 to 3 halogen atoms or hydroxyl, C2-C5 alkenyl, or —C(O)OR11;
R7 is H or optionally substituted C1-C5 alkyl;
R8 is H, hydroxyl, —OC(O)C1-C5 alkyl optionally substituted with amino, N(R11)R12, SR13, S(O)R13 or SO2R13;
each R11, R12 and R13 is independently H or optionally substituted C1-C5 alkyl;
each X1, X2 and X is N or CH such that no more than two of X1, X2 and X are N;
each Y1, Y2, Y3 and Y4 is N or CR4 such that no more than two of Y1, Y2, Y3 and Y4 are N, and wherein R4 is H, halo, CH3, CF3, or OCH3; and
n is 0 or 1.
In one variation of formula (C-I), one or more of the following apply (i) n is 1; (ii) R6 is other than Cl when n is 0, each R7 and R8 is H, each X1, X2, X, Y1, Y2 and Y4 is CH and Y3 is CF; (iii) R6 is other than H when n is 0 and (iv) R6 is other than CH3 when n is 0, each R7 and R8 is H,
each X1, X2, Y1 and Y4 is CH; each X and Y2 is N and Y3 is CCH3. In one such variation, R6 is a fluoro-containing moiety, such as —CF3, —CHF2, —CH2F, or —CH2F. In another variation, compounds of the formula (C-I) are provided, wherein the compounds are other than compounds (A)-(G) in Table A.
In one variation, compounds of formula (C-I) are embraced, provided that at least one of X1, X2 and X is CH. In another variation, at least two of X1, X2 and X is CH. In one aspect, when at least one or when at least two of X1, X2 and X is CH, one or more of the following apply (i) n is 1 and (ii) R6 is other than H, C1 or CH3. In another variation, when X2 is N then X is CH. In another variation, when X2 is CH then X is N. In one aspect, when X2 is CH and X is N, then one or more of the following apply (i) n is 1 and (ii) R6 is other than H or CH3.
In another variation of formula (C-I), R6 is halo, CH3, CH2F, CHF2, CF3 or CD3.
In another variation of formula (C-I), R7 is H or CH3. In one variation, R7 is H, CH3, CF3, CH2F, CHF2 or CH2OH.
In another variation of formula (C-I), R8 is H or OH. In one variation, R8 is —OC(O)C1-C5 alkyl optionally substituted with amino, N(R11)R12, SR13, S(O)R13 or SO2R13. In one variation, R8 is N(R11)R12. In one variation, R8 is SR13, S(O)R13 or SO2R13.
In another variation of formula (C-I), at least one of Y1, Y2, Y3 and Y4 is N. In another variation, Y1 and Y3 are each N. In another variation, Y2 and Y4 are each N. In another variation, Y1 and Y4 are each N.
In another variation of formula (C-I), Y1, Y2 and Y4 are each H, and Y3 is CR4, wherein R4 is halo, CH3, CF3 or OCH3.
In another variation of formula (C-I), R6 is F, Cl, Br, CD3 or CH2F; X1, X2 and X are each N or CH; Y2 and Y3 are each N or CR4, wherein R4 is CH3 or CF3; R8 is H or hydroxyl; and n is 0 or 1. In another variation, of formula (C-I), R6 is F, Cl, Br, CD3 or CH2F; R7 is H, CH3, CF3, CH2F, CHF2 or CH2OH; X1, X2 and X are each N or CH; Y2 and Y3 are each N or CR4, wherein R4 is CH3 or CF3; R8 is H or hydroxyl; and n is 0 or 1. In one such variation, Y1 and Y4 are both CH.
In certain embodiments, with respect to the compounds of formula (C-I), n is 0, R6 is Cl, R7 and R8 are both H, each X1, X2, X, Y1, Y2 and Y4 is CH and Y3 is other than CF.
In one embodiment, the compound is of formula (C-IA) or (C-IB):




wherein R6, R7, R8, X1, X2, X, Y1, Y2, Y3 and Y4 are as described for formula (C-I). In one variation of formula (C-IA), one or more of the following apply (i) R6 is other than Cl when n is 0, each R7 and R8 is H, each X1, X2, X, Y1, Y2 and Y4 is CH and Y3 is CF; (ii) R6 is other than H when n is 0 and (iii) R6 is other than CH3 when n is 0, each R7 and R8 is H, each X1, X2, Y1 and Y4 is CH; each X and Y2 is N and Y3 is CCH3. In one such variation, R6 is a fluoro-containing moiety, such as —CH2F. In another variation, compounds of the formula (C-IA) and (C-IB) are provided, wherein the compounds are other than compounds (A)-(G) in Table A.

In certain embodiments, with respect to the compounds of formula (C-IA), X1 is N, and the compound is Compound No. IV-3, IV-29 to IV-38, IV-109 to IV-118, IV-151, IV-152, IV-154 to W-158, or IV-230 to IV-238.
In certain embodiments, with respect to the compounds of formula (C-IA), X2 is N, and the compound is Compound No. II-5 or II-275.
In certain embodiments, with respect to the compounds of formula (C-IB), X is N, and the compound is Compound No. IV-8, IV-49 to IV-58, IV-169 to IV-177, or IV-178.
In certain embodiments, with respect to the compounds of formula (C-IB), X1 is N, and the compound is Compound No. IV-69 to IV-78, IV-189 to W-197, or IV-198.
In certain embodiments, with respect to the compounds of formula (C-IB), each of X, X1, and X2 is independently is CR6, and the compound is Compound No. 47.
In specific variations, compounds of formula (C-IA) have the structure:




or a salt or solvate thereof, wherein R6, X1, X2, X, Y1, Y2, Y3 and Y4 are defined as for formula (C-I).

In certain embodiments, with respect to the compounds of formula (C-IA-1), each of X, X1, and X2 is independently is CR6, and the compound is Compound No. 197.
In certain embodiments, with respect to the compounds of formula (C-IA-1), each of X, X1, and X2 is independently is CR6, and the compound is No. Compound II-290, IV-6, or IV-7.
In certain embodiments, with respect to the compounds of formula (C-IA-1), X is N, and the compound is Compound No. 74, 134, or 336.
In certain embodiments, with respect to the compounds of formula (C-IA-1), X is N, and the compound is Compound No. II-238, II-243 to II-245, II-268, or II-297.
In certain embodiments, with respect to the compounds of formula (C-IA-1), X is N, and the compound is Compound No. IV-2, IV-4, IV-9, IV-11 to IV-18, IV-89, IV-93 to IV-97, or IV-98.
In certain embodiments, with respect to the compounds of formula (C-IA-1), X1 is N, and the compound is Compound No. IV-29 to IV-38, IV-109 to IV-117, or IV-118 (Table IV).
In certain embodiments, with respect to the compounds of formula (C-IA-2), the compound is Compound No. II-129, II-168, or II-198.
In certain embodiments, with respect to the compounds of formula (C-IA-2), the compound is Compound No. IV-129 to IV-133, IV-149 to IV-152, IV-154 to IV-158, IV-209, IV-211 to IV-216, IV-219, IV-221, IV-229, IV-230, IV-232, IV-234, IV-236, IV-239, IV-241, IV-242, or IV-244 (Table IV).
In certain embodiments, with respect to the compounds of formula (C-IA-3), each of X, X1, and X2 is independently is CR6, and the compound is Compound No. 176.
In certain embodiments, with respect to the compounds of formula (C-IA-3), each of X, X1, and X2 is independently is CR6, and the compound is Compound No. II-121, II-127, II-128, II-130, II-291, II-294, or IV-7.
In certain embodiments, with respect to the compounds of formula (C-IA-3), X is N, and the compound is Compound No. 26 or 148.
In certain embodiments, with respect to the compounds of formula (C-IA-3), X is N, and the compound is Compound No. II-149.
In certain embodiments, with respect to the compounds of formula (C-IA-3), X is N, and the compound is Compound No. IV-134 to IV-138, IV-210, IV-217, or IV-218.
In certain embodiments, with respect to the compounds of formula (C-IA-3), X1 is N, and the compound is Compound No. II-17.
In certain embodiments, with respect to the compounds of formula (C-IA-3), X1 is N, and the compound is Compound No. IV-231, IV-233, IV-235, IV-237, or IV-238.
In other variations, compounds of formula (C-IA) have the structure:




or a salt or solvate thereof, wherein R6, R7, R8, Y1, Y2, Y3 and Y4 are defined as for formula (C-I). In one variation, R7 and R8 are both H.

In certain embodiments, with respect to the compounds of formula (C-IA-4), each Y1, Y2, Y3 and Y4 is independently CR4; and the compound is Compound No. II-120, II-121, II-266, II-271, or II-279.
In certain embodiments, with respect to the compounds of formula (C-IA-4), each Y1, Y2, Y3 and Y4 is independently CR4; and the compound is Compound No. W-6, IV-7, or IV-9.
In certain embodiments, with respect to the compounds of formula (C-IA-4), one of Y1, Y2, Y3 and Y4 is N, and the rest of Y1, Y2, Y3 and Y4 are independently CR4; and the compound is Compound No. 129, 168, 197, or 198.
In certain embodiments, with respect to the compounds of formula (C-IA-4), one of Y1, Y2, Y3 and Y4 is N, and the rest of Y1, Y2, Y3 and Y4 are independently CR4; and the compound is Compound No. II-125, II-127, II-128, II-130, II-131, II-281, II-282, II-284, II-290, II-291, or II-293.
In certain embodiments, with respect to the compounds of formula (C-IA-4), one of Y1, Y2, Y3 and Y4 is N, and the rest of Y1, Y2, Y3 and Y4 are independently CR4; and the compound is Compound No. IV-4, IV-5, IV-15, or IV-18.
In certain embodiments, with respect to the compounds of formula (C-IA-4), two of Y1, Y2, Y3 and Y4 are N, and the rest of Y1, Y2, Y3 and Y4 are independently CR4; and the compound is Compound No. 176.
In certain embodiments, with respect to the compounds of formula (C-IA-4), two of Y1, Y2, Y3 and Y4 are N, and the rest of Y1, Y2, Y3 and Y4 are independently CR4; and the compound is Compound No. II-6, II-7, II-261, II-276, or II-294.
In certain embodiments, with respect to the compounds of formula (C-IA-5), each Y1, Y2, Y3 and Y4 is independently CR4; and the compound is Compound No. 336.
In certain embodiments, with respect to the compounds of formula (C-IA-5), each Y1, Y2, Y3 and Y4 is independently CR4; and the compound is Compound No. II-149. In certain embodiments, with respect to the compounds of formula (C-IA-5), each Y1, Y2, Y3 and Y4 is independently CR4; and the compound is Compound No. II-149a, II-149b, II-149c, or II-149d.
In certain embodiments, with respect to the compounds of formula (C-IA-5), each Y1, Y2, Y3 and Y4 is independently CR4; and the compound is Compound No. W-1, IV-9, IV-11 to IV-18, IV-129, IV-130 to IV-137, or IV-138.
In certain embodiments, with respect to the compounds of formula (C-IA-5), one or two of Y1, Y2, Y3 and Y4 is N, and the rest of Y1, Y2, Y3 and Y4 are independently CR4; and the compound is Compound No. 26, 74, 134, 137, or 148.
In certain embodiments, with respect to the compounds of formula (C-IA-5), one or two of Y1, Y2, Y3 and Y4 is N, and the rest of Y1, Y2, Y3 and Y4 are independently CR4; and the compound is Compound No. II-79, II-238, II-243, II-244, II-245, II-268, or II-297.
In certain embodiments, with respect to the compounds of formula (C-IA-5), one or two of Y1, Y2, Y3 and Y4 is N, and the rest of Y1, Y2, Y3 and Y4 are independently CR4; and the compound is Compound No. IV-2, IV-4, IV-89, IV-91, IV-93 to IV-98, IV-209, IV-210, IV-211, IV-213 to IV-217, or IV-218.
In other variations, compounds of formula (C-IA) have the structure:




or a salt or solvate thereof, wherein X is C or N; and R6, Y1, Y2, Y3 and Y4 are defined as for formula (C-I).

In certain embodiments, with respect to the compounds of formula (C-IA-6), the compound is Compound No. 129, 168, or 198.
In certain embodiments, with respect to the compounds of formula (C-IA-6), the compound is Compound No. II-79, II-120, II-125, II-131, or II-293.
In certain embodiments, with respect to the compounds of formula (C-IA-6), the compound is Compound No. IV-129 to IV-133, IV-209, IV-211, IV-213 to IV-215, or IV-216.
In other variations, compounds of formula (C-IA) have the structure:




or a salt or solvate thereof, wherein R6, Y1, Y2, Y3 and Y4 are defined as for formula (C-I).

In certain embodiments, with respect to the compounds of formula (C-IA-7); the compound is Compound No. 74, 134, 137, or 336.
In certain embodiments, with respect to the compounds of formula (C-IA-7); the compound is Compound No. II-238, II-243, II-244, II-245, or II-297.
In certain embodiments, with respect to the compounds of formula (C-IA-7); the compound is Compound No. IV-2, IV-4, IV-9, IV-11, IV-13 to IV18, IV-89, IV-91, IV-93 to IV-97, or IV-98.
In one variation of formula (C-IA-1) one or more of the following apply: (i) R6 is other than Cl when each X1, X2, X, Y1, Y2 and Y4, a Y is CH and Y3 is CF; (ii) R6 is other than H when each X1, X2, X, Y1, Y2 and Y4 is CH and Y3 is CF; (iii) R6 is other than H when each X1, X2, Y1 and Y4 is CH; each X and Y2 is N and Y3 is CCH3; and (iv) R6 is other than CH3 when each X1, X2, Y1 and Y4 is CH; each X and Y2 is N and Y3 is CCH3.
In one variation of formula (C-IA-2), R6 is other than H when each X1, X2, Y1, Y2 and Y4 is CH; each X and Y3 is N.
In one variation of formula (C-IA-3), R6 is other than H when each X1, X2, X, Y1, Y2 and Y4 is CH and Y3 is N.
In certain embodiments, with respect to the compounds of formula (C-IA), (C-IA-1), (C-IA-3), or (C-IA-7), n is 0, R6 is Cl, R7 and R8 are both H, each X1, X2, X, Y1, Y2 and Y4 is CH and Y3 is other than CF.
In specific variations, compounds of formula (C-IB) have the structure:




or a salt or solvate thereof, wherein R6, X1, X2, X, Y1, Y2, Y3 and Y4 are defined as for formula (C-I).

In certain embodiments, with respect to the compounds of formula (C-IB-1); the compound is Compound No. IV-8, IV-49 to IV-87, or IV-88.
In certain embodiments, with respect to the compounds of formula (C-IB-2); the compound is Compound No. 47.
In certain embodiments, with respect to the compounds of formula (C-IB-2); the compound is Compound No. IV-179 to IV-188, IV-199 to IV-207, or IV-208.
In certain embodiments, with respect to the compounds of formula (C-IB-3); the compound is Compound No. IV-169 to IV-178, IV-190 to IV-197, or IV-198.
In one embodiment, the compound is of formula (C-IC-1):




or a salt or solvate thereof, wherein R6, X1, X2, X, Y1, Y2, Y3 and Y4 are defined as for formula (C-I).

In one embodiment, the compound is of formula (C-II):




wherein R6, R7, R8, X1, X2, X, Y2 and Y3 are as described for formula (C-I). In one variation of formula (C-II), one or more of the following apply (i) n is 1 and (ii) R6 is other than Cl when n is 0, each R7 and R8 is H, each X1, X2, X, Y1, Y2 and Y4 is CH and Y3 is CF; (iii) R6 is other than H when n is 0 and (iv) R6 is other than CH3 when n is 0, each R7 and R8 is H, each X1, X2, Y1 and Y4 is CH; each X and Y2 is N and Y3 is CCH3. In one such variation, R6 is a fluoro-containing moiety, such as —CH2F. In another variation, compounds of the formula (C-II) are provided, wherein the compounds are other than compounds (A)-(G) in Table A.

In one embodiment, the compound is of formula (C-IIA) or (C-IIB):




wherein R6, R7, R8, X1, X2, X, Y2, and Y3 are as described for formula (C-I). In one variation of formula (C-IIA), one or more of the following apply (i) R6 is other than Cl when n is 0, each R7 and R8 is H, each X1, X2, X, Y2 is CH and Y3 is CF; (ii) R6 is other than H when n is 0 and (iii) R6 is other than CH3 when n is 0, each R7 and R8 is H, each X1 and X2 is CH; each X and Y2 is N and Y3 is CCH3. In one variation, the compound of formula (C-IIA) is selected from Compounds (A)-(G), presented in Table A. In another variation, the compound of formula (C-IIA) is other than Compounds (A)-(G) in Table A. It is understood that each of compounds (A)-(G) may exist as individual isomers, e.g., isomer A1 and isomer A2 for compound A.








TABLE A







Representative Compounds of formula (C-IIA)















Compound
R6
R7
R8
X1
X2
X
Y2
Y3





A
Cl
H
H
CH
CH
CH
CH
CF


B
H
H
H
CH
CH
CH
CH
CH


C
H
CH3
OH
CH
CH
CH
CH
N


D
CH3
H
H
CH
CH
N
N
CCH3


E
H
H
H
CH
CH
N
N
CCH3


F
H
H
H
CH
CH
N
N
CCF3


G
H
H
OH
CH
CH
N
CH
N









In one embodiment, the compound is of formulae (C-IIIA): (C-IIIF):







wherein R6, R7, R8, X1, X2, X, Y2, Y3 and n are as described for formula (C-I). In one variation, the compound is of formula (C-IIIA), (C-IIIB), (C-IIIC), (C-IIID), (CIII-E) or (C-IIIF), wherein n is 0. In one variation compound is of formulae (C-IIIA), (C-IIIB), (C-IIIC), (C-IIID), (CIII-E) or (C-IIIF), wherein n is 0, and wherein one or more of the following provisions apply: (i) R6 is other than Cl when n is 0, each R7 and R8 is H, each X1, X2, X, Y1, Y2 and Y4 is CH. and Y3 is CF; (ii) R6 is other than H when n is 0 and (iii) R6 is other than CH3 when n is 0, each R7 and R8 is H, each X1, X2, Y1 and Y4 is CH; each X and Y2 is N and Y3 is CCH3. In another variation, the compound is of formulae (C-IIIA), (C-IIIB), (C-IIIC), (C-IIID), (CIII-E) or (C-IIIF), wherein n is 1.

In another embodiment the compound is according to formula (C-IVA), (C-IVB), (C-IVC), (C-IVD), (C-IVE), (C-IVF) or (C-IVG):







or a salt, solvate or N-oxide thereof, wherein:

n is 0 or 1;
each X1, U, X2, or X, where present, is independently CR6;
R6 is H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl, or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15, —OC(O)-aryl, —OC(O)-heteroaryl, or —OC(O)C1-C5 alkyl optionally substituted with amino, or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety; and
Q is cycloalkyl, aryl or heteroaryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.
In one embodiment, with respect to the compounds of formula (C-IVA), (C-IVB), (C-IVC), (C-IVD), (C-IVE), (C-IVF), or (C-IVG), each X1, U, X2, or X is independently CR6, and each R6 is H. In another embodiment, each R6 is independently selected from H, C1-C5 alkyl, and halo C1-C5 alkyl. In certain embodiments, each R6 is independently selected from H, methyl, ethyl, fluoro, chloro, CH2F, and CF3.
In one embodiment, with respect to the compounds of formula (C-IVA), (C-IVB), (C-IVD), (C-IVF) or (C-IVG), each X1, X2 and X (where present) is CR6, wherein R6 is H; U is CR6, wherein R6 is selected from H, C1-C5 alkyl and halo C1-C5 alkyl. In certain embodiments, each R6 is independently selected from methyl, ethyl, fluoro, chloro, CH2F, and CF3.
In one embodiment, with respect to the compounds of formula (C-IVA), (C-IVB), (C-IVC), (C-IVD), (C-IVE), (C-IVF) or (C-IVG), each R7 and R8 is H. In another embodiment, R7 is H or methyl, and R8 is H, OH or methyl.
In certain embodiments, with respect to the compounds of formula (C-IVA), (C-IVB), (C-IVC), (C-IVD), (C-IVE), (C-IVF) or (C-IVG), R7 is H; and R8 is OH, NH2, CF3 or methyl.
In one embodiment, with respect to the compounds of formula (C-IVA), (C-IVB), (C-IVC), (C-IVD), (C-IVE), (C-IVF) or (C-IVG), Q is optionally substituted phenyl.
In another embodiment, with respect to the compounds of formula (C-IVA), (C-IVB), (C-IVC), (C-IVD), (C-IVE), (C-IVF) or (C-IVG), Q is phenyl substituted with C1-C5 alkyl, halo, halo C1-C5 alkyl or C1-C5 alkoxy.
In another embodiment, with respect to the compounds of formula (C-IVA), (C-IVB), (C-IVC), (C-IVD), (C-IVE), (C-IVF), or (C-IVG), Q is phenyl substituted with methyl, ethyl, fluoro, chloro, methoxy or CF3. In certain embodiments, Q is phenyl substituted with 4-methyl, 4-ethyl, 4-fluoro, 4-chloro, 4-methoxy, or 4-CF3.
In another embodiment, with respect to the compounds of formula (C-IVA), (C-IVB), (C-IVC), (C-IVD), (C-IVE), (C-IVF), or (C-IVG), Q is optionally substituted pyridyl, or optionally substituted pyrimidinyl.
In another embodiment, with respect to the compounds of formula (C-IVA), (C-IVB), (C-IVC), (C-IVD), (C-IVE), (C-IVF), or (C-IVG), Q is pyridyl substituted with C1-C5 alkyl, halo, halo or C1-C5 alkyl.
In another embodiment, with respect to the compounds of formula (C-IVA), (C-IVB), (C-IVC), (C-IVD), (C-IVE), (C-IVF), or (C-IVG), Q is pyridyl substituted with methyl, ethyl, fluoro, chloro, or CF3.
In one embodiment, with respect to the compounds of formula (C-IVA), (C-IVB), (C-IVC), (C-IVD), (C-IVE), (C-IVF), or (C-IVG), n is 0. In another embodiment, n is 1.
In certain embodiments, with respect to the compounds of formula (C-IVA), (C-IVB), (C-IVC), (C-IVD), (C-IVE), (C-IVF) or (C-IVG), the compound is any one of compounds listed in Table IV. In another embodiment, with respect to the compounds of formula (C-IVA), (C-IVB), (C-IVC), (C-IVD), (C-IVE), (C-IVF), or (C-IVG), the compound is any one of compounds listed in Table IV, provided that the compound is other than Compound No. W-2, IV-4, IV-5, IV-6, or IV-7.
In certain embodiments, with respect to the compounds of formula (C-IVA), n is 0, Q is optionally substituted 4-pyridyl, and the compound is Compound No. II-79, II-89, II-209, or II-244.
In certain embodiments, with respect to the compounds of formula (C-IVA), n is 0, Q is optionally substituted 3-pyridyl, and the compound is Compound No. 26, 74, 134, 137, 148, II-238, II-243, II-268, II-297, IV-2, IV-4, IV-97 to IV-98, IV-210, IV-217, or IV-218.
In certain embodiments, with respect to the compounds of formula (C-IVA), n is 0, Q is optionally substituted 2-pyridyl, and the compound is Compound No. W-91, IV-95, IV-96, IV-211, IV-215, or IV-216.
In certain embodiments, with respect to the compounds of formula (C-IVA), n is 0, Q is optionally substituted pyrimidyl, and the compound is Compound No. IV-93 or IV-213.
In certain embodiments, with respect to the compounds of formula (C-IVA), n is 0, Q is optionally substituted pyrazinyl, and the compound is Compound No. II-245, IV-94, or IV-214.
In certain embodiments, with respect to the compounds of formula (C-IVA), n is 0, Q is optionally substituted phenyl, and the compound is Compound No. 336, II-149, IV-1, IV-9, IV-11 to W-18, IV-129 to IV-137, or IV-138.
In certain embodiments, with respect to the compounds of formula (C-IVA), n is 1, Q is optionally substituted phenyl, and the compound is Compound No. W-49 to IV-58, or IV-178.
In certain embodiments, with respect to the compounds of formula (C-IVA), n is 1, Q is optionally substituted 3-pyridyl, and the compound is Compound No. W-8.
In certain embodiments, with respect to the compounds of formula (C-IVB), n is 0, and the compound is Compound No. II-5 or II-275.
In certain embodiments, with respect to the compounds of formula (C-IVD), n is 0, and the compound is Compound IV-3, IV-29 to IV-38, IV-109 to IV-118, IV-149 to IV-158, IV-229 to IV-237, or IV-238.
In certain embodiments, with respect to the compounds of formula (C-IVD), n is 1, and the compound is Compound No. IV-69 to IV-78, IV-189 to W-197, or IV-198.
In certain embodiments, with respect to the compounds of formula (C-IVF), the compound is Compound No. IV-19 to IV-21, IV-25 to IV-28, IV-59 to IV-68, IV-100 to IV-108, IV-139 to IV-148, IV-179 to IV-188, IV-219 to IV-227 or IV-228.
In certain embodiments, with respect to the compounds of formula (C-IVG), the compound is Compound No. IV-10, IV-39 to IV-48, IV-79 to IV-88, IV-90, IV-92, IV-119 to IV-128, IV-159 to IV-168, IV-199 to VI-208, IV-212, IV-239 to IV-243, or IV-244.
In one embodiment, compounds of formula (C-VA) or (C-VB) are provided:




or a salt, solvate or N-oxide thereof, wherein:

each X1, X2, X and U is independently N or CR6;
each R6 is independently H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl, or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15, —OC(O)-aryl, —OC(O)-heteroaryl, or —OC(O)C1-C5 alkyl optionally substituted with amino, or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
Q is aryl or heteroaryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, —NHC(O)CH3 and —C(O)NR16R17; and
each R16 and R17 is independently H or optionally substituted C1-C5 alkyl.
In some embodiments, compounds of the formula (D-I) are provided:




or a salt, solvate or N-oxide thereof, wherein:

R6 is H, halo, C1-C5 alkyl or cycloalkyl optionally substituted with 1 to 3 halogen atoms or hydroxyl, C2-C5 alkenyl, or —C(O)OR11;
R7 is H or optionally substituted C1-C5 alkyl;
R8 is H, hydroxyl, —OC(O)C1-C5 alkyl optionally substituted with amino, N(R11)R12, SR13, S(O)R13 or SO2R13;
each R11, R12 and R13 is independently H or optionally substituted C1-C5 alkyl;
each X1, X2 and X is N or CH such that no more than two of X1, X2 and X are N;
each Y1, Y2, Y3 and Y4 is N or CR4 such that no more than two of Y1, Y2, Y3 and Y4 are N, and wherein R4 is H, halo, CH3, CF3, or OCH3; and
n is 0 or 1.
In one variation, the compound is of formula (D-IIA) or (D-IIB):




or a salt or solvate thereof, wherein R6, X1, X2, X, Y2 and Y3 are defined as for formula (D-I).

In other variations, compounds of formula (D-IIA) have the structure:




or a salt or solvate thereof, wherein R6, R7, R8, Y1, Y2, Y3 and Y4 are defined as for formula (D-I).

In certain embodiments, with respect to the compounds of formula (D-IIB), the compound is Compound No. 75.
In certain embodiments, with respect to the compounds of formula (D-IIA-1), the compound is Compound No. 76, III-122, III-356, III-358, or III-359.
In certain embodiments, with respect to the compounds of formula (D-IIA-2), the compound is Compound No. 37, II-86, II-234, II-235, II-236, or II-239.
In one embodiment, compounds of formula (D-IIIA) or (D-IIIB) are provided:




or a salt, solvate or N-oxide thereof, wherein:

each X1, X2, X and U is independently N or CR6;
each R6 is independently H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl, or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)ON(R14)R15, —OC(O)-aryl, —OC(O)-heteroaryl, or —OC(O)C1-C5 alkyl optionally substituted with amino, or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety;
Q is aryl or heteroaryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, —NHC(O)CH3 and —C(O)NR16R17; and
each R16 and R17 is independently H or optionally substituted C1-C5 alkyl.
In certain embodiments, with respect to the compounds of formula (D-IIIA), each X1, U, X2, and X is independently CR6, and the compound is Compound 75, or 76 (Table I); or III-122, III-125, III-126, III-131, III-134, III-135, III-203, III-207, III-208, III-301, III-305, III-314, III-356, III-358, or III-359.
In certain embodiments, with respect to the compounds of formula (D-IIIA), each X1, U, and X2 is independently CR6, X is N, and the compound is Compound No. 37, II-86, II-234, II-235, II-236, or II-239.
In certain embodiments, with respect to the compounds of formula (D-IIIB), the compound is Compound No. III-54, III-353, or III-354.
In some embodiments, compounds of the formula (E-I) are provided:




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl or cycloalkyl optionally substituted with 1 to 3 halogen atoms or hydroxyl, C2-C5 alkenyl, or —C(O)OR11;
R6 is H, halo, C1-C5 alkyl or cycloalkyl optionally substituted with 1 to 3 halogen atoms or hydroxyl, C2-C5 alkenyl, or —C(O)OR11;
R7 is H or optionally substituted C1-C5 alkyl;
R8 is H, hydroxyl, —OC(O)C1-C5 alkyl optionally substituted with amino, N(R11)R12, SR13, S(O)R13 or SO2R13;
each R11, R12 and R13 is independently H or optionally substituted C1-C5 alkyl;
each X1, X2 and X is N or CH such that no more than two of X1, X2 and X are N;
each Y1, Y2, Y3 and Y4 is N or CR4 such that no more than two of Y1, Y2, Y3 and Y4 are N, and wherein R4 is H, halo, CH3, CF3, or OCH3; and
n is 0 or 1.
In one variation, the compound is of formula (E-IIA) or (E-IIB):




or a salt or solvate thereof, wherein R1, R6, X1, X2, X, Y2 and Y3 are defined as for formula (E-I).

In other variations, compounds of formula (E-IIA) have the structure:




or a salt or solvate thereof, wherein R1, R6, R7, R8, Y1, Y2, Y3 and Y4 are defined as for formula (E-I).

In certain embodiments, with respect to the compounds of formula (E-IIA), the compound is Compound No. III-61.
In some embodiments, compounds of the formula (F-I) are provided:




or a salt, solvate or N-oxide thereof, wherein:

R6 is H, halo, C1-C5 alkyl or cycloalkyl optionally substituted with 1 to 3 halogen atoms or hydroxyl, C2-C5 alkenyl, or —C(O)OR11;
R7 is H or optionally substituted C1-C5 alkyl;
R8 is H, hydroxyl, —OC(O)C1-C5 alkyl optionally substituted with amino, N(R11)R12, SR13, S(O)R13 or SO2R13;
each R11, R12 and R13 is independently H or optionally substituted C1-C5 alkyl;
each X1, X2 and X is N or CH such that no more than two of X1, X2 and X are N;
each Y1, Y2, Y3 and Y4 is N or CR4 such that no more than two of Y1, Y2, Y3 and Y4 are N, and wherein R4 is H, halo, CH3, CF3, or OCH3; and
n is 0 or 1.
In one variation, the compound is of formula (F-IIA) or (F-IIB):




or a salt or solvate thereof, wherein R6, X1, X2, X, Y2 and Y3 are defined as for formula (F-I).

In other variations, compounds of formula (F-IIA) have the structure:




or a salt or solvate thereof, wherein R6, R7, R8, Y1, Y2, Y3 and Y4 are defined as for formula (F-I).

In certain embodiments, with respect to the compounds of formula (F-IIA), the compound is Compound No. III-54, III-353, or III-354.
In some embodiments, compounds of the formula (G-I) are provided:




or a salt, solvate or N-oxide thereof, wherein:

R1 is H, C1-C5 alkyl or cycloalkyl optionally substituted with 1 to 3 halogen atoms or hydroxyl, C2-C5 alkenyl, or —C(O)OR11;
R6 is H, halo, C1-C5 alkyl or cycloalkyl optionally substituted with 1 to 3 halogen atoms or hydroxyl, C2-C5 alkenyl, or —C(O)OR11;
R7 is H or optionally substituted C1-C5 alkyl;
R8 is H, hydroxyl, —OC(O)C1-C5 alkyl optionally substituted with amino, N(R11)R12, SR13, S(O)R13 or SO2R13;
each R11, R12 and R13 is independently H or optionally substituted C1-C5 alkyl;
each X1, X2 and X is N or CH such that no more than two of X1, X2 and X are N;
each Y1, Y2, Y3 and Y4 is N or CR4 such that no more than two of Y1, Y2, Y3 and Y4 are N, and wherein R4 is H, halo, CH3, CF3, or OCH3; and
n is 0 or 1.
In one variation, the compound is of formula (G-IIA) or (G-IIB):




or a salt or solvate thereof, wherein R1, R6, X1, X2, X, Y2 and Y3 are defined as for formula (G-I).

In other variations, compounds of formula (G-IIA) have the structure:




or a salt or solvate thereof, wherein R6, R7, R8, Y1, Y2, Y3 and Y4 are defined as for formula (G-I).
In certain embodiments, with respect to the compounds of formula (G-I), n is 0, R8 is OH, and the compound is Compound No. III-57.
In one embodiment, compounds of formula (H-IA), (H-IB), (H-IC) or (H-ID) are provided:




or a salt, solvate or N-oxide thereof, wherein:

each X1, X2, X and U is independently N or CR6;
R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl;
each R6 is independently H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl;
Q is aryl or heteroaryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, —NHC(O)CH3 and —C(O)NR16R17; and
each R16 and R17 is independently H or optionally substituted C1-C5 alkyl.
In certain embodiments, with respect to the compounds of formula (H-IA), (H-IB), (H-IC), or (H-ID), each X1, X2 and X is independently CR6; wherein each R6 is independently halo, C1-C5-alkyl, halo C1-C5-alkyl, perhalo C1-C5-alkyl, or C1-C5-alkoxy. In certain embodiments, each X1, X2 and X is independently CR6; wherein each R6 is independently fluoro, chloro, methyl, ethyl, CF3, or methoxy. In certain embodiments, U is CR6, wherein R6 is CF3, methyl, chloro, CONHCH3, COOH, COOCH3, H, or fluoro; provided that R1 is other than methyl.
In one embodiment, compounds of formula (H-IA-1), (H-IB-1), (H-IC-1) or (H-ID-1) are provided:




or a salt, solvate or N-oxide thereof, wherein:

U is N or CR6;
R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl;
R6 is independently H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl;
Q is aryl or heteroaryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, —NHC(O)CH3 and —C(O)NR16R17; and
each R16 and R17 is independently H or optionally substituted C1-C5 alkyl.
In certain embodiments, with respect to the compounds of formula (H-IA), (H-IB), (H-IC) or (H-ID), (H-IA-1), (H-IB-1), (H-IC-1) or (H-ID-1), Q is an optionally substituted 5-membered heteroaryl; R7 is F or methyl; R1 is methyl; each X1, X2 and X (when present) is CR6, wherein each R6 is H; U is CR6, wherein R6 is methyl or Cl; and Q is other than unsubstituted thienyl or unsubstituted thiazolyl.
In certain embodiments, with respect to the compounds of (H-IA), (H-IB), (H-IC) or (H-ID), (H-IA-1), (H-IB-1), (H-IC-1) or (H-ID-1), Q is optionally substituted pyridyl; each X1, X2 and X (when present) is CR6, wherein each R6 is H; U is CR6, wherein R6 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted C1-C5 alkoxy; and Q is other than unsubstituted pyridyl, or pyridyl substituted with methyl, Cl, Br, OCH3, or di-methyl.
In certain embodiments, with respect to the compounds of formula (H-IA), (H-IB), (H-IC) or (H-ID), (H-IA-1), (H-IB-1), (H-IC-1) or (H-ID-1), Q is optionally substituted pyrimidinyl; R1 is methyl; each X1, X2 and X (when present) is CR6, wherein each R6 is H; U is CR6, wherein R6 is methyl or Cl; and Q is other than unsubstituted pyrimidin-4-yl, pyrimidin-4-yl substituted with methyl, unsubstituted pyrimidin-5-yl, or pyrimidin-5-yl substituted with methyl.
In certain embodiments, with respect to the compounds of formula (H-IA-1), the compound is Compound No. 99, 106, 222, 226-230, 232-235, 238, 240-241, 244-249, or 251.
In certain embodiments, with respect to the compounds of formula (H-IB-1), the compound is Compound No. 224 or 239.
In certain embodiments, with respect to the compounds of formula (H-IC-1), Q is optionally substituted pyridyl, and the compound is Compound No. 78, 79, 100, 103, 105, 111, 112, 122, 124, 125, 126, 185, 186, 188, 250, 257, 259, 266, 269, 312, 329, or 331.
In certain embodiments, with respect to the compounds of formula (H-IC-1), Q is optionally substituted pyrimidyl, and the compound is Compound No. 101, 187, or 279.
In certain embodiments, with respect to the compounds of formula (H-IC-1), Q is optionally substituted pyridyl, and the compound is Compound No. II-2, II-3, II-59, II-76, II-77, II-96, or II-101.
In certain embodiments, with respect to the compounds of formula (H-IC-1), Q is optionally substituted 5-membered heteroaryl, and the compound is Compound No. 78, 108-110, 110, 115, 189, 273, 275, 277, 278, 285, or 287.
In certain embodiments, with respect to the compounds of formula (H-IC-1), Q is optionally substituted 9-membered heteroaryl, and the compound is Compound No. 282, 283, 284, 290, or 293.
In certain embodiments, with respect to the compounds of formula (H-IC-1), Q is optionally substituted quinolinyl or isoquinolinyl, and the compound is Compound No. 292, 311, 316, or 323.
In certain embodiments, with respect to the compounds of formula (H-IC), X is N, and the compound is Compound No. 78, 124, or 335.
In certain embodiments, with respect to the compounds of formula (H-IE-1), the compound is Compound No. 193 or 194. In certain embodiments, with respect to the compounds of formula (H-IE-1), the compound is Compound No. 193a, 193b, 194a, or 194b.
In certain embodiments, with respect to the compounds of formula (H-IF-1), the compound is Compound No. 199. In certain embodiments, with respect to the compounds of formula (H-IF-1), the compound is Compound No. 199a or 199b.
In certain embodiments, with respect to the compounds of formula (H-IIB-1), the compound is Compound No. 333.
In certain embodiments, with respect to the compounds of formula (H-IIC-1), the compound is Compound No. 242, 256, 264, 313, 321, 328, 330, or 334.
In certain embodiments, with respect to the compounds of formula (H-IID-1), the compound is Compound No. 95.
In certain embodiments, with respect to the compounds of formula (H-IA-1), (H-IB-1), (H—IC-1) or (H-ID-1) U is CR6, and R6 is CF3, methyl, chloro, —CONHCH3, —COOH, —COOCH3, H, or fluoro; and R1 is other than methyl.
In certain embodiments, with respect to the compounds of formula (H-IA), (H-IB), (H-IC) or (H-ID), (H-IA-1), (H-IB-1), (H-IC-1) or (H-ID-1), R7 is H, halo, or C1-C5 alkyl substituted with halo. In one embodiment, R7 is H, methyl, or CF3.
In another aspect, provided is a compound of formula (J):




wherein:

R1 is H; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl, SO3H, SR1a, S(O)R1a, SO2R1a and perhaloalkyl; C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; or —C(O)O—C1-C5 alkyl; or is taken together with R2a or R1a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R4a or R5a, where present, to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety;
R1a is H or optionally substituted C1-C5 alkyl;
R2a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R1 or R5a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R3a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R4a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R3a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R1 or R4a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R2a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R5a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R4a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R2a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety; or is taken together with R5a, where present, to form a methylene (—CH2—) moiety;
R5a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R2a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R3a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety; or is taken together with R4a, where present, to form a methylene (—CH2—) moiety;
each R2b, R3b, R4b and R5b is independently H, optionally substituted C1-C5 alkyl, optionally substituted C2-C5 alkenyl, or optionally substituted aryl;
each n and m is 1, or n is 0 and m is 1, or n is 1 and m is 0;
each X1, X2, X and U is independently N or CR6;
each R6 is independently H; hydroxyl; halo; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl; optionally substituted C1-C5 alkoxy; or optionally substituted —C(O)C1-C5 alkyl;
Q is optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
In one embodiment, compounds of formula (J-IA), (J-IB), (J-IC) or (J-ID):




or a salt, solvate or N-oxide thereof, wherein:

each X1, X2, X and U is independently N or CR6;
R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl;
each R6 is independently H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
Q is aryl or heteroaryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, —NHC(O)CH3 and —C(O)NR16R17; and
each R16 and R17 is independently H or optionally substituted C1-C5 alkyl.
In certain embodiments, with respect to the compounds of formula (J-IA), (J-IB), (J-IC) or (J-ID), each X1, X2 and X is independently CR6; wherein each R6 is independently halo, C1-C5-alkyl, halo C1-C5-alkyl, perhalo C1-C5-alkyl, or C1-C5-alkoxy. In certain embodiments, each X1, X2 and X is independently CR6; wherein each R6 is independently fluoro, chloro, methyl, ethyl, CF3, or methoxy. In certain embodiments, U is CR6, wherein R6 is CF3, methyl, chloro, CONHCH3, COOH, COOCH3, H, or fluoro; provided that R1 is other than methyl.
In certain embodiments, with respect to the compounds of formula (J-IA), (J-IB), (J-IC) or (J-ID), X is CR6, wherein R6 is fluoro; and R1 is other than methyl.
In one embodiment, compound is according to formula (J-IA-1), (J-IB-1), (J-IC-1) or (J-ID-1) are provided:




or a salt, solvate or N-oxide thereof, wherein:

U is N or CR6;
R1 is H, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, or —C(O)O—C1-C5 alkyl;
R6 is independently H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
Q is aryl or heteroaryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, —NHC(O)CH3 and —C(O)NR16R17; and
each R16 and R17 is independently H or optionally substituted C1-C5 alkyl.
In another embodiment, the compound is of the formula (K-IA), (K-IB), (K-IC) or (K-ID):




or a salt, solvate or N-oxide thereof, wherein:

X is N or CH;
R6 is C1, CF3, or methyl;
R7 is independently H or methyl;
R8 is H; azido; F; OH; NH2; N(CH3)H; N(CH3)2; NH-cyclopropyl; or NH-cyclobutyl; OC(O)N(CH3)2; or 3,3-dimethyl-2-hydroxybutyl; and
Q is unsubstituted 3-pyridyl; 3-pyridyl substituted with methyl, Cl, or CONH2; unsubstituted 4-pyridyl; 4-pyridyl substituted with OH; unsubstituted pyrazinyl; unsubstituted imidazolyl; or unsubstituted triazolyl.
In certain embodiments, with respect to the compounds of formula (K-IA), (K-IB), (K-IC) or (K-ID); R7 is H, and R8 is OH. In one embodiment, the compound is Compound 3, 4, 13, 39, 41, 129, or 144 (Table I); or II-132, II-138, II-139, or II-140 (Table II).
In certain embodiments, with respect to the compounds of formula (K-IA), (K-IB), (K-IC) or (K-ID); R7 is methyl, and R8 is OH. In one embodiment, the compound is Compound 5, 14, 26, 29, 31, 148, 173, 174, or 176 (Table I); or II-148 (Table II).
In certain embodiments, with respect to the compounds of formula (K-IA), (K-IB), (K-IC) or (K-ID); R8 is NH2, N(CH3)H, N(CH3)2, NH-cyclopropyl, or NH-cyclobutyl. In one embodiment, the compound is Compound 27, 150, 151, or 154 (Table I); or II-4, II-7, II-13, or II-260 (Table II).
In certain embodiments, with respect to the compounds of formula (K-IA), (K-IB), (K-IC) or (K-ID); each R7 and R8 is H. In one embodiment, the compound is Compound 74, 134, or II-244 (Table I and II).
In certain embodiments, with respect to the compounds of formula (K-IA), (K-IB), (K-IC) or (K-ID); R7Me, and R8 is F. In one embodiment, the compound is Compound II-212 (Table II).
In certain embodiments, with respect to the compounds of formula (K-IA), (K-IB), (K-IC) or (K-ID); R8 is —OC(O)N(CH3)2. In one embodiment, the compound is Compound 141.
In certain embodiments, with respect to the compounds of formula (K-IA), (K-IB), (K-IC) or (K-ID); R7 is 3,3-dimethyl-2-hydroxybutyl. In one embodiment, the compound is Compound II-227 (Table II).
In another embodiment, the compound is of the formula (K-IE), or (K-IF):




or a salt, solvate or N-oxide thereof, wherein:

R6 is Cl, or methyl;
R7 is H or methyl;
R8 is OH; N(CH3)2; or OC(O)-t-Bu; and
Q is phenyl substituted with F; unsubstituted 3-pyridyl; 3-pyridyl substituted with methyl; unsubstituted 4-pyridyl; or unsubstituted pyrazinyl.
In certain embodiments, with respect to the compounds of formula (K-IE), or (K-IF); R7 is H, and R8 is OH. In one embodiment, the compound is Compound 129 (Table I); or II-131 (Table II).
In certain embodiments, with respect to the compounds of formula (K-IE), or (K-IF); R7 is methyl, and R8 is OH. In one embodiment, the compound is II-121, II-127, II-128, or II-130 (Table II).
In certain embodiments, with respect to the compounds of formula (K-IE), or (K-IF), R8 is N(CH3)2. In one embodiment, the compound is Compound II-6 (Table II).
In certain embodiments, with respect to the compounds of formula (K-IE), or (K-IF); R8 is OC(O)-t-Bu. In one embodiment, the compound is Compound 130 (Table I).
In one embodiment, the compound is Compound II-123 (Table II).
In one embodiment, the compound is Compound 325 (Table I).
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), (A-IIIE-6), (A-IIIF-2), (A-IIIG-2), (A-IIIH-2), (C-IA-4), or (C-IA-5), and R1 is methyl.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), (A-IIIE-6), (A-IIIF-2), (A-IIIG-2), (A-IIIH-2), (C-IA-4), or (C-IA-5), and R6 is methyl, chloro, or trifluoromethyl.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), (A-IIIE-6), (A-IIIF-2), (A-IIIG-2), (A-IIIH-2), (C-IA-4), or (C-IA-5), and R7 is H, methyl, cyclopropyl, cyclobutyl, or 3,3-dimethyl-2-hydroxybutyl.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), (A-IIIE-6), (A-IIIF-2), (A-IIIG-2), (A-IIIH-2), (C-IA-4), or (C-IA-5), and R8 is H, F, OH, —N(CH3)2, or —OC(O)N(CH3)2.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), (A-IIIF-2), (A-IIIG-2), (A-IIIH-2), (C-IA-4), or (C-IA-5), and Y2 is N. In one embodiment, Y2 is N, and one of Y1, Y3, or Y4 is methyl.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), (A-IIIF-2), (A-IIIG-2), (A-IIIH-2), (C-IA-4), or (C-IA-5), and Y3 is N. In one embodiment, Y3 is N, and one of Y1, Y2, or Y4 is methyl.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), (A-IIIF-2), (A-IIIG-2), (A-IIIH-2), (C-IA-4), or (C-IA-5), and each of Y1 and Y4 is N.
In certain embodiments, with respect to the compounds of formula (A-IIIE-6), and Q is triazolyl, or imidazolyl.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), (A-IIIE-6), (A-IIIF-2), (A-IIIG-2), (A-IIIH-2), (C-IA-4), or (C-IA-5), R7 is H, R8 is OH, and the compound is Compound No. 3, 4, 13, 39, 41, 127, 144, II-132, II-138, II-139, or II-140.
In certain embodiments, with respect to the compounds of formula (I), (A-IIIE-2), (A-IIIE-6), (A-IIIF-2), (A-IIIG-2), (A-IIIH-2), (C-IA-4), or (C-IA-5), R7 is methyl, R8 is OH, and the compound is Compound No. 5, 14, 26, 29, 31, 148, 173, 174, 176, II-148, II-151, II-152, or II-220.
In certain embodiments, with respect to the compounds of formula (I), (A-IIIE-2), (A-IIIE-6), (A-IIIF-2), (A-IIIG-2), (A-IIIH-2), (C-IA-4), or (C-IA-5), R8 is NH2, N(CH3)H, N(CH3)2, NH-cyclopropyl, or NH-cyclobutyl, and the compound is Compound No. 27, 150, 151, 154, II-4, II-7, 11-13, or II-260.
In certain embodiments, with respect to the compounds of formula (I), (A-IIIE-2), (A-IIIE-6), (A-IIIF-2), (A-IIIG-2), (A-IIIH-2), (C-IA-4), or (C-IA-5), each R7 and R8 is H, and the compound is Compound No. 74, 134, or II-244.
In certain embodiments, with respect to the compounds of formula (I), (A-IIIE-2), (A-IIIE-6), (A-IIIF-2), (A-IIIG-2), (A-IIIH-2), (C-IA-4), or (C-IA-5), R7Me, and R8 is F, and the compound is Compound No. II-212.
In certain embodiments, with respect to the compounds of formula (I), (A-IIIE-2), (A-IIIE-6), (A-IIIF-2), (A-IIIG-2), (A-IIIH-2), (C-IA-4), or (C-IA-5), R8 is —OC(O)N(CH3)2, and the compound is Compound No. 141.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2), (A-IIIE-6), (A-IIIF-2), (A-IIIG-2), (A-IIIH-2), (C-IA-4), or (C-IA-5), and R7 is 3,3-dimethyl-2-hydroxybutyl, and the compound is Compound No. II-227.
In one embodiment, with respect to the compounds of formula (A-IB), (A-IC), (A-ID), (A-IE), (A-VIIIA), (A-VIIIB), (C-VA), (C-VB), (D-IIIA), (D-IIIB), (H-IA), (H-IB), (H-IC) or (H-ID), (H-IA-1), (H-IB-1), (H-IC-1), (H-ID-1), (J-IA), (J-IB), (J-IC) or (J-ID), (J-IA-1), (J-IB-1), (J-IC-1) or (J-ID-1), Q is optionally substituted phenyl.
In one embodiment, with respect to the compounds of formula (A-IB), (A-IC), (A-ID), (A-IE), (A-VIIIA), (A-VIIIB), (C-VA), (C-VB), (D-IIIA), (D-IIIB), (H-IA), (H-IB), (H-IC) or (H-ID), (H-IA-1), (H-IB-1), (H-IC-1), (H-ID-1), (J-IA), (J-IB), (J-IC) or (J-ID), (J-IA-1), (J-IB-1), (J-IC-1) or (J-ID-1), Q is phenyl substituted with C1-C5 alkyl, halo, halo C1-C5 alkyl, or C1-C5 alkoxy.
In one embodiment, with respect to the compounds of formula (A-IB), (A-IC), (A-ID), (A-IE), (A-VIIIA), (A-VIIIB), (C-VA), (C-VB), (D-IIIA), (D-IIIB), (H-IA), (H-IB), (H-IC) or (H-ID), (H-IA-1), (H-IB-1), (H-IC-1), (H-ID-1), (J-IA), (J-IB), (J-IC) or (J-ID), (J-IA-1), (J-IB-1), (J-IC-1) or (J-ID-1), Q is phenyl substituted with methyl, ethyl, F, Cl, OCH3, or CF3.
In one embodiment, with respect to the compounds of formula (A-IB), (A-IC), (A-ID), (A-IE), (A-VIIIA), (A-VIIIB), (C-VA), (C-VB), (D-IIIA), (D-IIIB), (H-IA), (H-IB), (H-IC) or (H-ID), (H-IA-1), (H-IB-1), (H-IC-1), (H-ID-1), (J-IA), (J-IB), (J-IC) or (J-ID), (J-IA-1), (J-IB-1), (J-IC-1) or (J-ID-1), Q is optionally substituted pyridyl, or optionally substituted pyrimidinyl.
In one embodiment, with respect to the compounds of formula (A-IB), (A-IC), (A-ID), (A-IE), (A-VIIIA), (A-VIIIB), (C-VA), (C-VB), (D-IIIA), (D-IIIB), (H-IA), (H-IB), (H-IC) or (H-ID), (H-IA-1), (H-IB-1), (H-IC-1), (H-ID-1), (J-IA), (H-IIB, (J-IC) or (J-ID), (J-IA-1), (J-IB-1), (J-IC-1) or (J-ID-1), Q is pyridyl substituted with C1-C5 alkyl, halo, halo or C1-C5 alkyl.
In one embodiment, with respect to the compounds of formula (A-IB), (A-IC), (A-ID), (A-IE), (A-VIIIA), (A-VIIIB), (C-VA), (C-VB), (D-IIIA), (D-IIIB), (H-IA), (H-IB), (H-IC) or (H-ID), (H-IA-1), (H-IB-1), (H-IC-1), (H-ID-1), (J-IA), (J-IB), (J-IC) or (J-ID), (J-IA-1), (J-IB-1), (J-IC-1) or -1), Q is pyridyl substituted with methyl, ethyl, F, Cl, or CF3.
In one embodiment, with respect to the compounds of formula (A-IB), (A-IC), (A-ID), (A-IE), (A-VIIIA), (A-VIIIB), (C-VA), (C-VB), (D-IIIA), (D-IIIB), (H-IA), (H-IB), (H-IC) or (H-ID), (H-IA-1), (H-IB-1), (H-IC-1), (H-ID-1), (J-IA), (J-IB), (J-IC) or (J-ID), (J-IA-1), (J-IB-1), (J-IC-1) or (J-ID-1), R1 is H; unsubstituted C1-C5alkyl; C1-C5 alkyl substituted with OH or SO3H; cycloalkyl; or C2-C5 alkenyl.
In one embodiment, with respect to the compounds of formula (A-IB), (A-IC), (A-ID), (A-IE), (A-VIIIA), (A-VIIIB), (C-VA), (C-VB), (D-IIIA), (D-IIIB), (H-IA), (H-IB), (H-IC) or (H-ID), (H-IA-1), (H-IB-1), (H-IC-1), (H-ID-1), (J-IA), (J-IB), (J-IC) or (J-ID), (J-IA-1), (J-IB-1), (J-IC-1) or (J-ID-1), R1 is H; unsubstituted C1-C5alkyl; C1-C5 alkyl substituted with up to three halogen atoms; cycloalkyl; or C2-C5 alkenyl.
In one embodiment, with respect to the compounds of formula (A-IB), (A-IC), (A-ID), (A-IE), (A-VIIIA), (A-VIIIB), (C-VA), (C-VB), (D-IIIA), (D-IIIB), (H-IA), (H-IB), (H-IC) or (H-ID), (H-IA-1), (H-IB-1), (H-IC-1), (H-ID-1), (J-IA), (J-IB), (J-IC) or (J-ID), (J-IA-1), (J-IB-1), (J-IC-1) or (J-ID-1), R1 is methyl, ethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, cyclobutyl, cyclopropyl, CF3, CH2CF3 or CH2CH2—SO3H.
In one particular embodiment, with respect to the compounds of formula (A-IB), (A-IC), (A-ID), (A-IE), (A-VIIIA), (A-VIIIB), (C-VA), (C-VB), (D-IIIA), (D-IIIB), (H-IA), (H-IB), (H-IC) or (H-ID), (H-IA-1), (H-IB-1), (H-IC-1), (H-ID-1), (J-IA), (J-IB), (J-IC) or (J-ID), (J-IA-1), (J-IB-1), (J-IC-1) or (J-ID-1), R1 is methyl.
In one embodiment, with respect to the compounds of formula (I); R4a is F. In another embodiment, each R4a and R4b is F. In a particular embodiment, the compound is Compound II-267 or II-280.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2); when R1 is methyl, R4a is F, R4b is H, R6 is Cl, each R7 and R8 is H, and Y3 is C—CF3; then Y2 is other than N.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2); when R1 is methyl, each R4a and R4b is F, H, R6 is methyl, each R7 and R8 is H, and Y3 is C—CH3; then Y2 is other than N.
In certain embodiments, with respect to the compounds of formula (A-IIIE-2); when R1 is methyl, each R4a and R4b is F, H, R6 is Cl or methyl, each R7 and R8 is H, and Y3 is C—F; then Y2 is other than CH.
In one embodiment, the invention relates to Compound No. 87, and uses thereof. In another embodiment, the invention relates to Compound No. 88, and uses thereof. In yet another embodiment, the invention relates to Compound No. 120, and uses thereof. In a further embodiment, the invention relates to Compound No. 324, and uses thereof.
In one embodiment, the invention relates to Compound No. 338, and uses thereof. In another embodiment, the invention relates to Compound No. II-1, and uses thereof.
In one embodiment, the invention relates to Compounds 25a, 25b, 27a, 27b, 54a and 54b, and uses thereof. In another embodiment, the invention relates to Compounds 25, 25a, 25b, 27, 27a, 27b, 54a, 54b, 130a, 130b, 141, 147 and 149-160, and uses thereof.
In another embodiment, the invention relates to Compounds 3a-5a, 3b-5b, 6,7a-9a, 7b-9b, 8-9, 39, 51, 55, 63-68, 70-73, 77-82, 91-92, 10a-31a, 10b-31b, 37c-37d, 39a-59a, 39b-59b, 69a-b, 74a-b, 75a-d and 76a-d, and uses thereof.
In another embodiment, the invention relates to Compounds 6, 9-12, 14, 16-21, 23-25, 27-28, 39-40, 42, 44-45, 48-49, 51-59, 63-72, 75-82, 108-122, 124-126, 128-131, 133-176; 1a-25a, 27a-31a, 36a-45a, 48a-49a, 51a-59a, 62a-67a, 69a-73a, 75a-76a, 81a-82a, 93a, 95a-98a, 102a, 127a-128a, 130a-131a, 133a, 135a-136a, 138a-179a; 1b-25b, 27b-31b, 36b-45b, 48b-49b, 51b-59b, 62b-67b, 69b-73b, 75b-76b, 81b-82b, 93b, 95b-98b, 102b, 127b-128b, 130b-131b, 133b, 135b-136b, 138b-179b; 36c-h, 37c-d, 38c-h, 70c-d, 73c-h, 75c-d, 76c-d, 95c-d, 97c-d, 127c-d, 148c-d, 155c-h, 161c-d, 162c-d, 163c-d, 164c-d, 168c-d, 176c-d and 177c-d, and uses thereof.
In another embodiment, the invention relates to Compounds 3, 3b, 4a, 5b and 39a. In another embodiment, the invention relates to Compounds 3, 3a, 3b, 5, 5a, 5b, 13b, 14a, 15b, 26a, 26b, 27a, 29a, 31a, 74a, 93a, 127a, 130a, 130b, 133b, 134b, 137a, 139a, 141, 144b, 147, 150a and 154, and uses thereof.
In another embodiment, the invention relates to Compound Nos. 3, 39, 4, 5, 13, 14, 41, 74, 26, 27, 29, 31, 127, 129, 134, 144, 148, 173, 174, 150, 176, IV-210, 151, II-4, II-132, 141, 154, II-135, II-138, II-139, II-140, V-22, II-244, II-7, II-146, II-151, II-152, II-227, II-220, II-148, II-13, II-212, II-260 and II-260b, and uses thereof. In another embodiment, the invention relates to Compound Nos. 3a, 3b, 39a, 4a, 5b, 13b, 14a, 41a, 74a, 26a, 26b, 27a, 29b, 31a, 127a, 129d, 134b, 144b, 148, 173a, 174a, 150a, 176a, IV-210a, 151a, II-4b, II-132b, 148b, 141b, 154b, II-135b, II-138, II-139, II-140, V-22, II-244a, II-7, II-146a, II-151b, II-152a, II-227c, II-220, II-148a, II-13a, II-212a, II-260a and II-260b, and uses thereof.
In one embodiment, the invention relates to Compound Nos. 3a, 3b, 4a, 4b, 5a, 5b, 6, 7a, 7b, 8a, 8b, 9, 9a, 9b, 10, 10a, 10b, 11, 11a, 11b, 12, 12a, 12b, 13a, 13b, 14, 14a, 14b, 15a, 15b, 16, 16a, 16b, 17, 17a, 17b, 18, 18a, 18b, 19, 19a, 19b, 20, 20a, 20b, 21, 21a, 21b, 22a, 22b, 23, 23a, 23b, 24, 24a, 24b, 25, 25a, 25b, 26, 26a, 26b, 26c, 26d, 27, 27a, 27b, 28, 28a, 28b, 29a, 29b, 30a, 30b, 31a, 31b, 36, 37, 37c, 37d, 39, 39a, 39b, 40, 40a, 40b, 41, 41a, 41b, 42, 42a, 42b, 43a, 43b, 44, 44a, 44b, 45, 45a, 45b, 47a, 47b, 47c, 47d, 48a, 48b, 49a, 49b, 51, 51a, 51b, 52, 52a, 52b, 53, 53a, 53b, 54, 54, 54a, 54b, 55, 55a, 55b, 56, 56a, 56b, 57, 57a, 57b, 58, 58a, 58b, 59, 59a, 59b, 63, 63a, 63b, 64, 65, 66, 67, 68, 69, 69a, 69b, 70, 71, 72, 75, 75a, 75b, 75c, 75d, 76, 76a, 76b, 76c, 76d, 77, 78, 79, 80, 81, 82, 90a, 90b, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 124, 125, 126, 127, 127a, 127b, 128a, 128b, 129a, 129b, 129c, 129d, 130a, 130b, 131a, 131b, 133a, 133b, 134a, 134b, 135a, 135b, 136a, 136b, 137a, 137b, 138a, 138b, 139, 139a, 139b, 140, 140a, 140b, 141, 141a, 141b, 142, 142a, 142b, 143, 143a, 143b, 144, 144a, 144b, 145, 146, 146a, 146b, 147, 147a, 147b, 148, 148a, 148b, 148c, 148d, 149, 149a, 149b, 150, 150a, 150b, 151, 151a, 151b, 152, 152a, 152b, 153, 154, 154a, 154b, 155, 155a, 155b, 156, 157, 158, 159, 159a, 159b, 160, 160a, 160b, 168, 169, 170, 171, 172a, 172b, 173, 173a, 173b, 174, 174a, 174b, 175, 175a, 175b, 176, 176a, 176b, 177, 178, 179, 189, 190, 191, 193, 193a, 193b, 194a, 194b, 196, 196a, 196b, 197, 197a, 197b, 198, 198a, 198b, 198c, 198d, 199a, 199b, 203a, 203b, 211a, 211b, 221a, 221b, 223a, 223b, 225a, 225b, 231a, 231b, 253a, 253b, 255a, 255b, 257a, 257b, 269, 270, 271, 272a, 272b, 273, 274, 274a, 274b, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288a, 288b, 289a, 289b, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 314a, 314b, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 336a, 336b, 338, 338a, 338b, 339a, 339b, II-1a, II-1b, II-2, II-3, II-4-a, II-4b, II-5, II-6a, II-6b, II-7, II-7a, II-7b, II-8, II-9, II-10, II-11, II-11a, II-11b, II-12, II-12a, II-12b, II-13, II-13a, II-13b, II-14a, II-14b, II-15a, II-15b, II-16a, II-16b, II-17, II-18, II-19, II-39, II-40, II-49a, II-49b, II-57a, II-57b, II-58, II-59, II-60, II-61, II-62, II-63, II-64, II-65, II-67, II-68, II-70, II-71, II-75, II-76, II-77, II-78, II-80, II-81, II-82, II-83, II-84, II-88, II-89, II-90, II-91, II-92, II-93a, II-93b, II-94a, II-94b, II-95a, II-95b, II-96, II-97, II-98a, II-98b, II-99a, II-99b, II-100a, II-100b, II-101, II-102, II-103, II-104, II-105, II-106a, II-106b, II-108a, II-108b, II-109a, II-109b, II-110, II-111, II-112a, II-112b, II-113a, II-113b, II-114a, II-114b, II-115a, II-115b, II-115c, II-115d, II-116, II-117, II-118a, II-118b, II-119, II-120a, II-120b, II-121a, II-121b, II-122, II-123a, II-123b, II-124a, II-124b, II-125a, II-125b, II-125c, II-125d, II-126, II-127a, II-127b, II-128a, II-128b, II-129, II-130, II-130a, II-130b, II-131, II-132a, II-132b, II-133, II-134a, II-134b, II-135a, II-135b, II-136a, II-136b, II-137, II-138, II-139, II-140, II-141, II-142, II-143, II-144, II-145, II-146a, II-146b, II-146c, II-146d, II-147a, II-147b, II-147c, II-147d, II-148, II-148a, II-148b, II-149a, II-149b, II-149c, II-149d, II-150, II-151a, II-151b, II-152a, II-152b, II-152c, II-152d, II-153, II-154, II-209, II-210, II-211, II-212, II-212a, II-212b, II-213, II-215, II-220, II-221, II-222, II-223, II-224, II-224a, II-224b, II-225, II-226, II-227a, II-227b, II-227c, II-227d, II-229, II-230, II-231, II-232, II-240, II-241, II-242, II-243, II-244a, II-244b, II-245, II-246, II-247, II-248, II-249, II-250, II-251, II-252, II-253, II-255a, II-255b, II-256, II-257, II-258, II-259, II-260a, II-260b, II-261, II-261a, II-261b, II-262, II-263, II-264, II-265a, II-265b, II-266, II-267, II-268, II-269, II-270, II-271, II-272, II-273, II-274, II-275, II-276, II-277, II-278, II-279, II-280, II-281, II-282a, II-282b, II-282c, II-282d, II-283, II-284, II-285, II-286, II-287, II-288, II-289, II-290a, II-290b, II-291a, II-291b, II-291c, II-291d, II-292, II-293a, II-293b, II-293c, II-293d, II-294a, II-294b, II-294c, II-294d, II-295, II-296a, II-296b, II-297, II-298, II-299, IV-8, IV-8a, IV-8b, IV-93a, IV-93b, IV-209a, IV-209b, IV-209c, IV-209d, IV-210a, IV-210b, IV-210c, IV-210d, V-1, V-1a, V-1b, V-2, V-2a, V-2b, V-3, V-3a, V-3b, V-14, V-14a, V-14b, V-15, V-15a, V-15b, V-15c, V-15d, V-18, V-18a, V-18b, V-18c, V-18d, V-21, V-21a, V-21b, V-22, V-22a, V-22b, V-23, V-23a and V-23b, and uses thereof.
In another embodiment, the invention relates to Compounds described in Table 1, and uses thereof. In another embodiment, the invention relates to one or more of the Compounds described in Table 2, and uses thereof.
In another embodiment, the invention relates to one or more of the Compounds described in Table 3, and uses thereof.
In another embodiment, the invention relates to one or more of the Compounds described in Table 4, and uses thereof.
In another embodiment, the invention relates to one or more of the Compounds described in Table 5, and uses thereof.
In one embodiment, the invention embraces compounds detailed herein provided that the compound is other than dimebon and metabolites of dimebon. In another embodiment, the invention embraces dimebon or a salt thereof for uses detailed herein. In another embodiment, the invention embraces a dimebon metabolite or salt thereof for uses detailed herein, such as use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption.
The embodiments and variations described herein are suitable for compounds of any formulae detailed herein, where applicable.
Representative examples of compounds detailed herein, including intermediates and final compounds according to the invention are depicted in the tables below. It is understood that in one aspect, any of the compounds may be used in the methods detailed herein, including, where applicable, intermediate compounds that may be isolated and administered to an individual.
The compounds depicted herein may be present as salts even if salts are not depicted and it is understood that the invention embraces all salts and solvates of the compounds depicted here, as well as the non-salt and non-solvate form of the compound, as is well understood by the skilled artisan. In some embodiments, the salts of the compounds of the invention are pharmaceutically acceptable salts. Where one or more tertiary amine moiety is present in the compound, the N-oxides are also provided and described.
Where tautomeric forms may be present for any of the compounds described herein, each and every tautomeric form is intended even though only one or some of the tautomeric forms may be explicitly depicted. For example, when a 2-hydroxypyridyl moiety is depicted, the corresponding 2-pyridone tautomer is also intended. The tautomeric forms specifically depicted may or may not be the predominant forms in solution or when used according to the methods described herein.
The invention also includes any or all of the stereochemical forms, including any enantiomeric or diasteriomeric forms of the compounds described. The structure or name is intended to embrace all possible stereoisomers of a compound depicted, and each unique stereoisomer has a compound number bearing a suffix “a”, “b”, etc. All forms of the compounds are also embraced by the invention, such as crystalline or non-crystalline forms of the compounds. Compositions comprising a compound of the invention are also intended, such as a composition of substantially pure compound, including a specific stereochemical form thereof, or a composition comprising mixtures of compounds of the invention in any ratio, including two or more stereochemical forms, such as in a racemic or non-racemic mixture.
Pharmaceutical compositions of any of the compounds detailed herein are embraced by this invention. Thus, the invention includes pharmaceutical compositions comprising a compound of the invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient. In one aspect, the pharmaceutically acceptable salt is an acid addition salt, such as a salt formed with an inorganic or organic acid. Pharmaceutical compositions according to the invention may take a form suitable for oral, buccal, parenteral, nasal, topical or rectal administration or a form suitable for administration by inhalation.
A compound as detailed herein may in one aspect be in a purified form and compositions comprising a compound in purified forms are detailed herein. Compositions comprising a compound as detailed herein or a salt thereof are provided, such as compositions of substantially pure compounds. In some embodiments, a composition containing a compound as detailed herein or a salt thereof is in substantially pure form. In one variation, “substantially pure” intends a composition that contains no more than 35% impurity, wherein the impurity denotes a compound other than the compound comprising the majority of the composition or a salt thereof. Taking compound 1 as an example, a composition of substantially pure compound 1 intends a composition that contains no more than 35% impurity, wherein the impurity denotes a compound other than compound 1 or a salt thereof. In one variation, a composition of substantially pure compound or a salt thereof is provided wherein the composition contains no more than 25% impurity. In another variation, a composition of substantially pure compound or a salt thereof is provided wherein the composition contains or no more than 20% impurity. In still another variation, a composition of substantially pure compound or a salt thereof is provided wherein the composition contains or no more than 10% impurity. In a further variation, a composition of substantially pure compound or a salt thereof is provided wherein the composition contains or no more than 5% impurity. In another variation, a composition of substantially pure compound or a salt thereof is provided wherein the composition contains or no more than 3% impurity. In still another variation, a composition of substantially pure compound or a salt thereof is provided wherein the composition contains or no more than 1% impurity. In a further variation, a composition of substantially pure compound or a salt thereof is provided wherein the composition contains or no more than 0.5% impurity. In yet other variations, a composition of substantially pure compound means that the composition contains no more than 15% or preferably no more than 10% or more preferably no more than 5% or even more preferably no more than 3% and most preferably no more than 1% impurity, which impurity may be the compound in a different stereochemical form. For instance, a composition of substantially pure (S) compound means that the composition contains no more than 15% or no more than 10% or no more than 5% or no more than 3% or no more than 1% of the (R) form of the compound.
In one variation, the compounds herein are synthetic compounds prepared for administration to an individual. In another variation, compositions are provided containing a compound in substantially pure form. In another variation, the invention embraces pharmaceutical compositions comprising a compound detailed herein and a pharmaceutically acceptable carrier. In another variation, methods of administering a compound are provided. The purified forms, pharmaceutical compositions and methods of administering the compounds are suitable for any compound or form thereof detailed herein.
Kits comprising a compound of the invention, or a salt or solvate thereof, and suitable packaging are provided. In one embodiment, a kit further comprises instructions for use. In one aspect, a kit comprises a compound of the invention, or a salt or solvate thereof, and instructions for use of the compounds in the treatment of a disease or condition for which a reduction in blood pressure and/or promoting renal blood flow and/or inhibiting or decreasing sodium reabsorption is expected to be or is beneficial.
Articles of manufacture comprising a compound of the invention, or a salt or solvate thereof, in a suitable container are provided. The container may be a vial, jar, ampoule, preloaded syringe, i.v. bag, and the like.
In one aspect, a compounds detailed herein as provided herein exhibits the ability to cross the blood-brain barrier. In another aspect, a compounds detailed herein as provided herein is not able to cross the blood-brain barrier. In one aspect, a compounds detailed herein as provided herein exerts its therapeutic effect in the brain only. In one aspect, a compounds detailed herein as provided herein exerts its therapeutic effect in the periphery only. In one aspect, a compounds detailed herein as provided herein exerts its therapeutic effect both in the brain and peripherally. In some embodiments, the adrenergic receptor α2B antagonist is a selective adrenergic receptor α2B antagonist. In some embodiments, the adrenergic receptor α2B antagonist also exhibits adrenergic receptor α2A antagonist and/or inverse agonist activity.
Blood brain barrier permeability can be measured in rodents or dog by administering the compound orally or intravenously, recovering a blood and brain tissue sample at different time points and comparing how much compound is in each sample. Blood fraction is typically processed to plasma for determination of compound content. Brain exposure can be described from the ratio of brain to plasma levels of drug. In one varioation, a compound that poorly crosses the blood brain barrier has a brain to plasma ratio of compound of about 0.1 or less. In another variation, the compound has a brain to plasma ratio of about 0.2 or less, about 0.3 or less, about 0.4 or less, about 0.5 or less, about 0.8 or less, or about 1.0 or less.
Preferably, the compounds detailed herein are orally bioavailable. However, the compounds may also be formulated for parenteral (e.g., intravenous) administration. In some settings, parenteral administration of an adrenergic receptor α2B antagonists (e.g., selective adrenergic receptor α2B antagonist) may be desired. For example, intra-renal delivery may offer treatment options for acute and chronic renal failure, end stage renal failure and acute decompensated congestive heart failure. Parenteral formulation may be preferred in the treatment of hypertensive urgency and emergency. In some embodiments, the adrenergic receptor α2B antagonist is a selective adrenergic receptor α2B antagonist. In some embodiments, the adrenergic receptor α2B antagonist also exhibits adrenergic receptor α2A antagonist and/or inverse agonist activity.
One or several compounds described herein can be used in the preparation of a medicament by combining the compound or compounds as an active ingredient with a pharmacologically acceptable carrier, which are known in the art. Depending on the therapeutic form of the medication, the carrier may be in various forms. In one variation, the manufacture of a medicament is for use in any of the methods disclosed herein, e.g., reducing the blood pressure of an individual, promoting renal blood flow and/or decreasing or inhibiting sodium reabsorption.
Methods as provided herein may comprise administering to an individual a pharmacological composition that contains an effective amount of a compound and a pharmaceutically acceptable carrier. The effective amount of the compound may in one aspect be a dose of between about 0.01 and about 100 mg.
The compound may be formulated for any available delivery route, including an oral, mucosal (e.g., nasal, sublingual, vaginal, buccal or rectal), parenteral (e.g., intramuscular, subcutaneous or intravenous), topical or transdermal delivery form. A compound may be formulated with suitable carriers to provide delivery forms that include, but are not limited to, tablets, caplets, capsules (such as hard gelatin capsules or soft elastic gelatin capsules), cachets, troches, lozenges, gums, dispersions, suppositories, ointments, cataplasms (poultices), pastes, powders, dressings, creams, solutions, patches, aerosols (e.g., nasal spray or inhalers), gels, suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions or water-in-oil liquid emulsions), solutions and elixirs.
One or several compounds described herein can be used in the preparation of a formulation, such as a pharmaceutical formulation, by combining the compound or compounds as an active ingredient with a pharmaceutically acceptable carrier, such as those mentioned above. Depending on the therapeutic form of the system (e.g., transdermal patch vs. oral tablet), the carrier may be in various forms. In addition, pharmaceutical formulations may contain preservatives, solubilizers, stabilizers, re-wetting agents, emulgators, sweeteners, dyes, adjusters, salts for the adjustment of osmotic pressure, buffers, coating agents or antioxidants. Formulations comprising the compound may also contain other substances which have valuable therapeutic properties. Pharmaceutical formulations may be prepared by known pharmaceutical methods. Suitable formulations can be found, e.g., in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, Pa., 20th ed. (2000), which is incorporated herein by reference.
Compounds as described herein may be administered to individuals in a form of generally accepted oral compositions, such as tablets, coated tablets, gel capsules in a hard or in soft shell, emulsions or suspensions. Examples of carriers, which may be used for the preparation of such compositions, are lactose, corn starch or its derivatives, talc, stearate or its salts, etc. Acceptable carriers for gel capsules with soft shell are, for instance, plant oils, wax, fats, semisolid and liquid poly-ols, and so on. In addition, pharmaceutical formulations may contain preservatives, solubilizers, stabilizers, re-wetting agents, emulgators, sweeteners, dyes, adjusters, salts for the adjustment of osmotic pressure, buffers, coating agents or antioxidants.
Any of the compounds described herein can be formulated in a tablet in any dosage form described, for example, a compound as described herein or a pharmaceutically acceptable salt thereof can be formulated as a 10 mg tablet.
The compound may be administered to an individual in accordance with an effective dosing regimen for a desired period of time or duration, such as at least about one month, at least about 2 months, at least about 3 months, at least about 6 months, or at least about 12 months or longer, which in some variations may be for the duration of the individual's life. In one variation, the compound is administered on a daily or intermittent schedule. The compound can be administered to an individual continuously (for example, at least once daily) over a period of time. The dosing frequency can also be less than once daily, e.g., about a once weekly dosing. The dosing frequency can be more than once daily, e.g., twice or three times daily. The dosing frequency can also be intermittent (e.g., once daily dosing for 7 days followed by no doses for 7 days, repeated for any 14 day time period, such as about 2 months, about 4 months, about 6 months or more). Any of the dosing frequencies can employ any of the compounds described herein together with any of the dosages described herein.
Compositions comprising a compound provided herein are also described. In one variation, the composition comprises a compound and a pharmaceutically acceptable carrier or excipient. In another variation, a composition of substantially pure compound is provided.
The invention further provides kits for carrying out the methods of the invention, which comprises one or more compounds described herein or a pharmacological composition comprising a compound described herein. The kits may employ any of the compounds disclosed herein. In one variation, the kit employs a compound described herein or a pharmaceutically acceptable salt thereof. The kits may be used for any one or more of the uses described herein, and, accordingly, may contain instructions for any one or more of the following uses: treating, preventing, and/or delaying the onset and/or development of hypertension and/or a disease or condition which is responsive, or expected to be responsive, to (i) a reduction in an individual's blood pressure and/or (ii) an increase in renal blood flow and/or (iii) a decrease or inhibition of sodium reabsorption.
Kits generally comprise suitable packaging. The kits may comprise one or more containers comprising any compound described herein. Each component (if there is more than one component) can be packaged in separate containers or some components can be combined in one container where cross-reactivity and shelf life permit.
The kits may be in unit dosage forms, bulk packages (e.g., multi-dose packages) or sub-unit doses. For example, kits may be provided that contain sufficient dosages of a compound as disclosed herein and/or a second pharmaceutically active compound useful for a disease detailed herein (e.g., hypertension) to provide effective treatment of an individual for an extended period, such as any of a week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 7 months, 8 months, 9 months, or more. Kits may also include multiple unit doses of the compounds and instructions for use and be packaged in quantities sufficient for storage and use in pharmacies (e.g., hospital pharmacies and compounding pharmacies).
The kits may optionally include a set of instructions, generally written instructions, although electronic storage media (e.g., magnetic diskette or optical disk) containing instructions are also acceptable, relating to the use of component(s) of the methods of the present invention. The instructions included with the kit generally include information as to the components and their administration to an individual.
The invention also provides compositions (including pharmacological compositions) as described herein for the use in treating, preventing, and/or delaying the onset and/or development of hypertension and/or a disease or condition which is responsive, or expected to be responsive, to (i) a reduction in an individual's blood pressure and/or (ii) an increase in renal blood flow and/or (iii) a decrease or inhibition of sodium reabsorption and other methods described herein. In certain embodiments, the composition comprises a pharmaceutical formulation which is present in a unit dosage form. As used herein, the term “unit dosage form” refers to a formulation that contains a predetermined dose of a compound as disclosed herein and optionally a second pharmaceutically active compound useful for treatment of a disease or condition detailed herein (e.g., hypertension).
For compounds bearing one or more chiral centers, each unique stereoisomer has a compound number bearing a suffix “a”, “b”, etc. As examples, racemic compound V-1, bearing one chiral center, can be resolved into its individual enantiomers V-1a and V-1b.




Similarly, racemic compound V-4, bearing two chiral centers, can be resolved into its individual diastereomers V-4a, V-4b, V-4c and V-4d.





Representative compounds of the invention are shown in Tables 1-5.







TABLE 1





Representative Compounds of the Invention













 


1 1a, 1b


 








 


2 2a, 2b


 








 


3 3a, 3b


 








 


4 4a, 4b


 








 


5 5a, 5b


 








 


6 6a, 6b


 








 


7 7a, 7b


 








 


8 8a, 8b


 








 


9 9a, 9b


 








 


10 10a, 10b


 








 


11 11a, 11b


 








 


12 12a, 12b


 








 


13 13a, 13b


 








 


14 14a, 14b


 








 


15 15a, 15b


 








 


16 16a, 16b


 








 


17 17a, 17b


 








 


18 18a, 18b


 








 


19 19a, 19b


 








 


20 20a, 20b


 








 


21 21a, 21b


 








 


22 22a, 22b


 








 


23 23a, 23b


 








 


24 24a, 24b


 








 


25 25a, 25b, 25c, 25d


 








 


26 26a, 26b, 26c, 26d


 








 


27 27a, 27b


 








 


28 28a, 28b


 








 


29 29a, 29b


 








 


30 30a, 30b


 








 


31 31a, 31b


 








 


32 32a, 32b


 








 


33 33a, 33b


 








 


34 34a, 34b


 








 


35 35a, 35b


 








 


36 36a, 36b, 36c, 36d


 








 


37 37a, 37b, 37c, 37d


 








 


38 38a, 38b, 38c, 38d, 38e, 38f, 38g, 38h


 








 


39 39a, 39b


 








 


40 40a, 40b


 








 


41 41a, 41b


 








 


42 42a, 42b


 








 


43 43a, 43b


 








 


44 44a, 44b


 








 


45 45a, 45b


 








 


46 46a, 46b


 








 


47 47a, 47b, 47c, 47d


 








 


48 48a, 48b


 








 


49 49a, 49b


 








 


50 50a, 50b, 50c, 50d


 








 


51 51a, 51b


 








 


52 52a, 52b


 








 


53 53a, 53b


 








 


54 54a, 54b


 








 


55 55a, 55b


 








 


56 56a, 56b


 








 


57 57a, 57b


 








 


58 58a, 58b


 








 


59 59a, 59b


 








 


60


 








 


61


 








 


62 62a, 62b


 








 


63 63a, 63b


 








 


64 64a, 64b


 








 


65 65a, 65b


 








 


66 66a, 66b


 








 


67 67a, 67b


 








 


68


 








 


69 69a, 69b


 








 


70 70a, 70b, 70c, 70d


 








 


71 71a, 71b


 








 


72 72a, 72b


 








 


73 73a, 73b, 73c, 73d


 








 


74 74a, 74b


 








 


75 75a, 75b, 75c, 75d


 








 


76 76a, 76b, 76c, 76d


 








 


77


 








 


78


 








 


79


 








 


80


 








 


81 81a, 81b


 








 


82 82a, 82b


 








 


83


 








 


84


 








 


85


 








 


86


 








 


87


 








 


88


 








 


89


 








 


90 90a, 90b


 








 


91


 








 


92


 








 


93 93a, 93b


 








 


94


 








 


95 95a, 95b


 








 


96 96a, 96b


 








 


97 97a, 97b


 








 


98 98a, 98b


 








 


99


 








 


100


 








 


101


 








 


102 102a, 102b


 








 


103


 








 


104 104a, 104b


 








 


105


 








 


106


 








 


107


 








 


108


 








 


109


 








 


110


 








 


111


 








 


112


 








 


113


 








 


114


 








 


115


 








 


116


 








 


117


 








 


118


 








 


119


 








 


120


 








 


121


 








 


122


 








 


123 123a, 123b


 








 


124


 








 


125


 








 


126


 








 


127 127a, 127b, 127c, 127d


 








 


128 128a, 128b


 








 


129 129a, 129b, 129c, 129d


 








 


130 130a, 130b


 








 


131 131a, 131b


 








 


132


 








 


133 133a, 133b


 








 


134 134a, 134b


 








 


135 135a, 135b


 








 


136 136a, 136b


 








 


137 137a, 137b


 








 


138 138a, 138b


 








 


139 139a, 139b


 








 


140 140a, 140b


 








 


141 141a, 141b


 








 


142 142, 142b


 








 


143 143a, 143b


 








 


144 144a, 144b


 








 


145 145a, 145b


 








 


146 146a, 146b


 








 


147 147a, 147b


 








 


148 148a, 148b, 148a, 148d


 








 


149 149a, 149b


 








 


150 150a, 150b


 








 


151 151a, 151b


 








 


152 152a, 152b


 








 


153 153a, 153b


 








 


154 154a, 154b


 








 


155 155a, 155b, 155c, 155d


 








 


156 156a, 156b


 








 


157 157a, 157b


 








 


158 158a, 158b


 








 


159 159a, 159b


 








 


160 160a, 160b


 








 


161 161a, 161b, 161c, 161d


 








 


162 162a, 162b, 162c, 162d


 








 


163 163a, 163b, 163c, 163d


 








 


164 164a, 164b, 164c, 164d


 








 


165 165a, 165b


 








 


166 166a, 166b


 








 


167 167a, 167b


 








 


168 168a, 168b, 168c, 168d


 








 


169 169a, 169b


 








 


170 170a, 170b


 








 


171 171a, 171b


 








 


172 172a, 172b


 








 


173 173a, 173b


 








 


174 174a, 174b


 








 


175 175a, 175b


 








 


176 176a, 176b, 176c, 176d


 








 


177 177a, 177b, 177c, 177d


 








 


178 178a, 178b


 








 


179 179a, 179b


 








 


180


 








 


181


 








 


182


 








 


183 183a, 183b


 








 


184


 








 


185


 








 


186


 








 


187


 








 


188


 








 


189


 








 


190


 








 


191


 








 


192 192a, 192b, 192c, 192d


 








 


193 193a, 193b


 








 


194 194a, 194b


 








 


195 195a, 195b


 








 


196 196a, 196b


 








 


197 197a, 197b


 








 


198 198a, 198b, 198c, 198d


 








 


199 199a, 199b


 








 


200


 








 


201


 








 


202


 








 


203


 








 


204


 








 


205


 








 


206


 








 


207


 








 


208


 








 


209


 








 


210


 








 


211 211a, 211b


 








 


212


 








 


213


 








 


214


 








 


215


 








 


216


 








 


217


 








 


218


 








 


219


 








 


220 220a, 220b


 








 


221 221a, 221b


 








 


222


 








 


223 223a, 223b


 








 


224


 








 


225 225a, 225b


 








 


226


 








 


227


 








 


228


 








 


229


 








 


230


 








 


231 231a, 231b


 








 


232


 








 


233


 








 


234


 








 


235


 








 


236


 








 


237


 








 


238


 








 


239


 








 


240


 








 


241


 








 


242


 








 


243


 








 


244


 








 


245


 








 


246


 








 


247


 








 


248


 








 


249


 








 


250


 








 


251


 








 


252


 








 


253 253a, 253b


 








 


254 254a, 254b


 








 


255 255a, 255b


 








 


256


 








 


257


 








 


258


 








 


259


 








 


260


 








 


261


 








 


262


 








 


263


 








 


264


 








 


265


 








 


266


 








 


267


 








 


268


 








 


269


 








 


270


 








 


271


 








 


272 272a, 272b


 








 


273


 








 


274 274a, 274b


 








 


275


 








 


276


 








 


277


 








 


278


 








 


279


 








 


280


 








 


281


 








 


282


 








 


283


 








 


284


 








 


285


 








 


286


 








 


287


 








 


288 288a, 288b


 








 


289 289a, 289b


 








 


290


 








 


291


 








 


292


 








 


293


 








 


294


 








 


295


 








 


296


 








 


297


 








 


298


 








 


299


 








 


300


 








 


301


 








 


302


 








 


303


 








 


304


 








 


305


 








 


306


 








 


307


 








 


308


 








 


309


 








 


310


 








 


311


 








 


312


 








 


313


 








 


314 314a, 314b


 








 


315


 








 


316


 








 


317


 








 


318


 








 


319


 








 


320


 








 


321


 








 


322


 








 


323


 








 


324


 








 


325


 








 


326


 








 


327


 








 


328


 








 


329


 








 


330


 








 


331


 








 


332


 








 


333


 








 


334


 








 


335


 








 


336 336a, 336b


 








 


337 337a, 337b


 








 


338 338a, 338b


 








 


339 339a, 339b


 








 


340 340a, 340b, 340c, 340d


 








 


341 341a, 341b, 341c, 341d


 








 


342 342a, 342b, 342c, 342d
















TABLE 2





Representative Compounds of the Invention





















   II-1a, II-1b
II-1



 







II-2



 







II-3



 






   II-4a, II-4b, II-4c, II-4d 
II-4



 






   II-5a, II-5 II-5c, II-5d
II-5



 






   II-6a, II-6b, II-6c, II-6d 
II-6



 






   II-7a, II-7b, II-7c, II-7d 
II-7



 






   II-8a, II-8b
II-8



 






   II-9a, II-9b
II-9



 






   II-10a, II-10b
II-10



 






   II-11a, II-11b
II-11



 






   II-12a, II-12b
II-12



 






   II-13a, II-13b
II-13



 






   II-14a, II-14b
II-14



 






   II-15a, II-15b
II-15



 






   II-16a, II-16b
II-16



 






   II-17a, II-17b, II-17c, II-17d
II-17



 







II-18



 






   II-19a, II-19b
II-19



 






   II-20a, II-20b
II-20



 






   II-21a, II-21b
II-21



 






   II-22a, II-22b
II-22



 






   II-23a, II-23b
II-23



 






   II-24a, II-24b
II-24



 






   II-25a, II-25b
II-25



 






   II-26a, II-26b
II-26



 






   II-27a, II-27b
II-27



 






   II-28a, II-28b
II-28



 






   II-29a, II-29b
II-29



 






   II-30a, II-30b
II-30



 






   II-31a, II-31b
II-31



 






   II-32a, II-32b
II-32



 






   II-33a, II-33b
II-33



 






   II-34a, II-34b
II-34



 






   II-35a, II-35b
II-35



 






   II-36a, II-36b
II-36



 






   II-37a, II-37b
II-37



 






   II-38a, II-38b
II-38



 







II-39



 







II-40



 






   II-41a, II-41b
II-41



 






   II-42a, II-42b
II-42



 






   II-43a, II-43b
II-43



 






   II-44a, II-44b
II-44



 






   II-45a, II-45b
II-45



 






   II-46a, II-46b
II-46



 






   II-47a, II-47b
II-47



 






   II-48a, II-48b
II-48



 






   II-49a, II-49b
II-49



 






   II-50a, II-50b
II-50



 






   II-51a, II-51b
II-51



 






   II-52a, II-52b
II-52



 






   II-53a, II-53b
II-53



 






   II-54a, II-54b
II-54



 






   II-55a, II-55b
II-55



 






   II-56a, II-56b
II-56



 






   II-57a, II-57b
II-57



 






   II-58a, II-58b
II-58



 







II-59



 






   II-60a, II-60b
II-60



 







II-61



 






   II-62a, II-62b
II-62



 






   II-63a, II-63b
II-63



 






   II-64a, II-64b
II-64



 






   II-65a, II-65b
II-65



 






   II-66a, II-66b
II-66



 






   II-67a, II-67b
II-67



 






   II-68a, II-68b
II-68



 






   II-69a, II-69b, II-69c, II-69d
II-69



 







II-70



 






   II-71a, II-71b
II-71



 






   II-72a, II-72b, II-72c, II-72d
II-72



 






   II-73a, II-73b, II-73c, II-73d
II-73



 






   II-74a, II-74b, II-74c, II-74d
II-74



 






   II-75a, II-75b
II-75



 







II-76



 







II-77



 






   II-78a, II-78b
II-78



 






   II-79a, II-79b, II-79c, II-79d
II-79



 






   II-80a, II-80b
II-80



 






   II-81a, II-81b
II-81



 







II-82



 






   II-83a, II-83b, II-83c, II-83d
II-83



 






   II-84a, II-84b
II-84



 






   II-85a, II-85b, II-85c, II-85d
II-85



 






   II-86a, II-86b, II-86c, II-86d
II-86



 






   II-87a, II-87b
II-87



 






   II-88a, II-88b
II-88



 






   II-89a, II-89b
II-89



 






   II-90a, II-90b
II-90



 






   II-91a, II-91b
II-91



 






   II-92a, II-92b
II-92



 






   II-93a, II-93b
II-93



 






   II-94a, II-94b
II-94



 






   II-95a, II-95b, II-95c, II-95d
II-95



 







II-96



 






   II-97a, II-97b
II-97



 






   II-98a, II-98b, II-98c, II-98d
II-98



 






   II-99a, II-99b
II-99



 






   II-100a, II-100b
II-100



 







II-101



 






   II-102a, II-102b
II-102



 







II-103



 






   II-104a, II-104b
II-104



 






   II-105a, II-105b
II-105



 






   II-106a, II-106b
II-106



 






   II-107a, II-107b, II-107c, II-107d
II-107



 






   II-108a, II-108b
II-108



 






   II-109a, II-109b
II-109



 







II-110



 






   II-111a, II-111b
II-111



 






   II-112a, II-112b, II-112c, II-112d
II-112



 






   II-113a, II-113b, II-113c, II-113d
II-113



 






   II-114a, II-114b
II-114



 






   II-115a, II-115b, II-115c, II-115d
II-115



 






   II-116a, II-116b
II-116



 






   II-117a, II-117b
II-117



 






   II-118a, II-118b
II-118



 







II-119



 






   II-120a, II-120b, II-120c, II-120d
II-120



 






   II-121a, II-121b, II-121c, II-121d
II-121



 






   II-122a, II-122b, II-122c, II-122d
II-122



 






   II-123a, II-123b
II-123



 






   II-124a, II-124b
II-124



 






   II-125a, II-125b, II-125c, II-125d
II-125



 






   II-126a, II-126b
II-126



 






   II-127a, II-127b, II-127c, II-127d
II-127



 






   II-128a, II-128b, II-128c, II-128d
II-128



 






   II-129a, II-129b
II-129



 






   II-130a, II-130b, II-130c, II-130d
II-130



 






   II-131a, II-131b, II-131c, II-131d
II-131



 






   II-132a, II-132b, II-132c, II-132d
II-132



 







II-133



 






   II-134a, II-134b
II-134



 






   II-135a, II-135b
II-135



 






   II-136a, II-136b
II-136



 






   II-137a, II-137b
II-137



 






   II-138a, II-138b, II-138c, II-138d
II-138



 






   II-139a, II-139b, II-139c, II-139d
II-139



 






   II-140a, II-140b, II-140c, II-140d
II-140



 






   II-141a, II-141b
II-141



 






   II-142a, II-142b
II-142



 






   II-143a, II-143b
II-143



 







II-144



 






   II-145a, II-145b
II-145



 






   II-146a, II-146b, II-146c, II-146d
II-146



 






   II-147a, II-147b, II-147c, II-147d
II-147



 






   II-148a, II-148b
II-148



 






   II-149a, II-149b, II-149c, II-149d
II-149



 






   II-150a, II-150b, II-150c, II-150d
II-150



 






   II-151a, II-151b, II-151c, II-151d
II-151



 






   II-152a, II-152b, II-152c, II-152d
II-152



 






   II-153a, II-153b
II-153



 






   II-154a, II-154b
II-154



 






   II-155a, II-155b
II-155



 






   II-156a, II-156b
II-156



 






   II-157a, II-157b
II-157



 






   II-158a, II-158b
II-158



 






   II-159a, II-159b
II-159



 






   II-160a, II-160b
II-160



 






   II-161a, II-161b, II-161c, II-161d
II-161



 






   II-162a, II-162b
II-162



 






   II-163a, II-163b
II-163



 






   II-164a, II-164b, II-164c, II-164d
II-164



 






   II-165a, II-165b, II-165c, II-165d
II-165



 






   II-166a, II-166b
II-166



 






   II-167a, II-167b
II-167



 






   II-168a, II-168b
II-168



 






   II-169a, II-169b
II-169



 






   II-170a, II-170b
II-170



 






   II-171a, II-171b
II-171



 






   II-172a, II-172b
II-172



 






   II-173a, II-173b
II-173



 






   II-174a, II-174b
II-174



 






   II-175a, II-175b
II-175



 






   II-176a, II-176b
II-176



 






   II-177a, II-177b
I-177



 






   II-178a, II-178b
II-178



 






   II-179a, II-179b
II-179



 






   II-180a, II-180b
II-180



 






   II-181a, II-181b
II-181



 






   II-182a, II-182b
II-182



 






   II-183a, II-183b
II-183



 






   II-184a, II-184b
II-184



 






   II-185a, II-185b, II-185c, II-185d
II-185



 







II-186



 






   II-187a, II-187b
II-187



 






   II-188a, II-188b
II-188



 






   II-189a, II-189b
I-189



 






   II-190a, II-190b
II-190



 






   II-191a, II-191b
II-191



 






   II-192a, II-192b
II-192



 






   II-193a, II-193b
II-193



 






   II-194a, II-194b
II-194



 






   II-195a, II-195b
II-195



 






   II-196a, II-196b
II-196



 






   II-197a, II-197b
II-197



 






   II-198a, II-198b
II-198



 






   II-199a, II-199b
II-199



 






   II-200a, II-200b
II-200



 






   II-201a, II-201b
II-201



 






   II-202a, II-202b
II-202



 






   II-203a, II-203b
II-203



 






   II-204a, II-204b
II-204



 






   II-205a, II-205b
II-205



 






   II-206a, II-206b
II-206



 






   II-207a, II-207b
II-207



 






   II-208a, II-208b
II-208



 







II-209



 






   II-210a, II-210b
II-210



 






   II-211a, II-211b
II-211



 






   II-212a, II-212b
II-212



 






   II-213a, II-213b
II-213



 






   II-214a, II-214b
II-214



 







II-215



 






   II-216a, II-216b
II-216



 






   II-217a, II-217b
II-217



 






   II-218a, II-218b
II-218



 






   II-219a, II-219b, II-219c, II-219d
II-219



 






   II-220a, II-220b
II-220



 






   II-221a, II-221b
II-221



 






   II-222a, II-222b
II-222



 






   II-223a, II-223b
II-223



 






   II-224a, II-224b
II-224



 






   II-225a, II-225b
II-225



 






   II-226a, II-226b
II-226



 






   II-227a, II-227b, II-227c, II-227d
II-227



 






   II-228a, II-228b
II-228



 






   II-229a, II-229b
II-229



 






   II-230a, II-230b
II-230



 






   II-231a, II-231b
II-231



 






   II-232a, II-232b
II-232



 







II-233



 






   II-234a, II-234b
II-234



 






   II-235a, II-235b
II-235



 






   II-236a, II-236b
II-236



 







II-237



 






   II-238a, II-238b
II-238



 






   II-239a, II-239b
II-239



 







II-240



 






   II-241a, II-241b
II-241



 






   II-242a, II-242b
II-242



 






   II-243a, II-243b
II-243



 






   II-244a, II-244b
II-244



 






   II-245a, II-245b
II-245



 







II-246



 







II-247



 







II-248



 







II-249



 







II-250



 







II-251



 







II-252



 







II-253



 







II-254



 






   II-255a, II-255b
II-255



 






   II-256a, II-256b
II-256



 






   II-257a, II-257b
II-257



 






   II-258a, II-258b
II-258



 






   II-259a, II-259b
II-259



 






   II-260a, II-260b
II-260



 






   II-261a, II-261b, II-261c, II-261d
II-261



 






   II-262a, II-262b
II-262



 






   II-263a, II-263b
II-263



 






   II-264a, II-264b
II-264



 






   II-265a, II-265b
II-265



 






   II-266a, II-266b, II-266c, II-266d
II-266



 






   II-267a, II-267b
II-267



 






   II-268a, II-268b
II-268



 






   II-269a, II-269b
II-269



 






   II-270a, II-270b
II-270



 






   II-271a, II-271b, II-271c, II-271d
II-271



 







II-272



 







II-273



 






   II-274a, II-274b
II-274



 






   II-275a, II-275b, II-275c, II-275d
II-275



 






   II-276a, II-276b, II-276c, II-276d
II-276



 






   II-277a, II-277b
II-277



 






   II-278a, II-278b
II-278



 






   II-279a, II-279b, II-279c, II-279d
II-279



 






   II-280a, II-280b, II-280c, II-280d
II-280



 






   II-281a, II-281b, II-281c, II-281d
II-281



 






   II-282a, II-282b, II-282c, II-282d, II-282e, II-282f, II-282g, II-282h
II-282



 






   II-283a, II-283b, II-283c, II-283d
II-283



 






   II-284a, II-284b, II-284c, II-284d
II-284



 






   II-285a, II-285b, II-285c, II-285d
II-285



 







II-286



 






   II-287a, II-287b, II-287c, II-287d
II-287



 






   II-288a, II-288b, II-288c, II-288d
II-288



 






   II-289a, II-289b
II-289



 






   II-290a, II-290b
II-290



 






   II-291a, II-291b, II-291c, II-291d
II-291



 






   II-292a, II-292b
II-292



 






   II-293a, II-293b, II-293c, II-293d
II-293



 






   II-294a, II-294b, II-294c, II-294d
II-294



 






   II-295a, II-295b
II-295



 






   II-296a, II-296b
II-296



 






   II-297a, II-297b
II-297



 






   II-298a, II-298b
II-298



 







II-299

















TABLE 3





Representative Compounds of the Invention.






















III-1



 







III-2



 







III-3



 







III-4



 







III-5



 







III-6



 







III-7



 







III-8



 







III-9



 







III-10



 







III-11



 







III-12



 







III-13



 







III-14



 







III-15



 







III-16



 







III-17



 







III-18



 







III-19



 







III-20



 







III-21



 







III-22



 







III-23



 







III-24



 







III-25



 







III-26



 







III-27



 







III-28



 







III-29



 







III-30



 







III-31



 







III-32



 







III-33



 







III-34



 







III-35



 







III-36



 







III-37



 







III-38



 







III-39



 







III-40



 







III-41



 







III-42



 







III-43



 







III-44



 







III-45



 







III-46



 







III-47



 







III-48



 







III-49



 







III-50



 







III-51



 







III-52



 







III-53



 







III-54



 







III-55



 







III-56



 







III-57



 







III-58



 







III-59



 







III-60



 







III-61



 







III-62



 







III-63



 







III-64



 







III-65



 







III-66



 







III-67



 







III-68



 







III-69



 







III-70



 







III-71



 







III-72



 







III-73



 







III-74



 







III-75



 







III-76



 







III-77



 







III-78



 







III-79



 







III-80



 







III-81



 







III-82



 







III-83



 







III-84



 







III-85



 







III-86



 







III-87



 







III-88



 







III-89



 







III-90



 







III-91



 







III-92



 







III-93



 







III-94



 







III-95



 







III-96



 







III-97



 







III-98



 







III-99



 







III-100



 







III-101



 







III-102



 







III-103



 







III-104



 







III-105



 







III-106



 







III-107



 







III-108



 







III-109



 







III-110



 







III-111



 







III-112



 







III-113



 







III-114



 







III-115



 







III-116



 







III-117



 







III-118



 







III-119



 







III-120



 







III-121



 







III-122



 







III-123



 







III-124



 







III-125



 







III-126



 







III-127



 







III-128



 







III-129



 







III-130



 







III-131



 







III-132



 







III-133



 







III-134



 







III-135



 







III-136



 







III-137



 







III-138



 







III-139



 







III-140



 







III-141



 







III-142



 







III-143



 







III-144



 







III-145



 







III-146



 







III-147



 







III-148



 







III-149



 







III-150



 







III-151



 







III-152



 







III-153



 







III-154



 







III-155



 







III-156



 







III-157



 







III-158



 







III-159



 







III-160



 







III-161



 







III-162



 







III-163



 







III-164



 







III-165



 







III-166



 







III-167



 







III-168



 







III-169



 







III-170



 







III-171



 







III-172



 







III-173



 







III-174



 







III-175



 







III-176



 







III-177



 







III-178



 







III-179



 







III-180



 







III-181



 







III-182



 







III-183



 







III-184



 







III-185



 







III-186



 







III-187



 







III-188



 







III-189



 







III-190



 







III-191



 







III-192



 







III-193



 







III-194



 







III-195



 







III-196



 







III-197



 







III-198



 







III-199



 







III-200



 







III-201



 







III-202



 







III-203



 







III-204



 







III-205



 







III-206



 







III-207



 







III-208



 







III-209



 







III-210



 







III-211



 







III-212



 







III-213



 







III-214



 







III-215



 







III-216



 







III-217



 







III-218



 







III-219



 







III-220



 







III-221



 







III-222



 







III-223



 







III-224



 







III-225



 







III-226



 







III-227



 







III-228



 







III-229



 







III-230



 







III-231



 







III-232



 







III-233



 







III-234



 







III-235



 







III-236



 







III-237



 







III-238



 







III-239



 







III-240



 







III-241



 







III-242



 







III-243



 







III-244



 







III-245



 







III-246



 







III-247



 







III-248



 







III-249



 







III-250



 







III-251



 







III-252



 







III-253



 







III-254



 







III-255



 







III-256



 







III-257



 







III-258



 







III-259



 







III-260



 







III-261



 







III-262



 







III-263



 







III-264



 







III-265



 







III-266



 







III-267



 







III-268



 







III-269



 







III-270



 







III-271



 







III-272



 







III-273



 







III-274



 







III-275



 







III-276



 







III-277



 







III-278



 







III-279



 







III-280



 







III-281



 







III-282



 







III-283



 







III-284



 







III-285



 







III-286



 







III-287



 







III-288



 







III-289



 







III-290



 







III-291



 







III-292



 







III-293



 







III-294



 







III-295



 







III-296



 







III-297



 







III-298



 







III-299



 







III-300



 







III-301



 







III-302



 







III-303



 







III-304



 







III-305



 







III-306



 







III-307



 







III-308



 







III-309



 







III-310



 







III-311



 







III-312



 







III-313



 







III-314



 







III-315



 







III-316



 







III-317



 







III-318



 







III-319



 







III-320



 







III-321



 







III-322



 







III-323



 







III-324



 







III-325



 







III-326



 







III-327



 







III-328



 







III-329



 







III-330



 







III-331



 







III-332



 







III-333



 







III-334



 







III-335



 







III-336



 







III-337



 







III-338



 







III-339



 







III-340



 







III-341



 







III-342



 







III-343



 







III-344



 







III-345



 







III-346



 







III-347



 







III-348



 







III-349



 







III-350



 







III-351



 







III-352



 







III-353



 







III-354



 







III-355



 







III-356



 







III-357



 







III-358



 







III-359

















TABLE 4





Representative Compounds of the Invention






















IV-1



 



IV-1a, IV-1b




 







IV-2



 



IV-2a, IV-2b




 







IV-3



 



IV-3a, IV-3b, IV-3c, IV-3d




 







IV-4



 



IV-4a, IV-4b




 







IV-5



 



IV-5a, IV-5b, IV-5c, IV-5d




 







IV-6



 



IV-6a, IV-6b




 







IV-7



 



IV-7a, IV-7b




 







IV-8



 



IV-8a, IV-8b




 







IV-9



 



IV-9a, IV-9b




 







IV-10



 



IV-10a, IV-10b, IV-10c, IV-10d




 







IV-11



 



IV-11a, IV-11b




 







IV-12



 



IV-12a, IV-12b




 







IV-13



 



IV-13a, IV-13b




 







IV-14



 



IV-14a, IV-14b




 







IV-15



 



IV-15a, IV-15b




 







IV-16



 



IV-16a, IV-16b




 







IV-17



 



IV-17a, IV-17b




 







IV-18



 



IV-18a, IV-18b




 







IV-19



 



IV-19a, IV-19b




 







IV-20



 



IV-20a, IV-20b




 







IV-21



 



IV-21a, IV-21b




 







IV-22



 



IV-22a, IV-22b




 







IV-23



 



IV-23a, IV-23b




 







IV-24



 



IV-24a, IV-24b




 







IV-25



 



IV-25a, IV-25b




 







IV-26



 



IV-26a, IV-26b




 







IV-27



 



IV-27a, IV-27b




 







IV-28



 



IV-28a, IV-28b




 







IV-29



 



IV-29a, IV-29b




 







IV-30



 



IV-30a, IV-30b




 







IV-31 



 



IV-31a, IV-31b




 







IV-32



 



IV-32a, IV-32b




 







IV-33



 



IV-33a, IV-33b




 







IV-34



 



IV-34a, IV-34b




 







IV-35 



 



IV-35a, IV-35b




 







IV-36



 



IV-36a, IV-36b




 







IV-37



 



IV-37a, IV-37b




 







IV-38



 



IV-38a, IV-38b




 







IV-39



 



IV-39a, IV-39b




 







IV-40



 



IV-40a, IV-40b




 







IV-41



 



IV-41a, IV-41b




 







IV-42 



 



IV-42a, IV-42b




 







IV-43



 



IV-43a, IV-43b




 







IV-44



 



IV-44a, IV-44b




 







IV-45



 



IV-45a, IV-45b




 







IV-46



 



IV-46a, IV-46b




 







IV-47 



 



IV-47a, IV-47b




 







IV-48



 



IV-48a, IV-48b




 







IV-49



 



IV-49a, IV-49b




 







IV-50



 



IV-50a, IV-50b




 







IV-51



 



IV-51a, IV-51b 




 







IV-52



 



IV-52a, IV-52b




 







IV-53



 



IV-53a, IV-53b




 







IV-54



 



IV-54a, IV-54b




 







IV-55



 



IV-55a, IV-55b




 







IV-56



 



IV-56a, IV-56b




 







IV-57



 



IV-57a, IV-57b




 







IV-58



 



IV-58a, IV-58b




 







IV-59



 



IV-59a, IV-59b




 







IV-60



 



IV-60a, IV-60b




 







IV-61



 



IV-61a, IV-61b




 







IV-62



 



IV-62a, IV-62b




 







IV-63



 



IV-63a, IV-63b




 







IV-64



 



IV-64a, IV-64b




 







IV-65



 



IV-65a, IV-65b




 







IV-66



 



IV-66a, IV-66b




 







IV-67



 



IV-67a, IV-67b




 







IV-68



 



IV-68a, IV-68b




 







IV-69



 



IV-69a, IV-69b




 







IV-70



 



IV-70a, IV-70b




 







IV-71



 



IV-71a, IV-71b




 







IV-72



 



IV-72a, IV-72b




 







IV-73



 



IV-73a, IV-73b




 







IV-74



 



IV-74a, IV-74b




 







IV-75



 



IV-75a, IV-75b




 







IV-76



 



IV-76a, IV-76b




 







IV-77



 



IV-77a, IV-77b




 







IV-78



 



IV-78a, IV-78b




 







IV-79



 



IV-79a, IV-79b




 







IV-80



 



IV-80a, IV-80b




 







IV-81



 



IV-81a, IV-81b




 







IV-82



 



IV-82a, IV-82b




 







IV-83



 



IV-83a, IV-83b




 







IV-84



 



IV-84a, IV-84b




 







IV-85



 



IV-85a, IV-85b




 







IV-86



 



IV-86a, IV-86b




 







IV-87



 



IV-87a, IV-87b




 







IV-88



 



IV-88a, IV-88b




 







IV-89



 



IV-89a, IV-89b




 







IV-90



 



IV-90a, IV-90b, IV-90c, IV-90d




 







IV-91



 



IV-91a, IV-91b




 







IV-92



 



IV-92a, IV-92b, IV-92c, IV-92d




 







IV-93



 



IV-93a, IV-93b




 







IV-94



 



IV-94a, IV-94b




 







IV-95



 



IV-95a, IV-95b




 







IV-96



 



IV-96a, IV-96b




 







IV-97



 



IV-97a, IV-97b




 







IV-98



 



IV-98a, IV-98b




 







IV-99



 



IV-99a, IV-99b




 







IV-100



 



IV-100a, IV-100b




 







IV-101



 



IV-101a, IV-101b




 







IV-102



 



IV-102a, IV-102b




 







IV-103



 



IV-103a, IV-103b




 







IV-104



 



IV-104a, IV-104b




 







IV-105



 



IV-105a, IV-105b




 







IV-106



 



IV-106a, IV-106b




 







IV-107



 



IV-107a, IV-107b




 







IV-108



 



IV-108a, IV-108b




 







IV109



 



IV-109a, IV-109b




 







IV-110



 



IV-110a, IV-110b




 







IV-111



 



IV-111a, IV-111b




 







IV-112



 



IV-112a, IV-112b




 







IV-113



 



IV-113a, IV-113b




 







IV-114



 



IV-114a, IV-114b




 







IV-115



 



IV-115a, IV-115b




 







IV-116



 



IV-116a, IV-116b




 







IV-117



 



IV-117a, IV-117b




 







IV-118



 



IV-118a, IV-118b




 







IV-119



 



IV-119a, IV-119b




 







IV-120



 



IV-120a, IV-120b




 







IV-121



 



IV-121a, IV-121b




 







IV-122



 



IV-122a, IV-122b




 







IV-123



 



IV-123a, IV-123b




 







IV-124



 



IV-124a, IV-124b




 







IV-125



 



IV-125a, IV-125b




 







IV-126



 



IV-126a, IV-126b




 







IV-127



 



IV-127a, IV-127b




 







IV-128



 



IV-128a, IV-128b




 







IV-129



 



IV-129a, IV-129b, IV-129c, IV-129d




 







IV-130



 



IV-130a, IV-130b, IV-130c, IV-130d




 







IV-131



 



IV-131a, IV-131b, IV-131c, IV-131d




 







IV-132



 



IV-132a, IV-132b, IV-132c, IV-132d




 







IV-133



 



IV-133a, IV-133b, IV-133c, IV-133d




 







IV-134



 



IV-134a, IV-134b, IV-134c, IV-134d




 







IV-135



 



IV-135a, IV-135b, IV-135c, IV-135d




 







IV-136



 



IV-136a, IV-136b, IV-136c, IV-136d




 







IV-137



 



IV-137a, IV-137b, IV-137c, IV-137d




 







IV-138



 



IV-138a, IV-138b, IV-138c, IV-138d




 







IV-139



 



IV-139a, IV-139b, IV-139c, IV-139d




 







IV-140



 



IV-140a, IV-140b, IV-140c, IV-140d




 







IV-141



 



IV-141a, IV-141b, IV-141c, IV-141d




 







IV-142



 



IV-142a, IV-142b, IV-142c, IV-142d




 







IV-143



 



IV-143a, IV-143b, IV-143c, IV-143d




 







IV-144



 



IV-144a, IV-144b, IV-144c, IV-144d




 







IV-145



 



IV-145a, IV-145b, IV-145c, IV-145d




 







IV-146



 



IV-146a, IV-146b, IV-146c, IV-146d




 







IV-147



 



IV-147a, IV-147b, IV-147c, IV-147d




 







IV-148



 



IV-148a, IV-148b, IV-148c, IV-148d




 







IV-149



 



IV-149a, IV-149b, IV-149c, IV-149d




 







IV-150



 



IV-150a, IV-150b, IV-150c, IV-150d




 







IV-151



 



IV-151a, IV-151b, IV-151c, IV-151d




 







IV-152



 



IV-152a, IV-152b, IV-152c, IV-152d




 







IV-153



 



IV-153a, IV-153b, IV-153c, IV-153d




 







IV-154



 



IV-154a, IV-154b, IV-154c, IV-154d




 







IV-155



 



IV-155a, IV-155b, IV-155c, IV-155d




 







IV-156



 



IV-156a, IV-156b, IV-156c, IV-156d




 







IV-157



 



IV-157a, IV-157b, IV-157c, IV-157d




 







IV-158



 



IV-158a, IV-158b, IV-158c, IV-158d




 







IV-159



 



IV-159a, IV-159b, IV-159c, IV-159d




 







IV-160



 



IV-160a, IV-160b, IV-160c, IV-160d




 







IV-161



 



IV-161a, IV-161b, IV-161c, IV-161d




 







IV-152



 



IV-162a, IV-162b, IV-162c, IV-162d




 







IV-163



 



IV-163a, IV-163b, IV-163c, IV-163d




 







IV-164



 



IV-164a, IV-164b, IV-164c, IV-164d




 







IV-165



 



IV-165a, IV-165b, IV-165c, IV-165d




 







IV-166



 



IV-166a, IV-166b, IV-166c, IV-166d




 







IV-167



 



IV-167a, IV-167b, IV-167c, IV-167d




 







IV-168



 



IV-168a, IV-168b, IV-168c, IV-168d




 







IV-169



 



IV-169a, IV-169b, IV-169c, IV-169d




 







IV-170



 



IV-170a, IV-170b, IV-170c, IV-170d




 







IV-171



 



IV-171a, IV-171b, IV-171c, IV-171d




 







IV-172



 



IV-172a, IV-172b, IV-172c, IV-172d




 







IV-173



 



IV-173a, IV-173b, IV-173c, IV-173d




 







IV-174



 



IV-174a, IV-174b, IV-174c, IV-174d




 







IV-175



 



IV-175a, IV-175b, IV-175c, IV-175d




 







IV-176



 



IV-176a, IV-176b, IV-176c, IV-176d




 







IV-177



 



IV-177a, IV-177b, IV-177c, IV-177d




 







IV-178



 



IV-178a, IV-178b, IV-178c, IV-178d




 







IV-179



 



IV-179a, IV-179b, IV-179c, IV-179d




 







IV-180



 



IV-180a, IV-180b, IV-180c, IV-180d




 







IV-181



 



IV-181a, IV-181b, IV-181c, IV-181d




 







IV-182



 



IV-182a, IV-182b, IV-182c, IV-182d




 







IV-183



 



IV-183a, IV-183b, IV-183c, IV-183d




 







IV-184



 



IV-184a, IV-184b, IV-184c, IV-184d




 







IV-185



 



IV-185a, IV-185b, IV-185c, IV-185d




 







IV-186



 



IV-186a, IV-186b, IV-186c, IV-186d




 







IV-187



 



IV-187a, IV-187b, IV-187c, IV-187d




 







IV-188



 



IV-188a, IV-188b, IV-188c, IV-188d




 







IV-189



 



IV-189a, IV-189b, IV-189c, IV-189d




 







IV-190



 



IV-190a, IV-190b, IV-190c, IV-190d




 







IV-191



 



IV-191a, IV-191b, IV-191c, IV-191d




 







IV-192



 



IV-192a, IV-192b, IV-192c, IV-192d




 







IV-193



 



IV-193a, IV-193b, IV-193c, IV-193d




 







IV-194



 



IV-194a, IV-194b, IV-194c, IV-194d




 







IV-195



 



IV-195a, IV-195b, IV-195c, IV-195d




 







IV-196



 



IV-196a, IV-196b, IV-196c, IV-196d




 







IV-197



 



IV-197a, IV-197b, IV-197c, IV-197d




 







IV-198



 



IV-198a, IV-198b, IV-198c, IV-198d




 







IV-199



 



IV-199a, IV-199b, IV-199c, IV-199d




 







IV-200



 



IV200a, IV-200b, IV-200c, IV-200d




 







IV-201



 



IV-201a, IV-201b, IV-201c, IV-201d




 







IV-202



 



IV-202a, IV-202b, IV-202c, IV-202d




 







IV-203



 



IV-203a, IV-203b, IV-203c, IV-203d




 







IV-204



 



IV-204a, IV-204b, IV-204c, IV-204d




 







IV-205



 



IV-205a, IV-205b, IV-205c, IV-205d




 







IV-206



 



IV-206a, IV-206b, IV-206c, IV-206d




 







IV-207



 



IV-207a, IV-207b, IV-207c, IV-207d




 







IV-208



 



IV-208a, IV-208b, IV-208c, IV-208d




 







IV-209



 



IV-209a, IV-209b, IV-209c, IV-209d




 







IV-210



 



IV-210a, IV-210b, IV-210c, IV-210d




 







IV-211



 



IV-211a, IV-211b, IV-211c, IV-211d




 







IV-212



 



IV-212a, IV-212b, IV-212c, IV-212d




 







IV-213



 



IV-213a, IV-213b, IV-213c, IV-213d




 







IV-214



 



IV-214a, IV-214b, IV-214c, IV-214d




 







IV-215



 



IV-215a, IV-215b, IV-215c, IV-215d




 







IV-216



 



IV-216a, IV-216b, IV-216c, IV-216d




 







IV-217



 



IV-217a, IV-217b, IV-217c, IV-217d




 







IV-218



 



IV-218a, IV-218b, IV-218c, IV-218d




 







IV-219



 



IV-219a, IV-219b, IV-219c, IV-219d




 







IV-220



 



IV-220a, IV-220b, IV-220c, IV-220d




 







IV-221



 



IV-221a, IV-221b, IV-221c, IV-221d




 







IV-222



 



IV-222a, IV-222b, IV-222c, IV-222d




 







IV-223



 



IV-223a, IV-223b, IV-223c, IV-223d




 







IV-224



 



IV-224a, IV-224b, IV-224c, IV-224d




 







IV-225



 



IV-225a, IV-225b, IV-225c, IV-225d




 







IV-226



 



IV-226a, IV-226b, IV-226c, IV-226d




 







IV-227



 



IV-227a, IV-227b, IV-227c, IV-227d




 







IV-228



 



IV-228a, IV-228b, IV-228c, IV-228d




 







IV-229



 



IV-229a, IV-229b, IV-229c, IV-229d




 







IV-230



 



IV-230a, IV-230b, IV-230c, IV-230d




 







IV-231



 



IV-231a, IV-231b, IV-231c, IV-231d




 







IV-232



 



IV-232a, IV-232b, IV-232c, IV-232d




 







IV-233



 



IV-233a, IV-233b, IV-233c, IV-233d




 







IV-234



 



IV-234a, IV-234b, IV-234c, IV-234d




 







IV-235



 



IV-235a, IV-235b, IV-235c, IV-235d




 







IV-236



 



IV-236a, IV-236b, IV-236c, IV-236d




 







IV-237



 



IV-237a, IV-237b, IV-237c, IV-237d




 







IV-238



 



IV-238a, IV-238b, IV-238c, IV-238d




 







IV-239



 



IV-239a, IV-239b, IV-239c, IV-239d




 







IV-240



 



IV-240a, IV-240b, IV-240c, IV-240d




 







IV-241



 



IV-241a, IV-241b, IV-241c, IV-241d




 







IV-242



 



IV-242a, IV-242b, IV-242c, IV-242d




 







IV-243



 



IV-243a, IV-243b, IV-243c, IV-243d




 







IV-244



 



IV-244a, IV-244b, IV-244c, IV-244d

















TABLE 5





Representative Compounds of the Invention




















V-1


 


V-1a, V-1b



 






V-2


 


V-2a, V-2b



 






V-3


 


V-3a, V-3b



 






V-4


 


V-4a, V-4b, V-4c, V-4d



 






V-5


 


V-5a, V-5b, V-5c, V-5d



 






V-6


 


V-6a, V-6b



 






V-7


 


V-7a, V-7b



 






V-8


 


V-8a, V-8b



 






V-9


 


V-9a, V-9b



 






V-10


 


V-10a, V-10b



 






V-11


 


V-11a, V-11b



 






V-12


 


V-12a, V-12b, V-12c, V-12d



 






V-13


 


V-13a, V-13b, V-13c, V-13d



 






V-14


 


V-14a, V-14b



 






V-15


 


V-15a, V-15b, V-15c, V-15d



 






V-16


 


V-16a, V-16b



 






V-17


 


V-17a, V-17b



 






V-18


 


V-18a, V-18b, V-18c, V-18d



 






V-19


 


V-19a, V-19b



 






V-20


 


V-20a, V-20b



 






V-21


 


V-21a, V-21b



 






V-22


 


V-22a, V-22b



 






V-23


 


V-23a, V-23b, V-23c, V-23d









General Synthetic Methods

The compounds of the invention may be prepared by a number of processes as generally described below and more specifically in the Examples hereinafter. In the following process descriptions, the symbols when used in the formulae depicted are to be understood to represent those groups described above in relation to the formulae herein.
Where it is desired to obtain a particular enantiomer of a compound, this may be accomplished from a corresponding mixture of enantiomers using any suitable conventional procedure for separating or resolving enantiomers. Thus, for example, diastereomeric derivatives may be produced by reaction of a mixture of enantiomers, e.g., a racemate, and an appropriate chiral compound. The diastereomers may then be separated by any convenient means, for example by crystallization and the desired enantiomer recovered. In another resolution process, a racemate may be separated using chiral High Performance Liquid Chromatography. Alternatively, if desired a particular enantiomer may be obtained by using an appropriate chiral intermediate in one of the processes described.
Chromatography, recrystallization and other conventional separation procedures may also be used with intermediates or final products where it is desired to obtain a particular isomer of a compound or to otherwise purify a product of a reaction.
General Protocol for Chiral Preparative HPLC Separation of Racemic Compounds
For chiral separations, samples were dissolved in MeOH and EtOH according to the solubility of sample and filtered through 0.22μ. PTFE filters. The columns used were CHIRALPAK-AD; 20*250 mm, 10μ and CHIRALCEL-ODH; 20*250 mm, 5μ. A flow rate of 12 mL/min-17 mL/min was used according to the resolution. Alkanes such as n-Pentane, Hexane and Heptane (40%-95%) and alcohols such as EtOH, Isopropyl alcohol and t-Butanol (5%-60%) were used as mobile phase. In some cases alcohol combinations i.e. (EtOH+MeOH), (EtOH+IPA), (IPA+MeOH), (t-Butanol+MeOH), (t-Butanol+EtOH) were used instead of a single alcohol. Diethyl amine (up to 0.3%) was used as modifier in the mobile phase.
Example H1: General Method for the Chiral HPLC Separation and Characterization of Compounds that were Synthesized Initially as a Mixture of Enantiomers
Crude or in some cases partially purified (normal or reverse phase HPLC) mixtures of enantiomers were analyzed by analytical chiral HPLC methods. Once adequate separation was achieved, larger quantities of the mixtures were separated using preparative scale columns as shown below for Compound Nos. 138a and 138b. Separation was followed by removal of solvents on a rotary evaporator to accomplish the isolation of the individual single enantiomers. In some cases where appropriate, after removal of solvent, the samples were lyophilized. After isolation, each individual enantiomer was further analyzed by analytical (reverse phase and chiral) HPLC, LCMS and NMR. When final products were converted to salts, final characterization of the compounds was carried out after conversion to the salt for each enantiomer.
Analytical Chiral HPLC of Compound Nos. 138a and 138b.
Column: Chiralcel OD-H; Column ID: 4.6*250 mm, 5μ. Mobile Phase:Hexane: (EtOH:MeOH 80:20)−93:7. Flow rate: 1 mL/min. Retention Time: Compound No. 138a-9.939 min. Compound No. 138b-13.660 min.
Chiral Preparative Data of Compound Nos. 138a and 138b.
Column: Chiralcel OD-H. Column ID: 20*250 mm, 5μ. Mobile Phase:Hexane: (EtOH:MeOH 80:20)−95:5. Flow rate: 15 mL/min. Solubility: 30 mg/mL in MeOH.
Example H2: General Method for the Chiral HPLC Separation and Characterization of Compounds that were Synthesized Initially as a Mixture of Diastereomers:
Crude or in some cases partially purified (normal or reverse phase HPLC) mixtures of diastereomers were analyzed by analytical chiral HPLC methods. Once adequate separation was achieved, larger quantities of the mixtures were separated using preparative scale columns as shown below for Compound Nos. II-149a-d. Separation was followed by removal of solvents on a rotary evaporator to accomplish the isolation of the individual single diastereomers. In some cases where appropriate, after removal of solvent, the samples were lyophilized. Once each individual diastereomer was isolated they were further analyzed by analytical (reverse phase and chiral) HPLC, LCMS and NMR. When final products were converted to salts, final characterization of the compounds was carried out after conversion to the salt for each diastereomer.
Analytical Chiral HPLC Data of Compound Nos. II-149a-d.
Column: Chiral Pak AD-H. Column ID: 4.6*250 mm, 5μ. Mobile Phase:Hexane (0.2% diethylamine):Isopropanol−93:7. Flow rate: 1 mL/min. Retention Time: Compound No. II-149a-15.470 min. Compound No. II-149b-19.808 min. Compound No. II-149c-33.280 min. Compound No. II-149d-39.585 min.
Chiral Preparative Data of Compound Nos. II-149a-d.
Column: Chiral PAK-AD-H. Column ID: 20*250 mm, 5μ. Mobile Phase:Hexane (0.2% diethylamine):Isopropanol−93:7. Flow rate: 15 mL/min. Solubility: 40 mg/mL in MeOH.
The following abbreviations are used herein: thin layer chromatography (TLC); hour (h); minute (min); second (sec); ethanol (EtOH); dimethylsulfoxide (DMSO); N,N-dimethylformamide (DMF); trifluoroacetic acid (TFA); tetrahydrofuran (THF); Normal (N); aqueous (aq.); methanol (MeOH); dichloromethane (DCM); ethyl acetate (EtOAc); Retention factor (Rf); room temperature (RT).
Compounds detailed herein may be prepared by those of skill in the art by referral to General Methods and Examples described in published PCT applications WO2009/055828 (see e.g., General Methods 1-24 and Examples 1-325), WO2010/127177 (General Methods 1-3 and Examples 1-58), WO2009/120720 (General Methods 1-15C and Examples 1-134), WO2009/120717 (General Methods 1-17 and Examples 1-134), WO2010/051501 (General Methods 1-10 and Examples 1-450) and WO2010/051503 (General Methods 1-15 and Examples 1-111), WO2011/019417 (General Methods 1-9 and Examples 1-10), WO2011/038164 (General Methods 1-19), WO2011/038162 (General Methods 1-21 and Examples 1-6), WO2011/038163 (General Methods 1-19 and Examples 1-49) and WO2011/038161 (General Methods 1-15B and Examples 1-22). The PCT publications described above are incorporated herein by reference in their entireties. Particular examples of each of the General Methods and Examples are provided in the Examples below.
General Method 1




In certain examples of formula (I) provided herein, and as similarly described in the publications presented above, alcohols of the type C can be prepared by treating appropriately functionalized carboline A with functionalized epoxide B, in the presence of a base. A selection of bases effective for this reaction will be apparent to those skilled in the art, such as for example, sodium hydride, sodium tert-butoxide, potassium tert-butoxide, lithium tert-butoxide, lithium diisopropylamide, lithium hexamethyldisilazide, sodium ethoxide, sodium methoxide, and the like. In some instances, one or more of the bases may be used interchangeably; for example, other bases such as sodium tert-butoxide, potassium tert-butoxide, lithium tert-butoxide, lithium diisopropylamide, lithium hexamethyldisilazide, sodium ethoxide or sodium methoxide may be substituted where sodium hydride is specifically described. It is understood that modifications to the specific materials shown are intended, e.g., where Compound B can be a heteroaryl group such as pyridyl, and Compound A can comprise structures such as pyrido[3,4-b]indoles, azepino[4,5-b]indoles, and indolizino[7,8-b]indoles, and the like.
The following Examples are provided to illustrate but not to limit the invention.
All references disclosed herein are incorporated herein by reference in their entireties.
EXAMPLES
Example 1
Preparation of Compound Nos. 1, 1a and 1b
Sodium hydride (1-3 equiv.) was added to a solution of 8-chloro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (1.0 equiv.) in DMF and heated to 120° C. for 1 h with stirring. The reaction mixture was cooled to 0° C. and 4-(2-methyloxiran-2-yl)pyridine (2-7.5 equiv.) was added dropwise over 5 min. The temperature was raised to 120° C. and stirred for 2 h. The reaction mixture was cooled to RT and partitioned between EtOAc and water. The organic layer was separated and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with water and followed by brine, dried over anhydrous sodium sulfate and concentrated under vacuum to provide the crude product. The product was purified by flash column chromatography over silica gel (230-400 mesh, deactivated with 1% triethylamine/hexane) using a gradient of 5 to 15% MeOH/EtOAc to yield the free base. The pure compound was converted to its oxalate salt. The analytical sample was prepared by dissolving free base in THF and treatment with 1 equiv. of oxalic acid dihydrate. 1H NMR (CDCl3, oxalate salt) δ (ppm): 8.42 (d, 2H), 7.35-7.20 (m, 3H), 7.00-6.90 (m, 2H), 4.10 (q, 2H), 3.50 (q, 2H), 2.95-2.68 (m, 4H), 2.42(s, 3H), 1.55 (s, 3H). Separation by chiral HPLC provides enantiomers 1a and 1b.
Example 2
Preparation of Compound Nos. 2, 2a and 2b
Sodium hydride (1-3 equiv.) was added to a solution of 2,3,4,5-tetrahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole (1.0 equiv.) in DMF, and heated to 120° C. for 1 h with stirring. The reaction mixture was cooled to 0° C. and 4-(2-methyloxiran-2-yl)pyridine (2-7.5 equiv.) was added dropwise over 5 min. The temperature was raised to 120° C. and stirred for 2 h. The reaction mixture was cooled to RT and partitioned between EtOAc and water. The organic layer was separated and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with water and followed by brine, dried over anhydrous sodium sulfate and concentrated under vacuum to provide the crude product. The product was purified by flash column chromatography over silica gel (230-400 mesh, deactivated with 1% triethylamine/hexane) using a gradient of 5 to 15% MeOH/EtOAc to yield the free base. The pure compound was converted to its oxalate salt. The analytical sample was prepared by dissolving free base in THF and treatment with 1 equiv. of oxalic acid dihydrate. 1H NMR (CD3OD, oxalate salt) δ (ppm): 8.38 (d, 2H), 7.50 (d, 2H), 7.15 (s, 1H), 7.06 (d, 1H), 6.86 (d, 1H), 4.45 (m, 2H), 4.31 (m, 1H), 4.22 (m, 1H), 3.61 (m, 2H), 3.19 (m, 1H), 3.06 (s, 3H), 2.78 (m, 2H), 2.35 (s, 3H), 1.60 (s, 3H). Separation by chiral HPLC provides enantiomers 2a and 2b.
Example 3
Preparation of Compound Nos. 3, 3a and 3b
Sodium hydride (2.4 g, 100 mmol) was washed with hexane and dried under vacuum. To this was added DMF (15 mL) and cooled to 0° C. Then to this was added 2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (4 g, 20 mmol) and the mixture stirred at 0° C. for 30 min. Then 4-oxiranyl-pyridine (2.90 g, 23.96 mmol) was dissolved in 5 mL DMF and added dropwise to the mixture, which was then left stirred at RT overnight. The reaction was monitored by TLC. The reaction mixture was poured into ice water and extracted with EtOAc (3×). The combined organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated. The resultant solid material was washed with hexane and crystallized from EtOH and ether. 1H NMR (DMSO-d6, HCl salt) δ (ppm): 8.70 (d, 2H), 7.70 (d, 2H), 7.38 (m, 1H), 7.20 (s, 1H), 6.90 (d, 1H), 5.05 (m, 1H), 4.58 (m, 1H), 4.30 (m, 1H), 4.20 (m, 2H), 3.70 (m, 2H), 3.20 (m, 4H), 2.90 (s, 1H), 2.38 (s, 3H). Separation by chiral HPLC provided enantiomers 3a and 3b. Optical rotations: Compound 3a; (−)31.32 (c 1, Chloroform, 94.1% HPLC purity); Compound 3b, (+)28.24 (c 1, Chloroform, 98.05% HPLC purity).
Example 4
Preparation of Compound Nos. 4, 4a, and 4b
Sodium hydride (2.72 g, 113.33 mmol) was washed with hexane and dried under vacuum. To this was added DMF (15 mL) and the mixture cooled to 0° C. 8-Chloro-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (5 g, 22.72 mmol) was added and the mixture stirred at 0° C. for 30 min, followed by 4-oxiranyl-pyridine (3.3 g, 27.27 mmol) dissolved in 5 mL DMF added dropwise. The reaction mixture was stirred at RT overnight. The reaction was monitored by TLC. The reaction mixture was poured into ice water and the product extracted into EtOAc (3×). The combined organic layers were washed with water, dried over anhydrous sodium sulfate and concentrated. The resultant solid material was washed with hexane and crystallized from EtOH and ether. 1H NMR (CD3OD, HCl salt) δ (ppm): 8.80 (d, 2H), 8.18 (d, 2H), 7.50 (s, 1H), 7.30 (m, 1H), 7.10 (d, 1H), 5.30 (m, 1H), 4.70 (m, 1H), 4.50 (m, 1H), 4.40 (m, 2H), 3.90 (m, 1H), 3.60 (m, 2H), 3.40 (m, 2H), 3.10 (s, 3H). Separation by chiral HPLC provided enantiomers 4a and 4b. Optical rotations: Compound 4a, (+)47.31 (c 0.58, Chloroform, 96.26% HPLC purity); Compound 4b, (−) 43.75 (c 0.55, Chloroform, 98.59% HPLC purity).
Example 5
Preparation of Compound Nos. 5, 5a and 5b
To a solution of 2,3,4,5-tetrahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole (290 mg, 1.4 mmol) in DMF (6 mL) was added sodium hydride (38 mg, 1.6 mmol) and the solution was stirred at 120° C. for 1 h. The reaction mixture was cooled to 0° C. and 3-(2-methyloxiran-2-yl)pyridine (400 mg, 2.96 mmol) was added dropwise over a period of 5 min. The reaction mixture was stirred at 120° C. for 2 h, quenched with ice-water (15 mL) and extracted with EtOAc (60 mL). The organic layer was washed with water, brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by flash column chromatography (5-15% MeOH/EtOAc) to yield 1-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-2-(pyridin-3-yl)propan-2-ol. Separation by chiral HPLC provided enantiomers 5a and 5b. 1H NMR (CDCl3, freebase) δ (ppm): 8.79 (s, 1H), 8.42 (d, 1H), 7.56 (d, 1H), 7.04 (s, 1H), 6.9 (m, 2H), 6.8 (d, 1H), 4.17 (dd, 2H), 3.42 (s, 2H), 2.8 (t, 2H), 2.62 (t, 2H), 2.42 (s, 3H), 2.39 (s, 3H), 1.61 (s, 3H). Optical rotations: Compound 5a, (−)39.27 (c 0.43, Chloroform, 99.69% HPLC purity); Compound 5b, (+)58.97 (c 0.58, Chloroform, 99.49% HPLC purity).
Example 6
Preparation of Compound Nos. 6, 6a and 6b
To a solution of 2-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.0 g, 3.937 mmol) in DMF (10 mL) was added sodium hydride (472 mg, 11.81 mmol) in portions at RT. After stirring at RT for 15 min, the suspension was allowed to cool to 0° C. and 4-(oxiran-2-yl)pyridine (762 mg, 6.299 mmol) was added dropwise into the reaction mixture, which was stirred at RT overnight. The reaction mixture was poured into ice-cooled water and extracted with EtOAc (3×50 mL). The organic layer was washed with water (2×50 mL), dried over anhydrous sodium sulfate and concentrated. The solid obtained was re-crystallized in DCM-diethyl ether to yield 2-(2-methyl-8-(trifluoromethyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(pyridin-4-yl)ethanol. 1H NMR (CDCl3, freebase) δ (ppm): 8.59 (d, 2H), 7.4 (s, 1H), 7.39 (d, 1H), 7.3 (d, 1H), 7.19 (d, 2H), 4.68 (m, 1H), 4.1 (m, 2H), 3.4 (dd, 2H), 2.82 (m, 1H), 2.74 (bs, 2H), 2.6 (m, 1H), 2.4 (s, 3H). Separation by chiral HPLC provides enantiomers 6a and 6b.
Example 7
Preparation of Compound Nos. 7, 7a and 7b
Chloro carboline (500 mg, 2.27 mmol) was taken in DMF. NaH (180 mg, 4.5 mmol) was added at RT and stirred for 10-15 min. Neat epoxide (450 mg, 3.7 mmol) was added dropwise at RT. The reaction was stirred at RT for 4 h and the reaction was monitored by LCMS. After completion, the reaction mixture was poured on ice water and extracted with EtOAc, dried and concentrated. The residue was purified by HPLC. 465 mg of product as a white solid (TFA salt). TLC: 5% MeOH-DCM, Rf 0.1 was observed. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.80 (s, 2H), 8.40 (s, 1H), 7.9 (t, 1H), 7.40 (s, 1H), 7.20 (d, 1H), 7.0 (d, 1H), 5.25 (bs, 1H), 4.7 (d, 1H), 4.4 (m, 2H), 4.3 (d, 1H), 3.9 (bs, 1H), 3.5 (bs, 1H), 3.3 (m, 2H), 3.10 (s, 3H). Separation by chiral HPLC provided enantiomers 7a and 7b. Optical rotations: Compound 7a, (−)21.05 (c 0.52, Chloroform, 89.7% HPLC purity); Compound 7b, (+)6.85 (c 0.69, Chloroform, 95.74% HPLC purity).
Example 8
Preparation of Compound Nos. 8, 8a and 8b
To a solution of 2,6-dimethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (1.0 g, 5.00 mmol) in DMF (20 mL) was added sodium hydride (600 mg, 15 mmol), the suspension stirred at RT for 10 min. A solution of 4-(oxiran-2-yl)pyridine (1.21 g, 10 mmol) in DMF (5 mL) was added slowly into the reaction mixture which was stirred at RT overnight. The progress of reaction was monitored by TLC and LCMS. The reaction mass was poured into ice cold water (200 mL) slowly and extracted with EtOAc (3×200 mL). The organic layer was washed with water (4×300 mL), dried over anhydrous sodium sulfate and concentrated. The residue obtained was washed with hexane (2×15 mL) and triturated with diethyl ether (50 mL) to yield the desired product. 1H NMR (CDCl3, freebase) δ (ppm): 8.62 (d, 2H), 7.31 (d, 2H), 7.28 (s, 1H), 7.21 (d, 1H), 7.02 (d, 1H), 5.05 (m, 1H), 4.14 (dd, 1H), 4.078 (dd, 1H), 3.74 (d, 1H), 3.37 (d, 1H), 2.83 (m, 3H), 2.72 (m, 1H), 2.51 (s, 3H), 2.46 (s, 3H). Separation by chiral HPLC provided enantiomers 8a and 8b.
Example 9
Preparation of Compound Nos. 9, 9a and 9b
2-(2-Allyl-8-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-3-yl-ethanol (1.0 g, 2.8 mmol) was dissolved in DCM and the solution was purged with nitrogen for 5 min. 1,3-Dimethylbarbituric acid (1.34 g, 8.6 mmol) and Pd(PPh3)4 (66.5 mg, 0.056 mmol) were added and the reaction mixture was stirred at RT for 3 h. The reaction mixture was concentrated under reduced pressure, and the residue was basified with saturated aqueous potassium carbonate, and extracted with EtOAc (3×50 mL). The combined organic layer was washed with saturated aqueous potassium carbonate (6×20 mL), dried over anhydrous sodium sulfate and concentrated. The crude product was purified by reverse phase chromatography to obtain 50 mg of 2-(8-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-3-yl-ethanol. 1H NMR (CDCl3, freebase) δ (ppm): 8.47 (s, 1H), 8.41 (d, 1H), 7.59 (d, 1H), 7.19 (m, 3H), 7.10 (s, 1H), 7.00 (d, 1H), 5.0 (t, 1H), 4.10 q (d, 2H), 3.92 q (d, 2H), 3.10 (m, 2H), 2.90 (m, 2H), 2.47 (m, 1H), 2.42 (s, 3H). This racemate was separated by chiral semi-preparative HPLC to obtain enantiomers 9a and 9b.
Example 10
Preparation of Compound Nos. 10, 10a and 10b
2-(2-Allyl-8-chloro-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethanol (4.0 g, 10.87 mmol) was dissolved in DCM (350 mL) and nitrogen was purged for 10 min into the reaction mixture. 1,3-Dimethyl barbituric acid (5.08 g, 32.62 mmol) and Pd(PPh3)4 (251 mg, 0.217 mmol) was added and stirred for 2 h at RT. After consumption of starting material, the reaction mixture was diluted with saturated potassium carbonate (200 mL) and extracted with DCM (2×100 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated, and the crude mixture crystallized in MeOH (5 mL) and ether (50 mL) to obtain 2.2 g of 2-(8-chloro-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethanol. 1H NMR (CDCl3, freebase) δ (ppm): 8.58 (d, 2H), 7.37 (s, 1H), 7.25 (d, 2H), 7.23 (d, 1H), 7.13 (d, 1H), 5.0 (t, 1H), 4.15 (d, 2H), 3.99 (s, 2H), 3.19 (m, 2H), 2.81 (m, 1H), 2.53 (m, 1H). Separation by chiral HPLC provided enantiomers 10a and 10b. Optical rotations: Compound 10a, (−)34.60 (c 0.55, Chloroform, 99.16% HPLC purity); Compound 10b, (+)31.78 (c 0.53, Chloroform, 92.71% HPLC purity).
Example 11
Preparation of Compound Nos. 11, 11a and 11b
3-[8-Chloro-5-(2-hydroxy-2-pyridin-4-yl-ethyl)-1,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl]-propionic acid methyl ester (200 mg, 0.484 mmol) was dissolved in dry THF (5 mL), and cooled to −78° C. Methyl magnesium chloride (0.2 mL, 1.93 mmol) was added dropwise and stirred for 15 min and allowed to RT and stirred for 2 h. After consumption of starting material, 2 mL MeOH was added into the reaction, which was then concentrated, and the residue diluted with water (20 mL) and extracted with EtOAc (3×30 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated, and the crude product purified by reverse phase chromatography to obtain 50 mg of 4-[8-chloro-5-(2-hydroxy-2-pyridin-4-yl-ethyl)-1,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl]-2-methyl-butan-2-ol. 1H NMR (CDCl3, freebase) δ (ppm): 8.48 (d, 2H), 7.35 (s, 1H), 7.18 (d, 2H), 7.16 (d, 1H), 7.10 (d, 1H), 4.90 (t, 1H), 4.05 (m, 2H), 3.68 (m, 2H), 2.87 (m, 3H), 2.79 (m, 2H), 2.49 (m, 1H), 1.72 (t, 2H), 1.24 (s, 6H). Separation by chiral HPLC provided enantiomers 11a and 11b. Optical rotations: Compound 11a, (−)25.66 (c 0.56, Chloroform, 96.42% HPLC purity); Compound 11b, (+)24.07 (c 0.56, Chloroform, 98.39% HPLC purity).
Example 12
Preparation of Compound Nos. 12, 12a and 12b
1-(6-Allyl-3-chloro-5,6,7,8-tetrahydro-1,6,9-triaza-fluoren-9-yl)-2-pyridin-4-yl-propan-2-ol (260 mg, 0.680 mmol) was dissolved in DCM (7 mL) and N2 was purged into the reaction mixture. 1,3-Dimethyl barbituric acid (318 mg, 2.04 mmol) and Pd(PPh3)4 (15 mg, 0.013 mmol) was added and the mixture stirred for 45 min at RT. After consumption of starting material, the reaction mixture was diluted with saturated potassium carbonate and extracted with DCM (3×50 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated, and the crude product was purified by reverse phase chromatography to obtain 100 mg of 1-(3-chloro-5,6,7,8-tetrahydro-1,6,9-triaza-fluoren-9-yl)-2-pyridin-4-yl-propan-2-ol. 1H NMR (CDCl3, freebase) δ (ppm): 8.51 (d, 2H), 8.14 (s, 1H), 7.67 (s, 1H), 7.33 (d, 2H), 4.39 (d, 1H), 4.36 (d, 1H), 3.93 q (d, 2H), 3.16 (m, 2H), 2.62 (m, 1H), 2.40 (m, 1H), 1.57 (s, 3H). Separation by chiral HPLC provided enantiomers 12a and 12b. Optical rotations: Compound 12a, (+)121.78 (c 0.53, Chloroform, 97.32% HPLC purity); Compound 12b, (−)118.34 (c 0.54, Chloroform, 99.01% HPLC purity).
Example 13
Preparation of Compound Nos. 13, 13a and 13b
3,9-Dimethyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole (300 mg, 1.40 mmol) was taken into DMF (6 mL). To a solution of sodium hydride (50%) (100 mg, 4.22 mmol) was added in portions at RT and stirred at RT for 10 min. A solution of 4-(oxiran-2-yl)pyridine (254 mg, 2.11 mmol) in DMF (1 mL) was added dropwise for 10 min. and stirred for 14 h at RT. The reaction was monitored by TLC and LCMS. The reaction mixture was quenched with ice water, extracted in ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure. The crude product was purified by reverse phase chromatography to get pure product 2-(3,9-dimethyl-2,3,4,5-tetrahydroazepino[4,5-b]indol-6(1H)-yl)-1-(pyridin-4-yl)ethanol as the TFA salt (250 mg). Separation by chiral HPLC provided enantiomers 13a and 13b. Optical rotations: Compound 13a, (−)5.03 (c 0.56, Chloroform, 99.17% HPLC purity); Compound 13b, (+)5.70 (c 0.56, Chloroform, 99.35% HPLC purity).
Example 14
Preparation of Compound Nos. 14, 14a and 14b
2,6-Dimethyl-2,3,4,9-tetrahydro-1H-β-carboline (1 g, 5 mmol) was dissolved in 15 mL DMF and stirred for 10 min at 0° C. Sodium hydride (600 mg, 15 mmol) was added portionwise at RT and stirred for 10 min. 3-(2-Methyl-oxiranyl)-pyridine (1.01 g, 7.5 mmol) was added dropwise at the same temperature and the mixture stirred for 12 h at RT. The reaction was monitored by TLC & LCMS. After consumption of starting material, the reaction mixture was quenched with ice water and extracted with EtOAc (3×100 mL). The combined organic layer was washed with water (4×100 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated and the residue was crystallized in EtOH and ether to obtain 375 mg of 1-(2,6-dimethyl-1,2,3,4-tetrahydro-β-carbolin-9-yl)-2-pyridin-3-yl-propan-2-ol. 1H NMR (CDCl3, freebase) δ (ppm): 8.76 (d, 1H), 8.55 (dd, 1H), 7.703 (d, 1H), 7.24 (s, 1H), 7.23 (dd, 1H), 7.15 (d, 1H), 6.95 (d, 1H), 4.13 (d, 1H), 4.08 (d, 1H), 3.38 (dd, 2H), 2.79 (q, 2H), 2.74 (q, 2H), 2.46 (s, 3H), 2.43 (s, 3H), 1.64 (s, 3H). Separation by chiral HPLC provided enantiomers 14a and 14b. Optical rotations: Compound 14a, (+)31.28 (c 0.58, Chloroform, 96.04% HPLC purity); Compound 14b, (−)27.23 (c 0.57, Chloroform, 96.09% HPLC purity).
Example 15
Preparation of Compound Nos. 15, 15a and 15b
9-Chloro-3-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole (300 mg, 1.27 mmol) was taken into DMF (6 mL). Sodium hydride (50%) (92 mg, 3.83 mmol) was added in portions at RT and the mixture was stirred at RT for 10 min. A solution of 4-(oxiran-2-yl)pyridine (232 mg, 1.9 mmol) in DMF (1 mL) was added dropwise for 10 min. and stirred for 14 h at RT. The reaction was monitored by TLC and LCMS. The reaction mixture was quenched with ice water, extracted in ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure. The crude product was purified by reverse phase chromatography to get pure product 2-(9-chloro-3-methyl-2,3,4,5-tetrahydroazepino[4,5-b]indol-6(1H)-yl)-1-(pyridin-4-yl)ethanol as the TFA salt (230 mg). 1HNMR (DMSO-d6, TFA salt) δ (ppm): 8.65 (m, 2H), 7.80-7.45 (m, 3H), 7.40 (m, 1H), 7.0 (m, 1H), 6.0 (m, 1H), 4.95 (m, 1H), 4.40 (m, 2H), 3.40 (m, 3H), 3.20 (m, 4H), 2.92 (s, 3H). Separation by chiral HPLC provided enantiomers 15a and 15b.
Example 16
Preparation of Compound Nos. 16, 16a and 16b
2,6-Dimethyl-2,3,4,9-tetrahydro-1H-β-carboline (500 mg, 2.5 mmol) was dissolved in 20 mL DMF and stirred for 10 min at RT. Sodium hydride (180 mg, 7.5 mmol) was added portionwise at RT and the mixture stirred for 10 min. 2-(2-Methyl-oxiranyl)-pyridine (472 mg, 3.5 mmol) was added dropwise at the same temperature and stirred for 12 h at RT. The reaction was monitored by TLC & LCMS. After consumption of starting material, the reaction mixture was quenched with ice water and extracted with EtOAc (3×100 mL). The combined organic layer was washed with water (3×100 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated and the residue was crystallized in hexane to obtain 115 mg of 1-(2,6-dimethyl-1,2,3,4-tetrahydro-β-carbolin-9-yl)-2-pyridin-2-yl-propan-2-ol. 1HNMR (CDCl3, freebase) δ (ppm): 8.51 (d,1H), 7.65 (t,1H), 7.29 (d, 1H), 7.22 (d,1H), 7.20 (s,1H), 6.95 (d,1H), 6.85 (d, 1H), 4.9 (bs,1H), 4.18 (s, 2H), 3.21 (dd, 2H), 2.77 (m, 2H), 2.69 (m, 2H), 2.42 (d, 6H), 1.63 (s, 3H). Separation by chiral HPLC provided enantiomers 16a and 16b. Optical rotations: Compound 16a, (−)5.77(c 0.52, Chloroform, 98.11% HPLC purity); Compound 16b, (+)5.85 (c 0.51, Chloroform, 98.06% HPLC purity).
Example 17
Preparation of Compound Nos. 17, 17a and 17b
6,8,8-Trimethyl-6,7,8,9-tetrahydro-5H-1,6,9-triaza-fluorene (100 mg, 0.465 mmol) was dissolved in DMF (2 mL) and sodium hydride (56 mg, 1.39 mmol) was added portionwise under nitrogen. 4-Oxiranyl-pyridine (113 mg, 0.933 mmol) was added dropwise at RT and stirred for 12 h. After consumption of starting material (by monitoring TLC and LCMS), the reaction mixture was poured in to ice water and extracted with EtOAc (2×25 mL). The combined organic layer was washed with water (5×10 mL), the organic layer was dried over anhydrous sodium sulfate and concentrated, and the crude product purified by reverse phase chromatography to obtain 15 mg of 1-pyridin-4-yl-2-(6,8,8-trimethyl-5,6,7,8-tetrahydro-1,6,9-triaza-fluoren-9-yl)-ethanol. 1HNMR (CDCl3, freebase) δ (ppm): 8.63 (d, 2H), 8.22 (d, 1H), 7.75 (d, 1H), 7.45 (d, 2H), 7.09 (dd, 1H), 5.17 (d, 1H), 4.53 (dd, 1H), 4.47 (d, 1H), 3.71 (d, 1H), 3.44 (d, 1H), 2.5 (s, 3H), 2.49 (d, 1H), 2.44 (d, 1H), 1.47 (s, 3H), 1.32 (s, 3H). Separation by chiral HPLC provided enantiomers 17a and 17b. Optical rotations: Compound 17a, (+)50.54 (c 0.56, Chloroform, 99.31% HPLC purity); Compound 17b, (−)51.38 (c 0.55, Chloroform, 95.62% HPLC purity).
Example 18
Preparation of Compound Nos. 18, 18a and 18b
2,6-Dimethyl-2,3,4,9-tetrahydro-1H-β-carboline (500 mg, 2.5 mmol) was dissolved in 5 mL DMF and sodium hydride (250 mg, 6.24 mmol) was added portionwise at 0° C. and the mixture stirred for 10 min. 2-(4-Fluoro-phenyl)-oxirane (450 mg, 3.26 mmol) was added dropwise at same temperature and stirred for 12 h at RT. The reaction was monitored by TLC & LCMS. After consumption of starting material, the reaction mixture was quenched with ice cold water. The resultant solid was filtered and washed with water (100 mL) and hexane (100 mL), and the crude product was crystallized in EtOH:hexane (5:95 ratio) to obtain 300 mg of 2-(2,6-dimethyl-1,2,3,4-tetrahydro-β-carbolin-9-yl)-1-(4-fluoro-phenyl)-ethanol. 1H NMR (CDCl3, Free base) δ (ppm): 7.30 (m, 2H), 7.20 (d, 1H), 7.05 (m, 3H), 7.0 (d, 1H), 5.0 (t, 1H), 4.05 (d, 2H), 3.62 (d, 1H), 3.30 (d, 1H), 2.80 (m, 3H), 2.70 (m, 1H), 2.50 (s, 3H), 2.44 (s, 3H). Separation by chiral HPLC provided enantiomers 18a and 18b. Optical rotations: Compound 18a, (−)6.97 (c 0.56, Chloroform, 89.35% HPLC purity); Compound 18b, (+)13.03 (c 0.51, Chloroform, 99.51% HPLC purity).
Example 19
Preparation of Compound Nos. 19, 19a and 19b
2,6-Dimethyl-2,3,4,9-tetrahydro-1H-β-carboline (500 mg, 2.5 mmol) was dissolved in 10 mL DMF and stirred for 10 min at 0° C. Sodium hydride (300 mg, 7.5 mmol) was added portionwise at RT and stirred for 10 min. 4-(2-Methyl-oxiranyl)-pyridine (472 mg, 3.5 mmol) was added dropwise at the same temperature and stirred for 4 h at RT. The reaction was monitored by TLC & LCMS. After consumption of starting material, the reaction mixture was quenched with ice water and extracted with EtOAc (2×60 mL). The combined organic layer was washed with water (5×75 mL), dried over anhydrous sodium sulfate and concentrated and the residue was crystallized in EtOH and hexane to obtain 175 mg of 1-(2,6-dimethyl-1,2,3,4-tetrahydro-β-carbolin-9-yl)-2-pyridin-4-yl-propan-2-ol. 1H NMR (CDCl3, Free base) δ (ppm): 8.58 (d, 2H), 7.40 (d, 2H), 7.25 (s, 1H), 7.16 (d, 1H), 6.92 (d, 1H), 4.18-4.0 (dd, 2H), 3.50-3.38 (dd, 2H), 2.80 (m, 2H), 2.70 (m, 2H), 2.44 (s, 3H), 2.42 (s, 3H), 1.58 (s, 3H). Separation by chiral HPLC provided enantiomers 19a and 19b. Optical rotations: Compound 19a, (+)22.35 (c 0.58, Chloroform, 98.36% HPLC purity); Compound 19b, (−)22.43 (c 0.55, Chloroform, 99.09% HPLC purity).
Example 20
Preparation of Compound Nos. 20, 20a and 20b
2,6-Dimethyl-2,3,4,9-tetrahydro-1H-β-carboline (1.0 g, 5.0 mmol) was dissolved in 15 mL DMF and sodium hydride (600 mg, 15 mmol) was added portionwise at 0° C. and stirred for 10 min. 2-(4-Methoxy-phenyl)-oxirane (900 mg, 6.0 mmol) was added dropwise at the same temperature and stirred for 12 h at RT. The reaction was monitored by TLC & LCMS. After consumption of starting material, the reaction mixture was quenched with ice cold water and filtered through a Celite bed. A cake of compound was formed which was dissolved in MeOH and DCM. This was again filtered through a Celite bed and the filtrate concentrated. The solid thus obtained was crystallized in ether & hexane to get 600 mg of 2-(2,6-dimethyl-1,2,3,4-tetrahydro-β-carbolin-9-yl)-1-(4-methoxy-phenyl)-ethanol. 1H NMR (CDCl3, freebase) δ (ppm): 7.27 (m, 3H), 7.24 (d, 1H), 7.00 (d, 1H), 6.98 (d, 2H), 4.98 (t, 1H), 4.09 (d, 2H), 3.81 (s, 3H), 3.67 (d, 1H), 3.32 (d, 1H), 2.79 (m, 3H), 2.7 (m, 1H), 2.49 (s, 3H), 2.45 (s, 3H). Separation by chiral HPLC provided enantiomers 20a and 20b. Optical rotations: Compound 20a, (−)10.20 (c 0.58, Chloroform, 99.61% HPLC purity); Compound 20b, (+)10.00 (c 0.59, Chloroform, 96.54% HPLC purity).
Example 21
Preparation of Compound Nos. 21, 21a and 21b
2-(8-Methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(pyridin-3-yl)ethanol (1.6 g) was dissolved in acetone (40 mL) followed by the addition of potassium carbonate (2.16 g) and 2-bromoethanol (1.29 g). The reaction mixture was heated at 80° C. for 2 h. The reaction was monitored by TLC and LCMS. The reaction mixture was cooled to RT and evaporated under reduced pressure. The residue was diluted with water and extracted with DCM, dried over anhydrous sodium sulfate, and evaporated under reduced pressure to obtain crude product. The crude product was purified by reverse phase column chromatography to obtain desired product. 1H NMR (CDCl3, freebase) δ (ppm): 8.33 (d, 1H), 8.24 (s, 1H), 7.56 (d, 1H), 7.16 (m, 2H), 7.11 (s, 1H), 6.99 (d, 1H), 4.82 (dd, 1H), 4.03 (dd, 1H), 3.98 (dd, 1H), 3.75 (d, 1H), 3.70 (m, 2H), 3.64 (d, 1H), 2.90 (m, 3H), 2.74 (m, 2H), 2.5 (dd, 1H), 2.44 (s, 3H). Separation by chiral HPLC provided enantiomers 21a and 21b. Optical rotations: Compound 21a, (−)12.41 (c 0.56, Chloroform, 97.75% HPLC purity); Compound 21b, (+)12.71 (c 0.56, Chloroform, 97.37% HPLC purity).
Example 22
Preparation of Compound Nos. 22, 22a and 22b
Sodium hydride (54 mg, 2.2 mmol) was dissolved in N,N-dimethylformamide (7.5 mL) and stirred for 10 min. 2,6-Dimethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (150 mg, 0.75 mmol) was added to the solution and stirred for 10 min, followed by addition of 2-(oxiran-2-yl)pyridine (133 mg, 1.1 mmol) and stirred overnight at RT. The progress of the reaction was monitored by TLC and LCMS. The reaction mixture was quenched with ice water, extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure. The crude product was purified by reverse phase chromatography to get pure title compound as the TFA salt (27 mg). 1H NMR (DMSO) δ (ppm): 10.30-10.10 (m, 1H), 8.70-8.55 (m, 1H), 7.95-7.50 (m, 2H), 7.45-7.05 (m, 2H), 7.00-6.75 (m, 2H), 4.95-4.70 (m, 1H), 4.60-4.40 (m, 2H), 4.20-3.60 (m, 4H), 3.55-3.35 (m, 2H), 3.00 (s, 3H), 2.38 (s, 3H). Separation by chiral HPLC provided enantiomers 22a and 22b. Optical rotations: Compound 22a, (−)58.57 (c 0.57, Chloroform, 98.5% HPLC purity); Compound 22b, (+)31.73 (c 0.52, Chloroform, 96.24% HPLC purity).
Example 23
Preparation of Compound Nos. 23, 23a and 23b
To a stirred solution of 2-(2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indol-8-yl)propan-2-ol (942 mg, 3.86 mmol) in DMF (5 mL) was added sodium hydride (60%, 464 mg, 11.58 mmol). After stirring for 10 min, the reaction mixture was cooled to 0° C. and a solution of 4-(oxiran-2-yl)pyridine (700 mg, 5.8 mmol) in DMF (2 mL) was added. The reaction mixture was allowed to warm to RT and stirring was continued for 16 h. The progress of reaction was monitored by LCMS and NMR. The reaction mixture was quenched with ice water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue obtained was crystallized from ether to yield 2-(2,3,4,5-tetrahydro-5-(2-hydroxy-2-(pyridin-4-yl)ethyl)-2-methyl-1H-pyrido[4,3-b]indol-8-yl)propan-2-ol (500 mg) as yellow solid. 1H NMR (CDCl3, freebase) δ (ppm): 8.37 (d, 2H), 7.36 (s, 1H), 7.20 (d, 1H), 7.11 (d, 2H), 7.04 (d, 1H), 4.82 (t, 1H), 4.05 (d, 2H), 3.49 (d, 1H), 3.4 (d, 1H), 2.9 (m, 1H), 2.85 (m, 1H), 2.64 (m, 2H), 2.40 (s, 3H), 1.65 (s, 6H). Separation by chiral HPLC provided enantiomers 23a and 23b. Optical rotations: Compound 23a, (−)52.54 (c 0.55, Chloroform, 95.4% HPLC purity); Compound 23b, (+)29.08 (c 0.56, Chloroform, 98.94% HPLC purity).
Example 24
Preparation of Compound Nos. 24, 24a and 24b
To a solution of carboline (320 mg, 1.49 mmol) in DMF (4 mL) was added sodium hydride (169 mg, 4.23 mmol). After stirring for 5 min, a solution of 3-(2-methyloxiran-2-yl)pyridine (285 mg, 2.11 mmol) in DMF was added to the reaction mixture, which was stirred at RT for 16 h. The reaction mixture was quenched with ice-water and extracted with EtOAc. The organic layer was dried over anhydrous sodium sulfate, concentrated and residue obtained was submitted for reverse phase HPLC purification. 1H NMR (CDCl3, freebase) δ (ppm): 8.72 (s, 1H), 8.52 (d, 1H), 7.69 (d, 1H), 7.21 (m, 3H), 6.95 (d, 1H), 4.21 (q, 2H), 4.00 (s, 2H), 3.11 (t, 2H), 2.48 (m, 2H), 2.43 (s, 3H), 1.65 (s, 3H). Separation by chiral HPLC provided enantiomers 24a and 24b. Optical rotations: Compound 24a, (+)25.89 (c 0.58, Chloroform, 96.39% HPLC purity); Compound 24b, (−)26.65 (c 0.56, Chloroform, 93.46% HPLC purity).
Example 25
Preparation of Compound Nos. 25, 25a and 25b
To an ice-cooled stirred solution of the Boc protected ester (75 mg) in DCM (1 mL) was added cold 20% TFA-DCM solution (5 mL). After stirring for 30 min at 0° C., the reaction mixture was stirred at RT for 2 h. The solvent was removed under reduced pressure to yield title compound as the TFA salt. HPLC provided enantiomers 25a and 25b. Compound No. 25a: 1H NMR (CD3OD, Di-TFA salt) δ (ppm): 8.74 (t, 2H), 7.84 (t, 2H), 7.29 (s, 1H), 7.03 (t, 1H), 6.4 (m, 1H), 4.66 (m, 3H), 4.32 (d, 1H), 3.98 (m, 2H), 3.5 (m, 1H), 3.2 (m, 1H), 3.11 (s, 3H), 3.06 (m, 1H), 2.4 (s, 3H), 2.38 (m, 1H), 0.95 (d, 3H), 0.91 (d,3H). Compound No. 25b: 1H NMR (CD3OD, Di-TFA salt) δ (ppm): 8.806 (d, 2H), 8.05 (t, 2H), 7.63 (t, 1H), 7.03 (d, 1H), 6.35 (s, 1H), 4.66 (m, 3H), 4.32 (m, 1H), 4.12 (dd, 1H), 3.97 (m, 1H), 3.59 (m, 1H), 3.30 (m, 2H), 3.27 (s, 3H), 3.25 (m, 1H) 2.41 (s, 3H), 1.95 (m, 1H), 0.88 (d, 3H), 0.59 (d, 3H).
Example 26
Preparation of Compound Nos. 26, 26a, 26b, 26c and 26d
To a stirred solution of 6-aza-8-methyl tetracyclic carboline (320 mg, 1.4 mmol) in DMF (4 mL) was added sodium hydride (169 mg, 4.2 mmol). After stirring for 5 min, a solution of 3-(2-methyloxiran-2-yl)pyridine (285 mg, 2.14 mmol) in DMF (1 mL) was added and the reaction mixture stirred at RT for 16 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with ice-water and extracted with EtOAc. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield title compound (574 mg). 1H NMR (CDCl3, freebase) δ (ppm): 8.64 (s, 1H), 8.42 (d, 1H), 8.03 (s, 1H), 7.7 (d, 1H), 7.53 (s, 1H), 7.14 (dd, 1H), 4.45 (d, 1H), 4.26 (d, 2H), 4.14 (t, 1H), 3.25 (d, 1H), 3.01 (m, 1H), 2.84 (m, 1H), 2.63 (q, 1H), 2.46 (m, 2H), 2.42 (s, 3H), 2.34 (m, 1H), 1.85 (m, 2H), 1.68 (m, 1H), 1.64 (s, 3H). Separation by chiral HPLC provided enantiomers 26a, 26b 26c and 26d.
Example 27
Preparation of Compound Nos. 27, 27a and 27b
To a solution of 5-(2-azido-2-(pyridin-4-yl)ethyl)-2,3,4,5-tetrahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole (2.4 g, 6.93 mmol) in EtOH-water (25-2.5 mL) were added zinc dust (1.8 g, 27.7 mmol) and ammonium chloride (1.5 g, 27.74 mmol) and the reaction mixture stirred at 80° C. for 45 min. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was basified with aq. ammonia and extracted with EtOAc. The organic layer was dried over anhydrous sodium sulfate and evaporated to yield 2-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-1-(pyridin-4-yl)ethanamine (1.2 g). 1H NMR (CDCl3, freebase) δ (ppm): 8.56 (d, 2H), 7.28 (d, 2H), 7.21 (m, 2H), 7.00 (d, 1H), 4.48 (t, 1H), 4.08 (m, 2H), 3.65 (q, 2H), 2.83 (m, 2H), 2.72 (m, 1H), 2.56 (m, 1H), 2.53 (s, 3H), 2.44 (s, 3H). Separation by chiral HPLC provided enantiomers 27a and 27b.
Example 28
Preparation of Compound Nos. 28, 28a and 28b
To a stirred solution of 6-chloro-2,3,4,9-tetrahydro-2-methyl-1H-pyrido[3,4-b]indole (550 mg, 2.5 mmol) in DMF (5 mL) was added sodium hydride (300 mg, 7.5 mmol). After stirring for 5 min, a solution of 3-(2-methyloxiran-2-yl)pyridine (506 mg, 3.75 mmol) in DMF (1 mL) was added and the reaction mixture stirred at RT for 16 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with ice-water and extracted with EtOAc. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The solid was crystallized from ether to yield the title compound (300 mg). 1H NMR (CDCl3, freebase) δ (ppm): 8.68 (s, 1H), 8.49 (d, 1H), 7.54 (d, 1H), 7.32 (s, 1H), 7.0 (t, 1H), 6.94 (s, 1H), 4.10 (d, 1H), 4.04 (d, 1H), 3.59 (d, 1H), 3.34 (d, 1H), 2.65 (m, 4H), 2.42 (s, 3H), 1.63 (s, 3H). Separation by chiral HPLC provided enantiomers 28a and 28b. Optical rotations: Compound 28a, (+)26.78 (c 0.54, Chloroform, 98.11% HPLC purity); Compound 28b, (−)20.39 (c 0.59, Chloroform, 93.42% HPLC purity).
Example 29
Preparation of Compound Nos. 29, 29a and 29b
A mixture of compound 2,3,4,5-tetrahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole (1.5 g, 7.5 mmol, 1 equiv.) and NaH (252 mg, 10.5 mmol, 1.4 equiv.) in DMF (30 mL) were heated to 120° C. for 1 h. The reaction mixture was cooled to RT and 2-methyl-5-(2-methyloxiran-2-yl)pyridine (2.46 g, 16.5 mmol, 2.2 equiv.) in DMF (17 mL) was added dropwise over 12 min. The temperature was again raised to 120° C. and stirred for 3 h. The reaction mixture was cooled to RT and water (5 mL) was added, diluted with EtOAc (700 mL) and the organic layer was washed with water (3×100 mL) and then with brine, dried over anhydrous sodium sulfate and concentrated under vacuum. The compound was purified by column chromatography over 230-400 mesh silica gel using a gradient of 10-20% MeOH in EtOAc. Yield: 2.3 g (87%). 1H NMR (DMSO-d6, oxalate salt) δ (ppm): 8.52 (bs, 1H), 7.73-7.71 (d, 1H), 7.31-7.29 (d, 1H), 7.17-7.15 (m, 2H), 6.88-6.86 (d, 1H), 4.34 (bs, 2H), 4.24-4.40 (dd, 2H), 3.47 (bs, 2H), 2.98 (bs, 2H), 2.91 (s, 3H), 2.42 (s, 3H), 2.35 (s, 3H), 1.48 (s, 3H). Separation by chiral HPLC provided enantiomers 29a and 29b.
Example 30
Preparation of Compound Nos. 30, 30a and 30b
Activated magnesium turnings (480 mg, 20 g/atom) and 2-3 crystals of iodine were stirred under anhydrous conditions. The excess of iodine was removed by heating with a heat gun. The magnesium turnings were now yellow in color. To this was added diethyl ether (15 mL) at 0° C. and stirred for 15 min. (until the color of the magnesium becomes white). To this was added cyclopentyl bromide (480 mg, 20 g/atom) dropwise with constant stirring. The reaction mixture was stirred until a dark grey-colored solution was obtained. Into a separate flask was placed the starting material 2-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(4-fluorophenyl)ethanone (168 mg, 5 mmol) in THF under anhydrous conditions. The solution of the prepared cyclopentylmagnesium bromide (5 mL) was added dropwise. After addition, the mixture was allowed to come to RT and stirred at RT for 2 h. The reaction was monitored by TLC and NMR. The reaction was quenched with ice water and the product extracted into EtOAc. The organic extracts were concentrated and the residue purified by silica gel column chromatography (#100-200 mesh) using 0-3% MeOH:DCM as eluent. (Note: The desired compound was not formed but reduction of keto group occurred to yield the hydroxy compound). 1H NMR (DMSO-d6, oxalate salt) δ (ppm): 7.55 (m, 3H), 7.18 (m, 3H), 6.95 (d, 1H), 4.85 (s, 1H), 4.30 (m, 2H), 4.15 (m, 2H), 3.60 (m, 2H), 3.10 (m, 3H), 2.90 (s, 3H), 2.40 (s, 3H). Separation by chiral HPLC provided enantiomers 30a and 30b.
Example 31
Preparation of Compound Nos. 31, 31a and 31b
Sodium hydride (1-3 equiv.) was added to a solution of 8-chloro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (1.0 equiv.) in DMF, and heated to 120° C. for 1 h with stirring. The reaction mixture was cooled to 0° C. and 3-(2-methyloxiran-2-yl)pyridine (2-7.5 equiv.) was added dropwise over 5 min. The temperature was raised to 120° C. and stirred for 2 h. The reaction mixture was cooled to RT and partitioned between EtOAc and water. The organic layer was separated and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with water and followed by brine, dried over anhydrous sodium sulfate and concentrated under vacuum to provide the crude product. The product was purified by flash column chromatography over silica gel (230-400 mesh, deactivated with 1% triethylamine/hexane) using a gradient of 5 to 15% MeOH/EtOAc to yield the free base. The pure compound was converted to its oxalate salt. The analytical sample was prepared by dissolving free base in THF and treatment with 1 equiv. of oxalic acid dihydrate. 1H NMR (CD3OD, oxalate salt) δ (ppm): 8.43 (s, 1H), 8.34 (d, 1H), 7.87 (d, 1H), 7.37 (s, 1H), 7.30 (m, 1H), 6.97 (m, 1H), 6.93 (d, 1H), 4.48 (m, 2H), 4.32 (m, 2H), 3.71 (m, 2H), 3.12 (s, 3H), 2.81 (m, 2H), 1.70 (s, 3H). Separation by chiral HPLC provided enantiomers 31a and 31b.
Example 32
Preparation of Compound Nos. 32, 32a and 32b
A flask was charged with 6-chloro-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.0 g, 4.5 mmol) in DMF (10 mL) and stirred for 5 min. To this was added NaH (60% in hexane) (220 mg, 6.8 mmol) and stirred at RT for 10 min., followed by 4-(2-methyloxiran-2-yl)pyridine (1.08 g, 9 mmol) and stirred at RT for 16 h. The progress of reaction was monitored by TLC. The mixture was poured into ice water and filtered. The filtrate was washed with water and concentrated. The residue was recrystallized from ether to get pure product. 1H NMR (DMSO-d6, HCl salt) δ (ppm): 8.70 (d, 2H), 7.90 (d, 2H), 7.40 (m, 1H), 7.0 (m, 2H), 6.0 (m, 1H), 4.80 (m, 1H), 4.60 (m, 2H), 4.25 (m, 2H), 3.80 (m, 2H), 2.90 (s, 3H), 1.60 (s, 3H). Separation by chiral HPLC provided enantiomers 32a and 32b.
Example 33
Preparation of Compound Nos. 33, 33a and 33b
8-Chloro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (1.3 g, 5 mmol) was dissolved in DMF (10 mL) and stirred for 5 min. Sodium hydride (709 mg, 17.7 mmol) was then added to it portionwise under nitrogen. This was followed by addition of 2-butyl-2-(4-fluorophenyl)oxirane (3.4 g, 17.7 mmol) at RT and the reaction mixture was stirred for 18 h. After completion of reaction, the reaction mixture was poured into ice water and the product extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude product which was purified by silica gel (#100-200 mesh) column chromatography using 1% MeOH in DCM as eluent. The pure compound was converted into the oxalate salt. 1HNMR (CDCl3, Oxalate salt) δ (ppm): 7.30 (m, 3H), 7.10 (d, 1H), 6.95 (m, 3H), 4.20 (m, 1H), 4.0 (m, 1H), 3.62 (m, 2H), 2.70 (m, 3H), 2.50 (s, 3H), 2.20 (m, 1H), 2.0 (m, 1H), 1.80 (m, 1H), 1.22 (m, 3H), 1.0 (m, 1H), 0.80 (t, 3H). Separation by chiral HPLC provided enantiomers 33a and 33b.
Example 34
Preparation of Compound Nos. 34, 34a and 34b
2-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(4-fluorophenyl)ethanone (168 mg, 5 mmol) was dissolved in 10 mL anhydrous THF. Ethyl magnesium bromide (1.5 mL, 0.0015 mol) was then added dropwise at RT under nitrogen. The reaction mixture was stirred at RT for 2 h. The reaction was monitored by LCMS. On completion of the reaction, water (3 mL) was added to the reaction mixture and the product extracted with EtOAc (3×). The combined organic layers were washed with water, dried over anhydrous sodium sulfate, and the solvent evaporated under reduced pressure to obtain the crude product, which was purified by HPLC. The pure compound was isolated as the TFA salt. 1HNMR (CD3OD, TFA salt) δ (ppm): 7.38 (m, 2H), 7.18 (d, 1H), 7.10 (m, 1H), 7.0 (m, 2H), 6.85 (d, 1H), 4.60 (m, 1H), 4.30 (m, 2H), 3.75 (m, 1H), 3.42 (m, 1H), 3.10 (s, 3H), 2.90 (m, 2H), 2.42 (d, 1H), 2.38 (s, 3H), 2.20 (m, 1H), 1.80 (m, 2H), 0.8 (t, 3H). Separation by chiral HPLC provided enantiomers 34a and 34b.
Example 35
Preparation of Compound Nos. 35, 35a and 35b
A flask was charged with sodium hydride (0.640 g, 50-60%) in dry DMF (10 mL) at 0° C. and to this was added 2,8-dimethyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole (0.8 g). The mixture was stirred at RT for 30 min and then 4-(2-ethyloxiran-2-yl)pyridine (0.834 g) dissolved in DMF (2 mL) was added, which was stirred at RT for 12 h. The reaction mixture was diluted with ice-water and extracted with EtOAc (3×30 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and evaporated. The crude product was triturated with diethyl ether to obtain the desired compound. 1HNMR (DMSO, Oxalate salt) δ (ppm): 8.45 (d, 2H), 7.42 (d, 2H), 7.30 (d, 1H), 7.10 (s, 1H), 6.82 (d, 1H), 4.30 (d, 1H), 4.18 (d, 1H), 3.60 (s, 2H), 3.50 (m, 2H), 3.38 (m, 1H), 3.0 (m, 2H), 2.90 (s, 3H), 3.32 (s, 3H), 2.10 (m, 1H), 0.6 (t, 3H). Separation by chiral HPLC provided enantiomers 35a and 35b.
Example 36
Preparation of Compound Nos. 36, 36a-36d
To a solution of 1-ethyl-7-methyl-3,4,5,10-tetrahydro-1H-2,5-methanoazepino[3,4-b]indole (1000 mg, 4.17 mmol) in DMF (10 mL) was added sodium hydride (500 mg, 12.498 mmol) portionwise. After stirring at RT for 5 min, 4-(oxiran-2-yl)pyridine (630 mg, 5.00 mmol) was added dropwise into the reaction mixture, which was stirred at RT overnight. The reaction mixture was quenched with ice-water and the solid mass was filtered. The residue was washed with water (2×10 mL), hexane (2×50 mL) and purified by reverse phase HPLC to yield the title compound. Separation by chiral HPLC provided enantiomers 36a and 36b.
Example 37
Preparation of Compound Nos. 37, 37a, 37c and 37d
To a solution of 2,3,4,9,10,10a-hexahydro-1H-3a,8,9-triaza-cyclopenta[b]fluorene (1 g, 0.0046 mol) in DMF (20 mL) was added NaH (60%, 0.552 g, 0.0138 mol) portionwise followed by 4-(oxiran-2-yl)pyridine (0.709 g, 0.0056 mol). The reaction mixture was stirred at RT overnight. The progress of reaction mixture was monitored by LCMS. The reaction mixture was quenched with ice cold water (300 mL) and extracted with EtOAc (3×100 mL). The combined organic layer was washed with water (10×100 mL) followed by brine (2×100 mL), dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography followed by reverse phase HPLC to obtain the desired compound. 1H NMR (CDCl3, freebase) δ (ppm): 8.56 (d, 2H), 8.21 (d, 1H), 7.74 (d, 1H), 7.32 (d, 2H), 7.06 (dd, 1H), 5.16 (dd, 1H), 4.44 (dd, 1H), 4.31 (dd, 1H), 4.2 (d, 1H), 3.32 (m, 2H), 2.85 (d, 1H), 2.5 (m, 1H), 2.39 (q, 2H), 2.11 (m, 1H), 1.93 (m, 2H). Separation by chiral HPLC provided enantiomers 37a, 37b, 37c and 37d.
Example 38
Preparation of Compound Nos. 38, 38a-38h
To a solution of 1,7-dimethyl-3,4,5,10-tetrahydro-1H-2,5-methanoazepino[3,4-b]indole (1 g, 4.42 mmol) in DMF (10 mL) was added sodium hydride (530 mg, 13.24 mmol) portionwise under nitrogen. After stirring for 10 min at 0° C., 4-oxiranyl-pyridine (1.07 g, 8.84 mmol) was added dropwise at 0° C. into the reaction mixture and stirring continued for 12 h at RT. After completion, the reaction mixture was poured into ice water and extracted with EtOAc (2×100 mL). The combined organic layers were washed with water (5×50 mL), dried over anhydrous sodium sulfate and concentrated to obtain 1.2 g of product. 1H NMR (CD3OD, Formate salt) δ (ppm): 8.42 (d, 2H), 7.8 (d, 2H), 7.22 (s, 1H), 6.78 (t, 2H), 5.67 (q, 1H), 5.4 (m, 1H), 4.77 (dd, 1H), 4.4 (dd, 1H), 3.82 (d, 1H), 3.7-3.8 (m, 3H), 3.6 (d, 1H), 2.4 (m, 1H), 2.3 (s, 3H), 2.18 (m, 1H), 1.97 (d, 3H). Separation by chiral HPLC provided enantiomers 38a and 38b.
Example 39
Preparation of Compound Nos. 39, 39a and 39b
2-(2-Allyl-8-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethanol (740 mg, 2.132 mmol) was dissolved in 40 mL DCM, and purged with nitrogen for 5 min. Pd(PPh3)4 (50 mg, 0.0432 mmol) and 1,3-dimethylbarbituric acid (998 mg, 6.397 mmol) were added and the reaction mixture was stirred at RT for 30 min. The reaction mixture was diluted with saturated aqueous potassium carbonate (20 mL) solution and extracted with DCM (2×20 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography over neutral alumina (eluent 50% MeOH in DCM) to obtain 400 mg of 2-(8-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethanol. 1H NMR (CD3OD, freebase) δ (ppm): 8.71 (d, 2H), 8.04 (d, 2H), 7.22 (s, 1H), 7.13 (d, 1H), 6.94 (d, 1H), 5.33 (t, 1H), 4.42 (m, 4H), 3.63 (t, 2H), 3.28 d (t, 1H), 3.22 (m 1H), 2.38 (s, 3H). This racemate was separated by chiral semi-preparative HPLC to obtain enantiomers 39a and 39b.
Example 40
Preparation of Compound Nos. 40, 40a and 40b
To a solution of 2-methyl-7-(trifluoromethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (500 mg, 1.96 mmol) in DMF (5 mL) was added sodium hydride (60%, 236 mg, 5.9 mmol) at RT under N2. After stirring for 10 min, a solution of 3-(oxiran-2-yl)pyridine (356 mg, 2.9 mmol) in DMF (1 mL) was added into the reaction mixture, which was stirred at RT for 16 h. The progress of reaction was monitored by TLC, LCMS and NMR. After completion, the reaction mixture was quenched with ice water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to obtain the desired compounds 40a and 40b.
Example 41
Preparation of Compound Nos. 41, 41a and 41b
To a solution of 6-chloro-2-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (1.0 g, 4.55 mmol) in DMF (20 mL), sodium hydride (546 mg, 13.65 mmol) was added and the suspension stirred at RT for 10 min. A solution of 4-(oxiran-2-yl)pyridine (1.10 g, 9.1 mmol) in DMF (5 mL) was added slowly into the reaction mixture, which was stirred at RT overnight. The progress of reaction was monitored by TLC and LCMS. The reaction mass was poured into ice cold water (200 mL) slowly and extracted with EtOAc (3×200 mL). The organic layer was washed with water (4×300 mL), dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography using 7% MeOH-DCM as eluent. The residue obtain was triturated with diethyl ether (20 mL) to yield the desired product. 1H NMR (CDCl3, freebase) δ (ppm): 8.42-8.58 (d, 2H), 7.4 (s, 1H), 7.26 (d, 2H), 7.15 (d, 1H), 7.11 (d, 1H), 4.9 (dd, 1H), 4.08 (dd, 1H), 4.04 (dd, 1H), 3.73 (d, 1H), 3.48 (s, 1H), 3.3 (d, 1H), 2.69 (m, 1H), 2.68 (m, 3H), 2.45 (s, 3H). Separation by chiral HPLC provided enantiomers 41a and 41b.
Example 42
Preparation of Compound Nos. 42, 42a and 42b
1-(2-Allyl-8-chloro-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2-pyrimidin-4-yl-propan-2-ol (300 mg, 0.785 mmol) was dissolved in DCM (6 mL) and N2 was purged for 5 min into the reaction mixture. 1,3-Dimethylbarbituricacid (367 mg, 2.356 mmol) and Pd(PPh3)4 (18 mg, 0.0157 mmol) was added and the mixture stirred for 1 h at RT. After consumption of starting material, the reaction mixture was diluted with saturated potassium carbonate (50 mL) and extracted with DCM (2×40 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated, crude was purified by reverse phase chromatography to obtain 97 mg of 1-(8-chloro-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2-pyrimidin-4-yl-propan-2-ol. 1H NMR (CDCl3, freebase) δ (ppm): 9.13 (s, 1H), 8.45 (d, 1H), 7.31 (d, 1H), 7.25 (s, 1H), 6.94 (s, 2H), 4.3 (q, 2H), 3.93 (q, 2H), 3.13 (m, 2H), 2.78 (d, 1H), 2.57 (d, 1H), 1.6 (s, 3H). Separation by chiral HPLC provided enantiomers 42a and 42b.
Example 43
Preparation of Compound Nos. 43, 43a and 43b
To a solution of 2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1 g, 5 mmol) in 10 mL DMF, was added sodium hydride (600 mg, 15 mmol) portionwise under nitrogen at 0° C. and stirred for 10 min. 3-Oxiranyl-pyridine (908 mg, 15.0 mmol) was added dropwise under nitrogen and the reaction mixture stirred at RT for 12 h. After the complete conversion of starting material (TLC and LCMS), the reaction mixture was poured in ice-cold water and extracted with EtOAc (2×100 mL). The combined organic layer was washed with water (5×50 mL), dried over anhydrous sodium sulfate, and concentrated. The crude mixture was purified by reverse phase chromatography to obtain 290 mg of 2-(2,6-dimethyl-1,2,3,4-tetrahydro-β-carbolin-9-yl)-1-pyridin-3-yl-ethanol. 1H NMR (CDCl3, freebase) δ (ppm): 8.62 (s, 1H), 8.57 (d, 1H), 7.67 (d, 1H), 7.3 (m, 2H), 7.19 (d, 1H), 7.01 (d, 1H), 5.09 (t, 1H), 4.13 (m, 2H), 3.70 (d, 1H), 3.36 (d, 1H), 2.79 (m, 3H), 2.703 (m, 1H), 2.5 (s, 3H), 2.45 (s, 3H). Separation by chiral HPLC provided enantiomers 43a and 43b.
Example 44
Preparation of Compound Nos. 44, 44a and 44b
Sodium hydride (60%) (555 mg, 13.88 mmol) was added portionwise to a solution of 6-methoxy-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.0 g, 4.629 mmol) in DMF (10 mL) and stirred at RT for 15 min, the suspension was allowed to cool at 0° C. 4-(Oxiran-2-yl)pyridine (896 mg, 7.407 mmol) was added dropwise and reaction mixture was stirred at RT for 48 h. The reaction mixture was poured in to ice-cooled water and extracted with EtOAc (3×50 mL), and the organic layer was washed with water (2×50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo, afforded crude was purified by reverse phase HPLC to afford 2-(6-methoxy-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(pyridin-4-yl)ethanol (165 mg) as the formate salt. 1H NMR (CDCl3, freebase) δ (ppm): 8.60 (d, 2H), 7.31 (d, 2H), 7.02 (m, 2H), 6.66 (d, 1H), 5.08 (dd, 1H), 4.66 (dd, 1H), 4.12 (dd, 1H), 3.99 (s, 3H), 3.60 (d, 1H), 3.56 (d, 1H), 2.9 (m, 1H), 2.81 (m, 1H), 2.72 (m, 1H), 2.64 (m, 1H), 2.55 (s, 3H). Separation by chiral HPLC provided enantiomers 44a and 44b.
Example 45
Preparation of Compound Nos. 45, 45a and 45b
To a stirred solution of 6-chloro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (1 g, 4.54 mmol) in DMF (8 mL) was added sodium hydride (60%, 545 mg, 13.6 mmol). After stirring for 10 min, a solution of 4-(oxiran-2-yl)pyridine (825 mg, 6.8 mmol) in DMF (2 mL) was added into the reaction mixture, which was stirred at RT for 16 h. The reaction mixture was poured into ice-cold water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. 1H NMR (CDCl3, freebase) δ (ppm): 8.54 (d, 2H), 7.31 (d, 2H), 7.19 (d, 1H), 7.11 (d, 1H), 7.01 (t, 1H), 5.04 (dd, 1H), 4.81 (dd, 1H), 3.99 (dd, 1H), 3.27 (dd, 2H), 3.11 (m, 1H), 2.84 (m, 1H), 2.51 (m, 2H), 2.32 (s, 3H). Separation by chiral HPLC provided enantiomers 45a and 45b.
Example 46
Preparation of Compound Nos. 47, 47a, 47b, 47c and 47d
To a solution of 11-methyl-1,2,3,4,6,7,8,12c-octahydro-indolo[3,2-a]quinolizine (800 mg, 3.33 mmol) in 12 mL DMF was added sodium hydride (400 mg, 13.2 mmol) under nitrogen at RT and stirred for 20 min. 4-Oxiranyl-pyridine (685 mg, 5.66 mmol) was added dropwise under nitrogen and the reaction mixture stirred at RT for 18 h. After complete conversion of starting material (TLC and LCMS), the reaction mixture was poured in ice-cold water and extracted with EtOAc (3×80 mL). The combined organic layer was washed with water (5×50 mL), dried over anhydrous sodium sulfate, concentrated and the crude product was recrystallized in EtOH (1 mL) and ether (50 mL) to obtain 700 mg of desired product. 1H NMR (CDCl3, freebase) δ (ppm): 8.53 (d, 2H), 7.36 (s, 1H), 7.21 (d, 2H), 7.12 (d, 1H), 6.94 (d, 1H), 4.99 (t, 1H), 4.1 (m, 2H), 3.35 (d, 1H), 3.13 (t, 1H), 3.0 (m, 2H), 2.63 (d, 1H), 2.56 (m, 1H), 2.46 (s, 3H), 2.4 (d, 1H), 1.8 (d, 1H), 1.7 (m, 1H), 1.5 (m, 2H). Separation by chiral HPLC provided enantiomers 47a 47b, 47c and 47d.
Example 47
Preparation of Compound Nos. 48, 48a and 48b
To a stirred solution of 6-bromo-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (1 g, 3.77 mmol) in DMF (8 mL) was added sodium hydride (60%, 452 mg, 11.32 mmol). After stirring for 10 min, a solution of 4-(oxiran-2-yl)pyridine (684 mg, 5.66 mmol) in DMF (2 mL) was added into the reaction mixture, which was stirred at RT for 16 h. The reaction mixture was poured into ice-cold water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was dissolved in DCM and pure product precipitated out as a white solid. 1H NMR (CDCl3, freebase) δ (ppm): 8.57 (d, 2H), 7.36 (d, 2H), 7.33 (d, 1H), 7.27 (d, 1H), 6.95 (t, 1H), 5.17 (dd, 1H), 4.96 (dd, 1H), 4.04 (dd, 1H), 3.34 (dd, 2H), 3.1 (m, 1H), 2.85 (m, 1H), 2.55 (m, 2H), 2.38 (s, 3H). Separation by chiral HPLC provided enantiomers 48a and 48b.
Example 48
Preparation of Compound Nos. 49, 49a and 49b
To a stirred solution of 1-(2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indol-8-yl)ethanone (80 mg, 0.35 mmol) in DMF (2 mL) was added sodium hydride (60%, 42 mg, 1.05 mmol). After stirring for 10 min, a solution of 4-(oxiran-2-yl)pyridine (62 mg, 0.51 mmol) in DMF (1 mL) was added into the reaction mixture, and stirred at RT for 4 h. The reaction mixture was quenched with ice water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue obtain was purified by crystallization with ether to yield 1-(2,3,4,5-tetrahydro-5-(2-hydroxy-2-(pyridin-4-yl)ethyl)-2-methyl-1H-pyrido[4,3-b]indol-8-yl)ethanone (6 mg). 1H NMR (CDCl3, freebase) δ (ppm): 8.5 (d, 2H), 7.95 (s, 1H), 7.73 (d, 1H), 7.26 (d, 2H), 7.12 (d, 1H), 4.78 (t, 1H), 4.8 (d, 2H), 3.49 (m, 2H), 2.90 (m, 1H), 2.8 (q, 2H), 2.79 (s, 3H), 2.6 (m, 1H), 2.37 (s, 3H). Separation by chiral HPLC provided enantiomers 49a and 49b.
Example 49
Preparation of Compound Nos. 51, 51a and 51b
2,8-Dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.0 g, 5.0 mmol) was dissolved in DMF (8 mL). Sodium hydride (600 mg, 15 mmol) was added portionwise under nitrogen at 0° C.
2-Methoxy-5-oxiranyl-pyridine (1.130 g, 7.5 mmol) was diluted in DMF (2 mL) was added dropwise under nitrogen atmosphere and the reaction mixture stirred at RT for 3 h. By monitoring TLC & NMR after consumption of starting material, the reaction mixture was then quenched with ice water and extracted with EtOAc (3×40 mL). The combined organic layer was washed with water (4×30 mL) and dried over anhydrous sodium sulfate and concentrated to obtain 1.0 g of 2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-(6-methoxy-pyridin-3-yl)-ethanol. 1H NMR (CDCl3, freebase) δ (ppm): 8.11 (s, 1H), 7.55 (d, 1H), 7.18 (s, 1H), 7.16 (d, 1H), 6.98 (d, 1H), 6.72 (d, 1H), 4.98 (t, 1H), 4.11 (m, 2H), 3.93 (s, 3H), 3.60 (q, 2H), 2.88 (d, 1H), 2.78 (m, 2H), 2.69 (d, 1H), 2.51 (s, 3H), 2.44 (s, 3H). Separation by chiral HPLC provided enantiomers 51a and 51b.
Example 50
Preparation of Compound Nos. 52, 52a and 52b
To a stirred solution of 2,3,4,5-tetrahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole (250 mg, 1.25 mmol) in DMF (5 mL) was added sodium hydride (60%, 150 mg, 3.75 mmol). After stirring for 10 min, a solution of ethyl 4-(oxiran-2-yl)benzoate (480 mg, 2.5 mmol) in DMF (1 mL) was added to the reaction mixture, which was stirred at RT for 16 h. The reaction mixture was quenched with ice water and extracted with EtOAc. The organic layer was dried over anhydrous sodium sulfate, evaporated and residue was purified by reverse phase HPLC. 1H NMR (CDCl3, freebase) δ (ppm): 7.28 (m, 4H), 7.12 (s, 1H), 7.04 (d, 1H), 6.88 (d, 1H), 4.91 (t, 1H), 4.09 (d, 2H), 3.58 (q, 2H), 3.1 (s, 3H), 2.92 (s, 3H), 2.87 (m, 1H), 2.80 (m, 2H), 2.68 (d, 1H), 2.47 (s, 3H), 2.41 (s, 3H). Separation by chiral HPLC provided enantiomers 52a and 52b.
Example 51
Preparation of Compound Nos. 53, 53a and 53b
To a stirred solution of 7-chloro-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (0.5 g, 2.265 mmol) in anhydrous DMF was added sodium hydride (271 mg, 3 eq.) portionwise followed by 4-(oxiran-2-yl)pyridine (548 mg, 4.5 mmol) at RT. The reaction mixture was stirred for 12 h. The reaction mixture was quenched with ice water and extracted with EtOAc, the organic layer washed with water, dried on anhydrous sodium sulfate, concentrated under vacuum to obtain crude product that was triturated with diethyl ether to obtain 2-(7-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(pyridin-4-yl)ethanol as solid. 1H NMR (CDCl3, freebase) δ (ppm): 8.53 (d, 2H), 7.2 (m, 3H), 7.14 (d, 1H), 7.05 (d, 1H), 4.82 (t, 1H), 4.03 (d, 2H), 3.4 (q, 2H), 2.85 (m, 1H), 2.76 (m, 1H), 2.64 (m, 2H), 2.37 (s, 3H). Separation by chiral HPLC provided enantiomers 53a and 53b.
Example 52
Preparation of Compound Nos. 54, 54a and 54b
To a solution of 2-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-1-(pyridin-4-yl)ethanol (500 mg, 1.55 mmol) and isobutyric acid (274 mg, 3.1 mmol) in DCM (100 mL) were added EDC.HCl (657 mg, 3.4 mmol), DMAP (19 mg, 0.16 mmol) and TEA (346 mg, 3.4 mmol). The reaction mixture was stirred at RT for 16 h and washed with water. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (4% MeOH-DCM) followed by reverse phase purification to yield 2-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-1-(pyridin-4-yl)ethyl isobutyrate (310 mg). 1H NMR (CDCl3, freebase) δ (ppm): 8.53 (d, 2H), 7.2 (d, 1H), 7.18 (s, 1H), 7.04 (d, 2H), 6.97 (d, 1H), 5.98 (t, 1H), 4.4 (dd, 1H), 4.14 (dd, 1H), 3.64 (q, 2H), 2.73 (m, 2H), 2.6 (m, 1H), 2.49 (s, 3H), 2.43 (s, 3H), 2.37 (m, 1H), 1.15 (d, 3H), 1.09 (d, 3H). Separation by chiral HPLC provided enantiomers 54a and 54b.
Example 53
Preparation of Compound Nos. 55, 55a and 55b
3,6-Dimethyl-6,7,8,9-tetrahydro-5H-1,6,9-triaza-fluorene (250 mg, 1.243 mmol) was dissolved in DMF (3 mL) and cooled to 0° C. Sodium hydride (149 mg, 3.729 mmol) was added portionwise and the mixture stirred at the same temperature for 10 min. 4-Oxiranyl-pyridine (240 mg, 1.990 mmol) was diluted in DMF (1 mL) and added dropwise in the reaction mixture at 0° C. The reaction mixture was stirred at RT for 12 h. The desired product was detected by LCMS. The reaction mixture was poured in ice cold water and extracted with EtOAc (3×25 mL). The combined organic layer was washed with water (5×30 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified by reverse phase chromatography to obtain 18 mg of 2-(3,6-dimethyl-5,6,7,8-tetrahydro-1,6,9-triaza-fluoren-9-yl)-1-pyridin-4-yl-ethanol. 1H NMR (CDCl3, freebase) δ (ppm): 8.48 (d, 2H), 7.95 (s, 1H), 7.43 (s, 1H), 7.18 (d, 2H) 5.06 (d, 1H), 4.37 (d, 1H), 4.24 (dd, 1H), 3.45 (q, 2H), 2.29 (t, 2H), 2.55 (t, 2H), 2.45 (s, 3H), 2.38 (s, 3H). Separation by chiral HPLC provided enantiomers 55a and 55b.
Example 54
Preparation of Compound Nos. 56, 56a and 56b
To a solution of 2-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-1-(pyridin-4-yl)ethanol (900 mg, 4.5 mmol) in DMF (4 mL) was added sodium hydride (540 mg, 13.5 mmol). After stirring for 10 min at RT, a solution of 3-(2-methyloxiran-2-yl)pyridine-N-oxide (1 g, 6.75 mmol) was added to the reaction mixture, and stirred at RT for 16 h. The reaction mixture was cooled to 0° C., quenched with ice water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and evaporated. The residue was triturated with ether to yield the title compound as yellow solid (220 mg). 1H NMR (CD3OD, freebase) δ (ppm): 8.27 (s, 1H), 8.12 (d, 1H), 7.58 (d, 1H), 7.32 (t, 1H), 7.07 (s, 1H), 6.94 (d, 1H), 6.79 (d, 1H) 4.14 (q, 2H), 3.63 (s, 2H), 2.88 (m, 1H), 2.82 (s, 2H), 2.79 (m, 1H), 2.51 (s, 3H), 2.331(s, 3H), 1.62 (s, 3H). Separation by chiral HPLC provided enantiomers 56a and 56b.
Example 55
Preparation of Compound Nos. 57, 57a and 57b
6-Chloro-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1 g, 4.5 mmol) was dissolved in 15 mL DMF and stirred for 5 min at RT. Sodium hydride (540 mg, 13.5 mmol) was added portionwise at RT under nitrogen. 3-(2-Methyl-oxiranyl)-pyridine (800 mg, 5.9 mmol) was diluted in 5 mL DMF and added dropwise at the same temperature and stirred for 16 h at RT. The reaction was monitored by TLC & LCMS. After consumption of starting material, the reaction mixture was quenched with ice water (30 mL) and filtered. The residue was crystallized in EtOH (1 mL) and ether (40 mL) and purified by reverse phase chromatography to obtain 620 mg of 1-(6-chloro-2-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2-pyridin-3-yl-propan-2-ol. 1H NMR (CDCl3, freebase) δ (ppm): 8.77 (s, 1H), 8.5 (d, 1H), 8.45 (s, 1H), 7.71 b(s, 1H), 7.17 b(s, 1H), 7.06 (d, 1H), 6.97 (t, 1H), 5.12 b(s, 1H), 4.3 b (s, 1H), 3.78 (m, 1H), 3.62 (m, 1H), 3.14 (m, 1H), 2.63 (m, 2H), 2.57 (s, 3H), 2.5 b(s, 2H), 1.53 (s, 3H). Separation by chiral HPLC provided enantiomers 57a and 57b.
Example 56
Preparation of Compound Nos. 58, 58a and 58b
To a degassed solution of 2-(6-allyl-3-methyl-5,6,7,8-tetrahydro-1,6,9-triaza-fluoren-9-yl)-1-pyridin-4-yl-ethanol (300 mg, 0.862 mmol) and 1,3 dimethyl barbituric acid (403 mg, 2.586 mmol) in DCM (7 mL) was added and Pd(PPh3)4 (20 mg, 0.0172 mmol) and the reaction mixture stirred at RT for 1 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was diluted with 20% aq potassium carbonate solution and extracted with DCM (3×25 mL). The combined organic layer was washed with 20% aq potassium carbonate solution, dried over anhydrous sodium sulfate and concentrated to yield 2-(3-methyl-5,6,7,8-tetrahydro-1,6,9-triaza-fluoren-9-yl)-1-pyridin-4-yl-ethanol. 1H NMR (CDCl3, freebase) δ (ppm):8.5 (d, 2H), 8.03 (s, 1H), 7.51(s, 1H), 7.22 (d, 2H) 5.14 (d, 1H), 4.4 (dd, 1H), 4.27 (dd, 1H), 3.93 (q, 2H), 3.13 (m, 2H), 2.54 (dd, 1H), 2.42 (s, 3H), 2.3 (dd, 1H). Separation by chiral HPLC provided enantiomers 58a and 58b.
Example 57
Preparation of Compound Nos. 59, 59a and 59b
To a solution of 2-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (200 mg, 0.78 mmol) in DMF (3 mL) was added sodium hydride (60%, 94 mg, 2.3 mmol) at RT under N2. After stirring for 10 min, a solution of 3-(oxiran-2-yl)pyridine (142 mg, 1.17 mmol) in DMF (1 mL) was added into the reaction mixture, which was stirred at RT for 16 h. The progress of reaction was monitored by TLC, LCMS and NMR. After completion, the reaction mixture was quenched with ice water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to obtain the desired compounds. 59a: 1H NMR (CDCl3, freebase) δ (ppm): 8.51 (s, 1H), 8.35 (d, 1H), 7.51 (s, 1H), 7.42 (d, 1H), 7.32 (d, 1H), 7.21 (d, 1H), 7.07 (t, 1H), 4.94 (t, 1H), 4.20 (dd, 1H), 4.09 (dd, 1H), 3.49 (q, 2H), 2.9 (d, 1H), 2.76 (m, 3H), 2.41 (s, 3H). 59b: 1H NMR (CDCl3, freebase) δ (ppm): 8.51 (s, 1H), 8.35 (d, 1H), 7.51 (s, 1H), 7.42 (d, 1H), 7.32 (d, 1H), 7.21 (d, 1H), 7.07 (t, 1H), 4.94 (t, 1H), 4.20 (dd, 1H), 4.09 (dd, 1H), 3.49 (q, 2H), 2.9 (d, 1H), 2.76 (m, 3H), 2.41 (s, 3H). Separation by chiral HPLC provided enantiomers 59a and 59b. Optical rotations: Compound 59a, (−)16.42 (c 0.54, Chloroform, 99.96% HPLC purity); Compound 59b, (+)11.20 (c 0.54, Chloroform, 99.01% HPLC purity).
Example 58
Preparation of Compound No. 60
To a solution of 8-chloro-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (0.2 g, 0.9 mmol) in N-methyl-2-pyrolidone (1.5 mL) was added powdered potassium hydroxide (0.507 g, 9.0 mmol). The reaction mixture was stirred for 10 min at RT. 3-Vinyl pyridine (0.3 g, 2.8 mmol) was added and the reaction mixture was stirred at 100° C. for 18 h. After consumption of starting material (TLC), the reaction mixture was diluted with water (15 mL) and extracted with EtOAc (3×100 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography over silica gel (eluent 8% MeOH: DCM) followed by preparative TLC to obtain the desired compound as a yellow oil (0.032 g, 11% yield). 1H NMR (DMSO, Oxalate salt) δ (ppm): 8.4 (d, 1H), 8.3 (s, 1H), 7.57 (d, 2H), 7.49 (d, 1H), 7.26 (m, 1H), 7.10 (d, 1H), 4.45 (m, 4H), 3.5 (bs, 2H), 3.0 (t, 2H), 2.95 (m, 2H), 2.90 (s, 3H).
Example 59
Preparation of Compound No. 61
To a solution of 2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (0.1 g, 0.49 mmol) in N-methyl-2-pyrrolidone (0.5 mL) was added powdered potassium hydroxide (0.274 g, 4.9 mmol) and the reaction mixture was stirred for 10 min at RT. 3-Vinyl pyridine (0.26 g, 2.49 mmol) was added and stirring was continued for further 18 h at 100° C. After consumption of starting material (TLC), the reaction mixture was diluted with water (15 mL) and extracted with EtOAc (3×50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel chromatography (eluent 7% MeOH: DCM) followed by preparative TLC, to obtain desired compound as yellow oil (0.040 g, 26% yield).
1H NMR (DMSO, Oxalate salt) δ (ppm): 8.4 (s, 1H), 8.3 (s, 1H), 7.55 (s, 2H), 7.35 (d, 1H), 7.25 (bs, 1H), 7.2 (s, 1H), 4.35 (bs, 4H), 3.5 (bs, 2H), 3.0 (m, 2H), 2.9 (m, 5H), 2.45 (s, 3H).
Example 60
Preparation of Compound Nos. 62, 62a and 62b
Carboline (500 mg, 2.5 mmol) was dissolved in DMF (5 mL). To this solution was added NaH (60%, 180 mg, 4.5 mmol) at RT and the reaction mixture was stirred for 10-15 min. after which 3-(oxiran-2-yl)pyridine (450 mg, 3.7 mmol) was added. The reaction mixture was stirred at RT for 4 h and the reaction was monitored by LCMS. After completion, the reaction mixture was poured on ice water and extracted with EtOAc. The organic layer was dried on sodium sulfate and concentrated under reduced pressure. The residue was purified by HPLC to obtain 420 mg of product as a white solid (TFA salt). TLC (silica gel) 5:95 MeOH:DCM, Rf 0.1 was observed. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.60 (d, 2H), 8.20 (bs, 1H), 7.85 (bs, 1H), 7.20 (s, 1H), 7.0 (d, 1H), 6.9 (d, 1H), 5.2 (bs, 1H), 4.8 (d, 2H), 4.4 (m, 4H), 3.9 (bs, 1H), 3.60 (bs, 2H), 3.10 (s, 3H), 2.40 (s, 3H). Separation by chiral HPLC provides enantiomers 62a and 62b.
Example 61
Preparation of Compound Nos. 63, 63a and 63b
2-(2,8-Dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethanol (200 mg.0.62 mmol) was dissolved in 10 mL DCM and m-CPBA (128 mg, 0.74 mmol) was diluted in DCM and added dropwise at RT. After consumption of starting material by monitoring TLC & LCMS reaction mixture was complete, the mixture was concentrated and the crude product was purified by reverse phase chromatography, to obtain 120 mg of 2-(2,8-dimethyl-2-oxy-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethanol. Separation by chiral HPLC provided enantiomers 63a and 63b. 63a: 1H NMR (CD3OD, TFA salt) δ (ppm): 8.56 (d, 2H), 7.9 (t, 2H), 7.22 (s, 1H), 7.2 (d, 1H), 7.0 (d, 1H), 5.23 (dd, 1H), 5.08 (d, 1H), 5.0 (d, 1H), 4.4 (m, 2H), 4.2 (d, 2H), 3.68 (s, 3H), 3.44 (m, 1H), 3.3 (m, 1H), 2.4 (s, 3H). 63b: 1H NMR (CD3OD, Free base) δ (ppm): 8.44 d (2H), 7.38 d (2H), 7.24 d (1H), 7.25 s (1H), 7.00 d (1H), 5.07 t (1H), 4.77 d (1H), 4.56 d (1H), 4.27 m (2H), 3.86 t (2H), 3.39 m (1H), 3.34 s (3H), 2.82 d t (1H), 2.4 s (3H).
Example 62
Preparation of Compound Nos. 64, 64a and 64b
2,8-Dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (500 mg, 2.5 mmol) was dissolved in 5 mL DMF and stirred for 10 min at RT. Sodium hydride (300 mg, 7.5 mmol) was added portionwise at 0° C. and the reaction mixture was stirred for 10 min. 2-Methoxy-5-(2-methyl-oxiranyl)-pyridine (566 mg, 3.75 mmol) was diluted in DMF (2 mL) and added dropwise at the same temperature and stirred for 12 h. After consumption of starting material, the reaction mixture was quenched with ice water and extracted with EtOAc (3×30 mL). The combined organic layer was washed with water (7×30 mL), dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography over silica gel (eluent: 15% MeOH in DCM) and further crystallized in ether-hexane to obtain 190 mg of 1-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2-(6-methoxy-pyridin-3-yl)-propan-2-ol. 1H NMR (CDCl3, freebase) δ (ppm): 8.22 (s, 1H), 7.5 (d, 1H), 7.1 (s, 1H), 7.0 (d, 1H), 6.83 (d, 1H), 6.5 (d, 1H), 4.1 (m, 2H), 3.91 (s, 3H), 3.5 (m, 2H), 2.63-2.81 (m, 4H), 2.41 (s, 3H), 2.39 (s, 3H), 1.58 (s, 3H). Separation by chiral HPLC provides enantiomers 64a and 64b.
Example 63
Preparation of Compound Nos. 65, 65a and 65b
To a solution of 2-methyl-7-(trifluoromethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.0 g, 3.937 mmol) in DMF (5 mL) was added NaH (472 mg, 11.81 mmol) in portions at 0° C. After stirring the reaction mixture at 0° C. for 15 min, a solution of 4-(oxiran-2-yl)pyridine (714 mg, 5.90 mmol) in DMF (1 mL) was dropwise added into the reaction mixture at the same temperature and stirring was continued at RT overnight. The progress of reaction was monitored by TLC, LCMS and NMR. After consumption of starting material, ice water was added into the reaction mixture and the product was extracted with EtOAc (3×50 mL). The organic layer was washed with water (5×50 mL), dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel chromatography to yield 2-(2-methyl-7-(trifluoromethyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(pyridin-4-yl)ethanol. 1H NMR (CDCl3, freebase) δ (ppm): 8.54 (d, 2H), 7.5 (s, 1H), 7.37 (d, 1H), 7.3 (d, 1H), 7.18 (d, 2H), 4.78 (m, 1H), 4.17 (m, 2H), 3.5 (m, 2H), 2.8 (m, 1H), 2.7 (m, 2H), 2.63 (m, 1H), 2.4 (s, 3H). Separation by chiral HPLC provides enantiomers 65a and 65b.
Example 64
Preparation of Compound Nos. 66, 66a and 66b
To a solution of 2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.2 g, 6.0 mmol) in 6 mL DMF, was added sodium hydride (720 mg, 12 mmol) under nitrogen at 0° C. and stirred for 5 min. 2-(3,4-Dimethoxy-phenyl)-oxirane (2.16 g, 18 mmol) was diluted in DMF (2 mL) and added dropwise to the reaction mixture under nitrogen atmosphere. The reaction mixture was stirred at RT for 5 h. After consumption of starting material (TLC and LCMS), the reaction mixture was poured in ice-cold water and extracted with EtOAc (3×50 mL). The combined organic layer was washed with water (5×30 mL) and dried over anhydrous sodium sulfate, concentrated and purified by column chromatography (silica gel 100-200 mesh, eluent: 6% MeOH in DCM) to obtain 590 mg of 1-(3,4-dimethoxy-phenyl)-2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-ethanol. 1H NMR (CDCl3, freebase) δ (ppm): 7.19 (m, 2H), 6.98 (d, 1H), 6.83 (m, 2H), 6.78 (s, 1H), 4.98 (t, 1H), 4.1 (m, 2H), 4.83 (s, 3H), 4.8 (s, 3H), 3.6 (dd, 2H), 2.68-2.88 (m, 3H), 2.53 (m, 1H), 2.5 (s, 3H), 2.4 (s, 3H). Separation by chiral HPLC provides enantiomers 66a and 66b.
Example 65
Preparation of Compound Nos. 67, 67a and 67b
To a solution of 4-[2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-hydroxy-ethyl]-benzoic acid ethyl ester (800 mg, 2.04 mmol) in 5 mL EtOH was added sodium hydroxide (327 mg, 8.17 mmol, in 5 mL water) and heated to 65° C. After complete conversion of starting material (TLC and LCMS), the EtOH and water were removed under reduced pressure. The crude product was passed through HPLC to yield 600 mg of 4-[2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-hydroxy-ethyl]-benzoic acid. 1H NMR (DMSO, freebase) δ (ppm): 7.79 (d, 2H), 7.29 (s, 1H), 7.17 (d, 2H), 7.09 (s, 1H), 6.88 (d, 1H), 5.5 b (s, 1H), 4.82 (t, 1H), 4.12 (dd, 1H), 4.06 (dd, 1H), 3.44 (s, 2H), 3.16 (s, 2H), 2.71 (d, 1H), 2.56 (m, 2H), 2.36 s (7H). Separation by chiral HPLC provides enantiomers 67a and 67b.
Example 66
Preparation of Compound No. 68
To a solution of 2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (145 mg, 0.72 mmol) in DMF (2 mL) was added sodium hydride (87 mg, 2.1 mmol). After stirring for 10 min at RT, a solution of 4-(oxiran-2-yl)pyridine-N-oxide (149 mg, 1.08 mmol) was added into the reaction mixture, which was stirred at RT for 16 h. The reaction mixture was cooled to 0° C., quenched with ice water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and evaporated. The residue was triturated with ether to yield the title compound (20 mg). 1H NMR (CDCl3, Free base) δ (ppm): 8.2 (d, 2H), 7.71 (d, 2H), 7.25 (d, 1H), 6.99 (s, 2H), 5.22 (s, 2H), 3.64 (s, 2H), 2.85 (t, 2H), 2.7 (t, 2H), 2.56 (s, 3H), 2.42 (s, 3H).
Example 67
Preparation of Compound Nos. 69, 69a and 69b
To a solution of 2-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-1-(pyridin-4-yl) ethanol (450 mg, 2.25 mmol) in DMF (2 mL) was added sodium hydride (270 mg, 6.75 mmol). After stirring for 10 min at RT, a solution of 4-(oxiran-2-yl)pyridine-N-oxide (462 mg, 3.37 mmol) was added into the reaction mixture, and stirred at RT for 16 h. The reaction mixture was cooled to 0° C., quenched with ice water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and evaporated. The aqueous layer was also lyophilized to get crude product, which was submitted for reverse phase HPLC purification. (The organic layer had the keto compound, and the aqueous layer had the hydroxy compound). 1H NMR (CDCl3, freebase) δ (ppm): 7.83 (d, 2H), 7.04 (s, 1H), 6.91 (m, 4H), 4.72 (t, 1H), 4.01 (dd, 1H), 3.9 (m, 1H), 3.65 (m, 1H), 3.46 (d, 1H), 3.4 (d, 1H), 2.77(m, 1H), 2.6 (m, 1H), 2.4 (m, 1H), 2.39 (s, 6H). Separation by chiral HPLC provided enantiomers 69a and 69b.
Example 68
Preparation of Compound Nos. 70, 70a, 70b, 70c and 70d
To an ice-cooled stirred solution of 1-(2,3,4,5-tetrahydro-5-(2-hydroxy-2-(pyridin-4-yl)ethyl)-2-methyl-1H-pyrido[4,3-b]indol-8-yl)ethanone (600 mg, 1.72 mmol) in anhydrous THF (10 mL) was portionwise added LAH (163 mg, 4.3 mmol) and stirred at 0° C. for 30 min. The reaction mixture was quenched by adding water, 15% NaOH and again water. The reaction mixture was filtered, and the filtrate was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield the title compound. 1H NMR (CDCl3, freebase) δ (ppm): 8.45 (d, 2H), 7.3 (d, 1H), 7.19 (d, 2H), 7.14 (m, 2H), 4.9 (m, 2H), 4.09 (m, 2H), 3.82 (dd, 1H), 3.7 (dd, 1H), 3.07 (m, 2H), 2.9 (m, 1H), 2.7 (d, 1H), 2.57 (s, 3H), 1.51 (d, 3H). Separation by chiral HPLC provides enantiomers 70a, 70b, 70c and 70d.
Example 69
Preparation of Compound Nos. 71, 71a and 71b
2,4,4,8-Tetramethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.0 gm, 4.385 mmol) was dissolved in DMF (8 mL) and sodium hydride (0.526 g, 13.15 mmol) was added portionwise under nitrogen. 4-Oxiranyl-pyridine (0.9 g, 7.45 mmol) was diluted in DMF (2 mL) and added dropwise at RT and stirred for 4 h. After consumption of starting material (by monitoring TLC & LCMS), the reaction mixture was poured in to ice water, product was precipitated and filtered, and the residue was washed with water & hexane, dried under reduced pressure and crystallized in EtOH (10 mL) and diethyl ether (50 mL) to obtain 900 mg of 1-pyridin-4-yl-2-(2,4,4,8-tetramethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-ethanol. 1H NMR (CDCl3, freebase) δ (ppm): 8.62 (d, 2H), 7.37 (d, 2H), 7.31 (d, 1H), 7.19 (s, 1H), 7.01 (d, 1H), 5.22 (t, 1H), 4.32 (d, 1H), 3.6 (d, 1H), 3.48 (d, 1H), 2.65 b (s, 1H), 2.44 (s, 3H), 1.47 (s, 3H), 1.28 (s, 3H). Separation by chiral HPLC provides enantiomers 71a and 71b.
Example 70
Preparation of Compound Nos. 72, 72a and 72b
To a stirred solution of 2-(1,2,3,4-tetrahydro-8-methylpyrido[4,3-b]indol-5-yl)-1-(pyridin-4-yl)ethanol (300 mg, 0.977 mmol) and triethyl amine (0.18 mL, 1.27 mmol) in DCM (6 mL) was added ethyl chloroformate (138 mg, 1.27 mmol), and the reaction mixture stirred at RT for 2 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was diluted with DCM and washed with water. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by silica gel column chromatography (MeOH-DCM) to yield ethyl 3,4-dihydro-5-(2-hydroxy-2-(pyridin-4-yl)ethyl)-8-methyl-1H-pyrido[4,3-b]indole-2(5H)-carboxylate (170 mg). 1H NMR (CDCl3, freebase) δ (ppm): 8.4 (d, 2H), 7.21 (m, 4H), 7.0 (d, 1H), 5.03 (t, 1H), 4.6 (m, 2H), 4.21 (m, 4H), 3.78 (m, 2H), 3.6 (m, 1H), 2.75 (m, 1H), 2.4 (s, 3H), 1.28 (t, 3H). Separation by chiral HPLC provides enantiomers 72a and 72b.
Example 71
Preparation of Compound Nos. 73, 73a-73d
To a solution of carboline (1 g, 4.4 mmol) in 10 mL DMF, was added sodium hydride (528 mg, 13.2 mmol) under nitrogen at RT and stirred for 5 min. 4-Oxiranyl-pyridine (803 mg, 6.6 mmol) was diluted in DMF and added dropwise under nitrogen and the reaction mixture stirred at RT for 16 h. After the complete conversion of starting material (TLC and LCMS), the reaction mixture was poured in ice-cold water and extracted with EtOAc (3×40 mL). The combined organic layer was washed with water (6×30 mL) and dried over anhydrous sodium sulfate, concentrated and crude was crystallized in EtOH in ether to obtain 1.2 g of desired product. 1H NMR (CDCl3, freebase) δ (ppm): 8.59 (d, 1H), 8.58 (d, 1H), 7.38 (d, 1H), 7.24 (d, 1H), 7.20 (d, 1H), 7.08 (d, 1H), 7.0 (d, 1H), 5.0 (m, 1H), 4.62 (dd, 1H), 4.18 (m, 2H), 4.0 (m, 1H), 2.70 (m, 2H), 2.58 (m, 2H), 2.45 (s, 3H), 2.42 (s, 3H), 2.10 (m, 1H), 1.70 (m, 1H). Separation by chiral HPLC provides enantiomers 73a-73d.
Example 72
Preparation of Compound Nos. 74, 74a and 74b
To a solution of 10-methyl-2,3,5,6,7,11c-hexahydro-1H-pyrido[3′,2′:4,5]pyrrolo[2,3-g]indolizine (110 mg, 0.484 mmol) in DMF (1 mL) was added a suspension of NaH (60.0 mg, 1.45 mmol) in DMF (1 mL). After stirring for 5 min at RT, a solution of 2-(6-methylpyridin-3-yl)ethyl 4-methylbenzenesulfonate (423 mg, 1.45 mmol) in DMF (1 mL) was added dropwise into the reaction mixture and stirring continued for another 2 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (3×25 mL). The organic layer was washed with water (3×20 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude material, which was purified by reverse phase HPLC to yield 10-methyl-7-(2-(6-methylpyridin-3-yl)ethyl)-2,3,5,6,7,11c-hexahydro-1H-pyrido[3′,2′:4,5]pyrrolo[2,3-g]indolizine. 1H NMR (CD3OD, Tri-HCl salt) δ (ppm): 8.7 (s, 1H), 8.4 (d, 1H), 8.25 (s, 2H), 7.8 (d, 1H), 5.1 (m, 1H), 4.8-4.6 (m, 2H), 3.9-3.7 (m, 3H), 3.4 (m, 2H), 3.4-3.2 (m, 2H), 2.9-2.7 (m, 2H), 2.8 (s, 3H), 2.5 (s, 3H), 2.3-2.15 (m, 3H). Separation by chiral HPLC provided enantiomers 74a and 74b.
Example 73
Preparation of Compound Nos. 75, 75a, 75b, 75c and 75d
To a solution of 2-methyl-6,7,8,9,10,12-hexahydro-5H,6aH-indolo[2,3-b]quinolizine (1.0 g, 4.16 mmol) in 15 mL DMF, was added sodium hydride (500 mg, 12.49 mmol) under nitrogen at RT and stirred for 20 min. 4-Oxiranyl-pyridine (857 mg, 7.08 mmol) was added dropwise under nitrogen and the reaction mixture stirred at RT for 18 h. After the complete conversion of starting material (TLC and LCMS), the reaction mixture was poured in ice-cold water and extracted with EtOAc (3×80 mL). The combined organic layer was washed with water (5×50 mL) and dried over anhydrous sodium sulfate, concentrated and crude was crystallized in EtOH (1 mL) and ether (40 mL) to obtain 800 mg of desired product. 1H NMR (CDCl3, freebase) δ (ppm): 8.54 (d, 2H), 7.22 (d, 2H), 7.102 (s, 1H), 7.00 (d, 1H), 6.92 (d, 1H), 4.78 (t, 1H), 4.02 (m, 2H), 3.81 (d, 1H), 3.26 (d, 1H), 2.99 (d, 1H), 2.7 (dd, 1H), 2.5 (d, 1H), 2.43 (s, 3H), 2.23 (m, 2H), 1.89 (d, 1H), 1.81 (d, 1H), 1.69 (m, 2H), 1.5 (q, 1H), 1.35 (t, 1H). This racemate was separated by semi-preparative chiral HPLC separation to give enantiomers 75a, 75b, 75c and 75d.
Example 74
Preparation of Compound Nos. 76, 76a, 76b, 76c and 76d
To a solution of 7-methyl-2,3,5,10,11,11a-hexahydro-1H-indolizino[7,6-b]indole (200 mg, 0.88 mmol) in DMF (2 mL) was added NaH (106 mg, 2.65 mmol). After stirring for 5 min, a solution of 4-(oxiran-2-yl)pyridine (161 mg, 1.32 mmol) in DMF was added into the reaction mixture, which was stirred at RT for 16 h. The reaction mixture was quenched with ice-water and extracted with EtOAc. The organic layer was dried over anhydrous sodium sulfate, concentrated and the residue obtained was purified by reverse phase HPLC to yield the title compound. 76a: 1H NMR (CDCl3, freebase) δ (ppm): 8.6 (d, 2H), 7.26 (d, 2H), 7.21 (s, 1H), 7.15 (d, 1H), 7.0 (d, 1H), 5.0 (dd, 1H), 4.2 (m, 3H), 3.29 (m, 2H), 2.7 (s, 2H), 2.42 (s, 3H), 2.4 (q, 1H), 2.1 (m, 1H), 2.0 (m, 1H), 1.85 (m, 1H), 1.62 (m, 2H). 76b: 1H NMR (CDCl3, freebase) δ (ppm): 8.53 (d, 2H), 7.24 (d, 2H), 7.17 (s, 1H), 7.14 (d, 1H), 6.97 (d, 1H), 4.95 (d, 1H), 4.10 (m, 3H), 3.28 (m, 2H), 3.0 (d, 1H), 2.49 (m, 2H), 2.44 (s, 3H), 2.37 (q, 1H), 2.11 (m, 1H), 1.97 (m, 1H), 1.87 (m, 1H), 1.63 (m, 1H). 76c: 1H NMR (CDCl3, freebase) δ (ppm): 8.5 (d, 2H), 7.17 (d, 2H), 7.06 (s, 1H), 6.97 (d, 1H), 6.9 (d, 1H), 4.76 (t, 1H), 4.0 (m, 2H), 3.9 (d, 1H), 3.19 (d, 1H), 3.13 (t, 1H), 2.67 (q, 2H), 2.42 (s, 3H), 2.39 (m, 1H), 2.28 (q, 1H), 2.08 (t, 1H), 1.93 (m, 1H), 1.86 (m, 1H), 1.64 (m, 1H). 76d: 1H NMR (CDCl3, freebase) δ (ppm): 8.53 (d, 2H), 7.24 (d, 2H), 7.17 (s, 1H), 7.14 (d, 1H), 6.97 (d, 1H), 4.95 (d, 1H), 4.10 (m, 3H), 3.28 (m, 2H), 3.0 (d, 1H), 2.49 (m, 2H), 2.44 (s, 3H), 2.37 (q, 1H), 2.11 (m, 1H), 1.97 (m, 1H), 1.87 (m, 1H), 1.63 (m, 1H).
Example 75
Preparation of Compound No. 77
A solution of 5-(2-bromocyclopent-1-enyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg, 0.29 mmol), 1H-pyrazole-4-boronic acid (75 mg, 0.580 mmol) and potassium carbonate (120 mg, 0.87 mmol) in 1,2-DME (4 mL)-water (2 mL) was purged with nitrogen. Pd(PPh3)4 (16 mg, 0.0147 mmol) was added and the reaction mixture was heated at 90° C. for 45 min. The reaction mixture concentrated under vacuum, residue diluted with water (20 mL) and extracted with EtOAc (50 mL). The organic layer was dried over anhydrous sodium sulfate, concentrated under vacuum to obtain crude which was purified by reverse phase HPLC to yield 5-(2-(1H-pyrazol-4-yl)cyclopent-1-enyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.38 (s, 1H), 7.0 (m, 2H), 6.4 (m, 2H), 4.7 (m, 1H), 4.4 (m, 1H), 3.78 (m, 1H), 3.42 (m, 1H), 3.11 (m, 4H), 2.6-3.0 (m, 5H), 2.4 (s, 3H), 2.2 (m, 2H).
Example 76
Preparation of Compound No. 78
To a degassed solution of 3,6-dimethyl-6,7,8,9-tetrahydro-5H-1,6,9-triaza-fluorene (201 mg, 1.00 mmol), potassium phosphate (466 mg, 2.20 mmol), L-proline (19 mg, 0.10 mmol) and copper iodide (23 mg, 0.20 mmol) in DMF (2 mL) was added 4-(2-bromo-1-methyl-vinyl)-pyridine (424 mg, 2.00 mmol). The reaction mixture was stirred at 120° C. for 20 h. The progress of reaction was monitored by TLC and LCMS. The reaction was monitored by TLC and LCMS. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (3×10 mL). The organic layer was washed with water (3×20 mL), followed by brine (25 mL), dried over anhydrous sodium sulfate and evaporated to afford crude material, which was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 9.0 (s, 1H), 8.8 (d, 1H), 8.2 (s, 1H), 8.0 (t, 2H), 7.3 (s, 1H), 4.8 (bs, 1H), 4.4 (bs, 1H), 3.9 (bs, 1H), 3.6 (bs, 1H), 3.2 (bs, 2H), 3.18 (s, 3H), 2.8 (s, 3H), 2.5 (s, 3H), 2.06 (s, 3H).
Example 77
Preparation of Compound No. 79
2-Allyl-8-methyl-5-(2-(pyridin-4-yl)vinyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (50 mg, 0.151 mmol) was dissolved in DCM (2 mL), which was degassed with nitrogen for 15 min. To this was added Pd(PPh3)4 (4 mg, 0.002 mmol) followed by 1,3-dimethyl barbituric acid (71 mg, 0.454 mmol). The reaction mixture was again degassed by nitrogen for 15 min. The resultant mixture was stirred at RT for 1 h. DCM was evaporated in vacuo. EtOAc (20 mL) was added to reaction mixture and was washed with saturated potassium carbonate solution (3×1 mL). The organic layer was dried over anhydrous sodium sulfate, evaporated in vacuo and purified by reverse phase HPLC to obtain 2 mg of 8-methyl-5-(2-(pyridin-4-yl)vinyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR (CD3OD, Free base): δ (ppm): 8.45 (d, 2H), 8.0 (d, 1H), 7.7 (d, 1H), 7.58 (d, 2H), 7.3 (s, 1H), 7.19 (d, 1H), 6.8 (d, 1H), 4.29 (s, 2H), 3.42 (m, 2H), 3.2 (m, 2H), 2.4 (s, 3H).
Example 78
Preparation of Compound No. 80
To a degassed solution of trifluoro-methanesulfonic acid 2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-methyl-vinylester (200 mg, 0.515 mmol), potassium carbonate (214 mg, 1.550 mmol) and 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole (150 mg, 0.773 mmol) in DME:water (2:1 mL) was added Pd(PPh3)4 (30 mg, 0.025 mmol) and the reaction mixture stirred at 90° C. for 1.5 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was diluted with water (25 mL) and extracted with EtOAc (2×25 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography followed by reverse phase HPLC to yield the desired product. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.3 (s, 1H), 7.08 (d, 1H), 7.0 (d, 1H), 6.92 (s, 2H), 6.5 (s, 1H), 4.76 (d, 1H), 4.39 (d, 1H), 3.75 (m, 1H), 3.43 (m, 1H), 3.05 (s, 3H), 2.9 (m, 2H), 2.41 (s, 3H), 2.25 (s, 3H).
Example 79
Preparation of Compound Nos. 81, 81a and 81b
To a solution of 8-isopropyl-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.0 g, 4.38 mmol) in DMF (20 mL) was added sodium hydride (526 mg, 13.14 mmol) and the suspension was stirred at RT for 10 min. A solution of 4-(oxiran-2-yl)pyridine (1.0 g, 8.26 mmol) in DMF (5 mL) was added dropwise, and stirring was continued overnight. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was poured into ice cold water (200 mL) and extracted with EtOAc (3×200 mL). The organic layer was washed with water (4×300 mL), dried over anhydrous sodium sulfate and concentrated. The residue obtained was triturated with diethyl ether (200 mL) to yield the desired product. 1H NMR (CDCl3, freebase) δ (ppm): 8.58 (d, 2H), 7.21 (d, 2H), 7.18 (d, 2H), 7.03 (d, 1H), 4.81 (t, 1H), 4.05 (d, 2H), 3.55 (dd, 2H), 3.0 (q, 1H), 2.82 (m, 1H), 2.7 (m, 2H), 2.6 (m, 1H), 2.4 (s, 3H), 1.3 (d, 6H). Separation by chiral HPLC provides enantiomers 81a and 81b.
Example 80
Preparation of Compound Nos. 82, 82a and 82b
To a solution of 2,6-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.0 g, 5.00 mmol) in DMF (10 mL) was added sodium hydride (600 mg, 15 mmol) under nitrogen atmosphere at 0° C. and stirred for 10 min. 4-(Oxiran-2-yl)pyridine (1.08 g, 8.92 mmol) was added dropwise under nitrogen atmosphere. The reaction mixture was stirred at RT for 12 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was poured in ice-cold water and extracted with EtOAc (2×100 mL). The combined organic layer was washed with water (5×50 mL), dried over anhydrous sodium sulfate and concentrated. The residue was crystallized with diethyl ether to yield 2-(2,6-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethanol. 1H NMR (CDCl3, freebase) δ (ppm): 8.58 (d, 2H), 7.23 (m, 3H), 7.0 (t, 1H), 6.9 (d, 1H), 4.81 (t, 1H), 4.3-4.4 (m, 2H), 3.5 (dd, 2H), 3.0 (m, 1H), 2.8 (m, 1H), 2.75 (s, 3H), 2.7 (m, 1H), 2.6 (m, 1H), 2.43 (s, 3H). Separation by chiral HPLC provides enantiomers 82a and 82b.
Example 81
Preparation of Compound No. 83
2,8-Dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (2 g, 10 mmol) was dissolved in 20 mL of DMF. The resulting solution was cooled in an ice-water bath and sodium hydride (840 mg, 4.2 mmol) was added under nitrogen atmosphere. 2-Bromomethyl-2-phenyl[1,3]dioxolane (2.43 g, 10 mmol) was added and the reaction mixture was heated at 100° C. overnight. Water was added and the product was extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with 0-5% MeOH:DCM.
Example 82
Compound Nos. 84, 85, 86, 89, 90, 90a, 90b and 91 were synthesized as described in PCT publication WO-2009/055828; see, for example, synthetic procedures 20, 23, 87, 178 and 274.
Example 83
Compound Nos. 87 and 88 were synthesized as described in PCT publication WO-2009/094668; see, for example, synthetic procedures 71 and 72.
Example 84
Compound Nos. 95,95a-b, 97 and 97a-b were synthesized as described in PCT publication WO-2009/120720; see, for example, synthetic procedures 109 and 115.
Example 85
Compound Nos. 96 and 96a-b were synthesized as described in PCT publication WO-2009/120717; see, for example, synthetic procedure 131.
Example 86
Compound Nos. 93,93a-b, 98,98a-b, 100, 101, 103, 105, 107 and 132 were synthesized as described in PCT publication WO-2010/051501; see, for example, synthetic procedures 45, 131, 199, 241, 273, 329, 341, 354 and 401.
Example 87
Compound Nos. 92, 99 and 106 were synthesized as described in PCT publication WO-2010/051503; see, for example, synthetic procedures 41, 147 and 168.
Example 88
Compound No. 94 was synthesized as described in PCT publication WO-2010/127177; see, for example, synthetic procedure 6.
Example 89
Compound Nos. 102 and 102a-b were synthesized as described in PCT publication WO-2011/019417; see, for example, synthetic procedure 9.
Example 90
Preparation of Compound No. 108
To a degassed solution of [(E,Z)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl trifluoromethanesulfonate] (50 mg, 0.128 mmol), potassium carbonate (17.8 mg, 0.1287 mmol) and 1-methyl-1H-pyrazole-5-boronic acid pinacol ester (53.5 mg, 0.2574 mmol) in DME-water (2 mL:1 mL) was added Pd(PPh3)4 (7.4 mg, 0.0064) and the reaction mixture was heated to reflux for 2.5 h. The reaction mixture was cooled to RT and the solvent was removed under reduced pressure. The residue was diluted with water and extracted with EtOAc. The organic layer was washed with brine, and concentrated under reduced pressure. The residue was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.58 (d, 1H), 7.26 (d, 1H), 7.18 (m, 2H), 6.93 (s, 1H), 6.45 (s, 1H), 4.78 (d, 1H), 4.39 (d, 1H), 4.02 (s, 3H), 3.86 (m, 1H), 3.59 (m, 1H), 3.23 (m, 1H), 3.18 (m, 4H), 2.42 (s, 3H), 1.87 (s, 3H).
Example 91
Preparation of Compound No. 109
To a degassed solution of [(E,Z)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl trifluoromethanesulfonate] (100 mg, 0.257 mmol), 1-methylpyrazole-4-boronic acid pinacol ester (108 mg, 0.515 mmol) and potassium carbonate (36 mg, 0.257 mmol) in DME-water (4:2 mL) was added Pd(PPh3)4 (15 mg, 0.0128) and the reaction mixture was heated to reflux for 45 min. The reaction mixture was cooled to RT, and the solvent was removed under reduced pressure. The residue was diluted with water and extracted with EtOAc. The organic layer was washed with brine, and concentrated under reduced pressure. The residue was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.92 (s, 1H), 7.89 (s, 1H), 7.26 (s, 1H), 7.16 (m, 2H), 6.98 (s, 1H), 4.78 (d, 1H), 4.37 (d, 1H), 3.85 (s, 3H), 3.82 (m, 1H), 3.58 (m, 1H), 3.18 (s, 3H), 3.13 (m, 2H), 2.43 (s, 3H), 1.82 (s, 3H).
Example 92
Preparation of Compound No. 110
To a degassed solution of [(E,Z)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl trifluoromethanesulfonate] (100 mg, 0.257 mmol), 3,5-dimethylisoxazole-4-boronic acid pinacol ester (115 mg, 0.515 mmol) and potassium carbonate (36 mg, 0.257 mmol) in DME-water (4:2 mL) was added Pd(PPh3)4 (15 mg, 0.0128) and the reaction mixture was heated to reflux for 45 min. The reaction mixture was cooled to RT, and the solvent was removed under reduced pressure. The residue was diluted with water and extracted with EtOAc. The organic layer was washed with brine, and concentrated under reduced pressure. The residue was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.27 (s, 1H), 7.17 (m, 2H), 6.61 (s, 1H), 4.78 (d, 1H), 4.39 (d, 1H), 3.83 (m, 1H), 3.60 (m, 1H), 3.02-3.23 (m, 5H), 2.31-2.60 (m, 9H), 1.81 (s, 3H).
Example 93
Preparation of Compound No. 111
To a solution of [(E,Z)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl trifluoromethanesulfonate] (100 mg), potassium carbonate (36 mg), and 2-acetamidopyridine-5-boronic acid pinacol ester (135 mg) in DME-water (4:2 mL) was added Pd(PPh3)4 (15 mg) and the reaction mixture was heated to reflux for 45 min. The reaction mixture was cooled to RT, and the solvent was removed under reduced pressure. The residue was diluted with water and extracted with EtOAc. The organic layer was washed with brine, and concentrated under reduced pressure. The residue was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.91 (s, 1H), 7.68 (d, 1H), 7.58 (d, 1H), 7.21 (s, 1H), 7.10 (d, 1H), 6.98 (d, 1H), 6.91 (s, 1H), 4.61 (d, 1H), 4.30 (d, 1H), 3.71 (m, 1H), 3.40 (m, 1H), 3.07 (s, 3H), 2.90 (m, 2H), 2.38 (m, 6H), 2.16 (s, 3H).
Example 94
Preparation of Compound No. 112
To a solution of [(E,Z)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl trifluoromethanesulfonate] (100 mg), potassium carbonate (36 mg), and 2-acetamidopyridine-5-boronic acid pinacol ester (135 mg) in DME-water (4:2 mL) was added Pd(PPh3)4 (15 mg) and the reaction mixture was heated to reflux for 45 min. The reaction mixture was cooled to RT, and the solvent was removed under reduced pressure. The residue was diluted with water and extracted with EtOAc. The organic layer was washed with brine, and concentrated under reduced pressure. The residue was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.58 (s, 1H), 8.35 (d, 1H), 7.96 (d, 1H), 7.30 (s, 1H), 7.11 (m, 3H), 4.37 (d, 1H), 4.40 (d, 1H), 3.83 (m, 1H), 3.58 (m, 1H), 3.12 (m, 5H), 2.42 (s, 3H), 2.21 (s, 3H), 2.0 (s, 3H).
Example 95
Preparation of Compound No. 113
To a degassed solution of [(E,Z)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl trifluoromethanesulfonate] (100 mg, 0.257 mmol), potassium carbonate (36 mg, 0.257 mmol) and naphthalene-1-boronic acid (88 mg, 0.515 mmol) in DME-water (4:2 mL) was added Pd(PPh3)4 (15 mg, 0.0128 mmol) and the reaction mixture was heated to reflux for 45 min. The reaction mixture was cooled to RT, and the solvent was removed under reduced pressure. The residue was diluted with water and extracted with EtOAc. The organic layer was washed with brine and concentrated under reduced pressure. The residue was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.18 (d, 1H), 7.84-7.98 (m, 2H), 7.51-7.62 (m, 4H), 7.38 (m, 2H), 7.18 (d, 1H), 6.78 (s, 1H), 4.67 (m, 1H), 4.42 (m, 1H), 3.81 (m, 1H), 3.63 (m, 1H), 3.24 (m, 1H), 3.21 (s, 3H), 3.19 (m, 1H), 2.47 (s, 3H), 2.12 (s, 3H).
Example 96
Preparation of Compound No. 114
To a degassed solution of 5-(2-bromocyclopent-1-enyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (120 mg, 0.348 mmol), 4-pyridineboronic acid (85 mg, 0.69 mmol) and potassium carbonate (144 mg, 1.04 mmol) in DME-water (4:2 mL) was added Pd(PPh3)4 (20 mg, 0.0174 mmol) and the reaction mixture was heated to reflux for 45 min. The reaction mixture was cooled to RT, and the solvent was removed under reduced pressure. The residue was diluted with water and extracted with EtOAc. The organic layer was washed with brine and concentrated under reduced pressure. The residue was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.52 (d, 2H), 7.40 (m, 2H), 7.36 (s, 1H), 6.92-7.15 (m, 2H), 4.78 (d, 1H), 4.40 (d, 1H), 3.80 (m, 1H), 3.51 (m, 1H), 3.20 (m, 6H), 2.80-3.00 (m, 3H), 2.41 (s, 3H), 2.37 (m, 2H).
Example 97
Preparation of Compound No. 115
To a degassed solution of (E,Z)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl trifluoromethanesulfonate (100 mg, 0.257 mmol), potassium carbonate (110 mg, 0.77 mmol) and 1H-pyrazole-4-boronic acid (60 mg, 0.540 mmol) in DME-water (2:1 mL) was added Pd(PPh3)4 (20 mg, 0.017 mmol) and the reaction mixture was heated to reflux for 45 min. The reaction mixture was cooled to RT, and the solvent was removed under reduced pressure. The residue was diluted with water and extracted with EtOAc. The organic layer was washed with brine and concentrated under reduced pressure. The residue was purified by reverse phase HPLC.
1H NMR (CD3OD, TFA salt) δ (ppm): 8.0 (s, 2H), 7.27 (s, 1H), 7.0-7.11 (m, 3H), 4.7 (d, 1H), 4.37 (d, 1H), 3.82 (m, 1H), 3.56 (m, 1H), 3.01-3.22 (m, 5H), 2.41 (s, 3H), 1.80 (s, 3H).
Example 98
Preparation of Compound No. 116
To a de-aerated solution of 8-chloro-5-(2-chloroallyl)-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (200 mg, 0.680 mmol) and potassium carbonate (281 mg, 2.039 mmol) in 1,2-dimethoxyethane-water (2:1) were added pyridine-4-boronic acid (167.2 mg, 1.36 mmol) and Pd(PPh3)4 (53 mg, 0.045 mmol). The reaction mixture was stirred at 90° C. for 45 min. The reaction mixture was concentrated under reduced pressure to dryness. The residue obtained was dissolved in EtOAc (50 mL) and washed with water (20 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude product, which was purified by reverse phase HPLC. 1H NMR (CDCl3, freebase) δ (ppm): 8.6 (d, 2H), 7.4 (s, 1H), 7.3 (d, 2H), 7.1 (s, 2H), 5.57 (s, 1H), 4.98 (s, 2H), 4.58 (s, 1H), 3.82 (s, 2H), 3.05 (t, 2H), 2.82 (t, 2H), 2.6 (s, 3H).
Example 99
Preparation of Compound No. 117
To a degassed solution of 5-(5-fluoro-pyridin-3-ylethynyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (60 mg, 0.188 mmol) in MeOH (3 mL) were added 10% dry Pd—C (35 mg) and ammonium formate (59 mg, 0.940 mmol). The reaction mixture was stirred at 75° C. for 1 h. The reaction mass was filtered through Celite and the filtrate concentrated under reduced pressure to afford crude product, which was purified by reverse phase HPLC to yield 5-[2-(5-fluoro-pyridin-3-yl)-ethyl]-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.3 (s, 1H), 7.9 (s, 1H), 7.38 (d, 1H), 7.21 (s, 1H), 7.2 (d, 1H), 7.0 (d, 1H), 4.62 (d, 1H), 4.4 (t, 2H), 4.3 (d, 1H), 3.78 (m, 1H), 3.4 (m, 1H), 3.18 (t, 2H), 3.1 (s, 3H), 2.9 (m, 1H), 2.8 (m, 1H), 2.4 (s, 3H).
Example 100
Preparation of Compound No. 118
A mixture of 5-ethynyl-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (300 mg, 1.33 mmol), 1H-imidazole (182 mg, 2.66 mmol), TBAF.3H2O (1.2 g, 3.80 mmol) and dichloro bis(triphenylphosphine) palladium (II) (47 mg, 0.06 mmol) was heated at 85° C. for 30 min. The reaction mixture was cooled to RT, diluted with water and extracted with EtOAc (3×25 mL). The organic layer was washed with water (3×25 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel chromatography (100-200 mesh) eluting with 4% MeOH-DCM to yield 90 mg of 5-(1-imidazol-1-yl-vinyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. The free base was converted into the di-HCl salt by treatment with ethanolic HCl. 1H NMR (CD3OD, D1-HCl salt) δ (ppm): 9.21 (s, 1H), 7.78 (d, 2H), 7.38 (s, 1H), 7.1 (d, 1H), 6.92 (d, 1H), 6.21 (d, 1H), 5.75 (d, 1H), 4.7 (d, 1H), 4.4 (d, 1H), 3.83 (m, 1H), 3.6 (m, 1H), 3.18 (m, 5H), 2.4 (s, 3H).
Example 101
Preparation of Compound No. 119
To a solution of 2-methyl-7-trifluoromethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg, 0.393 mmol) in DMF (2 mL) were added sodium hydride (60 mg, 1.17 mmol) and 2-(6-methylpyridin-3-yl)ethyl 4-methylbenzenesulfonate (300 mg, 0.98 mmol). The reaction mixture was irradiated in a microwave reactor at 90° C. for 1 h. The reaction mixture was cooled to RT and quenched with water and extracted with EtOAc (3×10 mL). The organic layer was washed with water (10 mL×2), dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude product, which was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.21 (s, 1H), 8.07 (d, 1H), 7.6 (dd, 2H), 7.28 (m, 2H), 4.78 (d, 1H), 4.6 (t, 2H), 4.4 (d, 1H), 3.9 (m, 1H), 3.6 (m, 1H), 3.2-3.4 (m, 4H), 3.18 (s, 3H), 2.6 (s, 3H).
Example 102
Preparation of Compound No. 120
To a solution of 2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (200 mg, 1.00 mmol) and 2-aminopyridine (188 mg, 2.00 mmol) in DCM (2 mL) was added powdered KOH (392 mg, 7.00 mmol), and the reaction mixture was stirred at 85° C. for 2 h. The progress of reaction was monitored by TLC and LCMS. DCM was removed under reduced pressure. Water was added to the residue and extracted with EtOAc (2×50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated to afford crude material, which was purified by reverse phase HPLC to yield (2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-ylmethyl)-pyridin-2-yl-amine. 1H NMR (CDCl3, freebase) δ (ppm): 8.1 (d, 1H), 7.38 (m, 2H), 7.18 (s, 1H), 7.0 (d, 1H), 6.6 (t, 1H), 6.3 (d, 1H), 5.57 (s, 2H), 5.26 (bs, 1H), 3.8 (s, 2H), 3.1 (t, 2H), 3.0 (t, 2H), 2.6 (s, 3H), 2.4 (s, 3H).
Example 103
Preparation of Compound No. 121
To a de-aerated solution of 5-(2-chloroallyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (150 mg, 0.547 mmol) and potassium carbonate (226 mg, 1.64 mmol) in 1,2-dimethoxyethane-water (2:1) were added pyridine-4-boronic acid (135 mg, 1.09 mmol) and Pd(PPh3)4 (44 mg, 0.0383 mmol). The reaction mixture was stirred at 90° C. for 45 min. The reaction mixture was cooled to RT and concentrated under reduced pressure to dryness. The residue obtained was dissolved in EtOAc (50 mL) and washed with water (20 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude product, which was purified by reverse phase HPLC as a TFA salt. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.8 (d, 2H), 8.2 (d, 2H), 7.3 (m, 2H), 7.05 (d, 1H), 6.0 (s, 1H), 5.3 (d, 2H), 4.8 (s, 1H), 4.7 (d, 1H), 4.37 (d, 1H), 3.86 (m, 1H), 3.6 (m, 1H), 3.17 (m, 2H), 3.1 (s, 3H), 2.43 (s, 3H).
Example 104
Preparation of Compound No. 122
To a degassed solution of (E,Z)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl trifluoromethanesulfonate (100 mg, 0.257 mmol) and potassium carbonate (110 mg, 0.796 mmol), in DME (2 mL) and water (1 mL) were added Pd(PPh3)4 (20 mg, 0.017 mmol) and N-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinamide (135 mg, 0.514 mmol) and the reaction mixture was heated to reflux for 45 min. The reaction mixture was cooled to RT, and the solvent was removed under reduced pressure. The residue was diluted with water and extracted with EtOAc. The organic layer was washed with brine and concentrated under reduced pressure. The residue was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.9 (s, 1H), 8.1-8.21 (m, 2H), 7.3 (s, 1H), 7.19 (s, 1H), 7.1 (m, 2H), 4.76 (d, 1H), 4.4 (d, 1H), 3.82 (bs, 1H), 3.6 (bs, 1H), 3.2 (m, 2H), 3.17 (s, 3H), 3.0 (s, 3H), 2.42 (s, 3H), 2.0 (s, 3H).
Example 105
Preparation of Compound No. 124
To a degassed solution of 3,6-dimethyl-6,7,8,9-tetrahydro-5H-1,6,9-triaza-fluorene (201 mg, 1.00 mmol), potassium phosphate (466 mg, 2.20 mmol), L-proline (19 mg, 0.10 mmol) and copper iodide (23 mg, 0.20 mmol) in DMF (2 mL) was added 4-(2-bromo-1-methyl-vinyl)-pyridine (396 mg, 2.00 mmol). The reaction mixture was stirred at 120° C. for 16 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (3×10 mL). The organic layer was washed with water (3×20 mL), followed by brine (25 mL), dried over anhydrous sodium sulfate and evaporated to afford crude material, which was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.8 (bs, 2H), 8.22 (d, 2H), 8.18 (s, 1H), 7.8 (s, 1H), 7.6 (s, 1H), 4.76 (bs, 1H), 4.4 (bs, 1H), 3.82 (bs, 1H), 3.6 (bs, 1H), 3.21 (bs, 2H), 3.1 (s, 3H), 2.42 (s, 3H), 2.1 (s, 3H).
Example 106
Preparation of Compound No. 125
To a stirred solution of (E)-5-(2-(6-(methoxymethyl)pyridin-3-yl)prop-1-en-1-yl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (90 mg, 0.249 mmol) in dry DCM (3 mL) was dropwise addition of solution of BBr3 (0.3 mL, 1.745 mmol) in dry DCM (2 mL) at −78° C. and the reaction mixture was stirred at −78° C. for 2 h. The solvent was removed under reduced pressure. The residue was basified with saturated sodium bicarbonate solution and extracted with DCM (3×20 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude product, which was purified by reverse phase HPLC to yield (E)-(5-(1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl)pyridin-2-yl)methanol as the TFA salt. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.9 (s, 1H), 8.77 (d, 1H), 8.0 (d, 1H), 7.4 (s, 1H), 7.3 (s, 1H), 7.17 (d, 1H), 7.1 (d, 1H), 5.1 (d, 1H), 5.0 (s, 2H), 4.6 (d, 1H), 4.1 (m, 2H), 3.17 (s, 3H), 3.1 (bs, 2H), 2.42 (s, 3H), 2.1 (s, 3H).
Example 107
Preparation of Compound No. 126
To a degassed solution of (Z)-2,8-dimethyl-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prop-1-en-1-yl)-2,3,4,5-tetrahydro-1H-pyrido[4,3b]indole (271 mg, 0.742 mmol), 5-bromo-2-(methoxymethyl)pyridine (100 mg, 0.495) and potassium carbonate (204 mg, 1.485 mmol) in DME-water (2:1 mL) and was added Pd(PPh3)4 (40.0 mg, 0.034 mmol), and the reaction mixture was heated to reflux for 45 min. The reaction mixture was cooled to RT, and the solvent was removed under reduced pressure. The residue was diluted with water and extracted with EtOAc. The organic layer was washed with brine and concentrated under reduced pressure. The residue was purified by reverse phase HPLC. 1H NMR (CD3OD, D1-HCl salt) δ (ppm): 9.0 (s, 1H), 8.84 (d, 1H), 8.05 (d, 1H), 7.42 (s, 1H), 7.3 (s, 1H), 7.15 (d, 1H), 7.1 (d, 1H), 4.9 (s, 2H), 4.78 (d, 1H), 4.4 (d, 1H), 3.82 (bs, 1H), 3.6 (s, 3H), 3.58 (bs, 1H), 3.2 (bs, 2H), 3.1 (s, 3H), 2.43 (s, 3H), 2.1 (s, 3H).
Example 108
Preparation of Compound Nos. 127 and 127a-d
To an ice-cooled stirred suspension of 4-bromopyridine hydrochloride salt (1.0 g, 5.1 mmol) in THF (5 mL) was added isopropyl magnesium chloride (2M in THF, 5 mL, 10.3 mmol) and stirred the reaction at RT for 30 min. A solution of 2-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)propanal (300 mg, 1.17 mmol) in THF (3 mL) was added into the brown colored reaction mixture, which was stirred at RT for 1.5 h. The progress of reaction was monitored by TLC and LCMS (45% conversion). The reaction mixture was cooled to 0° C. and quenched with cold saturated ammonium chloride solution (till effervescence stops) and added water, stirred at RT for 15 min and extracted with EtOAc. The organic layer was dried over anhydrous sodium sulfate and evaporated. The residue was purified by reverse phase HPLC. The product was further purified, and enantiomers separated, by chiral preparative HPLC. 1H NMR (CDCl3, freebase) δ (ppm): 8.20 (d, 2H), 7.1 (s, 1H), 7.06 (s, 1H), 6.86 (d, 1H), 6.8 (s, 2H), 4.85 (s, 1H), 4.2 (s, 1H), 3.49 (d, 1H), 3.39 (d, 1H), 2.61 (d, 2H), 2.41 (s, 3H), 2.33 (s, 3H), 1.56 (s, 3H). Separation by chiral HPLC provided diastereomers 127a-d.
Example 109
Preparation of Compound Nos. 128 and 128a-b
A solution of tert-butyl 9-(2-hydroxy-2-(pyridin-3-yl)propyl)-6-methyl-3,4-dihydro-1H-pyrido[3,4-b]indole-2(9H)-carboxylate (350 mg) in 3M aqueous HCl solution (10 mL) was stirred at RT for 1 h. The progress of reaction was monitored with TLC and LCMS. The reaction mixture was lyophilized and the solid obtained was washed with diethyl ether (2×30 mL), dried to yield the title compound. The product was further purified, and enantiomers separated, by chiral preparative HPLC. 1H NMR (CD3OD, HCl salt) δ (ppm): 8.67 (d, 1H), 8.6 (d, 1H), 8.54 (s, 1H), 7.9 (t, 1H), 7.2 (s, 1H), 6.8 (d, 1H), 6.7 (s, 1H), 4.98 (d, 1H), 4.6 (d, 1H), 4.4 (q, 2H), 3.62 (t, 2H), 3.07 (m, 2H), 2.32 (s. 3H), 1.8 (s, 3H). Separation by chiral HPLC provided enantiomers 128a and 128b.
Example 110
Preparation of Compound Nos. 129 and 129a-d
To a solution of 9-methyl-2,3,4,5,6,10c-hexahydro-1H-3a,6-diaza-cyclopenta[c]fluorene (100 mg, 0.442 mmol) in DMF (2 mL) was added sodium hydride (60%, 53 mg, 1.32 mmol,) at 0° C. After stirring for 5 min, 4-oxiranyl-pyridine (81 mg, 0.669 mmol) was added at 0° C. and the mixture stirred at RT for 12 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was poured into ice-cold water and extracted with EtOAc (2×25 mL). The combined organic layer was washed with water (5×25 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to compound 129 (90 mg), which was separated by chiral prep HPLC to give compounds 129a, 129b, 129c and 129d. Compound 129a: 1HNMR (CDCl3, freebase) δ (ppm): 8.58 (d, 2H), 7.25 (m, 4H), 7.04 (d, 1H), 5.08 (t, 1H), 4.3 (bs, 1H), 4.18 (d, 2H), 3.3 (d, 1H), 3.07 (m, 2H), 2.85 (m, 2H), 2.6 (m, 1H), 2.42 (m, 1H), 2.4 (s, 3H), 2.01 (m, 3H), 1.82 (m, 1H). Compound 129b: 1HNMR (CDCl3, freebase) δ (ppm): 8.55 (d, 2H), 7.25 (m, 4H), 7.0 (d, 1H), 5.0 (t, 1H), 4.3 (bs, 1H), 4.19 (m, 2H), 3.32 (d, 1H), 3.0 (m, 4H), 2.5 (m, 2H), 2.45 (s, 3H), 2.0 (m, 2H), 1.9 (m, 1H). Compound 129c: 1HNMR (CDCl3, freebase) δ (ppm): 8.6 (d, 2H), 7.25 (m, 4H), 7.0 (d, 1H), 5.05 (t, 1H), 4.2 (m, 2H), 3.9 (t, 1H), 3.3 (m, 1H), 2.91 (m, 2H), 2.8 (t, 1H), 2.7 (q, 1H), 2.43 (s, 3H), 2.4 (m, 2H), 1.9 (m, 3H). Compound 129d: 1HNMR (CDCl3, freebase) δ (ppm): 8.58 (d, 2H), 7.25 (m, 4H), 7.04 (d, 1H), 5.08 (t, 1H), 4.3 (bs, 1H), 4.18 (d, 2H), 3.3 (d, 1H), 3.07 (m, 2H), 2.85 (m, 2H), 2.6 (m, 1H), 2.42 (m, 1H), 2.4 (s, 3H), 2.01 (m, 3H), 1.82 (m, 1H).
Example 111
Preparation of Compound Nos. 130 and 130a-b
To an ice-cooled stirred solution of 2-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(pyridin-4-yl)ethanol (50 g, 155.76 mmol) in DMF (300 mL) was added NaH (60%, 12.5 g, 312.5 mmol). After stirring at RT for 15 min, pivaloyl chloride (37.38 g, 311.5 mmol) was added dropwise into the reaction mixture, which was stirred at RT for 1 h. The reaction was quenched with EtOH and diluted with ice water. The product was extracted with EtOAc, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was passed through a silica gel filter column to remove excess pivaloyl chloride and yield title compound as yellow solid (22.3 g). The product was further purified by chiral preparative HPLC. 1H NMR (CDCl3, freebase) δ (ppm): 8.54 (d, 2H), 7.21 (d, 1H), 7.2 (s, 1H), 7.0 (d, 2H), 6.95 (d, 1H), 6.0 (t, 1H), 4.4 (dd, 1H), 4.1 (dd, 1H), 3.62 (q, 2H), 2.7 (m, 3H), 2.52 (s, 3H), 2.41 (s, 3H), 2.3 (m, 1H), 1.19 (s, 9H).
Example 112
Preparation of Compound Nos. 131 and 131a-b
To solution of 2,3,4,5-tetrahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole (160 mg, 0.8 mmol) in DMF (3 mL) was added NaH (60%, 96 mg, 2.4 mmol). After stirring for 5 min at RT, 1-methyl-4-(oxiran-2-yl)-1H-pyrazole (150 mg, 1.2 mmol) was added into the reaction mixture, which was stirred at RT for 26 h. The progress of reaction was monitored by TLC, NMR and LCMS. The reaction mixture was quenched with ice-water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (EtOH-Hex) to yield 2-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-1-(1-methyl-1H-pyrazol-4-yl)ethanol. The product was further purified by chiral HPLC separation. 1H NMR (CDCl3, freebase) δ (ppm): 7.46 (s, 1H), 7.2 (s, 1H), 7.19 (s, 1H), 7.15 (d, 1H), 6.98 (d, 1H), 5.0 (t, 1H), 4.2 (d, 2H), 3.82 (s, 3H), 3.6 (s, 2H), 2.9 (m, 1H), 2.8 (m, 2H), 2.7 (m, 1H), 2.5 (s. 3H), 2.42 (s, 3H).
Example 113
Preparation of Compound Nos. 133 and 133a-b
To a solution of 2,3,4,5-tetrahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole (100 mg, 0.5 mmol) in DMF (2 mL) was added NaH (60 mg, 1.5 mmol). After stirring for 10 min at RT, a solution of 3-methyl-4-(oxiran-2-yl)pyridine (100 mg, 0.75 mmol) in DMF (1 mL) was added into the reaction mixture, which was stirred at RT for 16 h. The progress of reaction was monitored by TLC, LCMS and NMR. The reaction mixture was quenched with ice-water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC. 1H NMR (CDCl3, freebase) δ (ppm): 8.42 (d, 1H), 8.30 (s, 1H), 7.50 (d, 1H), 7.10 (m, 2H), 6.95 (d, 1H), 5.10 (m, 1H), 4.05 (m, 2H), 3.50 (s, 2H), 2.95-2.60 (m, 4H), 2.42 (s, 6H), 2.20 (s, 3H). Separation by chiral HPLC provided enantiomers 133a and 133b.
Example 114
Preparation of Compound Nos. 134 and 134a-b
A mixture of 9-methyl-2,3,4,5,6,10c-hexahydro-1H-3a,6,7-triaza-cyclopenta[c]fluorene (100 mg, 0.44 mmol), 3-vinyl-pyridine (185 mg, 1.762 mmol), tetrabutylammonium bromide (425 mg, 1.32 mmol) and 50% NaOH solution (6 mL) was stirred at 100° C. for 18 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2×50 mL). The combined organic layer was washed with brine solution (50 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 9-methyl-6-(2-pyridin-3-yl-ethyl)-2,3,4,5,6,10c-hexahydro-1H-3a,6,7-triaza-cyclopenta[c]fluorene (58 mg). 1H NMR (CDCl3, freebase) δ (ppm): 8.41 (d, 1H), 8.27 (s, 1H), 8.07 (s, 1H), 7.58 (s, 1H), 7.2 (d, 1H), 7.1 (dd, 1H), 4.4 (m, 2 H), 3.99 (bs, 1H), 3.2 (dd, 1H), 3.17 (t, 2H), 2.84-2.7 (m, 3H), 2.5 (m, 1H), 2.41 (s, 3H), 2.2 (dd, 1H), 1.9 (m, 4H). Separation by chiral HPLC provided enantiomers 134a and 134b.
Example 115
Preparation of Compound Nos. 135 and 135a-b
To a solution of 2,3,4,5-tetrahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole (400 mg, 1.61 mmol) in DMF (5 mL) was added NaH (240 mg, 6.0 mmol). After stirring at RT for 15 min, 3-chloro-4-(oxiran-2-yl)pyridine (620 mg, 4.0 mmol) was added into the reaction mixture, which was stirred at RT for 8 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with ice-water and extracted with EtOAc (3×50 mL). The organic layer was washed with water (5×50 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The product was crystallized from ether to yield title compound (430 mg) which was separated by chiral preparative HPLC to obtain 135a and 135b. 1H NMR (CDCl3, freebase) δ (ppm): 8.4 (s, 1H), 8.21 (d, 1H), 7.39 (d, 1H), 7.1 (d, 1H), 6.97 (s, 1H), 6.88 (d, 1H), 5.7 (bs, 1H), 5.19 (d, 1H), 4.21 (d, 1H), 3.89 (dd, 1H), 3.23 (dd, 2H), 2.86 (m, 2H), 2.67 (m, 2H), 2.45 (s, 3H), 2.29 (s, 3H).
Example 116
Preparation of Compound Nos. 136 and 136a-b
To a solution of aza carboline (500 mg, 2.48 mmol) in DMF (5 mL) was added NaH (298 mg, 7.46 mmol). After stirring at RT for 10 min, 2-(4-fluorophenyl)oxirane (515 mg, 3.73 mmol) was added into the reaction mixture, which was stirred at RT for 16 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with ice water and extracted with EtOAc. The organic layer was washed thoroughly with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The product was recrystallized from ether and further separated by chiral preparative HPLC to obtain 136a and 136b. 1H NMR (CDCl3, freebase) δ (ppm): 8.02 (s, 1H), 7.5 (s, 1H), 7.23 (m, 2H), 7.0 (t, 2H), 6.6 (bs, 1H), 5.11 (d, 1H), 4.3 (d, 1H), 4.24 (dd, 1H), 3.56 (dd, 2H), 2.74 (m, 2H), 2.6 (m, 1H), 2.49 (s, 3H), 2.44 (m, 1H), 2.41 (s, 3H).
Example 117
Preparation of Compound Nos. 137 and 137a-b
To a solution of 9-chloro-2,3,4,5,6,10c-hexahydro-1H-3a,6,7-triaza-cyclopenta[c]fluorene (400 mg, 1.61 mmol) in DMF (5 mL) was added sodium hydride (195 mg, 4.87 mmol). After stirring for 10 min at RT, 2-(6-methylpyridin-3-yl)ethyl 4-methylbenzenesulfonate (1.08 g, 3.71 mmol) was added into the reaction mixture, which was stirred at RT for 1 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with ice-water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography followed by reverse phase HPLC to yield the title compound. Separation by chiral HPLC provided enantiomers 133a and 133b. 1H NMR (CDCl3, freebase) δ (ppm): 8.2 (s, 1H), 8.19 (s, 1H), 7.7 (s, 1H), 7.1 (d, 1H), 7.0 (d, 1H), 4.38 (m, 2H), 3.8 (bs, 1H), 3.03 (t, 2H), 2.8 (m, 2H), 2.7 (m, 1H), 2.4 (m, 1H), 2.5 (s, 3H), 2.38 (m, 1H), 2.12 (dd, 1H), 1.8 (m, 4H). Separation by chiral HPLC provided enantiomers 137a and 137b.
Example 118
Preparation of Compound Nos. 138 and 138a-b
To a solution of dimethyl-aza carboline (693 mg, 3.4 mmol) in DMF (5 mL) was added NaH (413 mg, 10.3 mmol, 60%). After stirring at RT for 10 min, 2-(4-fluorophenyl)-2-methyloxirane (1.0 g, 6.8 mmol) was added into the reaction mixture, which was stirred at RT for 16 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with ice-water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified through reverse phase HPLC to obtain the racemate which was separated by chiral preparative HPLC to obtain 138a and 138b. 1H NMR (CDCl3, freebase) δ (ppm): 8.01 (s, 1H), 7.49 (s, 1H), 7.24 (m, 2H), 6.95 (t, 2H), 4.27 (dd, 2H), 3.62 (d, 1H), 3.5 (d, 1H), 2.8 (m, 3H), 2.49 (s, 3H), 2.45 (m, 1H), 2.4 (s, 3H), 1.53 (s, 3H).
Example 119
Preparation of Compound Nos. 139 and 139a-b
A solution of 4-[2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-hydroxy-ethyl]-benzoicacid ethyl ester (90 mg, 0.229 mmol) in 25% ammonium hydroxide solution (5 mL) was stirred at 120° C. for 1 h. The progress of reaction was monitored by NMR and LCMS. The reaction mixture was cooled to RT, diluted with water and extracted with EtOAc (3×30 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield 4-[2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-hydroxy-ethyl]-benzamide (3 mg) which was separated by chiral preparative HPLC to obtain 139a and 139b. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.18 (t, 2H), 7.4 (d, 1H), 7.31 (d, 2H), 7.23 (s, 1H), 7.03 (t, 1H), 5.08 (t,1H), 4.64 (dd, 1H), 4.33 (m, 2H), 4.21 (dd, 1H), 3.71 (t, 1H), 3.45 (bs, 1H), 3.12 (m, 1H), 3.09 (d, 3H), 2.6 (d, 1H), 2.41 (s, 3H).
Example 120
Preparation of Compound Nos. 140 and 140a-b
To a degassed solution of 1-(6-bromo-pyridin-3-yl)-2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-ethanol (1 g, 2.5 mmol) in DMF (10 mL) were added Pd(PPh3)4 (0.173 g, 0.15 mmol) and zinc cyanide (585 mg, 5.0 mmol) and the reaction mixture was stirred at 150° C. for 2 h. The reaction mixture was cooled to RT, diluted with EtOAc (250 mL) and filtered. The filtrate was washed with water (3×100 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by reverse phase HPLC to yield 5-[2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-hydroxy-ethyl]-pyridine-2-carbonitrile (350 mg). 1H NMR (CDCl3, freebase) δ (ppm): 8.55 (s, 1H), 7.38 (d, 1H), 7.23 (d, 1H), 6.93 (s, 1H), 6.81 (s 1H), 6.74 (s,1H), 4.96 (m, 1H), 4.11 (dd, 2H), 3.29 (dd, 2H), 2.95 (m, 1H), 2.88 (m 1H), 2.86 (m, 2H), 2.5 (s, 6H). Separation by chiral HPLC provided enantiomers 140a and 140b.
Example 121
Preparation of Compound Nos. 141 and 141a-b
To a solution of 2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethanol (2.0 g, 9.04 mmol) in DMF (20 mL) was added sodium hydride (1.0 g, 25 mmol). After stirring at RT for 20 min, a solution of N,N-dimethyl carbamoyl chloride (1.9 g, 17.7 mmol) in DMF (5 mL) was added dropwise into the reaction mixture, which was stirred at RT for 1 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was poured into ice water (400 mL) and extracted with EtOAc (3×200 mL). The organic layer was washed with water (3×300 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (5-7% MeOH in DCM) to yield N,N-dimethyl-carbamic acid 2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethyl ester (100 mg). 1H NMR (CD3OD, freebase) δ (ppm): 8.5 (d, 2H), 7.34 (d, 2H), 7.31 (d, 1H), 7.21 (s, 1H), 7.00 (d, 1H), 5.96 (t,1H), 4.53 (dd, 1H), 4.45 (dd, 1H), 3.49 (t, 2H), 2.98 (m, 2H), 2.95 (m, 5H), 2.92 (s, 3H), 2.77 (s, 3H), 2.39 (s, 3H). Separation by chiral HPLC provided enantiomers 141a and 141b.
Example 122
Preparation of Compound Nos. 142 and 142a-b
To an ice-cooled stirred solution of 2,3,4,5-tetrahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole (2.6 g, 13.24 mmol) in DMF (12 mL) was added sodium hydride (1.6 g, 39.72 mmol, 60%). After stirring at 0° C. for 10 min, 4-(oxiran-2-yl)benzonitrile (2.4 g, 16.55 mmol) was added into the reaction mixture, which was stirred at RT for 16 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with ice-water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The product was re-crystallized from ether (2.5 g) followed by chiral separation. 1H NMR (CDCl3, freebase) δ (ppm): 7.55 (d, 2H), 1.76 (d, 2H), 7.11 (s, 1H), 7.04 (d, 1H), 6.91 (d, 1H), 5.01 (m,1H), 4.1 (dd, 2H), 3.52 (dd, 2H), 2.79 (m, 2H), 2.67 (m, 2H), 2.46 (s, 3H), 2.43 (s, 3H).
Example 123
Preparation of Compound Nos. 143 and 143a-b
A solution of 8-chloro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (290 mg, 1.31 mmol) and sodium hydride (38 mg, 1.6 mmol) in DMF (6 mL) was stirred at 120° C. for 1 h. The reaction mixture was cooled to 0° C. and 2-(trifluoromethyl)-5-(2-methyloxiran-2-yl)pyridine (400 mg, 1.97 mmol) was added dropwise into the reaction mixture, which was stirred at 120° C. for 2 h. The reaction mixture was cooled to RT and partitioned between EtOAc (60 mL) and water (15 mL). The organic layer was separated and the aqueous layer was extracted with EtOAc (1×20 mL). The combined organic layer was washed with water, followed by brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel flash column chromatography to yield title compound. 1H NMR (CDCl3, freebase) δ (ppm): 8.79 (s, 1H), 7.21 (bs, 1H), 6.97 (s, 1H), 6.79 (d, 1H), 6.42 (bs, 2H), 4.15 (d,1H), 4.05 (d, 1H), 3.2 (m, 3H), 2.99 (s, 1H), 2.74 (d, 1H), 2.56 (t, 1H), 2.45 (s, 3H), 1.75 (s, 3H). Separation by chiral HPLC provided enantiomers 143a and 143b.
Example 124
Preparation of Compound Nos. 144 and 144a-b
To a solution of 5-[2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-hydroxy-ethyl]-pyridine-2-carbonitrile (1.5 g, 4.3 mmol) in tert-butanol (30 mL) was added crushed KOH (728 mg, 13 mmol) and the reaction mixture was stirred at 80° C. for 1 h. The progress of reaction was monitored by LCMS. The reaction mixture was concentrated. The residue was diluted with water (50 mL) and extracted with EtOAc (2×100 mL). The combined organic layer was washed with water (2×100 mL), dried over anhydrous sodium sulfate and concentrated. The crude material was purified by reverse phase HPLC to yield 5-[2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-hydroxy-ethyl]-pyridine-2-carboxylic acid amide (200 mg). 1H NMR (CDCl3, freebase) δ (ppm): 8.45 (d, 1H), 8.12 (t, 1H), 7.78 (s, 2H), 7.05 (m, 2H), 6.94 (t, 1H), 5.57 (bs,1H), 5.03 (m, 1H), 4.13 (s, 2H), 3.63 (m, 2H), 2.79 (m, 2H), 2.78 (bs 1H), 2.66 (d, 1H), 2.53 (d, 3H), 2.42 (s, 3H). Separation by chiral HPLC provided enantiomers 144a and 144b.
Example 125
Preparation of Compound Nos. 145 and 145a-b
To an ice-cooled stirred solution of aza dimethyl-carboline (1.8 g, 8.9 mmol) in DMF (10 mL) was added sodium hydride (1.0 g, 26.86 mmol, 60%). After stirring at 0° C. for 10 min, 4-(oxiran-2-yl)benzonitrile (2.6 g, 17.9 mmol) was added into the reaction mixture, which was stirred at RT for 16 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with ice-water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The product was re-crystallized from EtOH (825 mg). 1H NMR (CDCl3, freebase) δ (ppm): 8.03 (s, 1H), 7.58 (d, 2H), 7.51 (s, 1H), 7.39 (d, 2H), 7.1 (s 1H),5.19 (m, 1H), 4.4 (dd, 1H), 4.26 (dd, 1H), 3.55 (dd, 2H), 2.75 (m, 1H), 2.64 (m 1H), 2.49 (s, 3H), 2.42 (s, 3H), 2.38 (m, 1H). Separation by chiral HPLC provides enantiomers 133a and 133b.
Example 126
Preparation of Compound Nos. 146 and 146a-b
To a solution of 1-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-2-(pyridin-3-yl)propan-2-ol (1.0 g, 2.98 mmol) in DMF (10 mL) was added sodium hydride (60%, 0.36 g, 8.95 mmol). After stirring at RT for 10 min, isobutyryl chloride (0.95 g, 8.95 mmol) was added dropwise into the reaction mixture, which was stirred at RT for 15 min. The progress of reaction was monitored by TLC. The reaction mixture was quenched with water (5 mL), basified with sat. aq. sodium bicarbonate and extracted with EtOAc (3×50 mL). The organic layer was washed with water (3×50 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (0-6% MeOH-DCM) to yield the title compound (186.3 mg), which was resolved by chiral preparative HPLC. 1H NMR (CDCl3, freebase) δ (ppm): 8.5 (dd, 1H), 8.42 (s, 1H), 7.24 (d, 1H), 7.16 (m, 3H), 6.93 (d 1H),4.26 (dd,2H), 3.65 (dd, 2H), 2.7 (m, 1H),2.55 (m, 3H), 2.56 (m, 1H), 2.49 (s 3H), 2.43 (s, 3H), 2.0 (m, 1H), 1.98 (s, 3H), 1.1 (m, 6H).
Example 127
Preparation of Compound Nos. 147 and 147a-b
To a solution of isonicotinic acid (200 mg, 1.626 mmol) in DMF (10 mL) was added potassium carbonate (560 mg, 4.065 mmol) and stirred the solution at 80° C. for 30 min. Methanesulfonic acid 2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethyl ester (455 mg, 1.138 mmol) was added portionwise into the reaction mixture, which was stirred at 80° C. 30 min. The progress of reaction was monitored by LCMS and TLC. The reaction mixture was cooled to RT, diluted with water (30 mL) and extracted with EtOAc (2×50 mL). The combined organic layer was washed with water (4×50 mL), dried over anhydrous sodium sulfate and concentrated. The residue was purified by reverse phase HPLC to yield isonicotinic acid 2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethylester (30 mg). 1H NMR (CDCl3, freebase) δ (ppm): 8.79 (d, 2H), 8.58 (d, 2H), 7.77 (d, 2H), 7.23 (d, 1H), 7.18 (s 1H), 7.12 (d,2H), 7.0 (d, 1H), 6.24 (t, 1H), 4.54 (dd, 1H), 4.35 (dd, 1H), 3.68 (s, 2H), 2.76 (t, 2H), 2.61 (m, 1H), 2.51 (s, 3H), 2.43 (s, 3H), 2.43 (m, 1H). Separation by chiral HPLC provided enantiomers 147a and 147b.
Example 128
Preparation of Compound Nos. 148 and 148a-d
To a solution of 8-aza-10-methyl-2,3,5,6,7,11c-hexahydro-1H-indolizino[7,8-b]indole (500 mg, 2.2 mmol) in DMF (5 mL) was added sodium hydride (264 mg, 6.6 mmol). After stirring for 5 min at RT, 2-methyl-5-(2-methyloxiran-2-yl)pyridine (656 mg, 4.4 mmol) was added into the reaction mixture, which was stirred at RT for 16 h. The progress of reaction was monitored by LCMS. The reaction mixture was quenched with ice-water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated. The residue was purified by reverse phase HPLC to yield title compound, which was resolved by chiral preparative HPLC. 1H NMR (CDCl3, freebase) δ (ppm): 8.48 (s, 1H), 8.03 (s, 1H), 7.55 (d, 1H), 7.53 (s, 1H), 6.98 (d 1H), 4.41 (d,1H), 4.23 (d, 1H), 3.22 (m, 2H), 3.0 (m, 1H), 2.8 m, 2H), 2.6 (m, 1H), 2.46 (s, 3H), 2.41(s, 3H), 2.34 (m, 2H), 1.88 (m, 2H), 1.63 (s, 3H), 1.58 (m, 1H).
Example 129
Preparation of Compound Nos. 149 and 149a-b
5-(2-Azido-2-(pyridin-3-yl)propyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (Crude) (500 mg, 1.4 mmol) was dissolved in EtOH (4 mL) and water (1 mL). Ammonium chloride (243 mg, 4.5 mmol) followed by zinc dust (293 mg, 4.5 mmol) were added to the reaction mixture and heated at 80° C. for 1 h. The reaction mixture was concentrated to dryness, basified with aqueous ammonia solution and extracted with EtOAc (150 mL). The organic layer was dried over sodium sulfate, evaporated in vacuo and purified by reverse phase HPLC to afford 2 mg of 1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridin-3-yl)propan-2-amine. 1H NMR (CD3OD, freebase): δ (ppm): 8.39 s (1H), 8.3 d (1H), 7.72 d (1H), 7.32 t(1H), 7.11 (1H), 6.91 d (1H), 6.8 d (1H), 4.18 dd (2H), 3.61 dd (2H), 2.7 m (2H), 2.46 s (3H), 2.35 s (3H),2.26 m (2H). Chiral HPLC provided enantiomers 149a and 149b.
Example 130
Preparation of Compound Nos. 150 and 150a-b
A solution of 2-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-1-(pyridin-4-yl)ethyl methanesulfonate (250 mg, 0.62 mmol) in dimethyl amine (3 mL, 40% in water) was stirred at 90° C. for 16 h. The progress of reaction was monitored by LCMS. The reaction mixture was lyophilized and crude material was purified by reverse phase HPLC. The racemate was further separated into optically active forms by chiral preparative HPLC. 1H NMR (CDCl3, freebase) δ (ppm): 8.4 (d, 2H), 7.16 (s, 1H), 7.0 (d, 1H), 6.96 (m, 3H), 4.58 (dd, 1H), 4.0 (m, 1H), 3.62 (d, 1H), 3.58 (m, 1H), 3.4 (dd, 1H), 2.7 (t, 2H), 2.6 (t, 2H), 2.42(s, 3H), 2.4 (s, 3H), 2.3 (s, 6H).
Example 131
Preparation of Compound Nos. 151 and 151a-b
A solution of 2-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-1-(pyridin-4-yl)ethyl methanesulfonate (250 mg, 0.62 mmol) in methyl amine (3 mL, 40% in water) was stirred at 90° C. for 12 h. The progress of reaction was monitored by LCMS. The reaction mixture was extracted with EtOAc. The organic layer was dried and concentrated to get the crude product, which was purified by reverse phase HPLC to obtain the 2-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-N-methyl-1-(pyridin-4-yl)ethanamine. 1H NMR (CDCl3, freebase): δ (ppm): 8.59 d (2H), 7.3 d (2H), 7.29 d (1H), 7.23 s (1H), 7.03 d (1H), 4.19 m (1H), 4.03 m (2H), 3.66 dd (2H), 2.8 m (3H), 2.6 m (1H), 2.55 s (3H), 2.47 s (3H), 2.18 s (3H). Chiral HPLC provided enantiomers 151a and 151b.
Example 132
Preparation of Compound Nos. 152 and 152a-b
A solution of 2-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-1-(pyridin-4-yl)ethyl methanesulfonate (250 mg, 0.62 mmol) in pyrrolidine (2.5 mL) was irradiated in microwave at 90° C. for 1 h. The progress of reaction was monitored by LCMS. The volatiles were removed under reduced pressure. The residue was diluted with water and extracted with DCM. The organic layer was dried and concentrated under reduced pressure. The crude material was purified by reverse phase HPLC. The racemate was further separated into optically active forms by chiral preparative HPLC. 1H NMR (CDCl3, freebase) δ (ppm): 8.39 (d, 2H), 7.16 (s, 1H), 7.0 (d, 1H), 6.97 (m, 3H), 4.6 (dd, 1H), 4.0 (m, 1H), 3.79 (d, 1H), 3.6 (d, 1H), 3.57 (dd, 1H), 2.7-2.6 (m, 4H), 2.46-2.4 (m, 10H), 1.82 (m, 4H).
Example 133
Preparation of Compound Nos. 153 and 153a-b
To a solution of 9-(2-azido-2-(pyridin-4-yl)ethyl)-2,6-dimethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (800 mg, 2.3 mmol) in ethanol-water (9 mL:1 mL) were added zinc dust (600 mg, 9.2 mmol) and ammonium chloride (490 mg, 9.2 mmol) and the reaction mixture stirred at 85° C. for 45 min. The reaction mixture was filtered and the filtrate concentrated. The residue was basified with aqueous ammonia and extracted with EtOAc (2×50 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude material was purified by reverse phase HPLC to yield 2-(2,6-dimethyl-3,4-dihydro-1H-pyrido[3,4-b]indol-9(2H)-yl)-1-(pyridin-4-yl)ethanamine (25 mg). The racemate can be further separated into the optically active forms by chiral preparative HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.6 (s, 2H), 7.62 (bs, 2H), 7.23 (s, 1H), 7.0 (d, 1H), 6.98 (d, 1H), 4.9 (m, 1H), 4.8-4.58 (m, 3H), 4.0 (bs, 1H), 3.8 (bs, 1H), 3.6-3.4 (m, 2H), 3.1 (bs, 4H), 2.38 (s, 3H).
Example 134
Preparation of Compound Nos. 154 and 154a-b
To a solution of 6-(2-azido-2-(pyridin-4-yl)ethyl)-3,9-dimethyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole (188 mg, 0.522 mmol) in ethanol-water (9 mL:1 mL), zinc dust (135 mg, 2.08 mmol) and ammonium chloride (110 mg, 2.08 mmol) were added and the reaction mixture was stirred at 85° C. for 45 min. The reaction mixture was filtered and the filtrate concentrated. The residue was basified with aqueous ammonia and extracted with EtOAc (2×50 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude material was purified by reverse phase HPLC to yield 2-(3,9-dimethyl-2,3,4,5-tetrahydroazepino[4,5-b]indol-6(1H)-yl)-1-(pyridin-4-yl)ethanamine (45 mg). The racemate can be further separated into the optically active forms by chiral preparative HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.6 (d, 2H), 7.6 (d, 2H), 7.22 (s, 1H), 7.0 (s, 1H), 6.9 (s, 1H), 4.9 (m, 3H), 4.8 (m, 1H), 4.7 (m, 1H), 3.8-3.6 (m, 2H), 3.2 (m, 2H), 3.18-2.97 (m, 4H), 2.8 (bs, 1H), 2.38 (s, 3H).
Example 135
Preparation of Compound Nos. 155 and 155a-d
The azide compound (350 mg, 0.940 mmol) was dissolved in EtOH-water (10 mL: 1 mL). Zinc dust (244 mg, 3.763 mmol) and ammonium chloride (199 mg, 3.763 mmol) were added and the mixture was heated at 85° C. for 45 min. After consumption of starting material, the reaction mixture was filtered through Celite and filtrate was concentrated to obtain the residue. The residue was basified with aq ammonia and extracted with EtOAc (2×70 mL). The combined organic layer was dried over sodium sulfate and concentrated to obtain the crude product, which was crystallized in diethyl ether to obtain 150 mg of desired product. 1H NMR (CDCl3, freebase): δ (ppm): 8.55 d (2H), 7.29 d (2H), 7.25 d (1H), 7.2 s (1H), 7.02 d (1H), 4.77 m (2H), 4.49 t (1H), 4.1 m (1H), 4.08 m (2H), 3.51 m (1H), 2.7 dd (1H), 2.46 s (3H), 2.25 s (3H), 2.2 m (1H), 1.86 t (1H), 1.44 t (1H). Chiral HPLC provided enantiomers 155a and 155b.
Example 136
Preparation of Compound Nos. 156 and 156a-b
To a solution of 5-(2-azido-2-(pyridin-4-yl)ethyl)-2,8-dimethyl-6-aza-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (160 mg, 0.461 mmol) in EtOH:water (4:0.4 mL) were added zinc dust (119.8 mg, 1.84 mmol) and ammonium chloride (99.59 mg, 1.84 mmol) and the reaction mixture was stirred at 80° C. for 1 h. The progress of reaction was monitored by NMR. The mixture was filtered and the filtrate concentrated under reduced pressure. The residue was basified with aqueous ammonia and extracted with EtOAc. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield the title compound. The racemate can be further separated into the optically active forms by chiral preparative HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.8 (m, 2H), 8.19 (s, 1H), 7.9 (m, 2H), 7.7 (s,1H), 5.3 (m,1H), 4.8 (m, 2H), 4.63 (d, 1H), 4.25 (d, 1H), 3.85 (m, 1H), 3.5 (m, 1H), 3.2 (m, 2H), 3.17 (s, 3H), 2.4 (s, 3H).
Example 137
Preparation of Compound Nos. 157 and 157a-b
To a solution of 5-[1-amino-2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-ethyl]-pyridine-2-carbonitrile (400 mg, 1.15 mmol) in tert-butanol (20 mL) was added crushed KOH (194 mg, 3.47 mmol) and the reaction mixture was stirred at 80° C. for 1 h. The progress of reaction was monitored by LCMS. The reaction mixture was concentrated to dryness. The residue was diluted with water (50 mL) and extracted with EtOAc (2×100 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield 5-[1-amino-2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-ethyl]-pyridine-2-carboxylic acid amide (70 mg). The racemate can be further separated into the optically active forms by chiral preparative HPLC. 1H NMR (CDCl3, free base) δ (ppm): 8.5 (s, 1H), 8.2 (d, 1H), 7.9 (d, 1H), 7.2 (m, 2H), 7.0 (d, 1H), 5.6 (bs, 1H), 4.6 (t, 1H), 4.1 (d, 2H), 3.7 (q, 2H), 2.9 (t, 2H), 2.8 (m, 1H), 2.6 (m, 1H), 2.58 (s, 3H), 2.42 (s, 3H).
Example 138
Preparation of Compound Nos. 158 and 158a-b
To a solution of 5-(2-azido-2-(pyridin-4-yl)ethyl)-8-methyl-6-aza-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (730 mg, 2.19 mmol) in EtOH:H2O (15:1.5 mL) were added zinc dust (570 mg, 8.76 mmol) and ammonium chloride (473.5 mg, 8.76 mmol) and the reaction mixture was stirred at 80° C. for 1 h. The progress of reaction was monitored by NMR. The mixture was filtered and the filtrate concentrated under reduced pressure. The residue was basified with aqueous ammonia and extracted with EtOAc. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield the title compound. The racemate can be further separated into the optically active forms by chiral preparative HPLC. 1H NMR (CDCl3, free base) δ (ppm): 8.5 (d, 2H), 8.08 (s, 1H), 7.5 (s, 1H), 7.21 (d, 2H), 4.6 (t, 1H), 4.3 (dd, 1H), 4.2(dd, 1H), 4.0 (s, 2H), 3.1 (m, 2H), 2.6 (d, 1H), 2.4 (s, 3H), 2.3 (d, 1H).
Example 139
Preparation of Compound Nos. 159 and 159a-b
To a degassed solution of 4-(1-azido-2-(6-aza-2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)ethyl)benzonitrile (240 mg) in EtOAc:EtOH (7:7 mL) was added 10% Pd—C (100 mg), and hydrogen gas was bubbled into the reaction mixture with stirring at RT for 5 h. The progress of reaction was monitored by LCMS. The reaction mass was filtered through Celite and the filtrate concentrated under reduced pressure. The residue was purified through reverse phase HPLC to yield the racemate (200 mg), which was separated by chiral preparative HPLC. 1H NMR (CDCl3, free base) δ (ppm): 8.05 (s, 1H), 7.6 (d, 2H), 7.43 (m, 3H), 4.6 (t, 1H), 4.23 (dd, 2H), 3.7 (dd, 2H), 2.9 (m, 1H), 2.8 (m, 2H), 2.6 (s, 3H), 2.5 (m, 1H), 2.4 (s, 3H).
Example 140
Preparation of Compound Nos. 160 and 160a-b
To a degassed solution of 4-(1-azido-2-(6-aza-8-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)ethyl)benzonitrile (219 mg) in EtOAc:EtOH (7:7 mL) was added 10% Pd—C (100 mg), and hydrogen gas was bubbled into the reaction mixture with stirring at RT for 5 h. The progress of reaction was monitored by LCMS. The reaction mass was filtered through Celite and the filtrate concentrated under reduced pressure. The residue was purified through reverse phase HPLC to yield the racemate, which was separated by chiral preparative HPLC. 1H NMR (CDCl3, free base) δ (ppm): 8.1 (s, 1H), 7.6 (d, 2H), 7.47 (m, 3H), 4.6 (t, 1H), 4.2 (m, 2H), 4.18 (s, 2H), 3.21 (bm, 1H), 2.8 (bm, 1H), 2.7-2.6 (m, 2H), 2.6 (s, 3H).
Example 141
Compound Nos. 161, 161a-d, 162, 162a-d, 163, 163a-d, 164, 164a-d, 165, 165a-b, 166, 166a-b, 167, 167a-b, 171 and 171a-b can be prepared in analogous fashion to Compound Nos. 3 and 3a-b, using appropriately functionalized aromatic-tethered oxiranes as reagents. Compound Nos. 173, 174, 175 and 176 were prepared in analogous fashion to Compound Nos. 3 and 3a-b, using appropriately functionalized aromatic-tethered oxiranes as reagents. Chiral HPLC provided, respectively, Compound Nos. 173a-b, 174a-b, 175a-b and 176a-d.
Example 142
Preparation of Compound Nos. 168 and 168a-d
To a solution of 4-[1-hydroxy-2-(9-methyl-1,2,3,4,5,10c-hexahydro-3a,6-diaza-cyclopenta[c]fluoren-6-yl)-ethyl]-pyridine-2-carbonitrile (68 mg, 0.18 mmol) in 1 mL THF was added NaOH (21 mg, 0.52 mmol) i.e. 0.5 mL 1M NaOH solution and was heated at 80° C. for overnight. The reaction was monitored with LCMS. The solvent was removed under reduced pressure to obtain the crude product that was purified by reverse phase HPLC to obtain pure product as the TFA salt (8 mg). 1H NMR (CD3OD, TFA salt): δ (ppm): 8.55 t (1H), 7.95 d (1H), 7.61 d (1H), 7.25 s (1H), 7.2 dd (1H), 7.01 dd (1H), 5.16 m (1H),5.03 m (1H), 4.36 m (2H), 3.61 m (3H), 3.3 m (1H), 2.7 m (2H), 2.4 d (3H), 2.2 m (3H). Chiral HPLC provides diastereomers 168a-d.
Example 143
Preparation of Compound Nos. 169 and 169a-b
A solution of 5-(1-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-2-hydroxypropan-2-yl)pyridine-2-carbonitrile (1.6 g) in ethanol (4 mL) and 10 N NaOH (15 mL) was stirred at 100° C. for 45 min. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was lyophilized and purified with reverse phase HPLC to obtain the 5-(1-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-2-hydroxypropan-2-yl)pyridine-2-carboxylic acid. 1H NMR (CD3OD, TFA salt): δ (ppm): 8.6 d (1H), 8.1 s (1H), 8.0 d (1H), 7.19 d (1H), 6.9 d (1H), 6.8 d (1H), 4.7 dd (1H), 4.37 m (2H), 4.3 m (1H), 3.8 m (1H), 3.52 m (2H), 3.15 m (1H), 3.1 s (3H), 2.38 s (3H), 1.7 d (3H). Chiral HPLC provides enantiomers 169a and 169b.
Example 144
Preparation of Compound Nos. 170 and 170a-b
These compounds can be prepared in analogous fashion to Compound Nos. 67 and 67a-b, using ethyl 5-(1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-hydroxypropan-2-yl)nicotinate as starting material. Separation by chiral HPLC provides enantiomers 170a-b.
Example 145
Preparation of Compound Nos. 177 and 177a-d
These compounds can be prepared in analogous fashion to Compound Nos. 67 and 67a-b, using ethyl 4-(1-hydroxy-2-(10-methyl-2,3,5,6-tetrahydro-1H-indolizino[7,8-b]indol-7(11cH)-yl)ethyl)nicotinate as starting material. Separation by chiral HPLC provides diastereomers 177a-d.
Example 146
Preparation of Compound Nos. 178 and 178a-b
These compounds can be prepared in analogous fashion to Compound Nos. 67 and 67a-b, using ethyl 3-(1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-hydroxypropan-2-yl)picolinate as starting material. Separation by chiral HPLC provides enantiomers 178a-b.
Example 147
Preparation of Compound Nos. 179 and 179a-b
3-(1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-hydroxypropan-2-yl)isonicotinonitrile (200 mg, 0.554 mmol) was dissolved in ethanol and an aqueous solution of sodium hydroxide was added and heated at 100° C. for 1 h. The reaction was monitored by LCMS. After completion of reaction, solvent was removed under reduced pressure and the crude product was purified by reverse phase HPLC (8 mg). 1H NMR (CD3OD, freebase): 9.3 s (1H), 8.42 s (1H), 8.3 s (1H), 7.4 d (1H), 7.1 s (1H), 6.8 d (1H), 4.4 s (2H), 4.2 m (2H), 3.58 m (2H), 3.55 m (1H), 3.3 m (1H), 3.1 s (3H), 2.4 s (3H), 1.54 s (3H). Chiral separation provides enantiomers 179a and 179b.
Example 148
Preparation of Compound Nos. 46 and 46a-b
These compounds can be prepared in analogous fashion to Compound Nos. 67 and 67a-b, using ethyl 3-(1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-hydroxypropan-2-yl)picolinate as starting material. Separation by chiral HPLC provides enantiomers 46a-b.
Example 149
Preparation of Compound Nos. 50 and 50a-d
These compounds can be prepared in analogous fashion to Compound Nos. 67 and 67a-b, using ethyl 4-(1-ethoxy-2-(10-methyl-2,3,5,6-tetrahydro-1H-indolizino[7,8-b]indol-7(11cH)-yl)ethyl)nicotinate as starting material. Separation by chiral HPLC provides diastereomers 50a-d.
Example 150
Preparation of Compound Nos. 104 and 104a-b
These compounds can be prepared in analogous fashion to Compound Nos. 67 and 67a-b, using ethyl 4-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-hydroxy-3-(pyridin-3-yl)butanoate as starting material. Separation by chiral HPLC provides enantiomers 104a-b.
Example 151
Preparation of Compound Nos. 123 and 123a-b
These compounds can be prepared in analogous fashion to Compound Nos. 67 and 67a-b, using ethyl 5-(1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-hydroxypropan-2-yl)nicotinate as starting material. Separation by chiral HPLC provides enantiomers 123a-b.
Example 152
Preparation of Compound No. 180
2,3,4,5-Tetrahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole (200 mg, 1 mmol), 4-methylstyrene (239 mg, 2.3 mmol) and NaH (120 mg, 60% dispersion in oil, 3 mmol) were heated in DMSO (4 mL) at 120° C. overnight (16 h) after which methanol was added and the contents were concentrated to dryness. The resulting crude product was purified by reverse-phase chromatography (C-18, 500 mm×50 mm, Mobile Phase A=0.05% TFA in water, B=0.05% TFA in acetonitrile, Gradient: 10% B to 80% B in 30 min, injection vol: 5 mL) and/or silica gel (230-400 mesh) chromatography eluting with methanol-dichloromethane gradient to obtain 20 mg (6.2% yield) of 2,3,4,5-tetrahydro-2,8-dimethyl-5-(4-methylphenethyl)-1H-pyrido[4,3-b]indole as a trifluoroacetate salt. 1H NMR (CDCl3, TFA salt) δ (ppm): 13.3 (bs, 1H), 7.4-7.0 (m, 5H), 6.80-6.70 (d, 2H), 4.7-4.6 (d, 1H), 4.40-4.22 (m, 1H), 4.20-4.10 (m, 1H), 4.10-4.0 (d, 1H), 3.5-3.4 (t, 1H), 3.20-3.17 (t, 1H), 3.0 (t, 2H), 2.80 (s, 3H), 2.7-2.61 (m, 1H), 2.40 (s, 3H), 2.23 (s, 3H), 2.2-2.1 (m, 1H).
Example 153
Preparation of Compound No. 181
2,3,4,5-Tetrahydro-2-methyl-5-(4-methylphenethyl)-1H-pyrido[4,3-b]indole was prepared from 2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (200 mg, 1.07 mmol), 4-methylstyrene (1.41 mL, 10.7 mmol) and NaH (250 mg, 60% dispersion in oil, 6.25 mmol) in DMF (6 mL) at 200° C. for 16 h to obtain 7 mg of 2,3,4,5-tetrahydro-2-methyl-5-(4-methylphenethyl)-1H-pyrido[4,3-b]indole after purification. 1H NMR (CDCl3, TFA salt) δ (ppm): 7.45-7.40 (d, 2H), 7.25-7.16 (m, 2H), 7.1-6.9 (d, 2H), 6.8-6.7 (d, 2H), 4.7 (d, 1H), 4.4-4.3 (m, 1H), 4.20-4.03 (m, 2H), 3.55-3.40 (m, 1H), 3.22-3.10 (m, 1H), 3.09-2.90 (m, 2H), 2.83 (s, 3H), 2.65 (m, 1H), 2.35 (s, 3H), 2.2 (m, 1H).
Example 154
Preparation of Compound No. 182
2,3,4,5-Tetrahydro-2-methyl-5-phenethyl-1H-pyrido[4,3-b]indole was prepared from 2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (200 mg, 1.07), styrene (1.23 mL mmol, 10.65) and NaH (250 mg, 6.25 mmol) in DMF (6 mL) at 200° C. for 16 h to obtain 15 mg of 2,3,4,5-tetrahydro-2-methyl-5-phenethyl-1H-pyrido[4,3-b]indole after purification. 1H NMR (CDCl3, TFA salt) δ (ppm): 7.5-7.10 (m, 7H), 6.9-6.8 (m, 2H), 4.6 (d, 1H), 4.30-4.19 (m, 2H), 4.05 (d, 1H), 3.62-3.40 (m, 1H), 3.20-3.0 (m, 3H), 2.9 (s, 3H), 2.7-2.6 (t, 1H), 2.2-2.1 (t, 1H).
Example 155
Preparation of Compound Nos. 183 and 183a-b
3,4,5-Tetrahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole (2.2 g, 11 mmol, 1 equiv.), 4-methylstyrene oxide (5.8 g, 44 mmol, 4 equiv.) and NaH (1.3 g, 32.5 mmol, 2.95 eq) were heated in DMF (70 mL) at 120° C. for 16 h (overnight). The contents were quenched by MeOH and evaporated to dryness. The resulting crude product was purified by silica gel chromatography (230-400 mesh) using EtOAc-hexane gradient to obtain 1.3 g of racemic-2-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-1-p-tolylethanol. The free base was converted into its hydrochloride salt by treatment of ethanolic HCl. 1H NMR (DMSO-d6, HCl salt) δ (ppm): 10.30 (s, 1H), 7.42-7.0 (m, 7H), 5.6 (m, 1H), 4.90-4.80 (m, 1H), 4.60-4.55 (d, 1H), 4.30-4.00 (m, 3H), 3.70 (s, 1H), 3.4 (m, 1H), 3.22-3.10 (d, 1H), 3.00-2.90 (m, 3H), 2.80-2.60 (d, 1H), 2.40 (s, 3H), 2.30 (s, 3H). Separation by chiral HPLC provided enantiomers 183a and 183b.
Example 156
Preparation of Compound No. 184
5-(4-Chlorophenethyl)-2,3,4,5-tetrahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole was prepared from 2,3,4,5-tetrahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole (500 mg, 2.5 mmol), 4-chlorostyrene (3.18 mL, 25 mmol) and NaH (300 mg, 7.5 mmol) in DMF (10 mL) at 180° C. overnight (16 h) to obtain 15 mg of 5-(4-chlorophenethyl)-2,3,4,5-tetrahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole after purification. 1H NMR (CDCl3, TFA salt) δ (ppm): 7.30-7.08 (m, 5H), 6.85-6.78 (d, 2H), 4.70-4.60 (d, 1H), 4.40-4.20 (m, 1H), 4.20-4.0 (m, 2H), 3.65-3.50 (m, 1H), 3.10-3.00 (m, 3H), 2.85 (s, 3H), 2.80 (m, 1H), 2.45 (s, 3H), 2.2 (m, 1H).
Example 157
Preparation of Compound No. 185
1-(8-Chloro-1,2,3,4-tetrahydro-2-methylpyrido[4,3-b]indol-5-yl)-2-(pyridin-4-yl)propan-2-ol (1 equiv.) was refluxed with 25% sulfuric acid for 2 h. The reaction mixture was cooled to 5° C. with an ice-water bath. KOH (15% aq. solution) was added dropwise to the reaction mixture until pH 9-10 was achieved. The reaction mixture was extracted with EtOAc. The combined organic layers were washed with water followed by brine, dried over anhydrous sodium sulfate and evaporated under vacuum. The crude product was purified by column chromatography over silica gel (100-200 mesh) using a gradient of MeOH-EtOAc (0-10%) to obtain a mixture of 8-chloro-2,3,4,5-tetrahydro-2-methyl-5-((E)-2-(pyridin-4-yl)prop-1-enyl)-1H-pyrido[4,3-b]indole and 8-chloro-2,3,4,5-tetrahydro-2-methyl-5-(2-(pyridin-4-yl)allyl)-1H-pyrido[4,3-b]indole, which were separated by HPLC. 1HNMR (DMSO, Oxalate Salt) δ (ppm): 8.60 (d, 2H), 7.62 (m, 3H), 7.40 (s, 1H), 7.30 (d, 1H), 7.20 (d, 1H), 4.40 (m, 2H), 3.10 (m, 4H), 2.99 (s, 3H), 1.90 (s, 3H).
Example 158
Preparation of Compound No. 186
1-(1,2,3,4-Tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-2-(6-methylpyridin-3-yl)propan-2-ol (1 equiv.) was refluxed with 25% sulfuric acid for 2 h. The reaction mixture was cooled to 5° C. with an ice-water bath. KOH (15% aq. solution) was added dropwise to the reaction mixture until pH 9-10 was achieved. The reaction mixture was extracted with EtOAc. The combined organic layers were washed with water followed by brine, dried over anhydrous sodium sulfate and evaporated under vacuum. The crude product was purified by column chromatography over silica gel (100-200 mesh) using a gradient of MeOH-EtOAc (0-10%) to obtain a mixture of 2,3,4,5-tetrahydro-2,8-dimethyl-5-4E)-2-(6-methylpyridin-3-yl)prop-1-enyl)-1H-pyrido[4,3-b]indole and 2,3,4,5-tetrahydro-2,8-dimethyl-5-(2-(6-methylpyridin-3-yl)allyl)-1H-pyrido[4,3-b]indole, which were separated by HPLC. 1HNMR (CD3OD, TFA salt) δ (ppm) 8.90 (s, 1H), 8.60 (d, 1H), 7.80 (d, 1H), 7.30 (d, 2H), 7.16 (d, 1H), 7.10 (d, 1H), 4.78 (m, 1H), 4.40 (m, 1H), 3.90 (m, 1H), 3.60 (m, 1H), 3.20 (m, 2H), 3.16 (s, 3H), 3.80 (s, 3H), 2.42 (s, 3H), 2.05 (s, 3H).
Example 159
Preparation of Compound No. 187
To a solution of 1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl trifluoromethanesulfonate (100 mg, 0.257 mmol) in DME (4 mL) was added Pd(PPh3)4 (15 mg, 0.0128 mmol) and the solution was purged with nitrogen for 5 min. Potassium carbonate (36 mg, 0.257 mmol), water (2 mL) and 2-(dimethylamino)-pyrimidine-5-boronic acid pinacol ester (128 mg, 0.515 mmol) were added, the reaction mixture was purged with nitrogen and refluxed for 45 min. The reaction mixture was cooled to RT and the solvent evaporated under reduced pressure. The residue was dissolved in EtOAc and filtered. The filtrate was concentrated under reduced pressure and purified by reverse phase HPLC to obtain the desired product as its TFA salt. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.78 (s, 2H), 7.31 (s, 1H), 7.10 (m, 3H), 4.78 (d, 1H), 4.38 (d, 1H), 3.82 (m, 1H), 3.59 (m, 1H), 3.38 (s, 6H), 3.10 (m, 5H), 2.41 (s, 3H), 1.97 (s, 3H).
Example 160
Preparation of Compound No. 188
5-(1-Bromoprop-1-en-2-yl)-2-methylpyridine (254 mg, 1.2 mmol) was dissolved in DMF (2 mL) and potassium phosphate (424 mg, 2 mmol), copper (I) iodide (19 mg, 0.1 mmol) and L-proline (23 mg, 0.2 mmol) were added, followed by 2,3,4,5-tetrahydro-2,6,8-trimethyl-1H-pyrido[4,3-b]indole (214 mg, 1 mmol). The reaction mixture was purged with nitrogen and heated at 140° C. overnight. The reaction mixture was cooled to RT, diluted with ice water and extracted with EtOAc (3×15 mL). The combined organic layer was washed with water (2×10 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel chromatography (100-200 mesh) eluting with 0-6% MeOH:DCM. The compound was further purified by reverse phase HPLC to obtain 37 mg of product as a freebase. The free base was converted into HCl salt by treatment with ethanolic HCl. 1H NMR (CD3OD, HCl salt) δ (ppm): 8.98 (s, 1H), 8.78 (d, 1H), 8.0 (d, 1H), 7.6 (s, 1H), 7.17 (s, 1H), 6.82 (s, 1H), 4.7 (d, 1H), 4.4 (d, 1H), 3.82 (m, 1H), 3.61 (m, 1H), 3.18 (m, 5H), 2.90 (s, 3H), 2.51 (s, 3H), 2.38 (s, 3H), 2.01 (s, 3H).
Example 161
Preparation of Compound No. 189
To a degassed solution of [(E,Z)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl trifluoromethanesulfonate] (100 mg, 0.257 mmol) in DME (4 mL) were added Pd(PPh3)4 (15 mg, 0.0128 mmol), potassium carbonate (36 mg, 0.257 mmol), water (2 mL) and 3-methylthiophene-2-boronic acid pinacol ester (115 mg, 0.515 mmol) followed by nitrogen purging. The reaction mixture was refluxed for 45 min. At that point, TLC showed no starting material remaining. The reaction mixture was cooled to RT and the solvent evaporated under reduced pressure. The residue was dissolved in EtOAc and filtered through a sintered crucible. The filtrate was concentrated under vacuum and the product isolated by reverse phase HPLC. 1H NMR, (CD3OD, TFA salt) δ (ppm): 7.32 (m, 2H), 7.13 (m, 2H), 6.97 (d, 1H), 6.79 (s, 1H), 4.67 (d, 1H), 4.40 (d, 1H), 3.83 (m, 1H), 3.58 (m, 1H), 3.14 (m, 5H), 2.40 (s, 6H), 1.87 (s, 3H).
Example 162
Preparation of Compound No. 190
To a degassed solution of 5-(2-bromocyclopent-1-enyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg, 0.29 mmol), 5-methylthiophene-2-boronic acid pinacol ester (100 mg, 0.575 mmol) and potassium carbonate (120 mg, 0.87 mmol) in 1,2-DME (4 mL) and water (2 mL) was added Pd(PPh3)4 (17 mg, 0.0147 mmol). The reaction mixture was heated at 90° C. for 45 min. The reaction mixture was concentrated under reduced pressure and the residue diluted with water (20 mL) and extracted with EtOAc (50 mL). The organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure. The residue was purified by reverse phase HPLC to yield 2,8-dimethyl-5-(2-(5-methylthiophen-2-yl)cyclopent-1-enyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR, (CD3OD, TFA salt) δ (ppm): 7.3 (s, 1H), 7.0 (m, 2H), 6.71 (d, 1H), 6.58 (d, 1H), 4.72 (m, 1H), 4.4 (m, 1H), 3.8 (m, 1H), 3.51 (m, 1H), 3.12 (s, 3H), 3.03 (m, 4H), 2.8 (m, 2H), 2.4 (s, 3H), 2.2-2.3 (m, 5H).
Example 163
Preparation of Compound No. 191
To a degassed solution of 5-(2-bromocyclopent-1-enyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg, 0.29 mmol), 1-methylindole-5-boronic acid pinacol ester (149 mg, 0.579 mmol) and potassium carbonate (120 mg, 0.87 mmol) in 1,2-DME (4 mL) and water (2 mL) was added Pd(PPh3)4 (17 mg, 0.0147 mmol). The reaction mixture was heated at 90° C. for 45 min. The reaction mixture was concentrated under reduced pressure. The residue was diluted with water (20 mL) and extracted with EtOAc (50 mL). The organic layer was dried over anhydrous sodium sulfate and evaporated. The residue was purified by reverse phase HPLC to yield 2,8-dimethyl-5-(2-(1-methyl-1H-indol-5-yl)cyclopent-1-enyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR, (CD3OD, TFA salt) δ (ppm): 7.21-7.38 (m, 2H), 7.2 (s, 1H), 7.04 (m, 2H), 6.9 (d, 1H), 6.8 (d, 1H), 6.21 (s, 1H), 4.62 (m, 1H), 4.35 (m, 1H), 3.65 (s, 3H), 3.58 (m, 2H), 3.01 (s, 3H), 2.81 (m, 2H), 2.6 (m, 4H), 2.41 (s, 3H), 2.21 (m, 2H).
Example 164
Preparation of Compound Nos. 192 and 192a-d
To a solution of ethyl 4-(1-hydroxy-2-(10-methyl-2,3,5,6-tetrahydro-1H-indolizino[7,8-b]indol-7(11cH)-yl)ethyl)picolinate (1 eq) in EtOH is added sodium hydroxide (4 eq, in water) and heated to 65° C. After conversion of starting material (TLC and LCMS), the EtOH and water are removed under reduced pressure. The crude product is passed through HPLC to yield the title racemic compound. Separation by chiral HPLC provides enantiomers 192a-d.
Example 165
Preparation of Compound Nos. 193 and 193a-b
To a degassed solution of 10-methyl-2,3,5,6,7,11c-hexahydro-1H-indolizino[7,8-b]indole (50 mg, 0.22 mmol), potassium phosphate (93 mg, 0.44 mmol), L-proline (2 mg, 0.01 mmol) and Cu(I)iodide (8 mg, 0.04 mmol) in DMF (1 mL) was added 5-(1-bromoprop-1-en-2-yl)-2-methylpyridine (93 mg, 0.44 mmol). The reaction mixture was stirred at 120° C. for 18 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was filtered through Celite and the filtrate was diluted with water (50 mL), extracted with EtOAc (2×50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield 10-methyl-7-(2-(6-methylpyridin-3-yl)prop-1-enyl)-2,3,5,6,7,11c-hexahydro-1H-indolizino[7,8-b]indole. 1H NMR, (CD3OD, formate salt) δ (ppm): 8.65 (s, 1H), 8.0 (d, 1H), 7.4 (d, 1H), 7.35 (s, 1H), 7.15 (d, 1H), 7.08 (d, 2H), 5.0 (t, 1H), 3.6 (m, 3H), 3.4 (m, 1H), 3.09 (q, 2H), 2.85 (m, 1H), 2.6 (s, 3H), 2.42 (s, 3H), 2.2 (m, 3H), 2.0 (s, 3H). Chiral HPLC provided the enantiomers 193a and 193b.
Example 166
Preparation of Compound Nos. 194 and 194a-b
To a degassed solution of 10-methyl-2,3,5,6,7,11c-hexahydro-1H-indolizino[7,8-b]indole (50 mg, 0.22 mmol), potassium phosphate (93 mg, 0.44 mmol), L-proline (2 mg, 0.01 mmol) and Cu(I)iodide (8 mg, 0.04 mmol) in DMF (1 mL) was added 1-(1-bromoprop-1-en-2-yl)-4-fluorobenzene (95 mg, 0.44 mmol). The reaction mixture was stirred at 120° C. for 18 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was filtered through Celite. The filtrate was diluted with water (50 mL), extracted with EtOAc (2×50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield 7-(2-(4-fluorophenyl)prop-1-enyl)-10-methyl-2,3,5,6,7,11c-hexahydro-1H-indolizino[7,8-b]indole. 1H NMR, (CD3OD, TFA salt) δ (ppm): 7.65 (t, 2H), 7.35 (s, 1H), 7.19 (t, 2H), 7.1 (m, 2H), 6.95 (s, 1H), 5.1 (t, 1H), 3.79 (m, 1H), 3.62 (m, 2H), 3.41 (m, 1H), 3.1 (m, 2H), 2.75 (m, 1H), 2.41 (s, 3H), 2.28 (m, 3H), 1.95 (s, 3H). Chiral HPLC provided the enantiomers 194a and 194b.
Example 167
Preparation of Compound Nos. 195 and 195a-b
This compound is prepared in analogous fashion to Compound Nos. 30 and 30a-b, using 5-(2-methyloxiran-2-yl)oxazole as the oxirane reagent. Separation by chiral HPLC provides enantiomers 195a-b.
Example 168
Preparation of Compound Nos. 196 and 196a-b
To a stirred solution of 2,3,4,9-tetrahydro-2,6-dimethyl-1H-pyrido[3,4-b]indole (500 mg, 2.5 mmol) in DMF (2 mL) was added NaH (300 mg, 7.5 mmol). After stirring for 5 min, a solution of 2-methyl-5-(2-methyloxiran-2-yl)pyridine (558 mg, 3.7 mmol) in DMF (1 mL) was added and the reaction mixture stirred at RT for 16 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with ice-water and extracted with EtOAc. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield the title compound. The product was further purified by chiral HPLC separation to give enantiomers 196a and 196b. 1H NMR, (CDCl3, freebase) δ (ppm): 8.6 (s, 1H), 7.6 (d, 1H), 7.27 (s, 1H), 7.1 (d, 1H), 7.05 (d, 1H), 6.9 (d, 1H), 4.1 (d, 1H), 4.0 (d, 1H), 3.62 (d, 1H), 3.43 (d, 1H), 2.8 (m, 4H), 2.59 (s, 3H), 2.5 (s, 3H), 2.4 (s, 3H), 1.6 (s, 3H).
Example 169
Preparation of Compound Nos. 197 and 197a-b
To a solution of 9-methyl-2,3,4,5,6,10c-hexahydro-1H-3a,6-diaza-cyclopenta[c]fluorene (100 mg, 0.422 mmol) in DMF (1 mL) was added sodium hydride (53 mg, 1.326 mmol). After stirring for 5 min, a solution of toluene-4-sulfonic acid 2-(6-methyl-pyridin-3-yl)-ethyl ester (386 mg, 1.326 mmol) in DMF (1 mL) was added dropwise at 0° C. and the reaction mixture stirred at RT for 6 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was poured into ice-cold water and extracted with EtOAc (3×25 mL). The combined organic layer was washed with water (5×20 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield 9-methyl-6-[2-(6-methyl-pyridin-3-yl)-ethyl]-2,3,4,5,6,10c-hexahydro-1H-3a, 6-diaza-cyclopenta[c]fluorene. 1H NMR, (CDCl3, freebase) δ (ppm): 8.07 (s, 1H), 7.28 (m, 2H), 7.07 (d, 1H), 7.0 (s, 2H), 4.72 (m, 1H), 4.3 (m, 1H), 4.18 (m, 1H), 3.31 (m, 1H), 3.2 (m, 1H), 3.12 (m, 1H), 3.0 (m, 2H), 2.7 (m, 1H), 2.51 (m, 1H), 2.5 (s, 3H), 2.48 (s, 3H), 2.4 (d, 1H), 2.28 (m, 1H), 2.2 (m, 1H), 2.0 (m, 1H), 1.8 (m, 1H). Chiral HPLC provided enantiomers 197a and 197b.
Example 170
Preparation of Compound Nos. 198 and 198a-d
To a solution of 9-methyl-2,3,4,5,6,10c-hexahydro-1H-3a,6-diaza-cyclopenta[c]fluorene (200 mg, 0.88 mmol) in DMF (10 mL) was added sodium hydride (96 mg, 2.6 mmol). After stirring for 5 min, a solution of 2-methyl-5-oxiranyl-pyridine (175 mg, 1.3 mmol) in DMF (1 mL) was added dropwise into the reaction mixture, which was stirred at RT for 5 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was poured into ice-cold water and extracted with EtOAc (3×25 mL). The combined organic layer was washed with water (5×25 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield 2-(9-methyl-1,2,3,4,5,10c-hexahydro-3a,6-diaza-cyclopenta[c]fluoren-6-yl)-1-(6-methyl-pyridin-3-yl)-ethanol. The product was further purified by chiral HPLC separation to give enantiomers 198a and 198b. Enantiomers 198c and 198d are also obtained by this method. 1H NMR, (CDCl3, freebase) δ (ppm): 8.45 (s, 1H), 7.6 (dd, 1H), 7.22 (m, 2H), 7.1 (t, 1H), 7.05 (t, 1H), 5.08 (q, 1H), 4.8 (dt, 1H), 3.5 (m, 2H), 3.4 (m, 2H), 3.1 (d, 1H), 3.0 (m, 1H), 2.8 (m, 1H), 2.6 (m, 2H), 2.5 (s, 3H), 2.41 (s, 3H), 2.1 (m, 3H).
Example 171
Preparation of Compound Nos. 199 and 199a-b
To a degassed solution of 11-methyl-1,2,3,4,6,7,8,12c-octahydroindolo[3,2-a]quinolizine (100 mg, 0.41 mmol), copper(I)iodide, L-proline (9.6 mg, 0.08 mmol) and potassium phosphate (176 mg, 0.83 mmol) in DMF was added dropwise 1-(1-bromoprop-1-en-2-yl)-4-fluorobenzene (107 mg, 53 mmol) and the reaction mixture was stirred at 85° C. overnight. The DMF was evaporated under reduced pressure, and the residue was diluted with water and the solid filtered. The solid material was purified by silica gel chromatography (100-200 mesh) eluting with 0-5% MeOH-DCM. The product was further purified by reverse phase HPLC followed by chiral HPLC separation to give enantiomers 199a and 199b. 1H NMR, (CDCl3, freebase) δ (ppm): 7.5 (t, 2H), 7.4 (s, 1H), 7.1 (t, 2H), 7.08 (d, 1H), 7.0 (d, 1H), 6.8 (s, 1H), 3.5 (m, 1H), 3.4 (m, 1H), 3.0 (m, 2H), 2.6 (m, 3H), 2.4 (s, 3H), 2.05 (m, 1H), 2.0 (s, 3H), 1.8 (m, 2H), 1.5 (m, 3H).
Example 172
Compound Nos. 200-210, 212-219 and 223 were prepared as described in PCT publication WO2009-055828.
Example 173
Compound Nos. 211, 225 and 231 were prepared as described in PCT publication WO2009-120720.
Example 174
Compound Nos. 224 and 239 were prepared as described in PCT publication WO2009-120717.
Example 175
Compound Nos. 236-237, 243, 250, 252-254, 256-259 and 261-268 were prepared as described in PCT publication WO2010-051501.
Example 176
Compound Nos. 172, 221-222, 226-230, 232-235, 238, 240-242, 244-249 and 251 were prepared as described in PCT publication WO2010-051503.
Example 177
Compound Nos. 255 and 260 were prepared as described in PCT publication WO2010-127177.
Example 178
Preparation of Compound Nos. 220 and 220a-b
This compound is prepared in analogous fashion to Compound Nos. 30 and 30a-b, using 4-(2-methyloxiran-2-yl)oxazole as the oxirane reagent. Separation by chiral HPLC provides enantiomers 220a-b.
Example 179
Preparation of Compound No. 269
To a degassed solution of 2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (0.08 g, 0.0004 mol), potassium tert-butoxide (0.112 g, 0.001 mol), (E/Z)-4-(1-bromoprop-1-en-2-yl)-2-methoxypyridine (0.091 g, 0.0004 mol) and 9,9-dimethyl-4,5-bis(diphenylphosphine) xanthene (0.023 g, 0.00004 mol) in toluene (3 mL) was added Pd2(dba)3 (0.0219 g, 0.000064 mol) and irradiated the reaction mixture at 80° C. for 30 min. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (3×20 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (2% MeOH-DCM) followed by preparative TLC to yield the title compound. 1H NMR (CD3OD, Oxalate salt) δ (ppm): 8.19 (d, 1H), 7.27 (s, 1H), 7.24 (m, 2H), 7.05 (m, 2H), 7.0 (s, 1H), 4.58 (s, 3H), 3.93 (s, 3H), 3.65 (m, 2H), 3.17 (m, 4H), 2.41 (s, 3H), 2.01 (s, 3H).
Example 180
Preparation of Compound No. 270
To a degassed solution of 1-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)prop-1-en-2-yl trifluoromethanesulfonate (50 mg, 0.129 mmol), Pd(PPh3)4 (7.4 mg, 0.0064) in DME (2 mL) were added potassium carbonate (17.8 mg, 0.1287 mmol), water (1 mL) and naphthalene-2-boronic acid (44 mg, 0.258 mmol) and the reaction mixture refluxed for 45 min. The reaction mixture was cooled to RT, and the solvent was removed under reduced pressure. The residue was dissolved in water (10 mL), extracted into EtOAc (3×25 mL) and washed with brine. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (2.5% MeOH-DCM) to yield the title compound. 1H NMR (CD3OD, freebase) δ (ppm): 8.02 (s, 1H), 7.82 (m, 3H), 7.79 (d, 1H), 7.42 (m, 2H), 7.21 (s, 1H), 7.11 (m, 2H), 6.95 (m, 1H), 3.78 (s, 2H), 2.84 (m, 4H), 2.60 (s, 3H), 2.40 (s, 3H), 2.12 (s, 3H).
Example 181
Preparation of Compound No. 271
To a degassed solution of 1-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)prop-1-en-2-yl trifluoromethanesulfonate (50 mg, 0.129 mmol) and Pd(PPh3)4 (7.4 mg, 0.0064) in DME (2 mL) were added potassium carbonate (17.8 mg, 0.1287 mmol), water (1 mL) and naphthalene-2-boronic acid (44 mg, 0.258 mmol), and the reaction mixture refluxed for 45 min. The reaction mixture was cooled to RT, and the solvent was removed under reduced pressure. The residue was dissolved in water (10 mL), extracted into EtOAc (3×25 mL), washed with brine, and concentrated to afford crude material, which was purified by silica gel column chromatography (2.5% MeOH-DCM) to yield the desired compound. 1H NMR (CD3OD, freebase) δ (ppm): 7.64 (m, 3H), 7.34 (m, 1H), 7.29 (m, 2H), 7.18 (m, 2H), 6.97 (m, 1H), 6.82 (m, 2H), 3.67 (s, 2H), 2.63 (d, 2H), 2.38-2.47 (m, 8H), 1.84 (s, 3H).
Example 182
Preparation of Compound Nos. 272 and 272a-b
A solution of 8-chloro-5-(2-(4-fluorophenyl)allyl)-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (150 mg, 0.423 mmol) and 10% Pd/C (10 mg) in MeOH:acetic acid (9 mL, 10:1) was hydrogenated in a Parr shaker at RT and 50 psi for 18 h. The reaction mixture was filtered through a Celite bed and the filtrate concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield the title compound. The product was further purified by reverse phase HPLC followed by chiral HPLC separation to give enantiomers 272a and 272b. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.41-7.43 (m, 2H), 7.2-6.94 (m, 6H), 4.62 (m, 1H), 4.29 (m, 2H), 4.06 (m, 1H), 3.6 (m, 1H), 3.37 (m, 2H), 3.0-2.9 (m, 5H), 1.45 (m, 3H).
Example 183
Preparation of Compound No. 273
To a degassed solution of 1-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)prop-1-en-2-yl trifluoromethanesulfonate (50 mg, 0.128 mmol) and Pd(PPh3)4 (7.4 mg, 0.0064) in DME (2 mL) were added potassium carbonate (17.8 mg, 0.1287 mmol), water (1 mL) and 1-methyl-1H-pyrazole-5-boronic acid pinacol ester (53.5 mg, 0.2574 mmol) and the reaction mixture refluxed for 2.5 h. The reaction mixture was cooled to RT, and concentrated to dryness. The residue was extracted into EtOAc, washed with brine, and concentrated under reduced pressure. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.40 (d, 1H), 7.21 (s, 1H), 7.15 (m, 2H), 6.87 (d, 1H), 6.38 (s, 1H), 4.63 (d, 1H), 4.23 (d, 1H), 3.74 (m, 1H), 3.41 (m, 1H), 3.16 (s, 3H), 3.09 (s, 3H), 2.81 (m, 2H), 2.19 (s, 3H), 2.14 (s, 3H).
Example 184
Preparation of Compound Nos. 274 and 274a-b
A solution of 1-(4-allyl-2,4,8-trimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2-(4-fluoro-phenyl)-propan-2-ol (300 mg, 0.738 mmol) in 6N HCl (10 mL) was stirred at 80° C. for 2 h. The progress of reaction mass was monitored by TLC and LCMS. The reaction mixture was basified with saturated sodium bicarbonate solution and extracted with EtOAc (3×25 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (1% MeOH-DCM) to yield 4-allyl-5-[2-(4-fluoro-phenyl)-propenyl]-2,4,8-trimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. The product is further purified by reverse phase HPLC followed by chiral HPLC separation to give enantiomers 274a and 274b. 1H NMR (CD3OD, HCl salt) δ (ppm): 7.62 (m, 2H), 7.27 (s, 1H), 7.20 (m, 2H), 7.04 (m, 3H), 6.78-6.82 (m, 1H), 5.18 (d, 2H), 4.78 (d, 1H), 4.37 (d, 1H), 3.58 (m,2H), 3.18 (s, 3H), 2.40 (s, 3H), 2.38 (d, 2H), 1.82 (s, 3H), 1.58 (s, 3H).
Example 185
Preparation of Compound No. 275
To a degassed solution of 1-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)prop-1-en-2-yl trifluoromethanesulfonate (100 mg, 0.257 mmol) and Pd(PPh3)4 (15 mg, 0.0128) in DME (4 mL) were added 1-methylpyrazole-4-boronic acid pinacol ester (108 mg, 0.515 mmol), potassium carbonate (36 mg, 0.257 mmol) and water (2 mL) and the reaction mixture refluxed for 45 min. The reaction mixture was cooled to RT and the solvent was removed under reduced pressure. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.27 (s, 1H), 7.19 (s, 1H), 7.04 (d, 1H), 6.98 (d, 1H), 6.46 (m, 2H), 4.78 (d, 1H), 4.39 (d, 1H), 3.90 (m, 1H), 3.76 (s, 3H), 3.44 (m, 1H), 3.08 (s, 3H), 2.86 (m, 2H), 2.42 (s, 3H), 2.21 (s, 3H).
Example 186
Preparation of Compound No. 276
To a degassed solution of 1-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)prop-1-en-2-yl trifluoromethanesulfonate (100 mg, 0.257 mmol) in DME (4 mL) were added Pd(PPh3)4 (15 mg, 0.0128), 2-fluoropyridine-5-boronic acid pinacol ester (115 mg, 0.515 mmol), potassium carbonate (36 mg, 0.257 mmol) and water (2 mL) and the reaction mixture refluxed for 45 min. The reaction mixture was cooled to RT, and the solvent was removed under reduced pressure. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.79 (s, 1H), 7.60 (m, 1H), 7.21 (s, 1H), 7.05 (d, 1H), 6.93 (d, 1H), 6.88 (s, 1H), 6.82 (d, 1H), 4.62 (d, 1H), 4.25 (d, 1H), 3.78 (m, 1H), 3.42 (m, 1H), 3.13 (s, 3H), 2.87 (m, 2H), 2.38 (m, 6H).
Example 187
Preparation of Compound No. 277
To a degassed solution of 1-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)prop-1-en-2-yl trifluoromethanesulfonate (100 mg, 0.257 mmol) in DME (4 mL) were added Pd(PPh3)4 (15 mg, 0.0128), 5-methylthiophene-2-boronic acid pinacol ester (115 mg, 0.515 mmol), potassium carbonate (36 mg, 0.257 mmol) and water (2 mL) were added followed by nitrogen purging and water (2 mL) and the reaction mixture refluxed for 45 min. The reaction mixture was cooled to RT, and the solvent was removed under reduced pressure. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.25 (s, 1H), 7.13 (d, 1H), 7.0 (d, 1H), 6.82 (d, 1H), 6.60 (d, 1H), 6.43 (s, 1H), 4.76 (d, 1H), 4.40 (d, 1H), 3.67 (m, 1H), 3.43 (m, 1H), 3.13 (s, 3H), 2.81-2.93 (m, 2H), 2.30 (s, 3H), 2.25 (s, 3H), 2.20 (s, 3H).
Example 188
Preparation of Compound No. 278
To a degassed solution of 1-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)prop-1-en-2-yl trifluoromethanesulfonate (100 mg, 0.257 mmol) in DME (4 mL) were added Pd(PPh3)4 (15 mg, 0.0128), 5-methylthiophene-2-boronic acid pinacol ester (115 mg, 0.515 mmol), potassium carbonate (36 mg, 0.257 mmol) and water (2 mL) and the reaction mixture refluxed for 45 min. The reaction mixture was cooled to RT, and the solvent was removed under reduced pressure. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.27 (s, 1H), 7.09 (m, 3H), 6.98 (s, 1H), 6.79 (s, 1H), 4.78 (d, 1H), 4.40 (d, 1H), 3.87 (m, 1H), 3.61 (m, 1H), 3.0-3.20 (m, 5H), 2.45 (s, 3H), 2.40 (s, 3H), 1.89 (s, 3H).
Example 189
Preparation of Compound No. 279
To a degassed solution of 1-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)prop-1-en-2-yl trifluoromethanesulfonate (100 mg, 0.257 mmol) in DME (4 mL) were added Pd(PPh3)4 (15 mg, 0.0128 mmol), potassium carbonate (36 mg, 0.257 mmol), water (2 mL) and 2-(dimethylamino)pyrimidine-5-boronic acid pinacol ester (128 mg, 0.515 mmol). The reaction mixture was refluxed for 45 min. At that point, TLC showed no starting material. The reaction mixture was cooled to RT and the solvent evaporated under reduced pressure. The residue was dissolved in EtOAc and filtered through a sintered crucible. The filtrate was concentrated and residue purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.98 (s, 2H), 7.22 (s. 1H), 7.08 (d, 1H), 6.99 (d, 1H), 6.80 (s, 1H), 4.65 (d, 1H), 4.31 (d, 1H), 3.80 (m, 1H), 3.51 (m, 1H), 3.01-3.81 (m, 11H), 2.40 (s, 3H), 2.37 (s, 3H).
Example 190
Preparation of Compound No. 280
To a solution of (4-(1-bromoprop-1-en-2-yl)phenyl)(methyl)sulfane (132 mg, 0.55 mmol) in DMF (1 mL) were added potassium phosphate (212 mg, 2 mmol), copper(I)iodide (9.5 mg, 0.05 mmol), L-proline (11.5 mg, 0.1 mmol) and 8-chloro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (110 mg, 0.5 mmol) and the reaction mixture stirred at 85° C. for 16 h. Ice water was added into the reaction mixture and the solid obtained was filtered. The residue was purified by silica gel column chromatography (0-3% MeOH-DCM) to yield the title compound. 1H NMR (CD3OD, oxalate salt) δ (ppm): 7.58 (m, 3H), 7.37 (d, 2H), 7.21 (s, 2H), 7.0 (s, 1H), 4.60 (s, 2H), 3.76 (s, 2H), 3.16 (m, 5H), 2.57 (s, 3H), 1.97 (s, 3H).
Example 191
Preparation of Compound No. 281
To a solution of 1-(1-bromoprop-1-en-2-yl)-4-(methylsulfonyl)benzene (150 mg, 0.55 mmol) in DMF (1 mL) were added potassium phosphate (212 mg, 2 mmol), copper(I)iodide (9.5 mg, 0.05 mmol), L-proline (11.5 mg, 0.1 mmol) and 8-chloro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (110 mg, 0.5 mmol). The reaction mixture was stirred at 85° C. for 16 h. Ice water was added into the reaction mixture and the solid obtained was filtered. The residue was purified by silica gel column chromatography (0-3% MeOH-DCM) to yield the title compound. 1H NMR (CD3OD, oxalate salt) δ (ppm): 8.04 (d, 2H), 7.91 (d, 2H), 7.58 (s, 1H), 7.21 (d, 2H), 7.19 (s, 1H), 4.57 (s, 2H), 3.70 (s, 2H), 3.15-3.20 (m, 8H), 2.01 (s, 3H).
Example 192
Preparation of Compound No. 282
To a degassed solution of (E,Z)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl trifluoromethanesulfonate (100 mg, 0.257 mmol) in DME (4 mL) were added Pd(PPh3)4 (15 mg, 0.0128 mmol), potassium carbonate (36 mg, 0.257 mmol), water (2 mL) and 1H-benzimidazole-5-boronic acid pinacol ester (125 mg, 0.515 mmol). The reaction mixture was refluxed for 45 min. At that point, TLC showed no starting material. The reaction mixture was cooled to RT and the solvent evaporated under reduced pressure. The residue was dissolved in EtOAc and filtered through a sintered crucible. The filtrate was concentrated and the residue was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 9.37 (s, 1H), 8.02 (s, 1H), 7.90 (m, 2H), 7.37 (s, 1H), 7.16 (m, 3H), 4.76 (bs, 1H), 4.40 (bs, 1H), 3.90 (bs, 1H), 3.60 (bs, 1H), 3.18 (m, 5H), 2.41 (s, 3H), 2.07 (s, 3H).
Example 193
Preparation of Compound No. 283
To a degassed solution of (E,Z)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl trifluoromethanesulfonate (100 mg) in DME (4 mL) were added Pd(PPh3)4 (15 mg), potassium carbonate (36 mg), water (1 mL) and 1-methylindole-5-boronic acid pinacol ester (132 mg). The reaction mixture was refluxed for 45 min. At that point, TLC showed no starting material. The reaction mixture was cooled to RT and the solvent evaporated under reduced pressure. The residue was dissolved in EtOAc and filtered through a sintered crucible. The filtrate was concentrated and residue was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.80 (d, 1H), 7.42 (d, 1H), 7.39 (d, 1H), 7.31 (s, 1H), 7.20 (s, 1H), 7.18 (d, 1H), 7.10 (d, 1H), 6.91 (s, 1H), 6.43 (d, 1H), 4.73 (d, 1H), 4.38 (d, 1H), 3.81 (s, 4H), 3.60 (m, 1H), 3.17 (m, 5H), 2.42 (s, 3H), 1.98 (s, 3H).
Example 194
Preparation of Compound No. 284
To a degassed solution of (E,Z)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl trifluoromethanesulfonate (100 mg) in DME (4 mL) were added Pd(PPh3)4 (15 mg), potassium carbonate (36 mg), water (1 mL) and 1-methylindole-5-boronic acid pinacol ester (132 mg). The reaction mixture was refluxed for 45 min. At that point, TLC showed no starting material. The reaction mixture was cooled to RT and the solvent removed under reduced pressure. The residue was dissolved in EtOAc and filtered through a sintered crucible. The filtrate was concentrated and residue purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.31 (d, 2H), 7.20 (s, 1H), 7.05 (m, 3H), 6.80 (d, 1H), 6.76 (s, 1H), 6.21 (d, 1H), 4.51 (d, 1H), 4.20 (d, 1H), 3.70 (s, 3H), 3.52 (m, 2H), 3.19 (m, 2H), 2.80 (s, 3H), 2.40 (s, 3H), 2.38 (s, 3H).
Example 195
Preparation of Compound No. 285
To a degassed solution of [(E,Z)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl trifluoromethanesulfonate] (100 mg, 0.257 mmol) in DME (4 mL) were added Pd(PPh3)4 (15 mg, 0.0128 mmol), potassium carbonate (36 mg, 0.257 mmol), water (2 mL) and 4-methylthiophene-2-boronic acid pinacol ester (115 mg, 0.515 mmol). The reaction mixture was refluxed for 45 min. At that point, TLC showed no starting material. The reaction mixture was cooled to RT and the solvent evaporated under reduced pressure. The residue was dissolved in EtOAc and filtered through a sintered crucible. The filtrate was concentrated under vacuum and the residue was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.30 (s, 1H), 7.18 (s, 1H), 7.05 (m, 3H), 6.98 (s, 1H), 4.71 (d, 1H), 4.40 (d, 1H), 3.82 (m, 1H), 3.57 (m, 1H), 3.18 (m, 2H), 3.10 (s, 3H), 2.41 (s, 3H), 2.23 (s, 3H), 1.87 (s, 3H).
Example 196
Preparation of Compound No. 286
To a degassed solution of [(E,Z)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl trifluoromethanesulfonate] (100 mg, 0.257 mmol) in DME (4 mL) were added P(PPh3)4 (15 mg, 0.0128 mmol), potassium carbonate (36 mg, 0.257 mmol), water (2 mL) and naphthalene-1-boronic acid (88 mg, 0.515 mmol). The reaction mixture was refluxed for 45 min. At that point, TLC showed no starting material. The reaction mixture was cooled to RT and the solvent evaporated under reduced pressure. The residue was dissolved in EtOAc and filtered through a sintered crucible. The filtrate was concentrated and product isolated by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.92 (d, 1H), 7.78 (d, 1H), 7.67 (m, 1H), 7.29-7.41 (m, 5H), 7.13 (s, 1H), 7.0 (s, 1H), 6.98 (d, 1H), 4.40 (d, 1H), 4.11 (d, 1H), 3.51 (m, 1H), 3.21 (m, 1H), 2.80 (s, 3H), 2.71 (m, 2H), 2.42 (s, 3H), 2.37 (s, 3H).
Example 197
Preparation of Compound No. 287
To a solution of [(E,Z)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl trifluoromethanesulfonate] (100 mg, 0.257 mmol) in DME (4 mL) was added Pd(PPh3)4 (15 mg, 0.0128 mmol) and solution purged with nitrogen for 5 min. Potassium carbonate (36 mg, 0.257 mmol), water (2 mL) and 3-methylthiophene-2-boronic acid pinacol ester (115 mg, 0.515 mmol) were added followed by nitrogen purging. The reaction mixture was refluxed for 45 min. At that point, TLC showed no starting material. The reaction mixture was cooled to RT and the solvent evaporated under reduced pressure. The residue was dissolved in EtOAc and filtered through a sintered crucible. The filtrate was concentrated under reduced pressure and residue purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.21 (d, 1H), 7.19 (s, 1H), 7.12 (d, 1H), 6.96 (d, 1H), 6.82 (s, 1H), 6.61 (d, 1H), 4.60 (d, 1H), 4.23 (d, 1H), 3.68 (m, 1H), 3.40 (m, 1H), 3.0 (s, 3H), 2.80 (m, 2H), 2.40 (s, 3H), 2.37 (s, 3H), 1.58 (s, 3H).
Example 198
Preparation of Compound Nos. 288 and 288a-b
A solution of 5-(2-(4-fluorophenyl)prop-1-enyl)-2,3,4,5-tetrahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole and 5-(2-(4-fluorophenyl)allyl)-2,3,4,5-tetrahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole (1.8 g, 5.38 mmol) and 10% Pd/C (180 mg) in MeOH-acetic acid (50 mL, 10:1) was hydrogenated in a Parr shaker at RT and 60 psi for 18 h. The reaction mixture was filtered through a Celite bed and the filtrate concentrated under reduced pressure. The residue was diluted with EtOAc (500 mL) and washed with satd. sodium bicarbonate solution (50 mL) and then brine. The organic layer was dried over anhydrous sodium sulfate concentrated under reduced pressure. The residue was purified by silica gel column chromatography (0 to 50% EtOAc in hexanes) to yield the title compound. 1HNMR (DMSO, Oxalate salt) δ (ppm):7.38-7.3 (d, 1H), 7.36 (bs, 1H), 7.19 (s, 2H),7.07 (bs, 2H), 6.97-6.95 (d, 1H), 4.53 (m,1H), 4.24-4.12 (m, 3H), 3.86 (m,1H), 3.25 (m, 1H), 3.06 (m, 1H), 2.98 (s, 3H), 2.78 (bs, 1H), 2.62 (bs, 1H), 2.33 (s, 3H), 1.14 (bs, 3H). Separation by chiral HPLC provided enantiomers 288a-b.
Example 199
Preparation of Compound Nos. 289 and 289a-b
A solution of 2,8-dimethyl-5-(2-(6-methylpyridin-3-yl)prop-1-enyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg) and 10% Pd/C (20 mg) in MeOH (5 mL) was hydrogenated in a Parr shaker at RT and 50 psi for 72 h. The progress of reaction was monitored by LCMS. The reaction mass was filtered through a Celite bed and the filtrate concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield the title compound. 1HNMR (CD3OD, TFA salt) δ (ppm): 8.30 (m, 2H), 7.70 (s, 1H), 7.20 (s, 1H), 7.10 (d, 1H), 6.98 (d, 1H), 4.60 (m, 2H), 4.30 (m, 3H), 3.80 (m, 2H), 3.60 (m, 2H), 3.10 (s, 3H), 2.62 (s, 3H), 2.38 (s, 3H), 1.42 (d, 3H). Separation by chiral HPLC provided enantiomers 289a-b.
Example 200
Preparation of Compound No. 290
To a solution of [(E,Z)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl trifluoromethanesulfonate] (100 mg, 0.257 mmol) in DME (4 mL) was added Pd(PPh3)4 (15 mg, 0.0128 mmol) and solution purged with nitrogen for 5 min. Potassium carbonate (72 mg, 0.515 mmol), water (2 mL) and indazole-4-boronic acid.HCl (102 mg, 0.515 mmol) were added followed by nitrogen purging. The reaction mixture was refluxed for 45 min. At that point, TLC showed no starting material. The reaction mixture was cooled to RT and the solvent evaporated under reduced pressure. The residue was dissolved in EtOAc and filtered through a sintered crucible. The filtrate was concentrated under vacuum and the product isolated by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.57 (s, 1H), 7.40 (d, 1H), 7.31 (m, 2H), 7.12 (s, 1H), 7.05 (d, 1H), 7.0 (s, 2H), 4.51 (d, 1H), 4.17 (d, 1H), 3.58 (m, 1H), 3.21 (m, 1H), 2.81 (s, 3H), 2.60 (m, 2H), 2.41 (s, 3H), 2.38 (s, 3H).
Example 201
Preparation of Compound No. 291
To a solution of [(E,Z)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl trifluoromethanesulfonate] (100 mg, 0.257 mmol) in DME (4 mL) was added Pd(PPh3)4 (15 mg, 0.0128 mmol) and solution purged with nitrogen for 5 min. Potassium carbonate (36 mg, 0.257 mmol), water (2 mL) and 4-methylthiophene-2-boronic acid pinacol ester (115 mg, 0.515 mmol) were added followed by nitrogen purging. The reaction mixture was refluxed for 45 min. At that point, TLC showed no starting material. The reaction mixture was cooled to RT and the solvent evaporated under reduced pressure. The residue was dissolved in EtOAc and filtered through a sintered crucible. The filtrate was concentrated under vacuum and the product isolated by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.23 (s, 1H), 7.08 (d, 1H), 7.00 (d, 1H), 6.85 (s, 1H), 6.78 (s, 1H), 6.55 (s, 1H), 4.73 (d, 1H), 4.38 (d, 1H), 3.71 (m, 1H), 3.42 (m, 1H), 3.05 (s, 3H), 2.97 (m, 1H), 2.80 (m, 1H), 2.42 (s, 3H), 2.38 (s, 3H), 2.20 (s, 3H).
Example 202
Preparation of Compound No. 292
To a degassed solution of (E,Z)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl trifluoromethanesulfonate (100 mg, 0.257 mmol) in DME (2 mL) were added Pd(PPh3)4 (20 mg, 0.017 mmol), potassium carbonate (110 mg, 0.77 mmol), water (1 mL) and isoquinoline-4-boronic acid (89 mg, 0.515 mmol). The reaction mixture was refluxed for 45 min. At that point, TLC showed no starting material. The reaction mixture was cooled to RT and diluted with EtOAc. The aqueous layer was extracted with EtOAc (3×6 mL) and the combined organic layer was dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure and residue was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 9.8 (s, 1H), 8.78 (s, 1H), 8.6 (d, 1H), 8.46 (d, 1H), 8.38 (dd, 1H), 8.17 (dd, 1H), 7.4 (m, 2H), 7.2 (d, 1H), 7.02 (s, 1H), 4.8 (d, 1H), 4.41 (d, 1H), 3.82 (m, 1H), 3.62 (m, 1H), 3.36 (m, 2H), 3.19 (s, 3H), 2.41 (s, 3H), 2.18 (s, 3H).
Example 203
Preparation of Compound No. 293
To a degassed solution of (E,Z)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl trifluoromethanesulfonate (100 mg, 0.257 mmol) and potassium carbonate (110 mg, 0.796 mmol), in DME (2 mL)-water (1 mL) were added Pd(PPh3)4 (20 mg, 0.017 mmol) and thianaphthene-2-boronic acid (91.4 mg, 0.514 mmol) followed by nitrogen purging. The reaction mixture was refluxed for 45 min. At that point, TLC showed no starting material. The reaction mixture was cooled to RT and diluted with EtOAc. The aqueous layer was extracted with EtOAc (3×6 mL) and the combined organic layer dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to afford crude product which was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.78 (d, 1H), 7.52 (d, 1H), 7.5 (s, 1H), 7.32 (s, 1H), 7.2-7.3 (m, 2H), 7.18 (d, 1H), 7.03 (d, 1H), 6.78 (s, 1H), 4.7 (d, 1H), 4.4 (d, 1H), 3.7 (m, 1H), 3.43 (m, 1H), 3.08 (s, 3H), 2.8 (m, 2H), 2.49 (s, 3H), 2.41 (s, 3H).
Example 204
Preparation of Compound No. 294
To a solution of 2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (200 mg, 1.0 mmol) in NMP (1 mL) were added powdered KOH (392 mg, 7.0 mmol) and 3-vinyl-benzo[b]thiophene (320 mg, 2.0 mmol). The reaction mixture was stirred at 90° C. for 5 h. The reaction mixture was diluted with water (15 mL) and extracted with EtOAc (3×20 mL). The combined organic layer was washed with water (5×25 mL), dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (3% MeOH-DCM) followed by reverse phase HPLC to yield 5-(2-benzo[b]thiophen-3-yl-ethyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR (CDCl3, freebase) δ (ppm): 7.82 (d, 1H), 7.6 (d, 1H), 7.38 (m, 2H), 7.2 (m, 2H), 7.0 (d, 1H), 6.93 (s, 1H), 4.3 (t, 2H), 3.62 (s, 2H), 3.5 (s, 3H), 3.21 (t, 2H), 2.63 (t, 2H), 2.41 (m, 5H).
Example 205
Preparation of Compound No. 295
To a solution of 3-(1-bromoprop-1-en-2-yl)phenyl)(methyl)sulfane (300 mg, 1.2 mmol) in DMF (2 mL) were added potassium phosphate (424 mg, 2 mmol), copper(I)iodide (19 mg, 0.1 mmol), L-proline (23 mg, 0.2 mmol) and 8-chloro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (220 mg, 1 mmol). The reaction mixture was stirred at 140° C. for 16 h. Ice water was added to the reaction mixture and extracted with EtOAc (3×15 mL). The combined organic layer was washed with water (2×10 mL), dried and concentrated. The residue was purified by silica gel column chromatography (0-3% MeOH-DCM) followed by reverse phase HPLC to yield the title compound. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.57 (d, 1H), 7.5 (d, 1H), 7.38-7.42 (m, 2H), 7.3 (d, 1H), 7.2 (m, 2H), 6.97 (s, 1H), 4.7 (d, 1H), 4.4 (d, 1H), 3.82 (m, 1H), 3.6 (m, 1H), 3.1 (m, 5H), 2.5 (s, 3H), 1.98 (s, 3H).
Example 206
Preparation of Compound No. 296
To a solution of 1-(1-bromoprop-1-en-2-yl)-3-(methylsulfonyl)benzene (297 mg, 1.1 mmol) in DMF (2 mL) were added potassium phosphate (424 mg, 2 mmol), copper(I)iodide (19 mg, 0.1 mmol), L-proline (23 mg, 0.2 mmol) and 8-chloro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (220 mg, 1 mmol) and purged nitrogen for 2 min and heated at 90° C. for 16 h. Ice water (5 mL) was added and filtered the solid obtained and washed with water (2×10 mL). Product was purified on silica column (100-200 mesh) using 0-3% MeOH:DCM as eluant. The compound was further purified through reverse phase HPLC. Yield: 49.26 mg (freebase). 1H NMR (CD3OD, freebase) δ (ppm): 8.2 (s, 1H), 7.98 (m, 2H), 7.7 (dd, 1H), 7.48 (s, 1H), 7.18 (m, 2H), 7.1 (s, 1H), 4.2 (s, 2H), 3.4 (s, 2H), 3.2 (s, 3H), 3.1 (s, 2H), 2.9 (s, 3H), 1.8 (s, 3H).
Example 207
Preparation of Compound No. 297
To a degassed stirred solution of 2,8-dimethyl-5-(6-methyl-pyridin-2-ylethynyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg, 0.317 mmol) in MeOH (5 mL) was added Pd/C (35 mg, 35% w/w) and purged the reaction mixture with H2 gas at RT for 2 h. The progress of reaction was monitored by TLC and NMR. Reaction mass was filtered through a Celite bed washed with MeOH (3×5 mL). Filtrate was concentrated under reduced pressure and residue was purified by reverse phase HPLC to yield 2,8-dimethyl-5-[2-(6-methyl-pyridin-2-yl)-ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.2 (dd, 1H), 7.63 (d, 1H), 7.57 (d, 1H), 7.21 (d, 1H), 7.02 (d, 1H), 6.96 (d, 1H), 4.7 (d, 1H), 4.58 (t, 2H), 4.37 (d, 1H), 3.82 (m, 1H), 3.57 (m, 1H), 3.4 (t, 2H), 3.2 (m, 2H), 3.18 (s, 3H), 2.61 (s, 3H), 2.4 (s, 3H).
Example 208
Preparation of Compound No. 298
To a solution of 2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg, 0.5 mmol) was in NMP (1 mL) were added powdered KOH (196 mg, 3.5 mmol) and dimethyl-(3-vinyl-phenyl)-amine (147 mg, 1.0 mmol) and the reaction mixture stirred at 100° C. for 16 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was diluted with water (15 mL) and extracted with EtOAc (3×25 mL). The combined organic layer was washed with water (5×20 mL), dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (0-3% MeOH-DCM) to yield {3-[2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-ethyl]-phenyl}-dimethyl-amine. 1H NMR (CDCl3, freebase) δ (ppm): 7.21 (m, 2H), 7.18 (dd, 1H), 7.0 (d, 1H), 6.6 (d, 1H), 6.43 (d, 1H), 6.21 (s, 1H), 4.2 (t, 2H), 3.71 (s, 2H), 2.90 (t, 2H), 2.85 (s, 3H), 2.80 (m, 4H), 2.57 (s, 6H), 2.41 (s, 3H).
Example 209
Preparation of Compound No. 299
To a degassed stirred solution of 2,8-dimethyl-5-(5-methyl-pyridin-2-ylethynyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (110 mg, 0.349 mmol) in MeOH (5 mL) was added Pd/C (40 mg, 35% w/w) and purged the reaction mixture with H2 gas at RT for 2 h. The progress of reaction was monitored by TLC and NMR. Reaction mass was filtered through a Celite bed washed with MeOH (3×5 mL). Filtrate was concentrated under reduced pressure and residue was purified by reverse phase HPLC to yield 2,8-dimethyl-5-[2-(5-methyl-pyridin-2-yl)-ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.42 (s, 1H), 8.02 (d, 1H), 7.48 (d, 1H), 7.21 (s, 1H), 7.12 (d, 1H), 6.98 (d, 1H), 4.67 (d, 1H), 4.5 (t, 2H), 4.3 (d, 1H), 3.8 (m, 1H), 3.5 (m, 1H), 3.38 (t, 2H), 3.1 (m, 5H), 2.41 (s, 3H), 2.39 (s, 3H).
Example 210
Preparation of Compound No. 300
To a degassed stirred solution of 5-(2-bromocyclopent-1-enyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg, 0.29 mmol), 3-pyridinylboronic acid (71 mg, 0.577 mmol) and potassium carbonate (120 mg, 0.87 mmol) in 1,2-dimethoxyethane (4 mL)-water (2 mL) was added Pd(PPh3)4 (16 mg, 0.0147 mmol). The reaction mixture was stirred at 90° C. for 45 min. The reaction mixture concentrated, residue diluted with water (20 mL) and extracted with EtOAc (50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield 2,8-dimethyl-5-(2-(pyridin-3-yl)cyclopent-1-enyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.68 (d, 1H), 8.1 (d, 1H), 7.9 (m, 1H), 7.8 (m, 1H), 7.3 (s, 1H), 6.9-7.1 (m, 2H), 4.7 (m, 1H), 4.4 (m, 1H), 3.8 (m, 1H), 3.58 (m, 1H), 2.8-3.3 (m, 9H), 2.22-2.4 (m, 5H).
Example 211
Preparation of Compound No. 301
To a degassed stirred solution of 5-(2-bromocyclopent-1-enyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg, 0.29 mmol), 4-fluorophenylboronic acid (81 mg, 0.578 mmol) and potassium carbonate (120 mg, 0.87 mmol) in 1,2-dimethoxyethane (4 mL)-water (2 mL) was added Pd(PPh3)4 (17 mg, 0.0147 mmol). The reaction mixture was stirred at 90° C. for 45 min. The reaction mixture concentrated to dryness, residue diluted with water (20 mL) and extracted with EtOAc (50 mL). The organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield 5-(2-(4-fluorophenyl)cyclopent-1-enyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.3 (s, 1H), 7.17 (d, 1H), 7.02 (d, 1H), 6.8-6.98 (m, 4H), 4.7 (d, 1H), 4.3 (d, 1H), 3.65 (m, 1H), 3.41 (m, 1H), 2.9-3.18 (m, 7H), 2.52-2.77 (m, 2H), 2.45 (s, 3H), 2.21 (m, 2H).
Example 212
Preparation of Compound No. 302
To a degassed stirred solution of 5-(2-bromocyclopent-1-enyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg, 0.29 mmol), 3-methylthiophene-2-boronic acid pinacol ester (129 mg, 0.575 mmol) and potassium carbonate (120 mg, 0.87 mmol) in 1,2-dimethoxyethane (4 mL)-water (2 mL) was added Pd(PPh3)4 (16 mg, 0.0147 mmol). The reaction mixture was stirred at 90° C. for 45 min. The solvent was under reduced pressure, residue diluted with water (20 mL) and extracted with EtOAc (50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by reverse phase HPLC to yield 2,8-dimethyl-5-(2-(3-methylthiophen-2-yl)cyclopent-1-enyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.24 (s, 1H), 7.1-7.2 (m, 2H), 7.0 (dd, 1H), 6.6 (s, 1H), 4.6 (m, 1H), 4.4 (m, 1H), 3.64 (m, 1H), 3.2 (m, 1H), 2.8-3.17 (m, 7H), 2.6 (t, 2H), 2.4 (s, 3H), 2.2 (t, 2H), 1.8 (m, 3H).
Example 213
Preparation of Compound No. 303
To a degassed stirred solution of 5-(2-bromocyclopent-1-enyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg, 0.29 mmol), 2-(dimethylamino)pyrimidine-5-boronic acid pinacol ester (129 mg, 0.578 mmol) and potassium carbonate (120 mg, 0.87 mmol) in 1,2-dimethoxyethane (4 mL)-water (2 mL) was added Pd(PPh3)4 (16 mg, 0.0147 mmol). The reaction mixture was stirred at 90° C. for 45 min. The solvent was removed under reduced pressure, residue diluted with water (20 mL) and extracted with EtOAc (50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by reverse phase HPLC to yield 5-(2-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)cyclopent-1-enyl)-N,N-dimethylpyrimidin-2-amine. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.8 (d, 2H), 7.3 (s, 1H), 6.98-7.1 (m, 2H), 4.7 (m, 1H), 4.38 (m, 1H), 3.8 (m, 1H), 3.5 (m, 1H), 2.78-3.1 (m, 15H), 2.4 (s, 3H), 2.2 (m, 2H).
Example 214
Preparation of Compound No. 304
To a degassed stirred solution of 5-(2-bromocyclopent-1-enyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg, 0.29 mmol), 4-methylthiophene-2-boronic acid pinacol ester (129 mg, 0.578 mmol) and potassium carbonate (120 mg, 0.87 mmol) in 1,2-dimethoxyethane (4 mL)-water (2 mL) was purged with nitrogen followed by addition of Pd(PPh3)4 (16 mg, 0.0147 mmol). The reaction mixture was stirred at 90° C. for 45 min. The solvent was removed under reduced pressure, residue diluted with water (20 mL) and extracted with EtOAc (50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by reverse phase HPLC to yield 2,8-dimethyl-5-(2-(4-methylthiophen-2-yl)cyclopent-1-enyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.3 (s, 1H), 7.0 (m, 3H), 6.78 (s, 1H), 4.7 (m, 1H), 4.4 (m, 1H), 3.8 (m, 1H), 3.5 (m, 1H), 3.37 (s, 3H), 3.03 (m, 2H), 2.83 (m, 2H), 2.61 (m, 2H), 2.4 (s, 3H), 2.2 (m, 2H), 2.17 (s, 3H).
Example 215
Preparation of Compound No. 305
A solution of 5-(2-bromocyclopent-1-enyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg, 0.29 mmol), benzo[b]thien-2-ylboronic acid (103 mg, 0.578 mmol) and potassium carbonate (120 mg, 0.87 mmol) in 1,2-dimethoxyethane (4 mL)-water (2 mL) was purged with nitrogen followed by addition of Pd(PPh3)4 (16 mg, 0.0147 mmol). The reaction mixture was stirred at 90° C. for 45 min. The solvent was removed under reduced pressure, residue diluted with water (20 mL) and extracted with EtOAc (50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by reverse phase HPLC to yield 5-(2-(benzo[b]thiophen-2-yl)cyclopent-1-enyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.2 (d, 1H), 7.5 (d, 1H), 7.38 (s, 1H), 7.2-7.3 (m, 3H), 7.1 (d, 1H), 7.04 (d, 1H), 4.4 (m, 2H), 3.6 (m, 2H), 3.2 (m, 2H), 3.1 (s, 3H), 2.9 (m, 2H), 2.7 (m, 2H), 2.41 (s, 3H), 2.3 m, 2H).
Example 216
Preparation of Compound No. 306
A solution of 5-(2-bromocyclopent-1-enyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg, 0.29 mmol), naphthalene-1-boronic acid (99 mg, 0.575 mmol) and potassium carbonate (120 mg, 0.87 mmol) in mixture of 1,2-dimethoxyethane (4 mL)-water (2 mL) was purged with nitrogen followed by addition of Pd(PPh3)4 (16 mg, 0.0147 mmol). The reaction mixture was stirred at 90° C. for 45 min. The solvent was removed under reduced pressure, residue diluted with water (20 mL) and extracted with EtOAc (50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by reverse phase HPLC to yield 2,8-dimethyl-5-(2-(naphthalen-1-yl)cyclopent-1-enyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR (DMSO, TFA salt) δ (ppm): 8.0 (d, 1H), 7.8 (d, 1H), 7.79 (d, 1H), 7.3-7.5 (m, 5H), 7.1 (s, 1H), 6.9 (d, 1H), 4.21 (m, 2H), 3.4 (m, 2H), 2.77-3.0 (m, 9H), 2.3 (m, 5H).
Example 217
Preparation of Compound No. 307
To a solution of 2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (150 mg, 0.75 mmol) in NMP (1 mL) were added powdered KOH (294 mg, 5.25 mmol) and 2-methyl-5-vinyl-thiophene (186 mg, 1.50 mmol), and the reaction mixture stirred at 90° C. for 5 h. The reaction mixture was diluted with water (15 mL) and extracted with EtOAc (3×20 mL). The combined organic layer was washed with water (5×25 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (3% MeOH-DCM) followed by reverse phase HPLC to yield 2,8-dimethyl-5-[2-(5-methyl-thiophen-2-yl)-ethyl]-2,5-dihydro-1H-pyrido[4,3-b]indole. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.3 (d, 1H), 7.22 (s, 1H), 7.08 (d, 1H), 6.5 (d, 1H), 6.3 (d, 1H), 4.6 (d, 1H), 4.2-4.4 (m, 3H), 3.7 (m, 2H), 3.2 (m, 3H), 3.03 (s, 3H), 2.7 (m, 1H), 2.38-2.42 (m, 6H).
Example 218
Preparation of Compound No. 308
To a solution of 2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (250 mg, 1.25 mmol) in NMP (1 mL) were added powdered KOH (490 mg, 8.75 mmol) and 3-methyl-2-vinyl-thiophene (310 mg, 2.25 mmol), and the reaction mixture stirred at 90° C. for 5 h. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (3×20 mL). The combined organic layer was washed with water (5×25 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield 2,8-dimethyl-5-[2-(3-methyl-thiophen-2-yl)-ethyl]-2,5-dihydro-1H-pyrido[4,3-b]indole. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.25 (d, 1H), 7.22 (s, 1H), 7.1 (d, 1H), 7.02 (d, 1H), 6.7 (d, 1H), 4.41 (s, 2H), 4.3 (t, 2H), 2.42 (bs, 2H), 3.2 (t, 2H), 3.0 (s, 3H), 2.61 (bs, 2H), 2.4 (s, 3H), 1.6 (s, 3H).
Example 219
Preparation of Compound No. 309
To a degassed stirred solution of 5-(2-bromocyclopent-1-enyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg, 0.29 mmol), 1-methyl-1H-pyrazole-5-boronic acid pinacol ester (81 mg, 0.576 mmol) and potassium carbonate (120 mg, 0.87 mmol) in 1,2-dimethoxyethane (4 mL) and water (2 mL) was added Pd(PPh3)4 (17 mg, 0.0147 mmol). The reaction mixture was stirred at 90° C. for 45 min. The solvent was removed under reduced pressure, residue diluted with water (20 mL) and extracted with EtOAc (50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by reverse HPLC to yield 2,8-dimethyl-5-(2-(1-methyl-1H-pyrazol-5-yl)cyclopent-1-enyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR (CDCl3, freebase) δ (ppm): 7.32 (s, 1H), 7.18 (s, 1H), 7.0 (d, 1H), 6.9 (d, 1H), 6.01 (s, 1H), 3.6 (s, 2H), 3.2 (s, 3H), 3.0 (m, 4H), 2.7 (m, 4H), 2.52 (s, 3H), 2.4 (s, 3H), 2.2 (m, 2H).
Example 220
Preparation of Compound No. 310
To a solution of 1-(1-bromoprop-1-en-2-yl)-3-(methylsulfonyl)benzene (148 mg, 0.55 mmol) in DMF (1 mL) were added potassium phosphate (212 mg, 2 mmol), copper(I)iodide (9.5 mg, 0.05 mmol) and L-proline (11.5 mg, 0.1 mmol). The solution was de-aerated by purging nitrogen followed by addition of 2,3,4,5-tetrahydro-2,6,8-trimethyl-1H-pyrido[4,3-b]indole (114.5 mg, 0.5 mmol). The reaction mixture was again purged with nitrogen for two minutes and then stirred at 85° C. overnight. Ice water was poured into the reaction mixture and the solid obtained was filtered. The crude product was purified by column chromatography using 0-3% MeOH:DCM as eluant. The compound was further purified through reverse phase HPLC to yield the title compound. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.08 (s, 1H), 8.0 (m, 2H), 7.77 (t, 1H), 7.38 (s, 1H), 7.1 (s, 1H), 6.8 (s, 1H), 4.7 (d, 1H), 4.37 (d, 1H), 3.82 (m, 1H), 3.58 (m, 1H), 3.0-3.2 (m, 8H), 2.73 (s, 3H), 2.38 (s, 3H), 1.97 (s, 3H).
Example 221
Preparation of Compound No. 311
To a degassed solution of (E,Z)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl trifluoromethanesulfonate (100 mg, 0.257 mmol) and potassium carbonate (110 mg, 0.7 mmol) in DME-water (2:1) were added Pd(PPh3)4 (20 mg, 0.0130 mmol) and 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinoline (100 mg, 0.392 mmol), followed by nitrogen purging for 5 min. The reaction mixture was refluxed for 45 min. At that point, TLC showed no starting material. The reaction mixture was cooled to RT and extracted with EtOAc. The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 9.77 (s, 1H), 8.6 (d, 1H), 8.44-8.58 (m, 3H), 8.4 (d, 1H), 7.57 (s, 1H), 7.37 (s, 1H), 7.2 (d, 1H), 7.17 (d, 1H), 4.71 (d, 1H), 4.4 (d, 1H), 3.9 (m, 1H), 3.6 (m, 1H), 3.2 (m, 5H), 2.42 (s, 3H), 2.2 (s, 3H).
Example 222
Preparation of Compound No. 312
To a solution of 4-(1-bromoprop-1-en-2-yl)pyridine (238 mg, 1.2 mmol) in DMF (2 mL) were added potassium phosphate (424 mg, 2 mmol), copper(I)iodide (19 mg, 0.1 mmol), L-proline (23 mg, 0.2 mmol) and 2,3,4,5-tetrahydro-2,6,8-trimethyl-1H-pyrido[4,3-b]indole (214 mg, 1 mmol). The reaction mixture was degassed using nitrogen and stirred overnight at 85° C. Ice water (5 mL) was added into the reaction mixture and the solid obtained was filtered. The residue was washed with water (2×10 mL) and purified by column chromatography using neutral alumina and 0-1% MeOH:DCM as eluant to yield the desired compound. 1H NMR (CD3OD, HCl salt) δ (ppm): 8.9 (d, 2H), 8.39 (d, 2H), 7.98 (s, 1H), 7.17 (s, 1H), 6.86 (s, 1H), 4.7 (d, 1H), 4.4 (d, 1H), 3.82 (m, 1H), 3.6 (m, 1H), 3.2 (m, 4H), 3.0 (m, 1H), 2.5 (s, 3H), 2.4 (s, 3H), 2.1 (s, 3H).
Example 223
Preparation of Compound No. 313
A mixture of 5-ethynyl-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (194 mg, 0.866 mmol, 5-bromo-isoquinoline (150 mg, 0.721 mmol, TBAF.3H2O (680 mg, 2.15 mmol) and dichlorobis(triphenylphosphine) palladium(II) (25 mg, 0.035 mmol) was stirred at 85° C. for 5 min. The reaction mixture was diluted with water and extracted with EtOAc (3×40 mL). The organic layer was washed with water (5×30 mL), dried over anhydrous sodium sulfate and concentrated. The crude product was purified by column chromatography using silica (100:200) and 0.5% MeOH-DCM to yield 5-isoquinolin-5-ylethynyl-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR (CDCl3, freebase) δ (ppm): 9.3 (s, 1H), 8.62 (d, 1H), 8.17 (d, 1H), 7.93 (dd, 2H), 7.6 (t, 1H), 7.57 (d, 1H), 7.23 (s, 1H), 7.17 (d, 1H), 3.65 (s, 2H), 3.07 (t, 2H), 2.93 (t, 2H), 2.6 (s, 3H), 2.42 (s, 3H).
Example 224
Preparation of Compound Nos. 314 and 314a-b
To a solution of 2,3,4,9-tetrahydro-2,6-dimethyl-1-phenyl-1H-pyrido[3,4-b]indole (100 mg, 0.362 mmol) in DMF (2 mL) were added sodium hydride (60 mg, 1.08 mmol) and 2-(6-methylpyridin-3-yl)ethyl 4-methylbenzenesulfonate (300 mg, 1.03 mmol). The reaction mixture was irradiated in a microwave reactor at 90° C. for 1 h. The reaction mixture was cooled to RT and quenched with water. The aqueous layer was extracted with EtOAc (3×10 mL). The organic layer was washed with water (2×10 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude product, which was purified by reverse phase HPLC. The product is further purified by reverse phase HPLC followed by chiral HPLC separation to give enantiomers 314a and 314b. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.09 (s, 1H), 7.9 (d, 1H), 7.63 (t, 1H), 7.43-7.6 (m, 5H), 7.4 (s, 1H), 7.0 (m, 2H), 6.03 (s, 1H), 4.37 (t, 1H), 4.1 (m, 1H), 3.92 (m, 1H), 3.57-3.65 (m, 2H), 3.18 (t, 1H), 2.9 (bs, 3H), 2.63 (s, 3H), 2.6 (m, 2H), 2.4 (s, 3H). Separation by chiral HPLC provides enantiomers 314a-b.
Example 225
Preparation of Compound No. 315
To a solution of 7-chloro-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg, 0.453 mmol) in DMF (2 mL) were added sodium hydride (60 mg, 1.359 mmol) and 2-(6-methylpyridin-3-yl)ethyl 4-methylbenzenesulfonate (330 mg, 1.1322 mmol). The reaction mixture was irradiated in a microwave reactor at 90° C. for 1 h. The reaction mixture was cooled to RT and quenched with water. The aqueous layer was extracted with EtOAc (3×10 mL). The organic layer was washed with water (2×10 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude product, which was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.21 (s, 1H), 8.1 (d, 1H), 7.7 (d, 1H), 7.38 (d, 1H), 7.1 (s, 1H), 7.0 (d, 1H), 4.7 (d, 1H), 4.42 (t, 2H), 4.5 (d, 1H), 3.82 (m, 1H), 3.57 (m, 1H), 3.1-3.27 (m, 4H), 3.08 (s, 3H), 2.63 (s, 3H).
Example 226
Preparation of Compound No. 316
To a solution of 5-isoquinolin-5-ylethynyl-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (90 mg, 0.256 mmol) in MeOH (6 mL) were added 10% dry Pd—C (25 mg) and ammonium formate (81 mg, 1.282 mmol). The reaction mixture was refluxed for 2 h and filtered through Celite. The filtrate was concentrated under reduced pressure to afford crude product, which was purified by reverse phase HPLC to yield 20 mg of 5-(2-isoquinolin-5-yl-vinyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR (CD3OD, TFA salt) δ (ppm): 9.7 (s, 1H), 8.57 (d, 1H), 8.5 (d, 1H), 8.3 (d, 1H), 7.65 (t, 1H), 7.59 (d, 1H), 7.4 (d, 1H), 7.22 (d, 1H), 7.2 (s, 1H), 6.7 (m, 2H), 4.63 (d, 1H), 4.3 (d, 1H), 3.7 (m, 1H), 3.47 (m, 1H), 3.08 (s, 3H), 2.9-3.0 (m, 2H), 2.31 (s, 3H).
Example 227
Preparation of Compound No. 317
To a solution of 5-isoquinolin-5-ylethynyl-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (80 mg, 0.228 mmol) in MeOH (5 mL) were added 10% dry Pd—C (80 mg) and ammonium formate (72 mg, 1.14 mmol). The reaction mixture was refluxed for 4 h and filtered through Celite. The filtrate was concentrated under reduced pressure to afford crude product, which was purified by reverse phase HPLC to yield 20 mg of 2,8-dimethyl-5-[2-(1,2,3,4-tetrahydro-isoquinolin-5-yl)-ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.21 (d, 1H), 7.18 (m, 2H), 7.1 (d, 1H), 7.0 (d, 1H), 6.93 (d, 1H), 4.7 (d, 1H), 4.2-4.4 (m, 5H), 3.7 (m, 1H), 3.2 (m, 3H), 3.08 (t, 2H), 3.02 (s, 3H), 2.83 (m, 1H), 2.6-2.8 (m, 3H), 2.4 (s, 3H).
Example 228
Preparation of Compound No. 318
To a solution of 2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (250 mg, 1.255 mmol) in NMP (1 mL), was added powdered KOH (490 mg, 8.75 mmol). After stirring for 5 min, 3-methyl-4-vinyl-thiophene (310 mg, 2.50 mmol) was added into the reaction mixture, which was stirred at 85° C. for 16 h. The reaction mixture was diluted with water (15 mL) and extracted with EtOAc (3×20 mL). The organic layer was washed with water (6×30 mL), dried over anhydrous sodium sulfate and concentrated. The crude product was purified by column chromatography using silica (100:200) and 2% MeOH-DCM, followed by reverse phase HPLC to yield 1.10 mg of 2,8-dimethyl-5-[2-(4-methyl-thiophen-3-yl)-ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.3 (d, 1H), 7.24 (s, 1H), 7.07 (d, 1H), 6.92 (s, 1H), 6.78 (s, 1H), 4.6 (d, 1H), 4.3 (m, 3H), 3.62 (m, 1H), 3.3 (m, 3H), 3.0 (m, 4H), 2.8 (m, 1H), 2.4 (s, 3H), 1.95 (s, 3H).
Example 229
Preparation of Compound No. 319
To a solution of 8,9-dichloro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (100 mg, 0.392 mmol) in DMF (2 mL) were added sodium hydride (60 mg, 1.17 mmol) and 2-(6-methylpyridin-3-yl)ethyl 4-methylbenzenesulfonate (300 mg, 0.98 mmol). The reaction mixture was irradiated in a microwave reactor at 90° C. for 1 h. The reaction mixture was cooled to RT and quenched with water. The aqueous layer was extracted with EtOAc (3×10 mL). The organic layer was washed with water (2×10 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude product, which was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.39 (s, 1H), 8.2 (d, 1H), 7.7 (d, 1H), 7.2 (d, 2H), 5.1 (m, 1H), 4.6 (m, 1H), 4.43 (t, 2H), 3.82 (m, 1H), 3.5 (m, 1H), 3.2-3.3 (m, 4H), 3.1 (m, 3H), 2.7 (s, 3H).
Example 230
Preparation of Compound No. 320
To a degassed solution of 2,8-dimethyl-5-quinolin-3-ylethynyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (60 mg, 0.170 mmol) in MeOH (5 mL), were added Pd—C (30 mg, 50% w/w) and ammonium formate (54 mg, 0.857 mmol) under nitrogen. The reaction mixture was stirred at 75° C. for 1 h, filtered through a Celite bed and washed with MeOH (10 mL). The filtrate was concentrated under reduced pressure and residue was purified by reverse phase HPLC to yield the desired compound. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.6 (s, 2H), 8.02-8.18 (m, 3H), 7.82 (t, 1H), 7.2 (s, 1H), 6.98 (d, 1H), 6.77 (d, 1H), 4.68 (d, 1H), 4.56 (t, 2H), 4.3 (d, 1H), 3.8 (m, 1H), 3.45 (m, 1H), 3.4 (t, 2H), 3.21 (m, 1H), 3.1 (m, 4H), 2.3 (s, 3H).
Example 231
Preparation of Compound No. 321
A mixture of 5-ethynyl-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (260 mg, 1.160 mmol), 3-bromoquinoline (200 mg, 0.961 mmol), TBAF.3H2O (1.1 g, 3.492 mmol) and dichloro bis(triphenylphosphine) palladium (II) (41 mg, 0.058 mmol) was stirred at 85° C. for 10 min. The reaction mixture was diluted with water and extracted with EtOAc (4×30 mL). The combined organic layer was washed with water (4×30 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude product, which was purified by column chromatography using neutral alumina and 0.5% MeOH-DCM to yield 2,8-dimethyl-5-quinolin-3-ylethynyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR (CDCl3, freebase) δ (ppm): 9.0 (s, 1H), 8.25 (s, 1H), 8.1 (d, 1H), 7.8 (d, 1H), 7.7 (t, 1H), 7.6 (t, 1H), 7.5 (d, 1H), 7.2 (s, 1H), 7.1 (d, 1H), 3.62 (s, 2H), 3.0 (t, 2H), 2.7 (t, 2H), 2.6 (s, 3H), 2.42 (s, 3H).
Example 232
Preparation of Compound No. 322
To a solution of 7,8-dichloro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (100 mg, 0.392 mmol) in DMF (2 mL) were added sodium hydride (60 mg, 1.17 mmol) and 2-(6-methylpyridin-3-yl)ethyl 4-methylbenzenesulfonate (300 mg, 0.98 mmol). The reaction mixture was irradiated in a microwave reactor at 90° C. for 1 h. The reaction mixture was cooled to RT and quenched with water. The aqueous layer was extracted with EtOAc (3×10 mL). The organic layer was washed with water (2×10 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude product, which was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.37 (s, 1H), 8.18 (d, 1H), 7.7 (d, 1H), 7.61 (s, 1H), 7.39 (s, 1H), 4.68 (m, 1H), 4.48 (t, 2H), 4.37 (m, 1H), 3.92 (m, 1H), 3.57 (m, 1H), 3.2 (m, 4H), 3.1 (s, 3H), 2.7 (s, 3H).\
Example 233
Preparation of Compound No. 323
To a degassed solution of 2,8-dimethyl-5-quinolin-3-ylethynyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (60 mg, 0.170 mmol) in MeOH (5 mL), were added Pd—C (30 mg, 50% w/w) and ammonium formate (54 mg, 0.857 mmol) under nitrogen. The reaction mixture was stirred at 75° C. for 1 h, filtered through a Celite bed and washed with MeOH (10 mL). The filtrate was concentrated under reduced pressure to afford crude product, which was purified by reverse phase HPLC to yield the desired compound. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.3 (d, 2H), 8.0 (d, 1H), 7.9 (m, 2H), 7.70 (t, 1H), 7.3 (s, 1H), 7.21 (d, 1H), 6.98 (d, 1H), 6.82 (s, 2H), 4.78 (d, 1H), 4.4 (d, 1H), 3.8 (m, 1H), 3.58 (m, 1H), 3.1 (m, 5H), 2.38 (s, 3H).
Example 234
Preparation of Compound No. 324
To a solution of 2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (200 mg, 1.0 mmol) in DCM (4 mL) were added powdered KOH (392 mg, 7.0 mmol) and phenylamine (111 mg, 1.2 mmol). The reaction mixture was stirred at 85° C. for 2 h. The reaction mixture was diluted with water (20 mL) and extracted with DCM (3×20 mL). The combined organic layer was washed with water (3×30 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude material, which was purified by silica gel column chromatography (3% MeOH-DCM), followed by reverse phase HPLC to yield (2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-ylmethyl)-phenyl-amine (20 mg). 1H NMR (CD3OD, freebase) δ (ppm): 7.4 (d, 1H), 7.07 (s, 1H), 7.0 (t, 2H), 6.97 (d, 1H), 6.67 (d, 2H), 6.6 (t, 1H), 5.42 (s, 2H), 3.7 (s, 2H), 3.07 (t, 2H), 2.9 (t, 2H), 2.58 (s, 3H), 2.4 (s, 3H).
Example 235
Preparation of Compound No. 325
To a solution of 6,9-dichloro-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg, 0.392 mmol), in DMF (2 mL) were added sodium hydride (60 mg, 1.3 mmol) and 2-(6-methylpyridin-3-yl)ethyl 4-methylbenzenesulfonate (285 mg, 0.980 mmol). The reaction mixture was irradiated in a microwave reactor at 90° C. for 1 h. The reaction mixture was cooled to RT, quenched with water and extracted with EtOAc (3×10 mL). The organic layer was washed with water (2×10 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude product, which was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.41 (s, 1H), 8.18 (d, 1H), 7.78 (d, 1H), 7.1 (d, 1H), 7.06 (d, 1H), 5.1 (m, 1H), 4.8 (t, 2H), 4.6 (m, 1H), 3.8 (m, 1H), 3.57 (m, 1H), 3.22 (m, 4H), 3.18 (s, 3H), 2.7 (s, 3H).
Example 236
Preparation of Compound No. 326
To a stirred solution of 3-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)propanethioamide (0.287 g, 1.0 mmol) in EtOH.HCl (3 mL) was added 2-bromo-4′-chloroacetophenone (0.349 g, 1.5 mmol). The reaction mixture was stirred at 82° C. for 16 h. Solvent was removed under reduced pressure. The residue was basified with 1N NaOH solution and extracted with EtOAc (50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated to afford crude product, which was purified by column chromatography to yield the desired product. 1H NMR (CDCl3, freebase) δ (ppm): 7.8 (d, 2H), 7.4 (d, 2H), 7.3 (s, 1H), 7.2 (m, 2H), 6.98 (d, 1H), 4.46 (t, 2H), 3.6 (s, 2H), 3.4 (t, 2H), 2.1-2.78 (m, 4H), 2.53 (s, 3H), 2.4 (s, 3H).
Example 237
Preparation of Compound No. 327
To a de-aerated solution of 6-bromo-2,8-dimethyl-5-(2-(6-methylpyridin-3-yl)ethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (85 mg, 0.215 mmol) and potassium carbonate (89 mg, 0.642 mmol) in 1,2-dimethoxyethane-water (2:1) were added 3-methylthiophene-2-boronic acid pinacol ester (96 mg, 0.428 mmol) and Pd(PPh3)4 (17 mg, 0.015 mmol). The reaction mixture was stirred at 90° C. for 45 min and concentrated to dryness. The residue was dissolved in EtOAc (50 mL) and washed with water (20 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude product, which was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.0 (s, 1H), 7.77 (s, 2H), 7.47 (s, 1H), 7.38 (s, 1H), 7.02 (s, 1H), 6.9 (s, 1H), 4.78 (m, 1H), 4.38 (m, 1H), 4.1 (bs, 1H), 4.0 (m, 1H), 3.9 (bs, 1H), 3.6 (m, 1H), 3.1-3.27 (m, 5H), 2.8 (t, 2H), 2.7 (s, 3H), 2.4 (s, 3H), 1.99 (s, 3H).
Example 238
Preparation of Compound No. 328
A mixture of 2-bromo-5-methyl-pyridine (250 mg, 1.45 mmol), 5-ethynyl-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (391 mg, 1.74 mmol), TBAF.3H2O (1.374 g, 4.36 mmol) and dichloro bistriphenylphosphine palladium(II) (51 mg, 0.072 mmol) was stirred at 85° C. for 10 min. The reaction mixture was poured into water and extracted with EtOAc (3×100 mL). The organic layer was washed with water (3×100 mL), dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography (neutral alumina, eluent-0.5% MeOH in DCM) to yield 2,8-dimethyl-5-(5-methyl-pyridin-2-ylethynyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR (CDCl3, freebase) δ (ppm): 8.41 (s, 1H), 7.5 (m, 2H), 7.4 (d, 1H), 7.18 (s, 1H), 7.08 (d, 1H), 3.6 (s, 2H), 3.0 (t, 2H), 2.83 (t, 2H), 2.58 (s, 3H), 2.42 (s, 3H), 2.37 (s, 3H).
Example 239
Preparation of Compound No. 329
To a degassed solution of 2,8-dimethyl-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prop-1-en-1-yl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (276 mg, 0.753 mmol), 5-bromo-2-propylpyridine (100 mg, 0.502) and potassium carbonate (208 mg, 1.507 mmol) in DME (2 mL) and water (1 mL) was added Pd(PPh3)4 (40.6 mg, 0.035 mmol), followed by nitrogen purging. The reaction mixture was refluxed for 45 min. At that point, TLC showed no starting material. The reaction mixture was cooled to RT and diluted with EtOAc. The aqueous layer was extracted with EtOAc (3×6 mL) and the combined organic layer dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to afford crude product, which was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.8 (s, 1H), 8.36 (d, 1H), 7.62 (d, 1H), 7.3 (s, 1H), 7.2 (s, 1H), 7.16 (d, 1H), 7.05 (d, 1H), 4.7 (d, 1H), 4.4 (d, 1H), 3.83 (bs, 1H), 3.4 (bs, 1H), 3.18 (m, 2H), 3.1 (s, 3H), 2.9 (t, 2H), 2.4 (s, 3H), 2.0 (s, 3H), 1.8 (m, 2H), 1.0 (t, 3H).
Example 240
Preparation of Compound No. 330
A mixture of 4-bromobenzenesulfonamide (200 mg, 0.84 mmol), 5-ethynyl-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (391 mg, 1.0 mmol), TBAF.3H2O (793 mg, 2.5 mmol) and dichloro bis(triphenyl phosphine) palladium (II) (29 mg, 0.042 mmol) was stirred at 85° C. for 10 min. The reaction mixture was poured into water and extracted with EtOAc (3×50 mL). The organic layer was washed with water (3×100 mL), dried over anhydrous sodium sulfate and concentrated to afford crude material, which was purified by column chromatography using neutral alumina and 5% MeOH-DCM, followed by reverse phase HPLC to yield 4-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-ylethynyl)-benzenesulfonamide. 1H NMR (CD3OD, HCl salt) δ (ppm): 7.92 (d, 2H), 7.7 (d, 2H), 7.58 (d, 1H), 7.38 (s, 1H), 7.23 (d, 1H), 4.7 (d, 1H), 4.4 (d, 1H), 3.96 (m, 1H), 3.63 (m, 1H), 3.37 (m, 2H), 3.18 (s, 3H), 2.42 (s, 3H).
Example 241
Preparation of Compound No. 331
To a degassed solution of (Z)-2,8-dimethyl-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prop-1-en-1-yl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (140 mg, 0.382 mmol), 5-bromo-2-(trifluoromethyl)pyridine (87 mg, 0.382)and potassium carbonate (158 mg, 1.147 mmol) in DME (2 mL) and water (1 mL) was added Pd(PPh3)4 (20 mg, 0.017 mmol), followed by nitrogen purging. The reaction mixture was refluxed for 45 min. At that point, TLC showed no starting material. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layer dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude material, which was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 9.0 (s, 1H), 8.27 (d, 1H), 7.88 (d, 1H), 7.37 (s, 1H), 7.25 (s, 1H), 7.18 (d, 1H), 7.1 (d, 1H), 4.7 (d, 1H), 4.4 (d, 1H), 3.82 (bs, 1H), 3.6 (m, 1H), 3.37 (m, 1H), 3.2 (m, 1H), 3.6 (s, 3H), 2.42 (s, 3H), 2.01 (s, 3H).
Example 242
Preparation of Compound No. 332
To a de-aerated solution of 2,8-dimethyl-5-naphthalen-2-ylethynyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (50 mg, 0.14 mmol) in MeOH (5 mL), palladium hydroxide (25 mg, 50% w/w) and ammonium formate (45 mg, 0.71 mmol) were added. The reaction mixture was stirred at 80° C. for 1 h. The progress of reaction was monitored by TLC and LCMS. The reaction mass was filtered through Celite and washed the residue with MeOH (10 mL). The filtrate was concentrated under reduced pressure to afford crude material, which was purified by reverse phase HPLC to yield 2,8-dimethyl-5-[2-(5,6,7,8-tetrahydro-naphthalen-2-yl)-ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.26 (d, 1H), 7.22 (d, 1H), 7.02 (d, 1H), 6.9 (d, 1H), 6.63 (d, 1H), 6.58 (s, 1H), 4.6 (d, 1H), 4.4 (m, 1H), 4.2 (t, 2H), 3.62 (m, 1H), 3.02 (m, 1H), 2.9 (m, 4H), 3.0 (s, 3H), 2.7 (bs, 2H), 2.6 (bs, 2H), 2.4 (s, 3H), 1.8 (bs, 4H).
Example 243
Preparation of Compound No. 333
A mixture of 4-bromo-benzenesulfonamide (200 mg, 0.84 mmol), 9-ethynyl-2,6-dimethyl-2,3,4,9-tetrahydro-1H-β-carboline (228 mg, 1.01 mmol), TBAF.3H2O (801 mg, 2.54 mmol) and dichloro bis(triphenylphosphine) palladium(II) (30 mg, 0.042 mmol) was stirred at 85° C. for 10 min. The reaction mixture was poured into water and extracted with EtOAc (3×25 mL). The organic layer was washed with water (3×30 mL), dried over anhydrous sodium sulfate and evaporated to afford crude material, which was purified by reverse phase HPLC to yield 4-(2,6-dimethyl-1,2,3,4-tetrahydro-β-carbolin-9-ylethynyl)-benzenesulfonamide. 1H NMR (CDCl3, freebase) δ (ppm): 7.9 (d, 2H), 7.6 (d, 2H), 7.4 (d, 1H), 7.3 (s, 1H), 7.1 (d, 1H), 3.78 (s, 2H), 2.82 (t, 2H), 2.79 (t, 2H), 2.6 (s, 3H), 2.42 (s, 3H).
Example 244
Preparation of Compound No. 334
A mixture of 5-bromo-thiophene-2-sulfonic acid amide (200 mg, 0.8 mmol), 5-ethynyl-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (222 mg, 0.9 mmol), TBAF.3H2O (756 mg, 2.4 mmol) and dichloro bis(triphenyl phosphine) palladium (II) (28 mg, 0.04 mmol) was stirred at 85° C. for 10 min. The reaction mixture was poured into water and extracted with EtOAc (3×50 mL). The organic layer was washed with water (3×100 mL), dried over anhydrous sodium sulfate and concentrated to afford crude material, which was purified by column chromatography using neutral alumina and 5% MeOH-DCM, followed by reverse phase HPLC to yield 5-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-ylethynyl)-thiophene-2-sulfonic acid amide. 1H NMR (CD3OD, HCl salt) δ (ppm): 7.57 (d, 1H), 7.46 (d, 1H), 7.36 (m, 2H), 7.21 (d, 1H), 4.42 (s, 2H), 3.71 (s, 2H), 3.3 (m, 2H), 3.1 (s, 3H), 2.42 (s, 3H).
Example 245
Preparation of Compound No. 335
To a degassed solution of 3,6-dimethyl-6,7,8,9-tetrahydro-5H-1,6,9-triaza-fluorene (201 mg, 1.0 mmol), 1-(2-bromo-1-methyl-vinyl)-4-fluoro-benzene (279 mg, 1.3 mmol), potassium phosphate (530 mg, 2.5 mmol) in DMF (4 mL), L-proline (28 mg, 0.25 mmol) and cuprous iodide (47 mg, 0.25 mmol) were added. The reaction mixture was stirred at 120° C. for 8 h. The reaction mixture was cooled to RT, diluted with water (20 mL) and extracted with EtOAc (4×20 mL). The organic layer was washed with water (5×20 mL), dried over anhydrous sodium sulfate and evaporated to afford crude material, which was purified by silica gel flash chromatography to yield 9-[2-(4-fluoro-phenyl)-propenyl]-3,6-dimethyl-6,7,8,9-tetrahydro-5H-1,6,9-triaza-fluorene. 1H NMR (CDCl3, freebase) δ (ppm): 8.1 (s, 1H), 7.57 (m, 3H), 7.07 (t, 2H), 6.92 (s, 1H), 3.62 (s, 2H), 2.8 (s, 4H), 2.6 (s, 3H), 2.4 (s, 3H), 2.0 (s, 3H).
Example 246
Preparation of Compound Nos. 336 and 336a-b
To a solution of 8-aza-10-methyl-2,3,5,6,7,11c-hexahydro-1H-indolizino[7,8-b]indole (227 mg, 1.0 mmol) in DMF (5 mL) was added sodium hydride (120 mg, 3.0 mmol). After stirring at RT for 15 min, 4-fluorophenethyl 4-methyl-benzenesulfonate (1.47 g, 3 mmol) was added into the reaction mixture, which was stirred at RT for 12 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with ice-water and extracted with EtOAc (3×50 mL). The organic layer was washed with water (3×100 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield the title compound (125 mg). 1H NMR (CDCl3, freebase) δ (ppm): 8.18 (s, 1H), 7.53 (s, 1H), 6.82 (m, 4H), 4.86 (m, 1H), 4.44 (m 1H), 4.26 (m, 1H), 3.47 (m, 1H), 3.3 (m, 2H), 3.12 (m, 2H), 2.89 (q, 1H), 2.56 (m, 1H), 2.49 (m, 1H), 244 (s, 3H), 2.29 (m, 1H), 1.8 (m, 1H). Separation by chiral HPLC provides enantiomers 336a-b.
Example 247
Preparation of Compound Nos. 337 and 337a-b
This compound can be prepared in analogous fashion to Compound Nos. 30 and 30a-b, using 2-(2-methyloxiran-2-yl)oxazole as the oxirane reagent. Separation by chiral HPLC provides enantiomers 337a-b.
Example 248
Preparation of Compound Nos. 338 and 338a-b
To an ice-cooled stirred solution of 2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethanol (2.5 g, 7.78 mmol) in DMF (5 mL) was added sodium hydride (373 mg, 15.56 mmol). After stirring for 20 min, heptanoyl chloride (1.9 g, 13.23 mmol) was added into the reaction mixture, which was stirred at 0° C. for 30 min. The progress of reaction was monitored by LCMS and TLC. The reaction mixture was quenched with ice water (200 mL) and extracted with EtOAc (400 mL). The combined organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (6% MeOH-DCM), followed by reverse phase HPLC to yield heptanoic acid 2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethyl ester (20 mg). 1H NMR (CD3OD, TFA salt) δ (ppm): 8.74 (s, 2H), 7.91 (s, 2H), 7.28 (m, 2H), 7.04 (t, 1H), 6.2 (m 1H), 4.7 (d 1H), 4.59 (m, 2H), 4.3 (m, 1H), 3.5 (t, 1H), 3.34 (m, 1H), 3.31 (m, 2H), 3.12 (s, 3H), 2.4 (s, 3H), 2.3 (m, 2H), 2.1 (m, 1H), 1.35 (m, 2H), 1.22 (m, 2H), 1.15 (m, 3H), 0.86 (t, 3H). Separation by chiral HPLC provides enantiomers 338a-b.
Example 249
Preparation of Compound Nos. 339 and 339a-b
To a solution of 9-chloro-1,2,3,4,5,6-hexahydro-3-methylazepino [4,5-b]indole (1.0 g, 4.27 mmol) in DMF (10 mL) was added potassium tert-butoxide (717.9 mg, 6.41 mmol). After stirring at RT for 15 min, 2-(3,4-difluorophenyl)oxirane (1.33 g, 8.54 mmol) was added into the reaction mixture, which was stirred at RT for 3 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with ice-cold water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield the title compound, which was resolved by chiral preparative HPLC. 1H NMR (DMSO, TFA salt) δ (ppm): 7.62-7.50 (t, 1H), 7.50-7.30 (t, 3H), 7.25-7.00 (m, 2H), 4.85-4.75 (m, 1H), 4.30-4.20 (t, 2H), 3.80-3.60 (m, 4H), 3.25-3.10 (m, 4H), 2.90 (s, 3H).
Example 250
Preparation of Compound Nos. 340 and 340a-d
This compound can be prepared in analogous fashion to Compound Nos. 30 and 30a-b, using 5-(oxiran-2-yl)-1H-1,2,3-triazole as the oxirane reagent. Separation by chiral HPLC provides diastereomers 340a-d.
Example 251
Preparation of Compound Nos. 341 and 341a-d
This compound can be prepared in analogous fashion to Compound Nos. 30 and 30a-b, using 5-(oxiran-2-yl)-1H-tetrazole as the oxirane reagent. Separation by chiral HPLC provides diastereomers 341a-d.
Example 252
Preparation of Compound Nos. 342 and 342a-d
This compound can be prepared in analogous fashion to Compound Nos. 30 and 30a-b, using 2-(oxiran-2-yl)-1H-imidazole as the oxirane reagent. Separation by chiral HPLC provides diastereomers 342a-d.
Example 253
Preparation of Compound Nos. II-270 and II-270a-b
These compounds can be synthesized in an analogous fashion to Compound Nos. 55 and 55a-b, using 3,6-dimethyl-6,7,8,9-tetrahydro-5H-1,2,6,9-tetraaza-fluorene as the carboline portion and 4-(2-methyloxiran-2-yl)pyridine as the epoxide. Separation by chiral HPLC provides enantiomers II-270a-b.
Example 254
Preparation of Compound Nos. II-1 and II-1a-b
To a solution of 2-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-1-(pyridin-4-yl)ethanamine (500 mg, 1.56 mmol) in DCM (5 mL) was added pyridine (185 mg, 2.3 mmol). After stirring for 5 min at RT, a solution of acetyl chloride (147.2 mg, 1.88 mmol) in DCM (0.5 mL) was added into the reaction mixture, which was stirred at RT for 16 h. The reaction mixture was diluted with DCM and washed with saturated aq NaHCO3 solution. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was triturated with ether to yield N-(2-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-1-(pyridin-4-yl)ethyl)acetamide (500 mg). 1H NMR (CDCl3, Free base) δ (ppm): 8.42 (d, 2H), 7.25 (s, 1H), 7.15 (d, 1H), 6.92 (d, 2H), 6.9 (d, 1H), 6.2 (d, 1H), 5.3 (q, 1H), 4.4 (dd, 1H), 4.25 (dd, 1H), 3.58 (dd, 2H), 2.6 (m, 2H), 2.55 (s, 3H), 2.43 (s, 3H), 2.3 (m, 2H), 2.03 (s, 3H). Separation by chiral HPLC provided enantiomers II-1a-b.
Example 255
Preparation of Compound No. II-2
Crude 2-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(pyridin-4-yl)ethyl methanesulfonate was taken in NMP (5 mL), and KOH powder (873 mg, 15.5 mmol) was added at RT and the mixture stirred at 80° C. for 14 h. The product was detected by LCMS. Water was added to the reaction mixture, which was extracted with EtOAc. The organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure. The crude product was chromatographed on silica gel using 5% MeOH-DCM to afford 400 mg of the title compound. 1H NMR (DMSO, Formate salt) δ (ppm): 8.55-8.50 (d, 2H), 8.05-8.00 (d, 1H), 7.85-7.80 (d, 1H), 7.65-7.55 (d, 2H), 7.25 (s, 1H), 7.15-7.10 (m, 1H), 6.80-6.75 (d, 1H), 3.58 (s, 2H), 3.05 (t, 2H), 2.78 (t, 2H), 2.41 (s, 3H), 2.38 (s, 3H).
Example 256
Preparation of Compound No. II-3
To a stirred cooled (−70° C.) solution of 2-methyl-5-[2-(6-methyl-pyridin-3-yl)-propenyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole-8-carboxylic acid methyl ester (100 mg, 0.26 mmol) in THF (10 mL) was added portionwise LAH (30 mg, 0.79 mmol) and stirring continued at RT for 4 h. The reaction mixture was cooled to −70° C. and quenched with water (0.1 mL), 15% NaOH (0.1 mL) and water (0.2 mL). The solid was filtered and the filtrate concentrated to afford crude material, which was purified by reverse phase HPLC. 1H NMR (CD3OD, Formate salt) δ (ppm): 8.67 (s, 1H), 8.0 (d, 1H), 7.5 (s, 1H), 7.4 (d, 1H), 7.27 (d, 1H), 7.23 (d, 1H), 7.1 (s, 1H), 4.7 (s, 2H), 4.42 (s, 2H), 3.6 (t, 2H), 3.1 (t, 2H), 3.05 (s, 3H), 2.6 (s, 3H), 1.28 (s, 3H).
Example 257
Preparation of Compound Nos. II-4 and II-4a-d
6-(2-Azido-2-pyridin-4-yl-ethyl)-9-methyl-2,3,4,5,6,10c-hexahydro-1H-3a,6-diaza-cyclopenta[c]fluorene (400 mg, 1.07 mmol) was dissolved in ethanol-water (10 mL:1 mL). Zinc dust (280 mg, 4.3 mmol) and ammonium chloride (228 mg, 4.3 mmol) were added and the reaction mixture was heated at 80° C. for 1 h. After consumption of starting material, the reaction mixture was filtered through Celite and filtrate was concentrated to obtain the residue. The residue was basified with aq ammonia and extracted with EtOAc (2×100 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated to obtain the crude product, which was purified by reverse phase chromatography to obtain 40 mg of 2-(9-methyl-1,2,3,4,5,10c-hexahydro-3a,6-diaza-cyclopenta[c]fluoren-6-yl)-1-pyridin-4-yl-ethylamine as the TFA salt. 1H NMR (CDCl3, freebase): δ (ppm): 8.58 (d, 2H), 7.28 (d, 1H), 7.25 (s, 1H), 7.23 (d, 2H), 7.1 (d, 1H), 4.9 (m, 1H), 4.42 (t, 1H), 4.13 (dd, 1H), 3.63 (m, 1H), 3.4 (m, 2H), 3.01 (m, 2H), 2.71 (m, 2H), 2.45 (s, 3H), 2.23 (m, 2H), 2.01 (m, 1H). Chiral HPLC separated the racemate into diastereomers II-4a-d.
Example 258
Preparation of Compound Nos. II-5 and II-5a-d
To a solution of 9-aza-10-methyl-2,3,5,6,7,11c-hexahydro-1H-indolizino[7,8-b]indole (30 mg, 0.13 mmol) in DMF (5 mL) was added NaH (16 mg, 0.4 mmol, 60% dispersion in mineral oil) at 0° C. and the mixture was stirred for 10 min. 3-(2-Methyl-oxiranyl)-pyridine 36 mg, 0.26 mmol) was added and the reaction mixture was stirred overnight at RT. The reaction was monitored by LCMS. The reaction mixture was quenched with MeOH (1 mL), concentrated under reduced pressure to obtain the crude product, which was purified by reverse phase column chromatography to obtain the pure product (3.3 mg) as the free base. 1H NMR (CDCl3, freebase): δ (ppm): 9.1 & 8.91 (s, 1H), 8.8 & 8.7 (s, 1H), 8.6 & 8.5 (d, 1H), 7.6 & 7.8 (d, 1H), 7.18 (s, 2H), 4.4 (dd, 1H), 4.2 (m, 2H), 3.32 (m, 2H), 2.7 (dd, 1H), 2.66 (s, 3H), 1.99 (m, 2H), 1.9 (m, 2H), 1.76 & 1.67 (s, 3H), 1.6 (m, 3H). Chiral HPLC separates the racemate into diastereomers II-5a-d.
Example 259
Preparation of Compound Nos. II-6 and II-6a-d
6-(2-Chloro-2-pyrazin-2-yl-propyl)-9-methyl-2,3,4,5,6,10c-hexahydro-1H-3a,6-diaza-cyclopenta[c]fluorene (500 mg, 1.31 mmol) in 40% dimethylamine in water (30 mL) was heated at 100° C. for 3 h. The reaction mixture was cooled at RT and extracted with EtOAc (3×50 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated to obtain the crude product, which was purified by reverse phase chromatography to obtain 62 mg of dimethyl-[1-methyl-2-(9-methyl-1,2,3,4,5,10c-hexahydro-3a,6-diaza-cyclopenta[c]fluoren-6-yl)-1-pyrazin-2-yl-ethyl]-amine. 1H NMR (CD3OD, TFA salt): δ (ppm): 8.06 (s, 1H), 7.48 (s, 1H), 7.21 (s, 1H), 7.17 (d, 1H),7.00 (d, 1H), 4.98 (t, 1H), 4.28 (d, 2H), 3.6 (m, 3H), 3.39 (m, 2H), 3.2 (m, 1H), 3.15 (s, 6H), 2.8 (m, 1H), 2.7 (m, 1H), 2.39 (s, 3H), 2.17 (m, 3H). Chiral HPLC separated the racemate into diastereomers II-6a-d.
Example 260
Preparation of Compound Nos. II-7 and II-7a-d
Methanesulfonic acid 2-(9-methyl-1,2,3,4,5,10c-hexahydro-3a,6-diaza-cyclopenta[c] fluoren-6-yl)-1-pyrazin-2-yl-ethyl ester (300 mg, 0.70 mmol) in 40% dimethylamine in water (20 mL) was heated at 90° C. for 1 h. The reaction mixture was cooled to RT and extracted with DCM (12×50 mL)The combined organic layer was dried over anhydrous sodium sulfate and concentrated to obtain the crude product, which was purified by reverse phase chromatography to obtain 60 mg of dimethyl-[2-(9-methyl-1,2,3,4,5,10c-hexahydro-3a,6-diaza-cyclopenta[c]fluoren-6-yl)-1-pyrazin-2-yl-ethyl]-amine. 1H NMR (CD3OD, TFA salt): δ (ppm): 8.1 (s, 1H), 7.4(s, 1H), 7.1 (d, 1H), 5.1 (t, 1H), 4.42 (m, 2H), 3.6 (m, 3H), 3.2 (m, 1H), 3.17 (m, 1H), 3.15 (s, 6H), 2.85 (m, 2H), 2.63 (m, 1H), 2.42 (s, 3H), 2.3 (m, 2H), 2.15 (m, 1H). Chiral HPLC separates the racemate into diastereomers II-7a-d.
Example 261
Preparation of Compound Nos. II-8 and II-8a-b
Methanesulfonicacid-2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethylester (300 mg, 0.75 mmol) in 70% ethylamine in water (15 mL) was heated at 100° C. for 18 h. The reaction mixture was cooled to RT and extracted with EtOAc (2×100 mL). The combined organic layer was washed with water (2×20 mL), dried over anhydrous sodium sulfate and concentrated to obtain the crude product, which was purified by reverse phase chromatography to obtain 55 mg of [2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethyl]-ethyl-amine. 1H NMR (DMSO, TFA salt): δ (ppm): 8.5 (d, 2H), 7.3 (d, 1H), 7.2 (m, 3H), 6.9 (d, 1H), 4.7 (m, 2H), 4.43 (m, 2H), 4.1 (d, 1H), 3.3 (m, 1H), 3.0 (m, 2H), 2.85 (d, 6H), 2.8 (m, 1H), 2.5 (m, 2H), 2.3 (s, 3H), 1.22 (s, 3H). Chiral HPLC separates the racemate into enantiomers II-8a-b.
Example 262
Preparation of Compound Nos. II-9 and II-9a-b
Methanesulfonic acid 2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethylester (240 mg, 0.60 mmol) was dissolved in 10 mL of 70% cyclopentylamine solution in water and heated at 100° C. for 18 h. The reaction mixture was cooled to RT and concentrated to obtain the crude product, which was purified by reverse phase chromatography to obtain 11 mg of cyclopentyl-[2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethyl]-amine. 1H NMR (CDCl3, freebase): δ (ppm): 8.51 (d, 2H), 7.17 (m, 4H), 7.003 (d, 1H), 4.16 (m, 2H), 4.05 (dd, 1H), 3.79 (dd, 2H), 2.9 (m, 1H), 2.83 (m, 2H), 2.55 (s, 3H), 2.44 (s, 3H), 2.39 (m, 1H), 1.99 (s, 2H), 1.7 (m, 2H), 1.5 (m, 2H), 1.4 (m, 1H), 1.9 (m, 2H). Chiral HPLC separates the racemate into enantiomers II-9a-b.
Example 263
Preparation of Compound Nos. II-10 and II-10a-b
2-(2,8-Dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethylamine (200 mg, 0.62 mmol) was dissolved in 15 mL DCM, acetone (108 mg, 1.87 mmol), acetic acid (0.5 mL) was added and the reaction mixture was stirred at RT overnight. Sodiumcyanoborohydride (117 mg, 1.87 mmol) was added and stirred at for 1 h. The reaction mixture was diluted with DCM (300 mL) and washed with saturated bicarbonate solution (200 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated to obtain the crude product, which was purified by reverse phase chromatography to obtain 120 mg of [2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethyl]-isopropyl-amine as the TFA salt. 1H NMR (CD3OD, TFA salt): δ (ppm): 8.52 (m, 2H), 7.42 b (s, 2H), 7.30 b (s, 1H), 7.22 (s, 1H), 7.02 (m, 1H), 4.8 (m, 1H), 4.58 (m, 2H), 4.23 (t, 1H), 3.72 (m, 1H), 3.4 (m, 3H), 3.13 (m, 2H), 2.99 (d, 3H), 2.39 (s, 3H), 1.43 (d, 3H), 1.34 (d, 3H). Chiral HPLC separates the racemate into enantiomers II-10a-b.
Example 264
Preparation of Compound Nos. II-11 and II-11a-b
To a solution of 5-(2-azido-2-(4-fluorophenyl)ethyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1 g, 2.75 mmol) in ethanol-water (40-5 mL) was added ammonium chloride (590 mg, 11.02 mmol) and zinc dust (716 mg, 11.02 mmol) and heated at 100° C. for 1 h. After complete conversion of starting material (TLC), ethanol was removed under reduced pressure and 50 mL additional water was added and extracted with DCM (3×100 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum to obtain the crude product, which was purified by reverse phase HPLC to obtain 2-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(4-fluorophenyl)ethanamine (730 mg) as the TFA salt. 1H NMR (CD3OD, TFA salt): δ (ppm): 7.27 (m, 1H), 7.21 (m, 3H), 7.10 (m, 3H), 4.60 (m, 3H), 4.50 (m, 1H), 4.24 (m, 1H), 3.69 (m, 1H), 3.44 (m, 1H), 3.04 (m, 1H), 2.96 (s, 3H), 2.56 (m, 1H), 2.41 (s, 3H). Chiral HPLC separated the racemate into enantiomers II-11a-b.
Example 265
Preparation of Compound Nos. II-12 and II-12a-b
2-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(4-fluorophenyl)ethyl methane sulfonate (250 mg, 0.6 mmol) in methyl amine (40% solution in water, 5 mL) was heated at 100° C. for 4 h. The progress of the reaction was monitored by TLC and LCMS. 10 mL of water was added to the reaction mixture and then extracted with EtOAc (2×50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum to obtain the crude product, which was purified by reverse phase HPLC to obtain 2-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(4-fluorophenyl)-N-methyl ethanamine (30 mg) as the TFA salt. 1H NMR (CDCl3, freebase): δ (ppm): 7.32 (t, 2H), 7.24 (m, 1H), 7.21 (s, 1H), 7.01 (m, 3H), 3.91 (m, 2H), 3.65 (dd, 2H), 2.80 (m, 3H), 2.62 (m, 1H), 2.54 (s, 3H), 2.45 (s, 3H), 2.14 (s, 3H). Chiral HPLC separated the racemate into enantiomers II-12a-b.
Example 266
Preparation of Compound Nos. II-13 and II-13a-b
Methanesulfonicacid2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethylester (300 mg, 0.75 mmol) was dissolved in 70% cyclobutylamine in water (6 mL) and heated at 100° C. for 18 h. The reaction mixture was concentrated to obtain the crude product, which was purified by reverse phase chromatography to obtained 90 mg of cyclobutyl-[2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethyl]-amine as the TFA salt. 1H NMR (CD3OD, TFA salt): δ (ppm): 8.6 (dd, 2H), 7.63 (d, 1H), 7.54 (d, 1H), 7.19 (s, 1H), 7.10 (d, 1H), 6.99 (d, 1H), 4.82 (m, 2H), 4.72 (m, 1H), 4.6 (m, 1H), 4.23 (t, 1H), 3.8 (m, 2H), 3.5 (m, 1H), 3.2 (m, 1H), 3.07 (d, 3H), 2.7 (m, 1H), 2.37 (s, 3H), 2.5 (m, 3H), 2.1 (m, 1H), 1.8 (m, 2H). Chiral HPLC separated the racemate into enantiomers II-13a-b.
Example 267
Preparation of Compound Nos. II-14 and II-14a-b
2-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(4-fluorophenyl)ethanamine (250 mg, 0.741 mmol), formaldehyde 37-40% solution (5 mL) and formic acid (0.25 mL) was heated at 100° C. for 2 h. After the completion of reaction (TLC and LCMS), the reaction mixture was cooled to RT, neutralized by saturated sodium bicarbonate and extracted into DCM (2×50 mL). The combined organic layer was washed with water (50 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain 250 mg of 2-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(4-fluorophenyl)-N,N-dimethylethanamine. 1H NMR (CDCl3, freebase): δ (ppm): 7.13 (s, 1H), 7.05 (d, 1H), 7.02 (t, 2H), 6.88 (m, 3H), 4.56 (dd, 1H), 3.99 (m, 1H), 3.64 (d, 1H) 3.54 (dd, 1H), 3.46 (d, 1H), 2.79 (m, 1H), 2.6 (m, 2H), 2.45 (s, 3H), 2.42 (s, 3H), 2.3 (s, 6H), 1.9 (m, 1H). Chiral HPLC separated the racemate into enantiomers II-14a-b.
Example 268
Preparation of Compound Nos. II-15 and II-15a-b
1-(2,8-Dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2-pyridin-3-yl-propan-2-ol (2.0 g, 5.97 mmol) was dissolved in DMF (20 ml), sodium hydride (716 mg, 17.9 mmol) was added and the mixture stirred at RT for 20 min. Acetic anhydride (913 mg, 8.95 mmol) was added dropwise at the same temperature and stirring continued for 1.5 h. The reaction was monitored by TLC and LCMS. The reaction mixture was poured into 250 mL ice water and extracted with EtOAc (3×200 mL), washed with water (3×300 mL), dried over anhydrous sodium sulfate and concentrated to obtain the crude product that was purified by column chromatography (silica gel: 100-200 mesh, eluent: −6-8% MeOH in DCM) to obtain 110 mg of acetic acid 2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-methyl-1-pyridin-3-yl-ethyl ester, which was followed by chiral separation. 1H NMR (CD3OD, Free base) δ (ppm): 8.38 (d, 1H), 8.15 (s, 1H), 7.45 (d, 1H), 7.22 (t, 1H), 7.1 (s, 1H), 7.0 (s, 1H), 6.8 (d, 1H), 4.43 (d, 1H), 4.2 (d, 1H), 3.7 (d, 1H), 3.5 (d, 1H), 2.8 (m, 2H), 2.53 (m, 1H), 2.5 (s, 3H), 2.4 (s, 3H), 2.2 (m, 1H), 2.07 (d, 6H). Separation by chiral HPLC provided enantiomers II-15a-b.
Example 269
Preparation of Compound Nos. II-16 and II-16a-b
1-(2,8-Dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2-pyridin-3-yl-propan-2-ol (5.0 g, 14.9 mmol) was dissolved in DMF (100 mL) and sodium hydride (1.8 g, 45 mmol) was added, and the mixture stirred at RT for 15 min. Pivaloyl chloride (3 g, 25 mmol) was added dropwise at the same temperature, and the mixture stirred for 45 min. The reaction was monitored by TLC and LCMS. The reaction mixture was poured into 400 mL ice water to obtain a solid that was filtered. The solid was dissolved in DCM, dried over sodium sulfate and concentrated to obtain the crude product that was purified by column chromatography (silica gel: 100-200 mesh, Eluent: −4-6% MeOH in DCM) to obtain 1.8 g of 2,2-dimethyl-propionic acid 2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-methyl-1-pyridin-3-yl-ethyl ester. The product was further purified by chiral preparative HPLC to give enantiomers II-16a and II-16b. 1H NMR (CDCl3, Free base): δ (ppm): 8.55 (d, 1H), 8.5 (s, 1H), 7.2 (d, 1H), 7.18 (m, 3H), 6.9 (d, 1H), 4.3 (dd, 2H), 3.65 (d, 1H), 3.52 (d, 1H), 2.65 (m, 2H), 2.5 (m, 2H), 2.5 (s, 3H), 2.4 (s, 3H), 2.3 (d, 1H), 2.0 (s, 3H), 2.0 (m, 1H), 1.2 (s, 9H).
Example 270
Preparation of Compound Nos. II-17 and II-17a-d
To a solution of 11-aza-10-methyl-2,3,5,6,7,11c-hexahydro-1H-indolizino[7,8-b]indole (120 mg, 0.52 mmol) in DMF (5 mL) was added NaH (31 mg, 1.06 mmol, 60% dispersion in mineral oil) at 0° C. and the reaction mixture was stirred for 10 min. 3-(2-Methyl-oxiranyl)-pyridine 143 mg, 1.06 mmol) was added and the reaction mixture was stirred at RT overnight. The reaction was monitored with LCMS. The reaction mixture was quenched with MeOH (2 mL), concentrated under reduced pressure to obtain the crude product, which was purified by reverse phase column chromatography to obtain the 30 mg of product as the free base. 1H NMR (CDCl3, freebase): δ (ppm): 8.72 & 8.69 (s, 1H), 8.25 (t, 1H), 7.62 & 7.6 (d, 1H), 7.43 (t, 1H), 7.22 & 7.19 (m, 1H), 6.86 (t, 1H), 4.25 (m, 2H),3.2 (m, 1H), 2.99 (m, 1H), 2.85 (t, 2H), 2.7(m, 1H), 2.626 (s, 3H), 2.5 (m, 2H), 2.4 (m, 1H), 2.15 (m, 1H), 1.85 (m, 2H), 1.69 & 1.66 (s, 3H). Chiral HPLC separates the racemate into diastereomers II-17a-d.
Example 271
Preparation of Compound No. II-18
To a solution of 2,6,9-trimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg, 0.466 mmol) in DMF (2 mL) were added sodium hydride (60 mg, 1.3 mmol) and 2-(6-methylpyridin-3-yl)ethyl 4-methylbenzenesulfonate (337.5 mg, 1.16 mmol). The reaction mixture was irradiated in a microwave reactor at 90° C. for 1 h. The reaction mixture was cooled to RT, quenched with water and extracted with EtOAc (3×10 mL). The organic layer was washed with water (2×10 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford the crude product, which was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.1 (m, 2H), 7.7 (d, 1H), 6.6 (d, 2H), 4.98 (m, 1H), 4.5 (m, 1H), 4.4 (t, 2H), 3.82 (bs, 1H), 3.5 (bs, 1H), 3.2 (t, 2H), 3.1 (m, 5H), 2.65 (s, 3H), 2.5 (s, 3H), 2.31 (s, 3H).
Example 272
Preparation of Compound Nos. II-19 and II-19a-b
1-(2,8-Dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2-pyridin-3-yl-propan-2-ol (3.35 g, 10.0 mmol), isonicotinic acid (1.23 g, 10 mmol), DCC (5.0 g, 24.0 mmol) and DMAP (1.2 g, 10 mmol) were suspended in DCM (300 mL) and the resultant mixture was stirred overnight under nitrogen atmosphere. The reaction was monitored by LCMS. The reaction mixture was filtered to remove N,N-dicyclohexyl urea formed during the reaction. The filtrate was washed with water (3×300 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude product which was purified by column chromatography (neutral alumina; eluent: 0.5-1% MeOH in DCM) to obtain the product. The product obtained was triturated with diethyl ether (30 mL) to obtain the pure product (400 mg). 1H NMR (CDCl3, freebase): δ (ppm): 8.71 (d, 2H), 8.58 (s, 1H), 8.56 (d, 1H), 7.64 (d, 2H), 7.32 (d, 1H), 7.21 (s, 1H), 7.18 (d, 2H), 6.97 (d, 1H), 4.45 (dd, 2H), 3.65 (d, 1H), 3.57 (d, 1H), 2.7 (m, 1H), 2.52 (m, 1H), 2.49 (s, 3H), 2.46 (s, 3H), 2.43 (m, 1H), 2.16 (s, 3H), 2.01 (m, 1H). Separation by chiral HPLC provided enantiomers II-19a-b.
Example 273
Compound Nos. II-21, II-23, II-36, II-56, II-57, II-160, II-188-206, II-233, II-237 and II-254 were synthesized as described in PCT publication WO2009/055828. Compound Nos. II-107 and II-164-165 were synthesized as described in PCT publication WO2009/120720. Compound Nos. II-20, II-48-49, II-52-55, II-156-158 and II-161 were synthesized as described in PCT publication WO2009/120717. Compound Nos. II-47, II-95, II-162-163 and II-166-187 were synthesized as described in PCT publication WO2010/051501. Compound Nos. II-22, II-24-35, II-37-38, II-41-46, II-50-51, II-155 and II-159 were synthesized as described in PCT publication WO2010/051503. Compound No. II-219 was synthesized as described in PCT publication WO2010/127177. Compound Nos. II-207-208, II-216-218 and II-228 were synthesized as described in PCT publication WO2010/019417. Compound No. II-69 was synthesized as described in PCT publication WO2011/038163. Compound Nos. II-79, II-86, II-234-236 and II-238-239 were synthesized as described in PCT publication WO2011/038161. Compound Nos. II-72-74, II-87 and II-214 were synthesized as described in PCT publication WO2011/038162. Compound Nos. II-66 and II-85 were synthesized as described in PCT publication WO2011/038164.
Example 274
Preparation of Compound No. II-39
To a solution of 6-bromo-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg, 0.359 mmol), in DMF (2 mL) were added sodium hydride (50 mg, 1.07 mmol) and 2-(6-methylpyridin-3-yl)ethyl 4-methylbenzenesulfonate (262 mg, 0.899 mmol). The reaction mixture was irradiated in a microwave reactor at 90° C. for 1 h. The reaction mixture was cooled to RT, quenched with water and extracted with EtOAc (3×10 mL). The organic layer was washed with water (2×10 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude, which was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.36 (s, 1H), 8.17 (d, 1H), 7.7 (d, 1H), 7.21 (s, 1H), 7.18 (s, 1H), 4.8 (m, 1H), 4.62 (t, 2H), 4.3 (m, 1H), 3.82 (m, 1H), 3.5 (m, 1H), 3.2 (m, 3H), 3.1 (m, 4H), 2.7 (s, 3H), 2.38 (s, 3H).
Example 275
Preparation of Compound No. II-40
A solution of 2,3,4,5-tetrahydro-2,4,4,8-tetramethyl-1H-pyrido[4,3-b]indole (228 mg, 1 mmol) and KOH (448 mg, 8 mmol) in NMP was heated at 100° C. for 15 min. 2-(Trifluoromethyl)-5-vinylpyridine (381 mg, 2.2 mmol) was added dropwise into the reaction mixture and stirring continued at 45° C. for 30 min. The reaction mixture was diluted with water and extracted with EtOAc (3×25 mL). The organic extract was washed with water (3×25 mL), dried over anhydrous sodium sulfate and evaporated in vacuo to afford crude material, which was purified by silica gel column chromatography using 0-5% MeOH-DCM, followed by reverse phase HPLC to yield desired compound as the TFA salt (41 mg). 1H NMR (CD3OD, TFA salt) δ (ppm): 8.4 (s, 1H), 7.8 (d, 1H), 7.72 (d, 1H), 7.24 (d, 2H), 7.02 (d, 1H), 4.67 (d, 1H), 4.6 (t, 2H), 4.35 (d, 1H), 3.47 (d, 1H), 3.4 (d, 1H), 3.24 (t, 2H), 3.17 (s, 3H), 2.4 (s, 3H), 1.48 (s, 3H), 1.45 (s, 3H).
Example 276
Preparation of Compound Nos. II-49 and II-49a-b
Sodium hydride (36 mg, 1.5 mmol) was dissolved in THF. 2,6-Dimethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (100 mg, 0.05 mmol) in THF was added dropwise at 0° C. to the NaH solution and the reaction mixture was stirred for 0.5 h. A solution of 2-(2-fluorophenyl) oxirane (103 mg, 0.075 mmol) in THF was added dropwise to the reaction mixture and was stirred at RT for 2 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction was quenched with ice-water, the THF was evaporated and the aqueous layer was extracted with EtOAc. The organic layer was dried over anhydrous sodium sulfate. The crude compound was purified by column chromatography to yield the desired compound (30 mg) which was stirred in ethanolic HCl to yield 2-(2,6-dimethyl-3,4-dihydro-1H-pyrido[3,4-b]indol-9(2H)-yl)-1-(2-fluorophenyl)ethanol hydrochloride salt. 1H NMR (CDCl3, Free base) δ (ppm): 7.6 (t, 1H), 7.3 (m, 3H), 7.2 (t, 1H), 7.1 (t, 1H), 7.0 (d, 1H), 5.33 (d, 1H), 4.22 (d, 1H), 3.95 (dd, 1H), 3.8 (d, 1H), 3.5 (d, 1H), 2.8 (m, 4H), 2.5 (s, 3H), 2.4 (s, 3H). Separation by chiral HPLC provided enantiomers II-49a-b.
Example 277
Preparation of Compound Nos. II-57 and II-57a-b
2,8-Dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.35 g, 6.65 mmol) was taken in DMF (10 mL). NaH (0.9 g, 19.5 mmol) was added to it portionwise at RT and the mixture stirred for 15 min. 2-Methyl-5-(oxiran-2-yl)pyridine (0.9 g, 6.65 mmol) was added to the reaction mixture dropwise at RT. After complete addition, the reaction mixture was stirred at RT for 2 h. The product was detected by LCMS. The reaction mixture was quenched with MeOH and concentrated to dryness. Water (20 mL) was added and the reaction mixture was extracted in EtOAc (2×100 mL), the extracts dried over anhydrous sodium sulfate and concentrated to obtain a dark brown oil. The crude product was purified by reverse phase chromatography to obtain pure material as a TFA salt (310 mg). 1H NMR (CDCl3, Free base) δ (ppm): 8.45 (s, 1H), 7.52 (d, 1H), 7.2 (s, 1H), 7.19 (d, 1H), 7.12 (d, 1H), 6.97 (d, 1H), 5.0 (t, 1H), 4.18 (dd, 2H), 3.61 (dd, 2H), 2.9 (m, 1H), 2.82 (m, 2H), 2.65 (m, 1H), 2.50 (s, 3H), 2.48 (s, 3H), 2.41 (s, 3H). Separation by chiral HPLC provided enantiomers II-57a-b.
Example 278
Preparation of Compound Nos. II-58 and II-58a-b
1-(2,8-Dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2-pyridin-4-yl-propan-2-ol (350 mg. 1.0 mmol) was dissolved in 10 mL DCM and metachloro perbenzoic acid (216 mg, 1.2 mmol) was diluted in DCM and added dropwise at RT. After consumption of starting material by monitoring TLC & LCMS, the reaction mixture was concentrated and purified by reverse phase chromatography to obtain 200 mg of 1-(2,8-dimethyl-2-oxy-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2-pyridin-4-yl-propan-2-ol. 1H NMR (CDCl3, Free base) δ (ppm): 8.54 (d, 2H), 7.68 (d, 1H), 7.55 (d, 1H), 7.28 (d, 2H), 7.22 (s, 1H), 7.10 (d, 1H), 6.63 (d, 1H), 4.06 (d, 2H), 3.28 (t, 2H), 2.91 (t, 2H),), 2.46 (s, 3H). Separation by chiral HPLC provides enantiomers II-58a-b.
Example 279
Preparation of Compound No. II-59
To a de-aerated solution of 2-allyl-8-methyl-5-[2-(6-methyl-pyridin-3-yl)-propenyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (750 mg, 2.1 mmol) in DCM (7.5 mL) were added 1,3-dimethylbarbutaric acid (984 mg, 6.302 mmol) and Pd(PPh3)4 (48 mg, 0.042 mmol), and the reaction mixture stirred for 1 h at RT. The reaction mixture was concentrated and the residue diluted with 25% saturated potassium carbonate and extracted with EtOAc (3×30 mL). The combined organic layer was washed with water (2×25 mL), dried over anhydrous sodium sulfate and concentrated to afford crude material, which was purified by column chromatography using neutral alumina and 2% MeOH-DCM followed by reverse phase HPLC to yield 8-methyl-5-[2-(6-methyl-pyridin-3-yl)-propenyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (180 mg). 1H NMR (CD3OD, TFA salt) δ (ppm): 8.92 (s, 1H), 8.65 (d, 1H), 7.90 (d, 1H), 7.36 (d, 2H), 7.18 (d, 1H), 7.16 (d, 1H), 4.50 (s, 2H), 3.65 (t, 2H), 3.10 (t, 2H), 2.80 (s, 3H), 2.42 (s, 3H), 2.05 (s, 3H).
Example 280
Preparation of Compound No. II-60 and II-60a-b
To a solution of 5-(2-hydroxy-2-pyridin-4-yl-ethyl)-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole-8-carboxylic acid methyl ester (180 mg, 0.493 mmol) in dry THF (12 mL) was portionwise added LAH (56 mg, 1.479 mmol) under nitrogen atmosphere, and the reaction mixture stirred at RT for 2 h. The reaction mixture was cooled to −78° C. and quenched with ice water (0.6 mL), 10% NaOH (0.6 mL) and water (1.8 mL), and the solid filtered. The filtrate was concentrated and the residue was purified by reverse phase HPLC to yield 2-(8-hydroxymethyl-2-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethanol. 1H NMR (CD3OD, freebase) δ (ppm): 8.4 (d, 2H), 7.4 (s, 1H), 7.27-7.38 (m, 3H), 7.18 (d, 1H), 5.1 (t, 1H), 4.62 (s, 2H), 4.3 (d, 2H), 4.0 (dd, 2H), 3.2 (m, 1H), 3.1 (m, 2H), 2.73 (m, 1H), 2.7 (s, 3H). Separation by chiral HPLC provides enantiomers II-60a-b.
Example 281
Preparation of Compound No. II-61
To a de-aerated solution of 2,4,4,8-tetramethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (228 mg, 1.00 mmol), potassium phosphate (466 mg, 2.20 mmol), L-proline (19 mg, 0.10 mmol) and copper iodide (I) (23 mg, 0.20 mmol) in DMF (2 mL) was added 5-(1-bromoprop-1-en-2-yl)-2-methylpyridine (424 mg, 2.00 mmol), and the reaction mixture stirred at 120° C. for 20 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (3×10 mL). The combined organic layer was washed with water (3×20 mL), followed by brine (25 mL), dried over anhydrous sodium sulfate and evaporated to afford crude material, which was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.97 (s, 1H), 8.66 (d, 1H), 7.9 (d, 1H), 7.42 (s, 1H), 7.37 (s, 1H), 7.1 (q, 2H), 4.7 (m, 1H), 4.37 (m, 1H), 3.5 (m, 2H), 3.2 (s, 3H), 2.8 (s, 3H), 2.42 (s, 3H), 1.97 (s, 3H), 1.5 (bs, 6H).
Example 282
Preparation of Compound Nos. II-62 and II-62a-b
To a degassed solution of 1-(2-allyl-8-chloro-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2-pyridin-4-yl-propan-2-ol (300 mg, 0.78 mmol) in DCM (20 mL) were added 1,3-dimethyl barbituric acid (368 mg, 2.3 mmol) and Pd(PPh3)4 (18 mg, 0.015 mmol). After stirring at RT for 30 min, the reaction mixture was diluted with DCM and washed with saturated potassium carbonate solution. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield 1-(8-chloro-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2-pyridin-4-yl-propan-2-ol. 1H NMR (CD3OD, formate salt) δ (ppm): 8.4 (d, 2H), 7.48 (d, 2H), 7.4 (s, 1H), 7.18 (d, 1H), 6.98 (d, 1H), 4.6 (bs, 1H), 4.4 (s, 2H), 4.3 (m, 2H), 3.6 (m, 2H), 3.4 (m, 2H), 3.1 (m, 2H). Separation by chiral HPLC provides enantiomers II-62a-b.
Example 283
Preparation of Compound Nos. II-63 and II-63a-b
To a solution of 2-allyl-2,3,4,5-tetrahydro-8-methyl-1H-pyrido[4,3-b]indole (1000 mg, 4.42 mmol) in DMF (10 mL) was portionwise added sodium hydride (526 mg, 13.26 mmol). After stirring at RT for 5 min., 4-(oxiran-2-yl)pyridine (669 mg, 5.31 mmol) was added dropwise into the reaction mixture, which was stirred at RT for 16 h. Ice water was added into the reaction mixture and the solid mass obtained was filtered, washed with water (2×10 mL), hexane (2×50 mL) and ether to yield 2-(2-allyl-1,2,3,4-tetrahydro-8-methylpyrido[4,3-b]indol-5-yl)-1-(pyridin-4-yl)ethanol. 1H NMR (CDCl3, freebase) δ (ppm): 8.6 (d, 2H), 7.24 (s, 1H), 7.2 (d, 2H), 7.0 (d, 2H), 5.98 (m, 1H), 5.2 (dd, 2H), 5.0 (m, 1H), 4.1 (m, 2H), 3.6 (dd, 2H), 3.22 (d, 2H), 2.7-2.9 (m, 3H), 2.6 (m, 1H), 2.4 (s, 3H). Separation by chiral HPLC provides enantiomers II-63a-b.
Example 284
Preparation of Compound Nos. II-64 and II-64a-b
To a solution of 2-(8-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethanol (100 mg, 0.325 mmol) in acetonitrile (3 mL), potassium carbonate (135 mg, 0.977 mmol) and 2-bromoethanol (61 mg, 0.488 mmol) were added and the reaction mixture stirred at 60° C. for 1 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (3×20 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by reverse phase HPLC to yield 2-[2-(2-hydroxy-ethyl)-8-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-1-pyridin-4-yl-ethanol. 1H NMR (CD3OD, formate salt) δ (ppm): 8.41 (d, 2H), 7.38 (d, 2H), 7.2 (m, 2H), 6.99 (d, 1H), 5.03 (t, 1H), 4.4 (bs, 2H), 4.3 (d, 2H), 3.93 (t, 2H), 3.45-3.62 (m, 2H), 3.2 (m, 2H), 2.9 (m, 2H), 2.4 (s, 3H). Separation by chiral HPLC provides enantiomers II-64a-b.
Example 285
Preparation of Compound Nos. II-65 and II-65a-b
To a solution of 2-(8-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethanol (200 mg, 0.651 mmol) in acetonitrile (4 mL), potassium carbonate (270 mg, 1.953 mmol) and bromo-acetic acid ethyl ester (163 mg, 0.977 mmol) were added and the reaction mixture was stirred at RT for 1 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (3×30 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated to yield [5-(2-hydroxy-2-pyridin-4-yl-ethyl)-8-methyl-1,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl]-acetic acid ethyl ester (220 mg). To a solution of [5-(2-hydroxy-2-pyridin-4-yl-ethyl)-8-methyl-1,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl]-acetic acid ethyl ester (120 mg, 0.305 mmol) in ethanol (2 mL), 1N NaOH (3 mL) was added and the reaction mixture stirred at RT for 1 h. The progress of reaction was monitored by LCMS. The reaction mixture was neutralized with aq HCl. The solvent was removed under reduced pressure and the residue diluted with 90% MeOH in DCM and filtered. The filtrate was concentrated and residue was purified by reverse phase HPLC to yield [5-(2-hydroxy-2-pyridin-4-yl-ethyl)-8-methyl-1,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl]-acetic acid. 1H NMR (CD3OD, formate salt) δ (ppm): 8.42 (d, 2H), 7.4 (d, 2H), 7.2 (d, 2H), 6.9 (d, 1H), 5.03 (t, 1H), 4.6 (bs, 1H), 4.57 (bs, 2H), 4.3 (m, 2H), 3.8 (s, 2H), 3.7 (bs, 2H), 3.0 (m, 1H), 2.3 (s, 3H). Separation by chiral HPLC provides enantiomers II-65a-b.
Example 286
Preparation of Compound Nos. II-67 and II-67a-b
To a solution of 2-methyl-8-trifluoromethoxy-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.0 g, 3.70 mmol) in DMF (10 mL) was added sodium hydride (445 mg, 11.12 mmol) under nitrogen at 0° C. After stirring for 10 min, 4-(oxiran-2-yl)pyridine (806 g, 6.66 mmol) was added dropwise under nitrogen and the reaction mixture was stirred at RT for 12 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was poured into ice-cold water and extracted with EtOAc (2×100 mL). The combined organic layer was washed with water (5×50 mL) and dried over anhydrous sodium sulfate, concentrated and re-crystallized in diethyl ether to yield 2-(2-methyl-8-trifluoromethoxy-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethanol. 1H NMR (CDCl3, freebase) δ (ppm): 8.58 (d, 2H), 7.17-7.21 (m, 4H), 7.0 (d, 1H), 4.6 (m, 1H), 4.0 (m, 2H), 3.38 (dd, 2H), 2.8 (m, 1H), 2.7 (m, 2H), 2.6 (m, 1H), 2.18 (s, 3H). Separation by chiral HPLC provides enantiomers II-67a-b.
Example 287
Preparation of Compound Nos. II-68 and II-68a-b
To a solution of 8-tert-butyl-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.0 g, 4.1 mmol) in DMF (6 mL) was added sodium hydride (495 mg, 12.3 mmol) under nitrogen at 0° C. and stirred for 10 min. A solution of 4-(oxiran-2-yl)pyridine (898 mg, 7.4 mmol) in DMF (2 mL) was added dropwise into the reaction mixture at RT and stirred for 12 h. The progress of reaction was monitored by TLC and LCMS. The reaction mass was poured in ice-cold water and extracted with EtOAc (2×100 mL). The combined organic layer was washed with water (5×50 mL), dried over anhydrous sodium sulfate and concentrated. The residue was re-crystallized with hexane to yield 2-(8-tert-butyl-2-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethanol.
1H NMR (CDCl3, freebase) δ (ppm): 8.7 (d, 2H), 7.3 (s, 1H), 7.2 (d, 1H), 7.19 (d, 2H), 7.17 (d, 1H), 4.7 (t, 1H), 4.0 (d, 2H), 3.5 (dd, 2H), 2.82 (m, 1H), 2.7 (m, 2H), 2.58 (m, 1H), 2.4 (s, 3H), 1.4 (s, 9H). Separation by chiral HPLC provides enantiomers II-68a-b.
Example 288
Preparation of Compound No. II-70
A solution of 2-(pyridin-4-yl)-1-(2,4,4,8-tetramethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)propan-2-ol (110 mg) in thionyl chloride (2 mL) was stirred at RT for 20 min. The excess thionyl chloride was removed under reduced pressure, and to the residue were added DMF (2 mL) and powdered KOH (140 mg, 0.303 mmol), followed by stirring at 85° C. for 25 min. The progress of reaction was monitored by LCMS. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (3×30 mL). The organic layer was washed with water (2×20 mL), dried over anhydrous sodium sulfate and evaporated to afford crude material, which was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.7 (d, 2H), 8.0 (d, 2H), 7.58 (s, 1H), 7.37 (s, 1H), 7.1 (d, 1H), 7.05 (d, 1H), 4.7 (bs, 1H), 4.4 (bs, 1H), 3.5 (d, 2H), 3.18 (s, 3H), 2.42 (s, 3H), 1.97 (s, 3H), 1.57 (bs, 6H).
Example 289
Preparation of Compound Nos. II-71 and II-11a-b
To a solution of 9-chloro-2-methyl-1,2,3,4,5,6-hexahydroazepino[4,3-b]indole (1 g, 4.273 mmol) in DMF was added NaH (512 mg, 12.81 mmol) in portions at 0° C. After stirring the reaction mixture at 0° C. for 15 min, a solution of 4-(oxiran-2-yl)pyridine (775 mg, 6.409 mmol) in DMF (1 mL) was added dropwise into the mixture at the same temperature and stirring continued at RT overnight. The progress of reaction was monitored by TLC and LCMS. After completion, ice water was added into the reaction mixture and extracted with EtOAc (3×50 mL). The organic layer was washed with water (5×50 mL), dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography using 10% MeOH/DCM as eluent followed by recrystallization with MeOH and acetonitrile to yield 2-(9-chloro-2-methyl-2,3,4,5-tetrahydroazepino[4,3-b]indol-6(1H)-yl)-1-(pyridin-4-yl)ethanol. 1H NMR (CDCl3, Free base) δ (ppm): 8.5 (d, 2H), 7.4 (s, 1H), 7.3 (d, 2H), 7.19 (d, 1H), 7.05 (d, 1H), 4.85 (dd, 1H), 4.18 (m, 2H), 3.8 (d, 1H), 3.65 (d, 1H), 3.0 (m, 2H), 2.8 (m, 1H), 2.69 (m, 1H), 2.42 (s, 3H), 1.85 (m, 2H). Separation by chiral HPLC provides enantiomers II-71a-b.
Example 290
Preparation of Compound Nos. II-75 and II-75a-b
To a solution of 3-(3,4-dihydro-8-methyl-1H-pyrido[4,3-b]indol-2(5H)-yl)propan-1-ol (1000 mg, 4.0983 mmol) in DMF (10 mL) was portionwise added sodium hydride (491.8 mg, 12.25 mmol). After stirring at RT for 5 min, 4-(oxiran-2-yl)pyridine (620 mg, 4.92 mmol) was added dropwise into the reaction mixture, which was stirred at RT overnight. Ice water was added into the reaction mixture and the solid mass filtered, washed with water (2×10 mL) and hexane (2×50 mL). The residue was purified by reverse phase HPLC to yield 3-(3,4-dihydro-5-(2-hydroxy-2-(pyridin-4-yl)ethyl)-8-methyl-1H-pyrido[4,3-b]indol-2(5H)-yl)propan-1-ol. 1H NMR (CD3OD, formate salt) δ (ppm): 8.43 (bs, 2H), 7.39 (d, 2H), 7.23 (s, 1H), 7.2 (d, 1H), 7.0 (d, 1H), 5.07 (t, 1H), 4.48 (bs, 2H), 4.23 (m, 2H), 3.7 (t, 2H), 3.6 (bs, 2H), 3.4 (t, 2H), 3.2 (m, 1H), 2.95-3.03 (m, 1H), 2.4 (s, 3H), 2.03 (bs, 2H). Separation by chiral HPLC provides enantiomers II-75a-b.
Example 291
Preparation of Compound No. II-76
To a de-aerated solution of (E,Z)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)prop-1-en-2-yl trifluoromethanesulfonate (200 mg, 0.515 mmol), 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (225 mg, 1.03 mmol) and K2CO3 (215 mg, 1.55 mmol) in DME (2 mL) and water (1 mL) was added Pd(PPh3)4 (52 mg, 0.045 mmol). The reaction mixture was stirred at 90° C. for 45 min. The solvent was removed under reduced pressure, and the residue was diluted with water and extracted with EtOAc. The organic layer was dried over anhydrous sodium sulfate and evaporated to afford crude material, which was purified by reverse phase HPLC to yield (E)-2,8-dimethyl-5-(2-(4-methylpyridin-3-yl)prop-1-en-1-yl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole as the TFA salt. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.87 (s, 1H), 8.75 (d, 1H), 8.0 (d, 1H), 7.3 (s, 1H), 7.24 (d, 1H), 7.17 (d, 1H), 6.8 (s, 1H), 4.77 (d, 1H), 4.38 (d, 1H), 3.9 (bs, 1H), 3.4 (bs, 1H), 3.3 (m, 1H), 3.18 (m, 1H), 3.12 (s, 3H), 2.8 (s, 3H), 2.42 (s, 3H), 2.0 (s, 3H).
Example 292
Preparation of Compound No. II-77
To a degassed solution of 2,8-dimethyl-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prop-1-en-1-yl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (200 mg, 0.546 mmol), 5-bromo-2-ethylpyridine (50 mg, 0.273 mmol) and K2CO3 (113 mg, 0.819 mmol) in DME (2 mL) and water (1 mL) was added Pd(PPh3)4 (22 mg, 0.019 mmol). The reaction mixture was purged with nitrogen and heated to reflux for 45 min. The reaction mixture was cooled to RT, diluted with water and extracted with EtOAc(3×6 mL). The combined organic layer was dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to afford crude product which was purified by reverse phase HPLC as a TFA salt. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.98 (s, 1H), 8.78 (d, 1H), 8.0 (d, 1H), 7.38 (d, 2H), 7.18 (d, 1H), 7.1 (d, 1H), 4.76 (d, 1H), 4.4 (d, 1H), 3.85 (bs, 1H), 3.6 (bs, 1H), 3.2 (m, 2H), 3.18 (s, 3H), 3.1 (s, 2H), 2.64 (s, 3H), 2.05 (s, 3H), 1.5 (t, 3H).
Example 293
Preparation of Compound Nos. II-78 and II-78a-b
To a solution of 6-methyl-6,7,8,9-tetrahydro-5H-1,6,9-triaza-fluorene (1.0 g, 0.0053 mole) in DMF (15 mL) were added portionwise NaH (60%, 0.634 g, 0.0159 mole) and 4-(oxiran-2-yl)pyridine (0.807 g, 0.0064 mole). The reaction mixture was stirred at RT overnight. The progress of reaction was monitored by LCMS. The reaction mixture was quenched with ice cold water (300 mL) and extracted with EtOAc (3×100 mL). The combined organic layer was washed with water (10×100 mL), brine (2×100 mL), dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography followed by reverse phase HPLC to yield the title compound. 1H NMR (CDCl3, freebase) δ (ppm): 8.5 (d, 2H), 8.2 (d, 1H), 7.7 (d, 1H), 7.23 (d, 2H), 7.9 (m, 1H), 5.08 (m, 1H), 4.5 (d, 1H), 4.3 (d, 1H), 3.6 (dd, 2H), 2.9 (m, 1H), 2.8 (m, 1H), 2.7 (m, 1H), 2.6 (m, 1H), 2.5 (s, 3H). Separation by chiral HPLC provides enantiomers II-78a-b.
Example 294
Preparation of Compound Nos. II-80 and II-80a-b
A solution of 1-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2-(6-methoxy-pyridin-3-yl)-propan-2-ol (100 mg, 0.27 mmol) in 3N HCl (4 mL) was stirred at 100° C. for 4 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by reverse phase HPLC to yield 5-[2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-hydroxy-1-methyl-ethyl]-pyridin-2-ol. 1H NMR (CD3OD, freebase) δ (ppm): 7.58 (d, 1H), 7.2 (s, 1H), 7.1 (s, 1H), 7.0 (d, 1H), 6.8 (d, 1H), 6.4 (d, 1H), 4.6 (bs, 1H), 4.17 (m, 2H), 4.0 (m, 2H), 3.1-3.25 (m, 2H), 2.97 (m, 1H), 2.8 (s, 3H), 2.4 (s, 3H), 1.6 (s, 3H). Separation by chiral HPLC provides enantiomers II-80a-b.
Example 295
Preparation of Compound Nos. II-81 and II-81a-b
To a solution of 5-(2-hydroxy-2-pyridin-4-yl-ethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole-8-carboxylic acid ethyl ester (200 mg, 0.547 mmol) in dry THF (10 mL) was added portionwise LAH (63 mg, 1.65 mmol) under nitrogen at RT. After stirring for 2 h, the reaction mixture was quenched with water (0.5 mL), NaOH (1 mL). The organic layer was separated and concentrated under reduced pressure. The crude product was purified by reverse phase chromatography to yield 2-(8-hydroxymethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethanol. 1H NMR (CD3OD, freebase) δ (ppm): 8.41 (d, 2H), 7.42 (s, 1H), 7.39 (d, 2H), 7.3 (d, 1H), 7.19 (d, 1H), 5.08 (t, 1H), 4.66 (s, 2H), 4.4 (s, 2H), 4.3 (m, 2H), 3.5 (m, 2H), 3.2 (m, 1H), 2.9 (m, 1H). Separation by chiral HPLC provides enantiomers II-81a-b.
Example 296
Preparation of Compound No. II-82
5-(2-Bromocyclopent-1-enyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg, 0.29 mmol), 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (127 mg, 0.58 mmol) and K2CO3 (120 mg, 0.87 mmol) were mixed in 1,2-dimethoxyethane (4 mL) and water (2 mL). The reaction mixture was purged with nitrogen, Pd(PPh3)4 (17 mg, 0.0147 mmol) was added and the reaction mixture was heated at 90° C. for 45 min. The reaction mixture was cooled to RT and concentrated under reduced pressure. The residue was diluted with water (20 mL) and extracted with EtOAc (50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield 26 mg of 2,8-dimethyl-5-(2-(6-methylpyridin-3-yl)cyclopent-1-enyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole as the TFA salt. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.0 (d, 1H), 7.8 (dd, 1H), 7.61 (d, 1H), 7.31 (s, 1H), 6.95-7.10 (m, 2H), 4.7 (d, 1H), 4.38 (d, 1H), 3.8 (m, 1H), 3.55 (m, 1H), 2.82-3.2 (m, 9H), 2.61 (s, 3H), 2.4 (s, 3H), 2.3 (m, 2H).
Example 297
Preparation of Compound Nos. II-83 and II-83a-d
To a solution of 2-(8-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethanol (200 mg, 0.651 mmol) in acetonitrile (4 mL), potassium carbonate (270 mg, 1.95 mmol) and 1-bromopropan-2-ol (135 mg, 0.977 mmol) were added and stirred the reaction mixture at 100° C. for 2 h. The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (3×20 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield 1-[5-(2-hydroxy-2-pyridin-4-yl-ethyl)-8-methyl-1,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl]-propan-2-ol. 1H NMR, (CDCl3, freebase) δ (ppm): 8.58 (s, 2H), 7.36 (m, 2H), 7.2 (m, 2H), 7.02 (d, 1H), 5.1 (s, 1H), 4.3 (m, 1H), 4.1 (m, 2H), 4.0 (m, 2H), 3.56 (m, 1H), 3.37 (m, 1H), 3.1-3.3 (m, 2H), 2.8 (m, 2H), 2.42 (s, 3H), 1.2 (d, 3H). Separation by chiral HPLC provides diastereomers II-83a-d.
Example 298
Preparation of Compound Nos. II-84 and II-84a-b
To a solution of 2-(8-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethanol (200 mg, 0.651 mmol) in acetonitrile (4 mL), potassium carbonate (270 mg, 1.95 mmol) and 1-chloro-2-methyl-propan-2-ol (105 mg, 0.977 mmol) were added and the reaction mixture was stirred at 100° C. for 12 h. The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (3×20 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (Neutral alumina, 1% MeOH-DCM), to yield 1-[5-(2-hydroxy-2-pyridin-4-yl-ethyl)-8-methyl-1,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl]-2-methyl-propan-2-ol. 1H NMR (CDCl3, freebase) δ (ppm): 8.6 (d, 2H), 7.27 (m, 2H), 7.2 (m, 2H), 7.0 (d, 1H), 5.08 (t, 1H), 4.19 (m, 2H), 3.9 (bs, 2H), 3.0-3.1 (m, 2H), 2.9 (m, 1H), 2.6 (s, 2H), 2.56 (m, 1H), 2.21 (s, 3H), 1.21 (s, 6H). Separation by chiral HPLC provides enantiomers II-84a-b.
Example 299
Preparation of Compound Nos. II-88 and II-88a-b
To a solution of 1-(3,4-Bis-allyloxy-phenyl)-2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-ethanol (500 mg, 1.15 mmol) in 10 mL MeOH was purged with nitrogen for 10 min. 1,3-Dimethylbarbituric acid (903 mg, 5.79 mmol) and Pd(PPh3)4 (80 mg, 0.069 mmol) were added under nitrogen and the mixture stirred for 30 min at RT. After the complete conversion of starting material (TLC and LCMS), the MeOH was removed under reduced pressure. 100 mL of saturated sodium bicarbonate was added and the mixture was extracted with EtOAc (3×100 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated. The resultant crude product was purified by HPLC to obtain 160 mg of 4-[2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-hydroxy-ethyl]-benzene-1,2-diol. 1H NMR (CD3OD, Free base) δ (ppm): 7.3 (d, 1H), 7.2 (s, 1H), 7.05 (dd, 1H), 6.7 (d, 1H), 6.6 (s, 1H), 6.53 (d, 1H), 4.8 (t, 1H), 4.21 (m, 3H), 4.05 (dd, 1H), 3.34 (m, 1H), 3.3 (m, 1H), 2.88 (dt, 1H), 2.81 (s, 3H), 2.5 (dt, 1H), 2.4 (s, 3H). Separation by chiral HPLC provides enantiomers II-88a-b.
Example 300
Preparation of Compound Nos. II-89 and II-89a-b
To a degassed solution of 2-(2-allyl-8-chloro-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-3-yl-ethanol (1.0 g, 2.7 mmol) in DCM were added 1,3-dimethyl barbituric acid (1.27 g, 8.1 mmol) and Pd(PPh3)4 (63 mg, 0.054 mmol) and the reaction mixture was stirred at RT for 3 h. The solvent was removed under reduced pressure. The residue was dissolved in saturated potassium carbonate solution and extracted with EtOAc (3×50 mL). The combined organic layer was washed with saturated potassium carbonate (6×20 mL), dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography (neutral alumina, 20% methanol in DCM) followed by reverse phase HPLC to yield 2-(8-chloro-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-3-yl-ethanol. 1H NMR (CD3OD, freebase) δ (ppm): 8.4 (d, 1H), 8.37 (s, 1H), 7.8 (d, 1H), 7.4 (d, 1H), 7.39 (m, 1H), 7.2 (d, 1H), 7.02 (d, 1H), 5.1 (t, 1H), 4.33 (d, 2H), 4.3 (s, 2H), 3.38-3.5 (m, 2H), 3.1 (m, 1H), 2.9 (m, 1H). Separation by chiral HPLC provides enantiomers II-89a-b.
Example 301
Preparation of Compound Nos. II-90 and II-90a-b
To a solution of 2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (300 mg, 1.5 mmol) in DMF (5 mL) was added sodium hydride (180 mg, 4.5 mmol) under nitrogen. After stirring at RT for 10 min, 4-(oxiran-2-yl)quinoline (384 mg, 2.25 mmol) was added dropwise under nitrogen into the reaction mixture, which was stirred at RT for 18 h. The progress of reaction was monitored by TLC, LCMS and NMR. The reaction mixture was poured in ice-cold water and extracted with EtOAc (2×50 mL). The combined organic layer was washed with water (3×50 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. Re-crystallization with diethyl ether yielded 2-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(quinolin-4-yl)ethanol (140 mg). 1H NMR (CDCl3, freebase) δ (ppm): 8.86 (d, 1H), 8.19 (d, 1H), 7.97 (d, 1H), 7.78 (t, 1H), 7.41 (d, 1H), 7.56 (t, 1H), 7.2 (d, 1H), 6.93-7.01 (m, 2H), 5.57 (t, 1H), 4.2 (dd, 1H), 4.1 (dd, 1H), 3.37 (dd, 2H), 2.83 (m, 1H), 2.71 (bs, 3H), 2.4 (s, 3H), 2.38 (s, 3H). Separation by chiral HPLC provides enantiomers II-90a-b.
Example 302
Preparation of Compound Nos. II-91 and II-91a-b
To a solution of 2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (525 mg, 2.6 mmol) in DMF was added sodium hydride (312 mg, 7.8 mmol) at 0° C. After stirring the solution for 15 min, a solution of 2-cyclohexyloxirane (500 mg, 3.9 mmol) was added dropwise into the reaction mixture, which was stirred at RT overnight. The progress of reaction was monitored by TLC, NMR and LCMS. The reaction mixture was quenched with ice-cold water and extracted with EtOAc. The organic layer was thoroughly washed with water, dried over anhydrous sodium sulfate and concentrated. Re-crystallization with ether yielded the desired product (160 mg). 1H NMR (CDCl3, Free base) δ (ppm): 7.2 (s, 1H), 7.19 (d, 1H), 6.95 (d, 1H), 4.15 (dd, 1H), 3.92 (dd, 1H), 3.7 (m, 1H), 3.6 (s, 2H), 2.99 (m, 1H), 2.8 (m, 3H), 2.58 (s, 3H), 2.42 (s, 3H), 1.9 (d, 1H), 1.8 (m, 2H), 1.7 (d, 2H), 1.52 (m, 1H), 1.22 (m, 5H). Separation by chiral HPLC provides enantiomers II-91a-b.
Example 303
Preparation of Compound No. II-92 and II-92a-b
A solution of 2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-(6-methoxy-pyridin-3-yl)-ethanol (200 mg, 0.569 mmol) in 3N HCl (8 mL) was stirred at 100° C. for 3 h. The reaction mixture was concentrated under reduced pressure and residue was purified by reverse phase HPLC to yield 5-(2-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-1-hydroxyethyl)pyridin-2(1H)-one. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.5 (m, 1H), 7.23 (s, 1H), 7.2 (s, 1H), 7.19 (d, 1H), 6.5 (s, 1H), 4.62 (d, 1H), 4.19-4.37 (m, 3H), 3.8 (m, 1H), 3.5 (m, 1H), 3.24 (m, 2H), 3.1 (m, 4H), 2.4 (s, 3H). Separation by chiral HPLC provides enantiomers II-92a-b.
Example 304
Preparation of Compound Nos. II-93 and II-93a-b
To a solution of 2-(8-chloro-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl)-1-(pyridin-4-yl)ethanol (600 mg, 1.84 mmol) in acetone (20 mL) were added 2-bromoethanol (341 mg, 2.76 mmol) and K2CO3 (761 mg, 5.52 mmol) and the reaction mixture stirred at 80° C. for 4 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was cooled to RT, filtered and the filtrate concentrated under reduced pressure. The residue was diluted with water and extracted with EtOAc. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by reverse phase HPLC to yield the title compound. 1H NMR (CDCl3, Free base) δ (ppm): 8.41 (d, 2H), 7.31 (s, 1H), 7.18 (m, 4H), 4.79 (t, 1H), 4.0 (m, 2H), 3.68 (m, 3H), 3.56 (d, 1H), 2.8 (m, 3H), 2.65 (m, 2H), 2.58 (m, 1H). Separation by chiral HPLC provided enantiomers II-93a-b.
Example 305
Preparation of Compound Nos. II-94 and II-94a-b
To a solution of 2-(8-chloro-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl)-1-(pyridin-3-yl)ethanol (1.0 g, 3.05 mmol) in acetone (30 mL) were added 2-bromoethanol (758 mg, 6.12 mmol) and K2CO3 (1.3 g, 9.43 mmol) and the reaction mixture stirred at 80° C. for 4 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was cooled to RT, filtered and the filtrate concentrated under reduced pressure. The residue was diluted with water and extracted with EtOAc. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by reverse phase HPLC to yield the title compound. 1H NMR (CDCl3, Free base) δ (ppm): 8.39 (d, 1H), 8.2 (s, 1H), 7.6 (d, 1H), 7.27 (s, 1H), 7.2 (m, 2H), 7.16 (d, 1H), 4.8 (m, 1H), 4.1 (dd, 1H), 4.0 (dd, 1H), 3.7 (m, 2H), 3.6 (d, 1H), 3.5 (d, 1H), 2.85 (m, 3H), 2.8 (m, 1H), 2.63 (m, 2H). Separation by chiral HPLC provided enantiomers II-94a-b.
Example 306
Preparation of Compound Nos. II-95 and II-95a-d
Phenyl magnesium bromide (1M solution in THF) (6.24 mL, 6.24 mmol) was added dropwise at −70° C. to a stirred solution of 2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-propionaldehyde (400 mg, 1.56 mmol) in THF (40 mL), the reaction mixture stirred at RT for 16 h, diluted with EtOAc (75 mL) and water (60 mL). The two layers were separated, the aq. layer extracted with EtOAc (2×75 mL), and the combined organic layers dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude (500 mg) was purified by prep. HPLC to afford 2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)1-phenyl-propan-1-ol yielded as the TFA salt (65 mg). 1H NMR (CDCl3, Free base) δ (ppm): 7.37 (d, 1H), 7.17 (t, 3H), 7.12 (s, 1H), 7.06 (m, 2H), 6.95 (d, 1H), 5.11 (t, 1H), 4.37 (t, 1H), 3.57 (dd, 1H), 3.46 (d, 1H), 2.67 (m, 2H), 2.51 (m, 1H), 2.43 (s, 3H), 2.41 (s, 3H), 1.68 (d, 3H). Separation by chiral HPLC provides diastereomers II-95a-d.
Example 307
Preparation of Compound No. II-96
To a solution of 1-(2,8-dimethyl-3,4-dihydro-1 h-pyrido[4,3-b]indol-5(2h)-yl)prop-1-en-2-yltrifluoromethanesulfonate (100 mg, 0.257 mmol) in DME (4 mL) was added Pd(PPh3)4 (15 mg, 0.0128) and the reaction mixture was purged with N2. 2-Fluoropyridine-5-boronic acid pinacol ester (115 mg, 0.515 mmol), K2CO3 (36 mg, 0.257 mmol) and water (2 mL) were added, the reaction mixture was purged with nitrogen and refluxed for 45 min. The reaction mixture was cooled to RT, and the solvent was removed under reduced pressure. The residue was dissolved in water, extracted with EtOAc, washed with brine, and concentrated to afford crude product which was purified by silica gel chromatography followed by reverse phase HPLC to obtain the products as TFA salts. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.42 (s, 1H), 8.21 (m, 1H), 7.28 (s, 1H), 7.02-7.21 (m, 4H), 4.78 (d, 1H), 4.40 (d, 1H), 3.82 (m, 1H), 3.58 (m, 1H), 3.16 (m, 5H), 2.41 (s, 3H), 2.0 (s, 3H).
Example 308
Preparation of Compound Nos. II-97 and II-97a-b
To a solution of 2-(1,2,3,4-tetrahydro-8-methylpyrido[4,3-b]indol-5-yl)-1-(pyridin-4-yl)ethanol (200 mg, 0.652 mmol) and sodium 2-bromoethanesulfonate (164 mg, 0.78 mmol) in DMF (3 mL) and water (0.5 mL), were added sodium bicarbonate (164 mg, 1.95 mmol) and potassium iodide (128 mg, 0.78 mmol) and the reaction mixture was stirred at 90° C. for 2 h. The reaction mixture was diluted with water and extracted with DCM. The aqueous layer was neutralized with aq HCl and the solid obtained was recrystallized from MeOH to yield 2-(3,4-dihydro-5-(2-hydroxy-2-(pyridin-4-yl)ethyl)-8-methyl-1H-pyrido[4,3-b]indol-2(5H)-yl)ethanesulfonic acid as a white solid (80 mg). 1H NMR (CD3OD, Free base) δ (ppm): 8.45 (d, 2H), 7.40 (d, 2H), 7.26 (s, 1H), 7.23 (d, 1H), 7.00 (s, 1H), 5.06 (t, 1H), 4.59 (m, 2H), 4.29 (m, 2H), 3.71 (t, 4H), 3.55 (m, 2H), 3.0 (d, 1H), 2.4 (s, 3H). Separation by chiral HPLC provides enantiomers II-97a-b.
Example 309
Preparation of Compound No. II-98 and II-98a-d
To an ice-cooled stirred suspension of 4-bromopyridine hydrochloride salt (1.0 g, 5.1 mmol) in THF (5 mL) was added isopropyl magnesium chloride (2M in THF, 5 mL, 10.3 mmol) and stirred the reaction at RT for 30 min. A solution of 2-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)propanal (300 mg, 1.17 mmol) in THF (3 mL) was added into the brown colored reaction mixture, which was stirred at RT for 1.5 h. The progress of reaction was monitored by TLC and LCMS (45% conversion). The reaction mixture was cooled to 0° C. and quenched with cold saturated ammonium chloride solution (till effervescence stopped) and water was added, stirred at RT for 15 min and extracted with EtOAc. The organic layer was dried over anhydrous sodium sulfate and evaporated. The residue was purified by reverse phase HPLC. 1H NMR (CDCl3, Free base) δ (ppm): 8.60 (d, 2H), 7.4 (d, 1H), 7.55 (d, 2H), 7.18 (s, 1H), 6.98 (d, 1H), 5.15 (d, 1H), 4.2 (t, 1H), 3.4 (d, 1H), 3.28 (d, 1H), 2.94 (m, 1H), 2.784 (m, 1H), 2.68 (m, 2H), 2.48(s, 3H), 2.43 (s, 3H), 1.37 (s, 3H). Separation by chiral HPLC provides diastereomers II-98a-d.
Example 310
Preparation of Compound Nos. II-99 and II-99a-b
To a solution of 6-aza-2,8-dimethyl carboline (500 mg, 2.5 mmol) in DMF (5 mL) was added NaH (60%, 300 mg, 7.5 mmol). After stirring for 5 min at RT, a solution of 3-(2-methyloxiran-2-yl)pyridine (506.2 mmol, 3.75 mmol) in DMF (1 mL) was added dropwise into the reaction mixture, which was stirred at RT for 12 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with ice-water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was triturated with ether to yield the desired compound (150 mg). 1H NMR (CDCl3, Free base) δ (ppm): 8.7 (s, 1H), 8.41 (d, 1H), 8.02 (s, 1H), 7.8 (d, 1H), 7.5 (s, 1H), 7.19 (dd, 1H), 4.3 (dd, 2H), 3.6 (d, 1H), 3.5 (d, 1H), 2.8 (m, 2H), 2.65 (m, 1H), 2.55 (s, 3H), 2.49 (m, 1H), 2.4 (s, 3H), 1.6 (s, 3H). Separation by chiral HPLC provided enantiomers II-99a-b.
Example 311
Preparation of Compound Nos. II-100 and II-100a-b
Aza-dimethyl-carboline (100 mg, 0.497 mmol) was charged in a reaction bottle and N,N-dimethylformamide (2 mL) was added. Sodium hydride (60% suspension in mineral oil) (60 mg, 1.49 mmol) was added portionwise. The reaction mixture was stirred at RT for 5 min and 2-methyl-5-(oxiran-2-yl)pyridine (300 mg, 2.22 mmol) was added dropwise. The reaction mixture was stirred at RT overnight. The reaction was monitored by LCMS. Ice water (5 mL) was added and the organic layer was extracted with EtOAc (2×15 mL). The combined organic layer was washed with water (3×5 mL) and concentrated. The desired product was purified through reverse phase chromatography as a racemate (12.92 mg). 1H NMR (CDCl3, Free base) δ (ppm): 8.42 (s, 1H), 8.0 (s, 1H), 7.5 (s, 1H), 7.47 (d, 1H), 7.07 (d, 1H), 5.1 (m, 1H), 4.37 (dd, 1H), 4.26 (dd, 1H), 3.59 (dd, 2H), 2.78 (m, 1H), 2.7 (m, 2H), 2.52 (s, 3H), 2.5 (s, 3H), 2.45 (m, 1H), 2.42 (s, 3H). Separation by chiral HPLC provided enantiomers II-100a-b.
Example 312
Preparation of Compound No. II-101
2,8-Dimethyl-5-(2-pyridin-4-yl-propenyl)-2,3,4,5-tetrahydro-pyrido[4,3-b]indol-1-one (350 mg, 1.057 mmol) was dissolved in dry toluene (6 mL). Methyl magnesium bromide (3M solution in diethyl ether, 1.76 mL, 5.28 mmol) was added and the reaction mixture was heated at 100° C. for 1 h. The reaction mixture was cooled to RT, quenched with ice water and filtered through a Celite bed. The filtrate was extracted with EtOAc (3×70 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography over neutral alumina followed by reverse phase HPLC to obtain 6.5 mg of 1,1,2,8-tetramethyl-5-(2-pyridin-4-yl-propenyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole as a formate salt. 1H NMR (CD3OD, formate salt) δ (ppm): 8.60 (d, 2H), 7.70 (d, 2H), 7.50 (s, 1H), 7.30 (s, 1H), 7.12 (m, 2H), 3.70 (t, 2H), 3.10 (t, 2H), 3.02 (s, 3H), 2.44 (s, 3H), 2.02 (s, 3H), 1.90 (s, 6H).
Example 313
Preparation of Compound Nos. II-102 and II-102a-b
To a solution of methyl carboline ethyl ester (500 mg, 1.27 mmol) in THF (30 mL) was added LAH (145 mg, 3.81 mmol) under nitrogen at RT and stirred for 1 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched by adding water (0.5 mL), 1N NaOH (1 mL) and water (0.5 mL). The inorganic material was removed by filtration and the filtrate concentrated under reduced pressure. The residue was triturated with ether to yield the title compound (450 mg). 1H NMR (CD3OD, Free base) δ (ppm): 8.5 (s, 1H), 8.39 (d, 1H), 7.8 (d, 1H), 7.26 (m, 2H), 7.1 (d, 1H), 7.0 (d, 1H), 4.6 (s,2H), 4.21 (q, 2H), 3.62 (s, 2H), 2.79 (m, 4H), 2.49 (s, 3H), 1.64 (s, 3H). Separation by chiral HPLC provides enantiomers II-102a-b.
Example 314
Preparation of Compound No. II-103
To a stirred solution of 6-methyl-6,7,8,9-tetrahydro-5H-pyrrolo[2,3-b:4,5-c′]dipyridine (200 mg, 1.068 mmol) in NMP (3 mL) was added powdered KOH (419 mg, 7.486 mmol). After stirring for 10 min at RT, 2-(trifluoromethyl)-5-vinylpyridine (370 mg, 2.14 mmol) was added to the reaction mixture and stirring continued for another 3 h. The progress of reaction was monitored by TLC and NMR. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (3×20 mL). The organic layer was washed with water (5×20 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude material, which was purified by reverse phase HPLC to yield 6-methyl-9-(2-(6-(trifluoromethyl)pyridin-3-yl)ethyl)-6,7,8,9-tetrahydro-5H-pyrrolo[2,3-b:4,5-c′]dipyridine as the TFA salt (100 mg). 1H NMR (CDCl3, TFA salt) δ (ppm): 8.4 (s, 1H), 8.2 (s, 1H), 7.7 (d, 1H), 7.5 (d, 1H), 7.4 (d, 1H), 7.0 (s, 1H), 4.4 (s, 2H), 3.6 (s, 2H), 3.2 (s, 2H), 2.78 (s, 2H), 2.6 (s, 2H), 2.5 (s, 3H).
Example 315
Preparation of Compound Nos. II-104 and II-104a-b
To a solution of methyl carboline ethyl ester (350 mg, 0.92 mmol) in THF (5 mL) was added LAH (175 mg, 4.6 mmol) under nitrogen at RT and stirred for 1 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched by adding water (0.5 mL), 1N NaOH (1 mL) and water (0.5 mL). The inorganic material was removed by filtration, and the filtrate concentrated under reduced pressure. The residue was purified through reverse phase HPLC to yield the title compound. 1H NMR (CD3OD, Free base) δ (ppm): 8.5 (s, 1H), 8.3 (d, 1H), 7.82 (d, 1H), 7.4 (s, 1H), 7.3 (dd, 1H), 7.0 (m, 2H), 4.6 (s,2H), 4.4 (dd, 2H), 4.41 (d, 1H), 4.2 (d, 1H), 3.5 (m, 2H), 3.21 (m, 1H), 3.0 (m, 1H), 1.64 (s, 3H). Separation by chiral HPLC provides enantiomers II-104a-b.
Example 316
Preparation of Compound Nos. II-105 and II-105a-b
1-(2,8-Dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2-pyridin-3-yl-propan-2-ol (500 mg, 1.49 mmol) was dissolved in 10 mL DCM and m-chloro perbenzoic acid (383 mg, 2.24 mmol) was added and the mixture stirred at RT. After consumption of starting material by monitoring TLC and LCMS, the reaction mixture was concentrated and the crude product was purified by reverse phase chromatography, to obtain 110 mg of 1-(2,8-dimethyl-2-oxy-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2-pyridin-3-yl-propan-2-ol. 1H NMR (CDCl3, Free base) δ (ppm): 8.7 (s, 1H), 8.25 (d, 1H), 7.8 (d, 1H), 7.4 (bs, 1H), 7.27 (d, 1H), 7.2 (m, 2H), 7.0 (d, 1H), 4.79 (d, 1H), 4.6 (d, 1H), 4.2 (d, 1H), 4.05 (d, 1H), 3.85 (m, 1H), 3.6 (m, 1H), 3.4 (m, 1H), 2.64 (m, 1H), 2.4 (s, 3H), 1.6 (s, 3H). Separation by chiral HPLC provides enantiomers II-105a-b.
Example 317
Preparation of Compound Nos. II-106 and II-106a-b
1-(1-(1-Ethoxyethyl)-1H-pyrazol-4-yl)-2-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)ethanol (147 mg, 0.3848 mmol) was dissolved in 1,4-dioxane (15 mL) and to it was added 20% aqueous hydrochloride solution (15 mL). The mixture was heated at 55° C. for 1 h. The reaction mixture was neutralized with a saturated solution of sodium bicarbonate and was extracted with EtOAc (3×60 mL). The combined organic layer was washed with water (15 mL) and then brine (2×30 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified by reverse phase chromatography. Yield: 36.6 mg (TFA salt). 1H NMR (CDCl3, Free base) δ (ppm): 7.35 (s, 1H), 7.0 (s, 1H), 6.9 (d, 1H), 6.8 (d, 1H), 6.2 (s, 1H), 4.9 (t, 1H), 4.2 (dd, 2H), 3.55 (d,1H), 3.4 (d, 1H), 2.8 (m, 2H), 2.6 (m, 2H), 2.5 (s, 3H), 2.39 (s, 3H). Separation by chiral HPLC provided enantiomers II-106a-b.
Example 318
Preparation of Compound Nos. II-108 and II-108a-b
To a solution of dimethyl-aza carboline (400 mg, 1.99 mmol) in DMF (5 mL) was added NaH (239 mg, 5.97 mmol, 60%). After stirring at RT for 10 min, the epoxide (606 mg, 2.98 mmol) was added into the reaction mixture, which was stirred at RT for 16 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with ice-water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The product was re-crystallized from ether (250 mg). 1H NMR (CDCl3, Free base) δ (ppm): 8.81 (s, 1H), 8.0 (m, 2H), 7.6 (d, 1H), 7.52 (s, 1H), 4.23 (q, 2H), 3.6 (d, 1H), 3.5 (d, 1H), 2.8 (m, 1H), 2.72 (m, 3H), 2.5 (s, 3H), 2.4 (m, 1H), 2.4 (s, 3H), 1.6 (s, 3H). Separation by chiral HPLC provided enantiomers II-108a-b.
Example 319
Preparation of Compound Nos. II-109 and II-109a-b
To a solution of 6-aza-8-chloro-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (400 mg, 1.8 mmol) in DMF (5 mL) was added NaH (217 mg, 5.42 mmol, 60%). After stirring at RT for 10 min, the epoxide (552 mg, 2.71 mmol) was added into the reaction mixture, which was stirred at RT for 16 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with ice-water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The product was re-crystallized from ether (340 mg). 1H NMR (CDCl3, Free base) δ (ppm): 8.8 (s, 1H), 8.15 (s, 1H), 8.0 (d, 1H), 7.68 (s, 1H), 7.6 (d, 1H), 4.23 (q, 2H), 3.6 (d, 1H), 3.5 (d, 1H), 2.8 (m, 3H), 2.72 (m, 1H), 2.5 (s, 3H), 2.4 (m, 1H), 1.6 (s, 3H). Separation by chiral HPLC provided enantiomers II-109a-b.
Example 320
Preparation of Compound No. II-110
To a solution of 3,6-dimethyl-6,7,8,9-tetrahydro-5H-pyrrolo[2,3-b:4,5-c′]dipyridine (201 mg, 1.0 mmol) in DMF (1 mL) was added a suspension of NaH (128.0 mg, 3.24 mmol) in DMF (1 mL). After stirring for 5 min at RT, a solution of 2-(6-methylpyridin-3-yl)ethyl 4-methylbenzenesulfonate (873 mg, 3.0 mmol) in DMF (1 mL) was added dropwise into the reaction mixture and stirring continued for another 3 h. The progress of reaction was monitored by TLC and NMR. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (3×25 mL). The organic layer was washed with water (3×20 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude material, which was purified by silica gel flash chromatography and 10% MeOH-DCM to yield 3,6-dimethyl-9-(2-(6-methylpyridin-3-yl)ethyl)-6,7,8,9-tetrahydro-5H-pyrrolo[2,3-b:4,5-c′]dipyridine (190 mg). 1H NMR (CDCl3, TFA salt) δ (ppm): 8.2 (s, 1H), 8.04 (s, 1H), 7.43 (s, 1H), 7.18 (d, 1H), 7.0 (d, 1H), 4.3 (t, 2H), 3.6 (s, 2H), 3.0 (t, 2H), 2.7 (t, 2H), 2.5 (s, 8H), 2.4 (s, 3H).
Example 321
Preparation of Compound Nos. II-111 and II-111a-b
5-[2-(3,6-Dimethyl-5,6,7,8-tetrahydro-1,6,9-triaza-fluoren-9-yl)-1-hydroxy-ethyl]-pyridine-2-carbonitrile (600 mg, 1.729 mmol) was dissolved in tert-butanol (12 mL), crushed potassium hydroxide (290 mg, 5.187 mmol) was added, and the mixture heated at 80° C. for 1 h. The reaction was monitored by TLC & LCMS. The reaction mixture was allowed to cool to RT, the solvent was removed under vacuum, and the residue was diluted with water (20 ml) and extracted with EtOAc (2×75 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated to obtain the crude product that was purified by reverse phase chromatography to afford 100 mg of 5-[2-(3,6-dimethyl-5,6,7,8-tetrahydro-1,6,9-triaza-fluoren-9-yl)-1-hydroxy-ethyl]-pyridine-2-carboxylic acid amide. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.62 (s, 1H), 8.1 (s, 1H), 8.05 (d, 1H), 7.95 (d, 1H), 7.8 (s, 1H), 5.23 (t, 1H), 4.7 (d, 1H), 4.53 (d, 1H), 4.4 (m, 2H), 3.83 (m, 1H), 3.6 (m, 1H), 3.4 (m, 2H), 3.2 (s, 3H), 2.43 (s, 3H). Separation by chiral HPLC provides enantiomers II-111a-b.
Example 322
Preparation of Compound Nos. II-112 and II-112a-d
2,6-Dimethyl-1-phenyl-2,3,4,9-tetrahydro-1H-β-carboline (300 mg, 1.08 mmol) was dissolved in DMF (4 mL). Sodium hydride (172 mg, 4.32 mmol) was added and the mixture was stirred at RT for 30 min. 3-(2-Methyl-oxiranyl)-pyridine (733 mg, 5.43 mmol) in 1 mL DMF was added dropwise into the reaction mixture, which was stirred for 5 h at RT. The reaction was monitored by TLC and LCMS. After consumption of starting material, the reaction was quenched with ice and extracted with EtOAc (2×100 mL). The organic layer was washed with water (2×100 mL), dried over anhydrous sodium sulfate and concentrated to obtain the crude that was purified by column chromatography (silica gel 100-200 mesh, Eluent: 6% MeOH in DCM) to obtain 120 mg of 1-(2,6-dimethyl-1-phenyl-1,2,3,4-tetrahydro-β-carbolin-9-yl)-2-pyridin-3-yl-propan-2-ol (racemate) and followed by chiral separation. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.25 (s, 1H), 8.2 (d, 1H), 7.6 (d, 1H), 7.4 (m, 3H), 7.2 (s, 1H), 7.19 (m, 3H), 6.65 (d, 1H), 6.4 (d, 1H), 5.5 (s, 1H), 4.0 (d, 1H), 3.43 (d, 1H), 3.2 (m, 1H), 3.0 (m, 3H), 2.6 (s, 3H), 2.3 (s, 3H), 1.6 (s, 3H). Separation by chiral HPLC provided diastereomers II-112a-b.
Example 323
Preparation of Compound Nos. II-113 and II-113a-d
2,6-Dimethyl-1-phenyl-2,3,4,9-tetrahydro-1H-β-carboline (300 mg, 1.08 mmol) was dissolved in DMF (3 mL). Sodium hydride (172 mg, 4.32 mmol) was added and the mixture stirred at RT for 30 min. 4-Oxiranyl-pyridine (657 mg, 5.43 mmol) in 1 mL DMF was added dropwise into the reaction mixture, which was stirred at RT for 5 h. The reaction was monitored by TLC and LCMS. After consumption of starting material, the reaction was quenched with ice and extracted with EtOAc (2×100 mL). The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated to obtain the crude product that was purified by column chromatography (eluent: 10% MeOH in DCM) to obtain 220 mg of 2-(2,6-dimethyl-1-phenyl-1,2,3,4-tetrahydro-(3-carbolin-9-yl)-1-pyridin-4-yl-ethanol (M6792, racemate) and followed by chiral separation. 1H NMR (CD3OD, Free base) δ (ppm): 8.17 (d, 2H), 7.35 (m, 4H), 7.09 (d, 2H), 7.0 (m, 3H), 6.9 (d, 1H), 4.8 (t, 1H), 4.6 (s, 1H), 4.08 (dd, 1H), 3.45 (dd, 1H), 3.0 (m, 1H), 2.8 (m, 2H), 2.6 (m, 1H), 2.4 (s, 3H), 2.2 (s, 3H). Separation by chiral HPLC provided diastereomers II-113a-b.
Example 324
Preparation of Compound Nos. II-114 and II-114a-b
1-(6-Bromo-pyridin-3-yl)-2-(3,6-dimethyl-5,6,7,8-tetrahydro-1,6,9-triaza-fluoren-9-yl)-ethanol (2 g, 4.9 mmol) was dissolved in DMF (20 mL), and the mixture was purged with nitrogen. Zinc cyanide (1.16 g, 9.9 mmol) and Pd(PPh3)4 (339 mg, 0.294 mmol) were added, and the mixture heated at 150° C. for 2 h. The reaction was monitored by LCMS. The reaction mixture was allowed to cool at RT, diluted with EtOAc (250 mL) and filtered. The filtrate was washed with water (3×100 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated to obtain the crude that was purified by reverse phase chromatography to obtain 100 mg of 5-[2-(3,6-dimethyl-5,6,7,8-tetrahydro-1,6,9-triaza-fluoren-9-yl)-1-hydroxy-ethyl]-pyridine-2-carbonitrile. This was followed by chiral separation. 1H NMR (CDCl3, Free base) δ (ppm): 8.62 (s, 1H), 8.03 (s, 1H), 7.73 (d, 1H), 7.6 (d, 1H), 7.5 (s, 1H), 5.25 (d, 1H), 4.45 (d, 1H), 4.3 (dd, 1H), 3.55 (dd, 2H), 2.8 (m, 1H), 2.7 (m, 2H), 2.5 (s, 3H), 2.45 (s, 3H), 2.4 (m, 1H). Separation by chiral HPLC provided enantiomers II-114a-b.
Example 325
Preparation of Compound Nos. II-115 and II-115a-d
Compound Nos. II-115 and II-115a-d are prepared in an analogous fashion to Compound Nos. 129 and 129a-d (Example 110), using 2,3,5,6,7,11c-hexahydro-1H-indolizino[7,8-b]indole as the starting material.
Example 326
Preparation of Compound Nos. II-116 and II-116a-b
To a degassed solution of aza-allylcyano alcohol (200 mg, 0.53 mmol) and 1,3-dimethylbarbituric acid (251 mg, 1.61 mmol) in DCM (5 mL) was added Pd(PPh3)4 (24 mg, 0.020 mmol) at RT and the reaction mixture was stirred at RT for 45 min. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was diluted with water and the organic layer was separated. The aqueous layer was basified with saturated aq NaHCO3 and extracted with DCM. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield title compound. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.2 (s, 1H), 8.0 (s, 1H), 7.68 (d, 2H), 7.6 (d, 2H), 5.2 (dd, 1H), 4.5 (dd, 1H), 4.45 (s, 2H), 4.33 (dd, 1H), 3.6 (t, 2H), 3.25 (d, 1H), 3.1 (d, 1H), 2.5 (s, 3H). Separation by chiral HPLC provides enantiomers II-116a-b.
Example 327
Preparation of Compound Nos. II-117 and II-117a-b
Compound Nos. II-117 and II-117a-b are prepared in an analogous fashion to Compound Nos. 5 and 5a-b (Example 5), using 2-fluoro-5-(2-methyloxiran-2-yl)pyridine as the epoxide.
Example 328
Preparation of Compound Nos. II-118 and II-118a-b
To an ice-cooled stirred solution of 8-chloro-2-cyclobutyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.0 g, 3.84 mmol) in DMF (10 mL) was added sodium hydride (60%, 462 mg, 11.55 mmol). After stirring for 10 min, 3-(2-methyloxiran-2-yl)pyridine (780 mg, 5.77 mmol) was added into the reaction mixture, which was stirred at RT for 16 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with ice-water and extracted with EtOAc (2×100 mL). The organic layer was washed with water (5×100 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The product was crystallized from ether:hexane (50:50) to yield the title compound (1.0 g). The product was further purified by chiral HPLC to give enantiomers II-118a and II-118b. 1H NMR (CD3OD, D1-HCl salt) δ (ppm): 8.7 (m, 3H), 7.79 (d, 1H), 7.43 (d, 1H), 6.9 (m, 2H), 4.7 (d, 1H), 4.4 (dd, 2H), 4.15 (t, 1H), 3.95 (m, 1H), 3.8 (m, 1H), 3.6 (m, 1H), 3.5 (m, 1H), 2.4 (m, 4H), 1.9 (m, 3H), 1.8 (d, 3H).
Example 329
Preparation of Compound No. II-119
To a stirred solution of 3,6-dimethyl-6,7,8,9-tetrahydro-5H-pyrrolo[2,3-b:4,5-c′]dipyridine (201 mg, 1.0 mmol) in NMP (3 mL) was added powdered KOH (392 mg, 7.0 mmol). After stirring for 10 min at RT, 2-(trifluoromethyl)-5-vinylpyridine (346 mg, 2.0 mmol) was added to the reaction mixture and stirring continued for another 3 h. The progress of reaction was monitored by TLC and NMR. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (3×20 mL). The organic layer was washed with water (5×20 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude material, which was purified by reverse phase HPLC to yield 3,6-dimethyl-9-(2-(6-(trifluoromethyl)pyridin-3-yl)ethyl)-6,7,8,9-tetrahydro-5H-pyrrolo[2,3-b:4,5-c′]dipyridine (80 mg). 1H NMR (CDCl3, TFA salt) δ (ppm): 8.38 (s, 1H), 8.0 (s, 1H), 7.5 (d, 2H), 7.4 (d, 1H), 4.4 (t, 2H), 3.58 (s, 2H), 3.2 (t, 2H), 2.68 (t, 2H), 2.5 (t, 2H), 2.47 (s, 3H), 2.38 (s, 3H).
Example 330
Preparation of Compound Nos. II-120 and II-120a-d
9-Methyl-2,3,4,5,6,10c-hexahydro-1H-3a,6-diaza-cyclopenta[c]fluorine (250 mg, 1.10 mmol) was dissolved in DMF (3 mL), sodium hydride (221 mg, 5.53 mmol) was added and the mixture stirred at RT for 5 min. 2-(4-Fluoro-phenyl)-oxirane (305 mg, 2.21 mmol) in 2 mL DMF was added dropwise into the reaction mixture and was stirred at RT for 16 h. The reaction was monitored by TLC and LCMS. After completion of reaction, the mixture was quenched with ice cold water (100 mL) and extracted with EtOAc (100 mL). The organic layer was washed with water (5×50 mL), dried over sodium sulfate and concentrated to obtain the crude product that was purified by reverse phase HPLC followed by chiral HPLC to obtain 190 mg of 1-(4-fluoro-phenyl)-2-(9-methyl-1,2,3,4,5,10c-hexahydro-3a,6-diaza-cyclopenta[c]fluoren-6-yl)-ethanol. 1H NMR (CD3OD, HCl salt) δ (ppm): 7.32 (d, 1H), 7.3 (s, 1H), 7.1 (t, 2H), 7.0 (m, 3H), 5.08 (t, 1H), 4.4 (dd, 1H), 4.19 (dd, 1H), 3.6 (m, 2H), 3.45 (m, 1H), 3.0 (d, 1H), 2.6 (m, 2H), 2.4 (s, 3H), 2.2 (m, 2H), 2.0 (m, 1H). Separation by chiral HPLC provided diastereomers II-120a-b.
Example 331
Preparation of Compound Nos. II-121 and II-121a-d
9-Methyl-2,3,4,5,6,10c-hexahydro-1H-3a,6-diaza-cyclopenta[c]fluorene (150 mg, 0.66 mmol) was dissolved in DMF (2 mL), sodium hydride (79 mg, 1.98 mmol) was added and the mixture was stirred at RT for 5 min. 2-(4-Fluoro-phenyl)-2-methyl-oxirane (201 mg, 1.32 mmol) was added dropwise into the reaction mixture and stirred at RT for 18 h. The reaction was monitored by TLC and LCMS. After consumption of starting material, the reaction mixture was quenched with ice cold water (100 mL) and extracted with EtOAc (2×100 mL). The combined organic layer was washed with water (2×100 mL), dried over anhydrous sodium sulfate and concentrated to obtain the crude product, which was purified by column chromatography (neutral alumina) Eluent: −2% MeOH in DCM followed by chiral HPLC to obtain 77 mg of 2-(4-fluoro-phenyl)-1-(9-methyl-1,2,3,4,5,10c-hexahydro-3a,6-diaza-cyclopenta[c]fluoren-6-yl)-propan-2-ol. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.4 (m, 2H), 7.2 (m, 2H), 7.0 (m, 3H), 5.08 (t, 1H), 4.3 (d, 1H), 4.15 (d, 1H), 3.65 (m, 1H), 3.5 (m, 2H), 3.3 (m, 1H), 2.90 (m, 2H), 2.7 (m, 1H), 2.4 (s, 3H), 2.2 (m, 3H), 1.62 (s, 3H). Separation by chiral HPLC provided diastereomers II-121a-b.
Example 332
Preparation of Compound Nos. II-122 and II-122a-d
To a solution of 11-aza-10-methyl-2,3,5,6,7,11c-hexahydro-1H-indolizino[7,8-b]indole (200 mg, 0.88 mmol) in DMF (5 mL), NaH (105 mg, 2.6 mmol, 60% dispersion in mineral oil) was added at 0° C. and the reaction mixture was stirred for 10 min. 4-oxiranyl-pyridine (213 mg, 1.76 mmol) was added and the reaction mixture was stirred at RT overnight. The reaction was monitored with LCMS. The reaction mixture was quenched with MeOH (2 mL), concentrated under reduced pressure to obtain the product that was purified by reverse phase column chromatography to obtain the 39 mg of product as the free base. 1H NMR (CD3OD, freebase) δ (ppm): 8.4 (d, 2H), 7.63 (d, 1H), 7.29 (dd, 2H), 6.95 (t, 1H), 5.0 (t, 1H), 4.3 (m, 3H), 3.21 (m, 1H), 2.9 (m, 4H), 2.7 (m, 1H), 2.57 (s, 3H), 2.52 (m, 1H), 1.9 (m, 3H). Separation by chiral HPLC provides diastereomers II-122a-b.
Example 333
Preparation of Compound Nos. II-123 and II-123a-b
A mixture of 9-chloro-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole and 7-chloro-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (2.00 g, 8.5 mmol) was dissolved in DMF (15 mL). Sodium hydride (1.708 g, 42.71 mmol) was added at 0-10° C. and stirred at the same temperature for 15 min., 3-(2-methyloxiran-2-yl)pyridine (2.309 g, 17.08 mmol) was added dropwise into the reaction mixture and the mixture was stirred at RT for 16 h. The reaction was monitored by TLC and LCMS. After consumption of starting material, the reaction mixture was quenched with ice cold water (100 mL) and extract with EtOAc (300 mL). The organic layer was washed with water (5×100 mL). The organic layer dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude. The crude product was purified by reverse phase column chromatography to obtain 350 mg of 1-(7-chloro-2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridin-3-yl)propan-2-ol. 1H NMR (CD3OD, HCl salt) δ (ppm): 8.68 (m, 3H), 7.95 (m, 1H), 7.29 (d, 1H), 6.9 (m, 1H), 4.68 (dd, 1H), 4.38 (m, 2H), 4.32 (dd, 1H), 3.9 (m, 1H), 3.52 (m, 2H), 3.25 (m, 1H), 3.12 (s, 3H), 2.35 (d, 3H), 1.83 (d, 3H). Separation by chiral HPLC provided enantiomers II-123a-b.
Example 334
Preparation of Compound Nos. II-124 and II-124a-b
A mixture of 9-chloro-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole and 7-chloro-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (2.00 g, 8.5 mmol) was dissolved in DMF (15 mL). Sodium hydride (1.708 g, 42.71 mmol) was added at 0-10° C. and stirred at the same temperature for 15 min., 3-(2-methyloxiran-2-yl)pyridine (2.309 g, 17.08 mmol) was added dropwise into the reaction mixture and the mixture was stirred at RT for 16 h. The reaction was monitored by TLC and LCMS. After consumption of starting material, the reaction mixture was quenched with ice cold water (100 mL) and extract with EtOAc (300 mL). The organic layer was washed with water (5×100 mL). The organic layer dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude. The crude product was purified by reverse phase column chromatography to obtain 35 mg of 1-(9-chloro-2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridin-3-yl)propan-2-ol. 1H NMR (CD3OD, freebase) δ (ppm): 8.46 (s, 1H), 8.34 (d, 1H), 7.82 (d, 1H), 7.29 (t, 1H), 6.87 (d, 1H), 6.77 (d, 1H), 4.22 (dd, 2H), 3.99 (q, 2H), 2.73 (m, 4H), 2.5 (s, 3H), 2.3 (s, 3H), 1.66 (s, 3H). Separation by chiral HPLC provided enantiomers II-124a-b.
Example 335
Preparation of Compound Nos. II-125 and II-125a-d
8,10-Dimethyl-2,3,5,6,7,11c-hexahydro-1H-indolizino[7,8-b]indole (700 mg, 2.92 mmol) in DMF (20 mL) was stirred at 0° C. for 5 min. NaH (580 mg, 14.60 mmol) was added slowly at 0° C. After 10 min. stirring, 4-(oxiran-2-yl)pyridine (710 mg, 5.87 mmol) was added and the reaction mixture was stirred at RT for 15 h. The reaction mixture was poured in ice-cold water (150 mL) and extracted with EtOAc (3×200 mL). The combined organic layer was washed with water (6×300 mL), dried over anhydrous sodium sulfate and concentrated to obtain semi-solid residue that was washed with hexane (3×20 mL). The residue was suspended in ether (30 mL) stirred for 1 h. The suspension was filtered to give 200 mg of 2-(8,10-dimethyl-2,3,5,6-tetrahydro-1H-indolizino[7,8-b]indol-7(11cH)-yl)-1-(pyridin-4-yl)ethanol. 1H NMR (CD3OD, HCl salt) δ (ppm): 8.79 (d, 2H), 8.03 (d, 2H), 7.13 (s, 1H), 6.82 (s, 1H), 5.22 (dd, 1H),5.01 (t, 1H), 4.67 (dd, 1H), 4.48 (dd, 1H), 4.79 (m, 1H), 3.64 (t, 2H), 3.4 (m, 3H), 2.9 (m, 1H), 2.73 (s, 3H), 2.37 (s, 3H), 2.22 (m, 3H). Separation by chiral HPLC provided diastereomers II-125a-b.
Example 336
Preparation of Compound Nos. II-126 and II-126a-b
9-Aza-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (160 mg, 0.88 mmol) was dissolved in DMF (8 mL). Sodium hydride (63 mg, 2.64 mmol) was added at 0-10° C. and stirred at the same temperature for 15 min., 3-(2-methyloxiran-2-yl)pyridine (480 mg, 3.55 mmol) in DMF (2 mL) was added dropwise into the reaction mixture and the mixture was stirred at RT for 16 h. The reaction was monitored by LCMS. After consumption of starting material, the reaction mixture was quenched with ice cold water (4 mL) and solvent was evaporated to obtain the crude product, which was purified by reverse phase column chromatography to obtain 15 mg of product. 1H NMR (CD3OD, freebase) δ (ppm): 8.51 (s, 1H), 8.3 (d, 1H), 8.13 (d, 1H), 7.83 (d, 1H), 7.57 (d, 1H),7.31 (t, 1H), 6.99 (t, 1H), 4.33 (dd, 2H), 3.78 (dd, 2H), 3.0 (m, 1H), 2.85 (m, 1H), 2.75 (m, 2H), 2.53 (s, 3H), 1.69 (s, 3H). Separation by chiral HPLC provides enantiomers II-126a-b.
Example 337
Preparation of Compound Nos. II-127 and II-127a-d
9-Methyl-2,3,4,5,6,10c-hexahydro-1H-3a,6-diaza-cyclopenta[c]fluorene (150 mg, 0.66 mmol) was dissolved in DMF (1 mL), sodium hydride (47 mg, 1.98 mmol) was added and the mixture was stirred at RT for 5 min. 3-(2-Methyl-oxiranyl)-pyridine (143 mg, 1.06 mmol) was added dropwise into the reaction mixture and stirred at RT for 2 h. The reaction was monitored by TLC and LCMS. After consumption of starting material, the reaction mixture was quenched with ice cold water (20 mL) and extracted with EtOAc (2×100 mL). The combined organic layer was washed with water (2×100 mL), dried over anhydrous sodium sulfate and concentrated to obtain the crude product, which was purified by column chromatography (silica gel 100-200 mesh, Eluent: −15% MeOH in DCM) to obtain 80 mg of 1-(9-methyl-1,2,3,4,5,10c-hexahydro-3a,6-diaza-cyclopenta[c]fluoren-6-yl)-2-pyridin-3-yl-propan-2-ol. 1H NMR (CD3OD, HCl salt) δ (ppm): 8.66 (dd, 2H), 8.56 (s, 1H), 7.92 (t, 1H), 7.20 (s, 1H), 6.77 (t, 2H), 5.04 (t, 1H), 3.75 (dd, 2H),3.72 (m, 2H), 3.6 (m, 1H), 3.44 (m, 2H), 3.22 (d, 1H), 2.75 (m, 1H), 2.73 (s, 3H), 2.16 (m, 3H), 1.8 (s, 3H). Separation by chiral HPLC provided enantiomers II-127a-b.
Example 338
Preparation of Compound Nos. II-128 and II-128a-d
9-Methyl-2,3,4,5,6,10c-hexahydro-1H-3a,6-diaza-cyclopenta[c]fluorene (200 mg, 0.88 mmol) was dissolved in DMF (3 mL), sodium hydride (106 mg, 2.65 mmol) was added and stirred for 15 min. at RT. 2-Methyl-5-(2-methyl-oxiranyl)-pyridine (263 mg, 1.76 mmol) was added dropwise into the reaction mixture and the mixture was stirred at RT for 3 h. The reaction was monitored by TLC and LCMS. After consumption of starting material, the reaction mixture was quenched with ice cold water (20 mL) and extracted with EtOAc (3×30 mL). The combined organic layer was washed with water (2×60 mL), dried over anhydrous sodium sulfate and concentrated to obtain the crude product, which was purified by reverse phase chromatography to obtain 200 mg of 1-(9-methyl-1,2,3,4,5,10c-hexahydro-3a,6-diaza-cyclopenta[c]fluoren-6-yl)-2-(6-methyl-pyridin-3-yl)-propan-2-ol. 1H NMR (CD3OD, HCl salt) δ (ppm): 8.5 (d, 1H), 8.3 (s, 1H), 7.79 (d, 1H), 7.22 (s, 1H), 6.82 (s, 2H), 5.03 (t, 1H), 4.38 (dd, 2H), 3.8 (m, 1H), 3.66 (m, 2H),3.46 (m, 2H), 3.2 (m, 2H), 2.7 (m, 1H), 2.67 (s, 3H), 2.36 (s, 3H), 2.22 (m, 2H), 1.77 (s, 3H). Separation by chiral HPLC provided enantiomers II-128a-b.
Example 339
Preparation of Compound Nos. II-129 and II-129a-b
7-Aza-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (160 mg, 0.88 mmol) was dissolved in DMF (8 mL). Sodium hydride (63 mg, 2.64 mmol) was added at 0-10° C. and stirred at the same temperature for 15 min., 3-(2-methyloxiran-2-yl)pyridine (480 mg, 3.55 mmol) in DMF (2 mL) was added dropwise into the reaction mixture and the mixture was stirred at RT for 16 h. The reaction was monitored by LCMS. After consumption of starting material, the reaction mixture was quenched with ice cold water (4 mL) and solvent was evaporated to obtain the crude product, which was purified by reverse phase column chromatography to obtain 3 mg of product as the free base.
1H NMR (CD3OD, freebase) δ (ppm): 8.46 (s, 1H), 8.39 (s, 1H), 8.36 (d, 1H), 7.96 (d, 1H), 7.82 (d, 1H), 7.37 (d, 1H), 7.31 (t, 1H), 4.4 (dd, 2H),3.71 (dd, 2H), 3.0 (m, 1H), 2.9 (m, 1H), 2.72 (m, 1H), 2.62 (m, 1H), 2.52 (s, 3H), 1.72 (s, 3H). Separation by chiral HPLC provides enantiomers II-129a-b.
Example 340
Preparation of Compound Nos. II-130 and II-130a-d
To a stirred solution of 10-chloro-2,3,5,6,7,11c-hexahydro-1H-indolizino[7,8-b]indole (1.0 g, 4.06 mmol) in DMF (50 mL) was added sodium hydride (60%, 406 mg, 10.15 mmol). After stirring for 10 min., 3-(2-methyloxiran-2-yl)pyridine (823 mg, 6.09 mmol) was added to the reaction mixture, which was stirred at RT for 16 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with ice-water and extracted with EtOAc (2×100 mL). The organic layer was washed with water (5×100 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the residue that was crystallized with ethanol-hexane to yield the 1.2 g of 1-(10-chloro-2,3,5,6-tetrahydro-1H-indolizino[7,8-b]indol-7(11cH)-yl)-2-(pyridin-3-yl)propan-2-ol. 1H NMR (CDCl3, freebase) δ (ppm): 8.70 (s, 1H), 8.49 (d, 1H), 7.62 (d, 1H), 7.36 (s, 1H), 7.12 (m, 2H), 7.02 (d, 1H), 4.17 (q, 2H), 3.86 (t, 1H), 3.19 (m, 1H), 2.86 (m, 1H), 2.74 (m, 3H), 2.41 (m, 2H), 1.85 (m, 3H), 1.7 (s, 3H). Separation by chiral HPLC provides diastereomers II-130a-d.
Example 341
Preparation of Compound Nos. II-131 and II-131a-d
9-Methyl-2,3,4,5,6,10c-hexahydro-1H-3a,6-diaza-cyclopenta[c]fluorene (200 mg, 0.88 mmol) was dissolved in DMF (3 ml), sodium hydride (106 mg, 2.65 mmol) was added and the mixture was stirred at RT for 15 min. 3-Oxiranyl-pyridine (214 mg, 1.76 mmol) was added dropwise into the reaction mixture and the mixture was stirred at RT for 3 h. The reaction was monitored by TLC and LCMS. After consumption of starting material, the reaction mixture was quenched with ice cold water (20 mL) and extracted with EtOAc (3×30 mL). The combined organic layer was washed with water (2×60 mL), dried over anhydrous sodium sulfate and concentrated to obtain the crude product, which was purified by reverse phase chromatography to obtain 60 mg of 2-(9-Methyl-1,2,3,4,5,10c-hexahydro-3a,6-diaza-cyclopenta[c]fluoren-6-yl)-1-pyridin-3-yl-ethanol as the TFA salt. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.7 (d, 1H), 8.53 (s, 1H), 8.4 (d, 1H), 7.85 (t, 1H), 7.25 (s, 1H), 7.08 (t, 1H),6.9 (d, 1H), 5.28 (t, 1H), 5.03 (t, 1H), 4.42 (s, 2H), 3.76 (m, 1H), 3.6 (m, 2H), 3.4 (m, 1H), 3.2 (m, 2H),2.7 (m, 1H), 2.38 (s, 3H), 2.2 (m, 3H). Separation by chiral HPLC provides diastereomers II-131a-d.
Example 342
Preparation of Compound Nos. II-132 and II-132a-d
1-(2-Methoxy-pyridin-4-yl)-2-(9-methyl-1,2,3,4,5,10c-hexahydro-3a,6-diaza-cyclopenta[c]fluoren-6-yl)-ethanol (45 mg, 0.119 mmol) and 47% aqueous HBr (4 mL) and heated at 100° C. for 45 min. The reaction was monitored by TLC and LCMS. After consumption of starting material, the reaction mixture was cooled to RT and basified with ammonia and extracted with EtOAc (2×25 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated and the crude product was purified by reverse phase chromatography to obtain 20 mg of 4-(2-(2,3,5,6-tetrahydro-10-methyl-1H-indolizino[7,8-b]indol-7(11cH)-yl)-1-hydroxyethyl)pyridin-2(1H)-one. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.43 (d, 1H), 7.23 (m, 2H), 7.05 (t, 1H), 6.7 (m, 1H), 6.5 (d, 1H),4.79 (m, 1H), 4.3 (m, 2H), 3.9 (m, 2H), 3.8 (m, 1H), 3.6 (m, 1H), 3.4 (m, 2H), 3.1 (m, 1H), 2.6 (m, 1H), 2.4 (s, 3H), 2.3 (m, 2H), 1.9 (m, 1H). Separation by chiral HPLC provided enantiomers II-132a-b.
Example 343
Preparation of Compound No. II-133
To a stirred solution of 6,8,8-trimethyl-6,7,8,9-tetrahydro-5H-pyrrolo[2,3-b:4,5-e]dipyridine (75 mg, 0.348 mmol) in DMF (1.5 mL) was added sodium hydride (42 mg, 1.0465 mmol). After stirring for 10 min at RT, a solution of 2-(6-methylpyridin-3-yl)ethyl trifluoromethanesulfonate (304 mg, 1.046 mmol) in DMF (1.5 mL) was added to the reaction mixture and stirring continued at RT for 16 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was diluted with water and extracted with EtOAc (3×25 mL). The organic layer was washed with water (3×25 mL), dried over anhydrous sodium sulfate and concentrated to afford crude mass, which was purified by reverse phase HPLC. 1H NMR (CDCl3, TFA salt) δ (ppm): 8.42 (s, 1H), 8.31 (d, 1H), 7.7 (d, 1H), 7.57 (d, 1H), 7.1 (d, 1H), 7.0 (t, 1H), 4.5 (t, 2H), 3.63 (s, 2H), 3.2 (t, 2H), 2.57 (s, 8H), 1.42 (s, 6H).
Example 344
Preparation of Compound Nos. II-134 and II-134a-b
To a solution of 1,2,3,4,5,6-hexahydro-3,9-dimethylazepino[4,5-b]indole (3 g, 14.01 mmol) in DMF (40 mL), NaH (2.8 g, 70 mmol, 60% dispersion in mineral oil) was added slowly at 0° C. The solution was stirred at 0° C. for 10 min. 4-(2-Methyloxiran-2-yl)pyridine (3.8 g, 2.8 mmol) was added and the reaction mixture was stirred at RT for 15 h. The reaction mixture was poured into ice-cold water (300 mL) and extracted with EtOAc (2×200 mL). The organic layer was washed with water (5×200 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure gave an oily residue that was purified by column chromatography using silica gel (100-200 mesh) and 10 MeOH-DCM as eluting system followed by chiral preparative HPLC to afford the 300 mg of pure product. 1H NMR (CDCl3, freebase) δ (ppm): 8.59 (d, 2H), 7.38 (d, 2H), 7.25 (s, 1H), 7.18 (d, 1H), 6.96 (d, 1H), 4.23 (dd, 2H), 2.89 (m, 2H), 2.75 (m, 4H), 2.6 (m, 2H), 2.43 (s, 3H), 2.42 (s, 3H),1.58 (s, 3H). Separation by chiral HPLC provided enantiomers II-134a-b.
Example 345
Preparation of Compound Nos. II-135 and II-135a-b
3,9-Dimethyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole (1 g, 4.6 mmol) in DMF (10 mL) was stirred at RT for 5 min. NaH (60%, 933 mg, 23.33 mmol) was added and the reaction mixture was stirred at RT for 10 min. 3-(2-methyloxiran-2-yl)pyridine (1.26 g, 9.34 mmol) was added to the reaction mixture and the mixture was stirred at RT for 16 h. The reaction mixture was poured into ice-water and extracted with EtOAc (200 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum to obtain the crude product, which was purified by column chromatography using silica gel: 100-200 mesh and 10% MeOH/DCM/1 mL NH4OH to obtain 600 mg of 1-(3,9-dimethyl-2,3,4,5-tetrahydroazepino[4,5-b]indol-6(1H)-yl)-2-(pyridin-3-yl)propan-2-ol. 1H NMR (CDCl3, freebase) δ (ppm): 8.74 (s, 1H), 8.54 (d, 1H), 7.71 (d, 1H), 7.26 (s, 1H), 7.27 (m, 1H),7.19 (d, 1H), 6.96 (d, 1H), 4.26 (dd, 2H), 2.91 (m, 2H), 2.9 (m, 4H), 2.74 (m, 2H), 2.44 (s, 6H), 1.63 (s, 3H). Separation by chiral HPLC provided enantiomers II-135a-b.
Example 346
Preparation of Compound Nos. II-136 and II-136a-b
A mixture of 5-(1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-hydroxypropan-2-yl)picolinonitrile (300 mg, 0.833 mmol), crushed KOH (140 mg, 2.499 mmol) in 12 mL tert-butanol was heated at 80° C. for 2 h. The reaction was monitored by TLC. The reaction mixture was allowed to cool at RT, diluted with brine (30 mL) and extracted with ethyl acetate (2×100 mL). The combined organic layer was washed with water (3×100 mL), dried over anhydrous sodium sulfate and concentrated to obtain the crude product, which was purified by Preparative HPLC followed by chiral HPLC to obtain 5-(1-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-2-hydroxypropan-2-yl)pyridine-2-carboxamide. 1H NMR (CDCl3, freebase) δ (ppm): 8.49 (s, 1H), 8.04 (d, 1H), 7.86 (d, 1H), 7.66 (s, 1H), 7.01 (s, 1H), 6.85 (s, 1H), 6.78 bs (NH), 5.48 s (OH),4.16 (dd, 2H), 3.44 (q, 2H), 2.9 (m, 2H), 2.7 (m, 2H), 2.45 (s, 3H), 2.35 (s, 3H), 2.35 (s, 3H), 1.6 (s, 3H). Separation by chiral HPLC provided enantiomers II-136a-b.
Example 347
Preparation of Compound Nos. II-137 and II-137a-b
These compounds were synthesized in an analogous fashion to Compound Nos. 55 and 55a-b, using 3,6-dimethyl-6,7,8,9-tetrahydro-5H-1,2,6,9-tetraaza-fluorene as the carboline portion. Separation by chiral HPLC provides enantiomers II-137a-b.
Example 348
Preparation of Compound Nos. II-138 and II-138a-d
A solution of benzyl protected fused carboline compound (70 mg, 0.16 mmol) in HPLC grade MeOH (70 mL) was subjected to hydrogenation in H-Cube. The solvent was removed under reduced pressure to afford an oily residue that was purified by preparative HPLC to give 3 mg of desired compound. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.67 (s, 2H), 7.28 (m, 3H), 7.04 (d, 1H), 5.21 (m, 1H), 5.04 (t, 1H), 4.39 (m, 2H), 3.67 (m, 3H), 3.25 (m, 2H), 3.03 (m, 1H), 2.68 (m, 1H), 2.41 (s, 3H), 2.19 (m, 3H). Separation by chiral HPLC provides diastereomers II-138a-d.
Example 349
Preparation of Compound Nos. II-139 and II-139a-d
A suspension of 2-(10-methyl-2,3,5,6-tetrahydro-1H-indolizino[7,8-b]indol-7(11cH)-yl)-1-(1-trityl-1H-imidazol-2-yl)ethanol (0.4 g, 0.69 mmol) in MeOH (10 mL), 1N HCl (1 mL) was added and the reaction mixture was stirred at RT for 2 h. The reaction mixture concentrated under vacuum to obtain the crude product that was basified with satd. sodium bicarbonate solution and extracted with EtOAc (50 mL). The organic layer was dried over anhydrous sodium sulfate, and concentrated under vacuum to obtain the crude product, which was purified by reverse HPLC to obtain 11.30 mg 1-(1H-imidazol-2-yl)-2-(10-methyl-2,3,5,6-tetrahydro-1H-indolizino[7,8-b]indol-7(11cH)-yl)ethanol. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.44 (s, 2H), 7.27 (s, 1H), 7.13 (d, 1H), 6.99 (d, 1H), 5.37 (t, 1H), 5.1 (m, 1H),4.56 (dd, 1H), 4.46 (dd, 1H), 3.67 (m, 3H), 3.42 (m, 1H), 3.24 (m, 2H), 2.7 (m, 1H), 2.4 (s, 3H), 2.2 (m, 3H).
Example 350
Preparation of Compound Nos. II-140 and II-140a-d
To a stirred solution of compound 2-(10-methyl-2,3,5,6-tetrahydro-1H-indolizino[7,8-b]indol-7(11cH)-yl)-1-(1-trityl-1H-imidazol-5-yl)ethanol (400 mg, 0.69 mmol) in MeOH (10 mL), 1N HCl (1 mL) at 0° C. was added. The reaction mixture was stirred at RT for 2 h. The reaction mixture concentrated under vacuum to obtain the crude product that was basified with sat sodium bicarbonate solution and extracted with EtOAc (50 mL). The organic layer dried on anhydrous sodium sulfate, and concentrated under vacuum to obtain the crude product that was purified by reverse phase HPLC to obtain 1-(1H-imidazol-5-yl)-2-(10-methyl-2,3,5,6-tetrahydro-1H-indolizino[7,8-b]indol-7(11cH)-yl)ethanol (12 mg) as the TFA salt. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.79 (s, 1H), 7.4 (s, 1H), 7.27 (s, 1H), 7.2 (dd, 1H), 7.01 (d, 1H), 5.18 (t, 1H), 5.04 (m, 1H), 4.39 (m, 2H), 3.67 (m, 3H), 3.42 (m, 2H), 3.2 (m, 1H), 2.7 (m, 1H), 2.4 (s, 3H), 2.2 (m, 3H). Separation by chiral HPLC provides diastereomers II-140a-d.
Example 351
Preparation of Compound Nos. II-141 and II-141-a-b
To a solution of 2,3,4,5-tetrahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole (90 mg, 0.466 mmol) in DMF (2 mL), sodium hydride (60%, 33 mg, 1.44 mmol) was added. After stirring for 10 min., methyl 5-(2-methyloxiran-2-yl)nicotinate (1.09 g, 12.4 mmol) was added to the reaction mixture, which was stirred at RT for 16 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with ice-water and extracted with EtOAc (2×100 mL). The aqueous layer was lyophilized and purified by reverse phase HPLC purification to obtain the 10 mg of 5-(1-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-2-hydroxypropan-2-yl)pyridine-3-carboxylic acid. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.9 (d, 1H), 8.7 (d, 1H), 8.57 (d, 1H), 7.11 (s, 1H), 6.74 (d, 2H), 4.67 (dd, 1H),4.33 (m, 2H), 4.29 (dd, 1H), 3.9 (t, 1H), 3.6 (m, 2H), 3.2 (m, 1H), 3.11 (s, 3H), 2.3 (s, 3H), 1.79 (d, 3H). Separation by chiral HPLC provides enantiomers II-141a-b.
Example 352
Preparation of Compound Nos. II-142 and II-142a-b
2,8-Dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (40 mg, 0.200 mmol) was dissolved in 1 ml DMF. Sodium hydride (24 mg, 0.600 mmol) was added at 0° C. and the reaction mixture was stirred at RT for 10 min. 5-(2-methyloxiran-2-yl)oxazole (35 mg, 0.280 mmol) in DMF (1 mL) was added dropwise over 10 min. and the reaction mixture was stirred at RT for 12 h. The reaction was monitored by TLC and LCMS. Ice cold water was added to the reaction mixture and then extracted with EtOAc (3×20 mL). The combined organic layer was washed with water (4×10 mL), dried over anhydrous sodium sulfate and concentrated to obtain the crude product, which was purified by reverse phase chromatography to obtain the 20 mg of 1-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-2-(oxazol-5-yl)propan-2-ol as the TFA salt. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.09 (s, 1H), 7.18 (s, 1H), 6.97 (d, 1H), 6.92 (d, 1H), 6.8 (s, 1H), 4.7 (m, 1H), 4.35 (m, 3H), 3.9 (m, 1H), 3.56 (m, 1H), 3.25 (m, 2H), 3.09 (s, 3H), 2.37 (s, 3H), 1.58 (s, 3H). Separation by chiral HPLC provides enantiomers II-142a-b.
Example 353
Preparation of Compound Nos. II-143 and II-143a-b
2-(2-Chloropyridin-3-yl)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)propan-2-ol (100 mg, 0.277 mmol) and crushed potassium hydroxide (106 mg, 1.89 mmol) in 3 mL tert. butanol were heated at 90° C. for 4 h. The reaction mixture was monitored by TLC and LCMS. The reaction mixture was cooled at RT, diluted with 100 mL brine solution and extracted with EtOAc (3×100 mL). The combined organic layer was washed with brine (3×100 mL), dried over anhydrous sodium sulfate and concentrated to obtain the crude product, which was purified by reverse phase chromatography to get the 35 mg of 3-(1-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-2-hydroxypropan-2-yl)pyridin-2(1H)-one as the TFA salt. 1H NMR (CD3OD, TFA salt) δ (ppm): 7.79 (d, 1H), 7.35 (m, 2H), 7.17 (s, 1H), 6.93 (d, 1H), 6.34 (t, 1H), 4.61 (d, 2H), 4.3 (d, 2H), 3.9 (m, 1H), 3.8 (m, 1H), 3.36 (m, 2H), 3.1 (s, 3H), 2.37 (s, 3H), 1.51 (s, 3H). Separation by chiral HPLC provides enantiomers II-143a-b.
Example 354
Preparation of Compound No. II-144
To a solution of 6-methyl-6,7,8,9-tetrahydro-5H-pyrrolo[2,3-b:4,5-c′]dipyridine (200 mg, 1.068 mmol) in DMF (1 mL) was added a suspension of NaH (128.0 mg, 3.24 mmol) in DMF (1 mL). After stirring for 5 min. at RT, a solution of 2-(6-methylpyridin-3-yl)ethyl 4-methylbenzenesulfonate (932 mg, 3.204 mmol) in DMF (1 mL) was added dropwise into the reaction mixture and stirring continued for another 3 h. The progress of reaction was monitored by TLC and NMR. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (3×25 mL). The organic layer was washed with water (3×20 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude material, which was purified by silica gel flash chromatography eluting with 10% MeOH-DCM to yield 6-methyl-9-(2-(6-methylpyridin-3-yl)ethyl)-6,7,8,9-tetrahydro-5H-pyrrolo[2,3-b:4,5-c′]dipyridine (90 mg) as a free base. The free base was converted into tri-HCl salt by treatment with ethanolic HCl. 1H NMR (CD3OD, Tri-HCl salt) δ (ppm): 8.76 (s, 1H), 8.40 (m, 3H), 7.80 (d, 1H), 7.50 (t, 1H), 4.90-4.70 (m, 3H), 4.42 (m, 1H), 3.95 (m, 1H), 3.66 (m, 1H), 3.42-3.30 (m, 4H), 3.15 (s, 3H), 2.76 (s, 3H).
Example 355
Preparation of Compound Nos. II-145 and II-145a-b
2,8,9-Trimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (400 mg, 1.86 mmol) 4 mL DMF, cooled to 0° C. and sodium hydride (224 mg, 5.60 mmol) was added portionwise at the same temperature. 3-(2-methyloxiran-2-yl)pyridine (504 mg, 3.73 mmol) in DMF (1 mL) was added to the reaction mixture and allowed to stir at RT for 12 h. After complete consumption of starting material, the reaction mixture was poured in to ice water and extracted with EtOAc (3×100 mL). The combined organic layer was washed with water (3×50 mL), dried over anhydrous sodium sulfate and concentrated to obtain the crude product, which was crystallized with ether and hexane to obtain 400 mg of 2-(pyridin-3-yl)-1-(2,8,9-trimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)propan-2-ol. 1H NMR (DMSO, freebase) δ (ppm): 8.59 (s, 1H), 8.42 (d, 1H), 7.73 (d, 1H), 7.31 (t, 1H), 7.1 (d, 1H), 6.73 (d, 1H), 4.11 (dd, 2H), 3.74 (s, 2H), 3.4 (m, 2H), 2.6 (m, 2H), 2.37 (s, 6H), 2.22 (s, 3H), 1.5 (s, 3H). Separation by chiral HPLC provides enantiomers II-145a-b.
Example 356
Preparation of Compound Nos. II-146 and II-146a-d
2,3,8-Trimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (214 mg, 1 mmol) was dissolved in DMF (3 mL) and NaH (80 mg, 3.33 mmol) was added portionwise at 0° C. The reaction mixture was stirred at 0° C. for 15 min. The solution of 3-(2-methyloxiran-2-yl)pyridine (270 mg, 2 mmol) in DMF (2 mL) was added dropwise at 0° C. and the reaction mixture was stirred at 0° C. for 10 min and at RT for 16 h. Completion of reaction was monitored by LCMS. The reaction mixture was poured onto crushed ice slowly and extracted with EtOAc (3×30 mL). The organic layer was washed with water (7×40 mL), dried over anhydrous sodium sulfate and concentrated under vacuum to obtain the crude product that was purified by reverse HPLC to give 23 mg of 2-(pyridin-3-yl)-1-(2,3,8-trimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)propan-2-ol. 1H NMR (CDCl3, freebase) δ (ppm): 8.73 (s, 1H), 8.47 (d, 1H), 7.2 (d, 1H), 7.11 (s, 1H), 7.04 (d, 2H), 6.90 (d, 1H), 4.15 (dd, 2H), 3.78 (dd, 1H), 3.6 (dd, 1H), 2.9 (m, 2H), 2.7 (dd, 1H), 2.43 (s, 3H), 2.4 (s, 3H), 1.6 (s, 3H), 1.14 (d, 3H). Separation by chiral HPLC provided diastereomers II-146a-d.
Example 357
Preparation of Compound Nos. II-147 and II-147a-d
To a solution of 8-chloro-2,3-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (500 mg, 2.13 mmol) in 4 mL of DMF was added sodium hydride (256 mg, 6.40 mmol) at 0° C., and stirred for 10 min. 3-(2-methyloxiran-2-yl)pyridine (432 mg, 3.20 mmol) was added and the mixture was stirred at RT for 12 h. The reaction was monitored by TLC and LCMS. The reaction mixture was poured into ice cold water and extracted with EtOAc (2×50 mL). The combined organic layer was washed with water (5×25 mL), dried over anhydrous sodium sulfate, concentrated to obtain the crude product, which was crystallized in n-hexane to obtain 350 mg of 1-(8-chloro-2,3-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridin-3-yl)propan-2-ol. 1H NMR (CDCl3, freebase) δ (ppm): 8.72 (s, 1H), 8.47 (d, 1H), 7.52 (d, 1H), 7.23 (s, 1H), 6.94 (m, 3H), 4.10 (dd, 2H), 3.65 (m, 1H), 3.40 (m, 1H), 2.86 (m, 2H), 2.38 (s, 3H), 2.36 (m, 1H), 1.62 (s, 3H), 1.07 (d, 3H). Separation by chiral HPLC provided diastereomers II-147a-b.
Example 358
Preparation of Compound Nos. II-148 and II-148a-b
To a solution of 2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (700 mg, 3.5 mmol) in 3 mL of DMF was added sodium hydride at 0° C. and stirred for 10 min. 4-Chloro-3-(2-methyloxiran-2-yl)pyridine (888 mg, 5.25 mmol) in 2 mL of DMF was added and allowed to stir at RT for 12 h. The reaction was monitored by TLC and LCMS. After completion of reaction, the reaction mixture was poured into ice cold water and extracted with EtOAc (3×50 mL). The combined organic layer was washed with water (5×50 mL), Dried over anhydrous sodium sulfate, concentrated under reduced pressure and crystallized in diethyl ether to get the desired compound (700 mg). 1H NMR (CDCl3, freebase) δ (ppm): 9.1 (s, 1H), 8.43 (d, 1H), 7.38 (d, 1H), 7.29 (d, 1H), 7.25 (d, 1H), 6.97 (d, 1H), 4.7 (d, 1H), 4.23 (d, 1H), 3.63 (m, 2H), 2.8 (m, 2H), 2.75 (m, 2H), 2.51 (s, 3H), 2.41 (s, 3H), 1.71 (s, 3H). Separation by chiral HPLC provided enantiomers II-148a-b.
Example 359
Preparation of Compound Nos. II-149 and II-149a-d
9-Methyl-2,3,4,5,6,10c-hexahydro-1H-3a,6,7-triaza-cyclopenta[c]fluorene (700 mg, 3.0 mmol) was dissolved in DMF (7 mL) and sodium hydride (360 mg, 9.0 mmol) was added portionwise at 0° C. and stirred for 10 min. 2-(4-Fluoro-phenyl)-2-methyl-oxirane (720 mg, 4.8 mmol) in 3 mL DMF was added dropwise into the reaction mixture and the mixture was stirred at RT for 18 h. The reaction mixture was quenched with ice cooled water and extracted with EtOAc (3×100 mL). The combined organic layer was washed with water (4×75 mL), dried over anhydrous sodium sulfate and concentrated to obtain the crude product, which was purified by passing through a column of silica gel (100-200 mesh), using the eluent 5% MeOH in DCM to obtain 520 mg of 2-(4-fluoro-phenyl)-1-(9-methyl-1,2,3,4,5,10c-hexahydro-3a,6,7-triaza cyclopenta[c]fluoren-6-yl)-propan-2-ol. 1H NMR (CDCl3, freebase) δ (ppm): 8.02 (s, 1H), 7.54 (s, 1H), 7.43 s (OH), 7.37 (t, 2H), 6.93 (t, 2H), 4.37 (d, 1H), 4.22 (d, 1H), 4.04 (t, 1H), 3.23 (dd, 1H), 2.9 (m, 1H), 2.7 (m, 2H), 2.5 (m, 2H), 2.42 (s, 3H), 2.3 (m, 1H), 1.84 (m, 3H), 1.6 (s, 3H). Separation by chiral HPLC provided diastereomers II-149a-d.
Example 360
Preparation of Compound Nos. II-150 and II-150a-d
2-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(pyridin-4-yl)ethanol (350 mg, 1 mmol), formaldehyde (37%, 0.89 g, 10 mmol) and formic acid (922 mg, 20 mmol) was stirred at 100° C. for 12 h. The progress of the reaction was monitored by TLC and LCMS. The reaction mixture was washed with saturated sodium bicarbonate and extracted with DCM (2×25 mL). The combined organic layer was washed with water (5×25 mL) dried over anhydrous sodium sulfate and concentrated under vacuum to obtain the crude product, which was subjected to preparative HPLC to obtain 25 mg of 2-(9-(hydroxymethyl)-2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(pyridin-4-yl)ethanol. 1H NMR (CDCl3, freebase) δ (ppm): 8.56 (d, 2H), 7.29 (d, 2H), 7.12 (d, 1H), 6.98 (d, 1H), 4.9 (dd, 1H), 4.79 (q, 2H), 4.13 (m, 2H), 3.78 (d, 1H), 3.72 (d, 1H), 3.0 (m, 1H), 2.8 (m, 1H), 2.67 (m, 2H), 2.49 (s, 3H), 2.32 (s, 3H). Separation by chiral HPLC provided diastereomers II-150a-d.
Example 361
Preparation of Compound Nos. II-151 and II-151a-d
2,8-Dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-4-ol (500 mg, 2.314 mmol) in DMF (5.0 mL) was cooled to 0° C. NaH (0.462 mg, 11.57 mmol) was added portionwise and stirred for 5 min. 3-(2-Methyl-oxiranyl)-pyridine (620 mg, 4.629 mmol) was added dropwise and the reaction mixture was stirred at RT for 4 h. The reaction was quenched with ice water and extracted with EtOAc (3×50 mL). The combined organic layer was washed with water (2×25 mL), dried over anhydrous sodium sulfate and concentrated to get 900 mg crude that was purified by reverse phase HPLC to obtain the product. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.57 (m, 2H), 8.48 (m, 1H), 7.85 (m, 1H), 7.21 (s, 1H), 6.78 (d, 1H), 6.64 (m, 1H), 5.72 (m, 1H), 4.66 (t, 2H), 4.45 (d, 1H), 4.30 (d, 1H), 3.78 (m, 2H), 3.16 (s, 3H), 2.31 (s, 3H), 1.87 (s, 3H). Separation by chiral HPLC provided diastereomers II-151a-b.
Example 362
Preparation of Compound Nos. II-152 and II-152a-d
1,2,8-Trimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (500 mg, 2.3 mmol) in DMF (2.5 mL) was stirred at 0° C. for 5 min. NaH (279 mg, 6.97 mmol) was added slowly at 0° C. After 10 min. stirring, 3-(2-methyloxiran-2-yl)pyridine (630 mg, 4.6 mmol) in DMF (2.5 mL) was added and the reaction mixture was stirred at RT for 18 h. The reaction mixture was poured in ice-cold water (50 mL) and extracted with EtOAc (2×50 mL). The combined organic layer was washed with water (6×50 mL), dried over anhydrous sodium sulfate and concentrated to obtain semi-solid residue that was washed with hexane (3×20 mL) to obtain 350 mg of product that was submitted to chiral reverse phase column chromatography. 1H NMR (CDCl3, freebase) δ (ppm): 8.74 (s, 1H), 8.49 (d, 1H), 7.60 (d, 1H), 7.20 (s, 1H), 7.07 (m, 2H), 6.90 (d, 1H), 4.16 (dd, 2H), 3.72 (m, 1H), 2.97 (m, 1H), 2.69 (m, 2H), 2.47 (s, 3H), 2.44 (m, 1H), 2.42 (s, 3H), 1.66 (s, 3H), 1.42 (d, 3H). Separation by chiral HPLC provided diastereomers II-152a-d.
Example 363
Preparation of Compound Nos. II-153 and II-153a-b
1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridin-3-yl)propan-2-ol (1 g, 2.99 mmol) in formaldehyde (37%, 5.69 mL, 59.6 mmol) and formic acid (2.25 mL, 59.6 mmol) was stirred at 100° C. for 24 h. The progress of the reaction was monitored by TLC and LCMS. The reaction mixture was concentrated under vacuum to obtain the crude product, which was subjected to preparative HPLC to obtain pure compound (100 mg). 1H NMR (CDCl3, freebase) δ (ppm): 8.7 (s, 1H), 8.5 (d, 1H), 7.8 (d, 1H), 7.23 (m, 1H), 7.15 (d, 1H), 6.94 (d, 1H), 4.80 (q, 2H), 4.19 (dd, 2H), 4.17 (m, 2H), 3.0 (m, 4H), 2.6 (s, 3H), 2.47 (s, 3H), 1.6 (s, 3H). Separation by chiral HPLC provides enantiomers II-153a-b.
Example 364
Preparation of Compound Nos. II-154 and II-154a-b
1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridin-3-yl)propan-2-ol (1 g, 2.99 mmol) in formaldehyde (37%, 5.69 mL, 59.6 mmol) and formic acid (2.25 mL, 59.6 mmol) was stirred at 100° C. for 24 h. The progress of the reaction was monitored by TLC and LCMS. The reaction mixture was concentrated under vacuum to obtain the crude product, which was subjected to preparative HPLC to obtain pure compound (100 mg). 1H NMR (CDCl3, freebase) δ (ppm): 8.7 (s, 1H), 8.42 (d, 1H), 7.6 (d, 1H), 7.1 (s, 1H), 6.9 b(s, 2H), 4.7 (s, 2H), 4.1 (q, 2H), 3.9 (s, 2H), 2.9 (m, 3H), 2.8 (m, 1H), 2.6 (s, 3H), 2.39 (s, 3H), 1.6 (s, 3H). Separation by chiral HPLC provides enantiomers II-154a-b.
Example 365
Preparation of Compound No. II-209
2-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(pyridin-4-yl)ethanone (0.1 g, 0.313 mmol) in 6 mL of DCM was cooled to 0° C., DAST (0.062 mL, 0.47 mmol) was added dropwise and the mixture stirred at RT for 2 h. The reaction was monitored by LCMS. After completion of the reaction, DCM (10 mL) was added, and the reaction was quenched with satd. NaHCO3 solution. The organic layer was separated, dried over anhydrous sodium sulfate and evaporated to dryness. The crude product was purified by preparative HPLC to afford 40 mg of the desired compound as the TFA salt. 1H NMR (CDCl3, Free base) δ (ppm): 8.61 (d, 2H), 7.15-7.2 (m, 3H), 6.83-6.95 (m, 2H), 4.5 (t, 2H), 3.6 (s, 2H), 2.78-2.63 (m, 2H), 2.6-2.45 (m, 5H), 2.4 (s, 3H).
Example 366
Preparation of Compound No. II-210 and II-210a-b
To an ice-cooled stirred solution of 1-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido(4,3-b)indol-5-yl)-2-(4-fluorophenyl)-propan-2-ol (500 mg, 1.418 mmol) in DCM (50 mL) was added diethylaminosulfur trifluoride (DAST) (0.374 mL, 2.85 mmol) and the reaction mixture was stirred at RT for 1 h. The DCM layer was diluted and washed with aqueous sodium bicarbonate solution. The organic layer was dried over anhydrous sodium sulfate and evaporated. The residue was purified by reverse phase HPLC. 1H NMR (DMSO, oxalate salt) δ (ppm): 7.45 (m, 2H), 7.30 (d, 1H), 7.18 (m, 3H), 6.90 (d, 1H), 4.50 (m, 2H), 4.30 (s, 2H), 3.40 (m, 2H), 3.05 (m, 1H), 2.85 (s, 3H), 2.78 (m, 1H), 2.38 (s, 3H), 1.65 (d, 3H). Separation by chiral HPLC provides enantiomers II-210a-b.
Example 367
Preparation of Compound No. II-211 and II-211a-b
To an ice-cooled stirred solution of 1-(8-chloro-1,2,3,4-tetrahydro-2-methylpyrido[4,3-b]indol-5-yl)-2-(4-fluorophenyl)propan-2-ol (500 mg, 1.3 mmol) in DCM (50 mL) was dropwise added DAST (443 mg, 2.6 mmol) and the reaction mixture was stirred at 0° C. for 1 h. The reaction mixture was diluted with DCM (50 mL), washed with saturated sodium bicarbonate solution (3×30 mL), dried over anhydrous sodium sulfate and concentrated. The residue was purified with reverse phase HPLC to yield 8-chloro-5-(2-fluoro-2-(4-fluorophenyl)propyl)-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole. 1H-NMR (DMSO-d6, oxalate salt) δ (ppm): 7.50 (s, 1H), 7.40 (m, 3H), 7.18 (t, 2H), 7.05 (d, 1H), 4.60 (m, 2H), 4.25 (m, 2H), 3.05 (m, 2H), 2.85 (s, 3H), 2.70 (m, 2H), 1.65 (d, 3H). Separation by chiral HPLC provides enantiomers II-211a-b.
Example 368
Preparation of Compound Nos. II-212 and II-212a-b
1-(2,8-Dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2-pyridin-3-yl-propan-2-ol (500 mg, 1.492 mmol) was dissolved in 20 mL DCM, cooled to 0° C. and diethylaminosulfur trifluoride (720 mg, 4.477 mmol) in DCM (5 mL) was added dropwise at the same temperature and stirred for 1 h. The reaction was monitored by TLC and LCMS. After consumption of starting material, the reaction mixture was quenched with saturated bicarbonate and extracted with DCM. The organic layer was washed with bicarbonate and brine solution, dried over anhydrous sodium sulfate and concentrated to obtain the crude product, which was purified by reverse phase chromatography to obtain 60 mg of 5-(2-Fluoro-2-pyridin-3-yl-propyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole. 1H NMR (CDCl3, freebase) δ (ppm): 8.61 (s, 1H), 8.56 (d, 1H), 7.55 (d, 1H), 7.23 (d, 1H), 7.16 (s, 1H), 7.05 (d, 1H), 6.93 (d, 1H), 4.3 (m, 2H), 3.8 (dd, 2H), 2.96 (m, 1H), 2.9 (m, 1H), 2.7 (m, 1H), 2.6 (m, 1H), 2.58 (s, 3H), 2.41 (s, 3H), 1.75 (d, 3H). Separation by chiral HPLC provided enantiomers II-212a-b.
Example 369
Preparation of Compound Nos. II-213 and II-213a-b
1-(8-Hydroxymethyl-2-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2-pyridin-3-yl-propan-2-ol (700 mg, 1.99 mmol) was dissolved in 70 mL DCM and cooled to 0° C. Diethylaminosulfur trifluoride (800 mg, 4.9 mmol) in DCM (5 mL) was added dropwise at the same temperature and stirred for 45 min. The reaction was monitored by TLC and LCMS. After consumption of starting material, the reaction mixture was quenched with saturated bicarbonate and extracted with DCM. The organic layer was washed with water and brine solution, dried over anhydrous sodium sulfate and concentrated to obtain the crude product, which was purified by reverse phase chromatography to obtain 14 mg of [5-(2-fluoro-2-pyridin-3-yl-propyl)-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-8-yl]-methanol. 1H NMR (CDCl3, freebase) δ (ppm): 8.6 (s, 1H), 8.57 (d, 1H), 7.6 (d, 1H), 7.35 (s, 1H), 7.2 (m, 1H), 7.125 (m, 2H), 4.72 (s, 2H), 4.3 (m, 2H), 3.6 (q, 2H), 2.8 (m, 1H), 2.7 (dd, 2H), 2.6 (m, 1H), 2.52 (s, 3H), 1.75 (d, 3H). Separation by chiral HPLC provides enantiomers II-213a-b.
Example 370
Preparation of Compound No. II-215
To a stirred solution of 6,8,8-trimethyl-6,7,8,9-tetrahydro-5H-pyrrolo[2,3-b:4,5-c′]dipyridine (75 mg, 0.348 mmol) in DMF (1.5 mL) was added potassium hydroxide (156 mg, 2.784 mmol). After stirring for 10 min at RT, a solution of 2-(trifluoromethyl)-5-vinylpyridine (181 mg, 1.046 mmol) in DMF (1.5 mL) was added to the reaction mixture and stirring continued at RT for 24 h and then at 80° C. for 48 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was diluted with water and extracted with EtOAc (3×30 mL). The organic layer was washed with water (2×20 mL), dried over anhydrous sodium sulfate and concentrated to afford crude product, which was purified by reverse phase HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.48 (s, 1H), 8.3 (d, 1H), 7.97 (d, 1H), 7.9 (d, 1H), 7.7 (d, 1H), 7.2 (t, 1H), 4.6 (m, 3H), 4.3 (m, 1H), 3.5 (d, 2H), 3.38 (bs, 2H), 3.2 (s, 3H), 1.6 (s, 6H).
Example 371
Preparation of Compound Nos. II-220 and II-220a-b
2,7,8-Trimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (400 mg, 1.86 mmol) was dissolved in DMF (4 mL), cooled to 0° C. and sodium hydride (224 mg, 5.60 mmol) was added portionwise at the same temperature. 3-(2-methyloxiran-2-yl)pyridine (504 mg, 3.73 mmol) in DMF (1 mL) was added to the reaction mixture and allowed to stir at RT for 12 h. After complete consumption of starting material, the reaction mixture was poured in to ice water and extracted with EtOAc (3×100 mL). The combined organic layer was washed with water (3×50 mL), dried over anhydrous sodium sulfate and concentrated to obtain the crude product, which was crystallized with ether and hexane to obtain 400 mg 2-(pyridin-3-yl)-1-(2,7,8-trimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)propan-2-ol. 1H NMR (DMSO, freebase) δ (ppm): 8.60 (s, 1H), 8.4 (d, 1H), 7.7 (d, 1H), 7.28 (t, 1H), 7.06 (s, 1H), 7.01 (s, 1H), 4.11 (dd, 2H), 3.41 (m, 2H), 2.53 (m, 2H), 2.44 (m, 2H), 2.35 (s, 3H), 2.22 (s, 6H), 1.5 (s, 3H). Separation by chiral HPLC provides enantiomers II-220a-b.
Example 372
Preparation of Compound Nos. II-221 and II-221a-b
To a solution of 3-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2-pyridine-4-yl-propionitrile (50 mg, 0.1515 mmol) in anhydrous THF (4 mL) was added LiAlH4 (17 mg, 0.4545 mmol) at 0° C. under nitrogen atmosphere. After the addition, the reaction mixture was stirred at RT for 1 h. The progress of the reaction was monitored by LCMS. After completion of reaction, 0.5 mL of water was added dropwise and then 0.5 mL of NaOH solution to quench the excess LiAlH4. The reaction mixture was evaporated and the crude product purified by preparative HPLC. 1H NMR (CDCl3, freebase) δ (ppm): 8.36 (d, 2H), 7.35 (m, 1H), 7.22 (s, 1H), 6.99 (d, 1H), 6.72 b (s, 2H), 4.23 (m, 1H), 3.71 (dd, 1H), 3.59 (m, 3H), 3.15 (dd, 1H), 3.07 (dd, 1H), 2.77 (m, 2H), 2.47 (s, 3H), 2.45 (s, 3H), 2.1 (m, 3H). Separation by chiral HPLC provides enantiomers II-221a-b.
Example 373
Preparation of Compound Nos. II-222 and II-222a-b
4-(2,8-Dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-3-pyridin-4-yl-butyricacidmethylester (1.5 g, 3.9 mmol) was dissolved in THF (50 mL) and cooled to −78° C., tert-butyl lithium (16% in pentane) (6 mL, 15.13 mmol) was added dropwise under nitrogen. The reaction mixture was stirred at −78° C. for 90 min. After complete consumption of starting material, the reaction mixture was quenched with ammonium chloride solution and the reaction mixture was allowed to come to RT and extracted with EtOAc (3×100 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated to obtain 1.7 g of crude 6-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2,2-dimethyl-5-pyridin-4-yl-hexan-3-one. 1H NMR (CDCl3, freebase) δ (ppm): 8.41 (d, 2H), 7.31 (d, 1H), 7.19 (s, 1H), 7.1 (d, 1H), 6.93 (d, 2H), 4.25 (dd, 1H), 3.9 (t, 2H), 3.8 (m, 1H), 3.67 (dd, 1H), 2.87 (m, 3H), 2.71 (m, 2H), 2.51 (s, 3H), 2.42 (s, 3H), 2.1 (m, 1H), 1.21 s (9H). Separation by chiral HPLC provides enantiomers II-222a-b.
Example 374
Preparation of Compound Nos. II-223 and II-223a-b
4-(2,8-Dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-3-pyridin-4-yl-but-3-enoicacid methyl ester (100 mg, 0.266 mmol) was dissolved in MeOH (10 mL) and 10% dry Pd/C (50 mg) was added and hydrogen gas was purged in to the reaction mixture at RT for 12 h. The reaction was monitored by TLC and LCMS. After consumption of starting material, the reaction mixture was filtered through Celite. The filtrate was concentrated to obtain the crude product, which was recrystallized in ether-hexane to obtained 50 mg of 4-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-3-pyridin-4-yl-butyric acid methyl ester. 1H NMR (CDCl3, freebase) δ (ppm): 8.47 (d, 2H), 7.18 (s, 1H), 7.16 (d, 1H), 6.98 (d, 3H), 4.22 (dd, 1H), 4.05 (dd, 1H), 3.7 (m, 2H), 3.57 (s, 3H), 3.5 (dd, 1H), 2.74 (m, 3H), 2.71 (m, 2H), 2.49 (s, 3H), 2.43 (s, 3H), 2.2 (m, 1H). Separation by chiral HPLC provides enantiomers II-223a-b.
Example 375
Preparation of Compound Nos. II-224 and II-224a-b
A solution of 4-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-3-pyridin-4-yl-butyric acid methyl ester (300 mg, 0.795 mmol) in THF (5 mL) was added dropwise to a solution of LiAlH4 (93 mg, 2.37 mmol) in THF (10 mL). The reaction mixture was stirred at RT for 30 min. After consumption of starting material, the reaction mixture was cooled to −78° C. 0.2 mL of water and 0.2 mL of 15% NaOH solution was added and the reaction mixture was allowed to come to RT and diluted with THF and filtered. The filtrate was concentrated and the crude product was purified by passing through a column of silica gel (100-200 mesh) by using eluent 2% MeOH in DCM to obtain 69 mg of 4-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-3-pyridin-4-yl-butan-1-ol. 1H NMR (CDCl3, freebase) δ (ppm): 8.48 (d, 2H), 7.18 (s, 1H), 7.1 (d, 1H), 7.01 (d, 2H), 6.97 (d, 1H), 4.2 (dd, 1H), 4.15 (dd, 1H), 3.64 (d, 1H), 3.56 (m, 2H), 3.4 (m, 2H), 2.7 (m, 3H), 2.4 (m, 1H), 2.5 (s, 3H), 2.43 (s, 3H), 1.94 (m, 2H). Separation by chiral HPLC provided enantiomers II-224a-b.
Example 376
Preparation of Compound Nos. II-225 and II-225a-b
To a compound 3-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridin-4-yl)propanoic acid (250 mg, 0.7 mmol) in THF was added LiAlH4 (81.6 mg, 2.1 mmol) and the resultant reaction mixture was stirred at RT for 1 h. The progress of the reaction was monitored by TLC and LCMS. The reaction was quenched by NaOH (0.5 mL), water (3 mL) at 0° C. and extracted with DCM (3×25 mL). The combined organic layer was dried on anhydrous sodium sulfate and concentrated under vacuum to obtain the crude product, which was subjected to reverse phase HPLC to obtain pure compound (30 mg). 1H NMR (CDCl3, freebase) δ (ppm): 8.41 (d, 2H), 7.28 b (s, 1H), 7.2 (s, 1H), 7.1 (d, 1H), 6.78 (d, 2H), 4.4 bs (OH), 4.3 (m, 1H), 4.0 (m, 1H), 3.62 (d, 1H), 3.42 (m, 3H), 3.1 (dd, 1H), 2.7 (m, 3H), 2.46 (m, 1H), 2.43 (s, 6H). Separation by chiral HPLC provides enantiomers II-225a-b.
Example 377
Preparation of Compound Nos. II-226 and II-226a-b
4-(2,8-Dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-3-pyridin-4-yl-butyricacid methyl ester (400 mg, 1.06 mmol) was dissolved in THF (20 mL) and methyl magnesium chloride (3 M in THF) (2 mL, 6.3 mmol) was added dropwise under nitrogen. The reaction mixture was stirred at 60° C. for 1 h. After consumption of starting material, the reaction mixture was quenched with ammonium chloride solution and the reaction mixture was extracted with EtOAc (3×100 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated to obtain 400 mg crude of 5-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2-methyl-4-pyridin-4-yl-pentan-2-ol. 1H NMR (CDCl3, freebase) δ (ppm): 8.43 (d, 2H), 7.16 (s, 1H), 7.14 (d, 1H), 6.99 (d, 3H), 4.3 (dd, 1H), 3.98 (d, 1H), 3.9 (dd, 1H), 3.8 (d, 1H), 3.5 (m, 1H), 3.15 (dd, 1H), 2.84 (m, 3H), 2.59 (s, 3H), 2.42 (s, 3H), 2.3 (dd, 1H), 1.85 (dd, 1H), 1.15 (s, 3H), 1.02 (s, 3H). Separation by chiral HPLC provides enantiomers II-226a-b.
Example 378
Preparation of Compound Nos. II-227 and II-227a-d
6-(2,8-Dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2,2-dimethyl-5-pyridin-4-yl-hexan-3-one (400 mg, 0.99 mmol) was dissolved in MeOH (30 mL). Sodium borohydride (263 mg, 6.9 mmol) was added under nitrogen. The reaction mixture was heated at 60° C. for 8 h. After consumption of starting material, the reaction mixture was concentrated and 2N HCl was added (pH-acidic) and extracted with DCM (2×200 mL) for removing impurities. The aqueous layer was basified with saturated bicarbonate and extracted with DCM. The organic layer was dried over anhydrous sodium sulfate and concentrated to obtain 350 mg of 6-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2,2-dimethyl-5-pyridin-4-yl-hexan-3-ol. 1H NMR (CDCl3, freebase) δ (ppm): 8.44 (d, 2H), 7.15 (s, 1H), 7.0 (d, 1H), 6.94 (d, 1H), 6.92 (d, 2H),4.25 (dd, 1H), 4.0 (dd, 1H), 3.64 (d, 1H), 3.51 (m, 2H), 2.88 (dd, 1H), 2.73 (t, 1H), 2.58 (m, 1H), 2.48 (s, 3H), 2.42 (s, 3H), 2.2 (m, 1H), 2.02 (t, 1H), 1.71 (t, 2H), 0.837 s (9H). Separation by chiral HPLC provided diastereomers II-227a-b.
Example 379
Preparation of Compound Nos. II-229 and II-229a-b
4-(2,8-Dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-3-pyridin-4-yl-butyric acid (175 mg, 0.482 mmol) was dissolved in DCM (5 mL), ammonium chloride (51 mg, 0.964 mmol), PYBOP (300 mg, 0.578 mmol) and triethylamine (0.69 mL, 4.82 mmol) were added and the reaction mixture was stirred at RT for 4 h. The reaction progress was monitored by LC-MS. After completion of the reaction, the reaction mixture was concentrated and the crude product was purified by reverse phase chromatography to obtain 45 mg of 4-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-3-pyridin-4-yl-butyramide as the TFA salt. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.6 (d, 2H), 7.8 (d, 2H), 7.25 (s, 1H), 7.15 (d, 1H), 6.9 (d, 1H), 4.63 (t, 1H), 4.5 (m, 1H), 4.4 (m, 1H), 4.3 (dd, 1H), 4.0 (m, 1H), 3.85 (m, 1H), 3.6 (m, 1H), 3.2 (m, 1H), 3.1 (s, 3H), 3.0 (m, 1H), 2.9 (m, 2H), 2.4 (d, 3H). Separation by chiral HPLC provides enantiomers II-229a-b.
Example 380
Preparation of Compound Nos. II-230 and II-230a-b
4-(2,8-Dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-3-pyridin-4-yl-butyric acid (130 mg, 0.358 mmol) was dissolved in DCM (5 mL), dimethyl amine hydrochloride (57 mg, 0.716 mmol), PYBOP (223 mg, 0.429 mmol) and triethylamine (0.51 mL, 3.58 mmol) were added and the reaction mixture was stirred at RT for 4 h. The reaction progress was monitored by LC-MS. After completion of the reaction, the reaction mixture was concentrated and the crude product was purified by reverse phase chromatography to obtain 77 mg of 4-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-N,N-dimethyl-3-pyridin-4-yl-butyramide as the TFA salt. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.56 (d, 2H), 7.28 (d, 2H), 7.19 (s, 1H), 7.17 (d, 1H), 6.94 (d, 1H), 4.63 (dd, 1H), 4.54 (dd, 1H), 4.39 (d, 1H), 4.37 (t, 1H), 4.0 (m, 1H), 3.8 (m, 1H), 3.6 (m, 1H), 3.45 (m, 1H), 3.3 (m, 1H), 3.1 (s, 6H), 3.0 (d, 3H), 2.9 (m, 2H), 2.8 (d, 3H). Separation by chiral HPLC provides enantiomers II-230a-b.
Example 381
Preparation of Compound Nos. II-231 and II-231a-b
Methanesulfonic acid-4-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-3-pyridin-4-yl-butyl ester (200 mg, 0.468 mmol) in 10 mL of aqueous ammonia was heated at 100° C. for 1 h. The progress of reaction was monitored by TLC. After consumption of starting material, the reaction mixture was dried and the crude product was purified by reverse phase chromatography to obtain 33 mg of 4-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-3-pyridin-4-yl-butylamine as the TFA salt. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.5 (d, 2H), 7.5 (m, 2H), 7.25 (d, 1H), 7.24 (s, 1H), 7.05 (t, 1H), 4.6 (d, 1H), 4.5 (d, 1H), 4.3 (m, 1H), 4.23 (t, 1H), 3.8 (m, 1H), 3.5 (m, 1H), 3.08 (d, 3H), 2.8 (m, 2H), 2.7 (m, 2H), 2.4 (s, 3H), 2.25 (m, 1H), 2.2 (m, 1H). Separation by chiral HPLC provides enantiomers II-231a-b.
Example 382
Preparation of Compound Nos. II-232 and II-232a-b
Methanesulfonic acid-4-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-3-pyridin-4-yl-butyl ester (200 mg, 0.468 mmol) in 10 mL of 40% aqueous dimethyl amine was heated at 100° C. for 1 h. The progress of reaction was monitored by TLC. After consumption of starting material, the reaction mixture was dried and the crude product was purified by reverse phase chromatography to obtain 170 mg of [4-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-3-pyridin-4-yl-butyl]-dimethyl-amine as the TFA salt. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.57 b (s, 2H), 7.65 (dd, 2H), 7.23 (d, 1H), 7.21 (s, 1H), 6.99 (d, 1H), 4.62 (m, 1H), 4.48 (m, 1H), 4.42 (m, 1H), 4.26 (t, 1H), 3.81 (m, 1H), 3.55 (m, 2H), 3.35 (m, 1H), 3.1 (m, 1H), 3.0 (s, 3H), 2.9 (m, 2H), 2.83 (s, 6H), 2.4 (m, 1H), 2.38 (s, 3H), 2.29 (m, 1H). Separation by chiral HPLC provides enantiomers II-232a-b.
Example 383
Preparation of Compound No. II-240
Aza-methylcarboline (50 mg, 0.248 mmol), 4-vinylpyridine (49.6 mg, 0.472 mmol), tetrabutylammoniumbromide (79.8 mg, 0.248 mmol) were charged in 50% solution of sodium hydroxide (2 mL), and the reaction mixture was heated at 95° C. for 1.5 h. The reaction mixture was monitored with TLC and LCMS. The reaction mixture was extracted with EtOAc (2×25 mL). The combined organic layer was washed with water (2×20 mL) and dried over anhydrous sodium sulfate. The organic layer was concentrated and purified through reverse phase chromatography. Yield: 19.20 mg. 1H NMR (CD3OD, Free base) δ (ppm): 8.38 (d, 2H), 8.0 (s, 1H), 7.63 (s, 1H), 7.1 (d, 2H), 4.4 (t, 2H), 3.8 (s, 2H), 3.15 (t, 2H), 3.0 (t, 2H), 2.75 (t, 2H), 2.61 (s, 3H), 2.4 (s, 3H).
Example 384
Preparation of Compound Nos. II-241 and II-241a-b
Aza-carboline (100 mg, 0.53 mmol) was dissolved in DMF (8 mL). Sodium hydride (38 mg, 1.59 mmol) was added at 0-10° C. and stirred at the same temperature for 15 min. 4-(oxiran-2-yl)pyridine (254 mg, 2.12 mmol) in DMF (2 mL) was added dropwise into the reaction mixture and the mixture was stirred at RT for 16 h. The reaction was monitored by LCMS. After consumption of starting material, the reaction mixture was quenched with ice cold water (4 mL) and solvent was evaporated to obtain the crude product, which was purified by reverse phase column chromatography to obtain 10 mg of product. 1H NMR (CD3OD, freebase) δ (ppm): 8.41 (d, 2H), 8.19 (d, 1H), 7.73 (s, 1H), 7.36 (d, 2H), 7.06 (m, 1H), 5.04 (t, 1H), 4.6 (m, 1H), 4.33 (m, 2H), 3.76 (dd, 2H), 2.9 (m, 4H), 2.5 (s, 3H). Separation by chiral HPLC provides enantiomers II-241a-b.
Example 385
Preparation of Compound No. II-242 and II-242a-b
Aza-carboline (300 mg, 1.60 mmol) was dissolved in DMF (8 mL). Sodium hydride (153 mg, 6.4 mmol) was added at 0-10° C. and stirred at the same temperature for 15 min., 4-(oxiran-2-yl)pyridine (769 mg, 6.41 mmol) in DMF (2 mL) was added dropwise into the reaction mixture and the mixture was stirred at RT for 16 h. The reaction was monitored by LCMS. After consumption of starting material, the reaction mixture was quenched with ice cold water (4 mL) and solvent was evaporated to obtain the crude product, which was purified by reverse phase column chromatography to obtain 8 mg of product. 1H NMR (CD3OD, freebase) δ (ppm): 8.5 (s, 1H), 8.43 (d, 2H), 8.01 (d, 1H), 7.4 (d, 1H), 7.38 (d, 2H), 5.07 (t, 1H), 4.4 (m, 2H), 3.68 (s, 2H), 3.3 (s, 2H), 2.85 (m, 4H), 2.45 (s, 3H). Separation by chiral HPLC provides enantiomers II-242a-b.
Example 386
Preparation of Compound Nos. II-243 and II-243a-b
5-[2-(9-Methyl-1,2,3,4,5,10c-hexahydro-3a,6,7-triaza-cyclopenta[c]fluoren-6-yl)-ethyl]-pyridine-2-carboxylic acid (400 mg, 1.063 mmol) was dissolved in 15 mL DCM and cooled at 0° C. Oxalyl chloride (669 mg, 5.315 mmol) and catalytic amount of DMF was added and the reaction mixture was stirred at RT for 1 h. The reaction was monitored by LCMS. The reaction mixture was concentrated and aqueous ammonia was added at 0° C. The reaction mixture was warmed to RT and stirred for 1 h. The reaction mixture was concentrated to obtain the crude product that was purified by reverse phase chromatography to obtain 2.5 mg of 5-[2-(9-methyl-1,2,3,4,5,10c-hexahydro-3a,6,7-triaza-cyclopenta[c]fluoren-6-yl)-ethyl]-pyridine-2-carboxylic acid amide as the TFA salt. 1H NMR TFA:—CD3OD: 8.2 (s, 2H), 7.95 (d, 1H), 7.8 (s, 1H), 7.6 (d, 1H), 5.0 (t, 1H), 4.6 (m, 2H), 3.62 (m, 1H), 3.5 (m, 2H), 3.3 (m, 3H), 2.8 (d, 1H), 2.63 (m, 2H), 2.4 (s, 3H), 2.2 (m, 2H), 2.1 (m, 1H). Separation by chiral HPLC provides enantiomers II-243a-b.
Example 387
Preparation of Compound Nos. II-244 and II-244a-b
9-Methyl-2,3,4,5,6,10c-hexahydro-1H-3a,6,7-triaza-cyclopenta[c]fluorene (250 mg, 1.10 mmol), 4-vinyl-pyridine (347 mg, 3.30 mmol), tetrabutyl ammonium bromide (355 mg, 1.10 mmol) were charged in a screw cap bottle and a 60% solution of sodium hydroxide (5 mL) was added and heated to 100° C. for 12 h. The reaction was monitored by TLC and LCMS. The reaction mixture was diluted with 25 mL of water and extracted with EtOAc (2×50 mL). The combined organic extracts were washed with water (25 mL), dried over anhydrous sodium sulfate and concentrated. The resultant crude product was purified by reverse phase chromatography to obtain 85 mg of 9-methyl-6-(2-pyridin-4-yl-ethyl)-2,3,4,5,6,10c-hexahydro-1H-3a,6,7-triaza-cyclopenta[c]fluorene as the formate salt (the product was a racemate which was purified by chiral prep HPLC to obtain product II-244a & product II-244b as the freebase). 1H NMR (CDCl3, freebase) δ (ppm): 8.45 (d, 2H), 8.17 (s, 1H), 7.56 (s, 1H), 6.91 (d, 2H), 4.5 (m, 1H),4.42 (t, 1H), 4.35 (m, 1H), 3.26 (m, 2H), 3.16 (m, 5H), 2.81 (m, 1H), 2.45 (m, 1H), 2.41 (s, 3H), 2.1 (m, 2H), 1.9 (m, 1H). Separation by chiral HPLC provided enantiomers II-244a-b.
Example 388
Preparation of Compound Nos. II-245 and II-245a-b
A suspension of azabicyclic carboline (0.2 g, 0.8 mmol), vinylpyrazine (0.375 g, 3.5 mmol), and tetrabutylammoniumbromide (0.855 g, 2.6 mmol) in 50% NaOH solution (2 mL) was heated at 100° C. for overnight. The reaction mixture diluted with EtOAc (50 mL), organic layer washed with water (20 mL), dried over anhydrous sodium sulfate, and concentrated under vacuum to obtain the crude product that was purified by reverse phase HPLC to obtain 2.4 mg of desired compound. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.48 (s, 1H), 8.39 (s, 1H), 8.1 (s, 1H), 8.06 (s, 1H), 7.7 (s, 1H),5.1 (m, 1H), 4.64 (t, 2H), 3.7 (m, 4H), 3.03 (t, 2H), 2.7 (m, 2H), 2.45 (s, 3H), 2.15 (m, 4H). Separation by chiral HPLC provides enantiomers II-245a-b.
Example 389
Preparation of Compound No. II-246
To a solution of 7,10-dichloro-1,2,3,4,5,6-hexahydro-3-methylazepino[4,5-b]indole (200 mg, 0.746 mmol) in DMF (2 mL), sodium hydride (90 mg, 2.25 mmol) was added. After stirring at 60° C. for 30 min., 2-(6-methylpyridin-3-yl)ethyl 4-methylbenzenesulfonate (543 mg, 1.86 mmol) was added to the reaction mixture and the reaction mixture was stirred at the same temperature for 40 min. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated to obtain the residue that was purified by reverse phase HPLC to obtain 7,10-dichloro-1,2,3,4,5,6-hexahydro-3-methyl-6-(2-(6-methylpyridin-3-yl)ethyl)azepino [4,5-b]indole. 1H NMR TFA:—CD3OD: 8.4 (s, 1H), 8.1 (d, 1H), 7.75 (d, 1H), 7.0 (q, 2H), 4.8 (m, 1H), 4.0 (m, 1H), 3.8 (m, 2H), 3.4 (m, 3H), 3.3 (m, 2H),3.2 (t, 3H),3.0 (s, 3H), 2.7 (s, 3H).
Example 390
Preparation of Compound No. II-247
To a solution of 9-bromo-6-chloro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (500 mg, 1.67 mmol) in DMF (5 mL), sodium hydride (200 mg, 5.0 mmol) was added. After stirring at 60° C. for 30 min., 2-(6-methylpyridin-3-yl)ethyl 4-methylbenzenesulfonate (1.2 g, 4.2 mmol) was added to the reaction mixture and stirred at the same temperature for 1 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated to obtain the crude product, which was purified by reverse phase HPLC to obtain the 9-bromo-6-chloro-2,3,4,5-tetrahydro-2-methyl-5-(2-(6-methylpyridin-3-yl)ethyl)-1H-pyrido[4,3-b]indole. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.39 (s, 1H), 8.12 (d, 1H), 7.66 (d, 1H), 7.26 (d, 1H), 7.1 (d, 1H),4.67 (m, 4H), 3.7 (m, 2H), 3.27 (t, 2H), 3.18 (m, 2H), 3.15 (s, 3H), 2.69 (s, 3H).
Example 391
Preparation of Compound No. II-248
To a solution of 9-chloro-6-fluoro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (500 mg, 2.1 mmol) in DMF (5 mL), sodium hydride (252 mg, 6.3 mmol) was added. After stirring at 60° C. for 30 min., 2-(6-methylpyridin-3-yl)ethyl 4-methylbenzenesulfonate (1.5 g, 5.25 mmol) was added to the reaction mixture and stirred at the same temperature for 1 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated to obtain the crude product, which was purified by reverse phase HPLC to obtain the 9-chloro-6-fluoro-2,3,4,5-tetrahydro-2-methyl-5-(2-(6-methylpyridin-3-yl)ethyl)-1H-pyrido[4,3-b]indole. 1H NMR (CD3OD, TFA) δ (ppm): 8.37 (s, 1H), 8.12 (d, 1H), 7.73 (d, 1H), 7.02 (dd, 1H), 6.86 (t, 1H), 5.1 (m, 1H), 4.57 (t, 2H), 4.56 (m, 1H), 3.85 (m, 1H), 3.6 (m, 1H), 3.27 (m, 3H), 3.2 m (2H), 3.1 (s, 3H), 2.69 (s, 3H).
Example 392
Preparation of Compound No. II-249
To a solution of 5,8-dichloro-2,3,4,9-tetrahydro-2-methyl-1H-pyrido[3,4-b]indole (200 mg, 0.78 mmol) in DMF (2 mL), sodium hydride (94 mg, 2.36 mmol) was added. After stirring at 60° C. for 30 min., 2-(6-methylpyridin-3-yl)ethyl 4-methylbenzenesulfonate (572 mg, 1.96 mmol) was added to the reaction mixture and stirred at the same temperature for 40 min. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated to get the residue that was purified by reverse phase HPLC to obtain the 5,8-dichloro-2,3,4,9-tetrahydro-2-methyl-9-(2-(6-methylpyridin-3-yl)ethyl)-1H-pyrido[3,4-b]indole.
1H NMR (CD3OD, TFA salt) δ (ppm): 8.43 (s, 1H), 8.18 (d, 1H), 7.74 (d, 1H), 7.09 (d, 1H), 7.04 (d, 1H), 4.79 (t, 2H), 4.65 b(s, 1H), 3.62 b(s, 1H), 3.5 (m, 2H), 3.35 (m, 2H), 3.25 (t, 2H), 3.16 (s, 3H), 2.75 (s, 3H).
Example 393
Preparation of Compound No. II-250
To a solution of 6,9-difluoro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (550 mg, 2.42 mmol) in DMF (3.5 mL) was added sodium hydride (300 mg, 7.4 mmol). After stirring at 60° C. for 30 min., 2-(6-methylpyridin-3-yl)ethyl 4-methylbenzenesulfonate (1.8 g, 6.1 mmol) was added to the reaction mixture, which was stirred at the same temperature for 1 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated. The residue was purified by reverse phase HPLC (540 mg, TFA salt). 1H NMR (CD3OD, TFA salt) δ (ppm): 8.35 (s, 1H), 8.13 (d, 1H), 7.73 (d, 1H), 6.7 (m, 2H), 4.8 (m, 1H), 4.57 (t, 2H),4.5 (m, 1H), 3.9 (m, 1H), 3.6 (m, 1H), 3.35 (m, 2H), 3.19 (m, 2H), 3.13 (s, 3H), 2.69 (s, 3H).
Example 394
Preparation of Compound No. II-251
To a solution of 6,9-dibromo-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (800 mg, 2.32 mmol) in DMF (5 mL) was added sodium hydride (0.279 g, 6.9 mmol). After stirring at 60° C. for 30 min., 2-(6-methylpyridin-3-yl)ethyl 4-methylbenzenesulfonate (1.7 g, 5.8 mmol) was added to the reaction mixture, which was stirred at the same temperature for 1 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated. The residue was purified by reverse phase HPLC (460 mg, TFA salt). 1H NMR (CD3OD, TFA salt) δ (ppm): 8.46 (s, 1H), 8.18 (d, 1H), 7.72 (d, 1H), 7.28 (d, 1H), 7.18 (d, 1H), 5.2 (m, 2H),4.6 (m, 2H), 3.9 (m, 1H), 3.6 (m, 1H), 3.2 (m, 4H), 3.15 (s, 3H), 2.71 (s, 3H).
Example 395
Preparation of Compound No. II-252
To a solution of 6-bromo-9-chloro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (500 mg, 1.67 mmol) in DMF (4 mL) was added sodium hydride (120 mg, 5.0 mmol). After stirring at 60° C. for 30 min., 2-(6-methylpyridin-3-yl)ethyl 4-methylbenzenesulfonate (1.2 g, 4.19 mmol) was added to the reaction mixture, which was stirred at the same temperature for 1 h. The progress of the reaction was monitored by TLC and LCMS. The reaction mixture was quenched with water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated. The residue was purified by reverse phase HPLC (279 mg, TFA salt). 1H NMR (CD3OD, TFA salt) δ (ppm): 8.43 (s, 1H), 8.14 (d, 1H), 7.7 (d, 1H), 7.35 (d, 1H), 7.03 (d, 1H), 5.0 (m, 2H), 4.6 (m, 2H), 3.8 (m, 1H), 3.6 (m, 1H), 3.27 (t, 2H), 3.22 (t, 2H), 3.14 (s, 3H), 2.7 (s, 3H).
Example 396
Preparation of Compound No. II-253
To a solution of 6-chloro-9-fluoro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (500 mg, 2.1 mmol) in DMF (5 mL) was added sodium hydride (252 mg, 6.3 mmol). After stirring at 60° C. for 30 min., 2-(6-methylpyridin-3-yl)ethyl 4-methylbenzenesulfonate (1.5 g, 5.25 mmol) was added to the reaction mixture, which was stirred at the same temperature for 1 h. The progress of the reaction was monitored by TLC and LCMS. The reaction mixture was quenched with water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated. The residue was purified by reverse phase HPLC (463 mg, TFA salt). 1H NMR (CD3OD, TFA salt) δ (ppm): 8.42 (s, 1H), 8.15 (d, 1H), 7.7 (d, 1H), 7.1 (dd, 1H), 6.8 (t, 1H),4.8 (m, 2H), 4.5 (m, 2H), 3.8 (m, 1H), 3.6 (m, 1H), 3.3 (t, 2H), 3.2 (t, 2H), 3.1 (s, 3H), 2.7 (s, 3H).
Example 397
Preparation of Compound Nos. II-255 and II-255a-b
3-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-hydroxy-2-(pyridin-4-yl)propanenitrile.diHCl salt (500 mg, 1.19 mmol) was dissolved in 500 mL Ethanol. The solution was passed through H-Cube as condition 70 mbar at 70° C. (Ra/Ni as catalyst). The product formation observed by LCMS. The solvent was concentrated under reduced pressure. The crude product was purified by reverse phase column chromatography to obtain 1-amino-3-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridin-4-yl)propan-2-ol (31 mg) as the TFA salt. 1H NMR (CDCl3, freebase) δ (ppm): 8.61 (d, 2H), 7.42 (d, 2H), 7.23 (d, 1H), 7.18 (s, 1H), 6.95 (d, 1H), 4.17 (dd, 2H), 3.68 (q, 2H), 3.2 (d, 1H), 3.1 (m, 1H), 2.76 (m, 3H), 2.63 (m, 1H), 2.55 (s, 3H), 2.43 (s, 3H). Separation by chiral HPLC provided enantiomers II-255a-b.
Example 398
Preparation of Compound Nos. II-256 and II-256a-b
A solution of alcohol (2 g, 6.2 mmol) in THF (150 mL) was cooled at −78° C., NaH (0.3 g, 12.4 mmol, 60% dispersion in mineral oil) was added and the reaction mixture was stirred at the same temperature for 30 min. Methyl acrylate (2.1 g, 31.1 mmol) was added slowly and the reaction mixture was stirred at −78° C. for 1 h and at RT for further 2 h. The reaction mixture was quenched with water (60 mL) and extracted with EtOAc (2×60 mL). The combined organic layer was washed with brine (50 mL), dried over anhydrous Sodium sulfate. Removal of solvent under reduced pressure gave crude product that was purified by column chromatography using neutral alumina and 1-2% MeOH-DCM system as eluent to give 0.8 g pure desired ester. To a solution of ester (0.2 g, 0.49 mmol) in MeOH (5 mL) was added 1 N LiOH (1 mL) at RT and the reaction mixture was stirred at 50° C. for 1 h. The reaction mixture was concentrated to dryness under reduce pressure to give crude product which was purified by reverse phase preparative HPLC to give 108 mg pure product. 1H NMR (CD3OD, TFA) δ (ppm): 8.66 (d, 2H), 7.8 (d, 2H), 7.23 (s, 1H), 7.1 (d, 1H), 7.0 & 6.9 (d, 1H), 4.8 (m, 1H), 4.7 (m, 1H), 4.4 (m, 3H), 3.85 (m, 1H), 3.6 (m, 2H), 3.45 (m, 1H), 3.24 (m, 4H), 3.12 (s, 3H), 2.4 (s, 3H). Separation by chiral HPLC provides enantiomers II-256a-b.
Example 399
Preparation of Compound Nos. II-257 and II-257a-b
A mixture of 2,8-dimethyl-5-((2-(pyridin-3-yl)oxiran-2-yl)methyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg, 0.3 mmol) in 20% aq. TFA (2 mL) was stirred at RT overnight. The reaction mixture was neutralized with saturated sodium bicarbonate solution and extracted with EtOAc (2×30 mL) to remove the impurities. The aqueous layer was lyophilized to obtain the crude product that was purified by reverse phase HPLC to obtain 5 mg of 3-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridin-3-yl)propane-1,2-diol as the TFA salt. 1H NMR (CD3OD, TFA) δ (ppm): 8.75 (s, 1H), 8.6 (m, 2H), 7.83 (m, 1H), 7.25 (s, 1H), 6.9 (d, 1H), 6.8 (d, 1H), 4.62 (d, 1H), 4.45 (dd, 2H), 4.3 (t, 1H), 4.05 (t, 1H), 3.8 (m, 2H), 3.5 (m, 3H), 3.1 (s, 3H), 2.3 (s, 3H). Separation by chiral HPLC provides enantiomers II-257a-b.
Example 400
Preparation of Compound Nos. II-258 and II-258a-b
3-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridin-4-yl)propanoic acid (20 mg, 0.057 mmol) was charged in pyridine (0.5 mL) under nitrogen. DMAP (9.73 mg, 0.08 mmol) and (Boc)2O (14 mg, 0.069 mmol) were added into it. The reaction mixture was stirred at 60° C. for 30 min and allowed to come to RT. Tert-butanol (84.81 mg, 1.146 mmol) was added dropwise and the reaction mixture was stirred at RT for 1 h. 1M citric acid (5 mL) was added and reaction mixture was then washed with DCM (5 mL). The organic layer was concentrated and the crude product was purified by reverse phase HPLC to obtain tert-butyl 3-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridin-4-yl)propanoate (15.4 mg, TFA salt). 1H NMR (CD3OD, TFA salt) δ (ppm): 8.49 (d, 2H), 7.53 (d, 2H), 7.3 (t, 1H), 7.24 (s, 1H), 7.05 (m, 1H), 5.5 (m, 1H), 4.6 (t, 1H), 4.24 (t, 1H), 3.8 (m, 3H), 3.3 (m, 2H), 3.13 (d, 2H), 2.89 (m, 1H), 2.77 (m, 1H), 2.4 (s, 3H), 1.39 s (9H). Separation by chiral HPLC provides enantiomers II-258a-b.
Example 401
Preparation of Compound Nos. II-259 and II-259a-b
2,8-Dimethyl-5-((2-(pyridin-4-yl)oxiran-2-yl)methyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg, 0.3 mmol) was added to 2M dimethyl amine solution in THF (5 mL) and the reaction mixture was allowed to stir at 60° C. overnight. The progress of reaction was monitored by LCMS. The solvent was removed under reduced pressure to obtain a crude oily product that was purified by reverse phase HPLC to afford 5 mg of 1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(dimethylamino)-2-(pyridin-4-yl)propan-2-ol as the TFA salt. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.58 (d, 2H), 7.81 (m, 2H), 7.18 (d, 1H), 7.05 (m, 1H), 6.91 (m, 1H), 4.63 (m, 1H), 4.51 (s, 2H), 4.27 (d, 1H), 4.18 (m, 2H), 3.58 (m, 2H), 3.48 (m, 1H), 3.1 (s, 6H), 2.89 (m, 1H), 2.8 (s, 3H), 2.35 (s, 3H). Separation by chiral HPLC provides enantiomers II-259a-b.
Example 402
Preparation of Compound Nos. II-260 and II-260a-b
Methanesulfonic acid 2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethylester (1.0 g, 3.5 mmol) was dissolved in 70% cyclopropylamine in water (50 mL) and heated at 90° C. for 18 h. The reaction mixture was concentrated to obtain the crude product that was purified by reverse phase chromatography to obtain 300 mg of cyclopropyl-[2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-yl-ethyl]-amine. 1H NMR (CDCl3, Free base) δ (ppm): 8.52 (d, 2H), 7.18 (s, 1H), 7.14 (d, 1H), 7.13 (d, 2H), 6.99 (d, 1H), 4.22 (m, 2H), 3.98 (dd, 1H), 3.76 (d, 1H), 3.70 (d, 1H), 2.85 (m, 1H), 2.74 (m, 2H), 2.55 (s, 3H), 2.44 (s, 3H), 2.36 (m, 2H), 0.33 (m, 2H), 0.23 (m, 2H). Separation by chiral HPLC provided enantiomers II-260a-b.
Example 403
Preparation of Compound Nos. II-261 and II-261a-d
Methanesulfonicacid2-(9-methyl-1,2,3,4,5,10c-hexahydro-3a,6-diaza-cyclopenta[c] fluoren-6-yl)-1-pyrazin-2-yl-ethyl ester (280 mg, 0.65 mmol) was dissolved in 3 mL DMF, sodium azide (64 mg, 0.98 mmol) was added and heated at 90° C. for 1 h. The reaction mixture was monitored by LCMS. After consumption of starting material, the reaction mixture was cooled to RT, diluted with water (3 mL) and concentrated to obtain the crude product, which was purified by reverse phase chromatography to obtain 60 mg of 6-(2-azido-2-pyrazin-2-yl-ethyl)-9-methyl-2,3,4,5,6,10c-hexahydro-1H-3a,6-diaza-cyclopenta[c]fluorene. 1H NMR (CDCl3, freebase) δ (ppm): 8.65 (d, 1H), 8.60 (s, 1H), 8.50 (s, 1H), 7.8 (d, 1H), 7.22 (d, 1H), 7.09 (t, 1H), 5.1 (m, 1H), 4.8 (m, 1H), 4.6 (dd, 1H), 4.3 (m, 1H), 3.45 (m, 3H), 2.97 (m, 2H), 2.84 (m, 2H), 2.6 (m, 1H), 2.45 (d, 3H), 2.2 (m, 1H), 1.9 m (1′H). Separation by chiral HPLC provided enantiomers II-261a-b.
Example 404
Preparation of Compound Nos. II-262 and II-262a-b
3-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridin-4-yl)propanenitrile (80 mg, 0.24 mmol) in conc. HCl (2 mL) was heated at 80° C. for 1 h. The reaction mixture was concentrated to obtain a residue that was purified by reverse phase chromatography to obtain 5.3 mg of 3-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridin-4-yl)propanoic acid as the free base. 1H NMR (CD3OD, freebase) δ (ppm): 8.1 (d, 2H), 7.3 (d, 1H), 7.13 (s, 1H), 6.98 (d, 1H), 6.8 (d, 2H), 4.09 (s, 2H), 3.6 (dd, 1H), 3.4 (m, 3H), 2.9 (m, 2H), 2.8 (s, 3H), 2.39 (s, 3H), 2.32 (m, 1H). Chiral HPLC provides enantiomers II-262a and II-262b.
Example 405
Preparation of Compound Nos. II-263 and II-263a-b
To a solution of tert-butanol (4 mL) containing crushed KOH (20.36 mg, 0.363 mmol) was added 3-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-2-pyridine-4-yl-propionitrile (40 mg, 0.121 mmol) and the resultant reaction mixture was stirred at 80° C. for 90 min. The progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the tert-butanol was evaporated under vacuum and resultant reaction mixture was purified by preparative HPLC to obtain the desired compound (15 mg). 1H NMR (CDCl3, freebase): 8.32 (d, 2H), 7.25 (d, 2H), 7.15 (d, 1H), 7.01 (d, 1H), 6.63 (d, 1H), 4.8 (d, 1H), 3.77 (m, 2H), 3.39 (t, 2H), 2.8 (m, 1H), 2.7 (m, 1H), 2.5 (m, 1H), 2.47 (s, 3H), 2.45 (s, 3H), 2.3 (m, 1H). Chiral HPLC provides enantiomers II-263a and II-263b.
Example 406
Preparation of Compound Nos. II-264 and II-264a-b
2,8-Dimethyl-5-((2-(pyridin-3-yl)oxiran-2-yl)methyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100 mg, 0.3 mmol) was dissolved in MeOH (2 mL) and aq. ammonia (2 mL) and the reaction mixture was allowed to stir at RT for 24 h. The progress of reaction was monitored by LCMS. The volatiles were removed under reduced pressure to obtain a crude oily product that was purified by reverse phase HPLC to afford 7 mg of 1-amino-3-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridin-3-yl)propan-2-ol as TFA salt. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.65 (m, 2H), 8.43 (dd, 1H), 7.75 (m, 1H), 7.18 (d, 1H), 6.88 (m, 2H), 4.67 (d, 1H), 4.55 (m, 2H), 4.29 (t, 1H), 3.90 (m, 2H), 3.69 (m, 1H), 3.5 (m, 2H), 3.1 (m, 1H), 3.11 (s, 3H), 2.34 (s, 3H). Separation by chiral HPLC provides enantiomers II-264a-b.
Example 407
Preparation of Compound Nos. II-265 and II-265a-b
2,8-Dimethyl-5-((2-(pyridin-3-yl)oxiran-2-yl)methyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (200 mg, 0.6 mmol) was added to 2M dimethylamine solution in THF (5 mL) and the reaction mixture was allowed to stir at 40° C. overnight. The progress of reaction was monitored by LCMS. The solvent was removed under reduced pressure to obtain a crude oily product that was purified by reverse phase HPLC to afford 50 mg of 1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(dimethylamino)-2-(pyridin-3-yl)propan-2-ol as the TFA salt. 1H NMR (CDCl3, Free base) δ (ppm): 8.74 (s, 1H), 8.50 (d, 1H), 7.79 (d, 1H), 7.25 (dd, 1H), 7.16 (s, 1H), 7.1 (d, 1H), 6.97 (d, 1H), 4.08 (m, 2H), 3.83 (dd, 2H), 2.98 (m, 4H), 2.74 (d, 2H), 2.70 (s, 3H), 2.42 (s, 3H), 1.98 (s, 6H). Separation by chiral HPLC provided enantiomers II-265a-b.
Example 408
Compounds III-1, III-53 and III-223-224 were synthesized as described in PCT publication WO2009/055828. Compounds III-2-3 were synthesized as described in PCT publication WO2009/120720. Compounds III-4-9 were synthesized as described in PCT publication WO2009/120717. Compounds III-10-46, III-209-220 and III-320-352 were synthesized as described in PCT publication WO2010/051503. Compounds III-47-51 were synthesized as described in PCT publication WO2010/127177. Compounds III-52 and III-225-253 were synthesized as described in PCT publication WO2010/019417. Compounds III-54-58, III-353-355 and III-357 were synthesized as described in PCT publication WO2011/038163. Compounds III-59-61, III-356 and III-358-361 were synthesized as described in PCT publication WO2011/038161. Compounds III-62-98, III-187-197 and III-256-258 were synthesized as described in PCT publication WO2011/038162. Compounds III-99-138, III-198-208, III-221 and III-289-319 were synthesized as described in PCT publication WO2011/038164.
Example 409
Compounds W-2, IV-4-7 and IV-10 were synthesized as described in PCT publication WO2011/038161. Compounds IV-1, IV-3, IV-9, IV-11-92, IV-94-208 and IV-211-244 can be synthesized using similar conditions to those described in both Examples 410-412 below, and in PCT publication WO2011/038161.
Example 410
Preparation of Compound Nos. IV-8 and IV-8a-b
To a solution of 10-methyl-1,2,3,4,5,6,7,11c-octahydro-4a,7,8-triaza-benzo[c]fluorene (150 mg, 0.622 mmol) in DMF (2 mL) were added sodium hydride (75 mg, 1.86 mmol) and a solution of toluene-4-sulfonic acid 2-(6-methyl-pyridin-3-yl)-ethyl ester (544 mg, 1.86 mmol) in DMF (2 mL) at 0° C. The reaction mixture was stirred at RT for 1 h. The progress of reaction was monitored by TLC and LCMS. The reaction mixture was poured into ice-cold water and extracted with EtOAc (2×50 mL). The combined organic layer was washed with water (5×25 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase chromatography to yield compound 8 (140 mg). This product was further purified by chiral preparative HPLC to give compounds 8a and 8b. Compound 8a: 1HNMR (CDCl3, freebase) δ (ppm): 8.21 (s, 1H), 8.07 (s, 1H), 7.6 (s, 1H), 7.21 (d, 1H), 7.0 (d, 1H), 4.3 (m, 2H), 3.28 (d, 1H), 3.08 (m, 1H), 3.0 (m, 4H), 2.54 (m, 1H), 2.54 (s, 3H), 2.5 (m, 1H), 2.4 (m, 1H), 2.4 (s, 3H), 2.3 (d, 1H), 1.9 (m, 1H), 1.72 (m, 2H), 1.5 (q, 2H). Compound 8b: 1HNMR (CDCl3, freebase) δ (ppm): 8.21 (s, 1H), 8.07 (s, 1H), 7.6 (s, 1H), 7.21 (d, 1H), 7.0 (d, 1H), 4.3 (m, 2H), 3.28 (d, 1H), 3.08 (m, 1H), 3.0 (m, 4H), 2.54 (m, 1H), 2.54 (s, 3H), 2.5 (m, 1H), 2.4 (m, 1H), 2.4 (s, 3H), 2.3 (d, 1H), 1.9 (m, 1H), 1.72 (m, 2H), 1.5 (q, 2H).
Example 411
Preparation of Compound Nos. IV-209 and IV-209a-d
9-Methyl-2,3,4,5,6,10c-hexahydro-1H-3a,6,7-triaza-cyclopenta[c]fluorene (600 mg, 2.643 mmol) was dissolved in DMF (18 mL), and cooled to 0° C. Potassium tert-butoxide (444 mg, 3.964 mmol) was added and stirred for 5 min. 4-Oxiranyl-pyridine (639 mg, 5.286 mmol) in DMF (3 mL) was added dropwise into the reaction mixture and the mixture was stirred at RT for 12 h. The reaction was monitored by TLC and LCMS. After consumption of starting material, the reaction mixture was quenched with ice cold water (100 mL) and extracted with EtOAc (2×100 mL). The combined organic layer was washed with water (4×70 mL), dried over anhydrous sodium sulfate and concentrated to obtain the crude product, which was purified by reverse phase chromatography to obtain 400 mg of 2-(9-Methyl-1,2,3,4,5,10c-hexahydro-3a,6,7-triaza-cyclopenta[c]fluoren-6-yl)-1-pyridin-4-yl-ethanol. 1H NMR (CD3OD, HCl salt) δ (ppm): 8.8 (d, 2H), 8.2 (d, 2H), 8.1 (s, 1H), 7.9 (s, 1H), 5.38 (m, 1H), 5.09 (t, 1H), 4.68 (dd, 2H), 4.4 (m, 1H), 3.75 (m, 4H), 3.43 (m, 2H), 2.7 (m, 2H), 2.46 (s, 3H), 2.2 (m, 3H). Separation by chiral HPLC provided diastereomers IV-209a-d.
Example 412
Preparation of Compound Nos. IV-210 and IV-210a-d
Chloroaza carboline (500 mg, 2.02 mmol) was dissolved in DMF (8 mL), sodium hydride (404 mg, 10.12 mmol) was added at 0-10° C. and stirred at the same temperature for 15 min. 3-(2-Methyloxiran-2-yl)pyridine (546 g, 4.04 mmol) was added dropwise into the reaction mixture and the mixture was stirred at RT for 16 h. The reaction was monitored by TLC and LCMS. After consumption of starting material, the reaction mixture was quenched with ice cold water (100 mL) and extract with EtOAc (200 mL). The organic layer was washed with water (5×50 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude product, which was purified by crystallization using Diethyl ether to obtain 200 mg of product. 1H NMR (CD3OD, HCl salt): 8.8 (s, 1H), 8.6 (d, 2H), 7.88 (s, 2H), 7.84 (d, 1H), 4.99 (m, 2H), 4.4 (d, 1H), 3.78 (m, 2H),3.4 (m, 2H), 3.4 (m, 2H), 2.7 (m, 1H), 2.2 (m, 3H), 1.83 (s, 3H). Separation by chiral HPLC provided diastereomers IV-210a-d.
Example 413
Compound Nos. V-4 to V-13, V-16 to V-17 and V-19 to V-20 can be synthesized using similar conditions to those described in Examples 414-422 below.
Example 414
Preparation of Compound Nos. V-1 and V-1a-b
To a solution of 2-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-1-(pyridin-4-yl)ethyl methanesulfonate (900 mg, 2.18 mmol) in DMF (10 mL) was added sodium azide (212.5 mg, 3.2 mmol) and the reaction mixture was stirred at 100° C. for 1 h. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield 5-(2-azido-2-(pyridin-4-yl)ethyl)-2,3,4,5-tetrahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole (650 mg). The resulting racemate was purified and resolved by chiral preparative HPLC. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.8 (d, 2H), 8.0 (d, 2H), 7.31 (d, 1H), 7.3 (s, 1H), 7.04 (d, 1H), 5.45 (m, 1H), 4.7 (d, 1H), 4.59 (t, 1H), 4.4 (m, 2H), 3.9 (d, 1H), 3.6 (m, 1H), 3.4 (m, 1H), 3.2 (m, 1H), 3.1 (s, 3H), 2.4 (s, 3H).
Example 415
Preparation of Compound Nos. V-2 and V-2a-b
To a solution of 2-(2,8-dimethyl-6-aza-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(pyridin-4-yl)ethyl methanesulfonate (300 mg, 0.724 mmol) in DMF (4 mL) was added sodium azide (70.65 mg, 1.08 mmol) and the reaction mixture was stirred at 100° C. for 1 h. The progress of reaction was monitored by NMR. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was thoroughly washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield 9-(2-azido-2-(pyridin-4-yl)ethyl)-3,6-dimethyl-6,7,8,9-tetrahydro-5H-pyrrolo[2,3-b:4,5-c′]dipyridine (160 mg). 1H NMR (CDCl3, freebase) δ (ppm): 8.6 (d, 2H), 8.07 (s, 1H), 7.55 (s, 1H), 7.27 (d, 2H), 5.23 (m 1H), 4.37 (dd, 1H), 4.19 (m, 1H), 3.62 (dd, 2H), 2.88 (m, 2H), 2.82 m, 2H), 2.56 (s, 3H), 2.42 (s, 3H). Separation by chiral HPLC provided enantiomers V-2a-b.
Example 416
Preparation of Compound Nos. V-3 and V-3a-b
5-(2-Chloro-2-(pyridin-3-yl)propyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (crude) (700 mg) was dissolved in DMF (4 mL). Sodium azide (975 mg, 15 mmol) was added and reaction mixture was stirred at 80° C. for 1 h. The reaction mixture was diluted with water, basified with aqueous NaHCO3 solution and was extracted with EtOAc (200 mL). The organic layer was washed with water (6×50 mL), dried over anhydrous sodium sulfate and evaporated in vacuo to obtain the crude product that was purified by reverse phase HPLC to obtain 1 mg of 5-(2-azido-2-(pyridin-3-yl)propyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole as the TFA salt. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.56 (m, 2H), 8.11 (dd, 1H), 7.6 (t, 1H), 7.2 (s, 1H), 6.85 (m, 2H), 4.67 (d, 1H), 4.47 (d, 1H), 4.39 (s, 2H), 3.84 (m, 1H), 3.48 (m, 1H), 3.34 (m, 1H), 3.12 (s, 3H), 3.12 (m, 1H), 2.36 (s, 3H), 2.03 (s, 3H). Separation by chiral HPLC provides enantiomers V-3a-b.
Example 417
Preparation of Compound Nos. V-14 and V-14a-b
To a solution of 1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridin-3-yl)propan-2-ol (200 mg, 0.597 mmol) in DMF (5 mL) was added potassium carbonate (412 mg, 2.98 mmol). After stirring for 5 min at RT, ethyl bromoacetate (200 mg, 1.19 mmol) was added into the reaction mixture, which was stirred at RT for 2 h. The progress of reaction was monitored by LCMS. The reaction was quenched with water and extracted with EtOAc. The aqueous layer was concentrated and residue was purified by reverse HPLC to yield 2-((1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridin-3-yl)propan-2-yl)oxy)acetic acid (80 mg). The resulting racemate was purified and resolved by chiral preparative HPLC. 1H NMR (CD3OD, freebase) δ (ppm): 8.5 (d, 1H), 8.36 (s, 1H), 7.8 (dd, 1H), 7.31 (m, 1H), 7.19 (s, 1H), 7.1 (d, 1H), 6.88 (d, 1H), 4.86 (m, 1H), 4.58 (s, 1H), 4.32 (d, 1H), 4.25 (m, 2H), 3.94 (m, 2H), 3.8 (m, 1H), 3.35 (s, 3H), 3.2 (m, 1H), 3.0 (m, 1H), 2.36 (s, 3H), 1.69 (s, 3H).
Example 418
Preparation of Compound Nos. V-15 and V-15a-d
Ethyl 2-(2-(10-methyl-2,3,5,6-tetrahydro-1H-indolizino[7,8-b]indol-7(11cH)-yl)-1-(pyridin-4-yl)ethoxy)acetate (170 mg, 0.392 mmol) in 2N LiOH solution (5 mL) was stirred at RT for 3 h. The desired product was detected by LCMS. The reaction mixture was concentrated and the crude product was purified by reverse phase chromatography to yield 2-(2-(10-methyl-2,3,5,6-tetrahydro-1H-indolizino[7,8-b]indol-7(11cH)-yl)-1-(pyridin-4-yl)ethoxy)acetic acid (13 mg). 1H NMR (CD3OD, freebase) δ (ppm): 8.45 (d, 2H), 7.42 (d, 2H), 7.22 (s, 1H), 7.2 (d, 1H), 7.0 (d, 1H), 5.09 (m, 2H), 4.6 (s, 1H), 4.45 (dd, 1H), 4.29 (m, 2H), 4.19 (m, 1H), 3.96 (m, 2H), 3.81 (d, 1H), 3.7 (t, 1H), 3.2 (d, 1H), 3.1 (m, 1H), 3.82 (m, 1H), 2.4 (s, 3H), 2.34 (m, 1H), 2.09 (m, 1H). Separation by chiral HPLC provides diastereomers V-15a-d.
Example 419
Preparation of Compound Nos. V-18 and V-18a-d
2-(10-Methyl-2,3,5,6-tetrahydro-1H-indolizino[7,8-b]indol-7(11cH)-yl)-1-(pyridin-4-yl)ethanol (350 mg, 1 mmol), succinic acid (118 mg, 1 mmol) and dimethylaminopyridine (122 mg, 1 mmol) in DCM (20 mL) were stirred at RT. Dicyclohexylcarbodiimide (206 mg, 1.6 mmol) in DCM (20 mL) was added dropwise and the reaction mixture was stirred at RT for 2 h. The reaction mixture was concentrated to obtain the crude product that was purified by reverse phase HPLC to yield 4-(2-(10-methyl-2,3,5,6-tetrahydro-1H-indolizino[7,8-b]indol-7(11cH)-yl)-1-(pyridin-4-yl)ethoxy)-4-oxobutanoic acid (96 mg). 1H NMR (CD3OD, freebase) δ (ppm): 8.46 (d, 2H), 7.33 (d, 2H), 7.27 (d, 1H), 7.23 (s, 1H), 7.01 (d, 1H), 6.07 (t, 1H), 4.8 (t, 2H), 4.5 (m, 2H), 3.55 (m, 2H), 3.45 (m, 1H), 3.0 (q, 2H), 2.7 (m, 1H), 2.54 (m, 2H), 2.39 (s, 3H), 2.37 (m, 1H), 2.1 (m, 4H). Separation by chiral HPLC provided diastereomers V-18a-d.
Example 420
Preparation of Compound Nos. V-21 and V-21a-b
To a solution of the mesylate compound (2 g, 4.46 mmol) in DMF (25 mL) was added sodium azide (435 mg, 6.69 mmol) and reaction mixture was stirred at 100° C. for 1 h. The progress of reaction was monitored by NMR. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (2×150 mL). The organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield 6-(2-azido-2-(2,4-difluorophenyl)ethyl)-3,9-dimethyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole (1.6 g). 1H NMR (CDCl3, freebase) δ (ppm): 7.4 (q, 1H), 7.2 (s, 1H), 7.18 (d, 1H), 7.01 (d, 1H), 6.99 (d, 1H), 6.92 (d, 1H), 5.13 (dd, 1H), 4.26 (dd, 1H), 4.2 (dd, 1H), 2.9 (d, 1H), 2.93 (m, 2H), 2.8 (m, 1H), 2.83 m (4H), 2.5 (s, 3H), 2.46 (s, 3H). Separation by chiral HPLC provides enantiomers V-21a-b.
Example 421
Preparation of Compound Nos. V-22 and V-22a-b
Methanesulfonic acid-1-(6-carbamoyl-pyridin-3-yl)-2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-ethyl ester (300 mg, 0.678 mmol) was dissolved in 5 mL DMF, and sodium azide (88 mg, 1.357 mmol) was added, and the mixture heated at 100° C. for 1 h. The reaction mixture was monitored by LCMS. After completion of reaction, the reaction mixture was cooled to RT and diluted with water (15 mL) and extracted with EtOAc (3×30 mL). The combined organic layer was washed with water (4×40 mL), dried over anhydrous sodium sulfate and concentrated to obtain the crude product that was purified by reverse phase chromatography to yield 5-[1-azido-2-(2,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-ethyl]-pyridine-2-carboxylic acid amide (135 mg). 1H NMR (CD3OD, TFA salt) δ (ppm): 8.6 (dd, 1H), 8.1 (t, 1H), 7.9 (t, 1H), 7.33 (dd, 1H), 7.26 (s, 1H), 7.06 (t, 1H), 5.3 (t, 1H), 4.7 (dd, 1H), 4.42 (dd, 1H), 4.4 (dd, 2H), 4.3 (m, 1H), 3.8 (m, 1H),3.6 (m, 1H), 3.34 (dd, 1H), 3.1 (d, 3H), 2.4 (s, 3H). Separation by chiral HPLC provides enantiomers V-22a-b.
Example 422
Preparation of Compound Nos. V-23 and V-23a-d
A solution of 1-(4-fluorophenyl)-2-(10-methyl-2,3,5,6-tetrahydro-1H-indolizino[7,8-b]indol-7(11cH)-yl)ethyl methanesulfonate (400 mg, 0.9 mmol) and sodium azide (88 mg, 1.3 mmol) in dimethylformamide (10 mL) was stirred at RT for 18 h. The reaction mixture was diluted with ice cooled water (100 mL) and extracted with EtOAc (100 mL). The organic layer was washed with water (5×50 mL), dried over anhydrous sodium sulfate and concentrated to obtain the crude product that was purified by reverse phase HPLC to yield 7-(2-azido-2-(4-fluorophenyl)ethyl)-10-methyl-2,3,5,6,7,11c-hexahydro-1H-indolizino[7,8-b]indole (25 mg). 1H NMR (CD3OD, freebase) δ (ppm): 7.32 (m, 3H), 7.26 (s, 1H), 7.13 (m, 2H), 7.09 (d, 1H), 5.09 (t, 1H), 4.8 (m, 1H), 4.32 (m, 2H), 3.44 (m, 2H), 3.3 (m, 1H), 3.1 (m, 1H), 3.0 (d, 1H), 2.8 (m, 1H), 2.6 (m, 1H), 2.4 (s, 3H), 2.18 (m, 2H), 2.0 (m, 1H). Separation by chiral HPLC provides diastereomers V-23a-d.
Example 423
Compounds II-266 to II-269 and II-271 to II-299 can be synthesized in an analogous fashion to other compounds described herein and by reference to the PCT publications listed in the General Methods above.
Example B1: Determination of the Ability of Compounds of the Invention to Bind an Adrenergic Receptor
Adrenergic α2B 
To evaluate in radioligand binding assays the activity of compounds of the invention, human recombinant adrenergic α2B receptor expressed in Chinese hamster ovary (CHO) K1 cells (Uhlen, S. et al, Eur. J. Pharmacol. 343(1):93, 1998) in a modified Tris-HCl buffer (50 mM Tris-HCl, pH 7.4, 12.5 mM MgCl2, 1 mM EDTA, 0.2% BSA) was used. Compounds of the invention were incubated with 2.5 nM [3H]Rauwolscine for 60 min at 25° C. Non-specific binding was estimated in the presence of 10 μM Prazosin. Receptor proteins were filtered and washed, the filters were then counted to determine [3H]Rauwolscine specifically bound. Compounds were screened at 1 μM or lower, using 1% DMSO as vehicle. Compounds of the invention were tested in this biochemical assay and percent inhibition of specific binding was determined. Biochemical assay results are presented as the percent inhibition of specific binding in Table B1.
Adrenergic α2A 
To evaluate in radioligand binding assays the activity of compounds of the invention, human recombinant adrenergic α2A receptor expressed in insect Sf9 cells (Uhlen, S. et al, J. Pharmacol. Exp. Ther. 271:1558, 1994) in a modified Tris-HCl buffer (50 mM Tris-HCl, pH 7.4, 12.5 mM MgCl2, 2 mM EDTA) was used. Compounds of invention were incubated with 1 nM [3H]MK-912 for 60 min at 25° C. MK912 is (2S-trans)-1,3,4,5′,6,6′,7,12b-octahydro-1′,3′-dimethyl-spiro[2H-benzofuro[2,3-a]quinolizine-2,4′(1′H)-pyrimidin]-2′(3′H)-one hydrochloride. Non-specific binding was estimated in the presence of 10 μM WB-4101 (2-(2,6-Dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane hydrochloride). Receptor proteins were filtered and washed, the filters were then counted to determine [3H]MK-912 specifically bound. Compounds were screened at 1 μM or lower, using 1% DMSO as vehicle. Compounds of the invention were tested in this biochemical assay and percent inhibition of specific binding was determined. Biochemical assay results are presented as the percent inhibition of specific binding in Table B1.
Adrenergic α1B 
To evaluate in radioligand binding assays the activity of compounds of the invention, rat adrenergic α1B receptor obtained from Wistar Rat liver (Garcia-S'ainz, J. et al, Biochem. Biophys. Res. Commun. 186:760, 1992; Michel, A. et al, Br. J. Pharmacol. 98:883, 1989) in a modified Tris-HCl buffer (50 mM Tris-HCl buffer, pH 7.4, 0.5 mM EDTA) was used. Compounds of the invention were incubated with 0.25 nM [3H]Prazosin for 60 min at 25° C. Non-specific binding was estimated in the presence of 10 μM phentolamine. Receptor proteins were filtered and washed, the filters were then counted to determine [3H]Prazosin specifically bound. Compounds were screened at 1 μM or lower, using 1% DMSO as vehicle. Compounds of the invention were tested in this biochemical assay and percent inhibition of specific binding was determined. Biochemical assay results are presented as the percent inhibition of specific binding in Table B1.
Adrenergic α1D 
To evaluate in radioligand binding assays the activity of compounds of the invention, human recombinant adrenergic α1D receptor expressed in human embryonic kidney (HEK-293) cells (Kenny, B. et al, Br. J. Pharmacol. 115(6):981, 1995) in a 50 mM Tris-HCl buffer, pH 7.4, was used. Compounds were incubated with 0.6 nM [3H]Prazosin for 60 min at 25° C. Non-specific binding was estimated in the presence of 10 μM phentolamine. Receptor proteins were filtered and washed, the filters were then counted to determine [3H]Prazosin specifically bound. Compounds were screened at 1 μM or lower, using 1% DMSO as vehicle. Biochemical assay results are presented as the percent inhibition of specific binding in Table B1.







TABLE B1







Percentage inhibition of ligand binding to aminergic G protein-


coupled receptors by compounds of the invention:










Adrenergic
Adrenergic


Com-
(0.1 μM)*
(0.03 μM)*















pound
α1B
α1D
α2A
α2B
α1B
α1D
α2A
α2B


















 1
32
16
6
74
—
—
—
—


 2
27, 28
13
 4, 19
95
—
—
—
75


 3
51, 54
12
12, 37
100, 103
24
—
4
99


 3a
12, 44
—
16
62
18
—
—
26, 30


 3b
 50, 55, 
18
 21, 22, 
—
 27, 32, 
—
1
 100, 101, 



57, 61

23, 25

34


102, 112


 4
51, 60
12
12, 41
101
—
—
—
106


 4a
52, 57
—
19, 24
104
25
—
5
 99, 103


 4b
58
—
7
—
—
—
—
46


 5
14, 21
4
13
96
—
—
—
100


 5a
18
—
0
57
—
—
—
29, 38


 5b
 23, 30, 
1
 18, 21, 
  82, 100, 
 10, 11, 
—
 4, 6, 15
 81, 86, 



33

22
107
15


 90, 100


 6
8
—
2
—
—
—
—
62


 7
35
—
16
—
—
—
—
59


 7a
28
—
1
—
—
—
—
59


 7b
37
—
25
—
—
—
—
74


 8
58
—
23
—
—
—
—
61


 8a
39
—
15
—
—
—
—
22


 8b
61, 63
—
 8, 12
78
24
—
—
49


 9
5
—
−4
—
—
—
—
36


 9a
11
—
4
—
—
—
—
23


 9b
10
—
10
—
—
—
—
50


 10a
30
—
8
—
—
—
—
34


 10b
28
—
15
—
—
—
—
91


 11a
16
—
−6
—
—
—
—
28


 11b
18
—
13
—
—
—
—
64


 12a
23
—
3
—
—
—
—
24


 12b
8
—
3
—
—
—
—
21


 13
83
—
18
—
—
—
—
92


 13a
75
—
−2
—
—
—
—
37


 13b
91
—
−2, 21
—
68
—
—
100, 102


 14a
43, 44
—
 8, 26
—
17
—
—
97, 98


 14b
25
—
−6
—
—
—
—
14


 15
93
—
19
—
—
—
—
93


 15a
81
—
6
—
—
—
—
65


 15b
89, 93
—
21, 24
—
73
—
—
103


 16a
47
—
9
—
—
—
—
33


 16b
16
—
2
—
—
—
—
2


 17
18
—
19
—
—
—
—
37


 17a
13
—
19
—
—
—
—
32


 17b
16
—
9
—
—
—
—
20


 18a
55
—
50
—
—
—
—
54


 18b
87
—
32
—
—
—
—
61


 19a
75
—
21
—
—
—
—
75


 19b
62
—
9
—
—
—
—
27


 20a
67
—
29
—
—
—
—
28


 20b
94
—
28
—
—
—
—
36


 21a
5
—
−1
—
—
—
—
−2


 21b
−2
—
−3
—
—
—
—
1


 22a
19
—
16
—
—
—
—
22


 22b
9
—
0
—
—
—
—
30


 23a
−20
—
4
—
—
—
—
6


 23b
4
—
1
—
—
—
—
−3


 24a
8
—
8
—
—
—
—
63


 24b
8
—
15
—
—
—
—
29


 25a
4
—
15
—
—
—
—
54


 25b
12
—
18
—
—
—
—
75


 26a
52, 61
—
23, 33
—
32
—
14
101, 107


 26b
15
—
12
100
—
—
—
75, 88


 26c
1
—
19
—
—
—
—
1, 7


 26d
−2
—
0
—
—
—
—
 6, 11


 27a
59, 64
—
 2, 11
94
34
—
—
76, 83


 27b
 6, 16
—
 0, 18
48
—
—
—
30, 36


 28a
41
—
28
—
—
—
—
96


 28b
20
—
24
—
—
—
—
37


 29
24
1
10
100
—
—
—
—


 29a
32, 38
—
35, 39
—
19
—
16
98, 100


 29b
14
—
10
—
—
—
—
46


 30
86
49
63
91
—
—
—
—


 30a
57
—
19
—
—
—
—
79


 30b
89, 91
—
74, 75
—
68
—
42
100, 102


 31a
25, 28
—
19, 27
—
16
—
11
93, 97


 31b
3
—
14
—
—
—
—
36


 32
12
7
28
86
—
—
—
—


 33a
−2
23
26
−3
—
—
—
—


 33b
0
14
−7
2
—
—
—
—


 34
30
2
28
38
—
—
—
—


 34a
11
19
29
20
—
—
—
—


 34b
−2
13
3
1
—
—
—
—


 35a
9
6
20
62
—
—
—
—


 35b
5
−13
12
47
—
—
—
—


 36a
14
—
8
—
—
—
—
33


 36b
11
—
0
—
—
—
—
−1


 37a
−5
—
18
—
—
—
—
2


 37b
−10
—
−20
—
—
—
—
−3


 37c
2
—
6
—
—
—
—
0


 37d
2
—
8
—
—
—
—
−3


 38
20
—
−1
—
—
—
—
56


 38a
11
—
14
—
—
—
—
35


 38b
20
—
−1
—
—
—
—
17


 39
25
—
1
—
—
—
—
89


 39a
38, 33
—
13, 15
92
9
—
5
86


 39b
24
—
1
—
—
—
—
28


 40a
2
—
7
—
—
—
—
27


 40b
−2
—
13
—
—
—
—
29


 41
57
—
24
—
—
—
—
45


 41a
43
—
−9
—
—
—
—
14


 41b
50
—
8
—
—
—
—
50


 42a
15
—
3
—
—
—
—
29


 42b
19
—
12
—
—
—
—
34


 43
21
—
−1
—
—
—
—
24


 43a
33
—
9
—
—
—
—
51


 43b
46
—
13
—
—
—
—
27


 44
−3
—
−1
—
—
—
—
56


 44a
12
—
11
—
—
—
—
33


 44b
18
—
1
—
—
—
—
75


 45a
23
—
−4
—
—
—
—
54


 45b
24
—
16
—
—
—
—
96


 47a
58
—
10
—
—
—
—
40


 47b
70
—
41
—
—
—
—
119


 47c
6
—
4
—
—
—
—
53


 47d
5
—
−3
—
—
—
—
30


 48a
16
—
12
—
—
—
—
58


 48b
14
—
17
—
—
—
—
86


 49a
4
—
1
—
—
—
—
18


 49b
5
—
6
—
—
—
—
19


 51
43
—
20
—
—
—
—
82


 51a
8
—
11
—
—
—
—
21


 51b
36
—
26
—
—
—
—
90


 52a
9
—
5
—
—
—
—
21


 52b
73
—
29
—
—
—
—
93


 53a
12
—
10
—
—
—
—
37


 53b
14
—
12
—
—
—
—
85


 54a
39
—
30
—
—
—
—
105


 54b
71
—
66
—
—
—
—
106


 55
37
—
13
—
—
—
—
63


 55a
28
—
11
—
—
—
—
14


 55b
57
—
7
—
—
—
—
67


 56a
1
—
11
—
—
—
—
20


 56b
6
—
17
—
—
—
—
28


 57a
3
—
22
—
—
—
—
16


 57b
9
—
24
—
—
—
—
84


 58
21
—
−1
—
—
—
—
26


 58a
7
—
9
—
—
—
—
5


 58b
24
—
0
—
—
—
—
39


 59a
11
—
18
—
—
—
—
15


 59b
7
—
12
—
—
—
—
31


 60
65
35
26
93
—
—
—
66


 61
60
37
30
85, 94
28
14
—
65, 80


 62
16
—
1
—
—
—
—
76


 63a
10
—
16
—
—
—
—
83


 63b
−5
—
3
—
—
—
—
41


 64
25
—
12
—
—
—
—
62


 65
−13
—
−3
—
—
—
—
64


 66
48
—
15
—
—
—
—
69


 67
12
—
−7
—
—
—
—
17


 68
2
—
1
—
—
—
—
4


 69a
4
—
11
—
—
—
—
10


 69b
8
—
7
—
—
—
—
19


 70
8
—
10
—
—
—
—
26


 71
11
—
11
—
—
—
—
9


 72
6
—
−2
—
—
—
—
12


 73
17
—
15
—
—
—
—
61


 74
81
57
6
104
—
—
—
—


 74a
91, 96
61
22, 27
101
81
42
—
93


 74b
28
—
14
—
—
—
—
27


 75a
61
—
11
—
—
—
—
77


 75b
16
—
5
—
—
—
—
43


 75c
59
—
−2
—
—
—
—
11


 75d
26
—
49
—
—
—
—
102


 76a
78
—
21
—
—
—
—
92


 76b
71
—
18
—
—
—
—
34


 76c
33
—
5
—
—
—
—
35


 76d
51
—
40
—
—
—
—
91


 77
5, 6
10
−1, 22
91
—
—
—
84


 78
11, 12
22
−7, 18
87
—
—
—
67


 79
34
—
19
—
—
—
—
77


 80
49
—
12
—
—
—
—
81


 81
25
—
26
—
—
—
—
96


 82
16
—
5
—
—
—
—
79


 83
 9, 15
13
21, 29
78
—
—
—
63


 84
69
36
27
84
—
—
—
—


 85
26
17
12
60
−3
—
—
40


 86
62
62
27
77
—
—
—
—


 87
5
24
14
66
—
—
—
—


 88
10
36
2
90
—
—
—
—


 89
79
68
23
57, 79
—
—
—
25


 90
57
20
22
91
—
—
—
—


 90a
74
—
71
—
—
—
—
97


 90b
81
—
82
—
—
—
—
97


 91 
 52, 53,
25, 30
5
 82, 83,
 25, 28,
  7, 11, 
6
53, 56



58
32

87
32
21




 92
77
46
30
77
—
—
—
—


 93
25
6
21
87
—
—
—
—


 93a
37
—
25, 36
—
13
—
14
 63, 102


 93b
1
—
−5
—
—
—
—
26


 94
40
10
11
66
—
—
—
—


 95
52
29
9
105
—
—
—
—


 96
25
3
29
71
—
—
—
—


 97
3
−7
−12
88
—
—
—
—


 98
81, 83
31, 35
26, 32
 96, 103
—
—
—
—


 99
69
34
29
85
—
—
—
—


100
73
47
20
72
—
—
—
—


101
61, 79
45, 48
14, 15
63, 76
—
—
—
—


102
40
21
21
77
—
—
—
—


103
49
20
19
80
—
—
—
—


105
57
36
14
68
—
—
—
—


106
65
45
6
79
—
—
—
—


107
56
63
10
85
—
—
—
—


108
42
21
20
88
—
—
—
—


109
13
21
25
69
—
—
—
—


110
5
35
27
62
—
—
—
—


111
56
77
0
65
—
—
—
—


112
44
40
26
79
—
—
—
—


113
12
3
29
87
—
—
—
—


114
15
15
21
58, 71
—
—
—
42


115
19
24
21
94
—
—
—
—


116
23
26
22
75
—
—
—
—


117
59
—
18
68
—
—
—
—


118
35
7
19
60
—
—
—
—


119
14
−6
14
60
—
—
—
—


120
21, 22
14, 26
45, 48
55, 70
4
3
25
39


121
6
44
16
88
—
—
—
—


122
51
84
13
96
—
—
—
—


124
19
12
−2
63
—
—
—
—


125
−3
1
−4
68
—
—
—
—


126
30
46
12
82
—
—
—
—


127a
26
—
9
74
—
—
—
43


127b
13
—
4
—
—
—
—
1


128a
37, 45
—
31, 34
104
14

9
 97, 100


128b
45
—
22
—
—
—
—
54


129a
73
—
46
—
—
—
—
86


129b
69
—
55
—
—
—
—
89


129c
94, 96
—
29, 35
—
86
—
14
100


129d
94, 99
—
90, 96
—
93
—
87
 97, 104


130a
66, 68
—
82, 89
107
32
—
56
100, 104


130b
 8, 11
—
31, 44
93
2
—
13
89, 92


131a
24
—
10
—
—
—
—
30


131b
36
—
11
90
—
—
—
53, 63


132
28
—
19
—
—
—
—
91


133a
57
—
13
—
—
—
—
52


133b
40, 42
—
34, 39
94
16

27
87, 88


134a
27
—
4
—
—
—
—
42


134b
93, 95
—
23, 29
—
78
—
—
102, 103


135a
60
—
4
—
—
—
—
42


135b
30
—
22
—
—
—
—
68


136a
54
—
16
—
—
—
—
34


136b
90
—
21
—
—
—
—
69


137a
94
—
19
—
—
—
—
104


137b
23
—
6
—
—
—
—
30


138a
61
—
−8
—
—
—
—
63


138b
22
—
4
—
—
—
—
25


139
72
—
−2
87
46
—
—
59, 83


139a
17
—
16
—
—
—
—
 88, 101


139b
11
—
6
—
—
—
—
59


140
37
—
−2
—
—
—
—
49


140a
59
—
11
—
—
—
—
76


140b
18
—
3




52


141
23
—
5
—
—
—
—
76


141a
25
—
−5
—



70


141b
28
—
19
—



79, 86


142a
68
—
19
95
—
—
—
71


142b
83
—
63
—
—
—
—
99


143a
43
—
19
—
—
—
—
77


143b
17
—
0
—
—
—
—
49


144a
57
—
1
—
—
—
—
40


144b
53, 60, 66

3, 4
100, 102
28, 36
—
—
83, 85, 87


145
49
—
6
—
—
—
—
61


146a
41
—
−1
—
—
—
—
37


146b
11
—
21
—
—
—
—
63


147
7
—
19
—
—
—
—
 91, 102


147a
33
—
3
—
—
—
—
72


147b
82
—
36
—
—
—
—
93


148a
23
—
−5
—
—
—
—
52


148b
71, 74
—
37
106
35
—
—
105


148c
6
—
−1
—
—
—
—
16


148d
19
—
−11
—
—
—
—
11


149a
12
—
−4
—
—
—
—
16


149b
16
—
19
—
—
—
—
32


150a
16
—
16
100
—
—
—
88, 96


150b
7
—
5
—
—
—
—
9


151a
11
—
15
—
—
—
—
93


151b
9
—
8
—
—
—
—
37


152a
20
—
17
—
—
—
—
20


152b
7
—
10
—
—
—
—
19


153
17
—
6
—
—
—
—
17


154
86
—
15
—
—
—
—
58


154a
39
—
4
—
—
—
—
31


154b
95
—
5
95
80
—
—
80, 83


155
15
—
14
—
—
—
—
36


155a
9
—
−1
—
—
—
—
10


155b
1
—
5
—
—
—
—
5


156
21
—
1
—
—
—
—
6


157
57
—
6
—
—
—
—
43


158
8
—
−1
—
—
—
—
43


159a
−2
—
10
—
—
—
—
37


159b
53
—
−12
—
—
—
—
52


160a
35
—
−12
—
—
—
—
43


160b
65
—
5
—
—
—
—
41


168
23
—
16
—
—
—
—
32


169
2
—
15
—
—
—
—
20


172a
54
—
18
—
—
—
—
65


172b
92
—
46
—
—
—
—
93


173a
5
—
15
82
—
—
—
61, 68


173b
8
—
−2
—
—
—
—
28


174a
13
—
22
86
—
—
—
62, 71


174b
11
—
6
—
—
—
—
15


175a
11
—
11
90
—
—
—
69, 73


175b
4
—
7
—
—
—
—
4


176a
79
—
32
105
52
—
—
 93, 98, 100


176b
41
—
12
—
—
—
—
67


179
6
—
6
—
—
—
—
8


180
87
74
95
99
70
—
—
91


181
30
32
89
92
−4
—
—
70


182
29
16
69
91
13
—
—
83


183
71
36
93
80
50
—
—
68


183a
77
—
56
—
—
—
—
82


183b
93
—
93, 97
—
—
—
84
98


184
—
—
93
—
60
24
—
95


185
86
58
62
94, 97
63
47
37
73, 77


186
53, 55
51, 55 
54, 72
100, 101
24
31
53
94, 97


187
71
83
63, 84
84, 98
—
—
41
78


188
60
48
66, 90
105
—
—
35
—


189
31, 55
16
81, 86
104, 107
26
—
71
96


190
14, 15
31
70, 89
84, 99
9
—
49
88


191
10, 20
43
89, 98
89, 99
2
—
85
84


193
93
88
77
103
—
—
—
—


193a
89
—
85
—
—
—
—
98


193b
91
—
83
—
—
—
—
104


194a
100
—
98
—
—
—
—
106


194b
100
—
94
—
—
—
—
103


196a
54.6
—
58, 71
—
30
—
37
 93, 103


196b
37
—
19
—
—
—
—
−2


197a
82
—
31
—
—
—
—
81


197b
96
—
56, 77
—
89
—
50
101, 105


198a
24
—
10
—
—
—
—
47


198b
84
—
44
—
—
—
—
103


199a
82
—
96
—
—
—
—
94


199b
88
—
61
—
—
—
—
27


200
83
69
92
—
63
—
81
—


201
50
18
67
36
22
—
—
16


202
52
52
92
22
29
—
—
7


203
71
47
88
41
37
—
—
23


203a
76
—
71
—
—
—
—
36


203b
47
—
31
—
—
—
—
24


204
—
—
87
107
—
—
—
—


205
—
—
69
70
—
—
—
—


206
—
—
86
102
46
42
—
—


207
—
—
90
106
49
39
—
—


208
—
—
101
97
60
41
—
—


209
—
—
80
84
—
—
—
—


210
—
—
88
63
—
—
—
—


211
—
—
88
108
63
44
—
—


212
—
—
66
64
—
—
—
—


213
—
—
98
68, 97
53
53
—
26


214
18
—
58, 64
80
—
—
37
48


215
—
—
97
102
—
—
—
—


216
65
—
76, 98
103, 106
34, 47
38
58
98


217
62
—
74
102
—
—
—
—


218
—
—
—
—
79
60
85
110


219
—
—
—
—
—
3
69
—


221
65
16
56
80
—
—
—
—


222
95
101
96
104
—
—
—
—


223
21
—
69
—
—
—
—
47


224
70
26
52
69
—
—
—
—


225
27
12
75
80
—
—
—
—


226
88
48
85
83
—
—
—
—


227
21
−2
66
98
—
—
—
—


228
64
19
77
42
—
—
—
—


229
17
8
53
90
—
—
—
—


230
94
58
87
93
—
—
—
—


231
48
26
65
87
—
—
—
—


232
87
43
87
102
—
—
—
—


233
73
28
80
103
—
—
—
—


235
48
11
80
96
—
—
—
—


236
94
85
99
98
—
—
—
—


237
80
52
98
99
—
—
—
—


238
67
25
94
98
—
—
—
—


239
19
−11
52
30
—
—
—
—


240
74, 75
44, 47
82, 87
83, 97
—
—
—
—


241
81, 82
47, 49
75, 78
91, 93
—
—
—
—


242
53
37
50
98
—
—
—
—


243
58
45
90, 98
105
—
—
73
—


244
78
42
76
99
—
—
—
—


245
69
35
65
96
—
—
—
—


246
82
68
86
101
—
—
—
—


247
95
81
96
89
—
—
—
—


248
76
31
90
95
—
—
—
—


249
95
82
98
98
—
—
—
—


250
37
22
62
105
—
—
—
—


251
89
53
85
101
—
—
—
—


252
36
13
66
52
—
—
—
—


253
54, 55
18, 24
44, 64
64, 86
—
—
—
—


254a
75
36
58
85
—
—
—
—


254b
63
22
57
79
—
—
—
—


255
55
43
63
96
—
—
—
—


256
47
23
55
58
—
—
—
—


257
51
24
84
100
—
—
—
—


258
93
74
94
99
—
—
—
—


259
71
53
82
98
—
—
—
—


260
45
26
54
92
—
—
—
—


261
50
30
84
84
—
—
—
—


262
52
35
87
74
—
—
—
—


263
1
6
61
54
—
—
—
—


264
79
46
81
82
—
—
—
—


265
50
30
67
70
—
—
—
—


266
63
72
62
92
—
—
—
—


267
7
26
63
85
—
—
—
—


268
57
39
90
94
—
—
—
—


269
36
44
61
83
—
—
—
—


270
50
66
96
76
—
—
—
—


271
65
83
97
71
—
—
—
—


272a
27
12
33
−10
—
—
—
—


272b
30
36
68
72
—
—
—
—


273
88
71
67
89
—
—
—
—


274
28
25
68
27
—
—
—
—


275
75
61
51
94
—
—
—
—


276
86
81
71
101
—
—
—
—


277
71
84
98
97
—
—
—
—


278
62
44
93
98
—
—
—
—


279
79
93
90
92
—
—
—
—


280
76
65
97
98
—
—
—
—


281
67
47
72
90
—
—
—
—


282
33
30
75
101
—
—
—
—


283
63
46
90
89
—
—
—
—


284
83
81
97
76
—
—
—
—


285
63
71
98
97
—
—
—
—


286
26
19
80
60
—
—
—
—


287
81
69
99
98
—
—
—
—


288a
89
88
98
104
—
—
—
—


288b
39
17
67
84
—
—
—
—


289a
51
57
60
90
—
—
—
—


289b
12
−2
53
54
—
—
—
—


290
90
79
80
96
—
—
—
—


291
88
85
102
105
—
—
—
—


292
13
23
58
104
—
—
—
—


293
73
82
96
93
—
—
—
—


294
76
39
94
41
—
—
—
—


295
15
7
69
79
—
—
—
—


296
20
33
60
70
—
—
—
—


297
69
36
50
46
—
—
—
—


298
60
17
54
51
—
—
—
—


299
78
47
52
54
—
—
—
—


300
14
29
67
86
—
—
—
—


301
29
36
87
84
—
—
—
—


302
23
17
81
35
—
—
—
—


303
16
51
62
71
—
—
—
—


304
15
27
79
81
—
—
—
—


305
20
41
93
79
—
—
—
—


306
18
12
78
14
—
—
—
—


307
93
81
93
98
—
—
—
—


308
79
56
86
97
—
—
—
—


309
23
40
57
37
—
—
—
—


310
63
47
69
87
—
—
—
—


311
87
79
91
97
—
—
—
—


312
71
50
56
93
—
—
—
—


313
92
53
73
73
—
—
—
—


314
92
71
91
50
—
—
—
—


315
4
3
59
48
—
—
—
—


316
93
81
90
45
—
—
—
—


317
89
71
61
7
—
—
—
—


318
94
60
95
103
—
—
—
—


319
13
8
63
4
—
—
—
—


320
61
56
66
18
—
—
—
—


321
94
66
59
90
—
—
—
—


322
59
22
58
49
—
—
—
—


323
85
69
92
95
—
—
—
—


324
63
31
67
99
—
—
—
—


325
−1
1
81, 84
−6
—
—
53
—


326
33
35
51
93
—
—
—
—


327
−5
4
58
−4
—
—
—
—


328
95
80
76
93
—
—
—
—


329
68
78
60
104
—
—
—
—


330
98
72
58
99
—
—
—
—


331
53
70
53
99
—
—
—
—


332
41
51
94
86
—
—
—
—


333
65
16
52
88
—
—
—
—


334
91
72
55
82
—
—
—
—


335
82
73
60
99
—
—
—
—


336
98
—
66
—
—
—
—
104


338
16
—
60
—
—
—
—
102


339a
13
—
37
—
—
—
—
86


339b
10
—
64
—
—
—
—
87


II-1a
6
—
15
—
—
—
—
14


II-1b
−7
—
1
—
—
—
—
32


II-2
74
—
49
—
—
—
—
96


II-4a
72
—
35
—
—
—
—
79


II-4b
98
—
57
—
—
—
—
100


II-5
2
—
9
—
—
—
—
4


II-6a
66
—
45
—
—
—
—
85


II-6b
91
—
81
—
—
—
—
102


II-7
95
—
52
—
—
—
—
100


II-8
6
—
9
—
—
—
—
70


II-9
30
—
7
—
—
—
—
78


II-10
7
—
10
—
—
—
—
47


II-11 
63
—
25
—
—
—
—
70


II-11a
9
—
22
—
—
—
—
53


II-11b
76
—
43
—
—
—
—
89


II-12
18
—
11
—
—
—
—
65


II-12a
26
—
25
—
—
—
—
89


II-12b 
11
—
15
—
—
—
—
65


II-13
9
—
9
—
—
—
—
73


II-14a
30
—
34
—
—
—
—
88


II-14b
8
—
17
—
—
—
—
33


II-15a 
61
—
7
—
—
—
—
47


II-15b
5
—
18
—
—
—
—
40


II-16a 
20
—
11
—
—
—
—
39


II-16b
32, 46
—
32
88
16
—
—
65, 73


II-17
8
—
4
—
—
—
—
7


II-18 
−7
−9
14
−15

—
—
—


II-19 
8
—
8
—
—
—
—
21


II-39 
16
13
27
−14
—
—
—
—


II-40

—
—
36
—
—
—
—


II-48 
27
8
26
0
—
—
—
—


II-49a
47
—
34
—
—
—
—
43


II-49b
69
—
18
—
—
—
—
50


II-56
54
11
31
78
—
—
—
—


II-57a 
20
—
22
—
—
—
—
38


II-57b
31
—
31
—
—
—
—
45


II-58
16
—
16
—
—
—
—
58


II-60 
11
—
9
—
—
—
—
54


II-61
—
—
—
47
—
—
—
—


II-62 
14
—
5
—
—
—
—
37


II-63 
55
—
39
—
—
—
—
90


II-64
23
—
−3
—
—
—
—
54


II-65 
10
—
12
—
—
—
—
25


II-66
27
—
0
—
—
—
—
46


II-67 
7
—
−11
—
—
—
—
43


II-68
12
—
5
—
—
—
—
17


II-69
45
—
11
—
—
—
—
14


II-70
—
—
—
34
—
—
—
—


II-71
3
—
−3
—
—
—
—
11


II-72
30
—
25
—
—
—
—
47


II-73
34
—
28
—
—
—
—
33


II-74
11
—
10
—
—
—
—
18


II-75
8
—
15
—
—
—
—
35


II-76
—
—
—
103
—
—
—
—


II-77
54
66
43
108
—
—
—
—


II-78
−11
—
1
—
—
—
—
−9


II-79
7
—
0
—
—
—
—
59


II-80
4
—
3
—
—
—
—
9


II-81
−1
—
15
—
—
—
—
−9


II-82
13
23
45
48, 53
—
—
—
35


II-83
12
—
2
—
—
—
—
24


II-84
2
—
11
—
—
—
—
−11


II-85
−7
—
15
—
—
—
—
−2


II-86
44
—
27
—
—
—
—
35


II-87
11
—
1
—
—
—
—
24


II-88
68
—
−2
—
—
—
—
48


II-89
13
—
−5
—
—
—
—
35


II-90
62
—
19
—
—
—
—
55


II-91
16
—
−2
—
—
—
—
25


II-92
13
—
0
—
—
—
—
25


II-93a 
6
—
7
—
—
—
—
24


II-93b
18
—
4
—
—
—
—
56


II-94a 
10
—
0
—
—
—
—
8


II-94b
7
—
−5
—
—
—
—
24


II-95a
32
—
16
—
—
—
—
53


II-95b
−1
—
−1
—
—
—
—
12


II-96
39
31
49
95
—
—
—
—


II-97
−4
—
4
—
—
—
—
24


II-98a
33
—
12
—
—
—
—
10


II-98b
10
—
19
—
—
—
—
5


II-99a 
12
—
24
—
—
—
—
49


II-99b 
5
—
16
—
—
—
—
7


II-100a
10
—
7
—
—
—
—
12


II-100b 
24
—
4
—
—
—
—
1


II-102
2
—
10
—
—
—
—
49


II-103
1
8
−5
35
—
—
—
—


II-104
3
—
10
—
—
—
—
21


II-105
5
—
 7, 18
27
—
—
—
 5, 30


II-106a 
25
—
18
—
—
—
—
20


II-106b
31
—
8
—
—
—
—
36


II-108a
13
—
−2
—
—
—
—
27


II-108b
−2
—
−6
—
—
—
—
11


II-109a
27
—
2
—
—
—
—
41


II-109b
5
—
−10
—
—
—
—
2


II-110 
25, 36
17
1, 2
47
—
—
—
11


II-111
42
—
3
—
—
—
—
35


II-112a
5
—
10
—
—
—
—
36


II-112b
10
—
3
—
—
—
—
31


II-113a
9
—
−3
—
—
—
—
39


II-113b
5
—
19
—
—
—
—
38


II-114a 
45
—
12
—
—
—
—
40


II-114b
7
—
−5
—
—
—
—
40


II-116
4
—
3
—
—
—
—
43


II-118a
18
—
3
—
—
—
—
27


II-118b
11
—
5
—
—
—
—
−3


II-119
23
53
−4
27
—
—
—
—


II-120a 
99
—
65
—
—
—
—
101


II-120b
100
—
98
—
—
—
—
98


II-121a
97, 98
—
91, 92
—
90
—
65
103, 104


II-121b
93, 96
—
80, 85
—
77
—
54
100, 103


II-122
−2
—
−10
—
—
—
—
47


II-123a
41
—
16
—
—
—
—
62


II-123b 
61
—
75
—
—
—
—
93


II-124a 
−2
—
23
—
—
—
—
26


II-124b
10
—
7
—
—
—
—
18


II-125a
92
—
62
—
—
—
—
100


II-125b
97, 102
—
97, 98
—
89
—
89
103, 106


II-125c
42
—
9
—
—
—
—
67


II-125d
64
—
71
—
—
—
—
88


II-126
−4
—
4
—
—
—
—
4


II-127a
83
—
79
—
—
—
—
105


II-127b
65
—
54
—
—
—
—
104


II-128a
61
—
34
—
—
—
—
97


II-128b
84, 86
—
74, 77
—
56

50
102, 106


II-129
2
—
12
—
—
—
—
1


II-130
43
—
41
—
—
—
—
97


II-130a
92
—
86
—
—
—
—
103


II-130b
3
—
15
—
—
—
—
33


II-131
90
—
85
—
—
—
—
103


II-132a
33
—
8
—
—
—
—
40


II-132b
68
—
22
—
—
—
—
70


II-133
—
—
—
−5
—
—
—
—


II-134a
86
—
19
—
—
—
—
89


II-134b
65
—
6
—
—
—
—
79


II-135a 
48
—
−3
—
—
—
—
34


II-135b
60, 70
—
40
105
26
—
—
103, 105


II-136a
60
—
7
—
—
—
—
36


II-136b
31
—
5
—
—
—
—
32


II-138
57
—
9
—
—
—
—
77


II-139 
34
—
7
—
—
—
—
72


II-140
53
—
3
—
—
—
—
72


II-141
7
—
−2
—
—
—
—
22


II-142 
5
—
−4
—
—
—
—
23


II-143 
13
—
−3
—
—
—
—
22


II-146a
23
—
47
—
—
—
—
102


II-146b
13
—
5
—
—
—
—
43


II-146c
17
—
8
—
—
—
—
42


II-146d
13
—
3
—
—
—
—
16


II-147a 
32
—
57
—
—
—
—
102


II-147b
20
—
15
—
—
—
—
66


II-147c
7
—
3
—
—
—
—
38


II-147d
10
—
4
—
—
—
—
13


II-148 
21
—
27
—
—
—
—
93


II-149a
90
—
53
—
—
—
—
104


II-149b
59
—
27
—
—
—
—
96


II-149c 
49
—
5
—
—
—
—
41


II-149d 
41
—
7
—
—
—
—
44


II-150 
14
—
5
—
—
—
—
30


II-151a
11
—
1
—
—
—
—
27


II-151b 
13
—
11
—
—
—
—
78


II-152a
19
—
9
—
—
—
—
93


II-152b 
2
—
6
—
—
—
—
61


II-152c 
6
—
1
—
—
—
—
14


II-152d 
5
—
8
—
—
—
—
9


II-153 
2
—
2
—
—
—
—
7


II-154
2
—
11
—
—
—
—
73


II-160
 7, 14
15
17, 37
35
—
—
—
39


II-161
7
2
7
13
—
—
—
—


II-163 
66
28
41
86
—
—
—
—


II-164 
12
0
15
40
—
—
—
—


II-171 
95
55
96
94
—
—
—
—


II-187 
54
—
10
—
—
—
—
27


II-212 
29
—
19
—
—
—
—
73


II-213 
−3
—
12
—
—
—
—
11


II-215
—
—
—
−5
—
—
—
—


II-221 
−1
—
10
—
—
—
—
0


II-222
19
—
26
—
—
—
—
99


II-223
9
—
8
—
—
—
—
88


II-224
13
—
22
—
—
—
—
68


II-225 
9
—
−1
—
—
—
—
8


II-226 
15
—
4
—
—
—
—
40


II-227a
25
—
15
—
—
—
—
86


II-227b
8
—
6
—
—
—
—
18


II-227c
20
—
24
—
—
—
—
94


II-227d
12
—
6
—
—
—
—
26


II-228 
−2
—
3
—
—
—
—
10


II-229
3
—
6
—
—
—
—
12


II-230
−2
—
1
—
—
—
—
22


II-231 
11
—
9
—
—
—
—
−2


II-232
3
—
3
—
—
—
—
28


II-234
−8
−1
7
33
—
—
—
—


II-235
58
28
3
45
—
—
—
—


II-236
—
—
—
−4
—
—
—
—


II-238
—
—
—
98
—
—
—
—


II-239
—
—
—
17
—
—
—
—


II-240
57
—
7
—
—
—
—
53


II-241 
5
—
−1
—
—
—
—
−1


II-242 
4
—
2
—
—
—
—
3


II-243
91, 93
—
19
82
79
—
—
58, 61


II-244a 
95
—
22
—
—
—
—
102


II-244b 
12
—
2
—
—
—
—
16


II-245 
27
—
7
—
—
—
—
44


II-246
−2
—
47
—
—
—
—
5


II-247 
3
—
83
—
—
—
—
19


II-248 
4
—
88
—
—
—
—
5


II-249 
6
—
74
—
—
—
—
4


II-250 
−5
—
57
—
—
—
—
6


II-251 
−7
—
81
—
—
—
—
−4


II-252
−1
—
91
—
—
—
—
1


II-253
9
—
54
—
—
—
—
16


II-261
71
—
70
—
—
—
—
103


II-262 
3
—
10
—
—
—
—
11


II-263 
2
—
10
—
—
—
—
10


IV-2
—
—
—
50
—
—
—
—


IV-4
2
15
−3
56
—
—
—
—


IV-8a
49
—
7
—
—
—
—
4


IV-8b
5
—
22
—
—
—
—
3


IV-93a
7
—
18
—
—
—
—
52


IV-93b 
65
—
−1
—
—
—
—
44


IV-209a
89
—
6
—
—
—
—
72


IV-209b
11
—
10
—
—
—
—
13


IV-209c 
98
—
59
—
—
—
—
102


IV-209d 
54
—
8
—
—
—
—
79


IV-210a
70, 75
—
37
—
43
—
—
101, 103


IV-210b
10
—
8
—
—
—
—
29


IV-210c
−4
—
1
—
—
—
—
10


IV-210d
19
—
13
—
—
—
—
87


V-1
15
—
35
—
—
—
—
102


V-1a
20
—
36
—
—
—
—
88


V-1b
57
—
29
—
—
—
—
102


V-2
49
—
2
—
—
—
—
61


V-3
22
—
40
—
—
—
—
71


V-14a
0
—
18
—
—
—
—
7


V-14b
2
—
3
—
—
—
—
0


V-15
4
—
7
—
—
—
—
20


V-18a
78
—
13
—
—
—
—
57


V-18b
95
—
57
—
—
—
—
98


V-21a
68
—
62
—
—
—
—
98


V-21b
34
—
43
—
—
—
—
93


V-22
28
—
18
—
—
—
—
90


V-23
94
—
109
—
—
—
—
105





*Where shown, some compounds were tested in repeat assays, each datapoint is shown.













TABLE B2







Ki values of compounds of the invention:











Compound
α2B
α2A
α1B
α1D


No.
(nM)
(nM)
(nM)
(nM)














 3
0.64
0.26
—
—


 3a
27.41
—
—
—


 3b
0.26, 0.28, 0.46
139, 166, 222
51
258


 4a
0.64
176
—
—


 5a
35
—
—
—


 5b
0.95, 1.06, 4.53
152, 192, 195
184
—


 8b
11.65
2104
—
—


 13b
0.62
199
—
—


 14a
1.92
123
—
—


 15b
0.64
112
—
—


 26a
0.56
113
—
—


 26b
3.06

—
—


 27a
4.32
1101
—
—


 27b
43.43
3713
—
—


 29a
1.09
77.23
—
—


 30b
1.13
14.25
—
—


 31a
1.58
167
—
—


 39a
2.50
1659
—
—


 74a
1.42
234
4.72
—


 60
5.84
—
—
—


 61
5.89
—
—
—


 89
32
—
—
—


 91
 9.84, 10.68, 11.97
—
—
—


 93a
1.14
90.50
—
—


114
17.38
—
—
—


120
20.52
65.83
—
—


127a
15.14
—
—
—


128a
0.97
98.62
—
—


129c
0.77
88.55
—
—


129d
0.35
1.87
—
—


130a
1.66
6.91
—
—


130b
2.52
72.60
—
—


131b
7.95
—
—
—


133b
2.42
59.45
—
—


134b
0.43
102
—
—


139a
2.36
—
—
—


139
8.12
390
—
—


141b
3.44
—
—
—


144b
1.70, 2.36
—
—
—


148b
0.43
—
—
—


147
1.49
—
—
—


150a
1.57
—
—
—


154b
3.33
—
—
—


173a
8.77
—
—
—


174a
7.91
—
—
—


175a
4.42
—
—
—


176a
0.53
—
—
—


183b
—
2.72
—
—


184
—
184
—
—


185
3.80
20.97
—
—


186
0.52
11.04
—
—


187
4.43
17.89
—
—


189
0.86
2.86
—
—


190
2.26
12.83
—
—


191
3.23
2.10
—
—


196a
1.83
16.80
—
—


197b
0.78
11.90
—
—


200
—
1.63, 3.21
—
—


204
—
2.48
—
—


206
—
1.12, 6.79
—
—


207
—
1.16
—
—


213
26.30
—
—
—


214
12.91
22.67
—
—


216
0.95
9.59
—
—


243
—
3.86
—
—


325
206
9.88
—
—


II-16b
5.58
—
—
—


II-82
26.76
—
—
—


II-105
152
—
—
—


II-121a
—
4.52
—
—


II-121b
0.22
9.18
—
—


II-125b
0.16
1.21
—
—


II-128b
0.49
13.07
—
—


II-135b
0.53
—
—
—


II-243
9.44
—
—
—


IV-210a
0.33
—
—
—


V-1
0.51
—
—
—









Example B2. Functional Activity on Recombinant Adrenergic α1B, Adrenergic α2A, Adrenergic α2B and Adrenergic α1D Receptors Using Aequorin and GTPγS Functional Assays

To study the functional activity of compounds of the invention on the human recombinant adrenergic α2B, adrenergic α2A, adrenergic α1B or adrenergic α1D with Aequorin functional assays and on the human recombinant adrenergic α2B receptor with GTPγS assay, CHO-K1 cell lines expressing adrenergic α2B, adrenergic α2A, adrenergic α1B or adrenergic α1D recombinant receptor, mitochondrial apoaequorin and Gα16 were used for the Aequorin assay. CHO-K1 cell line expressing the recombinant α2B receptor was amplified to prepare membranes used for the GTPγS assay.
The following reference agonists were used as both the reference ligand in agonist mode and as the agonist that needs to be inhibited in antagonist mode.
















α1B
α1D
α2A
α2B
α2B


Assay
(aeq)
(aeq)
(aeq)
(aeq)
(GTPgS)







Agonist
Cirazoline
Cirazoline
UK
Oxyme-
Guanfacine


ligand


14304
tazoline









Aequorin Assay Procedure:
Aequorin adrenergic α1B (FAST-008A) (FIG. 5), adrenergic α2A (FAST-006A) (FIG. 3) or adrenergic α2B (FAST-007A) (FIGS. 1, 2, 3, 6) cells were grown 18 h prior to the test in media without antibiotics. They were then detached by gentle flushing with PBS-EDTA (5 mM EDTA), recovered by centrifugation and re-suspended in “assay buffer” (DMEM/HAM's F12 with HEPES+0.1% BSA protease free). Cells were incubated at RT for at least 4 h with Coelenterazine h (Molecular Probes). Dose response curves with reference compounds were performed before testing the compounds of the invention. The α1B reference agonist and antagonist were cirazoline and qinazoline, respectively. The α2A reference agonist and antagonist were UK14,304 and rauwolscine, respectively. The α2B reference agonist and antagonist were oxymetazoline and rauwolscine, respectively.
For agonist testing, 50 μL of cell suspension were injected on 50 μL of test compound or reference agonist plated in a 96-well plate. The resulting emission of light was recorded using the Hamamatsu Functional Drug Screening System 6000 (FDSS 6000). For antagonist testing, following an incubation of 15 min. after the first injection, 100 μL of reference agonist at a concentration corresponding to its EC80 was injected on the 100 μL of the mixture of cell suspension and test compound. The resulting emission of light was recorded using the same luminometer as for agonist testing. To standardize the emission of recorded light (determination of the “100% signal”) across plates and across different experiments, some of the wells contained 100 μM digitonin or a saturating concentration of ATP (20 μM). Plates also contained the reference agonist at a concentration equivalent to the EC80 obtained during the test validation.
Agonist activity of test compound was expressed as a percentage of the activity of the reference agonist at its EC100 concentration. Antagonist activity of test compound was expressed as a percentage of the inhibition of reference agonist activity at its EC80 concentration.
Compounds were tested for agonist & antagonist activity at the human adrenergic α1B (FAST-008A), adrenergic α2A (FAST-006A) or adrenergic α2B (FAST-007A) at the following nanomolar concentrations, in duplicate: Agonist (nM): 0.3, 1, 3, 10, 30, 100, 300, 1000, 3000, 10000; Antagonist (nM): 0.15, 0.5, 1.5, 5, 15, 50, 150, 500, 1500, 5000.
GTPγS Assay Procedure:
The procedure was carried out with the following: assay buffer [20 mM HEPES pH 7.4; 100 mM NaCl, 10 μg/mL saponin, 1 mM MgCl2]; membranes [Recombinant CHO-K1-adrenergic α2B membrane extracts thawed on ice and diluted in assay buffer to give 10 μg/well and kept on ice]; GDP [diluted in assay buffer to give 3 μM final concentration]; beads [PVT-WGA (Amersham, RPNQ0001), diluted in assay buffer at 0.5 mg/well]; GTPγ35S [(PerkinElmer NEG030X), diluted in assay buffer to give 0.1 nM final concentration]; ligand [Guanfacine (Tocris, 1030) as reference agonist and Rauwolscine (Tocris, 891) as reference antagonist, diluted in assay buffer]. Membranes were mixed with GDP (volume:volume) and incubated for at least 15 min. on ice. In parallel, GTPγ[35S] was mixed with the beads (volume:volume) just before starting the reaction.
For agonist testing, the following reagents were successively added in the wells of an Optiplate (Perkin Elmer): 50 μL of test or reference ligand, 20 μL of the membranes:GDP mix, 10 μL of assay buffer and 20 μL of the GTPγ[35S]:beads mix. For antagonist testing, the following reagents were successively added in the wells of an Optiplate (Perkin Elmer): 50 μL of test or reference ligand, 20 μL of the membranes:GDP mix, and then after an incubation of 15 min. at RT, 10 μL of reference ligand at historical EC80 concentration and 20 μL of the GTPγ[35S]:beads mix.
The plates were covered with a top seal, mixed on an orbital shaker for 2 min, and then incubated for 1 h at RT. Then the plates were centrifuged for 10 min. at 2000 rpm, incubated at RT 4 h and counted for 1 min/well with a Perkin Elmer TopCount reader.
Compounds were tested for antagonist activity at the human adrenergic α2B receptor (FAST-007G) (FIG. 4) at the following nanomolar concentrations, in duplicate: Agonist and antagonist (nM): 0.3, 1, 3, 10, 30, 100, 300, 1000, 3000, 10000.
Inverse Agonist Activity
SPA 35S-GTPgS and Radioligand Binding experiments were conducted with Euroscreen membrane preparations. Compound was tested for inverse agonist activity at the human Adrenergic a2A receptor using GTPg35S binding functional assay (FAST-006G) in dose-response and in duplicates. As shown in the FIG. 28, Compound 129d showed inverse agonist activity to adrenergic α2A receptor.
Example B3 Cell Culture and Cell Viability Assay
SH-SY5Y cells cultured in DMEM/F12 media supplemented with 10% FBS were seeded in 96-well microplates at 150,000 cells/cm2. After 24 h, cells were depleted from FBS and kept in culture for 24 h before the experiment. Cells were then treated with 4-Br-A23187 (2 μM), hydrogen peroxide (300 μM) or the mitochondrial toxin rotenone (25 μM) in the presence of vehicle or Compound of the Invention for 24 h. Cell death was determined by measurements of LDH release according to the Cytotoxicity Detection KitPlus (Roche, Mannheim, Germany). Cell viability was determined by measuring the capacity of cells to metabolize MTS tetrazolium (MTS) according to the Cytotoxicity Detection KitPlus (Roche, Mannheim, Germany) and MTS reduction is assessed by the CellTiter 96® AQueous One Solution Cell Proliferation assay (Promega Corporation, Madison, Wis., USA). Compounds were screened at 10 nM, using DMSO as vehicle. Assay results for the experiments with hydrogen peroxide are presented as the LDH release (cell death) of untreated cells (control), hydrogen peroxide-treated cells (vehicle), and co-incubation of hydrogen peroxide with Compounds of the Invention treated cells normalized to the vehicle (FIG. 17A). This assay assesses the ability of the test compounds to protect against cell death that is mediated by mitochondrial dysfunction. In the assay, the calcium ionophore 4-Br-A23187 is used to challenge the cells, causing calcium levels to rise in mitochondria, which leads to depolarization and cell death. Test compounds are assessed for their ability to prevent cell death in response to challenge with 4-Br-A23187.







TABLE B3







Relative Cell Death protection of compounds of the invention













Relative cell death





Compound No.
protection
SE
p value
















Control
43.78
2.72
<0.0001



Vehicle
100
0
—



Dimebon (DMB)
91.15
2.07
0.0128



3b
86.70
1.55
0.0033



39a
82.94
2.11
0.0013



4a
81.64
2.06
0.0009



5b
73.73
2.55
0.0005










Assay results for the experiments with Br-A23187 are presented as the MTS reduction capacity (cell viability) of untreated cells (control), 4-Br-A23187-treated cells (vehicle), and co-incubation of Br-A23187 with Compounds of the Invention treated cells and using p-trifluoromethoxyphenylhydrazone (FCCP) at 10 μM for 30 min as a control (FIG. 17B)







TABLE B4







Relative cell viability protection of compounds of the invention











Relative cell viability




Compound No.
protection
SE
p value













Control
0.3945
0.04025
—


Vehicle
0.23688
0.00966
 0.0034


Dimebon (DMB)
0.35375
0.02209
ns.


39a
0.36
0.00668
ns.


4a
0.34625
0.01367
ns.


5b
0.37475
0.01533
ns.


3b
0.36725
0.0224
ns.


FCCP
0.1035
2.89E−04
<0.0001









Example B4. Cell Culture and Cell Viability Assay

Cell Culture. SH-SY5Y cells stably transfected with a doxycyline-inducible wild-type α-synuclein (α-syn) gene along with control SH-SY5Y cells over-expressing the β-galactosidase (β-gal) gene (a gift from L. Stefanis, Division of Basic Neurosciences, Biomedical Research Foundation of the Academy of Athens, Athens, Greece) are cultured as described by Vekrellis et al. (Vekrellis K, Xilouri M, Emmanouilidou E, Stefanis L. (2009). Inducible over-expression of α-syn in human neuronal cells leads to caspase-dependent non-apoptotic death. J Neurochem 109, 1348-1362). In accordance with this method, cells are cultured and maintained in RPMI 1640, 10% fetal bovine serum supplemented with 250 μg/mL G418 and 50 μg/mL Hygromycin B. Expression of α-syn is switched off in stock cultures with doxycycline (2 μg/mL). For experimental procedures, cells are plated at (4−8×104 cells/cm2) and differentiated in absence of doxycycline and in the presence of 20 μM all-trans retinoic acid (RA) (Sigma, St Louis, Mo., USA).
Viability Assay: Cells are cultured in 96-well plates. After 24 h, cells are treated with RA and Compounds of Invention at 0.1 and 10 nM in the absence of doxycyline. Culture medium with RA and drugs is fully replaced after 7 days. Cell viability is measured by the release of lactate dehydrogenase (LDH) from necrotic cells into the culture medium and by measuring the capacity of cells to metabolize MTS tetrazolium (MTS) after 14 days in culture. LDH leakage is assessed according to the Cytotoxicity Detection KitPlus (Roche, Mannheim, Germany) and MTS reduction is assessed by the CellTiter 96® AQueous One Solution Cell Proliferation assay (Promega Corporation, Madison, Wis., USA).
Assay results for the experiments with α-syn over-expression are presented as the MTS reduction capacity (cell viability) of control cells (+dox), cells over-expressing α-syn (−dox), and cells over-expressing α-syn incubated with Compounds of the Invention at 0.1 nM (FIG. 18A) or 10 nM (FIG. 18B).







TABLE B5







Relative cell viability protection of compounds


of the invention at 0.1 nM (FIG. 17A)













Relative cell viability





Compound No.
protection
SE
p value
















+dox (control)
100
2.32




−dox
61.46
2.42



Dimebon (DMB)
70.53
1.74
0.0125



3b
70.84
1.25
0.0007



39a
72.53
3.07
0.0177



4a
73.39
2.41
0.0058



5b
76.52
3.24
0.0039

















TABLE B6







Relative cell viability protection of compounds


of the invention at 10 nM (FIG. 17B)













Relative cell viability





Compound No.
protection
SE
p value
















+dox (control)
100
2.32




−dox
61.46
2.42



DMB
85.70
3.10
<0.0001



Cpd3b
78.32
2.54
0.0007



Cpd39a
80.85
3.48
0.001



Cpd4a
77.46
2.28
0.0007



Cpd5b
85.29
3.92
0.0004










Immunoblotting of α-Synuclein and α-Synuclein Aggregates: Cells stably expressing α-synuclein are cultured in 6-well plates at a density of 4×104 cells/cm2 cells per well. Cells are differentiated and treated with Compound of the Invention at 10 nM in absence of dox after 24 h of plating. Drug treatments are repeated after 7 days in freshly prepared medium containing RA. After 14 days, cells are washed twice with cold PBS and lysed in lysis buffer containing 1% Triton X-100, 20 mM HEPES, 150 mM NaCl, 10% glycerol, 1 mM EGTA, 1.5 mM MgCl2, 1 mM PMSF pH 7.4, and 1× protease inhibitor mixture (Roche, Mannheim, Germany). Lysates are homogenized and subjected to four successive freeze-thaw cycles to disrupt membranes. Triton soluble fractions and triton insoluble pellets are obtained by ultracentrifugation at 100,000×g for 30 min at 4° C. The concentration of protein in each fraction is determined by BCA assay (Thermo Scientific). Samples from total, soluble and triton insoluble fractions, are boiled in 1× sample buffer (20 mM Tris, 1% glycerol, 180 mM (3-mercaptoethanol, 0.003% bromophenol blue, and 2% SDS, pH 6.8), loaded on 12% SDS-PAGE gels, and transferred to polyvinylidene difluoride (PVDF) membranes (0.2 μM-pore immobilon Biorad). Membranes are blocked in 1X TBS-Tween (20 mM Tris, pH 7.4, 150 mM NaCl, and 0.2% Tween 20) containing 5% milk for 1 h and incubated overnight at 4° C. with the following primary antibodies in blocking solution at the indicated dilutions: monoclonal anti-α-synuclein α-syn-1 (1:1000; BD Transduction Laboratories). (Perrin, R. J., Payton, J. E., Barnett, D. H., Wraight, C. L., Woods, W. S., Ye, L., and George, J. M. (2003). Epitope mapping and specificity of the anti-α-_synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines. Neurosci Lett 349, 133-135), and monoclonal vimentin (1:1000; BD PharMingen). Primary antibodies are detected with secondary anti-mouse antibodies conjugated to HRP (1:5000).
Isolation of RNA and RT-quantitative PCR (RT-qPCR): SH-SY5Y cells stably over-expressing α-syn are treated with Compound of the Invention (10 nM). Total RNA from these cells as well as control cells not treated with Compound is extracted using the E.Z.N.A RNA extraction Kit (OMEGAbiotek, Norcross, Ga.). 1 μg of RNA is reverse transcribed to cDNA using the M-Mulv reverse transcriptase enzyme (Promega Corporation, Madison, Wis., USA). RT-qPCR of cDNA templates is carried out using TAQMAN probes for human α-synuclein (Hs00240906_M1) and TAQMAN masterMix (Applied Biosystems) and a Mx3005P real-time PCR system (Agilent Technologies Inc., Santa Clara, Calif.). Levels of alpha-tubulin mRNA are used to normalize the amounts of total RNA between samples. Fold changes are calculated as described by (Pfaffl, M. W. (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29, e45).
Example B5. α2B Pharmacology: Studies in Spontaneously Hypertensive Rat (SHR) Model of Hypertension
Male spontaneously hypertensive rats (SHR), approximately 3 months of age and weighting approximately 250 grams were utilized. Free access to standard lab chow for rats and reverse osmosis (RO) water was granted. All aspects of this work, including housing, experimentation and disposal of animals were performed in general accordance with the Guide for the Care and Use of Laboratory Animals (National Academy Press, Washington, D.C., 1996).
The animals were anaesthetized with sodium pentobarbital (50 mg/kg IP). The left carotid artery when compound dosed orally (PO) or subcutaneously (SC); and both left carotid and femoral artery when compound dosed intravenous (i.v.) were cannulated with a polyethylene catheter (38 cm in length; PE60, Portex, Ltd.) connected with a polyurethane tubing (12 cm in length; PU-40, Cat. #BB520-40, Scientific Commodities, Inc.), which was tunneled under the skin and exited through the nape of the neck. The arterial cannula was connected to a pressure transducer through a swivel system, allowing free roaming during continuous recording of mean arterial pressure and heart rate. The animals were housed individually with food and water freely available during recovery. On the following day, the arterial cannula was connected via a Statham (P 23×L) pressure transducer to a NEC/San-Ei amplifier and data acquisition and analysis system (Power Lab 8/SP) for direct mean arterial pressure and heart rate measurements.
The test compounds, dissolved in sterile saline, were administered subcutaneously (SC) or orally (PO), or by intravenous (i.v.) bolus administration in two minutes or the escalating doses of compound administration in every 30 minutes, with each dose and its strength delivered over 2 minutes as shown in the respective figures; the internal standard phentolamine was given by oral gavage. The control group received vehicle alone. Immediately before (−10 min and −5 min) and at 15 min, 30 min, 1 hr, 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, and 4 hr post-dosing, systolic pressure blood pressure values were recorded.
Certain compounds of the invention, when they were administered SC route or PO, remarkably lowered systolic blood pressure from 15 minutes through 2.5 hours and the effect was still evident throughout the 4 hour study period (See FIG. 7). In addition, compound 3 was associated with a dose-dependent reduction in systolic blood pressure throughout the 4 hour study period (FIG. 8). As illustrated, compound 3b (FIG. 9) and compound 13b (FIG. 10) lowered systolic blood pressure in SHR rats. Compound 41a, a mixed inhibitor of α2B and α1B markedly lowered blood pressure in SHR rats (FIG. 10). When Compound 144b was tested i.v. bolus in 2 minutes, a marked reduction in systolic blood pressure was found (FIG. 19). Compound 27a, Compound 176a and Compound 26a were tested escalating doses (1, 3, 10 and 30 mg/kg/iv for every 30 minutes), their systolic blood pressure lowering effects were robust (FIG. 20, FIG. 21, and FIG. 22 respectively). Compound 27a had a neutral effect on heart rate when systolic blood pressure falls suggesting a peripheral effect (data not shown).
Example B6. α2B Pharmacology: Studies in Healthy Dogs and Dexmedetomidine (DEX) Induced Beagle Dog Model of Hypertension
These studies were conducted in both acute and chronic modes.
Four adult beagle dogs of both sex and weighted around 10 kg were chosen for the acute studies after a preliminary qualitative electrocardiogram/ECG, clinical pathology and physical examination. Upon arrival at the laboratory, the dogs were weighed and acclimated for a period of one week. Lab Diet certified canine diet #5007, PMI Nutrition International Inc was made available ad libitum to all dogs except during fasting periods. The dogs were surgically implanted with a pressure transducer equipped telemetry transmitter under sodium pentobarbitone anesthesia. The transmitter assembly was secured internally, the fluid-filled catheter was placed into an appropriate artery.
In the acute studies, the test compounds 3b and 5b at different doses (dosing sequences provided in Table B7 for compound 3b and Table B8 for compound 5b) was administered by oral gavage, 30 minutes prior to intravenous dexmedetomidine (5 μg/kg) challenge. Dexmedetomidine administration was enabled by prior placement of a peripheral intravenous line. The same four dogs were received all four treatments in the order noted in the table below, with at least a 3-day washout period between treatments.







TABLE B7







Acute dosing sequence for Compound 3b









Compound 3b - 30 minute
Dexmedetomidine



Pretreatment (mg/kg, p.o.)
Challenge (μg/kg, i.v.)
Number of Dogs












18
0
4


18
5
4


6
5
4


2
5
4
















TABLE B8







Acute dosing sequence for Compound 5b









Compound 5b - 30 minute
Dexmedetomidine



Pretreatment (mg/kg, p.o.)
Challenge (μg/kg, i.v.)
Number of Dogs












0
5
4


2
5
4


6
5
4


18
5
4


2
0
4


6
0
4


18
0
4









In another acute study with compound 41a, the test agent was administered a dose of 6 mg/kg by oral gavage to 4 healthy dogs; and the blood pressure monitored for a period of 4 hours.
For the chronic study mode (see Table B9), the test compound 3b at 3 doses was administered by oral gavage once on day 1 and then twice/day on days 2 to 14, and finally once on day 15. The dexmedetomidine was administered on day-4 to check its effectiveness in inducing blood pressure, and once following the morning dose of compound 3b or vehicle on days 2, 7 and 14. Blood pressure and heart rate data were collected 1 h prior & 4 h post-morning dose on days 1, 2, 7, 14 and 15 to allow the appropriate data comparisons. Blood aliquots were saved at 4 h post-morning dose for exposure determination.







TABLE B9







Chronic dosing sequence and study design for Compound 3b









Compound 3b—30 




minute




Pretreatment 
Dexmedeto-



(mg/kg, p.o.)
midine



with b.i.d. regimen
Challenge



for 14 days
(μg/kg, i.v.)
Number of Dogs





 0
5
6


 6
5
6


18
5
6












Day














−4
1
2
7
14
15





Compound
—
am
am/pm
from day 2
to day 14
am


dosed on



am/pm
am/pm



DEX*
am
—
am
am
am
—





*DEX administered 30 min following am dose of compound 3b.






In both acute and chronic studies, dogs were weighed before dosing. Cardiovascular evaluations at each dose of test compound were collected with animals gently restrained in a sling. Dogs were placed in the sling at least 1 hour prior to dose administration, and after at least 30 minutes of stable baseline data collection. The dogs were monitored continuously for 3-4 hours subsequent to test compound administration and summarized in 5-minute bins. The systolic blood pressure was collected. Data was reported as mean±SEM or mean as presented in the Figures.
In acute studies, oral administration of compound 3b dose-dependently reduced systolic blood pressure in both healthy and dexmedetomidine induced dogs that were tested in the acute mode. Data on dexmedetomidine induced dogs is presented in FIG. 11. Compound 5b as well dose-dependently reduced systolic blood pressure (FIG. 12) in both healthy and dexmedetomidine induced (FIG. 13) dogs tested. Compound 41a, mixed inhibitor of α2B and α1B caused a robust and long lasting reduction in systolic blood pressure (FIG. 14) in all the 4 healthy dogs, with a slight decrease or neutral effect but not with an expected raise on heart rate, i.e., blocking compensatory tachycardia when blood pressure falls suggests a peripheral mode of action. Compound 41a effects on several cardiovascular parameters and body temperature are also comparable with that of the same class (A1B) of marketed drug prazosin.
In chronic studies, oral administration of compound 3b dose dependently reduced systolic blood pressure on day 1 and 15 in healthy dogs; and dexmedetomidine induced dogs on day, 2, 7 and 14 of the 15-day study. Data on systolic blood pressure on day 1 in healthy dogs and dexmedetomidine induced dogs on day 2 are shown in the FIG. 15 and FIG. 16, respectively.
Adrenergic receptors α2B and α2A mixed inhibitor's pharmacology —Studies in Spontaneously Hypertensive Rat (SHR) Model of Hypertension: Similar to dosing regimen for selective antagonists of adrenergic receptor α2B, the mixed inhibitors (e.g., Compound 129d) was dosed orally (PO) or intravenous (i.v bolus or escalating doses) to SHR rats. When compound 129d was tested oral or iv bolus or i.v. escalating does, its effects on systolic blood pressure is robust (see FIG. 23, FIG. 24 and FIG. 25) with tachycardia; and it is a perfect example that a compound that is an adrenergic receptor α2B antagonist also showing adrenergic receptor α2A antagonist and/or inverse agonist activity may find use reducing blood pressure in an individual with hypertension who is also suffering from metabolic syndrome.
Example B7. Peripheral and Central Effects of Compound 3d on Blood Pressure in Conscious Rabbits
Methods: Four adult New Zealand White rabbits of both sexes were chosen for these studies. The experiments were conducted in accordance with the Australian code of Practice for the Care and use of Animals for Scientific Purposes and approval was sought from the Animal Experimental Committee of Alfred Hospital, Baker IDI, Melbourne, Australia. The conscious rabbits were implanted with an intravenous catheter in marginal ear vein or by centrally by intracisternal catheter interfaced to a pressure transducer connected to a suitable recorder. To unveil peripheral effects of Compound 3b, two sets of acute studies were conducted in rabbits. In the first set of studies, Compound 3b was dosed to rabbit intravenously for a dose-response study with cumulative doses starting 0 (Ringer's Lock solution as a vehicle), 0.1, 0.3, 1, 3.2 and 10 mg/kg where each dose was tested on a separate day. A single intravenous bolus dose at 3 mg/kg was given and a time-course study was conducted in the second set of studies. Systolic, diastolic, mean and diastolic blood pressures were recorded in both the studies. Data collections were made for 3 hours in the second set of studies. Heart rate (HR) was derived electronically using an algorithm to determine HR from pulse interval. In a separate set of studies, Clonidine (positive control) was tested where all experimental procedures including dose-regimen were identical to that of the studies with Compound 3d.
Results: The mean arterial pressure responses to Compound 3d are dose-dependent in the dose-response study with cumulative doses (FIG. 26, first panel). Compound 3b caused a maximum arterial blood drop of −11.6 mmHg at a dose of 10 mg/kg. This effect is similar to the effect on diastolic blood pressure and greater than on systolic blood pressure (FIG. 26, second and third panels). The dose that produced 80% of the maximum drop in blood pressure is 3 mg/kg. The reduction in blood pressure is associated with tachycardia (FIG. 26, fourth panel). Clonidine produced a maximum drop of arterial blood pressure of −6 mmHg before the blood pressure reversed back (FIG. 26, first panel). In a single bolus dose at 3 mg/kg time-course study, Compound 3b produced relatively−6 mmHg drop in arterial blood pressure and it is stable from 90 to 180 minutes and no indication of reversal of the effect (FIG. 27, first panel). Identical effects were seen with systolic and diastolic blood pressures (FIG. 27, second and third panels). These findings suggest that Compound 3b dose-dependently lowers blood pressure, most prominently mean arterial blood pressure, and these effects are stable for a period for 3 hours when it is administered intravenously.
In addition to studying the effect of Compound 3b on blood pressure and heart rate when the compound is administered intravenously, the blood pressure and heart rate effect of Compound 3b will also be measured following infusion of the compound directly into the brain with the cannula delivering the compound placed directly into the 4th ventrical of the brain. Several doses will be tested for cardiovascular effects following direct brain infusion. Comparison of the blood pressure effects following intravenous and ventricular infusion will determine whether the compound exerts its cardiovascular actions by the brain.
The long duration of blood pressure effect of Compound 3b suggests a reduction in blood volume that might result from diueresis and/or the movement of fluid from the vascular space to the extravascular space. This will be studied further by measuring the effect of Compound 3b as well as other α2B antagonists on hematocrit as agents that reduce blood volume should increase hematocrit. Characterization of the effect of α2B antagonists on renal function will also be studied by measuring urine volume, urine sodium and urine potassium using methods described by Burke et al. (Effects of chronic sympatho-inhibition on renal excretory function in renovascular hypertension Sandra L. Burke, Roger G. Evans and Geoffrey A. Head. Journal of Hypertens 29:945-952 (2011).
Example B8. Human Clinical Studies
The compound is studied in a clinical trial of hypertensive patients who have not reached their blood pressure goals on current therapy. The target patient population are patients with refractory hypertension that have not reached their blood pressure goals despite use of at least 3 different blood pressure agents. The study compares the active compound against a matched placebo compound with the primary objective of comparing mean blood pressure change from baseline to the end of the study between the active compound and placebo.
All references throughout, such as publications, patents, patent applications and published patent applications, are incorporated herein by reference in their entireties.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is apparent to those skilled in the art that certain minor changes and modifications will be practiced. Therefore, the description and examples should not be construed as limiting the scope of the invention.

## Claims

1. A method of lowering blood pressure in an individual in need thereof comprising administering to the individual an effective amount of a compound of the formula (A-III):




or a salt, solvate or N-oxide thereof, wherein:
R1 is H; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; or —C(O)O—C1-C5 alkyl; or is taken together with R2a or R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R4a or R5a, where present, to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety;
each n and m is 1, or n is 0 and m is 1, or n is 1 and m is 0;
R2a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R1 or R5a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R3a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R4a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R3a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R1 or R4a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R2a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R5a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R4a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R2a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety; or is taken together with R5a, where present, to form a methylene (—CH2—) moiety;
R5a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R2a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R3a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety; or is taken together with R4a, where present, to form a methylene (—CH2—) moiety;
each R2b, R3b, R4b and R5b is independently H, optionally substituted C1-C5 alkyl, optionally substituted C2-C5 alkenyl, or optionally substituted aryl;
X is N or CR6a;
t is 1, 2 or 3;
each R6 and R6a is independently H; hydroxyl; halo; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl; optionally substituted C1-C5 alkoxy; or optionally substituted —C(O)C1-C5 alkyl;
R7 is H; halo; optionally substituted C1-C5 alkyl; or optionally substituted aryl; or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety; or is taken together with R9 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R8 is H; halo; hydroxyl; N(R11)R12; SR13, S(O)R13; SO2R13; —OC(O)N(R14)R15; —OC(O)-aryl; —OC(O)-heteroaryl; or —OC(O)C1-C5 alkyl optionally substituted with amino; or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety; or is taken together with R10 to form a bond;
R9 is H or optionally substituted C1-C5 alkyl; or is taken together with R7 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R10 is H or optionally substituted C1-C5 alkyl; or is taken together with R8 to form a bond;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl; or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl; or R14 and R15 are taken together to form a C3-C5 alkylene; and
Q is unsubstituted aryl; unsubstituted heteroaryl; aryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino; or heteroaryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.

2. The method of claim 1, wherein the method reduces systolic blood pressure of the individual.

3. The method of claim 1, wherein the method reduces diastolic blood pressure of the individual.

4. The method of claim 2, wherein the method reduces (i) mean arterial blood pressure, or (ii) pulse pressure, of the individual.

5. The method of any one of claims 2 to 4, wherein the method does not substantially increase heart rate of the individual.

6. The method of claim 1, wherein the individual has one or more risk factors for developing high blood pressure.

7. A method of (i) increasing renal blood flow, and/or (ii) decreasing sodium reabsorption, in an individual in need thereof comprising administering to the individual an effective amount of a compound of the formula (A-III):




or a salt, solvate or N-oxide thereof, wherein:
R1 is H; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; or —C(O)O—C1-C5 alkyl; or is taken together with R2a or R1a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R4a or Rya, where present, to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety;
each n and m is 1, or n is 0 and m is 1, or n is 1 and m is 0;
R2a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R1 or R5a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R3a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R4a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R3a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R1 or R4a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R2a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R5a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R4a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R2a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety; or is taken together with R5a, where present, to form a methylene (—CH2—) moiety;
R5a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R2a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R3a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety; or is taken together with R4a, where present, to form a methylene (—CH2—) moiety;
each R2b, R3b, R4b and R5b is independently H, optionally substituted C1-C5 alkyl, optionally substituted C2-C5 alkenyl, or optionally substituted aryl;
X is N or CR6a;
t is 1, 2 or 3;
each R6 and R6a is independently H; hydroxyl; halo; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl; optionally substituted C1-C5 alkoxy; or optionally substituted —C(O)C1-C5 alkyl;
R7 is H; halo; optionally substituted C1-C5 alkyl; or optionally substituted aryl; or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety; or is taken together with R9 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R8 is H; halo; hydroxyl; N(R11)R12; SR13, S(O)R13; SO2R13; —OC(O)N(R14)R15; —OC(O)-aryl; —OC(O)-heteroaryl; or —OC(O)C1-C5 alkyl optionally substituted with amino; or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety; or is taken together with R10 to form a bond;
R9 is H or optionally substituted C1-C5 alkyl; or is taken together with R7 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R10 is H or optionally substituted C1-C5 alkyl; or is taken together with R8 to form a bond;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl; or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl; or R14 and R15 are taken together to form a C3-C5 alkylene; and
Q is unsubstituted aryl; unsubstituted heteroaryl; aryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino; or heteroaryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.

8. The method of claim 7, wherein the method results in increase in urine sodium content and/or increase in urine volume.

9. The method of claim 7, wherein the method results in any one or more of: (i) reducing edema, (ii) reducing elevated blood urea nitrogen to creatinine (BUN/Cr) ratio, and (iii) decreasing creatinine levels.

10. The method of claim 1, wherein the individual has or is at risk of developing acute or chronic congestive heart failure, acute decompensated congestive heart failure, acute or chronic renal failure, or acute or chronic renal failure due to renal insufficiency.

11. A method of treating a disease or condition that is responsive to any one or more of: (i) a decrease in blood pressure; (ii) an increase in renal blood flow; and (iii) a decrease of sodium reabsorption, comprising administering to an individual in need thereof an effective amount of a compound of the formula (A-III):




or a salt, solvate or N-oxide thereof, wherein:
R1 is H; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; or —C(O)O—C1-C5 alkyl; or is taken together with R2a or R1a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R4a or R5a, where present, to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety;
each n and m is 1, or n is 0 and m is 1, or n is 1 and m is 0;
R2a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R1 or R5a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R3a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R4a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R3a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R1 or R4a, where present, to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R2a to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R5a, where present, to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety;
R4a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R2a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety; or is taken together with R5a, where present, to form a methylene (—CH2—) moiety;
R5a is H; optionally substituted C1-C5 alkyl; optionally substituted C2-C5 alkenyl; or optionally substituted aryl; or is taken together with R2a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety; or is taken together with R1 to form an ethylene (—CH2CH2—) moiety or a propylene (—CH2CH2CH2—) moiety; or is taken together with R3a to form a methylene (—CH2—) moiety or an ethylene (—CH2CH2—) moiety; or is taken together with R4a, where present, to form a methylene (—CH2—) moiety;
each R2b, R3b, R4b and R5b is independently H, optionally substituted C1-C5 alkyl, optionally substituted C2-C5 alkenyl, or optionally substituted aryl;
X is N or CR6a;
t is 1, 2 or 3;
each R6 and R6a is independently H; hydroxyl; halo; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl; optionally substituted C1-C5 alkoxy; or optionally substituted —C(O)C1-C5 alkyl;
R7 is H; halo; optionally substituted C1-C5 alkyl; or optionally substituted aryl; or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety; or is taken together with R9 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R8 is H; halo; hydroxyl; N(R11)R12; SR13, S(O)R13; SO2R13; —OC(O)N(R14)R15; —OC(O)-aryl; —OC(O)-heteroaryl; or —OC(O)C1-C5 alkyl optionally substituted with amino; or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety; or is taken together with R10 to form a bond;
R9 is H or optionally substituted C1-C5 alkyl; or is taken together with R7 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R10 is H or optionally substituted C1-C5 alkyl; or is taken together with R8 to form a bond;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl; or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl; or R14 and R15 are taken together to form a C3-C5 alkylene; and
Q is unsubstituted aryl; unsubstituted heteroaryl; aryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino; or heteroaryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.

12. The method of claim 11, wherein the disease or condition is hypertension.

13. The method of claim 12, wherein the disease or condition is treatment-resistant hypertension.

14. The method of claim 11, wherein the disease or condition is hypertensive emergency.

15. The method of claim 11, wherein the disease or condition is a cardiac or renal disease or condition.

16. The method of any one of claims 1, 7 and 11, wherein X is CR6a, wherein R6a is H, halo or C1-C5 alkyl; and each R6 is independently H, halo or C1-C5 alkyl.

17. The method of any one of claims 1, 7 and 11, wherein X is N.

18. The method of any one of claims 1, 7 and 11, wherein R1 is H or C1-C5 alkyl.

19. The method of any one of claims 1, 7 and 11, wherein R7 is H or C1-C5 alkyl, and R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl.

20. The method of any one of claims 1, 7 and 11, wherein R7 is H or C1-C5 alkyl, and R8 is H or hydroxyl.

21. The method of any one of claims 1, 7 and 11, wherein R7 is H or C1-C5 alkyl, and R8 is hydroxyl.

22. The method of any one of claims 1, 7 and 11, wherein R7 is H, R8 is hydroxyl, n is zero and m is 1.

23. The method of any one of claims 1, 7 and 11, wherein R7 is methyl, R8 is hydroxyl, n is zero and m is 1.

24. The method of any one of claims 1, 7 and 11, wherein Q is:
unsubstituted pyridyl;
unsubstituted pyrimidyl;
unsubstituted pyrazinyl;
unsubstituted phenyl;
unsubstituted imidazolyl;
unsubstituted triazolyl;
pyridyl substituted with 1 to 3 substituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl;
pyrimidyl substituted with 1 to 3 sub stituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl;
pyrazinyl substituted with 1 to 3 sub stituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl;
phenyl substituted with 1 to 3 sub stituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl;
imidazolyl substituted with 1 to 3 sub stituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl; or
triazolyl substituted with 1 to 3 substituents independently selected form the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl.

25. The method of any one of claims 1, 7 and 11, wherein:
X is CR6a, wherein R6a is H, halo or C1-C5 alkyl;
each R6 is independently H, halo or C1-C5 alkyl;
R7 is H or C1-C5 alkyl;
R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl;
each R9 and R10 is hydrogen; and
Q is unsubstituted pyridyl; or pyridyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl.

26. The method of claim 25, wherein n is 0 and m is 1; R7 is H or CH3; and R8 is H or hydroxyl.

27. The method of any one of claims 1, 7 and 11, wherein:
X is N;
R7 is H or C1-C5 alkyl;
R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl;
each R9 and R10 is hydrogen; and
Q is unsubstituted pyridyl; or pyridyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl.

28. The method of claim 27, wherein n is 0 and m is 1; R7 is H or CH3; and R8 is H or hydroxyl.

29. The method of any one of claims 1, 7 and 11, wherein:
n is 0 and m is 1;
R1 is taken together with R2a to form a propylene (—CH2CH2CH2—) moiety;
X is CR6a, wherein R6a is H, halo or C1-C5 alkyl;
each R6 is independently H, halo or C1-C5 alkyl;
R7 is H or C1-C5 alkyl;
R8 is H, hydroxyl, N(R11)R12 or —OC(O)C1-C5 alkyl;
each R9 and R10 is hydrogen; and
Q is unsubstituted pyridyl; or pyridyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, halo-substituted C1-C5 alkyl, carboxyl and —C(O)NR16R17, wherein each R16 and R17 is independently H or optionally substituted C1-C5 alkyl.

30. The method of claim 29, wherein R7 is H or CH3; and R8 is H or hydroxyl.

31. The method of any one of claims 1, 7 and 11, wherein the compound is Compound No. 3a, 3b, 39a, 4a, 5b, 13b, 14a, 41a, 74a, 26a, 26b, 27a, 29b, 31a, 127a, 129d, 134b, 144b, 148, 173a, 174a, 150a, 176a, IV-210a, 151a, II-4b, II-132b, 148b, 141b, 154b, II-135b, II-138, II-139, 11-140, II-244a, II-7, II-146a, II-152a, II-227c, II-220, II-148a, II-13a, II-212a, II-260a or II-260b, or a salt, solvate or N-oxide thereof.

32. The method any one of claims 1, 7 and 11, wherein the compound is an adrenergic receptor α2B antagonist.

33. The method of claim 32, wherein the compound is also an adrenergic receptor α1B antagonist.

34. The method of claim 33, wherein the compound is also an adrenergic receptor α1D antagonist.

35. A method of lowering blood pressure in an individual in need thereof comprising administering to the individual an effective amount of a compound of the formula (A-IIIA):




or a salt, solvate or N-oxide thereof, wherein:
R1 is H; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl; C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl; or —C(O)O—C1-C5 alkyl, or is taken together with R2a or R1a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R2a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R3a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
X is N or CR6a;
each R6 and R6a is independently H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl, or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety, or is taken together with R9 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15, —OC(O)-aryl, —OC(O)-heteroaryl, or —OC(O)C1-C5 alkyl optionally substituted with amino, or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety, or is taken together with R10 to form a bond;
R9 is H or optionally substituted C1-C5 alkyl, or is taken together with R7 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R10 is H or optionally substituted C1-C5 alkyl, or is taken together with R8 to form a bond;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl, or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl, or R14 and R15 are taken together to form a C3-C5 alkylene; and
Q is unsubstituted aryl; unsubstituted heteroaryl; aryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino; or heteroaryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.

36. The method of claim 35, wherein the method reduces systolic blood pressure of the individual.

37. The method of claim 35, wherein the method reduces diastolic blood pressure of the individual.

38. The method of claim 36, wherein the method reduces (i) mean arterial blood pressure, or (ii) pulse pressure, of the individual.

39. The method of any one of claims 36 to 38, wherein the method does not substantially increase heart rate of the individual.

40. The method of claim 35, wherein the individual has one or more risk factors for developing high blood pressure.

41. A method of (i) increasing renal blood flow, and/or (ii) decreasing sodium reabsorption, in an individual in need thereof comprising administering to the individual an effective amount of a compound of the formula (A-IIIA):




or a salt, solvate or N-oxide thereof, wherein:
R1 is H; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl; C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl; or —C(O)O—C1-C5 alkyl, or is taken together with R2a or R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R2a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R3a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
X is N or CR6a;
each R6 and R6a is independently H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl, or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety, or is taken together with R9 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15, —OC(O)-aryl, —OC(O)-heteroaryl, or —OC(O)C1-C5 alkyl optionally substituted with amino, or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety, or is taken together with R10 to form a bond;
R9 is H or optionally substituted C1-C5 alkyl, or is taken together with R7 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R10 is H or optionally substituted C1-C5 alkyl, or is taken together with R8 to form a bond;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl, or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl, or R14 and R15 are taken together to form a C3-C5 alkylene; and
Q is unsubstituted aryl; unsubstituted heteroaryl; aryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino; or heteroaryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.

42. The method of claim 41, wherein the method results in increase in urine sodium content and/or increase in urine volume.

43. The method of claim 41, wherein the method results in any one or more of: (i) reducing edema, (ii) reducing elevated blood urea nitrogen to creatinine (BUN/Cr) ratio, and (iii) decreasing creatinine levels.

44. The method of claim 35, wherein the individual has or is at risk of developing acute or chronic congestive heart failure, acute decompensated congestive heart failure, acute or chonic renal failure, or acute or chronic renal failure due to renal insufficiency.

45. A method of treating a disease or condition that is responsive to any one or more of: (i) a decrease in blood pressure; (ii) an increase in renal blood flow; and (iii) a decrease of sodium reabsorption, comprising administering to an individual in need thereof an effective amount of a compound of the formula (A-IIIA):




or a salt, solvate or N-oxide thereof, wherein:
R1 is H; C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl; C3-C8 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl; C2-C5 alkenyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl; or —C(O)O—C1-C5 alkyl, or is taken together with R2a or R3a to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R2a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
R3a is H, optionally substituted C1-C5 alkyl, optionally substituted alkenyl or optionally substituted aryl, or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety or a butylene (—CH2CH2CH2CH2—) moiety;
X is N or CR6a;
each R6 and R6a is independently H, hydroxyl, halo, C1-C5 alkyl optionally substituted with 1 to 3 substituents independently selected from halo, hydroxyl, carboxyl and perhaloalkyl, optionally substituted C1-C5 alkoxy or optionally substituted —C(O)C1-C5 alkyl;
R7 is H, halo, optionally substituted C1-C5 alkyl, or optionally substituted aryl, or is taken together with R8 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety, or is taken together with R9 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R8 is H, halo, hydroxyl, N(R11)R12, SR13, S(O)R13, SO2R13, —OC(O)N(R14)R15, —OC(O)-aryl, —OC(O)-heteroaryl, or —OC(O)C1-C5 alkyl optionally substituted with amino, or is taken together with R7 and the carbon atom to which they are attached to form a dioxolane ring or a carbonyl moiety, or is taken together with R10 to form a bond;
R9 is H or optionally substituted C1-C5 alkyl, or is taken together with R7 to form a C3-C5 alkylene when R8 and R10 are taken together to form a bond;
R10 is H or optionally substituted C1-C5 alkyl, or is taken together with R8 to form a bond;
each R11 and R12 is independently H or optionally substituted C1-C5 alkyl, or R11 and R12 are taken together to form C3-C5 alkylene;
R13 is H or optionally substituted C1-C5 alkyl;
each R14 and R15 is independently H or optionally substituted C1-C5 alkyl, or R14 and R15 are taken together to form a C3-C5 alkylene; and
Q is unsubstituted aryl; unsubstituted heteroaryl; aryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino; or heteroaryl substituted with 1 to 3 substituents independently selected from the group consisting of halo, C1-C5 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C5 alkyl, halo-substituted C3-C8 cycloalkyl, C1-C5 alkoxy, C3-C8 cycloalkoxy, cyano, carboxyl, aminoacyl and acylamino.

46. The method of claim 45, wherein the disease or condition is hypertension.

47. The method of claim 46, wherein the disease or condition is treatment-resistant hypertension.

48. The method of claim 45, wherein the disease or condition is hypertensive emergency.

49. The method of claim 45, wherein the disease or condition is a cardiac or renal disease or condition.

50. The method of any one of claims 35, 41 and 45, wherein X is CH.

51. The method of any one of claims 35, 41 and 45, wherein X is N.

52. The method of any one of claims 35, 41 and 45, wherein R1 is H or CH3.

53. The method of any one of claims 35, 41 and 45, wherein R2a is H or is taken together with R1 to form a propylene (—CH2CH2CH2—) moiety.

54. The method of any one of claims 35, 41 and 45, wherein each R6 and R6a is independently H, halo or C1-C5 alkyl.

55. The method of any one of claims 35, 41 and 45, wherein R7 is H or CH3.

56. The method of any one of claims 35, 41 and 45, wherein R8 is hydroxyl.

57. The method of any one of claims 35, 41 and 45, wherein Q is:
unsubstituted pyridyl;
unsubstituted pyrimidyl;
unsubstituted pyrazinyl;
unsubstituted phenyl;
unsubstituted imidazolyl;
unsubstituted triazolyl;
pyridyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3;
pyrimidyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3;
pyrazinyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3; or
phenyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3.

58. The method of any one of claims 35, 41 and 45, wherein:
X is CH;
each R6 is independently H, halo or C1-C5 alkyl;
R7 is H or CH3;
R8 is hydroxyl; and
Q is unsubstituted pyridyl, or pyridyl substituted with halo, CH3, CF3, CONH2, OH, or OCH3.

59. The method of any one of claims 35, 41 and 45, wherein the compound is Compound No. 3a, 3b, 39a, 4a, 5b, 74a, 26a, 26b, 27a, 29b, 31a, 127a, 129d, 134b, 144b, 148, 173a, 174a, 150a, 176a, IV-210a, 151a, II-4b, II-132b, 148b, 141b, II-135b, II-138, II-139, II-140, II-244a, II-7, II-146a, II-151b, II-152a, II-227c, II-220, II-148a, II-13a, II-212a, II-260a and II-260b, or a salt, solvate or N-oxide thereof.

60. The method any one of claims 35, 41 and 45, wherein the compound is an adrenergic receptor α2B antagonist.

61. The method of claim 60, wherein the compound is also an adrenergic receptor α1B antagonist.

62. The method of claim 61, wherein the compound is also an adrenergic receptor α1D antagonist.